Therapeutic compounds and related methods of use

ABSTRACT

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.

RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §120 as a continuation of U.S. patent application Ser. No. 13/520,018 titled “THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE,” filed on Sep. 25, 2012, which is a national stage application under 35 U.S.C. §371 of PCT Application No. PCT/US2010/062555 titled “THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE,” filed Dec. 30, 2010, which claims priority to U.S. Provisional Application Ser. No. 61/291,544, titled “THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE” filed on Dec. 31, 2009; 61/291,550, titled “THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE,” filed on Dec. 31, 2009; and 61/291,554, titled “THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE” filed on Dec. 31, 2009, all of which are herein incorporated by reference in their entireties.

BACKGROUND OF INVENTION

Tyrosine phosphorylation of synaptic receptors and signaling molecules regulates synaptic activity. A number of protein tyrosine phosphatases specifically expressed within the brain have been identified, including STEP (for STriatal-Enriched tyrosine Phosphatase, also known as PTPN5). Recent evidence suggests that STEP plays an important role in synaptic plasticity, for review see (Braithwaite S P, et al., (2006), Trends Neurosci, 29 (8): 452; Baum M L, et al., (2010), Commun Integr Biol, 3 (5): 419). STEP is specifically expressed within neurons of the central nervous system. As its name indicates, the highest expression level is within the striatum. However, more recent work has found that it is expressed at lower levels in multiple brain regions including the neocortex, amygdala, hippocampus, and embryonic spinal cord.

Four groups of proteins that STEP regulates have been identified: the mitogen-activated protein kinases (MAPKs), the tyrosine kinase Fyn, the N-methyl-D-aspartate (NMDA) receptor complex (specifically the NR2B subunit) and AMPA receptors (specifically, GluR2, (Zhang Y, et al., (2008), J Neurosci, 28 (42): 10561)). Three additional new substrates for STEP have also been recently discovered; proline-rich tyrosine kinase 2 (Pyk2; Xu J, et al., (2010), Abstracts of the Society for Neuroscience Meetings), the fragile X mental retardation protein (FMRP) (Goebel-Goody S M, et al., (2010), Abstracts of the Society for Neuroscience Meetings) and the cell-death mediator Bak (Fox J L, et al., (2010), EMBO J, 29 (22): 3853). Tyrosine phosphorylation of one member of the MAPK family, the extracellular signal regulated kinase (ERK), is necessary for the expression and maintenance of synaptic plasticity in many brain regions, and disruption of the ERK pathway leads to a disruption of learning and memory. One of the functions of these src and Pyk2 kinases is to phosphorylate NMDA receptors, thereby modulating their channel conductance properties and facilitating their movement toward the surface of neuronal plasma membranes. Pyk2 and Fyn tyrosine kinases are activated by phosphorylation on tyrosine residues. NR2B phosphorylation on Tyrosine 1452 inhibits the receptor endocytosis. STEP acts as direct or indirect brake of NMDAR mediated signaling by either respectively dephosphorylating NR2B or its associated kinases, Pyk2 and Fyn. Activation of AMPA, NMDA receptors and MAPKs are required for the induction of several forms of long-term potentiation (LTP) and long-term depression (LTD). Hippocampal LTP is increased in transgenic mice model of Alzheimer lacking STEP (Zhang Y, et al., (2010), Proc Natl Acad Sci USA, 107 (44): 19014). NR2B and AMPA receptor surface expression is increased in STEP KO mice. AMPA receptor endocytosis in group I metabotropic glutamate receptor I (mGluR) mediated LTD is mediated by a tyrosine phosphatase. AMPA receptor endocytosis induced by activation of group I mGLuR is blocked in STEP KO mice suggesting that STEP might also control mGluR mediated LTD.

Compounds that inhibit STEP activity should mimic the effects observed with the STEP KO and may be useful for treating conditions mediated by abnormal NMDA-receptor (NMDA-Rs) and/or MAP kinase pathway signaling. Both may mediate cognition, learning and memory, neurogenesis, and may also affect neuronal plasticity, pain perception, mood and anxiety, and neuroendocrine regulation.

Modulation of NMDA-Rs:

STEP decreases the tyrosine phosphorylation level of NMDA-Rs. Less phosphorylated NMDA-Rs have lower conductance states and thus will allow less current and fewer ions to pass. The NMDA-Rs will therefore be functionally less active (Alvestad R M, et al., (2003), J Biol Chem, 278 (13): 11020), which can lead to schizophrenic symptoms. Hypofunction of NMDA-Rs has been liked to schizophrenia. For example, phencyclidine, ketamine, and other noncompetitive antagonists at NMDA-type glutamate receptors can exacerbate symptoms in patients (Lahti A C, et al., (1995), Neuropsychopharmacology, 13 (1): 9) and may produce a range of psychotic symptoms in volunteers that are similar to those of schizophrenic patients. NMDA-R hypofunction is also linked to psychosis and drug addiction (Javitt D C and Zukin S R, (1991), Am J Psychiatry, 148 (10): 1301). Chronic treatment of atypical antipsychotic clozapine and risperidone in mice result in significant increase of phosphorylation of ERK, NR2B and Pyk2 on tyrosine residues recognized by STEP (Carty N C, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Treatment of these anti-psychotics also enhances cAMP and STEP phosphorylation. Since PKA mediated phosphorylation of STEP is know to inactivate STEP, these results suggest that STEP inhibition mediates the beneficial effect of antipsychotic drugs. Recent studies have linked abnormal NMDA-R activity and expression of STEP to the cognitive decline observed in Alzheimer's disease or transgenic mice expressing mutant APP (Tg2576 mice) (Snyder E M, et al., (2005), Nat Neurosci, 8 (8): 1051; Hynd M R, et al., (2004), J Neurochem, 90 (4): 913; Kurup P, et al., (2010), Channels (Austin), 4 (5)). More specifically, STEP KO mice are less susceptible to PCP-induced hyperlocomotion and PCP-induced cognitive deficits in the object recognition tasks (Carty N C, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Compared to the Tg2576 mice expressing STEP, Tg2576 lacking STEP gene showed rescue in their deficits in hyppocampal LTP and in different behavioral cognitive tasks. Altogether, these results suggest that STEP inhibitors might represent a novel class of drugs that can treat both positive symptoms and cognitive deficit associated with schizophrenia.

Medications that modulate glutamatergic neurotransmission via NMDA-Rs may be also effective in treatment for mood and anxiety disorders. Administration of NMDA-R antagonists has anxiolytic effects in rodent models of anxiety (Falls W A, et al., (1992), J Neurosci, 12 (3): 854; Miserendino M J, et al., (1990), Nature, 345 (6277): 716). NMDA-Rs antagonist like ketamine has been shown to be effective in drug-resistant unipolar depression (Machado-Vieira R, et al., (2009), Pharmacol Ther, 123 (2): 143).

Abnormal balance between the activity of NMDA receptors at synaptic (prosurvival linked to ERK activation) and extrasynaptic (proapoptotic linked to p38 activation) sites has been proposed in cellular and mouse model of Huntington Disease (HD) (Milnerwood A J, et al., Neuron, 65 (2): 178). YAC128 mouse model (containing high number of glutamine repeat on huntingtin) of HD showed an increased activity of extrasynaptic NMDA receptors (NR2B subunit) and require p38 and caspase-6 cleavage activation. In YAC128 mice, NR2B synaptic expression is associated with high STEP expression and activity and a reduction in NR2B expression and phosphorylation (Gladding C M, et al., (2010), Abstracts of the Society for Neuroscience Meetings). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP and activation of p38 (Xu J, et al., (2009), J Neurosci, 29 (29): 9330) Inhibiting STEP activity might therefore shift the balance toward the NMDA receptor/ERK synaptic prosurvival signaling pathway.

Modulation of ERK Pathway:

STEP inhibition may translate into activation of ERK1/2 kinases, for example, in the central nervous system (CNS). Activation of the ERK pathway in the CNS can mediate neurotrophic pathways involved in cellular resilience. ERK signaling directly affects Bak phosphorylation through inhibition of STEP to promote cell survival (Fox J L, et al., (2010), EMBO J, 29 (22): 3853). BDNF and other neurotrophins can block apoptosis and increase cell survival of different type of CNS neurons in vitro and in vivo via stimulation of the ERK pathway. Mood stabilizers effective in bipolar disorder like valproate and lithium may be potent activators of ERK activity. This effect on ERK activation is believed to be responsible for the neurotrophic effects of mood stabilizers observed in vitro or in brains of treated patients with bipolar disorder, for review see (Engel S R, et al., (2009), Mol Psychiatry, 14 (4): 448; Chen G and Manji H K, (2006), Curr Opin Psychiatry, 19 (3): 313; Machado-Vieira R, et al., (2009), Bipolar Disord, 11 Suppl 2 92). In vivo disruption of STEP activity was shown to activate MAPK pathway, leading to significant rescue from neuronal cell death after pilocarpine-induced status epilepticus (Choi Y S, et al., (2007), J Neurosci, 27 (11): 2999). Increasing cellular resilience could therefore limit or reduce neuronal loss in several neurologic disorders. Recent work has suggested a positive role for STEP inhibition in fragile X syndrome (FXS). This disorder results from the mutation of fmr1 gene coding for the fragile X mental retardation protein (FMRP). STEP binds to FMRP and its expression is dysregulated in FXS. FMR KO mice model displayed audiogenic seizures. FMR KO mice lacking STEP gene show a significant reduction of these seizures (Goebel-Goody S M, et al., (2010), Abstracts of the Society for Neuroscience Meetings), suggesting that STEP modulators might be therapeutic approach for FXS.

Various substituted heterocyclic compounds are disclosed in the art. For example, WO 02/062767 discloses quinazoline derivatives; WO 03/000188 discloses quinazolines and uses thereof; WO 2005/042501 discloses norepinephrine reuptake inhibitors for the treatment of central nervous system disorders; WO2006/058201 discloses heterocyclic and bicyclic compounds, compositions and methods; WO 2007/104560 discloses substituted 4-amino-quinazoline derivatives as regulators of metabotropic glutamate receptors and their use for producing drugs; WO 2007/133773 discloses CDKI pathway inhibitors; WO 2008/009078 discloses 4,6-DL- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections; WO 2009/000085 discloses quinoline and quinazoline derivatives useful as modulators of gated ion channels; US 2009/0143399 discloses protein kinase inhibitors; and Japan Publication Number 2007-084494A discloses substituted bicyclic compounds.

SUMMARY OF INVENTION

Described herein are compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia or cognitive deficit, in a subject. The compounds disclosed herein include quinoline- and quinazoline-containing compounds that modulate (e.g., inhibit) the activity of STEP.

The present invention provides therapeutic compounds, pharmaceutical composition comprising said compounds, use of said compounds and method for treating or preventing a disorder as described in items 1 to 42 below,

-   Item 1. A compound of formula (I):

or a salt thereof,

wherein:

A is CR⁴ or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

n is 0, 1, 2, 3 or 4;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2 and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

a compound of formula (II):

or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

wherein, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is O or S;

q is 1 or 2 and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl and

a compound of formula (III):

or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NR⁶;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, 2 or 3;

n is 1, 2, 3 or 4;

-   -   R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,         alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl,         arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each         of which is optionally substituted with 1-3 R⁷;     -   R² is aryl or heteroaryl, each of which is optionally         substituted with 1-5 R⁹;     -   each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈         alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl,         arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl,         halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl,         dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy,         silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂,         —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′),         —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′),         —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′),         —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which         is optionally substituted with 1-3 R¹⁰;     -   R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl,         cyclyl or heterocyclyl, each of which is optionally substituted         with 1-3 R¹¹;     -   each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl,         C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl,         arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl,         halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl,         dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy,         silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN,         —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′),         —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′),         —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′),         —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which         is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁹         or two R¹⁰ are optionally be taken together with the atoms to         which they are attached to form an optionally substituted         cyclyl, heterocyclyl, aryl or heteroaryl ring;     -   each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl,         C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl,         arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl,         halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl,         dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy,         silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN,         —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′),         —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′),         —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′),         —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which         is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

-   -   Y is independently O or S;     -   q is 1 or 2;and     -   each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e)         and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl,         C₂-C₈ alkynyl, acyl, haloalkyl alkoxyalkyl, alkylaminoalkyl,         dialkylaminoalkyl, cyclyl, heterocyclyl, aryl, heteroaryl,         cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl;     -   with proviso R⁹ is not

-   Item 2. The compound according to item 1 represented by general     formula(I) or a salt thereof,

wherein:

A is CR⁴ or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 3. The compound according to item 2 represented by general     formula (I) or a salt thereof,

wherein:

A is CH or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

n is 0, 1 or 2;

when E is aryl, n is 0, 1 or 2 and when E is a 5-membered heteroaryl, n is 0 or 1;

p is 0, 1 or 2;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R⁶ is independently C₁-C₈ alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, haloalkyl, dialkylaminoalkyl, hydroxyalkyl or alkoxyalkyl.

-   Item 4. The compound according to Item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, quinolyl, isoquinolinyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothiophenyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolylalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl or alkoxyalkyl.

-   Item 5. The compound according to tem 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, isoquinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 0, for 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 6. The compound according to item 5 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁶;

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R⁶.

-   Item 7. The compound according to item 4 or 6 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridinylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d).

-   Item 8. The compound according to item 7 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, thiadiazolyl or pyridyl;

m is 1, 2, 3 or 4;

R¹ is C₁-C₈ alkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₃-C₈ cycloalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, C₃-C₈ cycloalkylalkyl, haloalkyl or alkoxyalkyl.

-   Item 9. The compound according to item 1 represented by general     formula (II) or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of

X¹, X², X³, X⁴ and X⁵ are N;

-   -   n is 0, 1, 2, 3 or 4;     -   p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl, or heteroarylalkyl.

-   Item 10. The compound according to item 9 represented by general     formula (II) or a salt thereof,

L is NR′;

n is 0, 1 or 2;

p is 0;

R¹ is C₁-C₈ alkyl, aryl or heteroaryl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, aryl, halo, heterocyclylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R⁷ is hydrogen; and

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, heterocyclyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(c);

Y is O;

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, aryl, or heteroaryl.

-   Item 11. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d);

R⁹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 12. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 13. The compound according to item 12 represented by general     formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′),′ —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R³ is hydrogen;

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′); and

R¹¹ is C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, —CN, —OR^(d) or —C(Y)R^(c);

-   Item 14. The compound according to item 11 or 13 represented by     general formula (II) or a salt thereof, wherein: -   R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl,     —NR^(c)C(Y)R^(c′),′ —NR^(b)R^(b′) or —OR^(d);

R³ is hydrogen; and

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′).

-   Item 15. The compound according to item 1 represented by general     formula (III) or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NH;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, 2 or 3;

n is 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷ or two R⁹ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, haloalkyl, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.

-   Item 16. The compound according to item 15 represented by general     formula (III) or a salt thereof,

wherein:

m is 1;

n is 1;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl, heterocyclyl, arylalkyl, cyclylalkyl, heteroarylalkyl, alkoxyalkyl, hydroxyalkyl or —C(O)R^(e), each of which is optionally substituted with 1-3 R⁷;

R² is aryl, heteroaryl or benzofuryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, aryl, heteroaryl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e) each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or heterocyclyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, arylalkyl, alkoxyalkyl, heterocyclylalkyl, heteroarylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 17. The compound according to Item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl isoindolyl, —C(O)R^(c), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzoisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 18. The compound according to item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

-   -   each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo,         haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN,         —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d),         —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally         substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or pyrrolidinyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 19. The compound according to item 18 represented by general     formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²;

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 20. The compound according to item 17 or 19 represented by     general formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d);

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, dihydrobenzoxazinylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 21. The compound according to item 20 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, which is optionally substituted with 1-5 R⁹; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, alkylaminoalkyl or phenyl.

-   Item 22. A pharmaceutical composition comprising the compound     according to any one of items 1 to 21 or a salt thereof as an active     ingredient and a pharmaceutically acceptable carrier. -   Item 23. The pharmaceutical composition according to item 22 for     preventing or treating central nervous system diseases. -   Item 24. The pharmaceutical composition according to item 23 for     treating or preventing central nervous system disorders selected     from the group consisting of schizophrenia; refractory, intractable     or chronic schizophrenia; emotional disturbance; psychotic disorder;     mood disorder; bipolar I type disorder; bipolar II type disorder;     depression; endogenous depression; major depression; melancholy and     refractory depression; dysthymic disorder; cyclothymic disorder;     panic attack; panic disorder; agoraphobia; social phobia;     obsessive-compulsive disorder; post-traumatic stress disorder;     generalized anxiety disorder; acute stress disorder; hysteria;     somatization disorder; conversion disorder; pain disorder;     hypochondriasis; factitious disorder; dissociative disorder; sexual     dysfunction; sexual desire disorder; sexual arousal disorder;     erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep     disorder; adjustment disorder; alcohol abuse; alcohol intoxication;     drug addiction; stimulant intoxication; narcotism; anhedonia;     iatrogenic anhedonia; anhedonia of a psychic or mental cause;     anhedonia associated with depression; anhedonia associated with     schizophrenia; delirium; cognitive impairment; cognitive impairment     associated with Alzheimer's disease, Parkinson's disease and other     neurodegenerative diseases; cognitive impairment caused by     Alzheimer's disease; Parkinson's disease and associated     neurodegenerative diseases; cognitive impairment of schizophrenia;     cognitive impairment caused by refractory, intractable or chronic     schizophrenia; vomiting; motion sickness; obesity; migraine; pain     (ache); mental retardation; autism disorder (autism); Tourette's     disorder; tic disorder; attention-deficit/hyperactivity disorder;     conduct disorder; and Down's syndrome. -   Item 25. A process for producing a pharmaceutical composition     comprising mixing a compound of the formula (I), (II), or (III) or a     salt thereof according to any one of items 1 to 21 with a     pharmaceutically acceptable carrier. -   Item 26. Use of a compound of the formula (I), (II) or (III) or a     salt thereof according to any one of items 1 to 21 as a drug. -   Item 27. Use of the compound according to any one of items 1 to 21     represented by general formula (I), (II) or (III) or a salt thereof     as a STEP inhibitor. -   Item 28. A method of treating a disorder that would benefit by the     modulation of STEP (e.g., by activation of inhibition of STEP) in a     subject, the method comprising administering to a compound of     formula (I), (II) or (III) or a salt thereof according to any one of     items 1 to 21. -   Item 29. The method of item 28, wherein the disorder is     schizophrenia. -   Item 30. The method of item 28, wherein the disorder is cognitive     deficit. -   Item 31. The method of item 28, wherein the compound of formula (I),     (II), or (III) is administered in combination with an additional     therapeutic agent. -   Item 32. The method of item 28, wherein the additional therapeutic     agent is an atypical antipsychotic. -   Item 33. The method of item 28, wherein the additional therapeutic     agent is selected from the group consisting of aripiprazole,     clozapine, ziprasidone, risperidone, quetiapine, olanzapine,     amisulpride, asenapine, iloperidone, melperone, paliperidone,     perospirone, sertindole and sulpiride. -   Item 34. The method of item 28, wherein the additional therapeutic     agent is a typical antipsychotic. -   Item 35. The method of item 28, wherein the additional therapeutic     agent is selected from the group consisting of haloperidol,     molindone, loxapine, thioridazine, molindone, thiothixene, pimozide,     fluphenazine, trifluoperazine, mesoridazine, chlorprothixene,     chlorpromazine, perphenazine, triflupromazine and zuclopenthixol. -   Item 36. A kit comprising a composition comprising a compound of     formula (I), (II), or (III) or a salt thereof according to any one     of items 1 to 21 and an acceptable carrier. -   Item 37. A kit comprising a pharmaceutical composition comprising a     compound of formula (I), (II), or (III) or a salt thereof according     to any one of items 1 to 21 and a pharmaceutically acceptable     carrier. -   Item 38. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring;

when B is phenyl, R² is not

and where in the compound is not:

-   Item 39. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, or aryl ring;

each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the carbons to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 40. A compound of formula (V):

wherein:

L is CR⁴R⁵, 0, C(O), NR⁶C(O), or NR′;

A is CR⁸, CH or N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl or heterocyclylalkyl, each of which may be optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ may optionally be taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁸, R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally further substituted; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁸, or a pharmaceutically acceptable derivative or prodrug thereof.

-   Item 41. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR^(b);

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when R¹ is cyclopropyl, R⁹ is not:

-   Item 42. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR⁶;

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R^(b) and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

wherein R⁹ is not:

Compounds of Formula (I)

The following aspects and embodiments relate to compounds of formula (I).

-   Item 2. The compound according to item 1 represented by general     formula (I) or a salt thereof,

wherein:

A is CR⁴ or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 0, 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵, S, O or a direct bond;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, silylalkoxy, silylalkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and one R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f),each of which is optionally substituted with 1-3 R⁹;

each R⁹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy or silylalkoxyalkyl;

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

-   Item 3. The compound according to item 2 represented by general     formula (I) or a salt thereof,

wherein:

A is CH or N;

B is aryl, cyclyl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3 or 4;

E is aryl or a 5-membered heteroaryl;

n is 0, 1 or 2;

when E is aryl, n is 0, 1 or 2 and when E is a 5-membered heteroaryl, n is 0 or 1;

p is 0, 1 or 2;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silyloxyalkynyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R⁶ is independently C₁-C₈ alkyl, heterocyclyl, heterocyclylalkyl, hydroxyalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷;

each R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, haloalkyl, dialkylaminoalkyl, hydroxyalkyl or alkoxyalkyl.

-   Item 4. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, quinolyl, isoquinolinyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothiophenyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 1 or 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, oxazolyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolylalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 5. The compound according to item 3 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroquinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, isoquinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, dihydroisobenzofuranyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, dihydrocyclopentathiophenyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyrrolyl or pyridyl;

E is phenyl, thienyl or pyrrolyl;

when E is phenyl, n is 0, for 2; and when E is thienyl, n is 0 or 1;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidyl, pyrrolidinyl, morpholinyl, dioxolanyl, phenylalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperidylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, oxo, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —OC(O)NR^(b)R^(b′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

each R⁶ is independently C₁-C₈ alkyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, morpholinylalkyl, dialkylaminoalkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —NR^(c)C(Y)R^(c′), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), alkoxyalkyl, —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁷; R⁷ is oxo; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, pyridyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, piperazinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, furylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, thiazolylalkyl, pyrazolylalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, benzothienylalkyl, C₃-C₈ cycloalkylalkyl, oxazolidinylalkyl, haloalkyl, or alkoxyalkyl.

-   Item 6. The compound according to item 5 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R⁶;

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e), each of which is optionally substituted with 1-3 R⁶;

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R⁶.

-   Item 7. The compound according to item 4 or 6 represented by general     formula (I) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl, thienyl, pyrrolyl, oxazolyl, C₃-C₈ cycloalkyl, dioxolanyl, phenylalkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₂-C₈ alkynyl, phenyl, thienyl, pyridyl, benzodioxolyl, furyl, pyrimidinyl, isoxazolyl, pyrazolyl, C₃-C₈ cycloalkyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, piperiridinylalkyl, piperazinylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, silyloxyalkynyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —OR^(d), —C(Y)R^(e) or —S(O)_(q)R^(f);

R³ is C₁-C₈ alkyl, halo, haloalkyl, —NR^(b)R^(b′) or —OR^(d).

-   Item 8. The compound according to item 7 represented by general     formula (I) or a salt thereof,

wherein:

B or two R1 and B are taken together to form a group is phenyl, dihydroindenyl, dihydrobenzoxazinyl, dihydrobenzodioxinyl, chromenyl, tetrahydroisoquinolyl, tetrahydroquinolinyl, dihydroquinolyl, quinolyl, tetrahydroquinazolinyl, indolinyl, dihydrobenzothiazolyl, dihydrobenzimidazolyl, dihydrobenzoxazolyl, isoindolinyl, benzofuryl, benzothienyl, benzodioxolyl, indolyl, indazolyl, benzoimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzoxadiazolyl, tetrahydrobenzothienyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, thiadiazolyl or pyridyl;

m is 1, 2, 3 or 4;

R¹ is C₁-C₈ alkyl, halo, haloalkyl, haloalkoxy, alkoxyalkyl, —CN, oxo, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —SO₂NR^(b)R^(b′), —OR^(d), or —S(O)_(q)R^(f);

R² is C₁-C₈ alkyl, C₃-C₈ cycloalkyl, thiomorpholinylalkyl, pyrrolidinylalkyl, morpholinylalkyl, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(Y)R^(c) or —S(O)_(q)R^(f);

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₈ cycloalkyl, phenyl, dihydroindenyl, morpholinyl, tetrahydropyranyl, piperidyl, pyrrolidinyl, thiomorpholinyl, phenylalkyl, thienylalkyl, pyridylalkyl, tetrahydropyranylalkyl, dihydroindenylalkyl, tetrahydrofurylalkyl, hydroxyalkyl, morpholinylalkyl, pyrrolidinylalkyl, dialkylaminoalkyl, piperidylalkyl, benzodioxolilalkyl, dihydrobenzodioxinylalkyl, C₃-C₈ cycloalkylalkyl, haloalkyl or alkoxyalkyl.

In some embodiments, A is N. In some embodiments, A is CH. In some embodiments, A is CR⁴.

In some embodiments, B is aryl (e.g., phenyl).

In some embodiments, m is 0.

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

In some embodiments, R¹ is in the ortho position. In some embodiments, R¹ is in the meta position. In some embodiments, R¹ is in the para position.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl or tert-butyl). In some embodiments, R¹ is heteroaryl (e.g., oxazolyl, oxadiazolyl or quinazolinyl).

In some embodiments, R¹ is heteroaryl substituted with 1-3 R⁶ (e.g., 1 R⁶).

In some embodiments, R¹ is oxadiazolyl substituted with 1 R⁶. some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is heteroaryl substituted with 2 R⁶. In some embodiments, R¹ is quinazolinyl substituted with 2 R⁶. In some embodiments, one R⁶ is halo (e.g., bromo) and the other is heteroaryl (e.g., pyridyl).

In some embodiments, m is 1 and R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 2 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 3 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, R¹ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R¹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, R¹ is haloalkoxy substituted with 1 R⁶. In some embodiments, R¹ is —O—CF₂—R⁶. In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O, R^(b) is hydrogen and R^(b′) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —O—CF₂—CH₂—R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino).

In some embodiments, R¹ is aminoalkyl. In some embodiments, R¹ is —CH₂NH₂. In some embodiments, R¹ is alkylaminoalkyl. In some embodiments, R¹ is —CH₂NHCH₂CH₂CH₃. In some embodiments, R¹ is dialkylaminoalkyl. In some embodiments, R¹ is —CH₂N(CH(CH₃)₂)₂.

In some embodiments, R¹ is hydroxyalkyl. In some embodiments, R¹ is —CH₂OH.

In some embodiments, R¹ is —CN.

In some embodiments, R¹ is —NO₂.

In some embodiments, R¹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —NR^(c)C(Y)R^(c′). In some embodiments, one of R^(c) and R^(c′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —SO₂NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, R¹ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(c) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl (e.g., pyrrolidinyl, piperidinyl or morpholino).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is S. In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) is hydrogen. In some embodiments, R^(b) is hydrogen and R^(b′) is aralkyl. In some embodiments, R^(b) is hydrogen and R^(b′) is optionally substituted benzyl. In some embodiments, R^(b′) is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, sec-butyl or tert-butyl), C₅ alkyl (e.g., n-pentyl, isopentyl or pentan-3-yl), C₆ alkyl (e.g., n-hexyl or 3,3-dimethylbutan-2-yl), or C₇ alkyl (e.g., n-heptyl or 2-heptyl).

In some embodiments, R^(b′) is bicyclyl (e.g., indanyl). In some embodiments, R^(b′) is heterocyclyl, e.g., a 6-membered heterocyclyl. In some embodiments, R^(b′) is a 6-membered oxygen-containing heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, R^(b′) is a 6-membered nitrogen-containing heterocyclyl (e.g., piperidinyl).

In some embodiments, R^(b′) is aralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the aryl is phenyl. In some embodiments, R^(b′) is benzyl. In some embodiments, R^(b′) is phenylethyl.

In some embodiments, R^(b′) is heteroaralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂ or C₃ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the heteroaryl is pyridyl. In some embodiments, the heteroaryl is furanyl. In some embodiments, the heteroaryl is thiazolyl. In some embodiments, the heteroaryl is thienyl.

In some embodiments, R^(b′) is cyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the cyclyl group is cyclopropyl. In some embodiments, the cyclyl group is cyclopentyl. In some embodiments, the cyclyl group is a bicyclic group. In some embodiments, the bicyclic group is indanyl. In some embodiments, R^(b′) is heterocyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the heterocyclyl group is tetrahydropyranyl.

In some embodiments, R^(b′) is haloalkyl (e.g., fluoroethyl, difluoroethyl, trifluoroethyl or trifluoropropyl).

In some embodiments, R^(b′) is alkoxyalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, both ethyl, or both isopropyl).

In some embodiments, two R¹ and B are taken together to form a bicyclic heteroaryl or heterocyclic ring.

In some embodiments, two R¹ and B are taken together to form

In some embodiments, R¹ is halo. In some embodiments, R¹ is at the 6, 7, or 8 position.

In some embodiments, two R¹ and B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently C₁-C₈ alkyl (e.g., each R¹ is methyl). In some embodiments, each R¹ is independently halo (e.g., each R¹ is fluoro or each R¹ is chloro). In some embodiments, one R¹ is fluoro and the other is chloro. In some embodiments, one R¹ is chloro and the other is bromo.

In some embodiments, each R¹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R¹ is halo (e.g., fluoro) and the other is heterocyclylalkyl (e.g., —CH₂-heterocyclyl). In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the piperazinyl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is haloalkyl (e.g., trifluoromethyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —CN.

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NO₂.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —NO₂. In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, each R^(a) and R^(d) is hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkoxy (e.g., trifluoromethoxy). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —S(O)_(q)R^(f). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —CN. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —NR^(c)C(O)R^(c′). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is haloalkyl (e.g., trifluoromethyl) and the other is —CN.

In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a substituted cyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring (e.g., a substituted heterocyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heteroaryl ring (e.g., a substituted heteroaryl ring).

In some embodiments, two R¹ and ring B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently halo (e.g., all three R¹ are fluoro or all three R¹ are chloro).

In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is heteroaryl (e.g., pyrrolyl). In some embodiments, two R¹ are independently halo (e.g., both are fluoro) and the other is —C(Y)NR^(b)R^(b′) (e.g., —C(O)NH₂). In some embodiments, two R¹ are independently C₁-C₈ alkyl (e.g., both are methyl) and the other is halo (e.g., chloro or bromo).

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring.

In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, three R¹ and ring B are taken together to form a group selected from:

In some embodiments, B is a 6-membered heteroaryl.

In some embodiments, B is pyridyl. In some embodiments, B is 3-pyridyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring).

In some embodiments, m is 3. In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, R^(d) is hydrogen.

In some embodiments, B is pyrazolyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a cyclohexyl ring).

In some embodiments, B is selected from:

In some embodiments, B is a 5-membered heteroaryl (e.g., pyrazolyl).

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is selected from:

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is aryl (e.g., phenyl). In some embodiments, the aryl is phenyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is:

In some embodiments, B is thienyl. In some embodiments, B is selected from:

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments m is 2 and two R¹, together with the atoms to which they are attached, form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring

In some embodiments, R¹ is —C(O)OR_(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, B is thiazolyl.

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, m is 2.

In some embodiments, two R¹, together with the atoms to which they are attached, form an aryl ring. In some embodiments, the aryl ring is substituted with —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, B is:

In some embodiments, B is:

In some embodiments, E is aryl (e.g., phenyl).

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is C₁-C₈ alkyl substituted with 1-3 R⁶. In some embodiments, R² is C₁ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl). In some embodiments, R^(d) is heterocyclylalkyl (e.g., —CH₂— tetrahydropyranyl).

In some embodiments, R² is C₂ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(b) is —C(Y)R^(c). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R^(e) is:

In some embodiments, R² is C₃ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy).

In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is C₂-C₈ alkynyl. In some embodiments, R² is C₂-C₈ alkynyl substituted with 1 R⁶ (e.g., C₃ alkynyl substituted with 1 R⁶). In some embodiments, R² is —C≡C—CH₂—R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R⁶ is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R⁶ is:

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl.

In some embodiments, R² is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is heterocyclylalkyl (e.g., —CH₂-morpholino). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —CN. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is phenyl substituted with 2 R⁶.

In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is halo (e.g., fluoro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, R^(a) and R^(d) are each independently C₁-C₈ alkyl (e.g., R^(a) and R^(d) are both methyl).

In some embodiments, R² is heteroaryl.

In some embodiments, R² is isoxazolyl. In some embodiments, R² is isoxazolyl substituted with 2 R⁶. In some embodiments, each R⁶ is independently C₁-C₈ alkyl (e.g., R⁶ is methyl).

In some embodiments, R² is pyrazolyl. In some embodiments, R² is pyrazolyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyridyl. In some embodiments, R² is unsubstituted pyridyl. In some embodiments, R² is pyridyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., fluoro). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or piperazinyl). In some embodiments, R⁶ is piperazinyl substituted with 1 R⁷. In some embodiments, R⁷ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyrimidinyl.

In some embodiments, R² is pyridazinyl.

In some embodiments, R² is cyclyl (e.g., cyclopropyl).

In some embodiments, R² is heterocyclyl (e.g., morpholino or pyrrolidinyl).

In some embodiments, R² is aralkyl (e.g., benzyl).

In some embodiments, R² is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the heterocyclyl is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is thiomorpholino. In some embodiments, the heterocyclyl is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, the heterocyclyl is:

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R² is haloalkoxy (e.g., trifluoromethoxy).

In some embodiments, R² is —CN.

In some embodiments, R² is —NO₂.

In some embodiments, R² is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl (e.g., —CH₂—CH₂-morpholino). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is hydroxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is tetrahydropyranyl.

In some embodiments, R² is —OR^(d).

In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(d) is ethyl. In some embodiments, R^(d) is C₃ alkyl (e.g., isopropyl or n-propyl). In some embodiments, R^(d) is optionally substituted heteroaralkyl. In some embodiments, R^(d) is optionally substituted pyrindinalkyl.

In some embodiments, R^(d) is n-propyl. In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl).

In some embodiments, R^(d) is heteroaralkyl (e.g., —CH₂-pyridyl).

In some embodiments, R^(d) is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkyl is C₄ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is piperidyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, R^(d) is cyclylalkyl (e.g., —CH₂-cyclobutyl).

In some embodiments, R^(d) is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(d) is dialkylaminoalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the dialkylamino is dimethylamino.

In some embodiments, R² is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is piperidyl. In some embodiments, R^(e) is pyrrolidinyl. In some embodiments, R^(e) is piperazinyl. In some embodiments, R^(e) is morpholino. In some embodiments, R^(e) is thiomorpholino.

In some embodiments, n is 2.

In some embodiments, each R² is independently halo (e.g., each R² is chloro).

In some embodiments, each R² is independently —OR^(d).

In some embodiments, each R^(d) is C₁-C₈ alkyl.

In some embodiments, each R² is methoxy. In some embodiments, one R² is methoxy and the other is ethoxy. In some embodiments, one R² is methoxy and the other is propoxy. In some embodiments, one R² is methoxy and the other is isopropoxy.

In some embodiments, one R² is methoxy and the other is ethoxy substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is methoxy and the other is propoxy substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —CN. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) and R^(a) are both hydrogen.

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(Y)R^(e). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, one R² is halo (e.g., chloro or bromo) and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is —CN.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heteroaryl (e.g., pyridyl). In some embodiments, the pyridyl is substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heterocyclylalkyl (e.g., —CH₂-morpholino).

In some embodiments, p is 0.

In some embodiments, p is 1.

In some embodiments, R³ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R³ is halo (e.g., chloro). In some embodiments, R³ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R³ is oxo.

In some embodiments, R³ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is heterocyclyl (e.g., piperazinyl). In some embodiments, R³ is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, E is a 5-membered heteroaryl ring.

In some embodiments, E is a thiophene ring.

In some embodiments, E is a pyrrole ring.

In some embodiments, n is 1. In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, E is an N-methylpyrrole ring.

In some embodiments, L is NR⁵. In some embodiments, R⁵ is hydrogen.

In some embodiments, L is O.

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments,

In some embodiments,

In some embodiments, L is NH, and

is selected from

In some embodiments R⁶ is halo.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo.

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

Compounds of Formula (II)

The following aspects and embodiments relate to compounds of formula (II).

-   Item 9. The compound according to item 1 represented by general     formula (II) or a salt thereof,

wherein:

L is CR⁴R⁵, O, C(O), NR⁶C(O) or NR⁷;

A is N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl or heterocyclylalkyl, each of which is optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ is optionally taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ is optionally taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is —OR^(d);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl, or heteroarylalkyl.

-   Item 10. The compound according to item 9 represented by general     formula (II) or a salt thereof,

L is NR⁷;

n is 0, 1 or 2;

p is 0;

R¹ is C₁-C₈ alkyl, aryl or heteroaryl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, aryl, halo, heterocyclylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R⁷ is hydrogen; and

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, heterocyclyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e);

Y is O;

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, aryl or heteroaryl.

-   Item 11. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d);

R⁹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl or pyridyl.

-   Item 12. The compound according to item 10 represented by general     formula (II) or a salt thereof,

wherein:

R¹ is C₁-C₈ alkyl, phenyl or benzodioxolyl;

each R² and R³ is independently hydrogen, C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

each R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, haloalkyl, haloalkoxy, —CN, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —OR^(d) or —C(Y)R^(e); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, tetrahydropyranyl, phenyl, or pyridyl.

-   Item 13. The compound according to Item 12 represented by general     formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d), each of which is optionally substituted with 1-3 R¹¹;

R³ is hydrogen;

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′); and

R¹¹ is C₁-C₈ alkyl, morpholinyl, tetrahydropyranyl, halo, —CN, —OR^(d) or —C(Y)R^(e);

-   Item 14. The compound according to item 11 or 13 represented by     general formula (II) or a salt thereof, wherein:

R² is C₁-C₈ alkyl, phenyl, halo, morholinylalkyl, —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′) or —OR^(d);

R³ is hydrogen; and

R⁹ is halo, haloalkoxy, —CN, —C(O)OR^(a) or —C(Y)NR^(b)R^(b′).

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁷. In some embodiments, R⁷ is H.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁹. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the ortho position. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the meta position. In some embodiments, R⁹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R⁹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R¹ is:

In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro or each R⁹ is chloro). In some embodiments, one R⁹ is fluoro and the other is chloro. In some embodiments, one R⁹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, 2 R⁹ are taken together with the atoms to which they are attached to form a heterocyclyl ring, e.g., a 5-membered heterocyclyl ring (e.g., a dioxole ring). In some embodiments, the dioxole ring is unsubstituted. In some embodiments, the dioxole ring is substituted. In some embodiments, the dioxole ring is substituted with two fluoro substituents. In some embodiments, R¹ is selected from:

In some embodiments, R¹ is aralkyl (e.g., benzyl). In some embodiments, R¹ is aralkyl substituted with 2 R⁹ (e.g., benzyl substituted with 2 R⁹). In some embodiments, 2 R⁹ substituents are on the phenyl ring. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is chloro).

In some embodiments, R¹ is alkyl (e.g., methyl).

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is C₁-C₈ alkyl substituted with 1 R¹¹ (e.g., methyl substituted with 1 R¹¹). In some embodiments, R¹¹ is heterocyclyl (e.g., morpholino).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is phenyl substituted with 1 R¹¹. In some embodiments, R¹¹ is —CN. In some embodiments, R¹¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹¹ is halo.

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is —NR^(c)C(Y)R^(c′). In some embodiments, R^(c) is hydrogen. In some embodiments, Y is O. In some embodiments, R^(c′) is alkyl (e.g., methyl). In some embodiments, R^(c′) is aryl (e.g., phenyl). In some embodiments, R^(c′) is phenyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heteroaryl. In some embodiments, R^(c′) is furanyl. In some embodiments, R^(c′) is pyridyl. In some embodiments, R^(c′) is pyridyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is cyclyl (e.g., cyclohexyl). In some embodiments, R^(c′) is cyclohexyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heterocyclyl (e.g., tetrahydropyranyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R² is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, R^(d) is ethyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is —OCH₂CH₂OCH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, n is 2.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is halo (e.g., chloro).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, X¹ and X⁴ are N and X², X³ and X⁵ are CH.

In some embodiments, X¹ and X³ are N and X², X⁴ and X⁵ are CH.

In some embodiments, X² and X³ are N and X¹, X⁴ and X⁵ are CH.

In some embodiments, X² and X⁴ are N and X¹, X³ and X⁵ are CH.

In some embodiments, the compound is:

wherein s is 0, 1, 2, 3 or 4.

In some embodiments, R⁹ is —C(O)NH₂, C₁-C₄ alkoxy, or substituted C₁-C₄ alkoxy. In some embodiments, R⁹ is halo.

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

Compounds of Formula (III)

The following aspects and embodiments relate to compounds of formula (III).

-   Item 15. The compound according to item 1 represented by general     formula (III) or a salt thereof,

wherein:

A is CH or N;

L is O, a direct bond or NH;

one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH;

m is 1, 2 or 3;

n is 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, heteroaryl, heteroarylalkyl, arylalkyl, —C(Y)R^(e), cyclyl, cyclylalkyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

each R⁷, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷ or two R⁹ are optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, arylalkyl, heteroarylalkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thioxo, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, haloalkyl, halo, heterocyclyl, cyclyl, oxo or —C(Y)NR^(b)R^(b′);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, haloalkyl, alkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, heteroaryl, cyclylalkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl.

-   Item 16. The compound according to item 15 represented by general     formula (III) or a salt thereof,

wherein:

m is 1;

n is 1;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, heteroaryl, heterocyclyl, arylalkyl, cyclylalkyl, heteroarylalkyl, alkoxyalkyl, hydroxyalkyl or —C(O)R^(e), each of which is optionally substituted with 1-3 R⁷;

R² is aryl, heteroaryl or benzofuryl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, aryl, heteroaryl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e) each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or heterocyclyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, cyclyl, heterocyclyl, arylalkyl, alkoxyalkyl, heterocyclylalkyl, heteroarylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 17. The compound according to Item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzoisoxazolyl, each of which is optionally substituted with 1-5 R⁹;

each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 18. The compound according to item 16 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d);

R⁶ is hydrogen or C₁-C₈ alkyl;

each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;

R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³;

R¹³ is independently C₁-C₈ alkyl, halo or pyrrolidinyl; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 19. The compound according to item 18 represented by general     formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²;

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 20. The compound according to item 17 or 19 represented by     general formula (III) or a salt thereof,

wherein:

A is N;

R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d);

R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d);

R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d);

R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, dihydrobenzoxazinylalkyl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.

-   Item 21. The compound according to item 20 represented by general     formula (III) or a salt thereof,

wherein:

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷;

R² is phenyl, which is optionally substituted with 1-5 R⁹; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, alkylaminoalkyl or phenyl.

In some embodiments, R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ and R⁶ may be taken together with the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁶. In some embodiments, R⁶ is hydrogen.

In some embodiments, R¹ is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, isobutyl or tert-butyl), or C₅ alkyl (e.g., pentan-3-yl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 1-3 R⁷ (e.g., C₁-C₈ alkyl substituted with 1 R⁷). In some embodiments, R¹ is methyl substituted with 1 R⁷. In some embodiments, R⁷ is cyclyl (e.g., cyclopropyl). In some embodiments, R⁷ is aryl (e.g., phenyl).

In some embodiments, R¹ is ethyl substituted with 1 R⁷. In some embodiments, R⁷ is aryl (e.g., phenyl). In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl).

In some embodiments, R¹ is n-propyl substituted with 1 R⁷. In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., C₃ alkyl, e.g., n-propyl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 3 R⁷. In some embodiments, R¹ is ethyl substituted with 3 R⁷. In some embodiments, each R⁷ is independently halo (e.g., each R⁷ is fluoro). In some embodiments, R¹ is 2,2,2-trifluoroethyl.

In some embodiments, R¹ is C₂-C₈ alkenyl, e.g., C₃ alkenyl (e.g., —CH₂—CH═CH₂).

In some embodiments, R¹ is C₂-C₈ alkynyl, e.g., C₃ alkynyl (e.g. —CH₂—C≡CH).

In some embodiments, R¹ is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). In some embodiments, the cyclyl group is a bicyclic group (e.g., indanyl).

In some embodiments, R¹ is heterocyclyl (e.g., piperidyl). In some embodiments, R¹ is piperidyl substituted with 1 R⁷. In some embodiments, R⁷ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁷ is —OR^(d).

In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heterocyclyl ring (e.g. a pyrrolidine ring).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heteroaryl ring (e.g., an imidazole ring).

In some embodiments, L is O.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl. In some embodiments, R² is phenyl substituted with 1-3 R⁹. In some embodiments, R² is phenyl substituted with 1 R⁹.

In some embodiments. R² is:

In some embodiments, R⁹ is halo (e.g., fluoro or chloro). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —NO₂. In some embodiments, R⁹ is haloalkoxy (e.g., trifluoroethoxy). In some embodiments, R⁹ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R⁹ is —OR^(d). In some embodiments, R⁹ is —OCH₂CH₂OCH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂OCH₃. In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is ethyl.

In some embodiments, R⁹ is hydroxyalkyl (e.g., —CH₂OH). In some embodiments, R⁹ is alkoxyalkyl (e.g., —CH₂—O—CH₃). In some embodiments, R⁹ is —C(O)R^(e). In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁹ is —S(O)_(q)R^(f). In some embodiments, q is 1. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl.).

In some embodiments, R² is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro). In some embodiments, each R⁹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, R² is heteroaryl. In some embodiments, R² is a 6-membered heteroaryl. In some embodiments, R² is a 6-membered nitrogen-containing heteroaryl, e.g., pyridyl. In some embodiments, R² is unsubstituted pyridyl.

In some embodiments, R² is pyridyl substituted with 1 R⁹. In some embodiments, R⁹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is a 5-membered heteroaryl. In some embodiments, R² is a 5-membered nitrogen-containing heteroaryl (e.g., pyrrolyl or oxazolyl).

In some embodiments, m is 0.

In some embodiments, m is 1.

In some embodiments, R⁴ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is halo. In some embodiments, R⁴ is methoxy. In some embodiments, R^(d) is C₁-C₈ alkyl.

In some embodiments, the compound has the following structure:

wherein one of X¹ and X² is N and the other is CH.

In some embodiments, X¹ is CH and X² is N. In some embodiments, X¹ is N and X² is CH. In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

wherein R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷.

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments R¹ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl,

or In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

Compounds of Formula (IV)

The following aspects and embodiments relate to compounds of formula (IV), corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,544, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 38. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5- or 6-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring;

when B is phenyl, R² is not

and where in the compound is not:

In some embodiments, when B is phenyl, R² is not a substituted pyridyl. In some embodiments, when B is phenyl and n=1, R² is not a substituted pyridyl.

In some embodiments, when X is N, B is not 4-pyridyl.

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In some embodiments, B is aryl.

-   Item 39. A compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

m is 0, 1, 2, 3, 4 or 5;

E is aryl or a 5-membered heteroaryl;

-   -   when E is aryl, n is 1, 2, 3 or 4; and when E is a 5-membered         heteroaryl, n is 0, 1, 2 or 3;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

p is 0, 1, 2, 3 or 4;

each R¹, R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R^(b);

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶ wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring; and

when B is phenyl, R² is not

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In some embodiments, when B is phenyl, R² is not a substituted pyridyl. In some embodiments, when B is phenyl and n=1, R² is not a substituted pyridyl.

In one aspect, the invention features a compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

-   -   each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈         alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl,         cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy,         aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl,         alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy,         silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′),         —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′),         —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′),         —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or         —S(O)_(q)R^(f), each of which may be optionally substituted with         1-3 R⁶; wherein two R¹, together with the carbons to which they         are attached, may form an optionally substituted cyclyl,         heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(c) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶ wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when B is phenyl, two R¹ are not taken together to form a pyrazole ring.

In some embodiments, each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy and silylalkoxyalkyl, each of which may be optionally substituted with 1-3 R⁶.

In one aspect, the invention features a compound of formula (IV):

wherein:

A is CH, CR⁴ or N;

B is aryl or a 5-membered heteroaryl;

E is aryl or a 5-membered heteroaryl;

L is NR⁵ or O;

one of X and Z is N and the other is CH;

m is 0, 1, 2, 3, 4 or 5;

n is 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

each R¹ and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the atoms to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, or aryl ring;

each R² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶; wherein two R¹, together with the carbons to which they are attached, may form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

R⁴ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁶;

R⁵ is hydrogen; or when m is not 0, R⁵ and 1 R¹ may be taken together with the atoms to which they are attached to form an optionally substituted heteroaryl or heterocyclyl ring;

each R⁶ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally substituted with 1-3 R⁷;

each R⁷ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

Y is O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally further substituted with 1-3 R⁶, wherein R^(b) and R^(b′), together with the atoms to which they are attached, may form an optionally substituted cyclyl or heterocyclyl ring.

In some embodiments, A is N. In some embodiments, A is CH. In some embodiments, A is CR⁴.

In some embodiments, B is aryl (e.g., phenyl).

In some embodiments, m is 0.

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.

In some embodiments, R¹ is in the ortho position. In some embodiments, R¹ is in the meta position. In some embodiments, R¹ is in the para position.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl or tert-butyl). In some embodiments, R¹ is heteroaryl (e.g., oxazolyl, oxadiazolyl or quinazolinyl).

In some embodiments, R¹ is heteroaryl substituted with 1-3 R⁶ (e.g., 1 R⁶).

In some embodiments, R¹ is oxadiazolyl substituted with 1 R⁶. some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is heteroaryl substituted with 2 R⁶. In some embodiments, R¹ is quinazolinyl substituted with 2 R⁶. In some embodiments, one R⁶ is halo (e.g., bromo) and the other is heteroaryl (e.g., pyridyl).

In some embodiments, m is 1 and R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 2 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, m is 3 and each R¹ is halo (e.g., fluoro, chloro or bromo). In some embodiments, R¹ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R¹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, R¹ is haloalkoxy substituted with 1 R⁶. In some embodiments, R¹ is —O—CF₂—R⁶. In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O, R^(b) is hydrogen and R^(b′) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹ is —O—CF₂—CH₂—R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino).

In some embodiments, R¹ is aminoalkyl. In some embodiments, R¹ is —CH₂NH₂. In some embodiments, R¹ is alkylaminoalkyl. In some embodiments, R¹ is —CH₂NHCH₂CH₂CH₃. In some embodiments, R¹ is dialkylaminoalkyl. In some embodiments, R¹ is —CH₂N(CH(CH₃)₂)₂.

In some embodiments, R¹ is hydroxyalkyl. In some embodiments, R¹ is —CH₂OH.

In some embodiments, R¹ is —CN.

In some embodiments, R¹ is —NO₂.

In some embodiments, R¹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —NR^(c)C(Y)R^(c′). In some embodiments, one of R^(c) and R^(c′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R¹ is —SO₂NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, R¹ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl (e.g., pyrrolidinyl, piperidinyl or morpholino).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is S. In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) is hydrogen. In some embodiments, R^(b) is hydrogen and R^(b′) is aralkyl. In some embodiments, R^(b) is hydrogen and R^(b′) is optionally substituted benzyl. In some embodiments, R^(b′) is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, sec-butyl or tert-butyl), C₅ alkyl (e.g., n-pentyl, isopentyl or pentan-3-yl), C₆ alkyl (e.g., n-hexyl or 3,3-dimethylbutan-2-yl), or C₇ alkyl (e.g., n-heptyl or 2-heptyl).

In some embodiments, R^(b′) is C₁-C₈ alkyl substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl). In some embodiments, R^(b′) is C₂-C₈ alkenyl, e.g., C₃ alkenyl (e.g., —CH₂—CH═CH₂). In some embodiments, R^(b′) is C₂-C₈ alkynyl, e.g., C₃ alkenyl (e.g., —CH₂—C≡CH).

In some embodiments, R^(b′) is aryl (e.g., phenyl). In some embodiments, R^(b′) is aryl substituted with 1 R⁶ (e.g., phenyl substituted with 1 R⁶). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b′) is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl). In some embodiments, R^(b′) is cyclyl substituted with 1 R⁶ (e.g., cyclopropyl substituted with 1 R⁶ or cyclopentyl substituted with 1 R⁶). In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is aralkyl (e.g., benzyl).

In some embodiments, R^(b′) is cyclohexyl substituted with 1 R⁶. In some embodiments, R⁶ is —C(O)OR^(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(b′) is bicyclyl (e.g., indanyl). In some embodiments, R^(b′) is heterocyclyl, e.g., a 6-membered heterocyclyl. In some embodiments, R^(b′) is a 6-membered oxygen-containing heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, R^(b′) is a 6-membered nitrogen-containing heterocyclyl (e.g., piperidinyl).

In some embodiments, R^(b′) is heterocyclyl substituted with 1 R⁶ (e.g., piperidinyl substituted with 1 R⁶). In some embodiments, R⁶ is —C(O)OR^(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl). In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R^(b′) is aralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the aryl is phenyl. In some embodiments, R^(b′) is benzyl. In some embodiments, R^(b′) is phenylethyl. In some embodiments, the aryl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is halo (e.g., fluoro or chloro). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the aryl is substituted with 2 R⁶. In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl). In some embodiments, each R⁶ is independently halo (e.g., each R⁶ is fluoro).

In some embodiments, R^(b′) is heteroaralkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂ or C₃ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the heteroaryl is pyridyl. In some embodiments, the heteroaryl is furanyl. In some embodiments, the heteroaryl is thiazolyl. In some embodiments, the heteroaryl is thienyl. In some embodiments, the heteroaryl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R^(b′) is cyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the cyclyl group is cyclopropyl. In some embodiments, the cyclyl group is cyclopentyl. In some embodiments, the cyclyl group is a bicyclic group. In some embodiments, the bicyclic group is indanyl. In some embodiments, R^(b′) is cyclylalkyl substituted with 1 R⁶. In some embodiments, R⁶ is aryl (e.g., phenyl).

In some embodiments, R^(b′) is heterocyclylalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁ alkyl). In some embodiments, the heterocyclyl group is tetrahydropyranyl.

In some embodiments, R^(b′) is haloalkyl (e.g., fluoroethyl, difluoroethyl, trifluoroethyl or trifluoropropyl).

In some embodiments, R^(b′) is alkoxyalkyl. In some embodiments, the alkyl is a C₁-C₈ alkyl (e.g., C₁, C₂, C₃ or C₄ alkyl). In some embodiments, the alkyl is a straight-chain alkyl. In some embodiments, the alkyl is a branched alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, both ethyl or both isopropyl).

In some embodiments, R¹ and R⁵, together with the atoms to which they are attached, form a heteroaryl ring (e.g., a substituted heteroaryl ring). In some embodiments, R¹ and R⁵, together with the atoms to which they are attached, form a heterocyclyl ring (e.g., a substituted heterocyclyl ring).

In some embodiments, R¹, R⁵, B and L are taken together to form a bicyclic heteroaryl or heterocyclic ring.

In some embodiments, R¹, R⁵, B and L are taken together to form

In some embodiments, R⁶ is halo. In some embodiments, R⁶ is at the 6, 7, or 8 position.

In some embodiments, R¹, R⁵, B and L are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently C₁-C₈ alkyl (e.g., each R¹ is methyl). In some embodiments, each R¹ is independently halo (e.g., each R¹ is fluoro or each R¹ is chloro). In some embodiments, one R¹ is fluoro and the other is chloro. In some embodiments, one R¹ is chloro and the other is bromo.

In some embodiments, each R¹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R¹ is halo (e.g., fluoro) and the other is heterocyclylalkyl (e.g., —CH₂-heterocyclyl). In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the piperazinyl is substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is haloalkyl (e.g., trifluoromethyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is halo (e.g., fluoro or chloro) and the other is —CN.

In some embodiments, one R¹ is halo (e.g., chloro) and the other is —NO₂.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —NO₂. In some embodiments, R^(a) is hydrogen.

In some embodiments, one R¹ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, each R^(a) and R^(d) is hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is haloalkoxy (e.g., trifluoromethoxy). In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —S(O)_(q)R^(f). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —C(Y)NR^(b)R^(b′) and the other is —CN. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, one R¹ is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is haloalkyl (e.g., trifluoromethyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is —OR^(d) and the other is —NR^(c)C(O)R^(c′). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(c) is hydrogen and R^(c′) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R¹ is haloalkyl (e.g., trifluoromethyl) and the other is —CN.

In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a substituted cyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring (e.g., a substituted heterocyclyl ring). In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a heteroaryl ring (e.g., a substituted heteroaryl ring).

In some embodiments, two R¹ and ring B are taken together to form a group selected from:

In some embodiments, R² is aryl.

In some embodiments, each R¹ is independently halo (e.g., all three R¹ are fluoro or all three R¹ are chloro).

In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, two R¹ are independently halo (e.g., both are chloro) and the other is heteroaryl (e.g., pyrrolyl). In some embodiments, two R¹ are independently halo (e.g., both are fluoro) and the other is —C(Y)NR^(b)R^(b′) (e.g., —C(O)NH₂). In some embodiments, two R¹ are independently C₁-C₈ alkyl (e.g., both are methyl) and the other is halo (e.g., chloro or bromo).

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring.

In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form a heterocyclyl ring. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, three R¹ and ring B are taken together to form a group selected from:

In some embodiments, B is a 6-membered heteroaryl.

In some embodiments, B is pyridyl. In some embodiments, B is 3-pyridyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, m is 3. In some embodiments, one R¹ is —OR^(d), and two R¹, together with the atoms to which they are attached, are taken together to form an aryl ring (e.g., a phenyl ring). In some embodiments, R^(d) is hydrogen.

In some embodiments, B is pyrazolyl. In some embodiments, m is 2. In some embodiments, two R¹, together with the atoms to which they are attached, are taken together to form a cyclyl ring (e.g., a cyclohexyl ring).

In some embodiments, B is selected from:

In some embodiments, B is a 5-membered heteroaryl (e.g., pyrazolyl).

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is selected from:

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is aryl (e.g., phenyl). In some embodiments, the aryl is phenyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., chloro). In some embodiments, R¹ is:

In some embodiments, B is thienyl. In some embodiments, B is selected from:

In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments m is 2 and two R¹, together with the atoms to which they are attached, form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring

In some embodiments, R¹ is —C(O)OR_(a). In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., ethyl).

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, m is 2.

In some embodiments, one R¹ is C₁-C₈ alkyl (e.g., methyl) and the other is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen.

In some embodiments, B is thiazolyl.

In some embodiments, m is 1.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, m is 2.

In some embodiments, two R¹, together with the atoms to which they are attached, form an aryl ring. In some embodiments, the aryl ring is substituted with —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, B is:

In some embodiments, B is:

In some embodiments, E is aryl (e.g., phenyl).

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is C₁-C₈ alkyl substituted with 1-3 R⁶. In some embodiments, R² is C₁ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl, or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl). In some embodiments, R^(d) is heterocyclylalkyl (e.g., —CH₂— tetrahydropyranyl).

In some embodiments, R² is C₂ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(b) is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, R^(e) is:

In some embodiments, R² is C₃ alkyl substituted with 1 R⁶.

In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is —NR^(c)C(Y)R^(c′). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl).

In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy).

In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is C₂-C₈ alkynyl. In some embodiments, R² is C₂-C₈ alkynyl substituted with 1 R⁶ (e.g., C₃ alkynyl substituted with 1 R⁶). In some embodiments, R² is —C≡C—CH₂—R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R⁶ is silyloxy (e.g., tert-butyldimethylsilyloxy). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or thiomorpholino). In some embodiments, R⁶ is thiomorpholino substituted with 2 R⁷. In some embodiments, each R⁷ is oxo. In some embodiments, R⁶ is:

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl.

In some embodiments, R² is phenyl substituted with 1 R⁶.

In some embodiments, R⁶ is heterocyclylalkyl (e.g., —CH₂-morpholino). In some embodiments, R⁶ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R⁶ is —CN. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, R² is phenyl substituted with 2 R⁶.

In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is halo (e.g., fluoro) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one R⁶ is —C(O)OR^(a) and the other is —OR^(d). In some embodiments, R^(a) and R^(d) are each independently C₁-C₈ alkyl (e.g., R^(a) and R^(d) are both methyl).

In some embodiments, R² is heteroaryl.

In some embodiments, R² is isoxazolyl. In some embodiments, R² is isoxazolyl substituted with 2 R⁶. In some embodiments, each R⁶ is independently C₁-C₈ alkyl (e.g., R⁶ is methyl).

In some embodiments, R² is pyrazolyl. In some embodiments, R² is pyrazolyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyridyl. In some embodiments, R² is unsubstituted pyridyl. In some embodiments, R² is pyridyl substituted with 1 R⁶. In some embodiments, R⁶ is halo (e.g., fluoro). In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁶ is heterocyclyl (e.g., morpholino or piperazinyl). In some embodiments, R⁶ is piperazinyl substituted with 1 R⁷. In some embodiments, R⁷ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is pyrimidinyl.

In some embodiments, R² is pyridazinyl.

In some embodiments, R² is cyclyl (e.g., cyclopropyl).

In some embodiments, R² is heterocyclyl (e.g., morpholino or pyrrolidinyl). In some embodiments, R² is aralkyl (e.g., benzyl).

In some embodiments, R² is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is piperazinyl. In some embodiments, the heterocyclyl is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is thiomorpholino. In some embodiments, the heterocyclyl is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, the heterocyclyl is:

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo). In some embodiments, R² is haloalkyl (e.g., trifluoromethyl).

In some embodiments, R² is haloalkoxy (e.g., trifluoromethoxy).

In some embodiments, R² is —CN.

In some embodiments, R² is —NO₂.

In some embodiments, R² is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R^(a) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, the C₁-C₈ alkyl is ethyl substituted with 2 R⁶. In some embodiments, each R⁶ is independently —OR^(d). In some embodiments, each R^(d) is C₁-C₈ alkyl (e.g., each R^(d) is methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl (e.g., —CH₂—CH₂-morpholino). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is haloalkyl (e.g., trifluoroethyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclyl (e.g., tetrahydropyranyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is pyrrolidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is hydroxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is tetrahydropyranyl.

In some embodiments, R² is —OR^(d).

In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is methyl substituted with 1 R⁶. In some embodiments, R⁶ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁶ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl or R^(b) and R^(b′) are both ethyl). In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, R^(d) is ethyl. In some embodiments, R^(d) is C₃ alkyl (e.g., isopropyl or n-propyl). In some embodiments, R^(d) is optionally substituted heteroaralkyl. In some embodiments, R^(d) is optionally substituted pyrindinalkyl.

In some embodiments, R^(d) is n-propyl substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(c)C(Y)R^(c). In some embodiments, Y is O. In some embodiments, R^(c) and R^(c′) are each independently C₁-C₈ alkyl (e.g., R^(c) and R^(c′) are both methyl). In some embodiments, R^(d) is cyclyl (e.g., cyclopentyl).

In some embodiments, R^(d) is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, the pyridyl is substituted with 1 R⁶. In some embodiments, R⁶ is alkyl (e.g., methyl) or haloalkyl (e.g., CF₃). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(d) is heterocyclylalkyl. In some embodiments, the alkyl is C₁ alkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkyl is C₄ alkyl. In some embodiments, the heterocyclyl is morpholino. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is tetrahydrofuranyl. In some embodiments, R^(d) is cyclylalkyl (e.g., —CH₂-cyclobutyl).

In some embodiments, R^(d) is alkoxyalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the alkoxy is methoxy.

In some embodiments, R^(d) is dialkylaminoalkyl. In some embodiments, the alkyl is C₂ alkyl. In some embodiments, the alkyl is C₃ alkyl. In some embodiments, the dialkylamino is dimethylamino.

In some embodiments, R² is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl. In some embodiments, R^(e) is piperidinyl. In some embodiments, R^(e) is pyrrolidinyl. In some embodiments, R^(e) is piperazinyl. In some embodiments, R^(e) is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(e) is morpholino. In some embodiments, R^(e) is thiomorpholino. In some embodiments, R^(e) is thiomorpholino substituted with 2 R⁶. In some embodiments, each R⁶ is oxo. In some embodiments, R^(e) is:

In some embodiments, n is 2.

In some embodiments, each R² is independently halo (e.g., each R² is chloro).

In some embodiments, each R² is independently —OR^(d).

In some embodiments, each R^(d) is C₁-C₈ alkyl.

In some embodiments, each R² is methoxy. In some embodiments, one R² is methoxy and the other is ethoxy. In some embodiments, one R² is methoxy and the other is propoxy. In some embodiments, one R² is methoxy and the other is isopropoxy.

In some embodiments, one R² is methoxy and the other is ethoxy substituted with 1 R⁶. In some embodiments, R⁶ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is methoxy and the other is propoxy substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —CN. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(O)OR^(a). In some embodiments, R^(d) and R^(a) are both hydrogen.

In some embodiments, one R² is —OR^(d) and the other is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is —OR^(d) and the other is —C(Y)R^(e). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, Y is O. In some embodiments, R^(e) is heterocyclyl (e.g., morpholino).

In some embodiments, one R² is halo (e.g., chloro or bromo) and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is —CN.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heteroaryl (e.g., pyridyl). In some embodiments, the pyridyl is substituted with 1 R⁶. In some embodiments, R⁶ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is heterocyclylalkyl (e.g., —CH₂-morpholino).

In some embodiments, p is 0.

In some embodiments, p is 1.

In some embodiments, R³ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R³ is halo (e.g., chloro). In some embodiments, R³ is haloalkyl (e.g., trifluoromethyl). In some embodiments, R³ is oxo.

In some embodiments, R³ is —OR^(d). In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R³ is heterocyclyl (e.g., piperazinyl). In some embodiments, R³ is piperazinyl substituted with 1 R⁶. In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, E is a 5-membered heteroaryl ring.

In some embodiments, E is a thiophene ring.

In some embodiments, E is a pyrrole ring.

In some embodiments, n is 1. In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, E is an N-methylpyrrole ring.

In some embodiments, L is NR⁵. In some embodiments, R⁵ is hydrogen.

In some embodiments, L is O.

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments, the compound is:

In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, R¹ is —C(Y)NR^(b)R^(b′).

In some embodiments, L and

In some embodiments, L and

In some embodiments, L is NH, and

is selected from

In some embodiments R⁶ is halo. In some embodiments, R^(b) or R^(b′) are disubstituted with R⁶ (e.g., dichloro, 4-fluoro, 3-chloro, or difluoro).

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

In some embodiments, the compound is:

In some embodiments, R¹ is —C(Y)NR^(b)R^(b′). In some embodiments, R¹ is halo. In some embodiments, R² is C₁-C₄ alkoxy. In some embodiments, R² is halo. In some embodiments, m is 2 and two R¹ are 3,4-dichloro; 3,4-difluoro, 3,5-dichloro; 3,5-difluoro; 3-chloro,4-fluoro; or 3-chloro,5-fluoro. In some embodiments, R² is —C(O)NR^(b)R^(b′) and R³ is H. In some embodiments, R^(b) and R^(b′) are H. In some embodiments, R^(b) and R^(b′) are independently C₁-C₄ alkyl or halo-substituted C₁-C₄ alkyl. In some embodiments, R^(b) is methyl and R^(b′) is trifluoroethyl. In some embodiments, R¹ is C₁-C₄ alkoxy or halo-substituted C₁-C₄ alkoxy. In some embodiments, n and p are zero.

Compounds of Formula (V)

The following aspects and embodiments relate to compounds of formula (V), corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,550, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 40. A compound of formula (V):

wherein:

L is CR⁴R⁵, 0, C(O), NR⁶C(O), or NR⁷;

A is CR⁸, CH or N;

each X¹, X², X³, X⁴ and X⁵ is independently CH or N, provided that at least two of X¹, X², X³, X⁴ and X⁵ are N;

-   -   n is 0, 1, 2, 3 or 4;

p is 0, 1, 2 or 3;

R¹ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl or heterocyclylalkyl, each of which may be optionally substituted with 1-5 R⁹; wherein R¹ or R⁹ may optionally be taken together with one of R⁴, R⁵, R⁶ or R⁷, and the atoms to which they are attached, to form a cyclyl, heterocyclyl, aryl or heteroaryl ring that is optionally substituted with 1-3 R¹⁰;

each R² and R³ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f); each of which is optionally substituted with 1-3 R¹¹;

each R⁴, R⁵, R⁶ and R⁷ is independently H, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each R⁸, R⁹, R¹⁰ and R¹¹ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which may be optionally further substituted; wherein two R⁸, two R⁹, two R¹⁰ or two R¹¹ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁸,

or a pharmaceutically acceptable derivative or prodrug thereof.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁷. In some embodiments, R⁷ is H.

In some embodiments, R¹ is aryl (e.g., phenyl).

In some embodiments, R¹ is phenyl substituted with 1 R⁹. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the ortho position. In some embodiments, R¹ is phenyl substituted with 1 R⁹ in the meta position. In some embodiments, R⁹ is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —C(O)OR^(a). In some embodiments, R^(a) is hydrogen. In some embodiments, R⁹ is —C(Y)NR^(b)R^(b′). In some embodiments, Y is O. In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R¹ is:

In some embodiments, one of R^(b) and R^(b′) is hydrogen and the other is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro or each R⁹ is chloro). In some embodiments, one R⁹ is fluoro and the other is chloro. In some embodiments, one R⁹ is halo (e.g., chloro) and the other is haloalkoxy (e.g., difluoromethoxy or trifluoromethoxy).

In some embodiments, 2 R⁹ are taken together with the atoms to which they are attached to form a heterocyclyl ring, e.g., a 5-membered heterocyclyl ring (e.g., a dioxole ring). In some embodiments, the dioxole ring is unsubstituted. In some embodiments, the dioxole ring is substituted. In some embodiments, the dioxole ring is substituted with two fluoro substituents. In some embodiments, R¹ is selected from:

In some embodiments, R¹ is aralkyl (e.g., benzyl). In some embodiments, R¹ is aralkyl substituted with 2 R⁹ (e.g., benzyl substituted with 2 R⁹). In some embodiments, 2 R⁹ substituents are on the phenyl ring. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is chloro).

In some embodiments, R¹ is alkyl (e.g., methyl).

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, R² is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is C₁-C₈ alkyl substituted with 1 R¹¹ (e.g., methyl substituted with 1 R¹¹). In some embodiments, R¹¹ is heterocyclyl (e.g., morpholino).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is phenyl substituted with 1 R¹¹. In some embodiments, R¹¹ is —CN. In some embodiments, R¹¹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R¹¹ is halo.

In some embodiments, R² is halo (e.g., fluoro, chloro, bromo or iodo).

In some embodiments, R² is —NR^(c)C(Y)R^(c′). In some embodiments, R^(c) is hydrogen. In some embodiments, Y is O. In some embodiments, R^(c′) is alkyl (e.g., methyl). In some embodiments, R^(c′) is aryl (e.g., phenyl). In some embodiments, R^(c′) is phenyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heteroaryl. In some embodiments, R^(c′) is furanyl. In some embodiments, R^(c′) is pyridyl. In some embodiments, R^(c′) is pyridyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is cyclyl (e.g., cyclohexyl). In some embodiments, R^(c′) is cyclohexyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R^(c′) is heterocyclyl (e.g., tetrahydropyranyl).

In some embodiments, R² is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are both hydrogen. In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R² is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl or ethyl). In some embodiments, R^(d) is ethyl substituted with 1 R⁸. In some embodiments, R⁸ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is —OCH₂CH₂OCH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R² is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, n is 2.

In some embodiments, one R² is C₁-C₈ alkyl (e.g., methyl) and the other is halo (e.g., chloro).

In some embodiments, one R² is —OR^(d) and the other is halo (e.g., chloro). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, X¹ and X⁴ are N and X², X³ and X⁵ are CH.

In some embodiments, X¹ and X³ are N and X², X⁴ and X⁵ are CH.

In some embodiments, X² and X³ are N and X¹, X⁴ and X⁵ are CH.

In some embodiments, X² and X⁴ are N and X¹, X³ and X⁵ are CH.

In some embodiments, the compound is:

wherein s is 0, 1, 2, 3 or 4.

In some embodiments, R⁹ is —C(O)NH₂, C₁-C₄ alkoxy, or substituted C₁-C₄ alkoxy. In some embodiments, R⁹ is halo.

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃).

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, R₁ is heteroaralkyl (e.g., —CH₂-pyridyl). In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

In some embodiments, the compound is:

wherein t is 1-3.

In some embodiments, R₁ is selected from methyl, cyclohexyl, t-butyl, and pyridinyl. In some embodiments, LR¹ is NH(CH₃). In some embodiments, R¹¹ is independently halo, nitrile, C₁-C₄ alkoxy, —C(O)NH₂, hydroxy, or C₁-C₄ hydroxyalkyl. In some embodiments, R¹¹ is fluoro. In some embodiments, R¹¹ is methoxy, ethoxy, or methoxyethoxy ether. In some embodiments, R¹¹ is —OCH₂CH₂OCH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R¹¹ is —OCH₂CH₂OCH₂CH₂OCH₃.

Compounds of Formula (VI)

The following aspects and embodiments relate to compounds of formula (VI) corresponding to formula (I) of U.S. Provisional Patent Application No. 61/291,554, entitled “Therapeutic Compounds and Related Methods of Use” filed on Dec. 31, 2009, and incorporated herein by reference in its entirety.

-   Item 41. A compound of formula (VI):

wherein:

A is CR⁵, CH or N;

L is O or NR⁶;

1, 2 or 3 of X¹, X², X³, X⁴ and X⁵ are N and the others are CH;

m is 0, 1, 2 or 3;

n is 0, 1, 2, 3 or 4;

R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ or R⁷ may be taken together with R⁶ and the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸;

R² is aryl or heteroaryl, each of which is optionally substituted with 1-5 R⁹;

each R³, R⁴ and R⁵ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′),—SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹⁰;

R⁶ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cyclyl or heterocyclyl, each of which is optionally substituted with 1-3 R¹¹;

each R⁷, R⁸, R⁹ and R¹⁰ is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; wherein two R⁷, two R⁸, two R⁹ or two R¹⁰ may optionally be taken together with the atoms to which they are attached to form an optionally substituted cyclyl, heterocyclyl, aryl or heteroaryl ring;

each R¹¹ and R¹² is independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl, halo, haloalkyl, haloalkoxy, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, silyloxy, silyloxyalkyl, silylalkoxy, silylalkoxyalkyl, oxo, thiono, —CN, —NO₂, —C(O)OR^(a), —C(Y)NR^(b)R^(b′), —NR^(c)C(Y)R^(c′), —NR^(b)R^(b′), —OC(O)NR^(b)R^(b′), —NR^(c)C(O)OR^(c′), —SO₂NR^(b)R^(b′), —NR^(c)SO₂R^(c′), —NR^(c)C(Y)NR^(b)R^(b′), —OR^(d), —SR^(d′), —C(Y)R^(e) or —S(O)_(q)R^(f);

each Y is independently O or S;

q is 1 or 2; and

each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e), R^(e′) and R^(f) is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, acyl, cyclyl, heterocyclyl, aryl, heteroaryl, cyclylalkyl, heterocyclylalkyl, aralkyl and heteroaralkyl, each of which may be optionally substituted with 1-3 R⁷;

or a pharmaceutically acceptable derivative or prodrug thereof,

wherein when R¹ is cyclopropyl, R⁹ is not:

In some embodiments, R⁹ is not:

In some embodiments, R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷; or when L is NR⁶, R¹ and R⁶ may be taken together with the atoms to which they are attached to form a heterocyclyl or heteroaryl ring that is optionally substituted with 1-3 R⁸.

In some embodiments, A is CH. In some embodiments, A is N.

In some embodiments, L is NR⁶. In some embodiments, R⁶ is hydrogen.

In some embodiments, R¹ is C₁-C₈ alkyl, e.g., methyl, ethyl, C₃ alkyl (e.g., n-propyl or isopropyl), C₄ alkyl (e.g., n-butyl, isobutyl or tert-butyl), or C₅ alkyl (e.g., pentan-3-yl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 1-3 R⁷ (e.g., C₁-C₈ alkyl substituted with 1 R⁷). In some embodiments, R¹ is methyl substituted with 1 R⁷. In some embodiments, R⁷ is cyclyl (e.g., cyclopropyl). In some embodiments, R⁷ is aryl (e.g., phenyl).

In some embodiments, R¹ is ethyl substituted with 1 R⁷. In some embodiments, R⁷ is aryl (e.g., phenyl). In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is aryl (e.g., phenyl).

In some embodiments, R¹ is n-propyl substituted with 1 R⁷. In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., C₃ alkyl, e.g., n-propyl).

In some embodiments, R¹ is C₁-C₈ alkyl substituted with 3 R⁷. In some embodiments, R¹ is ethyl substituted with 3 R⁷. In some embodiments, each R⁷ is independently halo (e.g., each R⁷ is fluoro). In some embodiments, R¹ is 2,2,2-trifluoroethyl.

In some embodiments, R¹ is C₂-C₈ alkenyl, e.g., C₃ alkenyl (e.g., —CH₂—CH═CH₂).

In some embodiments, R¹ is C₂-C₈ alkynyl, e.g., C₃ alkynyl (e.g. —CH₂—C≡CH).

In some embodiments, R¹ is cyclyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl). In some embodiments, the cyclyl group is a bicyclic group (e.g., indanyl).

In some embodiments, R¹ is heterocyclyl (e.g., piperidyl). In some embodiments, R¹ is piperidyl substituted with 1 R⁷. In some embodiments, R⁷ is —C(Y)R^(e). In some embodiments, Y is O. In some embodiments, R^(e) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁷ is —OR^(d).

In some embodiments, R⁶ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heterocyclyl ring (e.g., a pyrrolidine ring).

In some embodiments, R¹ and R⁶ are taken together with the atoms to which they are attached to form a heteroaryl ring (e.g., an imidazole ring).

In some embodiments, L is O.

In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is aryl (e.g., phenyl). In some embodiments, R² is unsubstituted phenyl. In some embodiments, R² is phenyl substituted with 1-3 R⁹. In some embodiments, R² is phenyl substituted with 1 R⁹.

In some embodiments, R² is:

In some embodiments, R⁹ is halo (e.g., fluoro or chloro). In some embodiments, R⁹ is —CN. In some embodiments, R⁹ is —NO₂. In some embodiments, R⁹ is haloalkoxy (e.g., trifluoroethoxy). In some embodiments, R⁹ is —NR^(b)R^(b′). In some embodiments, R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl).

In some embodiments, R⁹ is —OR^(d). In some embodiments, R⁹ is —OCH₂CH₂OCH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂CH₃. In some embodiments, R⁹ is —OCH₂CH₂OCH₂CH₂OCH₃. In some embodiments, R^(d) is hydrogen. In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R^(d) is methyl substituted with 1 R⁷. In some embodiments, R⁷ is —CYNR^(b)R^(b′). In some embodiments, Y is O and R^(b) and R^(b′) are each independently C₁-C₈ alkyl (e.g., R^(b) and R^(b′) are both methyl). In some embodiments, R^(d) is ethyl. In some embodiments, R^(d) is ethyl substituted with 1 R⁷. In some embodiments, R⁷ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁷ is heterocyclyl (e.g., morpholino).

In some embodiments, R⁹ is hydroxyalkyl (e.g., —CH₂OH). In some embodiments, R⁹ is alkoxyalkyl (e.g., —CH₂—O—CH₃). In some embodiments, R⁹ is —C(O)R^(e). In some embodiments, R^(e) is heterocyclyl (e.g., morpholino). In some embodiments, R⁹ is —S(O)_(q)R^(f). In some embodiments, q is 1. In some embodiments, R^(f) is C₁-C₈ alkyl (e.g., methyl.).

In some embodiments, R² is phenyl substituted with 2 R⁹. In some embodiments, each R⁹ is independently halo (e.g., each R⁹ is fluoro). In some embodiments, each R⁹ is independently —OR^(d). In some embodiments, each R^(d) is independently C₁-C₈ alkyl (e.g., each R^(d) is methyl).

In some embodiments, R² is heteroaryl. In some embodiments, R² is a 6-membered heteroaryl. In some embodiments, R² is a 6-membered nitrogen-containing heteroaryl, e.g., pyridyl. In some embodiments, R² is unsubstituted pyridyl.

In some embodiments, R² is pyridyl substituted with 1 R⁹. In some embodiments, R⁹ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is a 5-membered heteroaryl. In some embodiments, R² is a 5-membered nitrogen-containing heteroaryl (e.g., pyrrolyl or oxazolyl).

In some embodiments, m is 0.

In some embodiments, m is 1.

In some embodiments, R⁴ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is —OR^(d). In some embodiments, R^(d) is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R⁴ is halo. In some embodiments, R⁴ is methoxy. In some embodiments, R^(d) is C₁-C₈ alkyl.

In some embodiments, the compound has the following structure:

wherein one of X¹ and X² is N and the other is CH.

In some embodiments, X¹ is CH and X² is N. In some embodiments, X¹ is N and X² is CH. In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

wherein R¹ is C₁-C₈ alkyl, which is optionally substituted with 1-3 R⁷.

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments, R¹ is C₁-C₈ alkyl (e.g., methyl).

In some embodiments, R² is

In some embodiments, the compound has the following structure:

In some embodiments, R² is aryl. In some embodiments, R² is heteroaryl. In some embodiments R¹ is C₁-C₈ alkyl (e.g., methyl). In some embodiments, R² is

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is 0. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

In some embodiments, the compound has the following structure:

wherein p is 1, 2, 3, 4 or 5.

In some embodiments, L is NR⁶. In some embodiments, L is O. In some embodiments, R¹ is hydrogen or C₁-C₈ alkyl. In some embodiments, R¹ is cyclyl or heterocyclyl. In some embodiments, R¹ is aralkyl or heteroaralkyl. In some embodiments, R¹ is methyl, cyclohexyl, t-butyl, or

In some embodiments, R⁶ is hydrogen or C₁-C₈ alkyl. In some embodiments, R⁹ is C₁-C₈ alkyl, halo, —CN, or —OR^(d). In some embodiments, R³ is hydrogen.

Aspects and Embodiments of Compounds of Formulas (I), (II), (III), (IV), (V), and (VI)

In one aspect, the invention features a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a kit comprising a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a kit comprising a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a dosage form comprising a composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and an acceptable carrier.

In one aspect, the invention features a dosage form comprising a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V), or (VI) and a pharmaceutically acceptable carrier.

In one aspect, the invention features a method of treating a disorder that would benefit by the modulation of STEP (e.g., by activation or inhibition of STEP) in a subject, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In one aspect, the invention features a method of treating a disorder that would benefit by the inhibition of STEP, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In some embodiments, the disorder is selected from schizophrenia, schizoaffective disorder, bipolar disorder, manic-depressive disorder, psychosis, mood and anxiety disorders, mania, drug or substance addiction, cognition disorders, learning disabilities, learning and memory disorders, aging and neurologic disorders associated with or linked with cognitive impairments; mild cognitive impairments (MCI), Alzheimer's disease, Alzheimer-related cognition disorders, Huntington's disease, Parkinson's disease, CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), amnesia, Wernicke-Korsakoff syndrome, Korsakoff syndrome, mild traumatic head injury (MBTI), traumatic head injury (TBI), fragile X syndrome, stroke, attention-deficit and hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), loss of concentration, autism, cerebral palsy, encephalopathy, and narcolepsy. In some embodiments, the disorder affects learning and memory, neurogenesis, neuronal plasticity, pain perception, mood and anxiety, or neuroendocrine regulation. In some embodiments, the disorder is a cognitive deficit disorder. In some embodiments, the disorder involves pain perception or neuroendocrine regulation. In some embodiments, the disorder affects the central nervous system. In some embodiments the disorder is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.

In one aspect, the invention features a method of treating a condition that would benefit by the modulation of STEP (e.g., by activation or inhibition of STEP) in a subject, the method comprising administering to a subject in need thereof a compound of formula (I), (II), (III), (IV), (V), or (VI). In some embodiments, the condition is selected from decreased neurogenesis, cell resilience, or neuronal plasticity due to normal aging, neurodegenerative disorders of the CNS; Alzheimer's disease, Huntington's disease, fragile X syndrome, amyotrophic lateral sclerosis/Lou Gehrig's disease, stroke, Parkinson's disease, parkinsonism, dementia, Pick disease, Corticobasal degeneration, Multiple system atrophy, Progressive supranuclear palsy, traumatic brain injury, head trauma, mild traumatic head injury (MBTI), traumatic head injury (TBI), encephalopathy, intoxication related to ethanol, alcoholism, fetal alcohol syndrome, drug addiction or drug abuse.

In some embodiments, a compound of formula (I), (II), (III), (IV), (V), or (VI) is administered in combination with an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an atypical antipsychotic. In some embodiments, the additional therapeutic agent is selected from the group consisting of aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride. In some embodiments, the additional therapeutic agent is a typical antipsychotic. In some embodiments, the additional therapeutic agent is selected from the group consisting of haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.

DETAILED DESCRIPTION

A compound or composition described herein can be used, e.g., in a method of treating schizophrenia or cognitive deficit. Many of the compounds described herein modulate STEP activity and can be used, e.g., to reduce or inhibit STEP activity, e.g., in a subject.

Definitions

The term “acyl” refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or heteroarylcarbonyl substituent, any of which may be further substituted (e.g., by one or more substituents).

The term “alkenyl” refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms (unless otherwise noted) and having one or more double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl groups. One of the double bond carbons may optionally be the point of attachment of the alkenyl substituent.

The term “alkenylene” refers to a divalent alkenyl, e.g. —CH═CH—, —CH₂—CH═CH—, and —CH═CH—CH₂—.

The term “alkynyl” refers to a straight or branched hydrocarbon chain containing 2-12 carbon atoms (unless otherwise noted) and characterized in having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.

The term “alkynylene” refers to a divalent alkynyl, e.g. —CH≡CH—, —CH₂—CH≡CH—, and —CH≡CH—CH₂—.

The terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined below, having an oxygen radical attached thereto. Representative alkoxy groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. The term “alkoxyalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by an alkoxy group.

An “ether” is two hydrocarbons covalently linked by an oxygen.

The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, and branched-chain alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 12 or fewer carbon atoms in its backbone (unless otherwise noted) e.g., from 1-12, 1-8, 1-6, or 1-4. Exemplary alkyl moieties include methyl, ethyl, propyl (e.g., n-propyl or isopropyl), butyl (e.g., n-butyl, isobutyl or t-butyl), pentyl (e.g., n-pentyl, isopentyl or pentan-3-yl), hexyl and hepty.

The term “alkylene” refers to a divalent alkyl, e.g., —CH₂—, —CH₂CH₂—, and —CH₂CH₂CH₂—.

The term “alkoxylene” refers to an alkylene wherein a CH₂ is substituted with an oxygen. For example, an aryl alkoxylene refers to a group with an alkylene attached to an aryl group through an oxygen, an optionally substituted heteroaryl alkoxylene refers to a group with an alkylene attached to an heteroaryl group through an oxygen.

The term “amino” refers to —NH₂.

The term “aminoalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by an amino group.

The terms “alkylamino” and “dialkylamino” refer to —NH(alkyl) and —N(alkyl)₂ radicals respectively.

The term “aralkylamino” or “arylalkylamino” refers to a —NH(aralkyl) radical. The term “alkylaminoalkyl” refers to a (alkyl)NH-alkyl-radical; the term “dialkylaminoalkyl” refers to an (alkyl)₂N-alkyl-radical.

The term “amido” refers to a —NHC(O)— or C(O)NH₂ substituent.

The term “aryl” refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl and the like. The term “arylalkyl” or “aralkyl” refers to alkyl substituted with an aryl. Exemplary aralkyls include but are not limited to benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzhydryl, phenethyl, and trityl groups. The term “arylalkenyl” refers to an alkenyl substituted with an aryl. The term “arylalkynyl” refers to an alkynyl substituted with an aryl. Terms such as “arylC₂-C₆alkyl” are to be read as a further limitation on the size of the alkyl group. The term “arylalkoxy” refers to an alkoxy substituted with aryl. The term “arylenyl” refers to a divalent aryl (i.e., —Ar—).

The terms “cycloalkyl” or “cyclyl” as employed herein include saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group may be optionally substituted. Exemplary cyclyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Cyclyl moieties also include both bridged and fused ring systems. Cyclyl groups also include those that are fused to additional ring systems, which may be saturated or unsaturated. A cyclyl group may thus be a bicyclic group in which one ring is saturated or partially unsaturated and the other is fully unsaturated (e.g., indanyl).

The term “cyclylalkyl” as used herein, refers to an alkyl group substituted with a cyclyl group. Cyclylalkyl includes groups in which more than one hydrogen atom of an alkyl group has been replaced by a cyclyl group.

The term “cycloalkylalkyl” as used herein, refers to an alkyl group substituted with a cycloalkyl group.

The term “halo” or “halogen” refers to any radical of fluorine, chlorine, bromine or iodine.

The term “haloalkyl” refers to an alkyl group that may have any number of hydrogens available on the group replaced with a halogen atom. Representative haloalkyl groups include but are not limited to: —CH₂Cl, —CH₂ClCF₃, —CHBr₂, —CF₃, —CH₂F, —CHF₂, and —CH₂CF₃. The term “fluoroalkyl” refers to an alkyl group that may have any number of hydrogens available on the group replaced with a fluorine atom. Representative fluoroalkyl groups include but are not limited to: —CH₂F, —CH₂FCF₃, —CHF₂ and —CF₃. The term “haloalkoxy” refers to an alkoxy group that may have any number of hydrogen atoms available on the alkyl group replaced with a halogen atom. Representative haloalkoxy groups include but are not limited to: —OCH₂Cl, —OCH₂ClCF₃, —OCHBr₂, —OCHF₂ or —OCF₃. The term “fluoroalkoxy” refers to an alkoxy group that may have any number of hydrogens available on the group replaced with a fluorine atom. Representative fluoroalkoxy groups include but are not limited to: —OCH₂F, —OCH₂FCF₃, —OCHF₂ or —OCF₃.

The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus and silicon. A heteroatom may be present in any oxidation state (e.g., any oxidized form of nitrogen, sulfur, phosphorus or silicon) and any charged state (e.g., the quaternized form of any basic nitrogen), and includes a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in N-substituted pyrrolidinyl).

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, oxazolyl and the like. The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkenyl” refers to an alkenyl substituted with a heteroaryl. The term “heteroarylalkynyl” refers to an alkynyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl.

The term “heteroaryl” refers to a group having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. A heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. When a heteroaryl is substituted by a hydroxy group, it also includes its corresponding tautomer. The term “heteroaryl,” as used herein, also includes groups in which a heteroaromatic ring is fused to one or more aryl rings. Nonlimiting examples of heteroaryl groups include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. A ring nitrogen atom of a heteroaryl may be oxidized to form the corresponding N-oxide compound. A nonlimiting example of such a heteroaryl having an oxidized ring nitrogen atom is N-oxopyridyl.

The term “heteroarylalkyl” or “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl. Heteroaralkyl includes groups in which more than one hydrogen atom has been replaced by a heteroaryl group.

As used herein, the terms “heterocycle,” “heterocyclyl” and “heterocyclic ring” are used interchangeably and refer to a stable 3- to 8-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2/y-pyrrolyl), NH (as in pyrrolidinyl), or NR⁺ (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, piperidinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and thiomorpholinyl. A heterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic. Additionally, a heterocyclic ring also includes groups in which the heterocyclyl ring is fused to one or more aryl, heteroaryl or cyclyl rings. A ring nitrogen atom of a heterocyclic ring also may be oxidized to form the corresponding N-hydroxy compound.

The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl. Heterocyclylalkyl includes groups in which more than one hydrogen atom has been replaced by a heterocyclyl group.

The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a heteroaryl group. Examplary heteroaralkyl groups include but are not limited to methylpyridyl or methylpyrimidyl.

The term “heterocyclyl” or “heterocyclylalkyl” refers to a nonaromatic 5-8 membered monocyclic, 5-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and include both bridged and fused ring systems. The term “heterocyclylalkyl” refers to an alkyl substituted with a heterocyclyl.

The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

The term “heteroalkyl,” as used herein, refers to a saturate or unsaturated, straight or branched chain aliphatic group, wherein one or more of the carbon atoms in the chain are independently replaced by a heteroatom. Exemplary hetero atoms include O, S, and N.

In the case of aralkyl, heteroaralkyl, cyclylalkyl, heterocyclylalkyl etc., groups described as optionally substituted, it is intended that either or both aryl, heteroaryl, cyclyl, heterocyclyl and alkyl moieties may be independently optionally substituted or unsubstituted.

The term “hydroxyalkyl” refers to an alkyl in which one or more hydrogen atoms are replaced by a hydroxy group.

The term “oxo” refers to an oxygen atom (═O), which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur.

The term “thioalkyl” as used herein refers to an —S(alkyl) group, where the point of attachment is through the sulfur atom and the alkyl group is as defined above. The term “thiono” or “thioxo” refers to a sulfur atom (═S), which forms a thioketone when attached to carbon.

The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.

The term “substituent” refers to a group “substituted” on a moiety described herein. Any atom on any substituent can be substituted. Substituents can include any substituents described herein. Examplary substituents include, without limitation, alkyl (e.g., C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12 straight or branched chain alkyl), cycloalkyl, haloalkyl (e.g., perfluoroalkyl such as CF₃), aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, alkenyl, alkynyl, cycloalkenyl, heterocycloalkenyl, alkoxy, haloalkoxy (e.g., perfluoroalkoxy such as OCF₃), halo, hydroxy, carboxy, carboxylate, cyano, nitro, amino, alkylamino, SO₃H, sulfate, phosphate, methylenedioxy (—O—CH₂—O— wherein oxygens are attached to vicinal atoms), ethylenedioxy, oxo, thioxo (e.g., C═S), imino (alkyl, aryl, aralkyl), S(O)_(n)alkyl (where n is 0-2), S(O)_(n) aryl (where n is 0-2), S(O)_(n) heteroaryl (where n is 0-2), S(O)_(n) heterocyclyl (where n is 0-2), amine (mono-, di-, alkyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, and combinations thereof), ester (alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl), amide (mono-, di-, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, and combinations thereof), sulfonamide (mono-, di-, alkyl, aralkyl, heteroaralkyl, and combinations thereof). In one aspect, the substituents on a group are independently any one single, or any subset of the aforementioned substituents. In another aspect, a substituent may itself be substituted with any one of the above substituents.

As used herein, the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, means that a hydrogen radical of the designated moiety is replaced with the radical of a specified substituent, provided that the substitution results in a stable or chemically feasible compound. The term “substitutable”, when used in reference to a designated atom, means that attached to the atom is a hydrogen radical, which hydrogen atom can be replaced with the radical of a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.

As used herein, the term “optionally substituted” means substituted or unsubstituted.

As used herein, the term “partially unsaturated” refers to a moiety that includes at least one double or triple bond between atoms. The term “partially unsaturated” encompasses rings, e.g., having one or more sites of unsaturation, but that are not completely unsaturated so as to be aryl or heteroaryl.

The term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. With respect to the nomenclature of a chiral center, terms “R” and “S” configuration are as defined by the IUPAC Recommendations. The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.” The term “isomers” or “stereoisomers” refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. For example, isomers include cis- and trans-isomers, E- and Z-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof. The term “diastereomers” refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.

The term “administration” or “administering” includes routes of introducing the compounds, or a composition thereof, of the invention to a subject to perform their intended function. Examples of routes of administration that may be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), oral, inhalation, rectal and transdermal. The pharmaceutical compositions may be given by forms suitable for each administration route. For example, these compositions are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, a compound described herein can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally affect its ability to perform its intended function. A compound or composition described herein can be administered alone, or in conjunction with either another agent as described above or with a pharmaceutically-acceptable carrier, or both. A compound or composition described herein can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent. Furthermore, a compound described herein can also be administered in a pro-drug form which is converted into its active metabolite, or more active metabolite in vivo.

The language “biological activities” of a compound described herein includes all activities elicited by a compound described herein in a responsive subject or cell. It includes genomic and non-genomic activities elicited by these compounds.

The terms “inhibit” and “inhibitor” as used herein means an agent that measurably slows or stops the production of STriatal-Enriched tyrosine Phosphatase (STEP), or decreases or inactivates STEP, or interferes with STEP-mediated biological pathways. Inhibitors of STEP include compounds of the invention, e.g., compounds of Formulas (I), (II), or (III). A compound can be evaluated to determine if it is an inhibitor by measuring either directly or indirectly the activity of STEP in the presence of the compound suspected to inhibit STEP. Exemplary methods of measure STEP inhibition are described in the EXAMPLES herein.

An “effective amount” or “an amount effective” refers to an amount of the compound or composition which is effective, upon single or multiple dose administrations to a subject and for periods of time necessary, in treating a cell, or curing, alleviating, relieving or improving a symptom of a disorder, e.g., a disorder described herein. An effective amount of a compound described herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of a compound described herein to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of a compound described herein are outweighed by the therapeutically beneficial effects. The term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., modulate or regulate protein tyrosine phosphatases, e.g., STEP, in a subject and/or treat a disorder described herein such as a protein tyrosine phosphatase related disorder. Exemplary disorders include those related to cognition, learning and memory, neurogenesis. An effective amount may also affect neuronal plasticity, pain perception, mood and anxiety, and neuroendocrine regulation.

An effective amount of a compound described herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of a compound described herein to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of a compound described herein are outweighed by the therapeutically beneficial effects.

A therapeutically effective amount of a compound described herein (i.e., an effective dosage) may range from about 0.001 to 50 mg/kg body weight, preferably about 0.01 to 40 mg/kg body weight, more preferably about 0.1 to 35 mg/kg body weight, still more preferably about 1 to 30 mg/kg, and even more preferably about 10 to 30 mg/kg. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound described herein can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a compound described herein in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of a compound described herein used for treatment may increase or decrease over the course of a particular treatment.

As used herein, an amount of a compound effective to prevent a disorder, or “a prophylactically effective amount” of the compound refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder or a symptom of the disorder.

The language “improved biological properties” refers to any activity inherent in a compound described herein that enhances its effectiveness in vivo. In a preferred embodiment, this term refers to any qualitative or quantitative improved therapeutic property of a compound described herein, such as reduced off-target effects.

The term “modulate” refers to an increase or decrease, e.g., in the activity of an enzyme in response to exposure to a compound or composition described herein, e.g., the activation or inhibition of STEP, in at least a sub-population of cells in a subject such that a desired end result is achieved (e.g., a therapeutic result). In some embodiments, a compound as described herein inhibits a target described herein, e.g., STEP. In some embodiments, a compound as described herein is activates a target described herein, e.g., STEP.

As used herein, the term “subject” is intended to include human and non-human animals. Exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein, or a normal subject. The term “non-human animals” includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dog, cat, cow, pig, etc.

As used herein, the term “treat” or “treating” is defined as applying or administering a compound or composition, alone or in combination with a second compound or composition, to a subject, e.g., a patient, or applying or administering the compound or composition to an isolated tissue or cell, e.g., cell line, from a subject, e.g., a patient, who has a disorder (e.g., a disorder as described herein), a symptom of a disorder, or a predisposition toward a disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, one or more symptoms of the disorder or the predisposition toward the disorder (e.g., to prevent at least one symptom of the disorder or to delay onset of at least one symptom of the disorder).

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

The term “prodrug” or “pro-drug” includes compounds with moieties that can be metabolized in vivo. Generally, the prodrugs are metabolized in vivo by esterases or by other mechanisms to active drugs. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl-amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionoic acid esters and acyl esters. Prodrugs which are converted to active forms through other mechanisms in vivo are also included.

The language “a prophylactically effective amount” of a compound refers to an amount of a compound described herein any formula herein or otherwise described herein which is effective, upon single or multiple dose administration to the patient, in preventing or treating a disease or condition.

The language “reduced off-target effects” is intended to include a reduction in any undesired side effect elicited by a compound described herein when administered in vivo. In some embodiments, a compound described herein has little to no cardio and/or pulmonary toxicity (e.g., when administered to a subject). In some embodiments, a compound described herein has little to no hallucinogenic activity (e.g., when administered to a subject).

The term “selective” means a greater activity against a first target. In some embodiments a compound has a selectivity of at least 1.25-fold, at least 1.5 fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 10-fold or at least 100-fold greater towards a first target relative to a second target. In some embodiments, a compound described herein, e.g., a compound of Formulas (I), (II), or (III) is selective toward STEP relative to one or more other protein tyrosine phosphatases.

The term “subject” includes organisms which are capable of suffering from a serotonin-receptor-related disorder or who could otherwise benefit from the administration of a compound described herein of the invention, such as human and non-human animals. Preferred humans include human patients suffering from or prone to suffering from a serotonin-related disorder or associated state, as described herein. The term “non-human animals” of the invention includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, and non-mammals, such as non-human primates, e.g., sheep, dog, cow, chickens, amphibians, reptiles, etc.

The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound described herein(s), drug or other material, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

Compounds

The compounds described herein can be used for a variety of purposes, e.g., therapeutic purposes. Many of the compounds modulate STEP activity and can be used, for example to inhibit STEP, e.g., in a subject.

Exemplary compounds include a compound of formula (I):

wherein A, B, E, L, X, Z, R¹, R², R³, m, n and p are as defined above in the section relating to compound of Formula (I). In preferred embodiments, L is NH, B is aryl (e.g., phenyl) that may be optionally substituted, E is aryl (e.g., phenyl), A is N, X is CH and Z is N.

Exemplary compounds include a compound of formula (II):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, n and p are as defined above in the section relating to compound of Formula (II).

Exemplary compounds include a compound of formula (III):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, R⁴, m, and n are as defined above in the section relating to compound of Formula (III).

Exemplary compounds include a compound of formula (IV):

wherein A, B, E, L, X, Z, R¹, R², R³, m, n and p are as defined above in the section relating to compound of Formula (IV). In preferred embodiments, L is NH, B is aryl (e.g., phenyl) that may be optionally substituted, E is aryl (e.g., phenyl), A is N, X is CH and Z is N.

Exemplary compounds include a compound of formula (V):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, n and p are as defined above in the section relating to compound of Formula (V).

Exemplary compounds include a compound of formula (VI):

wherein A, L, X¹, X², X³, X⁴, X⁵, R¹, R², R³, R⁴, m, and n are as defined above in the section relating to compound of Formula (VI).

The present invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbon, or the replacement of a fluorine by a ¹⁹F-enriched fluorine are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays, or as bioactive agents.

In the compounds of the present invention, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom unless otherwise stated (e.g., hydrogen, ²H or deuterium and ³H or tritium). The formulas described herein may or may not indicate whether atoms at certain positions are isotopically enriched. When a structural formula is silent with respect to whether a particular position is isotopically enriched, it is to be understood that the isotopes at that particular position are present in natural abundance or, that the particular position is isotopically enriched with one or more naturally occuring stable isotopes. For example, the formula —CH₂— represents the following possible structures: —CH₂—, —CHD- or —CD₂-.

The variable “D” is defined as deuterium.

The terms “compound” or “compounds,” when referring to a compound of this invention or a compound described herein, refers to a collection of molecules having an identical chemical structure, except that there may be isotopic variation among the constituent atoms of the molecules. Thus, it will be clear to those of skill in the art that a compound represented by a particular chemical structure containing indicated hydrogen atoms will contain lesser amounts of isotopologues having deuterium atoms at one or more of the designated hydrogen positions in that structure. Alternatively, a compound represented by a particular chemical structure containing indicated deuterium atoms will contain lesser amounts of isotopologues having hydrogen atoms at one or more of the designated deuterium positions in that structure. The relative amount of such isotopologues in a compound of this invention will depend on a number of factors including isotopic purity of deuterated reagents used to make the compound and the efficiency of incorporation of deuterium in the various synthetic steps used to prepare the compound. The relative amount of such isotopologues in total will be less than 55% of the compound. In other embodiments, the relative amount of such isotopologues in total will be less than 50%, less than 45%, less than 40%, less than 35%, less than 35%, less than 15%, less than 10%, less than 5%, less than 1% or less than 0.5% of the compound.

The term “isotopologue” refers to a species that differs from a specific compound of this invention only in the isotopic composition thereof. Isotopologues can differ in the level of isotopic enrichment at one or more positions and/or in the position(s) of isotopic enrichment.

The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. Described herein are enantiomerically enriched compounds (e.g., a compound resolved to an enantiomeric excess of 60%, 70%, 80%, 85%, 90%, 95%, 99% or greater). All such isomeric forms of these compounds are expressly included in the present invention. The compounds of this invention may also contain linkages (e.g., carbon-carbon bonds) or substituents that can restrict bond rotation, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included in the present invention. The compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented (e.g., alkylation of a ring system may result in alkylation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.

Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., “Chiral Liquid Chromatography,” W. J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. For example a compound can be resolved to an enantiomeric excess (e.g., 60%, 70%, 80%, 85%, 90%, 95%, 99% or greater) via formation of diasteromeric salts, e.g. with a chiral base, e.g., (+) or (−) α-methylbenzylamine, or via high performance liquid chromatography using a chiral column. In some embodiments a product is purified directly on a chiral column to provide enantiomerically enriched compound.

Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject).

Compounds of formulas (I), (II), (III), (IV), (V), and (VI) are described herein, for example as provided in the summary above. Exemplary compounds are shown in Tables 1-30 in the Examples section.

Synthetic Methods

A compound described herein may be prepared via a variety of synthetic methods. Representative syntheses are shown in the Examples section.

As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

Additionally, the compounds disclosed herein can be prepared on a solid support. The term “solid support” refers a material to which a compound is attached to facilitate identification, isolation, purification, or chemical reaction selectivity of the compound. Such materials are known in the art and include, for example, beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N′-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, and material having a rigid or semi-rigid surface. The solid supports optionally have functional groups such as amino, hydroxy, carboxy, or halo groups, (see, Obrecht, D. and Villalgrodo, J. M., Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries, Pergamon-Elsevier Science Limited (1998)), and include those useful in techniques such as the “split and pool” or “parallel” synthesis techniques, solid-phase and solution-phase techniques, and encoding techniques (see, for example, Czarnik, A. W., Curr. Opin. Chem. Bio., (1997) 1, 60).

A compound described herein may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., brain, blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

Included herein are pharmaceutically acceptable derivatives or prodrugs of the compounds described herein. A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention (for example an imidate ester of an amide), which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound described herein. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. In an exemplary embodiment, the prodrug is a derivative including a group that enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein. In another exemplary embodiment, the prodrug is suitable for treatment or prevention of those diseases and conditions that require the drug molecule to cross the blood brain barrier. In a preferred embodiment, the prodrug enters the brain, where it is converted into the active form of the drug molecule.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)₄ ⁺ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

Evaluating Compounds

A variety of methods can be used to evaluate a compound for ability to modulate STEP activity. Evaluation methods include in vitro assays (e.g., enzyme-based assays), in vitro cell-based signaling assays, and in vivo methods (e.g., testing in animal models). The evaluation methods can evaluate binding activity, phosphatase activity, or an activity downstream of STEP, such as the activity of ERK.

For example, a compound described herein may be evaluated using a fluorescence-based phosphatase assay. A phosphate-containing reagent may be used in the assay which, upon dephosphorylation by a phosphatase, generates a fluorescent product that may be detected using a fluorometer or fluorescence plate reader. Data may be expressed as percentage (%) inhibition of enzyme activity. For compounds showing enzymatic activation, data may be represented as percentage of inhibition but with negative values.

Compositions and Routes of Administration

The invention also provides a pharmaceutical composition, comprising an effective amount of a compound described herein (e.g., a compound capable of treating or preventing a condition as described herein, e.g., a compound of any formula herein or otherwise described herein) and a pharmaceutically acceptable carrier.

The compositions delineated herein include the compounds delineated herein (e.g., a compound described herein), as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.

The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.

Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

Methods of Treatment

The compounds and compositions described herein can be administered to cells in culture, e.g. in vitro or ex vivo, or to a subject, e.g., in vivo, to treat, prevent, and/or diagnose a variety of disorders, including those described herein below.

The compounds and compositions described herein can be administered to a subject, for example using a method described herein, who is suffering from a disorder described herein, e.g., a disorder that would benefit from the modulation of STEP (e.g., activating or inhibiting STEP). The compounds and compositions described herein can be administered to a subject, for example using a method described herein, who is at risk for a disorder described herein, e.g., a disorder that would benefit from the modulation of STEP (e.g., activating or inhibiting STEP).

Inhibitors of STEP may increase phosphorylation of an NMDA-R. Thus, in some embodiments, a compound described herein, e.g., a compound that inhibits STEP, may be useful for treating a disorder in which increasing phosphorylation of an NMDA-R would be beneficial.

Inhibitors of STEP may activate an ERK1 or ERK2 kinase, for example, in the CNS. Thus, in some embodiments, a compound described herein, e.g., a compound that inhibits STEP, may be useful for treating a disorder in which activate an ERK1 or ERK2 kinase would be beneficial.

Compounds described herein may be useful in treating a variety of disorders, including disorders of the CNS. Exemplary disorders include schizophrenia, schizoaffective disorders, major depression, bipolar disorder, cognitive deficit, mild cognitive impairment (MCI), Alzheimer's disease (AD), attention-deficit/hyperactivity disorder (ADHD), dementia, generalized anxiety disorders, panic disorders, obsessive-compulsive disorders, phobias, post-traumatic stress syndrome, anorexia nervosa, drug addiction, ischemic stroke, head trauma or brain injury, Huntington's disease, Parkinson's disease, spinocerebellar degeneration, motor neuron diseases, epilepsy, neuropathic pain, chronic pain, neuropathies, autism and autistic disorders.

Compounds described herein may be useful for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.

Compounds described herein may be useful for treating or preventing disorders selected from schizophrenia, schizoaffective disorder, bipolar disorder, manic-depressive disorder, psychosis, mood and anxiety disorders, mania, drug or substance addiction, cognition disorders, learning disabilities, learning and memory disorders, aging and neurologic disorders associated with or linked with cognitive impairments; mild cognitive impairments (MCI), Alzheimer's disease, Alzheimer-related cognition disorders, Huntington's disease, Parkinson's disease, CADASIL syndrome (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), amnesia, Wernicke-Korsakoff syndrome, Korsakoff syndrome, mild traumatic head injury (MBTI), traumatic head injury (TBI), fragile X syndrome, stroke, attention-deficit and hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), loss of concentration, autism, cerebral palsy, encephalopathy, and narcolepsy. The disorder may affect learning and memory, neurogenesis, neuronal plasticity, pain perception, mood and anxiety, or neuroendocrine regulation. The disorder may be a cognitive deficit disorder. The disorder may involve pain perception or neuroendocrine regulation.

Schizophrenia

In some embodiments, a compound or composition described herein can be used in the treatment of schizophrenia. Schizophrenia is a psychiatric diagnosis that describes a mental disorder characterized by abnormalities in the perception or expression of reality. Distortions in perception may affect all five senses, including sight, hearing, taste, smell and touch, but most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking with significant social or occupational dysfunction. Onset of symptoms typically occurs in young adulthood, with approximately 0.4-0.6% of the population affected. Diagnosis is based on the patient's self-reported experiences and observed behavior.

The disorder is thought to mainly affect cognition, but it also usually contributes to chronic problems with behavior and emotion. People with schizophrenia are likely to have additional (comorbid) conditions, including major depression and anxiety disorders. Social problems, such as long-term unemployment, poverty and homelessness, are common. Furthermore, the average life expectancy of people with the disorder is 10 to 12 years less than those without, due to increased physical health problems and a higher suicide rate.

The Diagnostic and Statistical Manual of Mental Disorders (DSM) contains five sub-classifications of schizophrenia. These include Paranoid type (where delusions and hallucinations are present but thought disorder, disorganized behavior, and affective flattening are absent); Disorganized type (also known as hebephrenic schizophrenia, where thought disorder and flat affect are present together); Catatonic type (the subject may be almost immobile or exhibit agitated, purposeless movement; symptoms can include catatonic stupor and waxy flexibility); Undifferentiated type (psychotic symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not been met); and Residual type (where positive symptoms are present at a low intensity only).

The International Statistical Classification of Diseases and Related Health Problems (10th Revision) defines two additional subtypes. These include Post-schizophrenic depression (a depressive episode arising in the aftermath of a schizophrenic illness where some low-level schizophrenic symptoms may still be present); and Simple schizophrenia (insidious and progressive development of prominent negative symptoms with no history of psychotic episodes.)

An agent for the treatment of schizophrenia may improve so-called positive symptoms in the acute period of schizophrenia such as hallucinations, delusions, excitations and the like. An agent for treating schizophrenia may also improve so-called negative symptoms that are observed in the chronic period of schizophrenia such as apathy, emotional depression, hyposychosis and the like.

Schizoaffective Disorder

Schizoaffective disorder is a psychiatric diagnosis that describes a mental disorder characterized by recurring episodes of elevated or depressed mood, or simultaneously elevated and depressed mood that alternate or occur together with distortions in perception. The perceptual distortion component of the disorder, called psychosis, may affect all five senses, including sight, hearing, taste, smell and touch, but most commonly manifest as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking with significant social and occupational dysfunction. The elevated, depressed or simultaneously elevated and depressed mood episode components of the disorder, called mood disorder, are broadly recognized as depressive and bipolar types of the illness; the division is based on whether the individual has ever had a manic, hypomanic or mixed episode. Onset of symptoms usually begins in early adulthood and is rarely diagnosed in childhood (prior to age 13). The lifetime prevalence of the disorder is uncertain (due to studies using varying diagnostic criteria), although it is generally agreed to be less than 1 percent, and possibly in the range of 0.5 to 0.8 percent. Diagnosis is based on the patient's self-reported experiences and observed behavior. No laboratory test for schizoaffective disorder currently exists. As a group, people with schizoaffective disorder have a more favorable prognosis than people with schizophrenia, but a worse prognosis than those with mood disorders.

The disorder is thought to mainly affect cognition and emotion, but it also usually contributes to ongoing problems with behavior and motivation. People with schizoaffective disorder are likely to have additional (comorbid) conditions, including anxiety disorders and substance abuse. Social problems, such as long-term unemployment, poverty and homelessness, are common. Furthermore, the average life expectancy of people with the disorder is shorter than those without the disorder, due to increased physical health problems and a higher suicide rate.

Cognitive Deficit

Treatment using a compound or composition described herein may improve a cognitive deficit associated with a cognition-related disorder. Cognitive deficit is an inclusive term to describe any characteristic that acts as a barrier to cognitive performance. The term may describe deficits in global intellectual performance, such as mental retardation, it may describe specific deficits in cognitive abilities (learning disorders, dyslexia), or it may describe drug-induced cognitive/memory impairment, such as that seen with alcohol and the benzodiazepines. Cognitive deficits may be congenital or caused by environmental factors such as brain injuries, neurological disorders, or mental illness.

Exemplary cognition-related disorders (e.g., cognitive dysfunction) include, without limitation, mild cognitive impairment (MCI), dementia, delirium, amnestic disorder, Alzheimer's disease, Parkinson's disease and Huntington's disease; memory disorders including memory deficits associated with depression, senile dementia, dementia of Alzheimer's disease; cognitive deficits or cognitive dysfunction associated with neurological conditions including, for example, Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, depression, schizophrenia and other psychotic disorders such as paranoia and manic-depressive illness; cognitive dysfunction in schizophrenia; disorders of attention and learning such as attention deficit disorders (e.g., attention deficit hyperactivity disorder (ADHD)) and dyslexia; cognitive dysfunction associated with developmental disorders such as Down's syndrome and Fragile X syndrome; loss of executive function; loss of learned information; vascular dementia; schizophrenia; cognitive decline; a neurodegenerative disorder; and other dementias, for example, dementia due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies. Cognition-related disorders also include, without limitation, cognitive dysfunction associated with MCI and dementias such as Lewy Body, vascular, and post stroke dementias. Cognitive dysfunction associated with surgical procedures, traumatic brain injury or stroke may also be treated in accordance with the embodiments described herein.

Major Depression

Major depression (also known as clinical depression, major depressive disorder, unipolar depression, or unipolar disorder) is a mental disorder characterized by a pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Types of Major depressive disorder include, e.g., Atypical depression, Melancholic depression, Psychotic depression, Catatonic depression, Postpartum depression, and Seasonal affective disorder.

Bipolar Disorder

Bipolar disorder, also known as manic depressive disorder, manic depressive psychosis, manic depression or bipolar affective disorder, is a psychiatric diagnosis that describes a category of mood disorders defined by the presence of one or more episodes of abnormally elevated mood clinically referred to as mania or, if milder, hypomania. Individuals who experience manic episodes also commonly experience depressive episodes or symptoms, or mixed episodes in which features of both mania and depression are present at the same time. These episodes are usually separated by periods of “normal” mood, but in some individuals, depression and mania may rapidly alternate, known as rapid cycling. Extreme manic episodes can sometimes lead to psychotic symptoms such as delusions and hallucinations. The disorder has been subdivided into bipolar I, bipolar II, cyclothymia, and other types, based on the nature and severity of mood episodes experienced; the range is often described as the bipolar spectrum.

Anxiety Disorders

Anxiety disorder is a blanket term covering several different forms of abnormal and pathological fear and anxiety. Current psychiatric diagnostic criteria recognize a wide variety of anxiety disorders. Recent surveys have found that as many as 18% of Americans may be affected by one or more of them.

Generalized anxiety disorder is a common chronic disorder characterized by long-lasting anxiety that is not focused on any one object or situation. Those suffering from generalized anxiety experience non-specific persistent fear and worry and become overly concerned with everyday matters. Generalized anxiety disorder is the most common anxiety disorder to affect older adults.

In panic disorder, a person suffers from brief attacks of intense terror and apprehension, often marked by trembling, shaking, confusion, dizziness, nausea, difficulty breathing. These panic attacks, defined by the APA as fear or discomfort that abruptly arises and peaks in less than ten minutes, can last for several hours and can be triggered by stress, fear, or even exercise; although the specific cause is not always apparent. In addition to recurrent unexpected panic attacks, a diagnosis of panic disorder also requires that said attacks have chronic consequences: either worry over the attacks' potential implications, persistent fear of future attacks, or significant changes in behavior related to the attacks. Accordingly, those suffering from panic disorder experience symptoms even outside of specific panic episodes. Often, normal changes in heartbeat are noticed by a panic sufferer, leading them to think something is wrong with their heart or they are about to have another panic attack. In some cases, a heightened awareness (hypervigilance) of body functioning occurs during panic attacks, wherein any perceived physiological change is interpreted as a possible life threatening illness (i.e. extreme hypochondriasis).

Obsessive compulsive disorder is a type of anxiety disorder primarily characterized by repetitive obsessions (distressing, persistent, and intrusive thoughts or images) and compulsions (urges to perform specific acts or rituals). The OCD thought pattern may be likened to superstitions insofar as it involves a belief in a causative relationship where, in reality, one does not exist. Often the process is entirely illogical; for example, the compulsion of walking in a certain pattern may be employed to alleviate the obsession of impending harm. And in many cases, the compulsion is entirely inexplicable, simply an urge to complete a ritual triggered by nervousness. In a minority of cases, sufferers of OCD may only experience obsessions, with no overt compulsions; a much smaller number of sufferers experience only compulsions.

The single largest category of anxiety disorders is that of Phobia, which includes all cases in which fear and anxiety is triggered by a specific stimulus or situation. Sufferers typically anticipate terrifying consequences from encountering the object of their fear, which can be anything from an animal to a location to a bodily fluid.

Post-traumatic stress disorder or PTSD is an anxiety disorder which results from a traumatic experience. Post-traumatic stress can result from an extreme situation, such as combat, rape, hostage situations, or even serious accident. It can also result from long term (chronic) exposure to a severe stressor, for example soldiers who endure individual battles but cannot cope with continuous combat. Common symptoms include flashbacks, avoidant behaviors, and depression.

Combination Therapies

In some embodiments, the subject is being treated with an additional therapeutic agent. Such additional agents include atypical antipsychotics such as aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride; and typical antipsychotics such as haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.

Clinical Outcomes

In some embodiments, treatment with a compound or composition described herein, for example, using a method described herein, improves one or more clinical outcomes. For example, in some embodiments, treatment with a compound or composition described herein may improve cognitive function. Elements of cognitive function include memory, orientation, attention, reasoning, language and praxis.

In some embodiments, clinical outcomes may be assessed using known methods. One such method is the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general psychopathology traditionally used to evaluate the effects of drug treatment in schizophrenia. The BPRS psychosis cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) is considered a particularly useful subset for assessing actively psychotic schizophrenic patients.

In some embodiments, clinical outcomes may be assessed using the 7-point Clinical Global Impression (CGI) rating scale, a commonly used measure of symptom severity, treatment response and the efficacy of treatments. The CGI reflects the impression of a skilled observer, fully familiar with the manifestations of schizophrenia, about the overall clinical state of the patient.

In some embodiments, clinical outcomes may be assessed using the 30-item Positive and Negative Symptoms Scale (PANSS). The name refers to the two types of symptoms in schizophrenia, as defined by the American Psychiatric Association: positive symptoms, which refer to an excess or distortion of normal functions (e.g. hallucinations and delusions), and negative symptoms, which represent a dimunition or loss of normal functions.

In some embodiments, clinical outcomes may be assessed using the Scale for Assessing Negative Symptoms (SANS). SANS assesses five symptom complexes to obtain clinical ratings of negative symptoms in patients with schizophrenia. They are: affective blunting; alogia (impoverished thinking); avolition/apathy; anhedonia/asociality; and disturbance of attention. Assessments are conducted on a six-point scale.

The invention is further illustrated by the following examples which are intended to illustrate but not limit the scope of the invention.

EXAMPLES Abbreviations

-   DCM: Dichloromethane -   EA, EtOAc or AcOEt: Ethyl acetate -   PE: Petroleum ether -   DIPEA: Diisopropylethylamine -   TEA: Triethylamine -   rt: Room temperature -   SOCl₂: Thionyl chloride -   POCl₃: Phosphorous oxychloride -   THF: Tetrahydrofuran -   NaOAc: Sodium acetate -   MeOH: Methanol -   i-AmOH: Isoamyl alcohol -   NaH: Sodium hydride -   NaBH₃CN: Sodium cyanoborohydride -   n-BuLi: n-Butyl lithium -   LHMDS: Lithium bis(trimethylsilyl)amide -   LDA: Lithium diisopropylamide -   i-PrOH: Isopropyl alcohol -   Na₂SO₄: Sodium sulfate -   Mg₂SO₄: Magnesium sulfate -   MeCN: Acetonitrile -   NaOH: Sodium hydroxide -   EtOH: Ethanol -   CuI: Copper(I) iodide -   Pd(PPh₃)₂Cl₂: trans-Dichlorobis(triphenylphosphine)palladium(II) -   MsCl: Methanesulfonyl chloride -   BINAM: [1,1′-Binaphthalene]-2,2′-diamine -   Xphos: 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl -   Sphos: 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl -   DavePhos: 2-(Dicyclohexylphosphino)-2′-(N,N-dimethylamino)biphenyl -   Cs₂CO₃: Cesium carbonate -   K₂CO₃: Potassium carbonate -   Mwave or μW or mW: Microwave -   t-BuOH: tert-Butanol -   K₃PO₄: Potassium phosphate -   Pd(APhos)₂Cl₂:Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloro     palladium(II) -   Pd(PPh₃)₄: Tetrakis(triphenylphosphine)palladium (O) -   Pd(dppf)₂Cl₂:     Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) -   PdOAc: Palladium(II) acetate -   Pd₂dba₃: Tris(dibenzylideneacetone)dipalladium (O) -   Pd-118:     Dichloro[1,1′-bis(di-t-butylphosphino)ferrocene]palladium(II) -   Xantphos: 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene -   BINAP: (±)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene -   EDCI: 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide -   HOBt: Hydroxybenzotriazole -   NH₄OH: Ammonium hydroxide -   H₂O: Water -   Pd/C: Palladium on carbon -   DMF: N,N-Dimethylformamide -   KOCN: Potassium cyanate -   WSC-HCl or WSCDI: Water Soluble Carbodiimide hydrochloride -   HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium     hexafluorophosphate -   HBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium     hexafluorophosphate -   Py-Brop: Bromotripyrrolidinophosphonium hexafluorophosphate -   BOP: Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium     hexafluoro phosphate -   DBU: diaza(1,3)bicyclo[5.4.0]undecene -   DMSO: Dimethyl sulfoxide -   LCMS: Liquid chromatography mass spectrometry -   HPLC: High performance liquid chromatography -   DMA: N,N-dimethylacetamide -   h: hour -   TLC: Thin layer chromatography -   TFA: Trifluoroacetic acid -   Et₃N: Triethylamine -   DIPEA: N,N-Diisopropylethylamine -   O.N: Overnight -   TBSO: tert-Butyldimethylsilyloxy -   DME: Dimethyl ether -   NMP: 1-methyl-2-pyrrolidinone -   PS-BEMP:     2-tert-Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine     supported on Polystyrene -   PBr₃: Phosphorus tribromide -   NaOtBu: Sodium tert-butoxide -   KI: Potassium iodide -   PPh₃: Triphenylphosphine -   NMM: N-Methylmorpholine -   HCHO: Formaldehyde -   PG: Protecting group -   ISCO: Teledyne ISCO purification systems -   BINAM: 1,1′-binaphthyl-2,2′-diamine.

General Experimental:

All exemplified target compounds are fully analyzed and characterized (TLC, LCMS, ¹H-NMR) prior to submission for biological evaluation. Thin-layer chromatography was carried out on native silica 254F plates. Visualization was accomplished with ultraviolet or phosphomolybdic acid. ¹H-NMR spectra were recorded on multiple NMR spectrometers, either on 400 MHz on a Avance III 400 Ultra shield-plus TM digital Spectrometer or on 300 MHz using a Varian Mercury 300Plus Spectrometer, designated by 400 MHz or 300 MHz, respectively. ¹H-NMR spectra were also recorded on a Bruker Spectrospin 300 MHz Spectrometer at 300.13 MHz in DMSO-d6 with TMS as an internal standard and will be designated as Bruker 300 Hz. NMR assignments are based on a combination of the ¹H, ¹³C, ¹HCOSY, HMBC and HMQC spectra. Coupling constants are given in hertz (Hz). Anhydrous methylene chloride, tetrahydrofuran, and dimethylformamide were obtained by distillation, and other materials are reagent grade.

LC-MS Methods are Listed Here:

Method A: Mobile phase: A=0.1% TFA/H₂O, B=0.01% TFA/MeCN; Gradient: B=5%-95% in 1.5 min; Flow rate: 2.0 mL/min; Column: sunfire-C₁₈, 50×4.6 mm, 3.5 um;

Method B: Mobile phase: A=10 mM NH₄HCO₃/H₂O, B=MeCN; Gradient: B=5%-95% in 1.5 min; Flow rate: 2.0 mL/min; Column: Xbridge-C₁₈, 50×4.6 mm, 3.5 um;

Method C: Mobile phase: A=10 mM ammonium formate/H₂O/4.9% MeCN, B=MeCN; Gradient: B=5%-100% in 2.0 min; Flow rate: 2.5 mL/min; Column: Atlantis T3 3 uM 4.6×30 mm

Method D: Mobile phase: A=0.1% formic acid/H₂O/4.9% MeCN, B=MeCN; Gradient: B=5%-100% in 2.0 min; Flow rate: 2.5 mL/min; Column: Atlantis T3 3 uM 4.6×30 mm

Method E: Mobile phase: A=0.05% TFA/H₂O, B=0.05% TFA/MeCN; Gradient: B=5%-100% in 3.0 min; Flow rate: 0.8 mL/min; Column: CAPCELL PAK C18 (Shiseido, UG120, 3 mM, 2.0 mm I.D.×50 mm)

Representative Conditions of PREP-HPLC are Listed Here:

PREP-HPLC Condition A (Basic Mobile Phase): Instrument: Gilson 281 Mobile Phase: A=0.01% NH₄HCO₃/H₂O, B=MeCN

Flow Rate: 40.0 mL/min Column: AGT Venusil XBP C₁₈, 10.0 um, 30 mm×100 mm

PREP-HPLC Condition B (Basic Mobile Phase): Instrument: Gilson 281

Mobile Phase: A=NH₃—H₂O, 10 mmol/L, B=MeCN Flow Rate: 40.0 mL/min Column: Waters X-Bridge, 5.0 um, 30 mm×150 mm

PREP-HPLC Condition C (Basic Mobile Phase): Instrument: Gilson 281 Mobile Phase: A=0.01% NH₄HCO₃/H₂O, B=MeCN

Flow Rate: 30.0 mL/min Column: Shimadzu PRC-ODS, 10.0 um, 20 mm×250 mm

Gradient:

-   -   B=xx %-yy % 0.0 to 8.0 min     -   yy %-95% 8.0 to 8.2 min     -   95%-95% 8.2 to 11.0 min         The following table shows the relationship of representative         value (xx %-yy %) of gradient and retention time on LC-MS of         corresponding compound.         25%-30% 0.5-1.0 min         30%-50% 1.0-1.5 min         50%-70% 1.5-1.75 min         70%-90% 1.7-2.0 min

PREP-HPLC Condition D:

Instrument: Waters 600 pump, Waters 2996, Photodiode Array Detector, Waters Micromass ZQ, Gilson 215 Liquid Handler.

Mobile Phase: A=0.05% TFA/H₂O, B=MeCN

Flow Rate: 36.0 mL/min

Column: Shiseido CAPCELL PAK C18, UG120, 5 uM, 20 mm I.D.×50 mm Gradient: B=5%-100% 0.0 to 4.0 min

Method A: 2-Nitro-5-propoxy-benzamide (i-a)

A mixture of 2-nitro-5-propoxy-benzoic acid (1.97 g, 8.75 mmol) and DMF (0.1 mL) in SOCl₂ (20 mL) was stirred at 65° C. for 2 h. After the reaction was completed, the mixture was cooled to room temperature. SOCl₂ was removed in vacuo and the residue was dissolved in anhydrous CH₂Cl₂ (10 mL), which was added to NH₃—H₂O (28%) dropwise. After 1 h, the precipitate was collected and dried in vacuo to give 1.68 g of i-a as a yellow solid (85.2%). LCMS m/z=208.1 (M-16), 225.1 (M+1) (Method B) (retention time=1.88 min)

Method B: 2-Amino-5-propoxy-benzamide (ii-a)

To a mixture of 2-nitro-5-propoxy-benzamide (1.20 g, 5.36 mmol) in MeOH—H₂O (v/v, 3:1, 60 mL) was added NH₄Cl (2.84 g, 53.6 mmol) and Fe (2.99 g, 53.6 mmol). The resulting mixture was stirred at 60° C. for 3 h. After the reaction was completed, the mixture was cooled to room temperature and the iron was filtered off. The filtrate was concentrated to 15 mL and the formed precipitate was collected and dried in vacuo to give 1.02 g of ii-a as a pale yellow solid (98%). LCMS m/z=178.1 (M-16), 195.1 (M+1) (Method B) (retention time=1.46 min)

Method I: 2-Amino-4-chlorobenzamide (ii-b)

To a mixture of 2-amino-4-chlorobenzoic acid (3.42 g, 20 mmol) in DMF (45 mL) was added HOBt (2.70 g, 20 mmol). After stirring for 10 min, EDC hydrogen chloride (3.82 g, 20 mmol) was added to the mixture. The resulted mixture was stirred at room temperature for 2 h. NH₄OH (28%, 5 mL) was added at 0° C. with vigorous stirring. After addition, the mixture was stirred at room temperature for another 2 h. The reaction mixture was added to water (200 mL) dropwise with stirring, then a precipitate formed. The precipitate was collected and dried in vacuo to give 2.98 g of ii-b as a grey solid (87.6% yield). LCMS m/z=171.0 (M+1), 173.0 (M+3) (Method B) (retention time=1.39 min). ¹H NMR (400 MHz, DMSO-d₆): δ 7.27 (d, J=9.6 Hz, 1H), 6.68 (d, J=2.4 Hz, 1H), 6.60 (dd, J=8.4, 2.0 Hz, 1H), 5.50-5.82 (m, 4H).

Method F for Chlorinating Conditions F1: POCl₃/N,N-dimethylbenzeneamine F2: SOCl₂/DMF/80° C.

F3: SOCl₂ (4-8 equiv.)/DMF/DCM/rt-40° C. F4: Phenylphosphinic dichloride/80-120° C.

F5: POCl₃/Δ F6: POCl₃/Toluene/100° C. F7: PBr₃/CH₂Cl₂/DMF/60° C. Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/reflux

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux G7: THF—H₂O/NaOAc/rt-60° C. G8: NaH/THF

G9: n-BuLi/THF

G10: LHMDS/THF G11: LDA/THF G12: K₂CO₃/DMF/60° C. G13: Cs₂CO₃/DMA/80° C. G14: NaOtBu/DMF/Microwave/100° C. Method J for Coupling Conditions

J1: Pd(PPh₃)₄/t-BuOK/Dioxane J2: Pd₂(dba)₃/Xantphos/Cs₂CO₃/Dioxane

Method C: N-(2-Carbamoyl-4-propoxy-phenyl)-nicotinamide (iii-a)

To a solution of 2-amino-5-propoxy-benzamide (760 mg, 3.91 mmol) in THF (15 mL) and Et₃N (1 mL) was added nicotinoyl chloride (607 mg, 4.30 mmol) in anhydrous THF (15 mL) dropwise. The resulting mixture was stirred at room temperature for 3 h. After the reaction was completed, the volatiles were removed. The residue was washed with H₂O (10 mL). The pH was adjusted to approximately 5 by adding dilute HCl (2N in water). The resulting solid was collected and dried in vacuo to give 1.00 g of iii-a as a pale yellow solid (89.0%). LCMS m/z=300.1 (M+1) (Method B) (retention time=1.60 min)

Method D: 2-benzamido-5-methoxy-3-methylbenzamide (iii-b)

A 50 mL round-bottom flask was charged with nicotinic acid (41 mg, 0.33 mmol, 1.0 eq.), 2-amino-5-methoxy-3-methylbenzamide (60 mg, 0.33 mmol, 1.0 eq.) and HBTU (190 mg, 0.50 mmol, 1.5 eq), which were suspended in 4 mL of DMF. DIPEA (86 mg, 0.66 mmol, 2.0 eq.) was added dropwise at room temperature and the reaction mixture was stirred overnight. The reaction mixture was added to water (10 mL) dropwise with stirring. The mixture was extracted with ethyl acetate. The ethyl acetate was evaporated and 55 mg of the orange solid (58.5% yield) was obtained. LCMS m/z=286.1 (M+1) (Method B) (retention time=1.24 min)

Method E: 6-Propoxy-2-pyridin-3-yl-1H-quinazolin-4-one (iv-a)

A mixture of N-(2-carbamoyl-4-propoxy-phenyl)-nicotinamide (980 mg, 3.27 mmol) in EtOH (20 mL) was treated with NaOH (654 mg, 16.37 mmol). The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed in vacuo. The residue was partitioned between H₂O (50 mL) and ethyl acetate (50 mL). The aqueous layer was neutralized to pH 7 by slowly adding aq. citric acid and then a precipitate formed. The precipitate was collected and dried to give 1.00 g of iv-a as a grey solid (quantitative yield). LCMS m/z=282.1 (M+1) (Method B) (retention time=1.60 min)

Method F1: 4-Chloro-6-propoxy-2-pyridin-3-yl-quinazoline (v-a)

(This method is representative of method F1, F2, F3 and F4. These three methods can be implemented in a similar way except for substitution of the appropriate chlorinating reagent, solvent and temperature) To a mixture of 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one (1.00 g, 3.56 mmol) in POCl₃ (10 mL) was added N,N-dimethylaniline (0.1 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to around 7 by slowly adding NaHCO₃ (sat.) at 0° C. The resultant solid was collected and purified by chromatography on silica gel eluted with petroleum ether/ethyl acetate (v/v=4:1 to 1:1) to give 580 mg of v-a as a pale yellow solid (54.7%).

Method F5: 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (v-c)

In a sealed tube, phosphorus oxychloride (11 mL, 120 mmol) was added to 6-methoxy-2-(pyridin-3-yl)quinazolin-4(3H)-one (2.70 g, 10.66 mmol). The mixture was refluxed at 120° C. for 12 h. After cooling, the remaining phosphorus oxychloride was removed in vacuo to leave a tan solid. This residue was added to an ice-water mixture (100 mL) with cooling and allowed to stir. The pH of the suspension was adjusted to about pH 9 via dropwise addition of 28% ammonium hydroxide, and stirring was continued for 30 mins. The resulting solid was filtered to give the desired product as a tan solid (2.55 g, 9.39 mmol, 88%). LC-MS m/z=272.0 (M+1) (retention time=2.05)¹H NMR (300 MHz, DMSO) δ 9.55 (s, 1H), 8.81-8.64 (m, 2H), 8.09 (d, J=9.2 Hz, 1H), 7.78 (dd, J=9.2, 2.8 Hz, 1H), 7.61 (dd, J=7.9, 4.8 Hz, 1H), 7.49 (d, J=2.5 Hz, 1H), 4.00 (s, 3H).

Method F6: 6-Bromo-4-chloro-8-fluoro-2-(pyridin-3-yl)quinazoline (v-d)

To a suspension of 6-bromo-8-fluoro-2-(pyridin-3-yl)quinazolin-4-ol (6.16 g, 0.0192 mol) in toluene (60 mL) was added phosphorus oxychloride (5.30 ml, 0.0579 mol) at room temperature. The mixture was refluxed for 3 h. The solvent was evaporated and water was added to the residue under cooling conditions. The suspension was stirred at room temperature for 30 min, the resulting precipitate was filtered and dried to give the title compound (6.5 g, quantitative). ¹H NMR (400 MHz, DMSO) δ 9.58 (d, J=1.6 Hz, 1H), 8.82 (dd, J=4.7, 1.5 Hz, 1H), 8.80-8.75 (m, 1H), 8.37 (dd, J=9.7, 1.9 Hz, 1H), 8.34-8.29 (m, 1H), 7.67 (dd, J=7.8, 4.6 Hz, 1H).

Method F7: 4-Bromo-6-methoxy-2-(pyridin-3-yl)quinazoline (v-e)

To a sealed tube containing 6-methoxy-2-(pyridin-3-yl)quinazolin-4(3H)-one (1.30 g, 5.13 mmol) in dichloromethane (20 mL) was added 1 M phosphorus tribromide in dichloromethane (10.3 mL, 10.3 mmol) and DMF (2 mL). The reaction mixture was heated at 60° C. for 4 h. After cooling, excess dichloromethane was evaporated leaving a tan residue. This solid was added to an ice-water mixture (100 mL) with cooling and allowed to stir. The pH of the suspension was adjusted to about pH 9 via dropwise addition of 28% ammonium hydroxide, and stirring was continued for 30 mins. The resulting solid was filtered to give the desired product as a tan solid (1.49 g, 4.71 mmol, 92%). LC-MS m/z=318.3 (M+2) (retention time=2.19).

Method G1: 2-(6-Propoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide (vi-a)

(This method is representative of method G1, G2, and G3. These three methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) A mixture of 4-chloro-6-propoxy-2-(pyridin-3-yl)quinazoline (90 mg, 0.3 mmol) and 2-aminobenzamide (52 mg, 0.4 mmol) in i-PrOH (5 mL) was stirred at 85° C. for 18 h. The yellow precipitate was collected and washed with i-PrOH (10 mL). The solid was suspended in water (10 mL) and NH₃—H₂O (1 mL) was added. After filtration the solid was dried in vacuo to afford 31.0 mg of vi-a as a white solid (30.8%). LCMS m/z=400.1 (M+1) (Method B) (retention time=1.96 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (d, J=2.0 Hz, 1H), 9.58 (d, J=7.6 Hz, 1H), 8.69-8.74 (m, 2H), 8.48 (s, 1H), 7.97 (d, J=6.8 Hz, 2H), 7.90 (d, J=8.8 Hz 1H), 7.74 (t, J=7.6 Hz, 1H), 7.56-7.61 (m, 3H), 7.20 (t, J=7.2 Hz, 1H), 4.16 (t, J=6.4 Hz, 2H), 1.86 (dd, J=14.0, 6.8 Hz, 2H), 1.07 (t, J=7.2 Hz, 3H).

Method G8: 2-(6-ethoxy-2-(pyridin-3-yl)quinazolin-4-yloxy)benzamide (vii-a)

(The method G8 is representative of method G6, G7, G9, G10 and G11. These six methods can be implemented in a similar way except for substitution of the appropriate base, solvent and temperature) To a 2.5 dram reaction vial was first added sodium hydride 60% (0.028 g, 0.700 mmol) and salicylamide (0.072 g, 0.525 mmol) in DMF (2 mL). The mixture was allowed to stir at room temperature for 1 h. Then, 4-chloro-6-ethoxy-2-(pyridin-3-yl)quinazoline (0.100 g, 0.350 mmol) was added to the mixture, and the reaction was allowed to proceed at room temperature overnight. LC-MS analysis of the crude mixture showed about 85% of product formed and 10% remaining starting material. Water (30 mL) was added to the mixture, and the product was extracted with chloroform (3×15 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The crude product was purified via ISCO (silica gel, 97.5:2.5 CH₂Cl₂/MeOH; 12 g column) to afford 13.9 mg of the desired product as a white solid (10.3%) LCMS m/z=387 (M+1) (Method C) (retention time=2.05 min). ¹H NMR (300 MHz, DMSO) δ 11.47 (s, 2H), 9.39 (s, 1H), 8.66 (d, J=2.8 Hz, 1H), 8.56-8.47 (m, 1H), 8.01-7.90 (m, 2H), 7.69-7.55 (m, 2H), 7.55-7.40 (m, 2H), 7.05 (t, J=7.5 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 4.23 (q, J=6.9 Hz, 2H), 1.44 (t, J=6.9 Hz, 3H).

Method G13: 4-(4-chlorophenyl)-N-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-yl)thiazol-2-amine (vi-c)

(The method G13 is representative of method G12 also. This method can be implemented in a similar way except for substitution of the appropriate base, solvent and temperature) To a suspension of 4-chloro-6-methoxy-2-(pyridine-3-yl)quinazoline (645.2 mg, 2.375 mmol) and 2-amino-4-(4-chlorophenyl)thiazole (1050 mg, 4.98 mmol) in DMA (40 mL) was added Cs₂CO₃ (2430 mg, 7.46 mmol) at room temperature. The mixture was stirred at 80° C. for 9.5 h. Water was added and a precipitate formed which was collected by filtration and washed with H₂O. Recrystallization from acetone/DMF/methanol gave 383.6 mg of the product in a 36% yield as yellow solid, >98% purity by ¹H NMR). ¹H NMR (400 MHz DMSO-d₆) δ 12.52 (s, 1H), 9.78 (d, J=1.56 Hz, 1H), 8.91-8.88 (m, 1H), 8.74 (dd, J=4.74, 1.60 Hz, 1H), 8.33 (brs, 1H), 8.06 (d, J=8.56 Hz, 2H), 7.93 (d, J=9.08 hz, 1H), 7.89 (s, 1H), 7.66-7.59 (m, 2H), 7.55 (d, J=8.56 Hz, 2H), 4.01 (s, 3H).

Method G14: 4-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-1H-pyrazole-5-carboxamide, 2HCl (vi-d)

The method G14 is representative of method G4 and G5 also. This method can be implemented in a similar way except for substitution of the appropriate solvent and adjustment of the temperature) To a microwave vial containing 4-bromo-6-methoxy-2-(pyridin-3-yl)quinazoline (150.0 mg, 0.47 mmol) in DMF (2 mL) was added 4-amino-1H-pyrazole-5-carboxamide (66.0 mg, 0.52 mmol) and sodium tert-butoxide (50 mg, 0.52 mmol). The reaction mixture was heated at 100° C. for 15 mins by microwave irradiation. Water (50 mL) was added to the reaction mixture, and extracted with ethyl acetate (5×50 mL). The crude material was purified via ISCO (silica, 12 g column, 93% CH₂Cl₂-7% MeOH-0.1% NH₄OH) giving the product as a yellow solid. The free base was then converted to the HCl salt to yield the final product as an orange solid (59.8 mg, 0.14 mmol, 22%). LC-MS m/z=362.4 (M+1) (retention time=1.57) ¹H NMR (300 MHz, DMSO) δ 11.28 (s, 1H), 9.62 (d, J=1.7 Hz, 1H), 9.17 (d, J=7.8 Hz, 1H), 8.93 (dd, J=5.2, 1.3 Hz, 1H), 8.60 (s, 1H), 8.05 (s, 1H), 8.03-7.94 (m, 2H), 7.77 (s, 1H), 7.64 (dd, J=9.2, 2.5 Hz 1H), 7.40 (d, J=2.6 Hz, 1H), 3.97 (s, 3H).

Method J1: 1-(6-Methoxy-2-(pyridin-3-yl)quinazolin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (vi-b)

To a 50-mL two-neck round bottom flask equipped with a reflux condenser was added a mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (50 mg, 0.18 mmol, 1 eq.) and 1H-benzo[d]imidazol-2(3H)-one (27 mg, 0.21 mmol, 1.1 eq.) in 5 mL of dry 1,4-dioxane. Pd(PPh₃)₄ (10.6 mg, 0.009 mmol, 0.05 eq) and t-BuOK (41 mg, 0.36 mmol, 2 eq.) were added. The resulting mixture was stirred at 100° C. under N₂ atmosphere overnight. After cooling, 20 mL of methanol was added. The mixture was filtered, the filtrate was concentrated in vacuo and then was purified with chromatography on silica gel (ethyl acetate/petroleum ether from 1:4 to 1:2) to give the crude product, which was further purified with reverse phase HPLC to afford 4.8 mg of vi-e as a pale yellow solid (7%). MS m/z=370.1 (M+1) (Method B) (retention time=1.680 min). ¹H NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H), 8.78 (d, J=8.0 Hz, 2H), 8.17 (d, J=9.2 Hz, 1H), 7.80 (dd, J=9.2, 2.8 Hz, 1H), 7.70-7.64 (m, 1H), 7.46 (d, J=2.8 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 7.20 (d, J=4.0 Hz, 2H), 7.16-7.08 (m, 1H), 3.89 (s, 3H).

Method J2: 6-methoxy-N-(pyridin-2-yl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (vi-e)

To a suspension of 4-chloro-6-methoxy-2-(pyridine-3-yl)quinazoline (600 mg, 2.208 mmol) in dioxane (40 mL) under N₂, was added tris(dibenzylideneacetone)dipalladium(O) (103.1 mg, 0.113 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (132.2 mg, 0.228 mmol) and cesium carbonate (1.1289 g, 3.46 mmol) at room temperature. 2-Aminopyridine (229 mg, 2.43 mmol) was added and the mixture was stirred at 100° C. for 2 h 30 min Water was added and then a precipitate formed. The solid was collected and washed with water. The solid was dissolved in CH₂Cl₂. Purification was carried out using NH-silica gel to give the free base (649.3 mg). The free base was converted to the HCl salt by dissolving the compound in CH₂Cl₂/MeOH and 1.5 ml of 4N HCl in ethyl acetate was added and then a precipitate formed. The solid was collected and dried in vacuo (at 40 degrees on and 60 degrees for ca. 3 h) and then washed with methanol. The resulting solid was dried in vacuo at 60 degrees to give 682 mg of the desired product as the HCl salt in a 77% yield as a pale yellow solid. ¹H NMR (DMSO-d₆) δ 11.14 (brs, 1H), 9.58 (s, 1H), 9.13 (dd, J=7.96 Hz, 1H), 8.93 (d, J=5.24 Hz, 1H), 8.54 (d, J=4.72 Hz, 1H), 8.48 (d, J=8.32 Hz, 1H), 8.28 (brs, 1H), 8.09 (brt, J=7.16 Hz, 1H), 8.02-7.96 (m, 2H), 7.65 (dd, J=8.80, 2.48 Hz, 1H), 7.34 (brt, J=6.52 Hz, 1H), 4.01 (s, 3H). The 1H of 2HCl was not observed.

Method J3: N-(Biphenyl-4-yl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine hydrochloride (vi-f)

To a suspension of N-(4-bromophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (548.7 mg, 1.347 mmol) and phenylboronic acid (270 mg, 2.21 mmol) in dioxane/H₂O (2/1) (30 mL) under N₂ was added Na₂CO₃ (485 mg, 4.58 mmol) and tetrakis(triphenylphosphine) palladium(O) (78 mg, 0.067 mmol) at room temperature. The mixture was stirred at 100° C. for 1 h. Water was added and then a precipitate formed. The solid was dissolved in methanol/acetone at 60° C. The solution was filtrated through Celite to remove any extra palladium. The filtrate was concentrated down to give 493.4 mg of a solid residue in. The solid was added to CH₂Cl₂ followed by addition of 4N HCl in ethyl acetate (0.4 mL) at room temperature to form the HCl salt. The mixture was stirred at room temperature and the resulting solid was filtered and dried in vacuo to give 435.2 mg and a yield of 73% as the HCl salt. ¹H NMR (DMSO-d6) δ 10.24 (br, 1H), 9.54 (s, 1H), 8.92 (d, J=7.52 Hz, 1H), 8.82 (d, J=3.96 Hz, 1H), 8.10 (d, J=2.44 Hz, 1H), 8.03 (d, J=8.68 Hz, 2H), 7.92 (d, J=9.08 Hz, 1H), 7.84 (d, J=8.68 Hz, 2H), 7.81 (m, 1H), 7.77-7.75 (m, 2H), 7.62 (dd, J=9.08, 2.44 Hz, 1H), 7.50 (m, 2H), 7.38 (m, 1H), 4.01 (s, 3H). The 1H of HCl was not observed.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 1 and 5 (prepared according to method procedure A-J as designated).

TABLE 1 Molecular ¹H-NMR Number Product Salt type Mass ¹H-NMR Solvent LCMS LCMS Protocol Purity percent Method for Coupling 1

399.45 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (d, J = 2.0 Hz, 1 H), 9.58 (d, J = 7.6 Hz, 1H), 8.69-8.74 (m, 2H), 8.48 (s, 1H), 7.97 (d, J = 6.8 Hz, 2H), 7.90 (d, J = 8.8 Hz 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.56- 7.61 (m, 3H), 7.20 (t, J = 7.2 Hz, 1H), 4.16 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.8 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 400.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 2

HCl 398.46 ¹H-NMR (400 MHz, DMSO-d₆): δ13.20 (s, 1 H), 9.79 (s, 1 H), 9.02-9.08 (m, 2H), 8.87 (d, J = 3.2 Hz, 1 H), 8.53 (s, 1 H), 8.34 (d, J = 8.0 Hz, 1 H), 8.19 (d, J = 6.8 Hz, 1 H), 7.74-7.99 (m, 5H), 7.28 (t, J = 7.6 Hz, 1H), 4.92 (d, J = 4.0 Hz, 2H), 2.87 (d, J = 3.2 Hz, 6H). DMSO 399.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 3

HCl 424.50 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.07 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1 H), 8.78 (ddd, J = 8.0, 4.0, 2.4 Hz, 1H), 8.73 (dd, J = 4.4, 1.2 Hz, 1H), 8.49 (s, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.92-7.69 (m, 3H), 7.67-7.74 (m, 2H), 7.62 (dd, J = 8.0, 4.8 Hz, 1 H), 7.22 (t, J = 7.6 Hz, 1H), 4.29 (s, 2H), 2.61 (brs, 4H), 1.70 (brs, 4H). DMSO 425.2  (M +1) Method B (NH4HCO3) 95 Method C, G1 4

422.43 1H-NMR (400 MHz, DMSO-d₆): δ 9.87 (s, 1H), 9.52 (s, 1H), 8.67 (d, J = 5.6 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.94 (s, 1 H), 7.86 (d, J = 9.2 Hz, 1 H), 7.80 (d, J = 8.0 Hz, 1 H), 7.50-7.58 (m, 3H), 7.30 (t, J = 34.0 Hz, 1 H), 7.00 (dd, J = 8.4, 2.0 Hz, 1H), 4.16 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.4 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 423.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 5

HCl 408.86 1H-NMR (400 MHz, DMSO-d₆): δ10.28 (s, 1 H), 9.48 (s, 1 H), 8.93 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.4 Hz, 1H), 8.18 (dd, J = 7.6, 2.4 Hz, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.85-7.93 (m, 3H), 7.62 (dd, J = 8.8, 6.4 Hz, 1 H), 7.55 (t, J = 8.8 Hz, 1 H), 4.17 (t, J = 6.4 Hz, 3H), 1.86 (dd, J = 7.6, 6.4 Hz, 2H), 1.06 (t, J = 7.6 Hz, 3H). DMSO 409.1, 411.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 6

425.31 1H-NMR (400 MHz, DMSO-d₆): δ9.93 (s, 1 H), 9.51 (s, 1 H), 8.68-8.71 (m, 2H), 8.16 (d, J = 2.4 Hz, 1 H), 7.94 (d, J = 2.0 Hz, 1 H), 7.86 (d, J = 8.8 Hz, 1 H), 7.56- 7.60 (m, 2H), 7.37 (s, 1 H), 4.14 (t, J = 6.4 Hz, 2H), 1.84 (dd, J = 10.4 Hz, 7.2 Hz, 2H), 1.07 (t, J = 7.6 Hz, 3H). DMSO 425.0, 427.0  (M +1) Method B (NH4HCO3) 95 Method C, G1 7

392.4 1H-NMR (400 MHz, DMSO-d₆): δ10.06 (s, 1 H), 9.49 (s, 1 H), 8.77-8.81 (m, 2H), 8.09 (ddd, J = 10.0, 7.6, 2.4 Hz, 1H), 7.88 (d, J = 9.2 Hz, 1 H), 7.69-7.74 (m, 2H), 7.54-7.61 (m, 2H), 4.15 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 14.0, 7.6 Hz, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 393.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 8

425.31 1H-NMR (400 MHz, DMSO-d₆): δ10.05 (s, 1 H), 9.51 (s, 1 H), 8.75-8.80 (m, 2H), 8.34 (d, J = 2.4 Hz, 1 H), 7.96-8.00 (m, 2H), 7.88 (d, J = 9.2 Hz, 1 H), 7.68-7.75 (m, 2H), 7.59 (dd, J = 9.2, 2.8 Hz, 1H), 4.15 (t, J = 6.4 Hz, 2H), 1.86 (dd, J = 7.2, 6.8 Hz, 2H), 1.06 (t, J = 7.6 Hz, 3H). DMSO 425.0, 427.0  (M +1) Method B (NH4HCO3) 95 Method C, G1 9

415.44 1H-NMR (400 MHz, DMSO-d₆): δ13.03 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 9.15 (d, J = 8.4 Hz, 1 H), 8.69-8.74 (m, 2H), 8.49 (s, 1H), 7.96-8.06 (m, 2H), 7.90 (d, J = 9.2 Hz, 1H), 7.56-7.63 (m, 3H), 7.20 (t, J = 8.0 Hz, 1 H), 4.31 (t, J = 4.0 Hz, 2H), 3.79 (t, J = 4.8 Hz, 2H), 3.31 (s, 3H). DMSO 416.0  (M +1) Method B (NH4HCO3) 95 Method C, G1 10

438.43 1H-NMR (400 MHz, DMSO-d₆): δ9.86 (s, 1H), 9.53 (s, 1H), 8.66-8.68 (m, 2H), 8.02 (d, J = 2.8 Hz, 1 H), 7.95 (t, J = 2.0 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.79 (d, J DMSO 439.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 11

HCl 424.86 1H-NMR (400 MHz, DMSO-d₆): δ10.27 (s, 1 H), 9.48 (s, 1 H), 8.93 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.19 (dd, J = 6.8, 2.4 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.85-7.93 (m, 3H), 7.64 (dd, J = 9.2, 6.8 Hz, 1H), 7.55 (t, J = 8.8 Hz, 1H), 4.34 (t, J = 4.4 Hz, 2H), 3.78 (t, J = 4.4 Hz, 2H), 3.31 (s, 3H). DMSO 425.1, 427.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 12

397.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.07 (s, 1H), 9.50 (s, 1H), 8.78 (dd, J = 17.6, 7.6 Hz, 1H), 8.39 (s, 1H), 8.26 (dd, J = 8.0, 2.0 Hz, 1 H), 8.02 (d, J = 2.0 Hz, 1 H), 7.90 (d, J = 9.2 Hz, 1 H), 7.61-7.73 (m, 4H), 4.34 (t, J = 4.8 Hz, 2H), 3.79 (t, J = 4.4 Hz, 2H), 3.35 (s, 3H). DMSO 398.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 13

408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.86 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.67 (dd, J = 4.8. 1.6 Hz, 1H), 8.64 (dt, J = 8.0, 1.6 Hz, 1H). 8.12 (ddd, J = 13.2, 7.2, 2.4 Hz, 1H), 7.98 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 9.2, 1H), 7.69-7.72 (m, 1H), 7.52-7.60 (m, 3H), 4.31 (t, J = 4.0 Hz, 2H), 3.76-3.80 (m, 2H), 3.37 (s, 3H). DMSO 409.1  (M +1) Method B (NH4HCO3) 95 Method C, G1 14

441.31 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.90 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.64-8.68 (m, 1H), 8.37 (d, J = 2.8 Hz, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.96 (dd, J = 10.6, 2.4 Hz, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 9.2 Hz, 1H), 7.59 (dd, J = 8.8, 2.4 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 4.31 (t, J = 4.08 Hz, 2H). 3.78 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). DMSO 441.0, 443.0  (M + 1) 221.9  (M/2 + 1) Method A (TFA) 95 Method C, G1 15

441.31 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.93 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.66-8.70 (m, 2H), 8.18 (s, 1H), 8.17 (s, 1H), 7.99 (d, J = 2.4 Hz, 1H). 7.89 (d, J = 8.8 Hz, 1H), 7.61 (dd, J = 8.8, 2.4 Hz, 1H), 7.56 (dd, J = 7.6, 4.8 Hz, 1H), 7.39 (t, J = 2.0 Hz, 1H), 4.33 (t, J = 4.8 Hz, 2H). 3.79 (t, J = 4.4 Hz, 2H). 3.37 (s, 3H). DMSO 441.0, 443.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 16

HCl 375.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.34 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 9.16 (d, J = 1.2 Hz, 1H), 8.74 (dd, J = 4.0, 1.6 Hz, 1H), 8.66-8.69 (m, 2H), 8.20-8.28 (m, 2H), 8.00 (d, J = 8.4 Hz, 1H), 7.89-7.93 (m, 1H), 7.55-7.61 (m, 2H). DMSO 376.0, 378.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 17

393.8 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.37 (s, 1H), 9.54 (d, J = 1.6 Hz; 1H), 9.09 (s, 1H), 8.69 (d, J = 10.0 Hz, 1H), 8.68 (d, J = 8.0 Hz, 1H), 8.23-8.27 (m, 2H), 8.11 (s, 1H), 8.78 (s, 2H), 7.50-7.58 (m, 3H). DMSO 394.1, 396.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 18

HCl 394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.81 (s, 1H), 9.48 (d, J = 0.8 Hz; 1H), 9.28 (cL J = 0.8 Hz, 1H), 8.69 (d, J = 10.0 Hz, 1H), 8.68 (d; J = 8.0 Hz, 1H), 8.23-8.27 (m, 2H), 8.11 (s, 1H), 8.78 (s, 2H), 7.50- 7.58 (m, 3H). DMSO 395.0, 397.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 19

422.38 1H-NMR (400 MHz, DMSO-d₆): δ 10.11 (brs, 1H), 9.48 (s, 1H), 8.79 (d, J = 4.8 Hz, 1H), 8.83 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 2.4 Hz, 1H), 7.88-7.90 (m, 1H), 1.77(d, J = 8.0 Hz, 1H), 7.52-7.62 (m, 3H), 4.27 (q, J = 7.2 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H). DMSO 423.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 20

HCl 408.81 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.73 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.32 (d, J = 1.6 Hz, 1 H), 9.01 (d, J = 4.8 Hz, 1H), 8.91 (d, J = 5.2 Hz, 1H), 8.39 (dd, J = 8.4, 1.6 Hz, 1H), 8.17 (dd, J = 6.8, 2.0 Hz, 1 H), 8.01 (d, J = 8.8 Hz, 1H), 7.90- 7.95 (m, 2H), 7.55 (t, J = 9.2 Hz, 1H), 3.98 (s, 3H). DMSO 409.1, 411.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 21

399.45 ¹H-NMR (400 MHz, DMSO-d₆) δ 12.94 (s, 1H), 9.56 (s, 1H), 9.14 (d, J = 8.0 Hz, 1H), 8.83-8.66 (m, 2H), 8.48 (s, 1H), 8.06-7.91 (m, 2H), 7.76-7.58 (m, 2H), 7.35 (s, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 4.15 (q; J = 6.8 Hz, 2H), 2.64 (s, 3H), 1.43 (t, J = 6.8 Hz, 1H). DMSO 400.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 22

440.42 ¹H-NMR (400 MHz, DMSO-d₆) δ 9.84 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H)t 8.73-8.60 (m, 2H), 8.14 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.53 (dd, J = 7.6, 4.8 Hz, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 4.23 (q, J = 6.8 Hz, 2H), 2.70 (s, 3H), 1.44 (t, J = 6.8 Hz, 3H) DMSO 440.9  (M + 1) Method A (TFA) 95 Method D, G1 23

405.81 ¹H-NMR (400 MHz, DMSO-d₆) δ 10.08 (s, 1H), 9.42 (s, 1H); 8.68 (d, J = 3.6 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.32 (s, 1H), 8.15 (dd, J = 6.8, 2.4 Hz, 1H), 8.04 (s, 1 H), 7.93-7.78 (m, 1H), 7.54 (td, J = 8.3, 6.9 Hz, 2H), 4.08 (s, 3H) DMSO 406.1, 408.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 24

493.92 ¹H-NMR (400 MHz, DMSO-d₆) δ 10.00 (s, 1H), 9.49-9.51 (m, 1H), 8.62-8.70 (m; 2H), 8.21 (dd, J = 6.8. 2.8 Hz, 1H), 8.03 (s, 1H), 7.87-7.91 (m, 1H), 7.75 (s, 1H), 7.53-7.59 (m, 2H), 4.02 (s, 3H), 3.64-3.73 (m, 4H), 3.49-3.58 (m, 2H). 3.14-3.22 (m, 2H). DMSO 494.1, 496.1  (M + 1) Method B (NH4HCO4) 95 Method C, G1 25

TFA 369.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H). 878 (d, J = 8.0 Hz, 2H). 8.17 (d, J = 9.2 Hz, 1H). 7.80 (dd, J = 9.2. 2.8 Hz, 1H). 7.70-7.64 (m, 1H). 7.46 (d, J = 2.8 Hz, 1H). 7.41 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 4.0 Hz, 2H), 7.16-7.08 (m, 1H). 3.89 (s, 3H). DMSO 370.1  (M + 1) Method B (NH4HCO3) 95 Method C, J1 26

408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.87 (s, 1H). 8.53 (dd, J = 4.7, 1.5 Hz, 1H), 8.23 (d, J = 6.8 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.8 (t, J = 2.1 Hz, 1H). 7.84 (d, J = 9.1 Hz, 1H), 7.73 (dd, J = 8.2, 1.2 Hz, 1H), 7.58 (dd, J = 9.1, 2.6 Hz, 1H), 7.41- 7.25 (m, 3H), 7.24 (t, J = 74.0 Hz, 1H), 6.96 (dd, J = 8.0, 2.2 Hz, 1H), 3.99 (s, 3H), 2.75 (s, 3H). DMSO 409.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 27

385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.09 (s, 1H), 9.08 (d, J = 7.8 Hz, 1H), 8.55 (dd, J = 4.8, 1.6 Hz, 1H), 8.49 (s, 1H), 8.22 (dd, J = 7.8, 1.7 Hz, 1H), 8.01 (s, 1H), 7.95 (dd, J = 7.9, 1.2 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1 H), 7.66-7.58 (m, 3H), 7.40 (dd, J = 7.7, 4.8 Hz, 1H), 7.15 (dd, J = 11.5, 4.4 Hz, 1H). 3.99 (s, 3H), 2.77 (s, 3H). DMSO 386.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 28

394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (S, 1H). 8.63 (d, J = 4.1 Hz, 1H), 8.43 (d, J = 7.6 Hz, 1H), 8.15 (dd, J = 6.8, 2.5 Hz, 1H), 8.03 (d, J = 2.3 Hz, 1H), 7.88-7.78 (m, 2H). 7.58 (ddd, J = 12.5. 8.3, 4.1 Hz, 2H), 7.49 (t, J = 9.1 Hz, 1H), 3.99 (s, 3H). 2.80 (s, 3H). DMSO 395.1, 397.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 29

HCl 440.5 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.19 (s, 1H), 11.12-10.93 (m, 1H), 9.83 (d, J = 1.5 Hz, 1H), 9.21 (d, J = 7.8 Hz, 1H), 9.01 (d, J = 7.8 Hz, 1H), 8.93-8.89 (m, 1H), 8.53 (s, 1H), 8.36 (dd, J = 11.8, 7.9 Hz, 2H), 8.02-7.73 (m, 6H), 7.29 (d, J = 8.02 Hz, 1H), 5.01 (s, 2H), 3.95-3.81 (m, 4H), , 3.37 (s, 4H). DMSO 441.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 30

HCl 449.91 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.05 (s, 1H), 9.56 (s, 1H). 8.73-8.66 (m, 2H). 8.47 (d, J = 8.1 Hz, 1H), 8.28 (dd, J = 6.8, 2.5 Hz, 1H), 7.99-7.90 (m, 2H). 7.67-7.50 (m, 3H). 4.16 (s, 2H), 3.62 (s, 4H), 2.53 (s, 4H). DMSO 450.1, 452.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 31

400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.47 (d, J = 2.0 Hz, 2H), 8.70 (dd, J = 4.8. 1.6 Hz, 1H), 8.65-8.59 (m, 1 H), 8.06 (s, 1H), 7.91 (dt, J = 8.1, 6.0 Hz, 1H), 7.82 (dd, J = 8.2, 1.2 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 8.2 Hz, 1H), 7.51 (ddd, J = 20.0, 10.0, 6.4 Hz, 2H), 7.21 (d, J = 8.4 Hz, 1H). DMSO 401.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 32

HCl 368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.53 (d, J = 11.3 Hz, 1H), 9.44 (d, J = 1.2 Hz, 1H), 8.84-8.79 (m, 2H), 8.09 (dd, J = 6.8, 2.6 Hz, 1H), 7.97-7.89 (m, 1H), 7.85-7.75 (m, 3H), 7.57- 7.47 (m, 2H). DMSO 369.1, 371.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 33

HCl 359.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.21 (d, J = 12.1 Hz, 1H), 9.53 (d, J = 1.2 Hz, 1H), 8.99 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 4.2 Hz, 1H), 8.71 (d, J = 7.9 Hz, 1H), 8.35 (s, 1H), 7.97-7.76 (m, 5H), 7.72- 7.65 (m, 1H), 7.50 (dd, J = 12.1. 7.5 Hz, 1H), 7.29 (t, J = 7.1 Hz, 1H). DMSO 360.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 34

382.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.49 (d, J = 1.8 Hz, 1H), 9.42 (s, 1H), 8.71 (dd, J = 4.6, 1.3 Hz, 1H), 8.65 (d, J = 7.8 Hz, 1H), 7.90 (dd, J = 15.8, 9.7 Hz, 2H), 7.73 (dd, J = 19.0, 8.26 Hz, 2H), 7.56- 7.12 (m, 4H), 7.04 (dd, J = 8.2, 1.8 Hz, 1H). DMSO 383.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 35

HCl 400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.52 (s, 1H), 8.89 (d, J = 8.2 Hz, 1H), 8.85 (d, J = 4.2 Hz, 1H), 8.78 (dd, J = 9.2. 5.9 Hz, 1H), 8.09 (s, 1H), 7.95 (dd, J = 8.2, 1.2 Hz, 1H), 7.80 (dd, J = 7.9, 5.2 Hz, 1H), 7.72-7.58 (m, 3H), 7.21 (d, J = 8.4 Hz, 1H). DMSO 401.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 36

HCl 405.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.74- 10.48 (m, 1H), 9.36 (d, J = 1.6 Hz, 1H), 8.95 (d, J = 8.2 Hz, 1H), 8.89-8.85 (m, 1H), 8.06 (d, J = 1.7 Hz, 1H), 8.02 (d, J = 9.15 Hz; 1H), 7.93-7.86 (m, 2H), 7.73- 7.63 (m, 3H), 7.60-7.52 (m, 2H), 3.98 (s, 3H). DMSO 406.1, 408.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 37

HCl 359.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 9.00 (dd, J = 15.4, 8.2 Hz, 2H), 8.86 (d, J = 4.13 Hz, 1H), 8.52 (s, 1H), 8.04-7.94 (m, 3H), 7.86-7.70 (m, 4H), 7.26 (dd, J = 11.2, 4.2 Hz, 1H). DMSO 360.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 38

HCl 368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.52 (s, 1H), 8.73 (d, J = 3.6 Hz, 1H), 8.69 (td, J = 8.0, 1.8 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 7.91 (ddd, J = 9.0, 4.2. 2.6 Hz, 1H), 7.79 (dd, J = 9.8, 7.9 Hz, 1H), 7.67 (dd, J = 8.2, 5.2 Hz, 1H), 7.61-7.53 (m, 2H). DMSO 369.0, 371.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 39

HCl 400.33 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.52 (d, J = 1.4 Hz, 1H), 9.04 (d, J = 8.0 Hz; 1H), 8.92 (dd, J = 5.2, 1.2 Hz, 1H), 8.52 (d, J = 8.4 Hz, 1H), 8.07 (s, 1H), 7.97 (d, J = 1.2 Hz, 2H), 7.86-7.80 (m, 1H), 7.74-7.68 (m, 1 H), 7.62 (t J = 8.2 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H). DMSO 401.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 40

360.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (d, J = 1.6 Hz, 1H), 8.82 (td, J = 7.9, 1.8 Hz, 1H), 8.71 (dd, J = 4.6, 1.6 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 7.87 (dd, J = 7.8, 1.9 Hz, 1H), 7.73 (dd, J = 9.2, 7.8 Hz, 1H), 7.59 (dt, J = 8.1, 5.0 Hz, 2H), 7.21-7.15 (m, 1H), 6.66 (d, J = 8.2 Hz, 1H), 6.54 (t, J = 7.4 Hz, 1H). DMSO 360.9  (M + 1), 382.9 (M + 23) Method B (NH4HCO3) 95 Method C, G1 41

380.08 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.56 (brs, 1H), 9.62 (d, J = 1.2 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 9.00 (dd, J = 1.6, 4.8 Hz, 1H), 8.71 (d, J = 9.2 Hz, 1H), 8.31 (dd, J = 2.0, 7.2 Hz, 1H), 8.02-7.99 (m, 2H), 7.66 (t, J = 9.2 Hz, 1H), 7.54 (s, 1H), 7.50 (dd, J = 2.4, 9.2 Hz, 1H), 4.11 (s, 3H). DMSO 381.1, 383.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 42

476.67 ¹H-NMR (400 MHz, DMSO-d₆): δ10.40 (s, 1H), 9.51 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.40 (d, J = 8.8 Hz, 1H)S 8.35 (d, J = 1.6 Hz, 1H), 8.20 (dd; J = 4.4, 6.8 Hz, 1H), 8.04 (dd, J = 7.2, 8.8 Hz, 1H), 7.93-7.86 (m, 2H), 7.35 (t, J = 9.2 Hz, 1H). DMSO 477.0, 499.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 43

429.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.46 (s, 1H), 9.49 (s, 1 H), 8.95 (d, J = 8.1 Hz, 1H), 8.89 (d, J = 4.97 Hz, 1H), 8.60 (d, J = 8.9 Hz, 1H), 8.19 (dd, J = 6.8, 2.6 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.96-7.83 (m, 3H), 7.53 (t, J = 9.0 Hz, 1H). DMSO 429.0, 430.9, 433.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 44

HCl 385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.05 (s, 1H), 9.44 (d, J = 1.7 Hz, 1H), 9.16- 8.91 (m, 2H), 8.03-7.89 (m, 3H), 7.88- 7.82 (m, 1H), 7.75-7.68 (m, 1H), 7.67- 7.60 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 4.00 (s, 3H), 2.74 (s, 3H). DMSO 386.0  (M + 1) 193.4  (M/2 + 1) Method A (TFA) 95 Method C, G1 45

HCl 408.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.37- 10.12 (m, 1H), 9.35 (d, J = 1.8 Hz, 1H), 8.95 (dd, J = 4.6, 3.4 Hz, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.87 (s, 1H), 7.84-7.74 (m, 2H), 7.62 (dd, J = 9.1, 2.6 Hz, 1 H), 7.54 (t, J = 8.2 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.05 (dd, J = 8.3; 1.9 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO 409.0  (M + 1) 205.0  (M/2 + 1) Method A (TFA) 95 Method C, G1 46

HCl 394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.27 (brs, 1H), 9.32 (d, J = 1.7 Hz, 1H), 8.93 (d, J = 7.5 Hz, 1H), 8.19 (dd, J = 6.8, 2.5 Hz, 1H), 8.07 (d, J = 2.3 Hz, 1H), 7.88- 7.92 (m, 2H), 7.84 (d, J = 8.1 Hz, 1H), 7.62 (dd; J = 9.2, 2.5 Hz, 1H), 7.54 (t, J = 9.1 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO 395.0, 397.0  (M + 1) 197.8, 198.8  (M/2 + 1) Method A (TFA) 95 Method C, G1 47

HCl 378.37 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.58- 10.30 (m, 1H), 9.32 (d, J = 1.9 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.17-8.04 (m, 2H), 7.95 (d, J = 9.0 Hz, 2H), 7.73-7.66 (m, 1H), 7.63 (dd, J = 9.2, 2.6 Hz, 1H), 7.60-7.50 (m, 1H), 4.01 (s, 3H), 2.76 (s, 3H). DMSO 379.0  (M + 1) 190.0  (M/2 + 1) Method A (TFA) 95 Method C, G1 48

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.29 (s, 1H), 9.33 (d, J = 1.7 Hz, 1H), 9.04- 8.89 (m, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.97 (dd, J = 8.8, 2.5 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 4.00 (s; 3H), 2.73 (s, 3H). DMSO 411.0, 413.0  (M + 1) 205.0, 206.9  (M/2 + 1) Method A (TFA) 95 Method C, G1 49

411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.30 (s, 1H), 9.31 (d, J = 1.5 Hz, 1H), 8.94 (d, J = 7.3 Hz, 1H), 8.13 (d, J = 1.7 Hz, 2H), 8.07 (d, J = 2.3 Hz, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.41 (d, J = 1.7 Hz, 1H), 4.00 (s, 3H), 2.72 (s, 3H). DMSO 411.0, 413.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 50

HCl 389.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.09 (s, 1H), 9.38 (s, 1H), 9.16 (d, J = 8.4 Hz, 1H), 8.83 (d, J = 8.3 Hz, 1H), 8.50 (s, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.05-7.99 (m, 2H), 7.97 (d, J = 7.9 Hz, 1H), 7.92 (s, 1H), 7.81 (dd, J = 8.8, 2.0 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 2.82 (s, 3H). DMSO 390.1, 392.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 51

HCl 412.82 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.49 (s, 1H), 9.35 (d, J = 1.7 Hz, 1H), 9.08 (dd, J = 8.3, 1.5 Hz, 1H), 8.75 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.87 (s, 1H), 7.80 (dd, J = 9.0, 2.0 Hz, 2H), 7.53 (t, J = 8.2 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1 H), 7.06 (dd, J = 8.1, 2.0 Hz, 1H), 2.79 (s, 3H). DMSO 413.0, 415.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 52

399.25 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.49 (S, 1H), 9.32 (d, J = 1.7 Hz, 1H), 9.00 (d, J = 8.4 Hz, 1H), 8.69 (d, J = 8.9 Hz, 1H), 8.20 (dd, J = 6.8, 2.6 Hz, 1 H), 8.00 (d, J = 2.1 Hz, 1H), 7.96-7.86 (m, 2H), 7.80 (dd, J = 8.9, 2.1 Hz, 1H), 7.53 (t, J = 9.1 Hz, 1H), 2.76 (s, 3H). DMSO 399.0, 401.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 53

HCl 382.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.55 (s, 1H), 9.32 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 8.2, 1.2 Hz, 1H), 8.73 (d, J = 8.9 Hz, 1H), 8.08 (ddd, J = 13.0, 7.5, 2.6 Hz, 1H), 8.00 (dd, J = 8.9, 5.2 Hz, 2H), 7.80 (dd, J = 8.9. 2.1 Hz, 1H), 7.71 (dd, J = 6.1, 2.9 Hz, 1H), 7.54 (dd, J = 19.7, 9.2 Hz, 1H), 2.78 (s, 3H) DMSO 383.0, 385.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 54

HCl 415.7 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.63 (s, 1H), 9.30 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 8.3, 1.8 Hz, 1H), 8.75 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.96 (dd, J = 8.9, 2.5 Hz, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 2.81 (s, 3H). DMSO 415.0, 417.0, 419.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 55

HCl 415.7 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.54 (s, 1H), 9.32 (s, 1H), 9.01 (dd, J = 8.0. 1.8 Hz, 1H), 8.72 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 1.8 Hz, 2H), 8.01 (d, J = 2.0 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.80 (dd, J = 8.9. 2.0 Hz, 1 H), 2.78 (s, 3H). DMSO 415.0, 417.0, 419.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 56

379.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.16 (s, 1H), 9.47 (s, 1H), 8.79 (dd, J = 8.9. 7.1 Hz, 2H), 7.91 (s? 1H), 7.84-7.77 (m, 2H), 7.76-7.68 (m, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.51 (t, J = 8.2 Hz, 1H), 7.39 (dd, J = 8.9, 2.2 Hzr 1H), 7.29 (t, J = 74.0 Hz, 1H), 7.00 (dd, J = 8.1, 2.1 Hz, 1H), 4.23 (bis, 2H). DMSO 380.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 57

HCl 463.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43- 10.20 (m, 2H), 9.72 (s, 1H), 8.89-8.67 (m, 3H), 8.29-8.21 (m, 1H), 7.97 (s, 1H), 7.87-7.80 (m, 1H), 7.81-7.73 (m, 1H), 7.63-7.46 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.08-6.98 (m, 1H), 5.00 (s, 2H), 4.05-3.65 (m, 4H), 3.39-3.36 (m, 4H). DMSO 464.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 58

HCl 399.45 ¹H-NMR (400 MHz, DMSO-d₆) δ 12.53 (s, 1H), 9.30 (d, J = 1.6 Hz, 1H), 9.03- 8.96 (m, 1H), 8.94-8.88 (m, 1H), 8.71 (d, J = 8.4 Hz, 1H), 7.91-7.83 (m, 3H), 7.67-7.55 (m, 3H), 7.25 (t, J = 7.2 Hz, 1H), 3.98 (s, 3H), 2.80-2.74 (m, 6H). DMSO 400.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 59

HCl 389.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.27 (s, 1H), 9.23 (s, 1H), 8.98 (d, J = 5.2 Hz, 1H), 8.91 (d, J = 8.0 Hz, 1H), 8.54 (dd, J = 12.0, 2.6 Hz, 1H), 8.48 (s, 1H), 8.07 (dd, J = 8.0, 5.6 Hz, 1H), 7.97-7.93 (m, 2H), 7.66 (d, J = 9.0 Hz, 1H), 7.37 (dd, J = 9.0, 2.4 Hz, 1H), 7.13 (d, J = 2.0 Hz, 1H), 6.91 (dt, J = 8.4. 2.G Hz, 1 H), 3.80 (s, 3H). DMSO 390.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 60

415.70 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.48 (s, 1H), 8.87 (dd, J = 14.0, 6.2 Hz, 2H), 8.54 (d, J = 1.7 Hz, 1H), 8.10 (d, J = 1.8 Hz, 2H), 7.89-7.78 (m, 2H), 7.37 (t, J = 1.8 Hz, 1H), 2.70 (s, 3H). DMSO 414.9, 416.9, 419.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 61

415.70 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 9.44 (s, 1 H), 8.86 (d, J = 7.8 Hz, 1H), 8.79 (d, J = 4.5 Hz, 1H), 8.50 (d, J = 1.7 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 7.89 (dd, J = 8.8, 2.4 Hz, 1H), 7.83- 7.71 (m, 2H), 7.62 (d, J = 8.8 Hz, 1H), 2.62 (s, 3H) DMSO 414.9, 416.9, 418.9  (M + 1) Method B (NH4HCO3) 95 Method C, G1 62

412.82 ¹H-NMR (400 MHz, DMSO-d₆): δ: 10.02 (s, 1H), 9.58 (d, J = 1.8 Hz, 1H), 8.76- 8.67 (m, 2H), 8.59 (d, J = 1.8 Hz, 1H), 7.96 (s, 1H), 7.82 (d, J = 6.6 Hz, 2H), 7.54 (ddd, J = 16.4, 10.0, 6.4 Hz, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 8.0, 2.0 Hz, 1H), 2.74 (s, 3H). DMSO 413.0, 415.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 63

389.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.15 (s, 1H), 9.58 (s, 1H), 9.03 (d, J = 0.8 Hz, 1H), 8.78-8.84 (m, 2H), 8.50 (s, 1H), 7.95-8.03 (m, 3H), 7.80 (s, 1H), 7.70- 7.74 (m, 2H), 7.23 (d, J = 7.2 Hz, 1H), 2.70 (s, 3H). DMSO 391.0, 392.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 64

371.82 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.31 (s, 1H); 9.48 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 8.4 Hz, 1H), 8.90 (d, J = 4.0 Hz, 1H), 8.61 (d, J = 1.6 Hz, 1H), 8.33 (s, 1H), 8.27 (dd, J = 6.0, 2.0 Hz, 1H), 7.95- 7.63 (m, 3H), 2.70 (s, 3H). DMSO 372.0  373.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 65

476.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.46 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 1.2 Hz, 1H), 8.83 (dd, J = 8.4. 1.6 Hz, 2H), 8.19-8.14 (m, 2H), 7.89-7.49 (m, 2H). DMSO 476.9, 478.9  (M + 1) Method B (NH4HCO3) 95 Method C, G1 66

399.25 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.03 (s, 1H), 8.54 (s, 1 H), 871-8.67 (m, 2H)S 8.53 (s, 1H), 8.26 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 7.83 (s, 1H), 7.58-7.52 (m, 2H), 2.72 (s, 3H). DMSO 399.0, 401.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 67

382.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.04 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.72- 8.69 (m, 2H), 8.53 (d, J = 2.0 Hz, 1H), 8.08 (ddd, J = 9.2, 7.6, 2.4 Hz, 1H), 7.79- 7.48 (m, 4H), 2.69 (s, 3H). DMSO 383.0, 385.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 68

HCl 399.45 ¹H-NMR (400 MHz, DMSO-d6): δ 13.02 (S, 1H), 9.59 (s, 1H), 9.09 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 8.4 Hz, 1H), 8.91 (d, J = 4.61 Hz, 1 H), 8.48 (s, 1H), 7.97 (dd, J = 8.0, 2.8 Hz, 4H), 7.72 (t, J = 7.6 Hz, 1H), 7.64-7.61 (m, 2H), 7.26 (t, J = 7.6 Hz, 1H), 4.88-4.82 (m, 1H), 1.43 (d, J = 6.0 Hz, 6H). DMSO 400.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 69

HCl 422.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.63 (s, 1H), 9.51 (s, 1 H), 9.09 (d, J = 7.6 Hz, 1H), 8.91 (d, J = 7.6 Hz, 1H), 8.23 (s, 1H), 8.03-7.97 (m, 1H), 7.83-7.80 (m, 2H), 7.64 (dd, J = 9.2, 2.4 Hz, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.08 (d, J = 7.4 Hz, 1H), 5.02-4.97 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 423.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 70

HCl 408.86 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.48 (s, 1 H), 9.05 (d, J = 7.2 Hz, 1H), 8.93 (d, J = 5.2 Hz, 1H), 8.19- 8.15 (m, 2H); 8.01-7.92 (m, 3H), 7.63- 7.53 (m, 2H), 5.01-4.94 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 409.1, 411.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 71

HCl 425.31 ¹H NMR (400 MHz, DMSO-d₆): δ 9.92 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.70-8.66 (m, 2H), 8.17 (d, J = 1.6 Hz, 2H), 7.98 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.60-7.56 (m, 2H), 7.39 (t, J = 1.8 Hz, 1H), 4.94-4.88 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 424.9, 426.9  (M + 1) Method B (NH4HCO3) 95 Method C, G1 72

HCl 392.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.49 (d, J = 1.2 Hz, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.86-8.84 (m, 1H), 8.10-8.05 (m, 2H), 7.93-7.85 (m, 2H), 7.71-7.69 (m, 2H), 7.61-7.52 (m, 1H), 4.97-4.91 (m, 1H), 1.39 (d, J = 6.0 Hz, 6H). DMSO 393.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 73

HCl 385.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.03 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.93-8.90 (m, 2H), 8.49 (s, 1H), 8.01-7.91 (m, 4H), 7.69 (t, J = 7.6 Hz, 1H), 7.59-7.54 (m, 2H), 7.24 (t, J = 7.6 Hz, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 386.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 74

HCl 367.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.35 (s, 1H), 9.49 (s, 1 H), 8.95 (d, J = 7.6 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.37 (s, 1H), 8.28 (d, J = 7.6 Hz, 1H), 8.08 (s, 1H), 7.94-7.85 (m, 2H), 7.73-7.60 (m, 3H), 4.28 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.8 Hz, 3H). DMSO 368.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 75

HCl 394.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.64 (s, 1H), 9.44 (s, 1 H), 8.99 (d, J = 8.4 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.17 (d, J = 3.2 Hz, 2H), 7.59-7.50 (m, 2H), 4.26 (q, J = 6.8 Hz, 2H), 1.44 (t, J = 6.8 Hz, 3H). DMSO 395.1  397.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 76

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48 (s, 1H), 9.47 (s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.13 (s, 1H), 8.01-7.91 (m, 3H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.57 (m, 1H), 4.26 (q, J = 6.8 Hz, 2H), 1.44 (t, J = 6.8 Hz, 3H). DMSO 411.0  413.0  415.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 77

HCl 411.28 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.48 (s, 1 H), 8.93 (d, J = 8.0 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.14 (s, 2H), 8.05 (d, J = 1.6 Hz, 1H), 7.92-7.85 (m, 2H), 7.61 (dd, J = 9.1, 1.8 Hz, 1H), 7.41 (s, 1H), 4.26 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 6.8 Hz, 3H). DMSO 411.0  413.0  415.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 78

HCl 378.37 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.39 (s, 1H), 9.49 (s, 1 H), 8.98 (d, J = 8.0 Hz, 1H), 8.88 (d J = 4.8 Hz, 1H), 8.11-8.05 (m, 2H), 7.95-7.91 (m, 2H), 7.72-7.52 (m, 3H), 4.28 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 6.8 Hz, 3H). DMSO 379.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 79

HCl 429.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.99 (s, 1H), 9.59 (d, J = 1.6 Hz, 1H), 9.14 (d, J = 7.6 Hz, 1H), 8.75-8.69 (m, 2H), 8.48 (s, 1H), 7.99-7.96 (m, 2H), 7.90 (d, J = 8.8 Hz,, 1H), 7.76-7.72 (m, 1H), 7.61-7.56 (m, 3H), 7.22-7.19 (m, 1H), 4.24 (t, J = 6.0 Hz, 2H), 3.56 (t, J = 6.0 Hz, 2H), 3.28 (s, 3H), 2.11-2.04 (m, 2H). DMSO 430.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 80

HCl 380.80 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.67 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.90 (d, J = 8.4 Hz, 1H), 8.66 (dd, J = 8.8, 2.4 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.14-8.08 (m, 2H), 7.90-7.81 (m, 2H), 7.62 (t, J = 9.2 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 3.98 (s, 3H). DMSO 380.9, 382.9  (M + 1) Method A (TFA) 95 Method C, G1 81

HCl 394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.81 (s, 1H), 9.49 (d, J = 1.2 Hz, 1H), 9.28 (d, J = 0.8 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 9.02 (d, J = 5.2 Hz, 1H), 8.37-8.34 (m, 1H), 8.12-8.09 (m, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.95-7.91 (m, 1 H), 7.53 (t, J = 9.0 Hz, 1H). DMSO 395.0, 397.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 82

385.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (d, J = 1.6 Hz, 1H), 9.13 (s, 1H), 8.80-8.75 (m, 2H), 8.21 (d, J = 9.2 Hz, 1H), 7.97- 7.94 (m, 1H), 7.82 (dd, J = 9.2, 2.8 Hz, 1H), 7.73 (dd, J = 9.2, 2.4 Hz, 1 H), 7.64- 7.61 (m, 1H), 7.38-7.32 (m, 2H), 4.18 (q, J = 6.8 Hz, 2H), 3.19 (t, J = 7.0 Hz, 3H). DMSO 386.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G10 83

HCl 426.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.49 (d, J = 1.6 Hz, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (dd, J = 9.2. 1.6 Hz, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.05 (s, 1H), 7.97-7.89 (m, 3H), 7.65-7.61 (m, 2H), 7.23 (d, J = 8.4 Hz, 1H), 4.29 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H). DMSO 427.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 84

426.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.00 (s, 1H), 9.55 (s, 1H), 9.12 (d, J = 8.0 Hz, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.11-8.09 (m, 1H), 8.02- 7.99 (m, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.82-7.11 (m, 1H), 7.65 (s, 1H), 7.62- 7.59 (m, 1H), 7.30 (t, J = 7.2, Hz, 1H), 5.06-5.03 (m, 1H), 2.15-2.09 (m, 2H), 1.86-1.74 (m, 4H), 1.68-1.65 (m, 2H). DMSO 427.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 85

375.81 ¹H-NMR (400 MHz, DMSO-d6): δ 13.09 (s, 1H), 9.58 (s, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 4.4 Hz, 1H), 8.88 (d, J = 8.4 Hz, 1H), 8.50 (s, 1H), 8.25 (s, 1H), 8.01-7.96 (m, 5H), 7.71 (t, J = 8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H). DMSO 376.0, 378.0  (M + 1) 397.9  (M + 23) 188.4  (M/2 + 1) Method A (TFA) 95 Method C, G10 86

398.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 9.54 (s, 1H), 8.78 (s, 1H), 8.71- 8 67 (m, ?H) 7 96 (s, 1H), 7 91 (d, = 8.0 Hz, 2H), 7.82 (d, J = 8.0 Hz, 1H), 7.56-7.51 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 2.0. 8.0 Hz, 1H). DMSO 399.0, 401.0  (M + 1) 199.9, 200.8  (M/2 + 1) Method A (TFA) 95 Method C, G1 87

443.7 ¹H-NMR (400 MHz, DMSO-d₆₎: δ 10.09 (s, 1H), 9.39 (s, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.90 (d, J = 5.6 Hz, 1H), 8.62 (d, J = 1.6 Hz, 1H), 8.11 (dd, J = 6.8, 2.4 Hz, 1H), 7.95-7.91 (m, 1H), 7.89-7.85 (m, 1H), 7.80 (s, 1H), 7.45 (t, J = 8.8 Hz, 1H), 2.66 (s, 3H). DMSO 443.0, 445.0, 447.0  (M + 1) Method B (NH₄HCO₃) 98 Method C, G1 88

401.42 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.19 (S, 1H), 9.43 (d J = 8.0 Hz, 1H), 8.53 (s, 1H), 8.31 (dd, J = 4.8, 1.6 Hz, 1H), 8.26 (dd, J = 1.6, 7.2 Hz, 1H), 8.03 (s, 1H), 7.96-7.89 (m, 1H), 7.86 (d, J = 9.2 Hz, 1H), 7.65-7.54 (m, 3H), 7.18-7.12 (mT 2H), 4.02 (s, 3H); 3.98 (s, 3H). DMSO 402.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 89

410.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.79 (s, 1H), 8.52 (dd, J = 2.4, 7.2 Hz, 1H), 8.28 (dd, J = 5.6, 2.4 Hz, 1H), 8.12 (dd, J = 2.4. 5.2 Hz, 1H), 7.98-7.94 (m, 2H), 7.82 (d, J = 9.2 Hz, 1H), 7.56 (dd, J = 9.2, 2.8 Hz, 1H), 7.47 (t, J = 9.2 Hz, 1H), 7.14-7.1 I (m, IH), 4.00 (s, 3H), 3.99 (s, 3H). DMSO 411.1, 413.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 90

415.44 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.03 (s, 1H); 9.21 (d, J = 2.2 Hz, 1H), 9.16 (d, J = 7.9 Hz, 1H), 8.67 (dd, J = 8.7, 2.4 Hz, 1H), 8.50 (s, 1H), 8.02 (s, 1H), 7.99- 7.93 (m, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.78-7.72 (m, 1H), 7.56 (dd, J = 11.2. 2.1 Hz, 2H), 7.19(t, J = 7.2 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 3.96 (s, 3H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 416.1  (M + 1) Method B (NH₄HCO₃) 95 Method D, G1 91

HCl 405.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.28 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.31 (d, J = 2.1 Hz, 1H), 8.90 (d, J = 8.3 Hz, 1H), 8.83 (dd, J = 5.0, 1.4 Hz, 1H), 8.58 (s, 1H), 8.12 (ss 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.82 (dd, J = 7.9, 5.0 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.30 (dd, J = 8.5. 2.2 Hz, 1 H), 3.98 (s, 3H). DMSO 406.0, 408.0  (M + 1) Method A (TFA) 95 Method C, G2 92

429.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.99 (s, 1H), 9.21 (d, J = 2.0 Hz, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.67 (dd, J = 8.7, 2.3 Hz, 1H), 8.49 (s, 1H), 8.05-7.90 (m, 2H), 7.85 (d, J = 9.0 Hz, 1H), 7.75 (t, J = 7.2 Hz, 1H), 7.67-7.47 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 4.15 (t, J = 6.3 Hz, 2H), 3.96 (s, 3H), 1.07 (t, J = 7.4 Hz, 3H), 1.86 (dd, J = 14.0, 6.7 Hz, 2H). DMSO 430.1  (M + 1) Method B (NH₄HCO₃) 95 Method D, G1 93

HCl 389.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.34 (s, 1H), 9.52 (d, J = 1.7 Hz, 1H), 8.99 (d, J = 7.8 Hz, 1H), 8.85 (dd, J = 5.2, 1.3 Hz, 1H), 8.22 (d, J = 8.1 Hz, 1H), 8.11-8.00 (m, 2H), 7.95 (d J = 9.1 Hz, 1H), 7.87 (dd, J = 7.9, 5.3 Hz, 1H), 7.77-7.59 (m, 3H), 7.27-7.16 (m, 1H), 3.99 (s, 3H). DMSO 390.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G3 94

436.29 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 9.17 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.76 (d, J = 4.0 Hz, 1H), 8.26-8.07 (m, 3H), 7.83 (dd, J = 9.1, 2.5 Hz, 1H), 7.63 (dd, J = 7.5. 5.0 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 4.18 (q, J = 6.8 Hz, 2H), 1.39 (t, J = 6.9 Hz, 3H). DMSO 436.1, 438.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G10 95

405.84 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.93 (s, 1H), 9.58 (s, 1H), 9.16 (d, J = 9.0 Hz, 1H), 8.70-8.74 (m, 2H), 8.59 (s, 1H), 8.13 (s, 1H), 8.05 (d, J = 2.3 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.82 (dd, J = 8.9, 2.1 Hz, 1H), 7.65-7.49 (m, 3H), 3.98 (s, 3H). DMSO 406.1, 408.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G3 96

429.67 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.45 (s, 1H), 9.47 (s, 1H), 9.02-8.92 (m, 3H), 8.18-8.16 (m, 1H), 8.06-8.04 (m, 1H), 7.96-7.84 (m, 3H), 7.54-7.50 (m, 1H). DMSO 429.9, 431.0, 433.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 97

398.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.58 (s, 1H), 8.85-8.76 (m, 2H), 8.60 (d, J = 7.2 Hz, 1H), 8.12-8.10 (m, 1H), 7.92 (s, 1H), 7.83-7.80 (m, 1H), 7.71-7.64 (m, 2H), 7.56-7.52 (m, 1H), 7.30 (t, J = 74.0 Hz, 1 H), 7.05-7.03 (m, 1H). DMSO 399.0, 401.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 98

385.22 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.50 (s, 1 H), 9.04 (d, J = 8.0 Hz, 1H), 8.93 (d, J = 5.2 Hz, 2H), 8.64 (d, J = 8.8 Hz, 1H), 8.20-8.18 (m, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.97-7.92 (m, 2H), 7.68-7.64 (m, 1H), 7.53 (t, J = 9.2 Hz, 1H). DMSO 385.0, 386.9  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 99

401.68 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.42 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.96 (d, J = 4.0 Hz, 1H), 8.88-8.87 (m, 1H), 8.61 (d, J = 7.6 Hz, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.14-8.12 (m, 1H), 7.99-7.95 (m, 1H), 7.88 (dd, J = 8.0, 5.2 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.70-7.67 (m, 1H). DMSO 400.9, 402.9, 404.9  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 100

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.92 (d, J = 5.6 Hz, 1H), 8.65 (d, J = 8.0 Hz, 1 H), 8.11-8.05 (m, 2H), 7.97 (dd, J = 8.0, 4.0 Hz, 1H), 7.75- 7.73 (m, 1H), 7.66 (t, J = 8.0 Hz; 1H), 7.58-7.51 (m, 1H). DMSO 369.0, 371.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 101

375.09 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.18 (s, 1H), 9.61 (s, 1 H), 9.02 (d, J = 8.4 Hz, 1H), 8.93 (d, J = 8.4 Hz, 1H), 8.83 (d, J = 4.0 Hz, 1H), 8.52 (s, 1H), 8.16-8.08 (m, 2H), 7.98-7.94 (m, 2H), 7.80-7.67 (m, 3H), 7.26 (t, J = 7.6 Hz, 1H). DMSO 376.0, 378.0  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 102

401.68 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.49 (d, J = 2.0 Hz, 1H), 9.00- 8.98 (m, 1H), 8.91 (dd, J = 5.2, 1.6 Hz, 1H), 8.64-8.62 (m, 1H), 8.12-8.09 (m, 3H), 7.94 (dd, J = 8.0, 5.2 Hz, 1 H), 7.67 (t, J = 8.0 Hz, 1H), 7.41 (t, J = 2.0 Hz, 1H). DMSO 400.9, 402.9, 404.9  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 103

434.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (d, J = 1.2 Hz, 1H), 9.51 (s, 1H), 8.71- 8.62 (m, 3H), 8.25-8.22 (m, 1H), 8.04- 8.00 (m, 1 H), 7.92-7.87 (m, 2H), 7.58- 7.53 (m, 2H). DMSO 435.1, 437.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 104

448.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.16 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.72- 8.68 (m, 3H), 8.05 (d, J = 9.2 Hz, 1H), 7.92-7.95 (m, 2H), 7.80 (dd, J = 8.0, 1.2 Hz, 1 H), 7.57-7.53 (m, 2H), 7.31 (t, J = 74.4 Hz, 1 H), 7.03 (dd, J = 8.0, 1.2 Hz, 1H). DMSO 449.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 105

425.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.24 (s, 1H), 9.59 (s, 1H), 9.06 (d, J = 8.0 Hz, 1H), 8.74-8.73 (m, 2H), 8.54 (s, 1H), 8.10-7.91 (m, 5H), 7.77-7.73 (m, 1H), 7.61-7.58 (m, 1H), 7.26 (t, J = 7.6 Hz, 1H). DMSO 426.1  (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 106

448.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.76 (d, J = 9.1 Hz, 1H), 8.74-8.67 (m, 2H), 7.94 (t, J = 2.0 Hz, 1H), 7.82-7.78 (m, J = 10.3 Hz, 2H), 7.68 (dd, J = 9.0, 1.8 Hz, 1H), 7.59-7.50 (m, 2H), 7.30 (t, J = 74.0 Hz, 1H), 7.03 (dd, J = 8.2, 2.2 Hz, 1H). DMSO 449.0  (M + 1) 225.0  (M/2 + 1) Method A (TFA) 95 Method C, G1 107

425.36 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.17 (s, 1H), 9.59 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.74-8.70 (m, 2H), 8.51 (s, 1H), 8.30 (d, J = 9.0 Hz, 1H), 8.02-7.90 (m, 2H), 7.86-7.69 (m, 3H), 7.65-7.56 (m, 1H), 7.25 (t, J = 9.8 Hz, 1H). DMSO 426.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 108

434.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.26 (s, 1H), 9.52 (s, 1 H), 8.81-8.59 (m, 3H), 8.24 (dd, J = 6.9, 2.5 Hz, 1H), 7.89- 7.52 (m, 1H), 7.79 (s, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.65-7.50 (m, 2H). DMSO 435.0, 437.0  (M + 1) 218.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 109

455.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.35 (s, 1H), 9.58 (s, 1H), 9.27 (s, 1H), 8.83- 8.70 (m, 2H), 8.62 (s, 1H), 8.18 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.68-7.58 (m, 2H), 7.54 (d, J = 2.5 Hz, 1H), 7.19 (dd, J = 8.4, 2.17 Hz, 1H), 3.98 (s, 3H). DMSO 456.0  (M + 1) 228.5  (M/2 + 1) Method A (TFA) 95 Method C, J1 110

425.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.08 (s, 1H), 9.59 (s, 1H), 9.07 (d J = 7.6 Hz, 1H), 9.02 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.0 Hz, 1 H), 8.50 (s, 1H), 7.92-7.99 (m, 4H), 7.73 (t, J = 7.6 Hz, 1H), 7.59-7.60 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 2.12- 2.15 (m, 2H), 5.02-5.03 (m, 1H), 1.67- 1.86 (m, 6H). DMSO 426.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 111

448.46 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.26 (S, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.95(d, J = 7.2 Hz, 1H), 8.55 (d, J = 4.4 Hz, 1H), 8.08 (s, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 9.6 Hz, 2H), 7.79 (d, J = 8.8 Hz, 1H), 7.60-7.63 (m, 1 H), 7.55 (t, J = 8.0 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 5.14 (s, 1H), 2.03-2.09 (m, 2H), 1.61-1.81 (m, 6H). DMSO 449.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 112

434.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.47 (s, 1 H), 8.97 (d, J = 7.6 Hz, 1H), 8.89 (d, J = 4.4 Hz, 1H), 8.16-8.19 (m, 1H), 7.53-7.61 (m, 2H), 8.10 (s, 1H), 7.90-7.96 (m, 3H), 5.15 (s, 1H), 2.09-2.10 (m, 2H), 1.67-1.78 (m, 6H). DMSO 435.0, 437.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 113

451.35 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.49 (s, 1H), 8.85 (d, J = 7.6 Hz, 1H), 8.80 (d, J = 4.0 Hz, 1H), 8.32 (s, 1H), 8.03 (s, 1H), 7.97-7.99 (m, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.77-7.79 (m, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.55-7.58 (m, 1H), 5.13 (s, 1H), 2.08 (d, J = 8.4 Hz, 2H), 1.79 (d, J = 9.6 Hz, 4H). DMSO 451.0, 453.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 114

418.44 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 9.49 (s, 1 H), 8.92 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 6.4 Hz, 1H), 8.04-8.11 (m; 2H), 7.92 (d, J = 9.2 Hz, 1H), 7.84- 7.91 (m, 1H), 7.69-7.71 (m, 1H), 7.52- 7.61 (m, 2H), 5.13 (s, 1H), 2.06-2.11 (m, 2H), 1.65-1.81 (m, 6H). DMSO 419.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 115

407.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.70 (s, 1H), 9.45 (s, 1H), 8.98 (d, J = 6.8 Hz, 1H), 8.89 (d, J = 6.0 Hz, 1H), 8.37 (s, 1H), 8.32 (d, J = 6.8 Hz, 1H), 8.18 (s, 1H), 7.93 (t, J = 9.2 Hz, 2H), 7.70 (t, J = 7.2 Hz, 2H), 7.56 (d, J = 8.8 Hz, 1H), 5.18 (s, 1H), 2.09 (s, 2H), 1.77 (m, 4H), 1.66 (m, 2H). DMSO 408.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 116

401.68 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 1H), 9.47 (s, 1H), 8.71 (d, J = 6.4 Hz, 1H), 8.62 (d, J = 7.6 Hz, 1H), 8.26 (s, 1H), 7.88 (t, J = 7.2 Hz, 3H), 7.75-7.73 (m, 2H), 7.57-7.56 (m, 1H). DMSO 401.0, 403.0  405.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 117

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74(s, 1H), 9.45 (d, J = 1.2 Hz, 1H), 8.70 (dd, J = 4.4. 1.6 Hz, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.04-8.00 (m, 1H), 7.88-7.85 (m, 2H), 7.74 (dd, J = 8.4, 1.6 Hz, 1H), 7.65- 7.63 (m, 1H), 7.57- 7.56 (m, 2H). DMSO 369.1, 371.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 118

436.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.33 (s, 1H), 8.87-8.20 (m, 2H), 8.27 (d, J = 1.6 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.90-7.72 (m, 3H), 7.39-7.36 (m, 2H), 3.44 (brs, 4H), 2.05 (brs, 4H). DMSO 435.9, 437.9, 439.8  (M + 1) Method B (NH4HCO3) 95 Method C, G1 119

403.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.38 (s, 1H), 9.43 (d, J = 1.2 Hz, 1H), 8.85- 8.80 (m, 2H), 8.07-8.05 (m, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.81 (t, J = 6.8 Hz, 1H), 7.69-7.67 (m, 1H), 7.58-7.83 (m, 1H), 7.43-7.41 (m, 2H), 3.45 (brs, 4H), 2.06 (brs, 4H). DMSO 403.9  (M + 1) Method B (NH4HCO3) 95 Method C, G1 120

368.77 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.28 (s, 1H), 9.49 (s, 1 H), 8.77-8.87 (m, 3H), 8.06-8.12 (m, 1H), 7.90-7.95 (m, 2H), 7.78-7.81 (m, 1H), 7.57-7.73 (m, 1H), 7.53 (dd, J = 19.6 Hz, 9.2 Hz, 1H). DMSO 369.0, 371.1  (M + 1) Method A (TFA) 95 Method C, G1 121

401.68 1H-NMR (400 MHz, DMSO-d6): δ 10.37 (s, 1H), 9.52 (s, 1H), 8.95 (d, J = 3.2 Hz, 1H), 8.87 (m, 1H), 8.81 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.95-7.99 (m, 3H), 7.87- 7.89 (m, 1H), 7.72 (d, J = 8.8 Hz, 1H). DMSO 401.0, 403.0, 405.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 122

385.22 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.50 (s, 1H), 8.69 (s, 2H), 8.64 (d, J = 8.0 Hz, 1H), 8.26 (dd, J = 10.6 Hz, 1.8 Hz, 1H), 7.89-7.90 (m, 3H), 7.51- 7.57 (m, 2H). DMSO 385.0, 387.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 123

357.8 1H-NMR (400 MHz, DMSO-d6): δ 10.25 (s, 1 H), 9.52 (s, 1 H), 8.67-8.76 (m, 3H), 8.44 (s, 1H), 8.27 (m, 1H), 7.96 (s, 2H), 7.66-7.69 (m, 2H), 7.57-7.59 (m, 1H). DMSO 358.0  (M + 1) Method A (TFA) 95 Method C, G1 124

411.86 1H-NMR (400 MHz, DMSO-d6): δ 10.53 (s, 1H), 9.54 (s, 1H), 9.08 (d, J = 8.4 Hz, 1H), 8.94-8.90 (m, 2H), 8.15 (d, J = 8.4 Hz, 2H), 8.00-7.93 (m, 5H), 7.39 (s, 2H). DMSO 412.0, 414.0  (M + 1) Method A (TFA) 95 Method C, G1 125

411.86 1H-NMR (400 MHz, DMSO-d6): δ 10.64 (s, 1H), 9.54 (s, 1H), 9.22 (s, 1H), 8.92- 8.98 (m, 2H), 8.70 (s, 1H), 8.10 (s, 1H), 8.03-8.05 (m, 1H), 7.95 (s, 2H), 7.69 (s, 2H), 7.53 (s, 2H). DMSO 412.0, 414.0  (M + 1) Method A (TFA) 95 Method C, G1 126

364.35 1H-NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H), 9.47 (s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 8.92 (s, 1H), 8.21 (s, 1H), 8.08- 8.10 (m, 1 H), 7.95-7.97 (m, 2H), 7.74- 7.75 (m, 1H), 7.54-7.62 (m, 2H), 4.00 (s, 3H). DMSO 364.1  (M + 1) 183.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 127

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.56 (s, 1H), 9.48 (s, 1 H), 9.02 (d, J = 8.0 Hz, 1H), 8.91-8.92 (m, 1H), 8.28 (d, J = 2.4 Hz, 1H), 8.16-8.17 (m, 1H), 7.92-8.03 (m, 3H), 7.72 (d, J = 8.8 Hz, 1H), 7.58- 7.61 (m, 1H), 4.00 (s, 3H). DMSO 397.0, 399.0  (M + 1), 200.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 128

407.45 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.55 (s, 1H), 8.92-8.84 (m, 2H), 8.16-8.09 (m, 3H), 7.95-7.89 (m, 3H), 7.83-7.79 (m, 1 H), 7.62-7.58 (m, 1H), 7.36 (s, 2H), 3.40 (s, 3H). DMSO 408.1  (M + 1) Method A (TFA) 95 Method C, G1 129

362.81 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.51 (s, 1 H), 8.82-8.85 (m, 2H), 8.10-8.11 (m, 1H), 8.05 (d . J = 2.0 Hz, 1H), 7.98-7.93 (m, 2H), 7.75-7.77 (m, 1H), 7.59-7.61 (m, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.27-7.28 (m, 1H), 3.99 (s, 3H). DMSO 363.0, 365.0  (M + 1), 182.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 130

380.8 1H-NMR (300 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.50 (s, 1H), 7.78-8.79 (m, 2H), 8.19-8.24 (m, 1H), 7.86-8.00 (m, 3H), 7.52-7.70 (m, 3H), 3.98 (s, 3H). DMSO 381.1, 383.1  (M + 1), 191.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 131

371.39 1H-NMR (300 MHz, DMSO-d6): δ 13.08 (s, 1H), 9.59 (s, 1 H), 9.07 (d, J = 8.1 Hz, 1H), 8.96(d, J = 8.1 Hz, 1H), 8.83 (d, J = 3.9 Hz, 1 H), 8.49(s, 1H), 7.89-7.99 (m, 3H), 7.80-7.84 (m, 1H), 7.72 (t, J = 7.8 Hz, 1 H), 7.60-7.63 (m, 2H), 7.23 (t, J = 7.5 Hz, 1H), 3.98 (s, 3H). DMSO 371.9  (M + 1) Method A (TFA) 95 Method C, G1 132

362.81 1H-NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 9.28 (s, 1H), 8.69 (d, J = 4.0 Hz, 1H), 8.59 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 2.8 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.68-7.70 (m, 2H), 7.57-7.63 (m, 2H), 7.48-7.53 (m, 1 H), 7.40-7.44 (m, 1 H), 3.86 (s, 3H). DMSO 363.0, 365.1  (M + 1), 182.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 133

348.35 1H-NMR (400 MHz, DMSO-d6): δ 9.46 (s, 1H), 9.11 (s, 1H), 8.79-8.76 (m, 2H), 8.00-7.94 (m, 1H), 7.83-7.73 (m, 3H), 7.62-7.48 (m, 3H), 3.00 (s, 3H). DMSO 349.1  (M + 1), 175.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 134

381.26 1H-NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H), 9.13 (s, 1H), 8.75-8.77 (m, 2H), 8.18 (s, 1H), 7.72-7.85 (m, 5H), 7.49- 7.50 (m, 1H), 3.00 (s, 3H). DMSO 381.0, 383.0, 385.0  (M + 1) Method A (TFA) 95 Method C, G1 135

364.8 1H-NMR (400 MHz, DMSO-d6): δ 9.43 (m, 2H), 8.94-8.89 (m, 2H), 8.08-8.06 (m, 1H), 7.92-7.81 (m, 4H), 7.57-7.53 (m, 2H)T 3.03 (s, 3H). DMSO 365.0, 367.0  (M + 1), 183.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 136

337.38 1H-NMR (400 MHz, DMSO-d6): δ 9.52- 9.44 (m, 2H), 8.98 (d, J = 8.0 Hz, 1H), 8.92 (d, J = 4.4 Hz, 1 H), 8.36-8.19 (m, 2H), 8.02-7.84 (m, 3H), 7.73-7.69 (m, 2H), 7.55 (d, J = 6.8 Hz, 1H), 3.04 (s, 3H). DMSO 338.1  (M + 1), 169.6  (M/2 + 1) Method A (TFA) 95 Method C, G1 137

364.35 1H-NMR (400 MHz, DMSO-d6): δ 9.97 (s, 1H), 9.51 (s, 1H), 8.69-8.66 (m, 2H), 8.16-8.08 (m, 2H), 7.75-7.73 (m, 1 H), 7.61-7.53 (m, 3H), 7.40 (d, J = 7.6 Hz, 1H), 4.01 (s, 3H). DMSO 183.1  (M/2 + 1) 365.1  (M + 1) Method A (TFA) 95 Method C, G1 138

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.01 (s, 1 H), 9.53 (s, 1H), 8.67-8.70 (m, 2H), 8.41 (d, J = 2.4 Hz, 1 H), 8.10 (d, J = 8.4 Hz, 1H), 7.95-7.99 (m, 1H), 7.73 (d, J = 8.8 Hz, 1 H), 7.56-7.63 (m, 2H), 7.42 (d, J = 8.4 Hz, 1H), 4.02 (s, 3H). DMSO 397.0, 399.0  (M + 1) Method A (TFA) 95 Method C, G1 139

380.8 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (S, 1H), 9.48 (s, 1 H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.8 Hz, 1H), 8.15-8.22 (m, 2H), 7.92-7.95 (m, 2H), 7.62 (t, J = 8.0 Hz, 1 H), 7.52 (t, J = 8.8 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 4.02 (s, 3H). DMSO 191.1  (M/2 + 1) 381.1, 383.1  (M + 1) Method A (TFA) 95 Method C, G1 140

401.68 1H-NMR (400 MHz, DMSO-d6): δ 10.11 (S, 1H), 8.50 (m, 1H), 8.63-8.70 (m, 3H), 8.14 (d, J = 2.0 Hz, 2H), 7.92 (m, 2H), 7.57 (m, 1H), 7.38 (t, J = 1.6 Hz, 1H). DMSO 401.0, 403.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 141

348.35 1H-NMR (400 MHz, DMSO-d6): δ 9.46 (s, 1 H), 9.11 (s, 1 H), 8.76-8.70 (m, 2H), 7.95-7.99 (m, 1H), 7.78-7.60 (m, 3H), 7.54-7 .44 (m: 3H), 3.00 (s, 3H). DMSO 175.1  (M/2 + 1) 349.1  (M + 1) Method A (TFA) 95 Method C, G1 142

397.26 1H-NMR (400 MHz, DMSO-d6): δ 10.30 (s, 1H), 8.39 (s, 1H), 8.83 (s, 2H), 8.03- 8.12 (m, 3H), 7.79-7.81 (m, 2H), 7.50- 7.51 (m, 1H), 7.32 (s, 1H), 3.96 (s, 3H). DMSO 397.0, 399.0, 401.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 143

452.34 1H-NMR (400 MHz, DMSO-d6): δ 9.86 (s, 1H), 9.51 (s, 1H), 8.65-8.66 (m, 2H), 8.34-8.35 (m, 1H), 7.95-7.96 (m, 1 H), 7.72-7.80 (m, 4H), 7.54 (m, 1H), 3.84 (m, 4H), 3.56 (m, 4H). DMSO 452.1, 454.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 144

435.88 1H-NMR (400 MHz, DMSO-d6): δ 9.83 (s, 1H), 9.49 (s, 1 H), 8.62-8.65 (m, 2H), 8.21-8.23 (m, 1H), 7.89-7.91 (m, 1H), 7.78-7.81 (m, 1H), 7.72-7.73 (m, 2H), 7.51-7.54 (m, 2H), 3.84 (t, J = 4.0 Hz, 4H), 3.36 (m, 4H). DMSO 436.1, 438.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 145

419.43 1H-NMR (400 MHz, DMSO-d6): δ 10.50 (s, 1 H), 9.45 (s, 1 H), 8.83-8.90 (m, 2H), 8.06-8.08 (m, 1H), 7.70-7.93 (m, 5H), 7.56 (dd, J = 19.6, 9.6 Hz, 1H), 3.82- 3.83 (m, 4H), 3.39-3.41 (m, 4H). DMSO 420.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 146

408.46 1H-NMR (400 MHz, DMSO-d6): δ 10.54 (s, 1H), 9.44 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.84 (d, J = 4.4 Hz, 1H), 8.34 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 7.67-7.92 (m, 6H), 3.82-3.83 (m, 4H), 3.39-3.40 (m, 4H). DMSO 409.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 147

452.34 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1 H), 9.42 (s, 1 H), 8.85-8.87 (m, 2H), 8.11 (s, 2H), 7.73-7.88 (m, 4H), 7.38 (s, 1H), 3.82-3.83 (m, 4H), 3.39-3.40 (m, 4H). DMSO 452.1, 454.1, 456.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 148

426.47 1H-NMR (400 MHz, DMSO-d6): δ 12.93 (s, 1H), 9.57 (m, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.68-8.72 (m, 2H), 8.56 (s, 1H), 8.02 (d, J = 6.8 Hz, 1H), 7.96 (s, 1H), 7.72-7.84 (m, 3H), 7.56-7.57 (m, 1 H), 7.40 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 3.84 (t, J = 4.4 Hz, 4H), 3.35 (t, J = 4.4 Hz, 4H). DMSO 427.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 149

393.84 1H-NMR (400 MHz, DMSO-d6): δ 9.71 (s, 1 H), 9.48 (s, 1 H), 8.62-8.63 (m, 2H): 8.23 (m, 1H), 7.92 (m, 1H), 7.77 (d, J = 9.6 Hz, 1H), 7.51-7.56 (m, 3H), 7.42 (m, 1H), 3.12 (s, 6H). DMSO 394.1, 396.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 150

377.39 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.48 (m, 1H), 8.60-8.63 (m, 2H), 8.08-8.14 (m, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.69-7.71 (m, 1 H), 7.50-7.57 (m, 3H), 7.42-7.43 (m, 1H), 3.12 (s, 6H). DMSO 378.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 151

410.3 1H-NMR (400 MHz, DMSO-d6): δ 9.72 (s, 1H), 9.49 (s, 1 H), 8.60-8.64 (m, 2H), 8.17 (s, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.51-7.53 (m, 2H), 7.37 (s, 1H), 7.32 (s, 1H), 3.11 (s, 6H). DMSO 410.1, 412.0, 414.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 152

410.3 1H-NMR (400 MHz, DMSO-d6): δ 10.44 (s, 1 H), 9.45 (s, 1 H), 8.83-8.91 (m, 2H), 8.26-8.27 (m, 1H), 7.72-7.99 (m, 4H), 7.57-7.61 (m, 2H), 3.14(s, 6H). DMSO 410.1, 412.1, 414.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 153

366.42 1H-NMR (400 MHz, DMSO-d6): δ 9.82 (s, 1H), 9.48 (s, 1H), 8.55-8.64 (rn, 2H), 8.41 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 9.6 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.50-7.61 (m, 3H), 7.43 (m, 1H), 3.12(s, 6H). DMSO 367.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 154

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.57 (s, 1H), 9.53 (s, 1 H), 8.86-8.94 (m, 3H), 8.32-8.33 (m, 1H), 8.21 (s, 1H), 7.97- 8.01 (m, 2H), 7.84-7.88 (m, 1H), 7.73 (d, J = 8.8 Hz, 1H). DMSO 435.1, 437.1, 439.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 155

402.32 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (S, 1H), 9.51-9.52 (m, 1H), 8.65-8.78 (m, 3H), 8.19 (s, 1H), 8.11 (m, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.71 (m, 1H), 7.55- 7.59 (m, 2H). DMSO 403.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 156

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.65 (s, 1H), 9.46(s, 1H), 8.88-8.97 (m, 3H): 8.17 (S, 1H), 8.10-8.11 (m, 2H), 7.97 (s, 1H), 7.95 (s, 1H), 7.39 (s, 1H). DMSO 435.1, 437.0, 439.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 157

418.77 1H-NMR (400 MHz, DMSO-d6): δ 10.62 (s, 1H), 9.52 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.88-8.90 (m, 2H), 8.20-8.23 (m, 2H), 8.01 (d, J = 8.0 Hz, 1H), 7.92-7.95 (m, 2H), 7.54 (t, J = 9.2 Hz, 1H). DMSO 419.1, 421.1  (M + 1) Method B (NH4HCO3) 95 Method C, G 158

409.36 1H-NMR (400 MHz, DMSO-d6): δ 13.24 (S, 1H), 9.56 (s, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.96 (s, 1H), 8.87 (d, J = 8.0 Hz, 1H), 8.54 (s, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.18 (s, 1H), 7.95-8.01 (m, 4H), 7.70 (t, J = 7.6 Hz, 1 H), 7.27 (t, J = 7.2 Hz, 1H). DMSO 410.1  (M + 1) Method B (NH4HCO3) 95 Method C, G 159

391.35 1H-NMR (400 MHz, DMSO-d6): δ 10.82 (s, 1H), 8.50 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.96 (d, J = 8.8 Hz, 2H), 8.37 (s, 1H), 8.30-8.28 (m, 1H), 8.21 (s, 1H), 7.98 (d, J = 7.6 Hz, 2H), 7.68-7.69 (m, 2H). DMSO 392.2  (M + 1) Method B (NH4HCO3) 95 Method C, G 160

450.34 1H-NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H), 9.54-9.55 (m, 1H). 8.82-8.84 (m, 1H), 8.67-8.73 (m, 2H). 8.16-8.21 (m, 2H), 7.93-8.00 (m, 2H), 7.54-7.64 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 451.1  (M + 1) Method B (NH4HCO3) 95 Method C, G 161

416.78 1H-NMR (400 MHz, DMSO-d6): δ 10.10 (s, 1H), 9.49 (s, 1 H), 8.62-8.72 (m, 3H). 8.13 (s, 1 H), 7.88-7.92 (m, 3H), 7.51- 7.60 (m, 2H), 7.14-7.16 (m, 1H). DMSO 417.1, 419.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 162

375.81 1H-NMR (400 MHz, DMSO-d6): δ 13.13 (s, 1H), 9.53 (s, 1H), 9.01 (d, J = 8.0 Hz, 1H), 8.68-8.72 (m, 2H). 8.50 (s, 1H). 8.10 (d, J = 8.8, 1H), 7.88-7.97 (m, 3H). 7.70-7.72 (m, 2H), 7.57-7.59 (m, 1 H), 7.22 (t, J = 7.6, 1H). DMSO 376.0, 378.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 163

376.8 1H-NMR (400 MHz, DMSO-d6): δ 12.07 (s, 1H). 9.56 (s, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.71-8.73 (m, 2H). 8.34 (s, 1H), 7.96-8.09(m, 3H). 7.59-7.80 (m, 2H), 7.29 (t, J = 7.2 Hz, 1 H). DMSO 377.0, 379.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 164

394.37 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H). 9.53 (s, 1H), 8.67 (d, J = 5.2 Hz, 2H). 7.99 (d, J = 2.4 Hz, 1H). 7.94 (m, 1H). 7.87 (d, J = 9.2 Hz, 1H). 7.80 (d, J = 8.4 Hz, 1H). 7.49-7.59 (m, 3H). 7.31 (t, J = 74.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 3.99 (s, 3H). DMSO 395.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 165

HCl 458.51 1H-NMR (400 MHz, DMSO-d6): δ 9.42 (s, 1H), 8.98 (d, J = 8.4 Hz, 1H), 8.68- 8.71 (m, 2H), 7.94 (d, J = 7.6 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.57 (t, J = 5.6 Hz, 1H), 7.53 (s, 1H), 7.38 (s, 1H), 7.19 (t, J = 7.2 Hz, 1H), 4.52 (s, 2H), 4.00 (s, 3H), 3.63 (s, 2H), 2.89 (s, 6H). DMSO 459.1  (M + 1) 230.2  (M/2 + 1) Method A (TFA) 95 Method C, G1 166

467.92 1H-NMR (400 MHz, DMSO-d6): δ 9.71 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.62- 8.67 (m, 2H), 8.20 (dd, J = 6.8, 2.4 Hz, 1H), 7.86-7.89 (m, 2H), 7.51-7.55 (m, 2H), 7.31 (s, 1H), 4.24 (t, J = 6.0 Hz, 2H), 3.98 (s, 3H), 2.77 (t, J = 5.6 Hz, 2H), 2.29 (s, 6H). DMSO 468.1  (M + 1) 234.6  (M/2 + 1) Method B (NH4HCO3) 95 Method C, G1 167

HCl 428.82 1H-NMR (400 MHz, DMSO-d6): δ 10.41 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.4 Hz, 1H), 8.88 (dd, J = 5.2, 1.6 Hz, 1H), 8.13 (d, J = 2.8 Hz, 1H), 8.00 (t, J = 2.0 Hz, 1H), 7.89-7.95 (m, 3H), 7.62 (dd, J = 9.2. 3.2 Hz, 1H), 7.36 (t, J = 73.6 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 4.01 (s, 3H). DMSO 429.1, 431.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 168

385.42 1H-NMR (400 MHz, DMSO-d6): δ 13.03 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.20 (d, J = 8.4 Hz, 1H), 8.74-8.77 (m, 1H), 8.70 (dd, J = 4.4, 1.6 Hz, 1H), 8.48 (s, 1H), 7.96-7.99 (m, 2H), 7.72-7.76 (m, 1H), 7.57-7.60 (m, 1H), 7.47 (m, 1H), 7.41 (m, 1H), 7.17-7.21 (m, 1H), 3.95 (s, 3H), 2.72 (s, 3H). DMSO 386.1  (M + 1) Method B (NH4HCO3) 95 Method D, G1 169

HCl 368.77 1H-NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.47 (s, 1H), 8.86-8.93 (m, 2H), 8.54 (dd, J = 10.0. 2.8 Hz, 1H), 8.21 (dd, J = 6.8, 2.4 Hz, 1H), 7.82-8.00 (m, 4H), 7.52 (t, J = 9.2 Hz, 1H). DMSO 369.0, 371.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 170

HCl 400.33 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.53 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 4.0 Hz, 1H), 8.60 (dd, J = 10.4, 3.2 Hz, 1H), 7.97-8.09 (m, 3H), 7.88-7.92 (m, 2H), 7.62 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 401.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 171

359.36 1H-NMR (400 MHz, DMSO-d6): δ 13.06 (s, 1H), 9.58 (s, 1H), 9.07 (d, J = 8.4 Hz, 1H), 8.72 (d, J = 5.6 Hz, 2H), 8.52 (s, 1H), 7.96-8.02 (m, 3H), 7.83-7.87 (m, 2H), 7.74 (t, J = 8.0 Hz, 1H), 7.59 (t, J = 6.0 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H). DMSO 360.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 172

HCl 382.34 1H-NMR (400 MHz, DMSO-d6): δ 10.30 (s, 1H), 9.53 (d, J = 1.2 Hz, 1H), 8.98 (d, J = 8.0 Hz, 1H), 8.88 (d, J = 4.4 Hz, 1H), 8.62 (dd, J = 10.0, 2.8 Hz, 1H), 8.01- 8.05 (m, 1 H), 7.84-7.92 (m, 4H), 7.50- 7.56 (m, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.03 (dd, J = 8.0, 2.0 Hz, 1H). DMSO 383.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 173

348.35 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1 H), 9.51 (s, 1 H), 8.79-8.76 (m, 2H), 8.38 (s, 1 H), 8.16-8.11 (m, 1H), 7.86- 7.66 (m, 4H), 7.59-7.50 (m, 1H), 2.57 (s, 3H). DMSO 349.1  (M + 1), 175.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 174

364.8 1 H-NMR (300 Hz, CD30D): δ 9.50 (d, J = 1.2 Hz, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.35 (s, 1H), 8.09-7.99 (m, 2H), 7.93 (s, 2H), 7.78- 7.73 (m, 1H), 7.39 (t, J = 9.0 Hz, 1H), 2.64 (s, 3H). CD3OD 365.1, 367.1  (M + 1) Method A (TFA) 95 Method C, G1 175

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (S, 1H), 9.51 (s, 1H), 8.84-8.79 (m, 2H), 8.36-8.34 (m, 2H), 7.96 (dd, J = 8.8. 2.5 Hz, 1H), 7.85-7.70 (m, 4H), 2.55 (s, 3H). DMSO 381.0, 383.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 176

346.81 1 H-NMR (300 Hz, CD3OD): δ 9.48 (d, J = 1.2 Hz, 1H), 8.99-8.95 (m, 1H), 8.82- 8.80 (m, 1H), 8.30-8.29 (m, 1H), 7.90- 7.81 (m, 5H), 7.52-7.46 (m, 2H), 2.62 (s, 3H). CD3OD 347.0, 349.1  (M + 1) Method A (TFA) 95 Method C, G1 177

346.81 1 H-NMR (400 MHz, DMSO-d6): δ 10.12 (s, 1H), 9.52 (s, 1 H), 8.84-8.78 (m, 2H), 8.42 (s, 1H), 8.16-8.15 (m, 1H), 7.94- 7.91 (m, 1H): 7.85 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.75-7.71 (m, 1H), 7.50 (t, J = 8.1 Hz, 1 H), 7.27-7.23 (m, 1H), 2.56 (s, 3H). DMSO 347.1, 349.1  (M + 1) Method A (TFA) 95 Method C, G1 178

380.37 1H-NMR (400 MHz, DMSO-d6): δ 10.60 (S, 1H), 9.50 (d, J = 2.1 Hz, 1H), 9.00 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.1, 1.2 Hz, 1H), 8.55 (s, 1H), 8.43 (s, 1H), 8.25 (d, J = 7.8 Hz, 1H), 7.96-7.90 (m, 2H), 7.84 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 8.2 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 2.62 (s, 3H). DMSO 381.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 179

414.81 1H-NMR (400 MHz, DMSO-d6): δ 10.59 (s, 1H), 9.50 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.92 (d, J = 5.2 Hz, 1H), 8.59 (d, J = 2.8 Hz, 1H), 8.54 (s, 1H), 8.34 (dd, J = 8.6. 2.6 Hz, 1H), 7.96-7.90 (m, 2H), 7.81 (d, J = 8.8 Hz, 2H), 2.56 (s, 3H). DMSO 415.1, 417.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 180

401.37 1H-NMR (400 MHz, DMSO-d6): δ 13.91 (s, 1H), 10.38 (s, 1H), 9.59 (s, 1H), 8.79- 8.76 (m, 1H), 8.73 (d, J = 4.8 Hz, 1H), 8.61 (d, J = 2.4 Hz, 1H), 8.44 (s, 1H), 8.33 (dd, J = 9.0. 2.6 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.81 (dd, J = 8.4, 1.2 Hz, 1H), 7.60- 7.57 (m, 1H), 2.58 (s, 3H). DMSO 402.0  (M + 1) Method A (TFA) 95 Method C, G1 181

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.40 (s, 1H), 9.47 (s, 1H), 8.98 (d, J = 7.5 Hz, 1H), 8.91 (d, J = 4.5 Hz, 1H), 8.48 (s, 1H), 8.12 (d, J = 2.1 Hz, 2H), 7.97-7.93 (m, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.40 (s, 1H), 2.55 (s, 3H). DMSO 381.0, 383.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 182

390.82 1H-NMR (400 MHz, DMSO-d6): δ 12.25 (S, 1H), 9.54 (s, 1H), 9.25 (s, 1 H), 8.84- 8.80 (m, 2H), 8.09 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 9.2 Hz, 1H), 7.77-7.75 (m, 1H), 7.29 (d, J = 8.4 Hz, 1H), 2.56 (s, 3H). DMSO 391.1, 393.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 183

366.34 1 H-NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.66-8.63 (m, 1H), 8.30 (s, 1H), 7.99-7.95 (m, 2H), 7.82 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.6. 1.4 Hz, 1H), 7.58-7.55 (m, 1H), 2.55 (s, 3H). DMSO 367.1  (M + 1), 184.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 184

415.7 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.51 (s, 1 H), 8.75-8.72 (m, 2H), 8.38 (s, 2H), 8.32 (s, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.66- 7.64 (m, 1H), 2.55 (s, 3H). DMSO 414.8, 416.8  (M + 1) Method B (NH4HCO3) 95 Method C, G1 185

354.4 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 9.56 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.81 (d, J = 4.0 Hz, 1H), 8.65 (s, 1H), 8.48 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1 H), 7.88-7.88 (m, 3H), 7.65 (t, J = 7.6 Hz, 1H), 2.65 (s, 3H), 2.58 (s, 3H). DMSO 355.1  (M + 1), 178.1  (M/2 + 1) Method A (TFA) 95 Method C, G1 186

356.38 1H-NMR (400 MHz, DMSO-d6): δ 12.18 (s, 1H), 9.57 (s, 1H), 9.07 (d, J = 8.4 Hz, 1H), 8.71 (d, J = 5.6 Hz, 2H), 8.10 (d, J = 8.0 Hz, 1 H), 7.99 (s, 1H), 7.86-7.76 (m, 3H), 7.58 (t, J = 6.2 Hz, 1H), 7.23 (t, J = 7.4 Hz, 1H), 2.55 (s, 3H). DMSO 357.1  (M + 1) Method A (TFA) 95 Method C, G1 187

337.38 1 H-NMR (400 MHz, DMSO-d6): δ 10.10 (s, 1H), 9.51 (s, 1H), 8.65-8.70 (m, 2H), 8.45 (s, 1H), 8.38 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1 H), 7.76 (d, J = 8.0 Hz, 1 H), 7.69 (t, J = 7.8 Hz, 1 H), 7.62 (d, J = 7.2 Hz, 1 H), 7.54-7.57 (m, 1H), 2.56 (s, 3H). DMSO 338.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 188

355.39 1H-NMR (400 MHz, DMSO-d6): δ 13.11 (s, 1H), 9.61 (s, 1H), 9.09 (d, J = 8.8 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.81 (s, 1H), 8.50 (S, 1H), 8.01-7.98 (m, 2H), 7.96 (dd, J = 7.8, 1.0 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.78-7.72 (m, 3H), 7.23 (t,J = 7.4 Hz, 1H), 2.56 (s, 3H). DMSO 356.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 189

385.42 1H-NMR (400 MHz, DMSO-d6): δ 12.62 (s, 1H), 9.58 (s, 1H), 9.03 (d, J = 8.4 Hz, 1H), 8.92 (d, J = 4.0 Hz, 1 H), 8.74-8.69 (m, 2H), 7.92-7.87 (m, 2H), 7.72 (t, J = 7.6 Hz, 1H), 7.66-7.56 (m, 3H), 7.23 (t, J = 7.6 Hz, 1H), 4.00 (s, 3H), 2.84 (d, J = 4.4 Hz, 3H). DMSO 386.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 190

461.51 1H-NMR (400 MHz, DMSO-d6): δ 12.40 (S, 1H), 9.57 (d, J = 1.2 Hz, 1H), 9.48 (t, J = 6.0 Hz, 1H), 8.89 (d, J = 8.8 Hz, 1H), 8.73-8.68 (m, 2H), 7.96 (dd, J = 8.0. 1.2 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.76-7.72 (m, 1H), 7.61-7.55 (m, 3H), 7.34-7.20 (m, 6H), 4.52 (d, J = 5.6 Hz, 2H), 3.93 (s, 3H). DMSO 462.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 191

368.77 1H NMR (300 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.55-9.45 (m, 1H), 8.93-8.76 (m, 2H), 8.63 (d, J = 8.9 Hz, 1H), 8.10 (ddd, J = 13.2, 7.5, 2.6 Hz, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.80-7.67 (m, 3H)T 7.62-7.49 (m, 1H). DMSO 369.0, 371.0  (M + 1) Method B (NH4HCO3) 97 Method C, G1 192

401.68 1H NMR (300 MHz, DMSO-d6): δ 10.38 (s, 1H), 9.58-9.43 (m, 1H), 8.90-8.79 (m, 2H), 8.65 (d, J = 9.0 Hz, 1H), 8.33 (d, J = 2.4 Hz, 1H), 8.01-7.90 (m, 2H), 7.82-7.68 (m, 3H). DMSO 401.0, 403.0, 405.0  (M + 1) Method B (NH4HCO3) 97 Method C, G1 193

367.23 1H NMR (300 MHz, DMSO-d6): δ 10.19 (S, 1H), 9.53 (d, J = 2.1 Hz, 1H), 8.78- 8.56 (m, 3H), 8.17 (t, J = 2.0 Hz, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.93-7.85 (m, 1H), 7.75 (dd, J = 8.9, 2.2 Hz, 1H), 7.58 (ddd, J = 8.0. 4.8, 0.7 Hz, 1H), 7.51 (t, J = 8.1 Hz, 1H), 7.26 (ddd, J = 8.0, 2.0, 0.8 Hz, 1H). DMSO 367.0, 369.0  (M + 1) Method B (NH4HCO3) 98 Method C, G1 194

376.80 1H NMR (300 MHz, DMSO-d6): δ 13.11 (s, 1H), 10.27 (s, 1H), 9.58 (d, J = 2.1 Hz, 1H), 8.87-8.62 (m, 4H), 8.21-8.10 (m, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.82- 7.68 (m, 2H), 7.64-7.53 (m, 2H). DMSO 377.0, 379.0  (M + 1) Method A (TFA) 95 Method C, G1 195

401.68 1H NMR (300 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.52-9.49 (m, 1H), 8.85-8.73 (m, 2H), 8.61 (d, J = 9.0 Hz, 1H), 8.18- 8.08 (m, 2H), 7.99-7.95 (m, 1H), 7.77 (dd, J = 8.9, 2.2 Hz, 1H), 7.71 (dd, J = 7.8, 5.0 Hz, 1H), 7.42-7.39 (m, 1H). DMSO 401.0, 403.0, 405.0  (M + 1) Method B (NH4HCO3) 97 Method C, G1 196

386.76 1H-NMR (300 MHz, DMSO-d6): δ 10.43 (s, 1H), 9.49 (d, J = 1.9 Hz, 1H), 8.95- 8.82 (m, 2H), 8.64 (d, J = 9.0 Hz, 1H), 8.01-7.82 (m, 4H), 7.78 (dd, J = 8.9, 2.2 Hz, 1H). DMSO 387.0, 389.1  (M + 1) Method B (NH4HCO3) 97 Method C, G1 197

411.86 1H NMR (400 MHz, DMSO-d6): δ 10.50 (brs, 1H), 9.56 (s, 1H), 9.08-8.93 (m, 1H), 8.92-8.82 (m, 1H), 8.73 (d, J = 8.9 Hz, 1H), 8.21-8.11 (m, 2H), 8.02 (d, J = 1.9 Hz, 1H), 7.98-7.77 (m, 4H), 7.38 (s, 2H). DMSO 412.1, 414.1  (M + 1) Method B (NH4HCO3) 97 Method C, G1 198

385.22 1H NMR (400 MHz, DMSO-d6): δ 10.25 (s, 1H), 9.51 (d, J = 1.4 Hz, 1H), 8.77- 8.69 (m, 2H), 8.60 (d, J = 9.0 Hz, 1H), 8.27-8.20 (m, 1 H), 7.97 (d, J = 2.1 Hz, 1H), 7.90 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 7.76 (dd, J = 8.9, 2.1 Hz, 1H), 7.64 (dd, J = 8.0, 4.9 Hz, 1H), 7.55 (t, J = 9.1 Hz, 1H). DMSO 385.0, 387.0  (M + 1) Method B (NH4HCO3) 100 Method C, G1 199

357.80 1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1 H), 9.53-9.49 (m, 1H), 8.81-8.70 (m, 2H), 8.64 (d, J = 8.9 Hz, 1H), 8.45- 8.36 (m, 1H), 8.29-8.21 (m, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.74-7.61 (m, 3H). DMSO 357.9, 359.9  (M + 1) Method B (NH4HCO3) 99 Method C, G1 200

435.23 1H-NMR (400 MHz, DMSO-d6): δ 10.44 (s, 1 H), 9.53 (s, 1H), 8.84-8.74 (m, 2H), 8.69-8.61 (m, 2H), 8.26 (dd, J = 8.8, 2.6 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.78 (dd, J = 8.9, 2.1 Hz, 1H), 7.70 (dd, J = 7.7, 5.3 Hz, 1H). DMSO 435.0, 437.0  (M + 1) Method B (NH4HCO3) 99 Method C, G1 201

400.78 1H-NMR (400 MHz, DMSO-d6): δ 10.45 (s, 1H), 9.53 (d, J = 1.5 Hz, 1H), 8.85 (d, J = 8.1 Hz, 1H), 8.82 (dd, J = 5.0, 1.4 Hz, 1H), 8.69 (d, J = 9.0 Hz, 1H), 8.49 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.83-7.67 (m, 3H), 7.56 (d, J = 7.8 Hz, 1H). DMSO 401.1, 403.0  (M + 1) Method B (NH4HCO3) 99 Method C, G1 202

375.79 1H-NMR (400 MHz, DMSO-d6): δ 10.47 (s, 1 H), 9.49 (s, 1H), 8.87-8.77 (m, 2H), 8.63 (d, J = 8.9 Hz, 1H), 8.42 (dd, J = 5.8, 2.7 Hz, 1H), 8.26 (ddd, J = 9.1, 4.9, 2.8 Hz, 1H), 7.98 (d, J = 2.1 Hz, 1H), 7.83-7.72 (m, 2H), 7.66 (t, J = 9.1 Hz, 1H). DMSO 375.9, 377.9  (M + 1) Method B (NH4HCO3) 99 Method C, G1 203

348.35 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.51 (s, 1H), 8.91 (d, J = 6.8 Hz, 1H), 8.86 (d, J = 4.4 Hz, 1H), 8.57 (d, J = 8.3 Hz, 1H), 8.11 (ddd, J = 13.0, 7.5, 2.5 Hz, 1H), 7.90-7.68 (m, 3H), 7.65-7.46 (m, 2H), 2.56 (s, 3H). DMSO 349.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 204

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1 H), 9.54 (s, 1H), 8.75-8.65 (m, 2H), 8.46 (d, J = 8.5 Hz, 1 H), 8.42 (d, J = 2.4 Hz, 1H), 7.98 (dd, J = 8.8, 2.4 Hz, 1H), 7.72 (d, J = 9.1 Hz, 2H), 7.57 (dd, J = 7.9, 4.9 Hz, 1 H), 7.53 (d, J = 8.5 Hz, 1H), 2.55 (s, 3H). DMSO 381.0, 383.0  (M + 1) Method B (NH4HCO3) 100 Method C, G1 205

364.35 1H-NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H), 9.53 (s, 1H), 8.79-8.58 (m, 2H), 8.49 (d, J = 9.0 Hz, 1H), 8.13 (ddd, J = 9.2, 7.1, 1.7 Hz, 1H), 7.84-7.65 (m, 1H), 7.67-7.46 (m, 2H), 7.41-7.23 (m, 2H), 3.97 (s, 3H). DMSO 365.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 206

364.80 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.50 (d, J = 1.4 Hz, 1H), 8.92- 8.77 (m, 2H), 8.53 (d, J = 8.5 Hz, 1H), 8.24 (dd, J = 6.8, 2.5 Hz, 1H), 7.98- 7.87 (m, 1 H), 7.83-7.70 (m, 2H), 7.60- 7.50 (m, 2H), 2.56 (s, 3H). DMSO 365.1, 367.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 207

381.26 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1 H), 9.53 (s, 1 H), 8.87-8.73 (m, 2H), 8.50 (d, J = 8.5 Hz, 1 H), 8.17 (d, J = 1.7 Hz, 2H), 7.77 (s, 1H), 7.72 (dd, J = 7.8, 5.1 Hz, 1H), 7.57 (dd, J = 8.4, 0.9 Hz, 1H), 7.39 (t, J = 1.6 Hz, 1 H), 2.56 (s, 3H). DMSO 381.1, 383.0  (M + 1) Method B (NH4HCO3) 99 Method C, G1 208

337.38 1H-NMR (400 MHz, DMSO-d6): δ 10.12 (S, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.77- 8.63 (m, 2H), 8.53-8.42 (m, 2H), 8.28 (d, J = 8.3 Hz, 1H), 7.75 (s, 1H), 7.69 (t, J = 7.9 Hz, 1 H), 7.62 (d, J = 7.7 Hz, 1H), 7.60-7.51 (m, 2H), 2.55 (s, 3H). DMSO 338.2  (M + 1) Method B (NH4HCO3) 100 Method C, G1 209

355.39 1H-NMR (400 MHz, DMSO-d6): δ 13.09 (s, 1H), 9.60 (s, 1 H), 9.02 (d, J = 8.4 Hz, 1H), 8.96 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 4.0 Hz, 1H), 8.49 (S, 1H), 8.13 (d, J = 8.4 Hz, 1 H), 7.97 (d, J = 7.8 Hz, 1H), 7.92 (s, 1H), 7.83 (dd, J = 8.0, 5.2 Hz, 1H), 7.80 (s, 1H), 7.73 (t, J = 7.4 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1 H), 7.25 (t, J = 7.6 Hz, 1 H), 2.56 (s, 3H). DMSO 356.1  (M + 1) Method B (NH4HCO3) 99 Method C, G1 210

375.81 1H-NMR (400 MHz, DMSO-d6): 13.13 (s, 1H), 9.59 (s, 1H), 9.03-8.89 (m, 3H), 8.50 (s, 1H), 8.21-8.19 (d, J = 8.6 Hz, 1H), 7.99-7.87 (m, 4H), 7.82-7.79 (dd, J = 8.8. 2.3 Hz, 1 H), 7.74-7.70 (m, 1 H), 7.28-7.24 (m, 1H). DMSO 376.1, 378.1  (M + 1) Method B (NH4HCO3) 98 Method C, G1 211

444.79 1H-NMR (400 MHz, DMSO-d6): δ 13.68 (bis, 1H), 11.98 (s, 1H), 9.49 (s, 1H), 8.83-8.64 (m, 2H), 8.11-7.90 (m, 3H), 7.81 (d, J = 2.0 Hz, 1H), 7.75-7.62 (m, 2H), 7.22 (t, J = 7.6 Hz, 1H). DMSO 444.9, 446.9  (M + 1) Method B (NH4HCO3) 100 Method C, G1 212

466.79 1H-NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.62 (s, 1H), 8.90 (dd, J = 8.2, 1.3 Hz, 1H), 8.69 (d, J = 9.0 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1 H), 7.99 (d, J = 2.1 Hz, 1H), 7.92-7.86 (m, 1 H), 7.86-7.79 (m, 1H), 7.77 (dd, J = 8.9, 2.1 Hz, 1H), 7.53 (t, J = 8.2 Hz, 1H), 7.30 (t, J = 73.3 Hz, 1H), 7.04 (dd, J = 8.1, 2.1 Hz, 1H). DMSO 466.9, 468.9  (M + 1) Method B (NH4HCO3) 100 Method C, G1 213

469.67 1H-NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H), 9.57 (s, 1H), 8.85 (dd, J = 8.1, 1.3 Hz, 1H), 8.60 (d, J = 9.0 Hz, 1H), 8.35-8.23 (m, 1 H), 8.06 (d, J = 8.2 Hz, 1H), 8.00-7.90 (m, 2H), 7.80-7.65 (m, 2H). DMSO 468.9, 470.8  (M + 1) Method B (NH4HCO3) 100 Method C, G1 214

436.77 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (S, 1H), 9.56 (s, 1 H), 8.84 (d, J = 8.3 Hz, 1H), 8.64 (d, J = 9.0 Hz, 1 H), 8.14-7.99 (m, 2H), 7.95 (d, J = 2.1 Hz, 1H), 7.81- 7.65 (m, 2H), 7.59-7.48 (m, 1H). DMSO 436.9, 438.9  (M + 1) Method B (NH4HCO3) 100 Method C, G1 215

440.37 1H-NMR (400 MHz, DMSO-d6): δ 13.81 (brs, 1H), 11.97 (s, 1H), 9.57 (s, 1H), 9.01-8.91 (m, 1 H), 8.84 (d, J = 8.3 Hz, 1H), 8.06 (dd, J = 7.9, 1.4 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.79-7.70 (m, 1H), 7.52 (dd, J = 9.1, 2.6 Hz, 1H), 7.49-7.44 (m, 1H), 7.20 (t, J = 7.6 Hz, 1H), 3.94 (s, 3H). DMSO 441.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 216

396.80 1H-NMR (400 MHz, DMSO-d6): δ 11.89 (s, 1H), 9.80 (s, 1H), 8.34 (dd, J = 9.6, 2.6 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J = 6.9, 2.6 Hz, 1 H), 7.88 (d, J = 2.7 Hz, 1H), 7.84-7.77 (m, 1 H), 7.74 (d, J = 9.1 Hz, 1H), 7.56-7.43 (m, 2H), 6.44 (d, J = 9.6 Hz, 1H), 3.95 (s, 3H). DMSO 397.1, 399.1  (M + 1) Method B (NH4HCO3) 100 Method D, G1 217

410.37 1H-NMR (400 MHz, DMSO-d6): δ 11.89 (s, 1H), 9.80 (s, 1H), 8.36 (dd, J = 9.6, 2.6 Hz, 1H), 8.25 (d, J = 2.2 Hz, 1H), 7.92 (d, J = 2.6 Hz, 1H), 7.80-7.67 (m, 3H), 7.53-7.46 (m, 2H), 7.27 (t, J = 74.0 Hz, 1H), 6.98 (dd, J = 8.2, 2.0 Hz, 1H), 6.43 (d, J = 9.6 Hz, 1 H), 3.96 (s, 3H). DMSO 411.1  (M + 1) Method B (NH4HCO3) 100 Method D, G1 218

387.39 1H-NMR (400 MHz, DMSO-d6): δ 12.98 (s, 1H), 12.58-12.05 (m, 1H), 8.55 (s, 2H), 8.41 (s, 1H), 8.33 (dd, J = 9.7, 2.5 Hz, 1H), 8.11-7.98 (m, 1H), 7.97-7.86 (m, 2H), 7.79-7.64 (m, 3H), 7.44-7.29 (m, 1 H), 6.52 (d, J = 9.7 Hz, 1H), 3.98 (s, 3H). DMSO 388.2  (M + 1) Method B (NH4HCO3) 100 Method D, G1 219

389.38 1H-NMR (400 MHz, DMSO-d6): δ 12.73 (s, 1H), 9.56 (s, 1H), 9.10 (dd, J = 8.9, 5.4 Hz, 1 H), 8.79-8.63 (m, 2H), 8.50 (s, 1H), 8.08 (s, 1H), 7.95-7.76 (m, 2H), 7.68-7.45 (m, 4H), 3.97 (s, 3H). DMSO 390.1  (M + 1) Method B (NH4HCO3) 98 Method C, G1 220

369.80 1H-NMR (400 MHz, DMSO-d6): δ 14.87 (brs, 1H), 10.08 (brs, 1H), 8.85-7.66 (m, 6H), 7.69-6.63 (m, 3H), 3.96 (s, 3H). DMSO 397.1, 399.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 221

387.39 1H-NMR (400 MHz, DMSO-d6): δ 14.80 (brs, 1H), 13.19 (s, 1H), 8.68 (d, J = 7.3 Hz, 1 H), 8.44 (s, 1H), 8.38 (d, J = 8.0 Hz, 1H), 8.13 (d, J = 9.1 Hz, 1H), 8.10-8.03 (m, 1 H), 7.95 (d, J = 7.8 Hz, 1 H), 7.90 (s, 1H), 7.86 (s, 1H), 7.78-7.65 (m, 2H), 7.43 (t, J = 7.5 Hz, 1H), 6.78 (t, J = 6.8 Hz, 1H), 3.99 (s, 3H). DMSO 388.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 222

410.37 1H-NMR (400 MHz, DMSO-d6): δ 15.33 (brs, 1H), 13.47 (brs, 1H), 11.69 (s, 1H), 8.62 (dd, J = 7.5, 2.1 Hz, 1H), 8.45 (d, J = 2.3 Hz, 1H), 8.17 (d, J = 9.2 Hz, 1H), 8.07 (dd, J = 6.2, 2.1 Hz, 1H), 7.81- 7.68 (m, 3H), 7.61 (t, J = 8.1 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1 H), 7.26-7.18 (m, 1H), 6.80-6.69 (m, 1 H), 4.03 (s, 3H). DMSO 411.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 223

401.22 1H-NMR (400 MHz, DMSO-d6): δ 11.22 (brs, 1H), 8.47 (d, J = 8.8 Hz, 1H), 8.30 (dd, J = 9.6, 2.3 Hz, 1H), 8.27-8.18 (m, 1H), 8.11 (dd, J = 6.8, 2.4 Hz, 1H), 7.90- 7.73 (m, 2H), 7.60 (dd, J = 8.8, 1.8 Hz, 1H), 7.47 (t, J = 9.1 Hz, 1 H), 6.44 (d, J = 9.6 Hz, 1H). DMSO 401.0, 403.0  (M + 1) Method B (NH4HCO3) 100 Method C, G1 224

414.79 1H-NMR (400 MHz, DMSO-d6): δ 12.00 (s, 1H), 10.07 (s, 1H), 8.54 (d, J = 8.9 Hz, 1H), 8.34 (dd, J = 9.6, 2.6 Hz, 1H), 8.30 (d, J = 2.3 Hz, 1 H), 7.87-7.69 (m, 3H), 7.62 (dd, J = 8.9, 2.1 Hz, 1H), 7.48 (t, J = 8.2 Hz, 1H), 7.26 (t, J = 74.0 Hz, 1H), 7.00 (dd, J = 8.1, 2.0 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1H). DMSO 415.1, 417.1  (M + 1) Method B (NH4HCO3) 100 Method C, G1 225

432.78 1H-NMR (400 MHz, DMSO-d6): δ 12.06 (s, 1H), 10.15 (s, 1H), 8.55 (d, J = 9.0 Hz, 1H), 8.34 (dd, J = 9.6, 2.5 Hz, 1H), 8.29 (s, 1H), 7.97 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.8, 2.1 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1 H), 7.17 (d, J = 7.8 Hz, 1 H), 6.44 (d, J = 9.6 Hz, 1H). DMSO 433.0, 435.0  (M + 1) Method B (NH4HCO3) 100 Method C, G1 226

428.36 1H-NMR (400 MHz, DMSO-d6): δ 12.28 (brs, 1H), 8.47-8.06 (m, 3H), 8.06- 7.76 (m, 3H), 7.67-7.59 (m, 2H), 7.28 (s, 1H), 6.47 (d, J = 9.7 Hz, 1H), 3.98 (s, 3H). DMSO 429.1  (M + 1) Method B (NH4HCO3) 94 Method D, G1 227

401.42 1H-NMR (400 MHz, DMSO-d6): δ 12.97 (s, 1H), 12.27 (s, 1H), 8.73-8.56 (m, 1H), 8.53 (s, 1H), 8.42 (s, 1H), 8.33 (dd, J = 9.7, 2.6 Hz, 1H), 8.04-7.86 (m, 3H), 7.74-7.59 (m, 3H), 7.34 (t, J = 8.7 Hz, 1H), 6.52 (d, J = 9.7 Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.45 (t, J = 6.9 Hz, 3H). DMSO 402.2  (M + 1) Method B (NH4HCO3) 100 Method D, G1 228

465.91 1H-NMR (400 MHz, DMSO-d6):δ 8.43- 8.31 (m, 2H), 8.27 (s, 1H), 8.14 (dd, J = 6.7, 2.3 Hz, 1H), 7.89-7.70 (m, 3H), 7.47 (t, J = 9.1 Hz, 1H), 6.44 (d, J = 9.6 Hz, 1 H), 3.62 (d, J = 9.3 Hz, 6H), 2.42 (s, 4H). DMSO 466.1, 468.1  (M + 1) Method B (NH4HCO3) 97 Method D, G1 229

436.41 1H-NMR (400 MHz, DMSO-d6): δ 10.28 (brs, 1H), 9.47 (s, 1H), 8.91 (d, J = 7.2 Hz, 1H), 8.84 (d, J = 5.2 Hz, 1H), 8.08- 8.06 (m, 2H), 7.91 (d, J = 7.6 Hz, 1H), 7.85 (t, J = 8 Hz, 1H), 7.65-7.60 (m, 2H), 7.54-7.52 (m, 1H), 4.17 (t, J = 7.6 Hz, 2H), 1.86 (q, J = 6.8 Hz, 2H), 1.08- 1.03 (m, 3H). DMSO 423.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 230

403.41 1H-NMR (400 MHz, DMSO-d6): δ 13.42 (s, 1H), 9.53 (s, 1H), 9.10 (d, J = 12.8 Hz, 1H), 8.70-8.65 (m, 2H), 8.50 (s, 1H), 8.07-8.04 (m, 2H), 7.86 (d, J = 8.8 Hz, 1H), 7.60-7.55 (m, 2H), 7.48 (s, 1H), 7.06-7.01 (m, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.45 (t, J = 7.2 Hz, 3H). DMSO 403.9  (M + 1) Method A (TFA) 95 Method C, G1 231

440.42 1H-NMR (400 MHz, DMSO-d6): δ 10.57 (s, 1H), 9.48 (s, 1H), 9.01 (d, J = 7.6 Hz, 1H), 8.90 (d, J = 5.2 Hz, 1 H), 8.19 (s, 1 H), 8.04 (s, 1H), 7.98 (d, J = 8.8 Hz, 2H), 7.93 (t, J = 5.6 Hz, 1H), 7.64-7.60 (m, 2H), 7.22 (d, J = 8.4 Hz, 1 H), 4.19 (t, J = 6.4 Hz, 1H), 1.87-1.81 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 440.9  (M + 1) Method A (TFA) 95 Method C, G1 232

359.12 1H-NMR (400 MHz, DMSO-d6): δ 13.10 (s, 1H), 9.54 (s, 1 H), 8.96 (d, J = 8.4 Hz, 1H), 8.82-8.80 (m, 2H), 8.52 (s, 1H), 8.22-8.17 (m, 1H), 7.97-7.93 (m, 2H), 7.70-7.59 (m, 4H), 7.21 (t, J = 8.0 Hz, 1H). DMSO 360.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 233

381.26 1H-NMR (400 MHz, DMSO-d6): δ 9.48 (s, 1H), 9.08 (s, 1 H), 8.67-8.70 (m, 1 H), 8.64 (d, J = 8.0 Hz, 1H), 7.98 (s, 2H), 7.76-7.78 (m, 2H), 7.55-7.57 (m, 1H), 7.43-7.46 (m, 1H), 7.36 (s, 1H), 2.99 (s, 3H). DMSO 381.0, 383.0, 385.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 234

408.4 1H-NMR (400 MHz, DMSO-d6): δ 10.38 (S, 1H), 9.51 (s, 1H), 9.00 (d, J = 7.2 Hz, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.13 (s, 1H), 7.96 (d, J = 7.2 Hz, 1H), 7.88- 7.91 (m, 2H), 7.86 (s, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.62 (del, J = 9.2, 2.0 Hz, 1 H), 7.55 (t, J = 8.4 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 4.28 (q, J = 6.8 Hz, 2H), 1.46 (t, J = 6.8 Hz, 3H). DMSO 409.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 235

412.36 1H-NMR (400 MHz, DMSO-d6): δ 10.81 (s, 1H), 9.49 (s, 1H), 9.02 (d, J = 8.4 Hz, 1H), 8.91 (dd, J = 5.2, 1.2 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.06 (s, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.94-7.91 (m, 1H), 7.64-7.60 (m, 2H), 7.22 (d, J = 8.4 Hz, 1H), 4.02 (s, 3H). DMSO 412.9  (M + 1) Method A (TFA) 95 Method C, J1 236

395.46 1H-NMR (400 MHz, DMSO-d6): δ 9.64 (s, 1H), 8.90 (s, 1H), 8.77 (dd, J = 13.5, 6.2 Hz, 2H), 8.19 (d, J = 9.2 Hz, 1H), 7.81 (dd, J = 9.2, 2.4 Hz, 1H), 7.72- 7.56 (m, 3H), 7.33 (d, J = 2.0 Hz, 1H), 4.15 (q, J = 6.8 Hz, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 1.38 (t, J = 6.8 Hz, 3H). DMSO 396.2  (M + 1) Method B (NH4HCO3) 98 Method C, G1 237

376.8 1H-NMR (400 MHz, DMSO-d6): δ 11.64 (brs, 1H), 11.31 (brs, 1H), 9.45 (s, 1H), 8.82-8.69 (m, 1H), 8.61 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 8.04-7.91 (m, 1H), 7.81 (dd, J = 8.9, 2.1 Hz, 1H), 7.70- 7.55 (m, 1H), 7.47 (s, 1H), 7.06 (s, 1H), 6.98 (d, J = 8.2 Hz, 1H). DMSO 376.9, 378.9  (M + 1) Method B (NH4HCO3) 95 Method C, G8 238

412.23 1H-NMR (400 MHz, DMSO-d6): δ 10.70 (s, 1H), 9.62 (d, J = 2.4 Hz, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.76-8.79 (m, 2H), 8.57 (dd, J = 6.8. 2.0 Hz, 1H), 8.29 (d, J = 2.4 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.94 (dd, J = 6.8, 2.0 Hz, 1H), 7.71 (m, 2H). DMSO 412.0, 414.0, 416.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 239

381.26 1H-NMR (400 MHz, DMSO-d6): 10.04 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.74-8.70 (m, 2H), 8.42-8.39 (m, 2H), 7.98 (dd, J = 2.4 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.55 (m, 2H), 2.75 (s, 3H). DMSO 381,   383    (M + 1) Method B (NH4HCO3) 95 Method C, G1 240

348.35 1H-NMR (400 MHz, DMSO-d6): 10.00 (s, 1H), 9.57 (d, J = 1.2 Hz, 1H), 8.72-8.70 (m, 2H), 8.38 (d J = 8.4 Hz, 1H), 8.17- 8.12 (m, 1 H), 7.79-7.74 (m, 2H), 7.59- 7.50 (m, 3H), 2.74 (s, 3H). DMSO 349.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 241

355.39 1H-NMR (400 MHz, DMSO-d6): 11.10 (s, 1H), 9.60 (d, J = 1.6 Hz, 1H), 9.16 (d, J = 8.4 Hz, 1 H), 8.82-8.72 (m, 2H), 8.50 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.97- 7.92 (m, 2H), 7.77-7.72 (m, 2H), 7.63- 7.60 (m, 2H), 7.24-7.19 (m, 1H), 2.76 (s, 3H). DMSO 356.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 242

337.4 1H-NMR (400 MHz, DMSO-d6): 10.12 (s, 1 H), 9.57 (s, 1 H), 8.73-8.70 (m, 2H), 8.46 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.72-7.56 (m, 4H), 2.76 (s, 3H). DMSO 338.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 243

396.37 1H-NMR (400 MHz, DMSO-d6): 10.07 (s, 1H), 9.59 (s, 1H), 8.75-8.69 (m, 2H), 8.44 (d, J = 8.0 Hz, IH), 8.20 (s, IH), 7.97-7.94 (m, 1 H), 7.89 (d, J = 7.2 Hz, 1H), 7.62-7.54 (m, 3H), 7.16 (d, J = 8.4 Hz, 1H), 2.76 (s, 3H). DMSO 397.1  (M + 1) Method B (NH4HCO3) 95 Method C, G1 244

378.37 1H-NMR (400 MHz, DMSO-d6): 9.98 (s, 1H), 9.60 (s, 1H), 8.75-8.69 (m, 2H), 8.44 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.84 (d, J = 7.6 Hz, 1 H), 7.79 (d, J = 6.8 Hz, 1H), 7.58-7.00 (m, 4H), 6.98 (d, J = 2.0 Hz, 1H), 2.76 (s, 3H). DMSO 379.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 245

360.34 1 H-NMR (400 MHz, DMSO-d6): δ 11.95- 11.11 (m, 2H), 9.43 (d, J = 1.6 Hz, 1 H), 8.71 (dd, J = 4.7. 1.5 Hz, 1H), 8.56 (td, J = 8.0, 1.9 Hz, 1H), 8.15 (dd, J = 9.2. 5.3 Hz, 1H), 8.08 (dd, J = 9.4, 2.7 Hz, 1H), 8.02-7.88 (m, 2H), 7.54 (dd, J = 7.90, 4.81 Hz, 1H), 7.50-7.40 (m, 1H), 7.04 (t, J = 7.1 Hz, 1H), 6.96 (d, J = 8.1 Hz, 1H). DMSO 360.8  (M + 1) Method B (NH4HCO3) 95 Method C, G8 246

393.8 1 H-NMR (400 MHz, DMSO-d6): δ 13.29 (s, 1H), 9.54 (s, 1H), 9.29 (s, 1 H), 8.06 (d, J = 0.9 Hz, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.82 (dd, J = 26.4, 8.4 Hz, 2H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1 H), 8.72 (d, J = 3.6 Hz, 1 H), 8.67 (d, J = 7.8 Hz, 1 H), 8.64-8.53 (m, 1H). DMSO 394.0, 396.0  (M + 1) Method B (NH4HCO3) 95 Method C, J1 247

1H-NMR (400 MHz, DMSO-d6): δ 13.36 (brs, 1H), 9.54 (s, 1H), 9.36-9.08 (m, 1H), 8.12 (d, J = 8.8 Hz, 2H), 8.08-7.96 (m, 1H), 7.94-7.78 (m, 2H), 7.57 (dd, J = 7.8, 4.8 Hz, 1H), 7.29-7.16 (m, 1H), 8.94-8.49 (m, 3H). DMSO 444.1  (M + 1) Method B (NH4HCO3) 95 Method C, J1 248

376.8 1H-NMR (400 MHz, DMSO-d6): δ 9.57 (S, 1H), 8.71 (d, J = 5.6 Hz, 2H), 8.40 (d, J = 1.8 Hz, 1H), 8.01-7.97 (m, 2H), 7.89 (dd, J = 7.8, 1.5 Hz, 1H), 7.63- 7.51 (m, 1H), 7.29 (t, J = 7.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 6.76-6.74 (m, 1H). DMSO 377.0, 379.0  (M + 1) Method B (NH4HCO3) 95 Method C, G8 249

426.35 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (d, J = 1.5 Hz, 1H), 8.74 (td, J = 8.0. 1.9 Hz, 1H), 8.71 (dd, J = 4.7, 1.7 Hz, 1H), 8.50 (d, J = 9.0 Hz, 1H), 7.88 (dd, J = 7.8, 1.9 Hz, 1H), 7.76 (d, J = 1.1 Hz, 1H), 7.20-7.11 (m, 1H), 7.64-7.56 (m, 2H)., 6.70-6.60 (m, 1H), 6.52 (dd, J = 10.8, 3.9 Hz, 1H). DMSO 427.1  (M + 1) Method B (NH4HCO3) 95 Method C, G8 250

360.34 1H-NMR (400 MHz, DMSO-d6): δ 9.69 (s, 1H), 8.83 (d, J = 7.4 Hz, 1H), 8.71 (d, J = 3.9 Hz, 1 H), 8.49 (t, J = 7.2 Hz, 1 H), 7.85 (d, J = 7.8 Hz, 1 H), 7.63-7.51 (m, 3H), 7.14 (t, J = 7.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1 H), 6.46 (t, J = 7.2 Hz, 1H). DMSO 360.8  (M + 1) Method B (NH4HCO3) 95 Method C, G8 251

400.43 1H-NMR (400 MHz, DMSO-d6): δ 12.92 (s, 1H), 9.04 (d, J = 8.3 Hz, 1H), 8.66 (del, J = 7.7, 1.7 Hz, 1H), 8.48 (s, 1H), 8.10 (dd, J = 4.6, 1.7 Hz, 1H), 8.01- 7.94 (m, 2H), 7.89 (d, J = 8.9 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.55 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 6.74 (dd, J = 7.7, 4.7 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 401.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 252

483.44 1H-NMR (400 MHz, DMSO-d6): δ 13.28 (s, 1H), 9.54 (s, 1H), 9.28 (s, 1 H), 8.70- 8.66 (m, 2H), 8.59 (s, 1H), 8.11 (d, J = 8.8 Hz, 2H), 7.90 (d, J = 8.9 Hz, 1H), 7.64-7.49 (m, 3H), 7.18 (d, J = 8.2 Hz, 1H), 4.14 (t, J = 6.2 Hz, 2H), 1.86 (q, J = 6.8 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 484.0  (M + 1) Method B (NH4HCO3) 95 Method C, J1 253

1H-NMR (400 MHz, DMSO-d6): δ 13.24 (s, 1H), 9.56 (s, 1H), 9.39 (d, J = 2.1 Hz, 1H), 8.77-8.73 (m, 2H), 8.55 (s, 1H), 8.09 (s, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.65 (dd, J = 7.9, 4.9 Hz, 1H), 7.59 (dd, J = 9.1, 2.5 Hz, 1H), 4.24 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 420.0, 422.0  (M + 1) Method B (NH4HCO3) 95 Method C, G1 254

469.42 1H-NMR (400 MHz, DMSO-d6): δ 13.34 (s, 1H), 9.60 (s, 1H), 9.35 (s, 1 H), 8.77 (d, J = 3.5 Hz, 1H), 8.72 (d, J = 7.9 Hz, 1H), 8.67 (s, 1H), 8.22 (s, 1 H), 8.17 (d, J = 8.8 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.69-7.58 (m, 2H), 7.55 (s, 1H), 7.24 (d, J = 8.5 Hz, 1 H), 4.29 (q, J = 7.0 Hz, 2H), 1.53 (t, J = 6.9 Hz, 3H). DMSO 470.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1 255

403.41 1H-NMR (400 MHz, DMSO-d6): δ 11.43 (s, 1H), 9.53 (s, 1H), 8.68-8.66 (m, 2H), 8.56 (d, J = 8.3 Hz, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.72-7.64 (m, 1H), 7.61-7.47 (m, 3H), 7.17-7.08 (m, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.46 (t, J = 6.9 Hz, 3H). DMSO 404.2  (M + 1) Method B (NH4HCO3) 95 Method C, G1

Retention Molecular Time Purity Method of Number Product Salt Type Mass ¹H NMR ¹H NMR Solvent LCMS (min) LCMS Protocol percent Coupling 256

HCl 456.723 ¹H NMR (300 MHz, DMSO) δ 9.55 (s, 1H), 9.09 (d, J = 8.0 Hz, 1H), 9.01-8.76 (m, 2H), 8.50 (s, 1H), 8.37 (s, 1H), 8.13-7.91 7.91 (m, 4H), 7.85 (d, J = 8.9 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.25 (1, J = 7.6 Hz, 1H). DMSO 420   (M + 1) 1.89 Method D 100 Method G1 257

HCl 524.39 ¹H NMR (300 MHz, DMSO) δ 10.68 (s, 1H), 9.50 (s, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.92 (d, J = 5.2 Hz, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 8.06-7.93 (m, 2H), 7.87 (d, J = 7.6 Hz, 1H), 7.70-7.51 (m, 2H), 7.19 (d, J = 7.6 Hz, 1H), 4.28 (t, J = 9.1 Hz, 2H), 4 DMSO 452   (M + 1) 1.34 Method D 100 Method G1 258

HCl 474.89 ¹H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.52 (s, 1H), 9.00 (d, J = 8.2 Hz, 1H), 8.89 (d, J = 4.4 Hz, 1H), 8.12 (s, 1H), 8.02- 7.78 (m, 4H), 7.64 (d, J = 9.2 Hz, 1H), 7.54 (t, J = 8.2 Hz, 1H), 7.07 (d, J = 7.7 Hz, 1H), 4.08-3.87 (m, 5H), 3.46 (s, 3H). DMSO 439   (M + 1) 2.21 Method C 98 Method G1 259

HCl 460.86 ¹H NMR (300 MHz, DMSO) δ 10.61 (s, 1H), 9.51 (s, 1H), 9.10 (d, J = 8.2 Hz, 1H), 8.94 (d, J = 4.9 Hz, 1H), 8.22 (s, 1H), 8.08- 7.94 (m, 2H), 7.93-7.78 (m, 2H), 7.65 (d, J = 9.1 Hz, 1H), 7.53 (t, J = 8.2 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 4.01 (s, 3H), 3 DMSO 425   (M + 1) 1.64 Method C 98 Method G1 260

HCl 429.67 No Data 428.9  (M + 1) 2.35 Method C 100 Method G1 261

HCl 443.24 ¹H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 8.97 (dd, J = 6.6, 1.8 Hz, 2H), 8.91-8.83 (m, 1H), 8.07 (dd, J = 8.9, 2.0 Hz, 1H), 7.85 (dd, J = 14.6, 8.2 Hz, 4H), 7.54 (dd, J = 11.7, 4.6 Hz, 1H), 7.31 (s, 1H), 7.10-6.99 (m, 1H). DMSO 442.96 (M + 1) 2.36 Method C 100 Method G1 262

HCl 426.39 ¹H NMR (300 MHz, DMSO) δ 10.71 (s, 1H), 9.47 (s, 1H), 9.01 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 4.0 Hz, 1H), 8.23 (s, 1H), 8.08- 7.86 (m, 4H), 7.61 (t, J = 8.2 Hz, 2H), 7.22 (d, J = 7.6 Hz, 1H), 4.28 (d, J = 7.0 Hz, 2H), 1.44 (t, J = 6.9 Hz, 3H). DMSO 427.1  (M + 1) 2.47 Method C 93 Method G1 263

HCl 446.13 1H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.47 (s, 1H), 8.90 (s, 3H), 8.27 (s, 1H), 8.02 (d, J = 8.9 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 9.0 Hz, 2H), 7.68 (d, J = 8.8 Hz, 1H). DMSO 494.0  (M + 1) 2.29 Method C 91 Method G1 264

395.46 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.88 (s, 1H), 8.83- 8.71 (m, 2H), 8.18 (d, J = 9.2 Hz, 1H), 7.80 (dd, J = 9.2, 2.3 Hz, 1H), 7.69-7.57 (m, 3H), 7.32 (d, J = 2.1 Hz, 1H), 4.14 (q, J = 6.6 Hz, 2H), 2.39 (s, 3H), 2.35 (s, 3H), 1.37 (t, J = 6.9 Hz, 3 DMSO 396.10 (M + 1) 2.3 Method C 100 Method G12 265

HCl 469.53 1H NMR (300 MHz, DMSO) δ 12.13 (s, 1H), 9.54 (s, 1H), 8.99 (d, J = 7.4 Hz, 1H), 8.85 (s, 2H), 8.61 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.86 (d, J = 7.3 Hz, 2H), 7.68 (dd, J = 15.1, 7.8 Hz, 3H), 7.32 (d, J = 6.8 Hz, 1H), 4.00 (s, 3H), 3.71 (d, J DMSO 470.1  (M + 1) 2.15 Method C 100 Method G1 266

HCl 455.51 1H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 9.52 (s, 1H), 8.82- 8.65 (m, 4H), 7.88 (dd, J = 8.1, 5.0 Hz, 2H), 7.73-7.55 (m, 4H), 7.27 (t, J = 7.2 Hz, 1H), 3.98 (m, 1H), 3.82 (d, J = 10.4 Hz, 2H), 3.35 (t, J = 11.7 Hz, 2H), 1.68 (d, J = 10.3 Hz, 2H), 1.55- DMSO 456.1  (M + 1) 2.09 Method C 100 Method G1 267

HCl 408.36 1H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 9.45 (d, J = 1.5 Hz, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.89 (d, J = 3.9 Hz, 1H), 8.16 (d, J = 2.3 Hz, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.94 (t, J = 7.4 Hz, 2H), 7.63 (ddd, J = 9.3, 6.9, 2.3 Hz, 2H), 7.52 (d, J = 8.7 Hz, DMSO 409.1  (M + 1) 2.3 Method C 100 Method G1 268

HCl 367.4 1H NMR (300 MHz, DMSO) δ 11.12 (s, 1H), 9.81 (s, 1H), 9.43- 9.37 (m, 1H), 8.58 (ddd, J = 8.0, 4.8, 1.4 Hz, 2H), 8.09 (d, J = 2.5 Hz, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.80 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.53-7.41 (m, 3H), 7.17 (1, J = 7.5 Hz, 1H), 7.0 DMSO 368.1  (M + 1) 1.98 Method C 100 Method G1 269

386.4 ¹H NMR (300 MHz, DMSO) δ 11.47 (s, 2H), 9.39 (s, 1H), 8.66 (d, J = 2.8 Hz, 1H), 8.56-8.47 (m, 1H), 8.01-7.90 (m, 2H), 7.69- 7.55 (m, 2H), 7.55-7.40 (m, 2H), 7.05 (t, J = 7.5 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H), 1.44 (t, J = DMSO 387.0  (M + 1) 2.05 Method C 100 Method G8 270

407.45 ¹H NMR (300 MHz, DMSO) δ 10.52 (s, 1H), 9.44 (s, 1H), 8.92 (d, J = 7.4 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.46 (d, J = 6.4 Hz, 1H), 8.01 (d, J = 8.7 Hz, 2H), 7.92- 7.74 (m, 6H), 7.68 (dd, J = 9.2, 2.4 Hz, 1H), 7.48 (t, J = 7.8 Hz, 1H), 3.98 (s, 4H). DMSO 408.0  (M + 1) 1.92 Method C 100 Method G1, with two drops of conc. HCl 271

HCl 385.42 ¹H NMR (300 MHz, DMSO) δ 9.75 (s, 1H), 9.66 (s, 1H), 9.39 (s, 1H), 8.61 (d, J = 3.1 Hz, 1H), 8.54 (d, J = 8.2 Hz, 1H), 7.85 (s, 1H), 7.82 (s, 2H), 7.71 (d, J = 7.4 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 7.5, 5.2 Hz, 1H), 7.35-7.23 (m, 2H), 3.9 DMSO 386.1  (M + 1) 1.79 Method C 96 Method G2 272

HCl 413.47 ¹HNMR (300 MHz, DMSO) δ 12.30 (s, 1H), 9.57 (d, J = 2.1 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.77- 8.67 (m, 2H), 8.63 (d, J = 7.7 Hz, 1H), 7.94-7.83 (m, 2H), 7.71 (t, J = 7.1 Hz, 1H), 7.66-7.52 (m, 3H), 7.25 (t, J = 7.4 Hz, 1H), 4.24- 4.06 (m, 1H), 3 DMSO 414.2  (M + 1) 2.36 Method C 100 Method G1 273

HCl 387.46 ¹H NMR (300 MHz, DMSO) δ 10.96 (s, 1H), 10.29 (s, 1H), 9.85 (s, 1H), 9.51 (d, J = 2.0 Hz, 1H), 8.71-8.62 (m, 2H), 8.47 (dd, J = 8.2, 0.9 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.67-7.62 (m, 2H), 7.60 (d, J = 2.5 Hz, 1H), 7.57 (d, J = 2.6 Hz, 1H), 7.55-7 DMSO 388.1  (M + 1) 2.01 Method C 95 Method G1 274

HCl 399.45 ¹H NMR (300 MHz, DMSO) δ 12.45 (s, 1H), 9.57 (d, J = 1.3 Hz, 1H), 8.96 (dd, J = 8.4, 0.9 Hz, 1H), 8.89 (t, J = 5.2 Hz, 1H), 8.75- 8.66 (m, 2H), 7.94-7.84 (m, 2H), 7.72 (t, J = 7.9 Hz, 1H), 7.65- 7.52 (m, 3H), 7.24 (1, J = 7.6 Hz, 1H), 4.00 (s, 3H), 3. DMSO 400.3  (M + 1) 2.21 Method C 100 Method G1 275

HCl 453.42 ¹H NMR (300 MHz, DMSO) δ 11.70 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 9.40 (t, J = 6.1 Hz, 1H), 8.79 (d, J = 7.7 Hz, 1H), 8.73-8.63 (m, 2H), 7.89 (d, J = 9.8 Hz, 2H), 7.76 (t, J = 7.1 Hz, 1H), 7.64- 7.50 (m, 3H), 7.30 (t, J = 7.1 Hz, 1H), 4.16-4.01 (m, 2 DMSO 454.0  (M + 1) 2.28 Method C 100 Method G1 276

421.25 ¹H NMR (300 MHz, DMSO) δ 9.26 (d, J = 2.2 Hz, 1H), 8.71-8.62 (m, 2H), 8.46 (dt, J = 8.0, 1.9 Hz, 1H), 8.21 (dd, J = 8.9, 2.3 Hz, 1H), 8.03 (d, J = 8.9 Hz, 1H), 7.89 (s, 1H), 7.78 (dd, J = 7.6, 1.6 Hz, 1H), 7.72-7.62 (m, 1H), 7.56- 7.45 (m, 3H), 7.32 DMSO 423.0  (M + 1) 1.85 Method C 94 Method G1 277

HCl 447.49 ¹H NMR (300 MHz, DMSO) δ 11.25 (s, 1H), 10.46 (s, 1H), 9.45 (s, 1H), 8.93 (d, J = 7.9 Hz, 1H), 8.82 (d, J = 3.9 Hz, 1H), 8.22 (d, J = 8.1 Hz, 1H), 7.97-7.79 (m, 4H), 7.73 (t, J = 7.1 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.53- 7.39 (m, 3H), 7.19 (t, DMSO 448.1  (M + 1) 2.67 Method C 100 Method G1 278

HCl 399.45 ¹H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.57 (d, J = 1.4 Hz, 1H), 9.03 (dd, J = 8.4, 0.9 Hz, 1H), 8.91 (d, J = 4.6 Hz, 1H), 8.76- 8.64 (m, 2H), 7.88 (t, J = 7.8 Hz, 2H), 7.72 (t, J = 7.9 Hz, 1H), 7.63- 7.53 (m, 3H), 7.22 (td, J = 7.9, 1.1 Hz, 1H), 4.28 DMSO 400.1  (M + 1) 2.5 Method C 100 Method G1 279

HCl 399.45 ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.37 (d, J = 1.4 Hz, 1H), 8.61 (dd, J = 4.7, 1.7 Hz, 1H), 8.58-8.51 (m, 1H), 7.84 (dd, J = 9.0, 5.3 Hz, 3H), 7.65-7.42 (m, 4H), 7.38 (t, J = 7.5 Hz, 1H), 3.95 (s, 3H), 2.74 (s, 6H). DMSO 400.1  (M + 1) 2.2 Method C 100 Method G1 280

HCl 439.51 ¹H NMR (300 MHz, DMSO) δ 12.05 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 8.1 Hz, 1H), 8.88 (dd, J = 5.2, 1.3 Hz, 1H), 8.60 (d, J = 7.0 Hz, 1H), 8.44 (d, J = 8.0 Hz, 1H), 8.00-7.87 (m, 2H), 7.83 (dd, J = 7.8, 1.4 Hz, 1H), 7.77 (d, J = 1.9 Hz, 1H), DMSO 440.1  (M + 1) 2.52 Method C 100 Method G1 281

HCl 403.41 ¹H NMR (300 MHz, DMSO) δ 10.98 (s, 1H), 9.50 (s, 1H), 8.72- 8.55 (m, 3H), 8.38 (d, J = 8.2 Hz, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.72- 7.45 (m, 4H), 7.19-7.07 (m, 1H), 3.96 (s, J = 5.2 Hz, 3H), 2.73 (d, J = 4.5 Hz, 3H). DMSO 404.1  (M + 1) 2.18 Method C 100 Method G1 282

HCl 417.44 ¹H NMR (300 MHz, DMSO) δ 10.96 (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 8.71-8.55 (m, 3H), 8.38 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.66 (dd, J = 14.8, 8.3 Hz, 1H), 7.60-7.47 (m, 3H), 7.21- 7.05 (m, 1H), 4.24 (q, J = 6.9 Hz, 2H), 2.73 (d, J = 4. DMSO 419.1  (M + 1) 2.38 Method C 100 Method G1 283

HCl 439.39 ¹H NMR (300 MHz, DMSO) δ 13.10 (s, 1H), 9.68 (d, J = 1.1 Hz, 1H), 9.52 (d, J = 1.4 Hz, 1H), 8.75- 8.58 (m, 3H), 8.26 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.59-7.47 (m, 3H), 7.45 (d, J = 2.5 Hz, 1H), 3.95 (s, 3H). DMSO 440.1  (M + 1) 2.25 Method C 100 Method G1 284

HCl 453.42 ¹H NMR (300 MHz, DMSO) δ 13.08 (s, 1H), 9.70 (s, 1H), 9.55 (d, J = 1.3 Hz, 1H), 8.77-8.60 (m, 3H), 8.26 (s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.62-7.39 (m, 4H), 4.21 (q, J = 7.1 Hz, 2H), 1.45 (t, J = 6.9 Hz, 3H). DMSO 454.1  (M + 1) 2.43 Method C 95 Method G1 285

HCl 410.43 ¹H NMR (300 MHz, DMSO) δ 12.87 (s, 1H), 9.50 (d, J = 1.5 Hz, 2H), 8.73-8.59 (m, 3H), 8.26 (s, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.64 (dd, J = 8.1, 1.5 Hz, 1H), 7.59-7.49 (m, 2H), 7.42 (d, J = 2.4 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H DMSO 411.1  (M + 1) 2.16 Method C 95 Method G1 286

HCl 397.43 ¹H NMR (300 MHz, DMSO) δ 13.63 (s, 1H), 9.55 (s, 1H), 9.13 (d, J = 8.3 Hz, 1H), 8.75-8.58 (m, 3H), 7.84 (d, J = 9.8 Hz, 1H), 7.69- 7.48 (m, 4H), 7.01 (d, J = 7.4 Hz, 1H), 3.94 (s, 3H), 3.46-3.36 (m, 2H), 2.96 (t, J = 5.7 Hz, 2H). DMSO 398.3  (M + 1) 2.12 Method C 100 Method G1 287

HCl 411.46 ¹H NMR (300 MHz, DMSO) δ 13.61 (s, 1H), 9.56 (s, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.75-8.60 (m, 3H), 7.84 (d, J = 9.8 Hz, 1H), 7.70- 7.46 (m, 4H), 7.02 (d, J = 7.2 Hz, 1H), 4.19 (q, J = 6.9 Hz, 3H), 3.48- 3.37 (m, 2H), 2.96 (t, J = 6.1 Hz, 2H), 1.44 (t, DMSO 412.4  (M + 1) 2.4 Method C 100 Method G1 288

HCl 383.4 ¹H NMR (300 MHz, DMSO) δ 11.62 (s, 1H), 9.60 (d, J = 1.5 Hz, 1H), 9.02 (s, 1H), 8.88 (d, J = 8.0 Hz, 1H), 8.80-8.65 (m, 2H), 7.90 (d, J = 9.0 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 7.66-7.51 (m, 3H), 7.27 (d, J = 7.6 Hz, 1H), 4.47 (s, 2H), 3.97 (s, 3H). DMSO 384.1  (M + 1) 2.01 Method C 95 Method G1 289

HCl 421.4 ¹H NMR (300 MHz, DMSO) δ 12.07 (s, 1H), 9.48 (d, J = 1.6 Hz, 1H), 8.76-8.55 (m, 3H), 8.34 (s, 1H), 8.14 (8, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.62-7.49 (m, 2H), 7.38 (d, J = 2.5 Hz, 1H), 7.14 (ddd, J = 11.5, 9.0, 2.6 Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 1. DMSO 422.2  (M + 1) 2.35 Method C 100 Method G1 290

HCl 412.44 ¹H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.58 (m, 2H), 7.98 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.80 (d, J = 9.1 Hz, 1H), 7.55- 7.43 (m, 3H), 7.23 (d, J = 8.4 Hz, 1H), 3.96 (s, 3H), 3.37 (d, J = 4.2 Hz, 6H). DMSO 413.0  (M + 1) 1.79 Method C Method G1 291

HCl 426.47 ¹H NMR (300 MHz, DMSO) δ 9.78 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.57 (m, 2H), 7.97 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.55- 7.43 (m, 3H), 7.22 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 3.37 (d, J = 4.3 H DMSO 427.1  (M + 1) 1.92 Method C Method G1 292

404.39 ¹H NMR (300 MHz, DMSO) δ 9.36 (d, J = 1.4 Hz, 1H), 8.66 (d, J = 2.7 Hz, 1H), 8.52 (d, J = 7.8 Hz, 1H), 7.97 (d, J = 8.9 Hz, 2H), 7.64 (d, J = 13.5 Hz, 2H), 7.50 (dd, J = 7.7, 4.2 Hz, 1H), 6.86 (t, J = 6.8 Hz, 1H), 6.70 (dd, J = 11.8, 1.7 Hz, 1H), 4.22 (q, DMSO 405.1  (M + 1) 1.98 Method C 95 Method G8 293

406.82 ¹H NMR (300 MHz, DMSO) δ 9.23 (d, J = 1.4 Hz, 1H), 8.63 (d, J = 3.6 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1H), 7.92 (s, 1H), 7.81-7.65 (m, 4H), 7.55 (dd, J = 8.4, 2.1 Hz, 1H), 7.48 (dd, J = 6.7, 3.8 Hz, 1H), 7.37 (s, 1H), 3.97 (s, 3H). DMSO 407.1  (M + 1) 1.88 Method C 100 Method G8 294

HCl 406.46 ¹H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.39 (d, J = 1.4 Hz, 1H), 8.63 (dd, J = 4.7, 1.7 Hz, 1H), 8.59-8.53 (m, 1H), 8.50 (dd, J = 8.2, 0.8 Hz, 1H), 8.03 (dd, J = 8.0, 1.4 Hz, 1H), 7.96-7.84 (m, 2H), 7.65-7.46 (m, 4H), 3.94 (s, 3H), 3.25 (s, 3H). DMSO 407.1  (M + 1) 2.13 Method C 95 Method G1

Pu- ¹H rity Method Num- Starting Starting Salt NMR per- of ber Material 1 Material 2 Product Type ¹H NMR Solvent cent Coupling 295

¹H NMR (400 MHz, DMSO) δ 13.12 (s, 1H), 9.90 (s, 1H), 9.47 (d, J = 1.4 Hz, 1H), 8.70-8.54 (m, 2H), 8.20- 8.15 (m, 1H), 8.14 (s, 1H), 8.01 (d, J = 2.6 Hz, 1H), 7.88-7.75 (m, 2H), 7.65 (d, J = 8.9 Hz, 1H), 7.59-7.44 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 296

¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.54-9.47 (m, 1 H), 9.36 (s, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.69- 8.59 (m, 2H), 8.19 (d, J = 8.8 Hz, 1H), 8.08-7.97 (m, 2H), 7.86 (d, J = 9.1 Hz, 1H), 7.61-7.47 (m, 2H), 3.99 (s, 3H). DMSO >98 G1 297

¹H NMR (400 MHz, DMSO) δ 9.64 (s, 1H), 9.55-9.45 (m, 1H), 8.72-8.60 (m, 2H), 7.95 (d, J = 2.7 Hz, 1 H), 7.82 (d, J = 9.1 Hz, 1H), 7.58-7.48 (m, 3H), 7.34 (dd, J = 8.7, 2.5 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1 H), 4.39-4.23 (m, 4H), 3.97 (s, 3H). DMSO >98 G1 298

¹H NMR (400 MHz, DMSO) δ 11.21 (s, 1H), 9.79 (s, 1H), 9.53 (d, J = 1.4 Hz, 1H), 8.75-8.58 (m, 2H), 8.07 (s, 1H), 8.03 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.56-7.47 (m, 2H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 7.39-7.34 (m, 1H), 6.50-6.41 (m, 1H), 3.99 (s, 3H). DMSO >98 G1 299

¹H NMR (400 MHz, DMSO) δ 9.54 (s, 1H), 9.42-9.34 (m, 1H), 8.61 (dd, J = 4.7, 1.7 Hz, 1H), 8.57-8.47 (m, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.56-7.44 (m, 2H), 7.19 (dd, J = 7.9, 1.5 Hz, 1 H), 7.00-6.91 (m, 1H), 6.86 (dd, J = 8.2, 1.6 Hz, 1H), 4.34-4.17 (m, 4H), 3.95 (s, 3H). DMSO >98 G1 300

¹H NMR (400 MHz, DMSO) δ 10.76 (s, 1H), 10.01 (s, 1H), 9.17-9.06 (m, 1H), 8.53 (dd, J = 4.7, 1.7 Hz, 1H), 8.36-8.27 (m, 1H), 8.05 (d, J = 2.7 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.60- 7.48 (m, 2H), 7.36 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.32-7.28 (m, 1H), 7.25 (d, J = 6.8 Hz, 1 H), 7.16-7.04 (m, 1H), 6.54 (dd, J = 3.0, 1.9 Hz, 1H), 3.98 (s, 3H). DMSO >98 G1 301

¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.48 (d, J = 1.5 Hz, 1H), 9.33 (d, J = 1.0 Hz, 1H), 8.69-8.59 (m, 2H), 8.37 (d, J = 1.7 Hz, 1H), 8.10 (dd, J = 9.0, 2.1 Hz, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.90 (d J = 9.0 Hz, 1H), 7.86 (d, J = 9.1 Hz, 1H), 7.57 (dd, J = 9.1, 2.7 Hz, 1H), 7.54-7.47 (m, 1H), 3.99 (s, 3H). DMSO >98 G1 302

¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.18 (dd, J = 2.2, 0.8 Hz, 1H), 8.60 (dd, J = 4.7, 1.7 Hz, 1H), 8.45- 8.36 (m, 1H), 8.03 (d, J = 2.7 Hz, 1H), 7.97-7.90 (m, 2H), 7.88 (d, J = 7.0 Hz, 1H), 7.77 (dd, J = 9.0, 7.1 Hz, 1H), 7.61 (dd, J = 9.1, 2.7 Hz, 1H), 7.44 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 4.01 (s, 3H). DMSO >98 G1 303

¹H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.60-9.56 (m, 1H), 8.72-8.67 (m, 1H), 8.65 (dd, J = 4.8, 1.7 Hz, 1H), 8.26-8.21 (m, 1H), 8.05 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1 H), 7.56-7.50 (m, 2H), 7.46 (dd, J = 8.5, 1.8 Hz, 1H), 7.35 (d, J = 3.1 Hz, 1H), 6.46 (dd, J = 3.1, 0.8 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H). DMSO >98 G1 304

¹H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 9.51-9.45 (m, 1H), 8.68-8.59 (m, 2H), 8.57-8.52 (m, 1H), 8.02- 7.88 (m, 3H), 7.87-7.80 (m, 1H), 7.58-7.46 (m, 2H), 3.98 (s, 3H), 2.83 (s, 3H). DMSO >98 G1 305

¹H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 9.51-9.43 (m, 1H), 8.68-8.58 (m, 2H), 8.39 (d, J = 2.0 Hz, 1 H), 7.99 (d, J = 2.7 Hz, 1H), 7.87-7.80 (m, 2H), 7.78 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 9.1, 2.7 Hz, 1 H), 7.51 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 4.19 (s, 3H), 3.98 (s, 3H). DMSO >98 G1 306

¹H NMR (400 MHz, DMSO) δ 9.72 (s, 1H), 9.52-9.47 (m, 1H), 8.67-8.60 (m, 2H), 7.98 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 9.1 Hz, 1H), 7.78-7.74 (m, 1H), 7.68-7.62 (m, 1H), 7.55-7.48 (m, 2H), 7.32 (d, J = 8.1 Hz, 1H), 3.97 (s, 3H), 2.99-2.88 (m, 4H), 2.15- 2.04 (m, 2H). DMSO >98 G1 307

¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 9.37-9.31 (m, 1H), 8.60 (dd, J = 4.7, 1.7 Hz, 1H), 8.53-8.46 (m, 1H), 7.95 (d, J = 2.7 Hz, 1 H), 7.82 (d, J = 9.1 Hz, 1H), 7.52 (dd, J = 9.1, 2.7 Hz, 1H), 7.47 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.34 (d, J = 7.0 Hz, 1H), 7.31- 7.24 (m, 1H), 7.22 (d, J = 7.1 Hz, 1H), 3.96 (s, 3H), 2.99 (t, J = 7.3 Hz, 2H), 2.82 (t, J = 7.4 Hz, 2H), 2.06-1.96 (m, 2H). DMSO >98 G1 308

HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.50-9.44 (m, 1H), 8.94- 8.87 (m, 1H), 8.83 (dd, J = 5.1, 1.5 Hz, 1H), 8.54 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.97-7.89 (m, 2H), 7.83 (dd, J = 8.0, 5.2 Hz, 1H), 7.63 (dd, J = 9.1, 2.7 Hz, 1H), 4.01 (s, 3H), 2.83 (s, 3H). DMSO >98 G1 309

HCl ¹H NMR (400 MHz, DMSO) δ 10.64 (S, 1H), 9.47 (d, J = 1.5 Hz, 1H), 8.94 (d, J = 8.1 Hz, 1H), 8.86 (dd, J = 5.2, 1.5 Hz, 1H), 8.54-8.48 (m, 1H), 8.23- 8.16 (m, 1H), 8.04-7.94 (m, 2H), 7.92-7.83 (m, 2H), 7.78 (d, J = 5.4 Hz, 1H), 7.65 (dd, J = 9.1, 2.6 Hz, 1H), 7.51 (dd, J = 5.4, 0.7 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 310

HCl ¹H NMR (400 MHz, DMSO) δ 10.86 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.94 (d, J = 7.5 Hz, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.30-8.20 (m, 1H), 8.13- 7.99 (m, 3H), 7.94-7.84 (m, 1H), 7.74 (d, J = 1.3 Hz, 2H), 7.67 (66, J = 9.1, 2.5 Hz, 1H), 7.08 (d, J = 2.2 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 311

HCl ¹ H NMR (400 MHz, DMSO) δ 10.53 (S, 1H), 9.48 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 7.7 Hz, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.44 (d, J = 1.9 Hz, 1H), 8.20-8.15(m, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.97 (d, J = 9.1 Hz, 1H), 7.92 (dd, J = 8.7, 2.0 Hz, 1H), 7.86 (dd, J = 7.8, 5.1 Hz, 1H), 7.64 (dd, J = 9.1, 2.6 Hz, 1H), 4.02 (s, 3H), 2.85 (s, 3H). DMSO >98 G1 312

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.85 (S, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.47 (s, 1H), 9.32 (s, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.93-8.87 (m, 1H), 8.86- 8.78 (m, 2H), 8.44 (dd, J = 8.8, 1.9 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.99-7.89 (m, 2H), 7.78-7.71 (m, 1H), 7.55 (d, J = 8.7 Hz, 1H). DMSO >98 G1 313

2 HCl ¹H NMR (400 MHz, DMSO) δ 11.07 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.51 (d, J = 2.0 Hz, 1H), 9.46-9.39 (m, 1H), 9.10-9.01 (m, 1H), 8.97-8.88 (m, 2H), 8.86 (dd, J = 5.3, 1.3 Hz, 1H), 8.63-8.55 (m, 1H), 8.48 (dd, J = 8.8, 1.9 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.04-7.90 (m, 4H), 7.79 (d, J = 5.4 Hz, 1H), 7.52 (dd, J = 5.4, 0.7 Hz, 1H). DMSO >98 G1 314

HCl ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.48 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 7.9 Hz, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.24 (s, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.05 (d, J = 2.2 Hz, 1H), 7.96 (d, J = 9.1 Hz, 1H), 7.87 (dd, J = 8.1, 5.3 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.72(dd, J = 8.4, 1.8 Hz, 1H), 7.64 (dd, J = 9.1, 2.6 Hz, 1H), 7.03 (dd, J = 2.2, 1.0 Hz, 1H), 4.02 (s, 3H). DMSO >98 G1 315

HCl ¹H NMR (400 MHz, DMSO) δ 10.72 (s, 1H), 9.46 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 8.2 Hz, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.50 (d, J = 1.8 Hz, 1 H), 8.21 (d, J = 2.4 Hz, 1H), 8.06-7.96 (m, 2H), 7.93-7.84 (m, 2H), 7.78 (d, J = 5.4 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.51 (dd, J = 5.4, 0.7 Hz, 1H), 4.29 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 316

¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.60-9.52 (m, 1H), 8.75- 8.63 (m, 2H), 8.16 (d, J = 2.0 Hz, 1H): 8.04-7.95 (m, 2H), 7.93-7.83 (m, 2H), 7.63-7.53 (m, 2H), 6.32 (d, J = 1.2 Hz, 1H), 4.01 (s, 3H), 2.47 (s, 3H). DMSO >98 G1 (0.1N HCl added) 317

¹H NMR (400 MHz, DMSO) δ 11.82 (s, 1H), 10.06 (s, 1H), 9.53-9.46 (m, 1H), 8.81-8.70 (m, 2H), 8.04 (d, J = 2.6 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1 H), 7.81 (d, J = 2.1 Hz, 1H), 7.67 (dd, J = 7.9, 5.0 Hz, 1H), 7.57 (dd, J = 9.1, 2.7 Hz, 1H), 7.53 (dd, 8.7, 2.1 Hz, 1H), 7.39 (d, J = 8.6 Hz, 1H), 4.00 (s, 3H). DMSO >98 G1 (0.1N HCl added) 318

¹H NMR (400 MHz, DMSO) δ 9.89 (s, 1H), 9.57-9.48 (m, 1H), 8.72-8.58 (m, 2H), 8.01 (d, J = 2.1 Hz, 1H), 7.99 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.59-7.49 (m, 3H), 7.43 (d, J = 8.6 Hz, 1 H), 3.98 (s, 3H), 3.41 (s, 3H). DMSO >98 G1 (0.1N HCl added) 319

¹H NMR (400 MHz, DMSO) δ 9.88 (s, 1H), 9.52-9.44 (m, 1H), 8.71-8.59 (m, 2H), 8.02-7.91 (m, 2H), 7.83 (d, J = 9.1 Hz, 1H), 7.66 (dd, J = 8.4, 2.0 Hz, 1H), 7.58-7.48 (m, 2H), 7.36 (d, J = 8.4 Hz, 1 H), 3.98 (s, 3H), 3.40 (s, 3H). DMSO >98 G1 (0.1N HCl added) 320

¹H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 9.58-9.51 (m, 1H), 9.45 (s, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.71- 8.63 (m, 2H), 8.25 (d, J = 8.7 Hz, 1H), 8.08-8.00 (m, 2H), 7.86 (d, J = 9.1 Hz, 1H), 7.61-7.50 (m, 2H), 4.00 (s, 3H). DMSO >98 G1 (0.1N HCl added) 321

¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.72 (s, 1H), 9.51-9.45 (m, 1H), 8.67-8.57 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.73-7.68 (m, 1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.56-7.48 (m, 2H), 6.93 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H), 3.58 (s, 2H). DMSO >98 G1 (0.1N HCl added) 322

¹H NMR (400 MHz, DMSO) δ 9.95 (s, 1H), 9.54-9.45 (m, 1H), 8.67 (dd, J = 4.7, 1.7 Hz, 1H), 8.66-8.60 (m, 1H), 8.15 (d, J = 2.4 Hz, 1 H), 7.94 (d, J = 2.6 Hz, 1H), 7.89-7.83 (m, 2H), 7.63- 7.52 (m, 3H), 3.98 (s, 3H). DMSO >98 G1 (0.1N HCl added) 323

¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.75 (s, 1H), 9.55-9.49 (m, 1H), 8.69-8.62 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.58-7.49 (m, 3H), 7.35 (dd, J = 8.7, 2.5 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 4.62 (s, 2H), 3.97 (s, 3H). DMSO >98 G1 (0.1N HCl added) 324

HCl ¹H NMR (400 MHz, DMSO) δ 10.24 (s, 1H), 9.58-9.51 (m, 1H), 8.92- 8.84 (m, 1H), 8.80 (dd, J = 5.0, 1.5 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 7.98 (dd, J = 8.8, 2.1 Hz, 1H), 7.91 (d, J = 9.1 Hz, 1H), 7.83-7.72 (m, 2H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 6.37 (s, 1H), 4.75 (d, J = 1.2 Hz, 2H), 4.01 (s, 3H), 3.47 (s, 3H). DMSO >98 G1 (0.1N HCl added) 325

HCl ¹H NMR (400 MHz, DMSO) δ 12.01 (s, 1H), 10.15 (s, 1H), 9.58 (d, J = 1.5 Hz, 1H), 8.94-8.86 (m, 1H), 8.78 (dd, J = 5.0, 1.5 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 8.04-7.98 (m, 1H), 7.91 (dd, J = 9.3, 2.2 Hz, 2H), 7.78-7.69 (m, 2H), 7.66 (dd, J = 8.5, 2.0 Hz, 1H), 7.61 (dd, J = 9.1, 2.7Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H), 4.01 (s, 3H). DMSO >98 G1 (0.1N HCl added) 326

HCl ¹H NMR (400 MHz, DMSO) δ 12.19 (s, 1H), 10.21 (s, 1H), 9.58-9.51 (m, 1H), 8.94-8.86 (m, 1H), 8.81 (dd, J = 5.1, 1.6 Hz, 1H), 8.10 (d, J = 2.6 Hz, 1H), 7.96-7.88 (m, 2H), 7.79 (dd, J = 7.9, 5.1 HZ, 1H), 7.68-7.56 (m, 3H), 4.00 (s, 3H). DMSO >98 G1 (0.1N HCl added) 327

HCl ¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.57-9.50 (m, 1H), 9.07- 8.98 (m, 1H), 8.88 (dd, J = 5.2, 1.4 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.06 (d, J = 1.9 Hz, 1 H), 8.00-7.89 (m, 2H), 7.75 (d, J = 8.5 Hz, 1H), 7.67 (dd, J = 8.5, 2.0 Hz, 1H), 7.63 (66, J = 9.1, 2.6 Hz, 1H), 4.02 (s, 3H), 3.47 (s, 3H). DMSO >98 G1 (0.1N HCl added) 328

HCl ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 10.24 (s, 1H), 9.45 (d, J = 1.6 Hz, 1H), 9.05-8.95 (m, 1H), 8.92 (dd, J = 5.2, 1.5 Hz, 1H), 8.25-8.16 (m, 1H), 8.09-7.99 (m, 1H), 7.98- 7.89 (m, 1H), 7.71-7.60 (m, 3H), 6.98 (d, J = 8.3 Hz, 1H), 4.00 (s, 3H), 2.99 (t, J = 7.5 Hz, 2H), 2.57-2.52 (m, 2H). DMSO >98 G1 (0.1N HCl added) 329

2 HCl ¹H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 10.98 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.32 (s, 1 H), 9.03 (d, J = 8.2 Hz, 1H), 8.98 (d, J = 1.7 Hz, 1H), 8.92 (dd, J = 5.3, 1.4 Hz, 1H), 8.53 (d, J = 2.6 Hz, 1H), 8.46 (dd, J = 8.8, 1.8 Hz, 1H), 8.30 (s, 1 H), 8.13 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 7.7, 5.3 Hz, 1H), 7.82 (dd, J = 8.6, 2.1 Hz, 1H), 7.26 (d, J = 8.6 Hz, DMSO >98 G1 (0.1N HCl added) 1H), 4.06 (s, 3H). 330

HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.05- 8.97 (m, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.15-8.06 (m, 3H), 8.00- 7.87 (m, 3H), 7.81 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 9.1, 2.7 Hz, 1H), 6.43 (d, J = 9.4 Hz, IH), 4.02 (S, 3H). DMSO >98 G1 (0.1N HCl added) 331

2 HCl ¹H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 10.77 (s, 1H), 9.51 (d, J = 1.5 Hz, 1H), 9.43-9.35 (m, 1H), 9.31- 9.21 (m, 1H), 9.04-8.93 (m, 1H), 8.88 (dd, J = 5.2, 1.5 Hz, 1H), 8.81 (dd, J = 5.1, 1.4 Hz, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.42 (dd, J = 8.8, 1.8 Hz, 1H), 8.13 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.94-7.83 (m, 2H), 7.80 (dd, J = 8.6, 2.2 Hz, 1H), 7.27 (d, J = 8.6 Hz, 1H). DMSO >98 G1 (0.1N HCl added) 332

HCl ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 9.09- 9.01 (m, 1H), 8.90 (dd, J = 5.3, 1.5 Hz, 1H), 8.65-8.59 (m, 1H), 8.24- 8.16 (m, 2H), 8.14 (dd, J = 9.6, 0.8 Hz, 1H), 8.03-7.92 (m, 2H), 7.65 (dd, J = 9.1, 2.7 Hz, 1H), 4.03 (s, 3H). DMSO >98 G1 (0.1N HCl added) 333

HCl ¹H NMR (400 MHz, DMSO) δ 11.81 (s, 1H), 10.31 (s, 1H), 9.58 (d, J = 1.5 Hz, 1H), 9.08 (d, J = 7.9 Hz, 1H), 8.87 (dd, J = 5.2, 1.5 Hz, 1H), 8.13 (d, J = 2.6 Hz, 1H), 8.04 (d, J = 2.0 Hz, 1H), 7.98-7.88 (m, 2H), 7.81 (d, J = 8.8 Hz, 1H), 7.69 (dd, J = 8.8, 2.1 Hz, 1H), 7.63 (dd, J = 9.1, 2.7 Hz, 1H), 6.36 (s, 1H), 4.02 (s, 3H), 2.46 (d; J = 1.1 Hz, 3H). DMSO >98 G1 (0.1N HCl added) 334

HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.08- 9.02 (m, 1H), 8.90 (dd, J = 5.3, 1.5 Hz, 1H), 8.63-8.59 (m, 1H), 8.22- 8.10 (m, 3H), 8.00-7.92 (m, 2H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 4.30 (q. J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1N HCl added) 335

HCl ¹H NMR (400 MHz, DMSO) δ 11.99 (s, 1H), 10.34 (s, 1H), 9.62-9.52 (m, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.13 (d, J = 2.6 Hz, 1H), 8.06 (d, J = 1.8 Hz, 1H), 8.00- 7.88 (m, 3H), 7.75 (d, J = 8.6 Hz, 1H), 7.68-7.60 (m, 2H), 6.46 (d, J = 9.5 Hz, 1H), 4.29 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1N HCl added) 336

HCl ¹H NMR (400 MHz, DMSO) δ 11.02 (s, 1H), 10.49 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.02 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.15 (d, J = 2.3 Hz, 1H), 8.00 (d, J = 9.1 Hz, 1 H), 7.93 (dd, J = 7.8, 5.4 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.54 (d, J = 2.4 Hz, 1H), 7.35 (dd, J = 8.7, 2.5 Hz, 1H), 7.08 (d, J = 8.6 Hz, 1H), 4.64 (s, 2H), 4.28 (q. J = 6.9 Hz, 2H), 1.45 (t, J = 7.0 Hz, 3H). DMSO >98 G1 (0.1N HCl added) 337

HCl ¹H NMR (400 MHz, DMSO) δ 10.36 (s, 1H), 10.25 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.1 Hz, 1H), 8.86 (dd, J = 5.2, 1.5 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.87 (dd, J = 7.7, 5.2 Hz, 1H), 7.61 (dd, J = 9.1, 2.6 Hz, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.36 (dd, J = 8.1, 2.1 Hz, 1H), 7.28 (d, J = 8.1 Hz, 1H), 4.27 (q, J = 7.0 Hz, 2H), 2.93 (t, J = 7.5 Hz, 2H), 2.56-2.52 (m, 2H), 1.45 (t, J = DMSO >98 G1 (0.1N HCl added) 7.0 Hz, 3H). 338

¹H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 9.50-9.39 (m, 1H), 9.03 (dd, J = 2.1, 0.7 Hz, 1H), 8.52 (dd, J = 4.7, 1.7 Hz, 1H), 8.48 (d, J = 6.0 Hz, 1H), 8.31-8.24 (m, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 2.7 Hz, 1H), 8.04 (d, J = 7.3 Hz, 1H), 7.91-7.78 (m, 3H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.35 (ddd, J = 8.0, 4.8, 0.7 Hz, 1H), 4.01 (s, 3H). DMSO >98 J2 339

¹H NMR (400 MHz, DMSO) δ 10.23 (s, 1H), 9.37 (dd, J = 2.1, 0.7 Hz, 1H), 8.62 (dd, J = 4.7, 1.7 Hz, 1H), 8.57- 8.49 (m, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.47 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.40-7.30 (m, 3H), 3.98 (s, 3H). DMSO >98 J2 340

¹H NMR (400 MHz, DMSO) δ 11.31 (s, 1H), 9.56 (s, 1H), 9.54 (dd, J = 2.1, 0.7 Hz, 1H), 8.80-8.66 (m, 2H), 8.14 (d, J = 9.2 Hz, 1H), 7.77 (dd, J = 9.2, 2.8 Hz, 1H), 7.58 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.36 (d, J = 2.8 Hz, 1H), 7.03-6.94 (m, 1H), 6.68 (dd, J = 7.8, 0.8 Hz, 1H), 6.56 (dd, J = 8.2, 0.8 Hz, 1H), 3.86 (s, 3H). DMSO >98 J2 341

¹H NMR (400 MHz, DMSO) δ 10.00 (s, 1H), 9.54-9.49 (m, 1H), 8.75 (s, 1H), 8.69-8.62 (m, 2H), 8.50 (d, J = 1.7 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1 H), 7.91-7.85 (m, 2H), 7.83 (dd, J = 8.6, 1.9 Hz, 1H), 7.60-7.51 (m, 2H), 4.00 (s, 3H). DMSO >98 J2 342

¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.34-9.27 (m, 1H), 8.60 (dd J = 4.7, 1.7 Hz, 1H), 8.51-8.44 (m, 1H), 7.94 (d, J = 2.7 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.58 (dd, J = 9.1, 2.7 Hz, 1H), 7.56-7.51 (m, 1H), 7.51- 7.47 (m, 2H), 7.45 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 3.98 (s, 3H). DMSO >98 J2 343

¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.93 (s, 1H), 9.26 (d, J = 1.4 Hz, 1H), 8.59 (dd, J = 4.8, 1.7 Hz, 1 H); 8.50-8.43 (m, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 9.1, 2.7 Hz, 1H), 7.49-7.42 (m, 1H), 7.36 (d, J = 8.3 Hz, 1H), 6.55 (dd, J = 9.5, 1.7 Hz, 1H), 3.98 (s, 3H), 2.33 (s, 3H). DMSO >98 J2 344

HCl ¹H NMR (400 MHz, DMSO) δ 9.34- 9.28 (m, 1H), 8.81-8.75 (m, 1H), 8.74-8.65 (m, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.93 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.80-7.72 (m, 2H); 7.69 (d, J = 2.8 Hz, 1H), 7.59 (dd, J = 8.8, 2.7 Hz, 1H), 4.00 (s, 3H). DMSO >98 G8 using DMF instead of THF 345

HCl ¹H NM R (400 MHz, DMSO) δ 9.35- 9.29 (m, 1H), 8.87-8.78 (m, 2H), 8.19 (d, J = 9.4 Hz, 1 H), 8.09 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.86 (dd, J = 8.0, 5.3 Hz, 1H), 7.77 (dd, J = 9.1, 2.9 Hz, 1H), 7.72 (d, J = 2.8 Hz, 1H), 7.67 (d, J = 2.3 Hz, 1H), 7.54 (dd, J = 8.5, 2.3 Hz, 1H), 6.56 (d, J = 9.6 Hz, 1H), 4.02 (s, 3H). DMSO >98 G12 at room temper- ature 346

HCl ¹H NMR (400 MHz, DMSO) δ 11.98 (s, 1H), 9.29 (d, J = 1.7 Hz, 1H), 8.88- 8.78 (m, 2H), 8.08 (d, J = 9.2 Hz, 1H), 7.97 (d, J = 9.6 Hz, 1H), 7.88 (dd, J = 8.1, 5.4 Hz, 1H), 7.81 (d, J = 2.6 Hz, 1H), 7.78-7.72 (m, 2H), 7.67 (dd, J = 8.9, 2.6 Hz, 1H), 7.48 (d, J = 8.9 Hz, 1H), 6.60 (d, J = 9.5 Hz, 1 H), 4.02 (s, 3H). DMSO >98 G12 at room temper- ature 347

HCl ¹H NMR (400 MHz, DMSO) δ 9.33- 9.28 (m, 1H), 8.87-8.67 (m, 2H), 8.06 (d, J = 9.1 Hz, 1 H), 7.91-7.79 (m, 1H), 7.75 (dd, J = 9.1, 2.9 Hz, 1H), 7.71 (d, J = 2.8 Hz, 1H), 7.67- 7.61 (m, 2H), 7.58-7.51 (m, 2H), 4.01 (s, 3H). DMSO >98 G12 at room temper- ature 348

HCl ¹H NMR (400 MHz, DMSO) δ 9.28 (d, J = 2.0 Hz, 1H), 8.85-8.67 (m, 2H), 8.06 (d, J = 9.0 Hz, 1 H), 7.88-7.77 (m, 1H), 7.77-7.69 (m, 2H), 7.62- 7.54 (m, 2H), 7.51-7.45 (m, 2H), 7.44-7.37 (m, 1H), 4.02 (d, J = 3.9 Hz, 3H). DMSO >98 G12 at room temper- ature 349

HCl ¹H NMR (400 MHz, DMSO) δ 9.23 (dd, J = 2.1, 0.7 Hz, 1 H); 8.80 (dd, J = 5.2, 1.6 Hz, 1H), 8.72-8.64 (m, 1H), 8.09 (d, J = 9.1 Hz, 1H), 7.84-7.71 (m, 4H), 7.66 (dd, J = 8.1, 1.6 Hz, 1H), 7.61-7.54 (m, 1H), 7.52-7.45 (m, 1H), 4.02 (s, 3H). DMSO >98 G12 at room temper- ature 350

HCl ¹H NMR (400 MHz, DMSO) δ 9.22 (d, J = 1.7 Hz, 1H), 8.87-8.79 (m, 1H), 8.77-8.67 (m, 1H), 8.06 (d, J = 92 Hz, 1H), 7.92-7.79 (m, 1H), 7.74 (dd, J = 9.1, 2.9 Hz, 1 H), 7.70 (d, J = 2.8 Hz, 1H), 7.45-7.37 (m, 2H), 7.33- 7.27 (m, 1H), 7.17-7.09 (m, 1H), 4.01 (s, 3H), 3.71 (s, 3H). DMSO >98 G12 at room temper- ature 351

2 HCl ¹H NMR (400 MHz, DMSO) δ 12.03 (s, 1H), 10.69 (S, 1H), 9.65 (d, J = 1.8 Hz, 1H), 9.26-9.21 (m, 1H), 9.20- 9.12 (m, 1H), 8.99-8.88 (m, 2H), 8.52 (d, J = 2.6 Hz, 1 H), 8.49-8.42 (m, 1H), 8.25-8.17 (m, 1H), 8.15- 8.08 (m, 2H), 8.02-7.96 (m, 1H), 7.93 (d, J = 9.4 Hz, 1 H), 7.77 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5, 1.9 Hz, 1H), 6.47 (d, J = 9.6 Hz, 1H), 4.04 (s, DMSO >98 G1 3H). 352

2 HCl ¹H NMR (400 MHz, DMSO) δ 12.04 (s, 1H), 10.92 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.58-9.50 (m, 1H), 9.46- 9.39 (m, 1H), 9.27-9.18 (m, 1H), 9.01-8.92 (m, 2H), 8.88 (dd, J = 5.3, 1.2 Hz, 1H), 8.48 (dd, J = 8.8, 1.9 Hz, 1H), 8.20-8.10 (m, 2H), 8.09-8.01 (m, 2H), 7.93 (d, J = 9.5 Hz, 1 H), 7.81-7.72 (m, 2H), 6.47 (d, J = 9.5 Hz, 1H). DMSO >98 G1 353

HCl 1H NMR (300 MHz, DMSO) δ 10.90 (s, 1 H), 9.63 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.76 (d, J = 4.0 Hz, 1H), 8.19 (d, J = 2.1 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1 H), 7.78-7.65 (m, 2H), 7.63-7.49 (m, 2H), 7.47-7.33 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 354

HCl 1H NMR (300 MHz, DMSO) δ 11.44 (s, 1 H), 9.58 (d, J = 1.8 Hz, 1 H), 9.16 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.29 (d, J = 2.5 Hz, 1H), 8.13 (d, J = 9.2 Hz, 1 H), 7.99 (dd, J = 8.0, 5.4 Hz, 1H), 7.72-7.49 (m, 2H), 7.44-7.27 (m, 3H), 7.12 (s, 1H), 3.99 (s, 3H), 2.52 (s, 3H). DMSO >98 G1 355

HCl 1H NMR (300 MHz, DMSO) δ 11.38 (s, 1 H), 9.53 (s, 1H), 9.18 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 5.3 Hz, 1 H), 8.21 (s, 1H), 8.14-8.02 (m, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.60 (d, J = 9.1 Hz, 1H), 6.90 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 356

HCl 1H NMR (300 MHz, DMSO) δ 11.30 (s, 1H); 9.59 (d, J = 1.8 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.3, 1.2 Hz, 1H), 8.24 (d, J = 2.5 Hz, 1H), 8.11-7.93 (m, 2H), 7.76-7.54 (m, 4H), 7.40 (t, J = 7.6 Hz, 1 H), 7.26 (s, 1H), 7.21 (d, J = 7.4 Hz, 1H), 3.98 (s, 3H), 2.41 (s, 3H). DMSO >98 G1 357

HCl 1H NMR (300 MHz, DMSO) δ 11.21 (s, 1 H), 9.59 (d, J = 1.7 Hz, 1 H), 9.22 (d, J = 8.1 Hz, 1H), 9.02-8.95 (m, 1H), 8.23 (d, J = 2.5 Hz, 1H), 8.13- 7.96 (m, 3H), 7.85 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.60 (dd, J = 9.1, 2.6 Hz, 1H), 7.31 (s, 1 H), 3.98 (s, 3H). DMSO >98 G1 358

HCl 1H NMR (300 MHz, DMSO) δ 10.87 (s, 1H), 9.65-9.55 (m, 1 H), 8.93 (dt J = 8.0, 1.8 Hz, 1H), 8.81 (dd, J = 5.0. 1.6 Hz, 1H), 8.18 (d, J = 2.6 Hz, 1H), 7.94-7.82 (m, 4H), 7.78 (dd, J = 8.0, 5.0 Hz, 1 H), 7.60-7.46 (m, 4H), 7.44- 7.35 (m, 1H), 7.32 (s, 1 H), 3.98 (s, 3H). DMSO >98 G1 359

HCl H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.59 (s, 1H), 9.20 (d, J = 8.1 Hz, 1H), 9.01-8.94 (m, 1H), 8.25 (s, 1H), 8.12-7.98 (m, 2H), 7.90-7.75 (m, 2H), 7.62(d, J = 9.1 Hz, 1H), 7.21 (s, 1H), 7.08 (d, J = 8.6 Hz, 2H), 3.99 (s, 3H), 3.84 (s, 3H). DMSO >98 G1 360

HCl 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.60 (s, 1H), 9.21 (d, J = 8.0 Hz, 1H), 8.99 (d, J = 5.3 Hz, 1H), 8.26 (d, J = 2.2 Hz, 1H), 8.11-7.99 (m, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.62 (dd, J = 9.1, 2.4 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 7.26 (s, 1H), 3.99 (s, 3H), 2.37 (s, 3H). DMSO >98 G1 361

HCl 1H NMR (300 MHz, DMSO) δ 11.00 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 8.96 (dt, J = 8.1, 1.7 Hz, 1H), 8.86 (dd, J = 5.1, 1.5 Hz, 1H), 8.19 (d, J = 2.6 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 7.83 (dt, J = 9.5, 4.8 Hz, 1H), 7.55 (dd, J = 9.1, 2.6 Hz, 1H), 6.72 (s, 1H), 3.95 (d, J = 7.0 Hz, 3H), 2.35 (d, J = 3.5 Hz, 3H). DMSO >98 G1 362

HCl H NMR (300 MHz, DMSO) δ 11.21 (s 1H), 9.58 (d, J = 1.5 Hz, 1H), 9.21- 9.06 (m, 1H), 8.95 (d, J = 4.3 Hz, 1H) 8.22 (d, J = 2.3 Hz, 1H), 8.09-7.92 (m, 2H), 7.70-7.51 (m, 3H), 7.24- 7.17 (m, 1H), 7.13 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 363

HCl 1H NMR (300 MHz, DMSO) δ 11.07 (s, 1H), 9.60 (s, 1H), 9.13 (d, J = 6.5 Hz, 1H), 8.93 (d, J = 5.1 Hz, 1H), 8.23 (s, 1H), 8.05-7.85 (m, 4H), 7.67- 7.54 (m, 1H), 7.43-7.23 (m, 3H), 3.99 (s, 3H). DMSO >98 G1 364

2 HCl 1H NMR (300 MHz, DMSO) δ 11.16 (s, 1H), 9.57 (d, J = 1.5 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.93 (d, J = 5.2 Hz, 1H), 8.18(d, J = 2.4 Hz, 1H), 8.03- 7.89 (m, 4H), 7.61-7.54 (m, 2H), 7.32 (s, 1H), 3.97 (s; 3H). DMSO >98 G1 365

2 HCl 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1H), 9.58 (d, J = 1.6 Hz, 1H), 9.27 (d, J = 8.2 Hz, 1H), 9.06-8.99 (m, 1H), 8.18 (d, J = 2.5 Hz, 1H), 8.10 (dd, J = 8.1, 5.5 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.91 (dd, J = 10.7, 1.8 Hz, 1H), 7.80-7.65 (m, 2H), 7.57 (dd, J = 9.1, 2.G Hz, 1H), 7.29 (s, 1H), 3.96 (s, 3H). DMSO >98 G1 366

2 HCl 1H NMR (300 MHz, DMSO) δ 11.17 (s, 1H), 9.60 (s, 1H), 9.24 (d, J = 8.2 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.22 (d, J = 2.5 Hz, 1H), 8.11-8.04 (m, 1H), 8.02-7.91 (m, 2H), 7.82-7.68 (m, 2H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.36 (s, 1H), 4.01 (d, J = 11.0 Hz, 3H). DMSO >98 G1 367

2 HCl 1H NMR (300 MHz, DMSO) δ 11.53 (s, 1H), 9.58 (d, J = 1.8 Hz, 1H), 9.20 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.3, 1.3 Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 8.12 (d, J = 9.1 Hz, 1H), 8.04-7.95 (m, 1H), 7.80-7.68 (m, 2H), 7.63- 7.57 (m, 1H), 7.56-7.48 (m, 1H), 7.31 (s, 1H), 3.99 (d, J = 6.7 Hz, 3H). DMSO >98 G1 368

2 HCl 1H NMR (300 MHz, DMSO) δ 11.24 (s, 1H), 9.59 (d, J = 1.7 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 2.6 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 8.09 (dd, J = 8.1, 5.4 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.91 (dd, J = 8.4, 2.1 Hz, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.62 (dd, J = 9.1, 2.5 Hz, 1H), 7.37 (s, 1H), 3.98 (s, 3H). DMSO >98 G1 369

HCl 1H NMR (300 MHz, DMSO) δ 11.33 (s, 1H), 9.62 (s, 1H), 9.27 (d, J = 8.4 Hz, 1H), 9.01 (d, J = 5.2 Hz, 1 H); 8.29 -8.19 (m, 3H), 8.13-8.01 (m, 2H), 7.79-7.73 (m, 2H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.42 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 370

HCl 1H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.92 (d, J = 4.0 Hz, 1H), 8.26 (d, J = 2.5 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.98-7.68(m, 5H), 7.63 (dd, J = 9.2, 2.5 Hz, 1H), 7.13 (s, 1H), 4.00 (S.3H). DMSO >98 G1 371

2 HCl 1H NMR (300 MHz, CDCl3) δ 11.29 (s, 1H), 9.57 (d, J = 1.8 Hz, 1H), 9.07 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.2, 1.3 Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 8.07-7.97 (m, 2H), 7.92 (dd, J = 8.0, 5.3 Hz, 1H), 7.67-7.51 (m, 4H), 7.28 (s, 1H), 3.99 (s, 3H). DMSO >98 G1 372

2 HCl 1H NMR (300 MHz, DMSO) δ 11.32 (s, 1 H), 9.60 (d, J = 1.7 Hz, 1H), 9.27 (d, J = 8.1 Hz, 1H), 9.03 (d, J = 5.4 Hz, 1H), 8.22 (d, J = 2.5 Hz, 1H), 8.12 (dd, J = 8.1, 5.7 Hz, 1H), 8.03 (d, J = 8.8 Hz, 3H), 7.59 (dd, J = 9.1, 2.5 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.32 (s, 1H), 3.98(d, J = 6.7 Hz, 3H). DMSO >98 G1 373

2 HCl 1H NMR (300 MHz, DMSO) δ 11.38 (s, 1 H), 9.61 (d, J = 1.6 Hz, 1H), 9.26 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.3 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.12- 8.01 (m, 2H), 7.95 (d, J = 8.0 Hz, 1H), 7.89 (s, 1H), 7.71-7.56 (m, 2H), 7.45-7.33 (m, 2H), 4.10-3.90 (m, 3H). DMSO >98 G1 374

2 HCl 1H NMR (300 MHz, DMSO) δ 11.29 (s, 1 H), 9.56 (s, 1H), 9.12 (d, J = 7.7 Hz, 1H), 8.94 (d, J = 4.9 Hz, 1H), 8.26 (d, J = 2.3 Hz, 1H), 8.07-7.90 (m, 2H), 7.71-7.57 (m, 2H), 7.51 (s, 1H), 7.47-7.37 (m, 1H), 7.17 (s, 1H), 3.99 (s, 3H), 2.53 (s, 3H). DMSO >98 G1 375

2 HCl 1H NMR (300 MHz, DMSO) δ 13.13- 11.88 (m, 1H), 9.66 (d, J = 1.4 Hz, 1H), 9.36 (d J = 8.2 Hz, 1 H), 9.00 (d, J = 5.4 Hz, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.14(dd, J = 8.1, 5.6 Hz, 1H), 8.01 (d, J = 7.5 Hz, 2H), 7.89 (d, J = 9.1 Hz, 1H), 7.78 (s, 1 H), 7.64-7.35 (m, 9H), 5.23 (s, 2H). DMSO >98 J NaOtBu, Pd(OAc)2, Tri-t- butyl- phospho- nium tetra- fluoro- borate, Toluene 376

2 HCl 1H NMR (300 MHz, DMSO) δ 12.49 (s, 1 H), 9.63 (s, 1H), 9.27 (d, J = 8.1 Hz, 1H), 8.96 (d, J = 5.4 Hz, 1H), 8.34 (s, 1H), 8.07 (dd, J = 8.1, 5.6 Hz, 1H), 7.99 (d, J = 8.3 Hz, 2H), 7.85 (d, J = 9.1 Hz, 1H), 7.80 (s, 1 H), 7.64-7.35 (m, 9H), 5.21 (s, 2H). DMSO >98 J NaOtBu, Pd(OAc)2, Tri-t- butyl- phospho- nium tetra- fluoro- borate, Toluene 377

2 HCl 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, 1H), 9.30-9.21 (m, 1H), 9.01 (dd, J = 5.5, 1.2 Hz, 1H), 8.18- 8.03 (m, 2H), 7.76-7.64 (m, 2H), 7.55-7.45 (m, 2H), 7.33 (dd, J = 8.6, 2.3 Hz, 1 H), 4.69 (t, J = 7.9 Hz, 2H), 3.92 (s, 3H), 3.26 (t, J = 7.8 Hz, 2H). DMSO >98 G8 378

2 HCl 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.9 Hz, 1H), 8.70-8.65 (m, 2H), 7.95 (d, J = 9.2 Hz, 1H), 7.66-7.50 (m, 2H), 7.45-7.36 (m, 2H), 7.27 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H), 4.61 (t, J = 8.1 Hz, 2H), 3.87 (s, 3H), 3.38-3.17 (m, 5H). DMSO >98 G8 at 50° C. 379

2 HCl 1H NMR (400 MHz, DMSO) δ 9.54 (d, J = 1.9 Hz, 1H), 9.28-9.18 (m, 1H), 8.99 (dd, J = 5.5, 1.3 Hz, 1H), 8.18- 8.02 (m, 2H), 7.69 (dd, J = 9.2, 2.7 Hz, 1H), 7.58-7.46 (m, 2H), 7.39 (dd, J = 8.2, 5.9 Hz, 1H), 6.96-6.85 (m, 1H), 4.71 (1, J = 8.0 Hz, 2H), 3.92 (s, 3H), 3.22 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 380

2 HCl 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.10-7.93 (m, 2H), 7.76 (dd, J = 8.7, 4.7 Hz, 1H), 7.67 (dd, J = 9.2, 2.6 Hz, 1H), 7.52 (d, J = 2.6 Hz, 1H), 7.28 (dd, J = 8.4, 2.6 Hz, 1 H), 7.12 (td, J = 9.0, 2.7 Hz, 1 H), 4.70 (t, J = 7.9 Hz, 2H), 3.92 (s, 3H), 3.26 (t, J = 7.5 Hz, 2H). DMSO >98 G8 at 50° C. 381

HCl 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 2.0 Hz, 1H), 9.15-9.06 (m, 1H), 8.91 (dd, J = 5.2, 1.5 Hz, 1H), 8.27- 8.17 (m, 2H), 8.01 (d, J = 8.9 Hz, 1H), 7.94 (dd, J = 8.2, 5.2 Hz, 1H), 7.88- 7.78 (m, 2H), 7.42 (d, J = 2.7 Hz, 1 H), 7.35 (dd, J = 8.8, 2.2 Hz, 1H), 6.96 (d, J = 3.5 Hz, 1H), 3.91 (s, 3H). DMSO >98 G8 at 50° C. 382

HCl 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.6 Hz, 1H), 9.26 (d, J = 8.2 Hz, 1H), 9.05-8.98 (m, 1H), 8.20-8.02 (m, 2H), 7.69 (dd, J = 9.2, 2.7 Hz, 1H), 7.53-7.40 (m, 2H), 7.32 (dd, J = 14.0, 8.0 Hz, 1H), 6.92 (1. J = 8.5 Hz, 1H), 4.71 (t, J = 7.9 Hz, 2H), 3.91 (s, 3H), 3.28 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 383

2 HCl 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 9.23-9.09 (m, 1H), 8.93 (dd, J = 5.3, 1.5 Hz, 1H), 8.31- 8.16 (m, 2H), 8.08-7.93 (m, 2H), 7.82 (dd, J = 9.2, 2.8 Hz, 1H), 7.56 (dd, J = 9.4, 2.5 Hz, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.19 (Id, J = 9.2, 2.7 Hz, 1H), 7.02-6.89 (m, 1H), 3.91 (s, 3H). DMSO >98 G8 at 50° C. 384

2 HCl 1H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.6 Hz, 1H), 9.23-9.09 (m, 1H), 8.94 (dd, J = 5.3, 1.5 Hz, 1H), 8.26- 8.14 (m, 2H), 8.00 (dd, J = 8.1, 5.3 Hz, 1H), 7.90-7.73 (m, 3H), 7.45 (d, J = 2.7 Hz, 1H), 7.25-7.10 (m, 1H), 6.98 (d, J = 3.5 Hz, 1H), 3.92 (s, 3H). DMSO >98 G8 at 50° C. 385

2 HCl 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.8 Hz, 1H), 9.21 (dt, J = 8.2, 1.6 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.20-8.00 (m, 2H), 7.68 (dd, J = 9.2, 2.7 Hz, 1H), 7.55-7.31 (m, 3H), 7.00-6.78 (m, 1H), 4.69 (t, J = 7.9 Hz, 2H), 4.19 (q, J = 7.0 Hz, 2H), 3.22 (t, J = 7.9 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H). DMSO >98 G8 at 50° C. 386

2 HCl 1H NMR (300 MHz, DMSO) δ 9.42 (d, J = 1.5 Hz, 1H), 9.06 (d, J = 8.1 Hz, 1H), 8.93 (d, J = 5.4 Hz, 1H), 8.09- 7.99 (m, 2H), 7.68 (dd, J = 9.1, 2.7 Hz, 1H), 7.53 (d, J = 2.6 Hz, 1H), 7.30- 7.16 (m, 3H), 4.66 (t, J = 7.9 Hz, 2H), 3.98 (s, 3H), 3.29 (t, J = 7.7 Hz, 2H). DMSO >98 G8 at 50° C. 387

2 HCl 1H NMR (300 MHz, DMSO) δ 9.37 (d, J = 1.4 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.99 (d, J = 4.9 Hz, 1H), 8.14 (dd, J = 8.2, 5.6 Hz, 1H), 8.06 (d, J = 9.2 Hz, 1H), 7.70 (dd, J = 9.2, 2.6 Hz, 1 H), 7.51 (d, J = 2.7 Hz, 1H), 7.45- 7.36 (m, 2H), 7.26-7.15 (m, 1H), 4.83 (d, J = 9.5 Hz, 1H), 4.49-4.38 (m, 2H), 4.00 (s, 3H), 3.48-3.28 (m, 1H), 3.27-3.05 (m, 1H). DMSO >98 G8 at 50° C. 388

2 HCl 1H NMR (400 MHz, DMSO) δ 9.56 (d, J = 1.9 Hz, 1H), 9.31-9.19 (m, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.21- 8.02 (m, 2H), 7.73-7.64 (m, 2H), 7.47 (dd, J = 5.4, 2.4 Hz, 2H), 7.32 (dd, J = 8.6, 2.3 Hz, 1H), 4.67 (t, J = 8.0 Hz, 2H), 4.18 (q, J = 7.0 Hz, 2H), 3.26 (t, J = 7.8 Hz, 2H), 1.41 (1, J = 6.9 Hz, 3H). DMSO >98 G8 at 50° C. 389

2 HCl 1H NMR (400 MHz, DMSO) δ 9.54 (d, J = 1.8 Hz, 1H), 9.25 (dt J = 8.2, 1.6 Hz, 1H), 9.04(dd, J = 5.5, 1.1 Hz, 1H), 8.26 (d, J = 2.1 Hz, 1H), 8.16 (dd, J = 8.0, 5.6 Hz, 1H), 8.11-7.96 (m, 2H), 7.91 (d, J = 8.6 Hz, 1H), 7.47 (d, J = 2.1 Hz, 1H), 7.34 (dd, J = 8.6, 2.3 Hz, 1H), 4.68 (t, J = 7.9 Hz, 2H), 3.25 (t, J = 7.8 Hz, 2H). DMSO >98 G8 at 50° C. 390

HCl ¹H NMR (400 MHz, DMSO) δ 9.37 (d, J = 1.4 Hz, 1H), 8.82 (dd, J = 5.1, 1.5 Hz, 1H), 8.76 (dd, J = 8.1 Hz, 1H), 8.62 (d; J = 1.9 Hz, 1H), 8.46 (dd, J = 8.8, 2.1 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 6.3, 2.6 Hz, 1H), 7.80 (dd, J = 8.0, 5.1 Hz, 1H), 7.71- 7.59 (m, 2H), 7.52-7.38 (m, 3H), 7.10-7.01 (m, 1H), 3.89 (s, 3H). DMSO >98 G8 with DMF in- stead of THF 391

HCl 1H NMR (400 MHz, DMSO) δ 9.38 (d, J = 1.4 Hz, 1H), 8.82(d, J = 5.1 Hz, 1H), 8.76 (d, J = 7.9 Hz, 1H), 8.63 (d, J = 1.8 Hz, 1 H), 8.46 (dd, J = 8.8, 2.2 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.97 (d, J = 2.7 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.84-7.76 (m, 1H), 7.64 (dd, J = 8.8, 2.7 Hz, 1H), 7.52-7.39 (m, 3H), 7.10-7.02 (m, 1H), 3.88 (s, 3H). DMSO >98 G8 with DMF in- stead of THF 392

HCl ¹H NMR (400 MHz, DMSO) δ 9.39 (t, J = 3.2 Hz, 1H), 8.93-8.82 (m, 2H), 8.62 (d, J = 1.8 Hz, 1H), 8.47 (dd, J = 8.8, 2.2 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 7.91 (dd, J = 8.1, 5.3 Hz, 1H), 7.84-7.77 (m, 1 H); 7.73-7.63 (m, 1H), 7.53-7.40 (m, 4H), 7.09-7.03 (m, 1H), 3.87 (d, J = 6.5 Hz, 3H). DMSO >98 G8 with DMF in- stead of THF 393

HCl ¹H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 11.10 (s, 1H), 9.42 (d, J = 1.9 Hz, 1H), 8.90-8.69 (m, 2H), 8.62 (d, J = 1.7 Hz, 1H), 8.40 (dd, J = 8.8; 1.9 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.84-7.69 (m, 1H), 7.57-7.40 (m, 3H), 7.11-7.02 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 3.89 (s, 3H). DMSO >98 G8 with DMF in- stead of THF 394

HCl ¹H NMR (400 MHz, DMSO) δ 9.43- 9.29 (m, 1H), 8.75-8.64 (m, 2H), 8.60-8.48 (m, 1 H); 8.47-8.32 (m, 1H), 8.21-8.01 (m, 2H), 7.86-7.74 (m, 2H), 7.64 (d, J = 8.6 Hz, 1H), 7.59- 7.34 (m, 4H), 7.13-7.01 (m, 1H), 6.87 (d, J = 8.7 Hz, 1H), 3.90 (t, J = 5.3 Hz, 3H). DMSO >98 G8 with DMF in- stead of THF 395

HCl ¹H NMR (400 MHz, DMSO) δ 9.24 (dd, J = 2.2, 0.8 Hz, 1H), 8.76 (dd, J = 5.0, 1.7 Hz, 1H), 8.61-8.54 (m, 1H), 8.49 (dd, J = 1.8, 1.1 Hz, 1H), 8.21- 8.12 (m, 2H), 7.75 (dd, J = 8.0, 1.5 Hz, 1H), 7.70-7.62 (m, 2H), 7.62- 7.53 (m, 1H), 7.53-7.44 (m, 1H). DMSO >98 G8 with DMF in- stead of THF 396

HCl ¹H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 11.10 (s, 1H), 9.42 (d; J = 1.9 Hz, 1H), 8.90-8.69 (m, 2H), 8.62 (d, J = 1.7 Hz, 1H), 8.40 (dd, J = 8.8, 1.9 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.84-7.69 (m, 1H), 7.57-7.40 (m, 3H), 7.11-7.02 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 3.89 DMSO >98 G12 397

HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.99 (d, J = 8.2 Hz, 1H), 8.88 (dd, J = 5.3, 1.5 Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 8.14-8.06 (m, 1H), 7.99-7.88 (m, 2H), 7.78-7.66 (m, 2H), 7.61-7.51 (m, 3H), 7.50-7.34 (m, 3H), 5.34 (s, 2H). DMSO >98 Method G1 398

¹H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 9.52 (d, J = 1.4 Hz, 1H), 8.68 (dd, J = 9.9 Hz, 1 H), 8.65 (d, J = 9.9 Hz, 1H), 8.16 (dd, J = 2.5, 5.4 Hz, 2H), 7.68-7.41 (m, 2H), 7.78-7.66 (m, 8H), 7.39-7.19 (m, 1H), 5.30 (s, 2H). DMSO >98 Method G1 399

1H NMR (DMSO-d6) ppm 12.52 (s, 1 H); 9.78 (d, J = 1.56 Hz, 1 H), 8.91 8.88 (m, 1H), 8.74 (dd, J = 4.74, 1.69 Hz, 1H), 8.33 (brs, 1H), 8.96 (d, J = 8.56 Hz, 2H), 7.93 (d, J = 9.08 hz, 1H), 7.89 (s, 1H), 7.66-7.59 (m, 2H), 7.55 (d, J = 8.56 Hz, 2H), 4.01 (s, 3H). DMSO >98 G13 400

2 HCl 1H NMR (DMSO-d6) ppm 12.80- 12.40 (br, 1H), 977 (d, J = 1.84 Hz, 1H), 9.32 (d, J = 8.04 Hz, 1H), 8.97 (dd, J = 5.36, 1.40 Hz, 1H), 8.34 (d, J = 2.68 Hz, 1 H), 8.09-8.06 (m, 3H), 7.97 (d, J = 9.12 Hz, 1H), 7.91 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.55 (d, J = 8.60 Hz, 2H), 4.01 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 401

2 HCl 1H NMR (DMSO-d6) ppm 11.14 (brs, 1H), 9.58 (s, 1H), 9.13 (dd, J = 7.96 Hz, 1H), 8.93 (d, J = 5.24 Hz, 1H), 8.54 (d, J = 4.72 Hz, 1H), 8.48 (d, J = 8.32 Hz, 1H), 8.28 (brs, 1H), 8.09 (bit, J = 7.16 Hz, 1H), 8.02-7.96 (m, 2H), 7.65 (dd, J = 8.80, 2.48 Hz, 1H), 7.34 (brt, J = 6.52 Hz, 1H), 4.01 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 402

2 HCl 1H NMR (DMSO-d6) ppm 10.89 (s, 1H), 9.57 (d, J = 1.60 Hz, 1H), 9.04 (d, J = 8.04 Hz, 1H), 8.88 (dd, J = 5.16, 1.40 Hz, 1H), 8.55 (dd, J = 2.64, 0.52 Hz, 1H), 8.50 (d, J = 8.92 Hz, 1H), 8.22 (d, J = 2.68 Hz, 1H), 8.08 (d, J = 8.92, 2.68 Hz, 1H), 7.94-7.90 (m, 2H), 7.61 (dd, J = 9.08, 2.68 Hz, 1H), 3.99 (s, 3H). The 1H of 2HCl was not observed. DMSO DMSO J2 403

2 HCl 1H NMR (DMSO-d6) ppm 10.53 (s, 1H), 9.38 (s, 1H), 8.99 (d, J = 8.08 Hz, 1H), 8.88 (d, J = 4.60 Hz, 1H), 8.11 (brs, 1H), 8.01-7.95 (m, 2H), 7.90 (d, J = 8.60 Hz, 2H), 7.66 (dd, J = 9.12, 2.68 Hz, 1H), 7.50 (d, J = 8.60 Hz, 2H), 6.93 (s, 1H), 4.00 (s, 3H), 3.80 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 404

HCl 1H NMR (DMS0-d6) ppm 11.81 (brs, 1H), 9.64 (s, 1H), 9.00 (d, J = 7.48 Hz, 1H), 8.85 (brs, 1H), 8.14 (d J = 2.56 Hz, 1H), 8.00 (d, J = 8.60 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.86 (br, 1H), 7.66-7.63 (m, 3H), 7.25 (s, 1H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 405

HCl 1H NMR (DMSO-d6) ppm 11.80 (brs, 1H), 9.65 (brs, 1H), 9.04 (d, J = 7.92 Hz, 1H), 8.88 (brs, 1H), 8.14 (d, J = 2.60 Hz, 1H), 8.05-8.02 (m, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.89 (m, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 7.42 (t, J = 8.84 Hz, 2H), 7.23 (s, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 406

HCl 1H NMR (DMSO-d6) ppm 10.31 (s, 1H), 9.37 (s, 1 H), 8.88 (m, 2H), 8.04 (d J = 2.60 Hz, 1 H), 7.94 (d, J = 9.12 Hz, 1H), 7.91 (m, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.56 (d, J = 1.88 Hz, 1H), 6.40 (d, J = 1.88Hz, 1H), 3.98 (s, 3H), 3.74 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 407

2 HCl 1H NMR (DMSO-d6) ppm 12.89 (brs, 1H), 9.56 (s, 1H), 8.92 (d, J = 4.92 Hz, 2H), 8.04 (d, J = 8.84 Hz, 1H), 7.98 (d, J = 2.88 Hz, 1H), 7.84 (br. 1H), 7.71-7.66 (m, 3H), 7.45-7.39 (m, 2H), 4.00 (s, 3H), 3.94 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 J2 408

HCl 1H NMR (DMSO-d6) ppm 10.39 (s, 1H), 9.38 (s, 1H), 8.90 (d, J = 8.00 Hz, 1H), 8.84 (d, J = 4.76 hz, 1H), 8.06 (d, J = 2.68 Hz, 1H), 7.95 (d, J = 9.16 Hz, 1H), 7.90-7.88 (m, 3H), 7.65 (dd, J = 9.16, 2.68 Hz, 1H), 7.44 (bit J = 7.40 Hz, 2H), 7.35-7.31 (m, 1H), 6.88 (s, 1H), 3.99 (s, 3H), 3.80 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 Tempera- ture at 100° C. 409

HCl 1H NMR (DMSO-d6) ppm 10.44 (brs, 1H), 9.01 (s, 1H), 8.68 (brs, 1H), 8.39 (brs, 1H), 8.23 (s, 1H), 8.07 (brs, 1H), 7.84 (d, J = 9.04 Hz, 1H), 7.70-7.54 (m, 2H), 7.44 (brd, J = 7.32 Hz, 2H), 7.15 (bit J = 7.56 Hz, 2H), 7.00 (brt, 7.40 Hz, 1H), 3.97 (s, 3H), 3.93 (s, 3H). The 1H of HCl was not observed. DMSO >98 J2 Tempera- ture at 100° C. 410

HCl 1H NMR (DMSO-d6) ppm 11.13 (s, 1H), 9.59 (d, J = 1.64 Hz, 1H), 9.03 (brs, 1H), 8.88 (brs, 1 H), 8.63 (d, J = 2.52 Hz, 1H), 8.23 (d, J = 2.32 Hz, 1H), 7.93-7.82 (brm, 4H), 7.61-7.53 (m, 3H), 7.35-7.31 (brm, 2H), 4.00 (s, 3H). The 1H of HCl was not obseived. DMSO >98 J2 Tempera- ture at 100° C. 411

1H NMR (DMSO-d6) ppm 9.54 (s, 1H), 8.79 (s, 1H), 8.69 (d, J = 7.60 Hz, 1H), 7.89 (brd, J = 8.96 Hz, 2H), 7.68-7.58 (m, 4H), 7.38-7.30 (m, 2H), 3.98 (s, 3H). The 1H of NH— was not observed. DMSO >98 J2 Tempera- ture at 100° C. 412

HCl 1H NMR (DMSO-d6) ppm 9.70 (s, 1H), 9.05 (d, J = 7.88 Hz, 1H), 8.85 (brd, J = 4.44 Hz, 1H), 8.24 (brs, 1H), 8.04 (d, J = 8.44 Hz, 2H), 7.94 (d, J = 9.00 Hz, 1H), 7.84 (m, 1 H), 7.66 (d, J = 8.44 Hz, 2H), 7.62 (dd, J = 9.00, 2.64 Hz, 1H), 3.99 (s, 3H). The 1H of HCl and NH— were not observed. DMSO >98 G12 Tempera- ture at 100° C. 413

1H NMR (CDCl3) ppm 15.18 (brs, 1H), 9.57 (d, J = 2.32 Hz, 1H), 8.86 (dd, J = 4.80, 1.56 Hz, 1H), 8.59-8.56 (m, 1 H), 7.78-7.73 (m, 4H), 7.55-7.52 (m, 1H), 7.43 (d, J = 8.56 Hz, 2H), 7.38 (dd, J = 8.88, 2.96 Hz, 1H), 7.34 (s, 1H), 3.97 (s, 3H), 3.30 (s, 3H), 3.11 (s, 3H). CDCl3 >98 J2 Tempera- ture at 100° C.

¹H Pu- Meth- NMR rity od of Reten- Num- Starting Starting Salt Sol- per- Cou- tion LCMS ber Material 1 Material 2 Product type ¹H NMR vent cent pling LCMS Time Method 414

2 HCl 1H NMR (DMSO- d6) ppm 9.72 (s, 1H), 9.16 (brs, 1H), 8.93 (d, J = 4.36 Hz, 1H), 8.14 (br, 1H), 7.96 (brm, 2H), 7.63 (dd, J = 9.08, 2.56 Hz, 1H), 7.00 (s, 1H), 3.98 (s, 3H), 2.37 (s, 3H). The 1H of 2HCL and NH— were not observed. DMSO >98 G12 Tem- pera- ture at 100° C. 415

2 HCl 1H NMR (DMSO- d6) ppm 12.60 (brs, 1H), 9.78 (s, 1H), 9.12 (d, J = 8.00 Hz, 1H), 8.86 (brs, 1H), 8.35 (brd, J = 2.60 Hz, 1H), 8.01 (d, J = 8.56 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.92 (s, 1H), 7.86 (m, 1H), 7.69 (d, J = 8-56 Hz, 2H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Tem- pera- ture at 100° C. 416

HCl 1H NMR (DMSO- d6) ppm 12.80- 12.40 (br, 1H), 9.79 (d, J = 1.64 Hz, 1H), 9.16 (d, J = 7.88 Hz, 1H), 8.88 (d, J = 3.88 Hz, 1H), 8.36 (brd, J = 2.64 Hz, 1H), 8.06-8.04 (m, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.90 (m, 1H), 7.85 (s, 1H), 7.63 (dd, J = 9.08, 2.64 Hz, 1H), 7.49 (m, 2H), 7.38 (m, 1H), 4.02 (s, DMSO >98 G12 Tem- pera- ture at 100° C. 3H). The 1H of HCl was not observed. 417

HCl 1H NMR (DMSO- d6) ppm 12.80 (s, 1H), 9.74 (d, J = 1.60 Hz, 1H), 9.01 (brs, 1H), 8.83 (brs, 1H), 8.31 (d, J = 2.64 Hz, 1H), 8.15 (d, J = 1.00 Hz, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.78 (br, 1H), 7.64 (dd, J = 9.12, 2.64 Hz, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Tem- pera- ture at 100° C. 418

HCl 1H NMR (DMSO- d6) ppm 12.60 (br, 1H), 9.79 (d, J = 1.72 Hz, 1H), 9.19 (d, J = 8.00 Hz, 1H), 8.93 (dd, J = 5.16 , 1.44 Hz, 1H), 8.23 (brs, 1H), 8.10 (s, 1H), 7.99 (m, 1H), 7.95 (d, J = 9.08 Hz, 1H), DMSO >98 G12 Tem- pera- ture at 100° C. 7.77-7.75 (br, 2H), 7.62 (dd, J = 9.08, 2.72 Hz, 1H), 7.50 (m, 2H), 7.37 (m, 1H), 3.99 (s,3H). The 1H of HCl was not observed. 419

HCl 1H NMR (DMSO- d6) ppm 12.56 (s, 1H), 9.78 (s, 1H), 9.09 (d, J = 8.20 Hz, 1H), 8.84 (d, J = 3.96 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.10- 8.07 (m, 2H), 7.95 (d, J = 9.12 Hz, 1H), 7.83 (bit, J = 6.60 Hz, 2H), 7.63 (dd, J = 9.12, 2.60 Hz, 1H), 7.32 (m, 2H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G12 Tem- pera- ture at 100° C. 420

HCl 1H NMR (DMSO- d6) ppm 9.74 (s, 1H), 9.04 (d, J = 6.68 Hz, 1H), 8.86 (brs, 1H), 8.29 (brs, 1H), 8.05 (brs, J = 7.44 Hz, 2H), 7.97 (d, J = 9.08 Hz, 1H), 7.89 (br, 1H), 7.67- 7.58 (m, 4H), 4.00 (s, 3H).The 1H of HCl and NH— were not observed. DMSO >98 G12 Tem- pera- ture at 100° C. 421

1H NMR (DMSO- d6) ppm 9.88 (s, 1H), 9.51 (dd, J = 2.16, 0.8 Hz, 1H), 8.68-8.64 (m, 2H), 7.98 (d, J = 2.40 Hz, 1H), 7.91 (d, J = 8.84 Hz, 2H), 7.86 (d, J = 9.12 Hz, 1H), 7.68 (d, J = 8.84 Hz, 2H), 7.58-7.53 (m, 2H), 3.98 (s, 3H). DMSO >98 G1 422

HCl 1H NMR (DMSO- d6) ppm 10.24 (br, 1H), 9.54 (s, 1H), 8.92 (d, J = 7.52 Hz, 1H), 8.82 (d, J = 3.96 Hz, 1H), 8.10 (d, J = 2.44 Hz, 1H), 8.03 (d, J = 8.68 Hz, 2H), 7.92 (d, J = 9.08 Hz, 1H), 7.84 (d, J = 8.68 Hz, 2H), 7.81 (m, 1H), 7.77- DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 7.75 (m, 2H), 7.62 (dd, J = 9.08, 2.44 Hz, 1H), 7.50 (m, 2H), 7.38 (m, 1H), 4.01 (s, 3H) The 1H of HCl was not observed. 423

HCl 1H NMR (DMSO- d6) ppm 9.72 (s, 1H), 9.09 (d, J = 8.00 Hz, 1H), 8.89 (d, J = 4.24 Hz, 1H), 8.26 (brs, 1H), 8.12-8.09 (m, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.91 (m, 1H), 7.64 (dd, J = 9.12, 2.64 Hz, 1H), 7.45 (t, J = 8.80 Hz, 2H), 3.99 (s, 3H). The 1H of HCl and NH— were not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 424

HCl 1H NMR (DMSO- d6) ppm 10.30- 10.15 (br, 1H), 9.54 (s, 1H), 8.91 (brs, 1H), 8.82 (brs, 1H), 8.10 (brs, 1H), 8.04 (d, J = 8.56 Hz, 2H), 7.92 (d, J = 9.6 Hz, 1H), 7.85 (d, J = 8.56 Hz, 2H), 7.80 (m, 1H), 7.79 (d, J = 8.56 Hz, 2H), 7.65-7.59 DMSO >98 J3 (brm, 1H), 7.55 (d, J = 8.56 Hz, 2H), 4.01 (s, 3H).The 1H of HCl was not ob- served. 425

HCl 1H NMR (DMSO- d6) ppm 9.91 (s, 1H), 9.53 (d, J = 1.84 Hz, 1H), 8.69 (d, J = 5.56 Hz, 2H), 8.31 (t, J = 1.88 Hz, 1H), 7.99 (d, J = 2.68 Hz, 1H), 7.98- 7.94 (m, 1H), 7.87 (d, J = 9.08 Hz, 1H), 7.60-7.54 (m, 2H), 7.46 (t, J = 8.04 Hz, 1H), 7.39-7.35 (m, 1H), 3.99 (s, 3H). The 1H of HCl was not observed. DMSO >98 G1 426

HCl 1H NMR (DMSO- d6) ppm 10.25 (br, 1H), 9.52 (s, 1H), 8.89 (brs, 1H), 8.88 (brs, 1H), 8.22 (brs, 1H), 8.11 (brs, 1H), 7.98- 7.92 (brm, 2H), 7.80-7.70 (brm, 3H), 7.63- 7,.69 (brm, 2H), 7.55- 7.50 (brm, 3H), 7.41 (m, 1H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 120° C. 427

HCl 1H NMR (DMSO- d6) ppm 10.31 (br, 1H), 9.51 (brs, 1H), 8.92 (brd, J = 7.44 Hz, 1H), 8.84 (brs, 1H), 8.22 (brs, 1H), 8.12 (brd, J = 2.28 Hz, 1H), 8.00-7.93 (brm, 2H), 7.83- 7.77 (brm, 3H), 7.64-7.54 (brm, 5H), 4.01 (s, 3H) . The 1H of HCl was not observed. DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 428

4 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.06 (d, J = 8.08 Hz, 1H), 8.88 (d, J = 3.72 Hz, 1H), 8.28 (brs, 1H), 8.01- 7.96 (m, 3H), 7.88 (m, 1H), 7.81 (d, J = 8.60 Hz, 2H), 7.65 (dd, J = 9.08, 2.64 Hz, 1H), 4.00 (s, 3H). The 1H of 4HCl and NH— were not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 429

HCl 1H NMR (DMSO- d6) ppm 12.60 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.28 (d, J = 8.04 Hz, 1H), 8.95 (dd, J = 5.20 , 1.20 Hz, 1H), 8.36 (d, J = 2.28 Hz, 1H), 8.04-7.93 (m, 4H), 7.77 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.30 (d, J = 8.04 Hz, 2H), 4.02 (s, 3H), 2.36 (s, 3H). The 1H of HCl was not ob- served. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 430

2 HCl 1H NMR (DMSO- d6) ppm 12.70- 12.40 (br, 1H), 9.71 (s, 1H), 9.27 (d, J = 8.20 Hz, 1H), 8.94 (d, J = 4.24 Hz, 1H), 8.34 (d, J = 2.64 Hz, 1H), 8.13 (t, J = 1.80 Hz, 1H), 8.04-7.95 (m, 4H), 7.63 (dd, J = 9.08, 2.68 Hz, 1H), 7.52 (t, J = 7.88 Hz, 1H), 7.44-7.42 (m, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 431

HCl 1H NMR (DMSO- d6) ppm 12.57 (br, 1H), 9.80 (brs, 1H), 9.04 (d, J = 7.36 Hz, 1H), 8.82 (brs, 1H), 8.34 (brs, 1H), 7.99 (brd, J = 7.28 Hz, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.82 (brs, 1H), 7.76 (brm, 1H), 7.62 (m, 2H), 7.50-7.41 (m, 2H), 4.00 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 432

HCl 1H NMR (DMSO- d6) ppm 10.40 (br, 1H), 9.23 (s, 1H), 8.80 (d, J = 4.68 Hz, 1H), 8.66 (brd, J = 8.20 Hz, 1H), 7.92 (brs, 1H), 7.87 (brd, J = 9.28 Hz, 1H), 7.78 (brm, 1H), 7.63-7.52 (m, 5H), 7.47-7.44 (m, 2H), 7.21-7.12 (m, 3H), 3.91 (s, 3H). . The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 433

HCl 1H NMR (DMSO- d6) ppm 12.34 (br, 1H), 9.75 (s, 1H), 9.01 (d, J = 7.52 Hz, 1H), 8.81 (brs, 1H), 8.40-8.20 (br, 1H), 7.92 (d, J = 9.08 Hz, 1H), 7.77 (m, 1H), 7.60 (dd, J = 9.08, 2.72 Hz, H), 6.95 (br, 1H), 3.98 (s, 3H), 2.67 (m, 1H), 2.05 (m, 2H), 1.83- 1.70 (m, 3H), 1.54- 1.23 (m, 5H) . The 1H of HClwas not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 434

2 HCl 1H NMR (DMSO- d6) ppm 12.58 (br, 1H), 9.79 (s, 1H), 9.19 (d, J = 7.32 Hz, 1H), 8.90 (d, J = 5.6 Hz, 1H), 8.36 (s,lH), 7.96 (d, J = 9.08 Hz, 1H), 7.94 (m, 1H), 7.88 (s, 1H), 7.65-7.62 (m, 3H), 7.40 (t, J = 8.16 Hz, 1H), 6.96-6.93 (m, 1H), 4.02 (s, 3H), 3.84 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 435

2 HCl 1H NMR (DMSO- d6) ppm 12.80- 12.40 (br, 1H), 9.79 (d, J = 1.44 Hz, 1H), 9.26 (d, J = 8.24 Hz, 1H), 8.93 (d, J = 4.08 Hz, 1H), 8.36 (d, J = 2.28 Hz, 1H), 8.02-7.96 (m, 4H), 7.68 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.05 (d, J = 8.92 Hz, 2H), 4.02 (s, 3H), 3.82 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 436

HCl 1H NMR (DMSO- d6) ppm 12.52 (br, 1H), 9.79 (s, 1H), 9.23 (d, J = 8.00 Hz, 1H), 8.91 (d, J = 4.12 Hz, 1H), 8.35 (brs, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.93 (m, 1H), 7.85 (s, 1H), 7.64 (dd, J = 9.08, 2.68 Hz, 1H), 7.39-7.35 (m, 1H), 7.18 (d, J = 7.72 Hz, 1H), 7.11- 7.07 (m, 1H), 4.02 (s, 3H), 3.96 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ 437

1H NMR (DMSO- d6) ppm 9.94 (s, 1H), 9.27 (d, J = 1.92 Hz, 1H), 8.59 (dd, J = 4.72, 1.68 Hz, 1H), 8.45 (dt, J = 8.04, 1.8 Hz, 1H), 7.96 (d, J = 2.72 Hz, 1H), 7.84 (d, J = 8.28 Hz, 2H), 7.67 (d, J = 8.00 Hz, 1H), 7.55 (m, 2H), 7.46- 7.43 (m, 1H), 7.33 DMSO >98 G13 using K₂CO₃ instead of Cs₂CO₃ (m, 1H), 3.96 (s, 3H). 438

HCl 1H NMR (DMSO- d6) ppm 10.48 (br, 1H), 9.23 (s,lH), 8.83 (brd, J = 3.68 Hz, 1H), 8.70 (brd, J = 7.36 Hz, 1H), 7.95 (brs, 1H), 7.91 (d, J = 9.12 Hz, 1H), 7.82 (m, 1H), 7.63- 7.51 (m, 5H), 7.48 (d, J = 8.52 Hz, 2H), 7.26 (d, J = 8.52 Hz, 2H), 3.93 (s, 3H). The 1H of HCl was not observed. DMSO >98 J3 using Na₂CO₃ instead of K₂CO₃ 439

HCl 1H NMR (DMSO- d6) ppm 12.60 (br, 1H), 9.78 (s, 1H), 9.17 (d, J = 7.96 Hz, 1H), 8.88 (d, J = 4.20 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.24-8.21 (m, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.91- 7.88 (brm, 1H), 7.74 (d, J = 2.48 Hz, 1H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 7.47- 7.41 (m, 1H), 7.36 8m, 2H), 4.02 (s, 3H). The 1H DMSO >98 G13 at 100° C. of HCl was not observed. 440

HCl 1H NMR (DMSO- d6) ppm 12.60- 12.45 (br, 1H), 9.79 (d, J = 1.52 Hz, 1H), 9.15 (d, J = 8.36 Hz, 1H), 8.88 (d, J = 5.04 Hz, 1H), 8.35(d, J = 2.44 Hz, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.89 (bit, J = 7.08 Hz, 2H), 7.82 (brm, 1H), 7.81 (s, 1H), 7.63 (dd, J = 9.12, 2.44 Hz, 1H), 7.37 (t, J = 7.64 Hz, 1H), 7.19 (d, DMSO >98 G13 at 100° C. J = 7.48 Hz, 1H), 4.02 (s, 3H), 2.40 (s, 3H). The 1H of HCl was not observed. 441

HCl 1H NMR (DMSO- d6) ppm 12.60 (br, 1H), 9.77 (s, 1H), 9.25 (d, J = 8.08 Hz, 1H), 8.93 (d, J = 4.28 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.01-7.84 (m, 5H), 7.63 (dd, J = 9.12, 2.60 Hz, 1H), 7.56-7.51 (m, 1H), 7.21 (m, 1H). The 1H of HCl was not observed. DMSO >98 G13 at 100° C. 442

2 HCl 1H NMR (DMSO- d6) ppm 12.66 (brs, 1H), 9.78 (d, J = 1.68 Hz, 1H), 9.27 (d, J = 8.08 Hz, 1H), 8.94 (dd, J = 5.20 , 1.40 Hz, 1H), 8.36 (d, J = 2.56 Hz, 1H), 8.17 (d, J = 8.84 Hz, 2H), 8.01 (m, 1H), 7.97 (d, J = 9.08 Hz, 1H), 7.93 (s, 1H), 7.64 (dd, J = 9.08, 2.56 Hz, 1H), 7.49 (brd, J = 8.84 Hz, 2H), 4.02 (s, 3H). The 1H of 2HCl was DMSO >98 G13 at 100° C. not observed. 443

2 HCl 1H NMR (DMSO- d6) ppm 12.64 (br, 1H), 9.79 (s, 1H), 9.13 (d, J = 7.56 Hz, 1H), 8.87 (d, J = 5.08 Hz, 1H), 8.36 (d, J = 2.60Hz, 1H), 8.27 (d, J = 8.00 Hz, 2H), 8.08 (s, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.87 (m, 1H), 7.86 (d, J = 8.00 Hz, 2H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 at 100° C. 444

2 HCl 1H NMR (MeOD- d4) ppm 9.79 (s, 1H), 9.37 (br, 1H), 8.49 (dd, J = 5.28, 1.32 Hz, 1H), 8.12 (m, 1H), 8.09 (d, J = 2.72 Hz, 1H), 7.98 (d, J = 9.16 Hz, 1H), 7.68 (dd, J = 9.16, 2.72 Hz, 1H), 7.58 (d, J = 7.12 Hz, 1H), 7.42-7.30 (m, 3H), 7.30 (s, 1H), 4.05 (s, 3H), 2.50 (s, 3H). The 1H of 2HCl was not MeOD >98 G13 observed. 445

2 HCl 1H NMR (DMSO- d6) ppm 12.59 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9,19 (d, J = 8.00 Hz, 1H), 8.90 (dd, J = 5.16, 1.48 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.10-8.04 (m, 1H), 7.97-7.88 (m, 4H), 7.64 (dd, J = 2.60 Hz, 1H), 7.59-7.52 (m, 1H), 4.02 (s, 3H) . The 1H of 2HCl was not observed. DMSO >98 G13 446

HCl 1H NMR (DMSO- d6) ppm 12.61 (br, 1H), 9.78 (d, J = 1.72 Hz, 1H), 9.20 (d, J = 7.92 Hz, 1H), 8.90 (d, J = 4.00 Hz, 1H), 8.35 (d, J = 2.60 Hz, 1H), 8.27-8.21 (m, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.93 (m, 1H), 7.71 (d, J = 2.56 Hz, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 7.43 (m, 1H), 7.27 (m, 1H), 4.02 (s, 1H). The 1H of HCl was not observed. DMSO >98 G13 447

2 HCl 1H NMR (DMSO- d6) ppm 12.57 (br, 1H), 9.77 (d, J = 1.76 Hz, 1H), 9.25 (d, J = 8.08 Hz, 1H), 8.93 (dd, J = 5.16, 1.2 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 8.29 (t, J = 1.76 Hz, 1H), 8.05 (dd, J = 7.84, 1.12 Hz, 1H), 8.02-7.98 (m, 1H), 7.99 (s, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.64 (dd, DMSO >98 G13 J = 9.08, 2.60 Hz, 1H), 7.58-7.56 (m, 1H), 7.45 (t, J = 7.84 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. 448

HCl 1H NMR (DMSO- d6) ppm 12.62 (br, 1H), 9.77 (d, J = 1.52 Hz, 1H), 9.10 (d, J = 8.16 Hz, 1H), 8.85 (dd, J = 5.00, 1.56 Hz, 1h), 8.34 (d, J = 2.60 Hz, 1H), 8.24 (d, J = 8.60 Hz, 2H), 8.13 (s, 1H), 7.96 (d, J = 8.60 Hz, 2H), 7.96 (d, J = 9.08 Hz, 1H), 7.86-7.83 (brm, 1H), 7.63 (dd, J = 9.08, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 449

2 HCl 1H NMR (DMSO- d6) ppm 12.56 (brs, 1H), 9.79 (brs, 1H), 9.11 (d, J = 8.04 Hz, 1H), 8.87 (brs, 1H), 8.43 (brs, 1H), 8.34 (brs, 2H), 8.09 (s, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.87 (brs, 1H), 7.74 (brd, J = 5.00 Hz, 2H), 7.64 (dd, J = 9.08, 2.48 Hz, 1H), 4.03 (s, 3H). The 1H of 2HCl was not DMSO >98 G13 at 100° C. observed. 450

2 HCl 1H NMR (DMSO- d6) ppm 12.63 (br, 1H), 9.80 (d, J = 1.72 Hz, 1H), 9.27 (d, J = 8.16 Hz, 1H), 8.93 (dd, J = 5.20 , 1.36 Hz, 1H), 8.33 (d, J = 2.24 Hz, 1H), 7.99 (m, 1H), 7.98 (d, J = 9.08 Hz, 1H), 7.88 (brd, J = 7.72 Hz, 1H), 7.71-7.75 (m, 2H), 7.70- 7.63 (m, 2H), DMSO >98 G13 at 100° C. 7.45 (s, 1H), 3.98 (s, 3H). The 1H of 2HCl was not observed. 451

HCl 1H NMR (DMSO- d6) ppm 12.70 (br, 1H), 9.79 (d, J = 1.60 Hz, 1H), 9.30 (d, J = 7.56 Hz, 1H), 8.95 (d, J = 4.96 Hz, 1H), 8.34 (d, J = 2.20 Hz, 1H), 8.02 (m, 1H), 7.98 (d, J = 9.12 Hz, 1H), 7.85- 7.77 (m, 2H), 7.73 (s, 1H), 7.64 (dd, J = 9.12, 2.68 Hz, 1H), 7.52 (m, 1H), 7.36 (m, 1H), 4.00 (s, 3H). The 1H DMSO >98 G13 of HCl was not observed. 452

HCl 1H NMR (DMSO- d6) ppm 12.64 (br, 1H), 9.78 (d, J = 1.72 Hz, 1H), 9.19 (d, J = 7.92 Hz, 1H), 8.90 (d, J = 3.88 Hz, 1H), 8.36 (d, J = 2.64 Hz, 1H), 8.02-7.91 (m, 3H), 7.83 (d, J = 2.40 hz, 1H), 7.64 (dd, J = 9.08, 2.64 Hz, 1H), 7.46 (m, 1H), 7.36 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not DMSO >98 G13 observed. 453

2 HCl 1H NMR (DMSO- d6) ppm 12.62 (br, 1H), 9.77 (d, J = 1.84 Hz, 1H), 9.30 (d, J = 8.00 Hz, 1H), 8.46 (dd, J = 5.36, 1.48 Hz, 1H), 8.48 (br, 1H), 8.39-8.33 (m, 2H), 8.08 (s, 1H), 8.05 (m, 1H), 7.97 (d, J = 9.12 Hz, 1H), 7.85-7.83 (m, DMSO >98 G13 1H), 7.71 (t, J = 7.84 Hz, 1H), 7.64 (dd, J = 9.12, 2.60 Hz, 1H), 4.02 (s, 3H). The 1H of 2HCl was not observed. 454

2 HCl 1H NMR (DMSO- d6) ppm 12.65 (br, 1H), 9.79 (d, J = 1.72 Hz, 1H), 9.25 (d, J = 8.04 Hz, 1H), 8.92 (d, J = 5.36 Hz, 1H), 8.36 (d, J = 2.60 Hz, 1H), 8.24-8.22 (,m, 1H), 7.97 (d, J = 9.08 Hz, 1H), 7.96 (m, 1H), 7.69 (s, 1H), 7.65 (dd, J = 9.08, 2.60 DMSO >98 G13 Hz, 1H), 7.55 (m, 3H), 4.02 (s, 3H). The 1H of 2HCl was not observed. 455

HCl 1H NMR (DMSO- d6) ppm 12.52 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9.03 (d, J = 6.6 Hz, 1H), 8.81 (d, J = 4.72 Hz, 1H), 8.34 (d, J = 2.56 Hz, 1H), 8.09 (d, J = 7.88 Hz, 1H), 8.03 (brs, 2H), 7.96 (d, J = 9.12 Hz, 1H), 7.78 (br, 1H),7.65 (m, 2H), 7.38 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 456

2 HCl 1H NMR (DMSO- d6) ppm 12.45 (br, 1H), 9.78 (d, J = 1.64 Hz, 1H), 9.15 (br, 1H), 8.89 (d, J = 4.52 Hz, 1H), 8.30 (brs, 1H), 7.94 (d, J = 9.08 Hz, 1H), 7.90 (brm, 1H), 7.76 (m, 2H), 7.62 (dd, J = 9.08, 2.64 Hz, 1H), 7.51 (m, 2H), 7.40 (m, 1H), 3.99 (s, 3H), 2.61 (s, 3H). The 1H of 2HCl was not observed. DMSO >98 G13 457

HCl 1H NMR (DMSO- d6) ppm 12.55 (br, 1H), 9.78 (d, J = 1.48 Hz, 1H), 9.08 (d, J = 8.48 Hz, 1H), 8.84 (dd, J = 5.04, 1.56 Hz, 1H), 8.34 (d, J = 2.72 Hz, 1H), 8.09 (s, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.84 (m, 1H), 7.77 (m, 2H), 7.64 (dd, J = 9.12, 2.72 Hz, 1H), 7.25 (m, 1H), 4.02 (s, 3H). The 1H of HCl was not observed. DMSO >98 G13 458

HCl 1H NMR (DMSO- d6) ppm 12.55 (br, 1H), 9.77 (d, J = 1.56 Hz, 1H), 9.14 (d, J = 8.00 Hz, 1H), 8.87 (dd, J = 5.08, 1.48 Hz, 1H), 8.34 (d, J = 2.60 Hz, 1H), 7.98 (m, 1H), 7.96 (d, J = 9.08 Hz, 1H), 7.89-7.86 (brm, 1H), 7.83 (d, J = 2.44 Hz, 1H), 7.64 (dd, J = 9.08, 2.60 Hz, 1H), 7.47-7.41 (m, 1H), 7.29 (m, 1H), 4.02 (s, 3H). DMSO >98 G13 The 1H of HCl was not observed. 459

HCl 1H NMR (DMSO- d6) ppm 12.66 (br, 1H), 9.79 (d, J = 1.60 Hz, 1H), 9.25 (d, J = 7.16 Hz, 1H), 8.92 (d, J = 5.20 Hz, 1H), 8.35 (d, J = 2.56 Hz, 1H), 7.98 (d, J = 9.12 Hz, 1H), 7.97 (m, 1H), 7.68 (s, 1H), 7.64 (dd, J = 9.12, 2.56 Hz, 1H), 7.55 (m, 1H), 7.27 (m, 2H), 3.99 (s, 3H).The 1H of HCl was not observed. DMSO >98 G13 460

2 HCl 1H NMR (DMSO- d6) ppm 9.73 (s, 1H), 9.17 (brs, 1H), 8.92 (dd, J = 5.16, 1.4 Hz, 1H), 8.30- 8.10 (br, 1H), 7.97 (d, J = 9.04 Hz, 1H), 7.96 (m, 1H), 7.63 (dd, J = 9.04, 2.72 Hz, 1H), 7.02 (s, 1H), 3.98 (s, 3H), 2.57 (d, J = 7.16 Hz, 2H), 2.08 (m, 1H), 0.94 (d, J = 6.60 Hz, 6H) .The 1H of HCl and NH— were not observed. DMSO >98 G13 461

2 HCl 1H NMR (DMSO- d6) ppm 12.80- 12.20 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.28 (d, J = 8.04 Hz, 1H), 8.96 (dd, J =5.28, 1.32 Hz, 1H), 8.29 (brs, 1H), 8.07-8.03 (brm, 1H), 7.95 (d, J = 9.12 Hz, 1H), 7.79 (d, J = 8.60 Hz, 2H), 7.62 (dd, J = 9.12, 2.64 Hz, 1H), 7.57 (d, J = 8.60 Hz, 2H), 3.99 (s, 3H), 2.61 (brs, 3H). The 1H of 2HCl DMSO >98 G13 was not observed. 462

2 HCl 1H NMR (DMSO- d6) ppm 12.80- 12.20 (br, 1H),. 9.74 (s, 1H), 9.19 (d, J = 4.96 Hz, 1H), 8.91 (dd, J = 5.2, 1.4 Hz, 1H), 8.22 (brs, 1H), 7.96 (br, 1H), 7.95 (d, J = 9.08 Hz, 1H), 7.61 (dd, J = 9.08, 2.68 Hz, 1H), 7.35-7.31 (m, 4H), 7.23 (m, 1H), 7.09 (brs, 1H), 4.07 DMSO >98 G13 (brs, 2H), 3.96 (brs, 3H). The 1H of 2HCl was not observed. 463

2 HCl 1H NMR (DMSO- d6) ppm 12.50 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.25 (brs, 1H), 8.96 (brd, J = 4.68 Hz, 1H), 8.29 (brs, 1H), 8.04 (brs, 1H), 7.96 (d, J = 9.20 Hz, 1H), 7.70 (brm, 2H), 7.63 (dd, J = 9.20, 2.68 Hz, 1H), 7.51 (brm, 2H), 7.41 (brm, 1H), 3.99 (s, 3H), 3.02 (q, J = 7.40 DMSO >98 G13 Hz, 2H), 1.49 (t, J = 7.40 Hz, 3H). The 1H of 2HCl was not observed. 464

2 HCl 1H NMR (DMSO- d6) ppm 12.53 (br, 1H), 9.78 (d, J = 1.76 Hz, 1H), 9.20 (d, J = 8.36 Hz, 1H), 8.94 (dd, J = 5.2, 1.4 Hz., 1H), 8.29 (brs, 1H), 8.00 (brm, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.66- 7.61 (m, 3H), 7.52 (brm, 2H), 7.43 (t, J 7.40 Hz, 1H), 3.98 (s, 3H), 1.43 (d, J = 6.8 Hz, 6H). The 1H of 2HCl DMSO >98 G13 was not observed. The CH proton of iPr group was not observed because of overlapping the H2O peak. 465

2 HCl 1H NMR (DMSO- d6) ppm 12.59 (brs, 1H), 9.77 (d, J = 1.72 Hz, 1H), 9.25 (d, J = 7.76 Hz, 1H), 8.96 (d, J = 4.04 Hz, 1H), 8.29 (br, 1H), 8.04 (m, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.69 (brd, J = 7.12 Hz, 2H), 7.63 (dd, J = 9.12, 2.68 Hz, H), 7.51 (t, J = 7.36 Hz, 2H), DMSO >98 G13 7.42 (t, J = 7.36 Hz, 1H), 3.99 (s, 3H), 2.96 (t, J = 7.52 Hz, 2H), 1.78 (m, 2H), 1.01 (t, J = 7.24 Hz, 3H). The 1H of 2HCl was not observed. 466

2 HCl 1H NMR (DMSO- d6) ppm 12.96 (brs, 1H), 9.74 (d, J = 2.04 Hz, 1H), 9.11 (d, J = 7.96 Hz, 1H), 8.90 (d, J = 4.96 Hz, 1H), 8.31 (brd, J = 2.64 Hz, 1H), 7.97 (d, J = 9.12 Hz, 1H), 7.87 (brm, 1H), 7.83- 7.80 (m, 2H), 7.64 (dd, J = 9.12, 2.62 Hz, DMSO >98 G13 1H), 7.48 (m, 3H), 4.25 (q, J = 7.04 Ha, 2H), 3.98 (s, 3H), 1.29 (t, J = 7.04 Hz, 3H). The 1H of 2HCl was not observed. 467

HCl 1H NMR (DMSO- d6) ppm 12.63 (br, 1H), 9.76 (d, J = 1.76 Hz, 1H), 9.29 (d, J =8.16 Hz, 1H), 8.95 (dd, J = 5.28, 1.36 Hz, 1H), 8.32 (brd, J =2.60 Hz, 1H), 8.07 (d, J = 8.52 Hz, 2H), 8.08-8.00 (m, 1H), 7.95 (d, J = 9.12 Hz, 1H), 7.90 (s, 1H), 7.61 (dd, J = 9.12, 2.60 Hz, 1H), 7.55 (d, J = 8.52 Hz, 2H), 4.24 (q, DMSO >98 G13 J =6.88 Hz,2H), 1.47 (t, J = 6.88 Hz, 3H). The 1H of HCl was not observed. 468

2 HCl 1H NMR (DMSO- d6) ppm 12.58 (brs, 1H), 9.76 (d, J = 1.80 Hz, 1H), 9.27 (d, J = 8.16 Hz, 1H), 8.94 (dd, J = 5.20, 1.32 Hz, 1H), 8.32 (d, J = 2.48 Hz, 1H), 8.09- 8.01 (m, 2H), 7.96-7.89 (m, 3H), 7.62-7.52 (m, 2H), 4.29 (q, J = 6.88 Hz, 2H), 1.47 (t, J = 6.88 Hz, 3H). The 1H of DMSO >98 G13 2HCl was not observed. 469

2 HCl 1H NMR (DMSO- d6) ppm 9.72 (s, 1H), 9.13 (brd, J = 5.52 Hz, 1H), 8.92 (d, J = 3.52 Hz, 1H), 8.16 (brs, 1H), 7.95 (brd, J = 9.08 Hz, 2H), 7.62 (dd, J = 2.4 Hz, 1H), 7.39 (brs, 1H), 3.97 (s, 3H), 2.47 (s, 3H). The 1H of 2HCl DMSO >98 G13 and NH— were not observed. 470

HCl 1H NMR (DMSO- d6) ppm 12.58 (brs, 1H), 9.76 (d, J = 1.68 Hz, 1H), 9.17 (d, J = 8.12 Hz, 1H), 8.89 (dd, J = 5.12, 1.48 Hz, 1H), 8.32 (d, J = 2.56 Hz, 1H), 8.01- 8.00 (m, 1H), 7.94 (d, J = 9.08 Hz, 1H), 7.930-7.90 (m, 1H), 7.81 DMSO >98 G13 (d, J = 2.4 Hz, 1H), 7.60 (dd, J = 9.08, 2.40 Hz, 1H), 7.50-7.43 (m, 1H), 7.38-7.33 (m, 1H), 4.28 (q, J = 7.00 Hz, 2H), 1.47 (t, J = 7.00 Hz, 3H). The 1H of HCl was not observed. 471

2 HCl 1H NMR (DMSO- d6) ppm 12.53 (brs, 1H), 9.73 (d, J = 1.76 Hz, 1H), 9.29 (d, J = 8.16 Hz, 1H), 8.95 (dd, J = 5.32, 1.36 Hz, 1H), 8.29 (d, J = 2.56 Hz, 1H), 8.05- 8.02 (brm, 1H), 7.97-7.92 (m, 1H), 7.93 (d, J = 9.08 Hz, 1H), 7.78 (d, J = 2.36 Hz, 1H), DMSO >98 G13 7.60 (dd, J = 9.08, 2.6 Hz, 1H), 7.46- 7.40 (m, 1H), 7.31-7.25 (m, 1H), 4.27 (q, J = 6.92 Hz, 2H), 1.47 (t, J = 6.92 Hz, 3H). The 1H of 2HCl was not observed. 472

3 HCl 1H NMR (DMSO- d6) ppm 12.61 (brs, 1H), 9.76 (d, J = 1.8 Hz, 1H), 9.29 (d, J = 8.16 Hz, 1H), 8.95 (dd, J = 5.24, 1.2 Hz, 1H), 8.32 (d, J = 2.52 Hz, 1H), 8.24- 8.20 (m, 1H), 8.05- 8.01 (brm, 1H),7.95 (d, J = 9.08 Hz, 1H), 7.68 (d, J =2.52 HZ, 1H), 7.61 (dd, J = 9.08, 2.52 Hz, 1H), 7.46-7.40 (m, 1H), 7.28-7.24 (m, 1H), 4.28 (q, DMSO >98 G13 J = 6.92 Hz, 2H), 1.47 (t, J = 6.92 Hz, 3H). The 1H of 3HCl was not observed. 473

2 HCl 1H NMR (DMSO- d6) ppm 12.63 (brs, 1H), 9.78 (d, J = 1.68 Hz, 1H), 9.32 (d, J = 8.12 Hz, 1H), 8.97 (d, J = 5.24 Hz, 1H), 8.35 (d, J = 2.16 Hz, 1H), 8.08-8.04 (m, 3H), 7.96 (d, J = 9.08 Hz, 1H), 7.85 (s, 1H), 7.62 (dd, J = 9.08, 2.52 Hz, 1H), 7.49 (t, J = 7.44 Hz, 2H), 7.38 (t, DMSO >98 G13 J = 7.28 Hz, 1H), 4.30 (q, J = 6.96 Hz, 2H), 1.47 (t, J = J = 6.96 Hz, 3H). The 1H of 2HCl was not observed. 474

1H NMR (DMSO- d6) ppm 12.68 (s, 1H), 9.73 (d, J = 1.64 Hz, 1H), 8.87-8.84 (m, 1H), 8.75-8.73 (m, 1H), 8.33 (brs, 1H), 8.24 (brs, 1H), 7.93 (d, J = 9.16 Hz, 1H), 7.64-7.59 (m, 2H), 4.34 (q, J = 7.08 Hz, 2H), 3.98 (s, 3H), 1.34 (t, J = 7.08 Hz, 3H). DMSO >98 G13 475

HCl ¹H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.42 (s, 1H), 8.99-8.76 (m, 2H), 8.11 (d, J = 6.7 Hz, 1H), 7.99-7.75 (m, 3H), 7.67-7.43 (m, 2H), 7.23 (d, J = 8.2 Hz, 1H), 4.14 (s, 3H). DMSO   98 G1 381   (M + 1) 2.07 Method A (Formic acid) 476

HCl 1H NMR (300 MHz, DMSO) δ 13.78 (s, 1H), 9.62 (d, J = 1.7 Hz, 1H), 9.21 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.07 (dd, J = 7.9, 5.3 Hz, 1H), 7.83 (d, J = 9.1 Hz, 2H), 7.63-7.50 (m, 4H), 7.41 (d, J = 6.5 Hz, 2H), 7.14 (d, J = 2.5 Hz, 1H), 5.30 (s, 1H), 3.91 (s, 3H), 2.15 (s, 3H). DMSO   95 Method G1 468.1 (M + 1) Method C 477

HCl 1H NMR (300 MHz, DMSO) δ 13.78 (s, 1H), 9.64 (d, J = 1.5 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 3.8 Hz, 1H), 7.95 (dd, J = 10.6, 2.6 Hz, 1H), 7.84 (d, J = 9.1 Hz, 2H), 7.60-7.48 (m, 4H), 7.38 (d, J = 6.5 Hz, 2H), 7.17 (d, J = 2.4 Hz, 1H), 5.28 (s, 1H), 4.14 (q, J = 6.9 Hz, 2H), 2.15 DMSO   95 Method G1 482.1 (M + 1) Method C (s, 3H), 1.42 (t, J = 6.9 Hz, 3H). 478

HCl 1H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.56 (s, 1H), 8.70 (d, J = 5.8 Hz, 2H), 8.58 (d, J = 5.2 Hz, 1H), 7.95 (d, J = 5.2 Hz, 2H), 7.87 (d, J = 9.1 Hz, 2H), 7.64-7.49 (m, 2H), 7.40 (d, J = 2.4 Hz, 1H), 4.21 (q, J = 6.8 Hz, 2H), 1.44 (t, J = 6.9 Hz, 3H). DMSO   99 Method G1 392.1 (M + 1) Method C 479

HCl 1H NMR (300 MHz, DMSO) δ 13.75 (s, 1H), 9.60 (s, 1H), 8.98 (s, 1H), 8.82 (d, J = 3.6 Hz, 1H), 7.82 (d, J = 9.0 Hz, 3H), 7.52 (d, J = 9.3 Hz, 1H), 7.15 (s, 1H), 6.94-6.62 (s, 1H), 4.13 (d, J = 6.9 Hz, 2H), 2.90 (d, J = 21.9 Hz, 4H), 2.41 (s, 2H), 1.43 (t, J = 6.9 Hz, 3H). DMSO   95 Method G1 432.1 (M + 1) Method C 480

HCl 1H NMR (300 MHz, DMSO) δ 12.50 (s, 1H), 9.56 (s, 1H), 8.89 (s, 1H), 8.68 (d, J = 5.3 Hz, 2H), 8.00-7.79 (m, 3H), 7.73 (d, J = 7.2 Hz, 4H), 7.62- 7.38 (m, 9H), 7.34 (d, J = 2.2 Hz, 2H), 4.18 (dd, J = 13.5, 6.5 Hz, 2H), 1.43 (t, J = 6.9 Hz, 3H). DMSO   99 Method G1 468.1 (M + 1) Method C 481

HCl 1H NMR (300 MHz, DMSO) δ 12.51 (s, 1H), 9.54 (s, 1H), 8.86 (s, 1H), 8.74-8.61 (m, 2H), 7.90 (s, J = 15.7 Hz, 2H), 7.83 (d, J = 9.1 Hz, 1H), 7.72 (d, J = 7.1 Hz, 2H), 7.63- 7.40 (m, 6H), 7.33 (d, J = 2.3 Hz, 1H), 3.92 (s, 3H). DMSO   99 Method G1 454.1 (M + 1) Method C 482

HCl 1H NMR (300 MHz, DMSO) δ 13.70 (s, 1H), 9.70 (d, J = 2.1 Hz, 1H), 8.81 (d, J = 8.0 Hz, 1H), 8.70 (dd, J = 4.8, 1.7 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 7.66- 7.53 (m, 2H), 7.29 (d, J = 2.2 Hz, 1H), 3.95 (s, 3H), 2.78 (d, J = 12.9 Hz, 4H), 1.78 (s, 4H). DMSO   99 Method G1 432.1 (M + 1) Method C 483

HCl 1H NMR (300 MHz, DMSO) δ 13.64 (s, 1H), 9.68 (s, 1H), 8.79 (d, J = 7.9 Hz, 1H), 8.69 (d, J = 4.7 Hz, 1H), 7.86 (d, J = 9.0 Hz, 1H), 7.63- 7.50 (m, 2H), 7.24 (s, 1H), 4.18 (q, J = 6.7 Hz, 2H), 2.76 (d, J = 10.4 Hz, 4H), 1.78 (s, 4H), 1.43 (t, J = 6.9 Hz, 3H). DMSO   99 Method G1 446.1 (M + 1) Method C 484

HCl 1H NMR (300 MHz, DMSO) δ 12.82 (s, 1H), 9.67 (d, J = 2.1 Hz, 1H), 8.77 (dt, J = 8.1, 2.0 Hz, 1H), 8.71 (dd, J = 4.8, 1.7 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.83 (s, 1H), 7.60- 7.53 (m, 3H), 7.48 (s, 1H), 7.20 (d, J = 2.6 Hz, 1H), 4.20 (q, J = DMSO   95 Method G1 422.1 (M + 1) Method C 6.9 Hz, 2H), 2.90 (d, J = 4.7 Hz, 3H), 1.44 (t, J = 6.9 Hz, 3H). 485

HCl 1H NMR (300 MHz, DMSO) δ 9.66 (s, 1H), 9.44 (d, J = 1.4 Hz, 1H), 8.64-8.55 (m, 2H), 7.90 (s, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.76 (d, J = 2.5 Hz, 1H), 7.69 (s, 2H), 7.54- 7.45 (m, 2H), 4.19 (q, J = 7.0 Hz, 2H), 4.04 (s, 3H), 1.42 (t, J = 6.9 Hz, 3H). DMSO   99 Method G1 390.1 (M + 1) Method C 486

2 HCl 1H NMR (300 MHz, DMSO) δ 9.57 (d, J = 1.5 Hz, 1H), 9.07 (d, J = 4.6 Hz, 1H), 8.94 (dd, J = 5.2, 1.4 Hz, 1H), 8.04 (d, J = 9.1 Hz, 1H), 7.97 (dd, J = 6.7, 6.0 Hz, 1H), 7.67 (dd, J = 9.1, 2.8 Hz, 1H), 7.55 (d, J = 2.7 Hz, 1H), 7.36 (dd, J = 6.4, 2.3 Hz, 2H), 7.14- DMSO   99 Method G1 382.5 (M + 1) Method C 7.03 (m, 2H), 3.74 (s, 3H), 3.69 (s, 3H). 487

2 HCl 1H NMR (300 MHz, DMSO) δ 12.59 (s, 1H), 9.58 (d, J = 2.0 Hz, 1H), 8.94 (d( J = 8.2 Hz, 1H), 8.84 (d, J = 5.2 Hz, 1H), 8.73 (s, 1H), 8.09 (s, 1H), 7.95 (s, 3H), 7.82 (dd, J = 8.4, 5.4 Hz, 2H), 7.75 (d, J = 7.4 Hz, 2H), 7.59- 7.42 (m, 3H). DMSO   99 Method G1 458.4 (M + 1) Method C 488

2 HCl 1H NMR (300 MHz, DMSO) δ 13.79 (s, 1H), 9.49 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 8.0 Hz, 1H), 8.86 (d, J = 3.7 Hz, 1H)( 7.95- 7.71 (m, 4H), 7.65 (d, J = 1.6 Hz, 1H), 6.76 (s, 1H), 2.85 (d, J = 22.5 Hz, 4H), 2.44-2.29 (m, 2H). DMSO   93 Method G1 422.4 (M + 1) Method C 489

2 HCl 1H NMR (300 MHz, DMSO) δ 9.53 (d, J = 1.8 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 3.9 Hz, 1H), 7.95 (dd, J = 8.0, 5.2 Hz, 1H), 7.90-7.78 (m, 2H), 7.70 (d, J = 1.7 Hz, 1H), 2.29 (s, 3H), 2.24 (s, 3H). DMSO   94 Method G1 410.3 (M + 1) Method C 490

1H NMR (300 MHz, DMSO) δ 13.07 (s, 1H), 9.93 (d, J = 1.8 Hz, 1H), 9.64 (d, J = 1.6 Hz, 1H), 8.90- 8.78 (m, 1H), 8.76-8.62 (m, 2H), 8.29 (s, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.89 (d, J = 9.1 Hz, 1H), 7.71 (dd, J = 8.3, 1.9 Hz, 1H), 7.65 (s, DMSO   99 Method G1 464.2 (M + 1) Method C 1H), 7.57 (dd, J = 9.1, 2.5 Hz, 1H), 7.53-7.44 (m, 2H), 7.01 (s, 1H), 4.21 (q, J = 6.9 Hz, 2H), 3.34 (s, 3H), 1.44 (t, J = 6.9 Hz, 3H). 491

1H NMR (300 MHz, DMSO) δ 9.78 (s, 1H), 9.50 (d, J = 2.0 Hz, 1H), 8.68-8.57 (m, 2H), 7.97 (d, J = 2.5 Hz, 1H), 7.85 (d, J = 1.8 Hz, 1H), 7.79 (d, J = 9.1 Hz, 1H), 7.55-7.43 (m, 3H), 7.22 (d, J = 8.4 DMSO   99 Method G1 427.5 (M + 1) Method C Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 3.37 (d, J = 4.3 Hz, 6H), 1.43 (t, J = 6.9 Hz, 3H). 492

1H NMR (300 MHz, DMSO) δ 11.48 (s, 1H), 10.97 (s, 1H), 9.28 (d, J = 1.5 Hz, 1H),8.64 (dd, J = 4.6, 1.7 Hz, 1H), 8.40 (d, J = 8.1 Hz, 1H), 7.94-7.80 (m, 3H), 7.53-7.35 (m, 2H), 7.02 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 4.04 (s, H). DMSO   99 Method F5, G13 391.1 (M + 1) Method C 493

2 HCl 1H NMR (300 MHz, DMSO) δ 11.28 (s, 1H), 9.62 (d, J = 1.7 Hz, 1H), 9.17 (d, J = 7.8 Hz, 1H), 8.93 (dd, J = 5.2, 1.3 Hz, 1H), 8.60 (s, 1H), 8.05 (s, 1H), 8.03- 7.94 (m, 2H), 7.77 (s, 1H), 7.64 (dd, J = 9.2, 2.5 Hz 1H), 7.40 (d, J = 2.6 Hz, 1H), 3.97 (s, 3H). DMSO   99 Method G14 362.4 (M + 1) Method C 494

¹H-NMR (400 MHz, DMSO-d6): δ 10.14 (s, 1H), 9.54 (s, 1H), 8.70- 8.67 (m, 2H), 8.48 (s, 1H), 8.16 (s, 1H), 7.96- 7.89 (m, 3H), 7.60 ft, J = 8.0 Hz, 1H), 7.55-7.52 (m, 1H), 7.17 (d, J = 8.8 Hz, 1H), 3.71 (s, 2H), 2.72- 2.65 (m, 8H). DMSO   95 Method G1 498.1 (M + 1) t = 2.128 min Method B (NH₄HCO₃) 495

¹H-NMR (400 MHz, DMSO-d6): δ 10.71 (s, 1H), 9.37 (s, 1H), 8.93 (s, 1H), 8.67 (d, J = 3.2 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 7.93 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.65 (m, 2H), 7.04 (d, J = 8.0 Hz, 1H), 2.95 (t, J = 8.0 Hz, 2H), 2.64 (t, J = 8.0 Hz, 2H). DMSO   95 Method G1 402.2 (M + 1) t = 1.746 min Method B (NH₄HCO₃) 496

¹H-NMR (400 MHz, DMSO-d6): δ 11.38 (s, 1H), 9.51 (s, 1H), 8.67- 8.60 (m, 3H), 8.24- 8.10 (m, 2H), 7.88-7.83 (m, 2H), 7.58-7.55 (m, 3H), 7.33 (dd, J = 7.2, 4.8 Hz, 1H), 3.97 (s, 3H). DMSO   95 Method J1 373.0 (M + 1) t = 1.523 min Method B (NH₄HCO₃) 497

2 HCl ¹H-NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 9.30 (s, 1H), 8.60 (d, J = 3.4 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 4.4 Hz, 1H), 7.87 (d, J = 2.2 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.59-7.40 (m, 5H), 4.24 (q, J = 6.9 Hz, 2H), 2.55 (d, J = 4.5 Hz, 3H), DMSO   95 Method G1 418.2 (M + 1) 1.782 min Method B (NH₄HCO₃) 1.45 (t, J = 6.9 Hz, 3H). 498

¹H-NMR (400 MHz, DMSO-d6): δ 10.14 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.70-8.67 (m, 2H), 8.50 (s, 1H), 8.15 (s, 1H), 7.94- 7.92 (m, 3H), 7.61 (t, J = 8.0 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 3.90 (s, 2H), 3.17 (s, 4H), 2.98 DMSO   95 Method G1 530.0 (M + 1) 1.856 min Method B (NH₄HCO₃) (s, 4H). 499

2 HCl ¹H-NMR (400 MHz, DMSO-d6): δ 13.19 (s, 1H), 9.65 (s, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.97 (d, J = 4.5 Hz, 1H), 8.93 (s, 1H), 8.81 (d, J = 8.2 Hz, 1H), 8.45 (s, 1H), 8.40 (dd, J = 8.7, 1.7 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 7.99 (dd, J = 16.0, 10.4 Hz, 3H), 7.74 (t, J = 7.4 Hz, 1H), DMSO   95 Method G1 420.1 (M + 1) t = 1.478 min Method B (NH₄HCO₃) 7.32 (t, J = 7.6 Hz, 1H), 3.38 (s, 3H). 501

HCl ¹H-NMR (400 MHz, DMSO-d6): δ 13.46 (s, 1H), 9.46 (s, 1H), 8.97 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 4.4 Hz, 1H), 8.77 (d, J = 12.1 Hz, 1H), 8.55 (s, 1H), 8.16- 7.91 (m, 4H), 7.83 (t, J = 7.5 Hz, 1H), 7.73 (d, J = 9.3 Hz, 1H), 7.05 (t, J = 6.9 Hz, 1H). DMSO   95 Method G1 378.1 (M + 1) t = 1.873 min Method B (NH₄HCO₃) 502

¹H-NMR (400 MHz, DMSO-d6): δ 13.00 (s, 1H), 9.83 (s, 1H), 9.17 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.73-8.72 (m, 1H), 8.49 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.76 (t, J = 7.2 Hz, 1H), 7.63- 7.53 (m, 3H), 7.28 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H). DMSO   95 Method G1 358.0 (M + 1) t = 1.644 min Method B (NH₄HCO₃) 503

¹H-NMR (400 MHz, DMSO-d6): δ 11.34 (s, 1H), 9.50 (s, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.65 (d, J = 7.6 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 8.00-7.97 (m, 1H), 7.91- 7.84 (m, 2H), 7.69- 7.66 (m, 1H), 7.55- 7.52 (m, 1H)( 7.16 (t, J = 9.2 Hz, 1H). DMSO   95 Method G1 378.0 (M + 1) t = 1.780 min Method B (NH₄HCO₃) 504

HCl 1H-NMR (300 MHz, DMSO): δ 10.48 (s, 1H), 9.57 (s, 1H), 9.13 (d, J = 7.6 Hz, 1H)( 8.97-8.80 (m, 2H), 8.31 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 6.5 Hz, 1H), 7.97 (d, J = 9.1 Hz, 2H), 7.83 (d, J = 7.7 Hz, 1H), 7.66 (t, J = 7.9 DMSO   95 Method G1 396.1 (M + 1) Method C Hz, 2H), 7.47 (d, J = 5.4 Hz, 1H), 4.02(s, 3H). 505

¹H NMR (400 MHz, DMSO) δ 15.71 (s, 1H), 10.01 (s, 1H), 9.59-9.51 (m, 1H), 8.73- 8.62 (m, 2H), 8.60- 8.54 (m, 1H), 8.13- 7.96 (m, 2H), 7.93- 7.82 (m, 2H), 7.62- 7.49 (m, 2H), 4.01 (s, 3H). DMSO >98 G1 506

¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.75 (s, 1H), 9.55-9.46 (m, 1H), 8.73- 8.60 (m, 2H), 7.96 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.63 (d, J = 2.1 Hz, 1H), 7.58- 7.47 (m, 3H), 6.99 (d, J = 8.5 Hz, 1H), DMSO >98 G1 (0.1N HCl added) 4.64 (s, 2H), 3.97 (s, 3H). 507

¹H NMR (400 MHz, DMSO) δ 12.54 (s, 1H), 9.85 (s, 1H), 9.51 (s, 1H), 8.70-8.60 (m, 2H), 8.27-8.16 (m, 2H), 8.03 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.72- 7.59 (m, 2H), 7.56- 7.47 (m, 2H), 3.99 (s, 3H). DMSO >98 G1 508

¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.50-9.47 (m, 1H), 8.66- 8.61 (m, 2H), 8.21 (s, 1H), 8.16 (4, J = 1.6 Hz, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.83 (d, J = 9.1 Hz, 1H), 7.74 (dd, J = 8.7, 1.9 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.56- 7.47 (m, 2H), 3.99 DMSO >98 G1 (s, 3H), 3.90 (s, 3H). 509

¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.47 (dd, J = 2.1, 0.8 Hz, 1H), 8.67-8.60 (m, 2H), 8.15 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 2.7 Hz, 1H), 7.88-7.81 (m, 2H), 7.57- 7.49 (m, 2H), 7.44 (d, J = 8.7 DMSO >98 G1 (0.1N HCl added) Hz, 1H), 3.98 (s, 3H), 3.47 (s, 3H). 510

¹H NMR (400 MHz, DMSO) δ 10.76 (s, 1H), 10.62 (s, 1H), 9.71 (s, 1H), 9.53-9.48 (m, 1H), 8.68-8.62 (m, 2H), 7.98 (d, J = 2.6 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.63 (d, J = 1.8 Hz, 1H), 7.55-7.49 (m, 2H), 7.37 (dd, J = 8.4, DMSO >98 G1 (0.1N HCl added) 2.0 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H). 511

¹H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 9.49 (dd, J = 2.1, 0.8 Hz, 1H), 8.79 (s, 1H), 8.67-8.61 (m, 2H), 8.39-8.36 (m, 1H), 8.02 (d, J = 2.7 Hz, 1H), 7.90- 7.84 (m, 3H), 7.56 (dd, J = 9.1, 2.7 Hz, 1H), 7.54-7.50 (m, 1H), 3.99 (s, 3H). DMSO >98 J2 512

¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.48 (dd, J = 2.1, 0.8 Hz, 1H), 8.67-8.61 (m, 2H), 8.10- 8.08 (m, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.65- 7.63 (m, 2H), 7.57- DMSO >98 G1 7.49 (m, 2H), 4.22 (s, 3H), 3.99 (s, 3H). 513

¹H NMR (100 MHz, DMSO) δ 9.92 (s, 1H), 9.49 (dd, J = 2.1, 0.8 Hz, 1H)( 8.67-8.60 (m, 2H), 8.22 (d, J = 1.8 Hz, 1H), 8.00 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.70-7.64 (m, 1H), DMSO >98 J2 7.60 (d, J = 8.5 Hz, 1H), 7.57-7.49 (m, 2H), 4.21 (s, 3H), 3.98 (s, 3H). 514

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.98-8.91 (m, 1H), 8.89 (dd, J = 5.2, 1.3 Hz, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 8.13-8.04 (m, 2H), 7.92-7.85 (m, 1H), 7.73 (d, J = DMSO >98 G1 9.2 Hz, 1H), 7.70- 7.63 (m, 2H), 4.21 (s, 3H), 4.02 (s, 3H). 515

HCl ¹H NMR (400 MHz, DMSO) δ 11.90 (s, 1H), 10.45 (s, 1H), 9.46 (d, J = 1.7Hz, 1H), 8.97- 8.89 (m, 1H), 8.85 (dd, J = 5.2, 1.5 Hz, 1H), 8.16- 8.10 (m( 2H), 8.03-7.97 (m, 2H), 7.94 (d, J = 9.1 Hz, 1H), 7.90- DMSO >98 G1 (0.1N HCl added) 7.82 (m, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 6.58 (d, J = 9.4 Hz, 1H), 4.00 (s, 3H). 516

¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.53-9.50 (m, 1H), 8.68-8.63 (m, 2H), 8.27 (d, J = 2.0 Hz, 1H) (8.01 (d, J = 2.7 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.81 DMSO >98 G1 (dd, J = 8.7, 2.1 Hz, 1H), 7.58- 7.50 (m, 2H), 4.20 (s, 3H), 3.99 (s, 3H). 517

HCl ¹H NMR (300 MHz, DMSO) δ 11.35 (s, 1H), 9.58 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 8.2 Hz, 1H), 9.05- 8.97 (m, 1H), 9.05-8.95 (m, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.11-8.02 (m, 3H), 7.90 (d, DMSO >98 G1 J = 7.8 Hz, 1H), 7.58 (dd, J =8.8, 2.0 Hz, 2H), 7.52- 7.46 (m, 1H), 7.28 (s, 1H), 3.98 (d, J = 9.2 Hz, 3H). 518

2 HCl ¹H NMR (300 MHz, DMSO) δ 11.32 (s, 1H), 9.60 (s, 1H),9.23 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.4 Hz, 1H), 8.26 (s, 1H), 8.06 (dd, J = 13.2, 7.3 Hz, 2H), 7.63 (d, J = 9.1 Hz, 1H), 7.50- DMSO >98 G1 7.36 (m, 4H), 7.32 (s, 1H), 7.06- 6.90 (m, 1H), 3.99 (s, 3H), 3.86 (s, 3H). 519

2 HCl 1H NMR (400 MHz, DMSO) δ 11.90 (s, 1H), 10.45 (s, 1H), 9.46 (d( J = 1.7 Hz, 1H), 8.97- 8.89 (m, 1H), 8.85 (66, J = 5.2, 1.5 Hz, 1H), 8.16- 8.10 (m( 2H), 8.03-7.97 (m, 2H), 7.94 (d, J = 9.1 Hz, 1H), 7.90-7.82 (m, 1H), 7.63 (dd, J = DMSO >98 G1 9.1, 2.6 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 6.58 (d, J = 9.4 Hz, 1H), 4.00 (s, 3H). 520

HCl ¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.53-9.50 (m, 1H), 8.68- 8.63 (m, 2H), 8.27 (d, J = 2.0 Hz, 1H), 8.01 (d, J = 2.7 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.81 DMSO >98 G1 (dd, J = 8.7, 2.1 Hz, 1H), 7.58- 7.50 (m, 2H), 4.20 (s, 3H), 3.99 (s, 3H). 521

HCl ¹H NMR (300 MHz, DMSO) δ 11.35 (s( 1H)( 9.58 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 8.2 Hz, 1H), 9.05-8.97 (m, 1H), 9.05-8.95 (m, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.11- 8.02 (m, 3H), 7.90 (d, J = 7.8 Hz, 1H), 7.58 (dd, J = 8.8, 2.0 Hz, 2H), DMSO >98 G1 7.52-7.46 (m, 1H), 7.28 (s, 1H), 3.98 (d, J = 9.2 Hz, 3H). 1758

3 HCl 1H NMR (300 MHz, DMSO) δ 11.32 (s, 1H), 9.60 (s, 1H), 9.23 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.4 Hz, 1H), 8.26 (s, 1H), 8.06 (dd, J = 13.2, 7.3 Hz, 2H), 7.63 (d, J = 9.1 Hz, 1H), 7.50-7.36 (m, 4H), 7.32 (s, 1H), 7.06- 6.90 (m, 1H), 3.99 (s, 3H), 3.86 (s, 3H). DMSO >98 G13 1759

3 HCl 1H NMR (DMSO- d6) ppm 10.35 (br, 1H), 9.37 (d, J = 1.6 Hz, 1H), 8.96 (d, J = 7.28 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 8.04 (s, 1H), 7.98 (m, 1H), 7.95 (d, J = 9.16 Hz, 1H), 7.64 (dd, J = 9.16, 2.56 Hz, 1H), 6.18 (s, 1H), 3.98 (s, 3H), 3.66 (s, 3H), 2.24 (s, 3H). The DMSO >98 J2 1H of 3HCl was not observed.

Method K: 2-Amino-5-methoxybenzoic acid (viii-a)

5-Methoxy-2-nitrobenzoic acid (30.0 g, 152.2 mmol) was hydrogenated over Pd/C (10%, 300 mg) in THF (250 mL) at room temperature under H₂ balloon. The mixture was stirred for 18 h. After the reaction was completed, the catalyst was removed by filtration over Celite and the filtrate was concentrated to afford 25.0 g of 2-amino-5-methoxybenzoic acid as a brown solid (98%). LCMS m/z=168.1 (M+1), 150.1 (M-17) (Method B) (retention time=0.53 min). ¹H NMR (400 MHz, DMSO-d₆): δ 7.31 (d, J=2.8 Hz, 1H), 6.61 (dd, J=8.8, 3.2 Hz, 1H), 6.44 (d, J=8.8 Hz, 1H), 3.60 (s, 3H).

Method H: 6-Methoxyquinazoline-2,4(1H, 3H)-dione (ix-a)

2-Amino-5-methoxybenzoic acid (13.0 g, 77.8 mmol, 1.0 eq.) was suspended in water (200 mL) and glacial acetic acid (5.2 mL) at 35° C. A freshly prepared solution of potassium cyanate (8.21 g, 101.4 mmol, 1.3 eq.) in water (86 mL) was added dropwise to the stirred mixture. After 4 h, NaOH (104.0 g, 2600 mL, 33.4 eq.) was added in portions, keeping the reaction temperature below 40° C. A clear solution was obtained momentarily before a precipitate formed. After cooling, the precipitate was filtered off and dissolved in hot water which was acidified to pH 5. The precipitate was collected and washed with water, dried by lyophilization to afford 9.63 g of 6-methoxyquinazoline-2, 4(1H, 3H)-dione as a white solid (65%). LCMS m/z=193.1 (M+1) (Method B) (retention time=1.22 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 11.26 (s, 1H), 11.01 (s, 1H), 7.31-7.25 (m, 2H), 7.10 (d, 1H, J=8.8 Hz), 3.77 (s, 3H).

Method F1: 2,4-Dichloro-6-methoxyquinazoline (x-a)

To a mixture of 6-methoxyquinazoline-2,4(1H, 3H)-dione (9.63 g, 50.2 mmol) in POCl₃ (150 mL) was added N,N-dimethylaniline (0.5 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NaHCO₃ (sat.) at 0° C., then a precipitate formed. The solid was collected and dried in vacuo to give 11.2 g of 2,4-dichloro-6-methoxyquinazoline in a 98% yield as a brown solid. LCMS m/z=229.1, 231.0 (M+1) (Method B) (retention time=1.87 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 7.89 (d, J=9.2 Hz, 1H), 7.71 (dd, J=8.8, 2.4 Hz, 1H), 7.38 (d, J=1.6 Hz, 1H), 3.91 (s, 3H).

Method M: 2-Chloro-6-methoxyquinazolin-4-ol (xi-a)

A mixture of 2,4-dichloro-6-methoxyquinazoline (4.20 g, 18.5 mmol, 1.0 eq.) in THF (60 mL) and H₂O (60 mL) was treated with NaOH (4.00 g, 100 mmol, 5.4 eq.). The resulting mixture was stirred at 40° C. for 2 h. The reaction color turned to dark green and then a precipitate formed. After the reaction was completed, the mixture was cooled to room temperature. The precipitate was filtered off and the filtrate was concentrated down to 60 mL. The pH was then adjusted to 6 by adding 2N HCl in water. The precipitate which formed was collected and dried in vacuo to give 4.00 g of 2-chloro-6-methoxyquinazolin-4-ol as a grey solid (98%). LCMS m/z=211.1, 213.0 (M+1) (Method B) (retention time=1.11 min)

Method N: 6-Methoxy-2-(pyridin-3-yl) quinazolin-4-ol (xii-a)

To a mixture of 2-chloro-6-methoxyquinazolin-4-ol (1.20 g, 5.7 mmol, 1.0 eq.), pyridin-3-ylboronic acid (1.27 g, 8.6 mmol, 1.5 eq.), K₂CO₃ (2.37 g, 17.1 mmol, 3.0 eq.) in dioxane (100 mL) and H₂O (10 mL) was added Pd(PPh₃)₂Cl₂ (230 mg, 0.29 mmol, 0.05 eq.) under N₂ atmosphere. The resulting mixture was stirred at 105° C. under N₂ atmosphere overnight. After reaction was completed, the mixture was cooled to room temperature, and the resultant precipitate was removed by filtration. The filtrate was concentrated in vacuo and the residue was partitioned between H₂O (30 mL) and ethyl acetate (100 mL×3). The combined organic layers were washed with brine, dried over MgSO₄. After filtration and evaporation, the crude product was obtained, which was combined with the filter cake and dried in vacuo to give 1.35 g of 6-methoxy-2-(pyridin-3-yl) quinazolin-4-ol as a gray solid. LCMS m/z=254.1 (M+1) (Method B) (retention time=1.39 min) The crude product was used for the next step without further purification.

Method F1: 4-Chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (xiii-a)

To a mixture of 6-methoxy-2-(pyridin-3-yl) quinazolin-4-ol (600 mg, 2.37 mmol) in POCl₃ (5 mL) was added N,N-dimethylaniline (1 drop). The resulting mixture was stirred at 120° C. for 30 min After the reaction was completed, POCl₃ was removed in vacuo, and the residue was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NaHCO₃ (sat.) at 0° C. and then a precipitate formed. The solid was collected and was purified by chromatography on silica gel eluted with petroleum ether/ethyl acetate (v/v=4:1 to 1:1) to give 260 mg of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline as a pale yellow solid (40.4%). LCMS m/z=272.1, 274.0 (M+1) (Method B) (retention time=1.90 min)

Method G1: N-(2-Fluorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (xiv-a)

A mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (80 mg, 0.293 mmol, 1.0 eq.) and 2-fluoroaniline (65 mg, 0.58 mmol, 2 eq.) in i-PrOH (5 mL) was stirred at 85° C. for 18 h. After the reaction was completed, the mixture was filtered, and the filter cake was washed with H₂O (10 mL) and diethyl ether (10 mL). After drying, the crude product was purified by PREP-HPLC (Condition C: Gradient: B=5%-50%, Target Peak: at 7.2 min) to give 16.5 mg of N-(2-fluorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine as a yellow solid, yield 16.4%. LCMS m/z=347.0 (M+1) (Method A) (retention time=1.31 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 10.08 (s, 1H), 9.33 (s, 1H), 8.72 (d, J=4.4 Hz, 1H), 8.66 (d, J=8.0 Hz, 1H), 8.80 (d, J=1.2 Hz, 1H), 7.88 (d, J=9.2 Hz, 1H), 7.70-7.65 (m, 2H), 7.58 (dd, J=8.8, 1.2 Hz, 1H), 7.44-7.35 (m, 3H), 3.97 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 6 substituting with appropriate nitro benzoic acid, boronic acid and aniline

TABLE 2 Mole- ¹H Purity Method Num- Salt cular NMR LCMS per- for ber Product type Mass ¹H-NMR Solvent LCMS Protocol cent Coupling 522

455.34  1H-NMR (400 MHz, DMSO- d6): δ 9.76 (s, 1H), 9.52-9.51 (m, 1H), 8.63- 8.66 (m, 2H), 8.32 (d, J = 2.4 Hz, 1H), 7.94- 7.91 (m, 2H), 7.72 (d, J = 8.8 Hz, 1H), 7.54 (q, J = 3.2 Hz, 1H), 7.32 (s, 1H), 4.87-4.90 (m, 1H), 3.96 (s, 3H), 1.38 (d, J = 6.0 Hz, 6H). DMSO 454.9, 457.0 (M + 1), 228.8 (M/2 + 1) Method A (TFA) 95 Method N, G1 523

438.88  1H-NMR (400 MHz, DMSO- d6): δ 9.68 (s, 1H), 9.49 (d, J = 2.0 Hz, 1H), 8.60-8.66 (m, 2H), 8.18 (dd, J = 6.4, 2.4 Hz, 1H), 7.84- 7.88 (m, 2H), 7.50-7.54 (m, 2H), 7.31 (s, 1H), 4.85-4.88 (m, 1H), 3.96 (s, 3H), 1.38 (d, J = 6.4 Hz, 6H). DMSO 439.1, 441.1 (M + 1), 220.1, 220.8 (M/2 + 1) Method A (TFA) 95 Method N,G1 524

422.43  1H-NMR (400 MHz, DMSO- d6): δ 9.76 (s, 1H), 9.48 (s, 1H), 8.60-8.65 (m, 2H), 8.04- 8.10 (m, 1H), 7.92 (s, 1H), 7.49-7.66 (m, 3H), 7.30 (s, 1H), 4.86-4.92 (m, 1H), 3.96 (s, 3H), 1.37 (d, J = 6.0 Hz, 6H) DMSO 423.2 (M + 1), 212.2 (M/2 + 1) Method A (TFA) 95 Method N, G1 525

HCl 429.47  1H-NMR (400 MHz, DMSO- d6): δ 12.96 (s, 1H), 9.60 (d, J = 8.0 Hz, 1H), 8.68-8.74 (m, 2H), 8.46 (s, 1H), 7.95-7.96 (m, 2H), 7.74- 7.70 (m, 1H), 7.59-7.54 (m, 2H), 7.36 (s, 1H), 7.19-7.15 (m, 1H), 4.76- 4.82 (m, 1H), 3.99 (s, 3H), 1.44 (d, J = 6.0 Hz, 6H). DMSO 430.2 (M + 1) 215.7 (M/2 + 1) Method A (TFA) 95 Method N, G1 526

452.45  1H-NMR (400 MHz, DMSO- d6): δ 9.70 (s, 1H), 9.52-9.53 (m, 1H), 8.64- 8.67 (m, 2H), 7.89-7.94 (m, 2H), 7.73-7.74 (m, 1H), 7.48- 7.53 (m, 3H), 7.32 (t, J = 83.6 Hz, 1H), 6.96- 6.99 (m, 1H), 4.89-4.92 (m, 1H), 3.98 (s, 3H), 1.38 (d, J = 6.0 Hz, 6H). DMSO 453.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 527

455.34  1H-NMR (400 MHz, DMSO- d6): δ 9.53 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.64-8.68 (m, 2H), 8.12-8.13 (m, 2H), 7.90 (s, 1H), 7.54- 7.58 (m, 1H), 7.34-7.36 (m, 2H), 4.86-4.92 (m, 1H), 3.98 (s, 3H), 1.40 (d, J = 6.0 Hz, 6H). DMSO 455.0, 457.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 528

455.34  1H-NMR (400 MHz, DMSO- d6): δ 9.76 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.64-8.67 (m, 2H), 8.32 (d, J = 2.8 Hz, 1H), 7.94 (dd, J = 8.8, 2.4 Hz, 1H), 7.86 (s, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.53- 7.56 (m, 1H), 7.32 (s, 1H), 4.14 (t, J = 6.4 Hz, 2H), 3.99 (s, 3H), 1.85- 1.92 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 455.1, 457.1 (M + 1) 229.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 529

438.88  1H-NMR (400 MHz, DMSO- d6): δ 9.72 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.62-8.66 (m, 2H), 8.20 (dd, J = 6.4, 2.4 Hz, 1H), 7.85-7.89 (m, 2H), 7.50-7.55 (m, 2H), 7.31 (s, 1H), 4.13 (t, J = 6.4 Hz, 2H), 3.98 (s, 3H), 1.82-1.90 (m, 2H), 1.06 (t, J = 7.6 Hz, 3H). DMSO 439.1, 441.1 (M + 1) 220.1, 220.8 (M/2 + 1) Method A (TFA) 95 Method N, G1 530

422.43  1H-NMR (400 MHz, DMSO- d6): δ 9.74-9.76 (m, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.64-8.69 (m, 2H), 8.08- 8.14 (m, 1H), 7.90 (s, 1H), 7.68-7.70 (m, 1H), 7.52-7.60 (m, 2H), 7.34 (s, 1H), 4.16 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 1.85-1.94 (m, 2H), 1.09 (t, J = 7.2 Hz, 3H). DMSO 423.0 (M + 1) 445.0 (M + 23) 212.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 531

HCl 429.47  1H-NMR (400 MHz, DMSO- d6): δ 12.86 (s, 1H), 9.59 (d, J = 1.6 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 8.0 Hz, 1H), 8.76-8.78 (m, 1H), 8.44 (s, 1H), 7.96 (dd, J = 8.0, 1.6 Hz, 2H), 7.70-7.73 (m, 2H), 7.53 (s, 1H), 7.37 (s, 1H), 6.96-7.22 (m, 1H), 4.16 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 1.86-1.90 (m, 2H), 1.07 (t, J = 7.2 Hz, 3H). DMSO 430.1 (M + 1) Method B (NH4CO3) 95 Method N, G1 532

452.45  1H-NMR (400 MHz, DMSO- d6): δ 9.67 (s, 1H), 9.50 (d, J = 4.0 Hz, 1H), 8.62-8.65 (m, 2H), 7.89-7.92 (m, 3H), 7.44- 7.54 (m, 1H), 7.29-7.31 (m, 3H), 7.26 (t, J = 74.0 Hz, 1H), 4.14 (t, J = 6.8 Hz, 2H), 3.98 (s, 3H), 1.84- 1.90 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H). DMSO 453.1 (M + 1) 227.2 (M/2 + 1) Method A (TFA) 95 Method N, G1 533

HCl 454.88  1H-NMR (400 MHz, DMSO- d6): δ 9.73 (s, 1H), 9.50 (d, J = 2.4 Hz, 1H), 8.62-8.67 (m, 2H), 8.20 (dd, J = 7.2 Hz, 2.8 Hz, 1H), 7.85- 7.89 (m, 2H), 7.51-7.57 (m, 2H), 7.33 (s, 1H), 4.31 (t, J = 4.0 Hz, 2H), 3.99 (s, 3H) 3.80 (t, J = 4.8 Hz, 2H), 3.37 (s, 3H). DMSO 455.1, 457.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 534

445.47  1H-NMR (400 MHz, CD3OD): δ 9.34 (s, 1H), 8.92 (d, J = 6.0 Hz, 1H), 8.73 (m, 2H), 7.84 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.15 (s, 2H), 4.21 (s, 2H), 3.92 (s, 3H), 3.78 (t, J = 4.4 Hz, 2H), 3.40 (s, 3H). CD3OD 446.2, 447.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 535

HCl 468.45  1H-NMR (400 MHz, DMSO- d6): δ 9.72 (s, 1H), 9.53 (s, 1H), 8.66 (d, J = 5.6 Hz, 2H), 7.91 (d, J = 6.4 Hz, 2H), 7.75 (d, J = 7.2 Hz, 1H), 7.51 (dd, J = 7.6 Hz, 2H), 7.34 (s, 1H), 7.30 (t, J = 74.0 Hz, 1H), 6.97 (dd, J = 8.0, 2.0 Hz, 1H), 4.32 (t, J = 4.4 Hz, 2H), 3.99 (s, 3H), 3.80 (t, J = 4.4 Hz, 2H), 3.37 (s, 3H). DMSO 469.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 536

468.91  1H-NMR (400 MHz, DMSO- d6): δ 10.42 (s, 1H), 9.47 (s, 1H), 8.96 (d, J = 6.4 Hz, 1H), 8.90 (d, J = 5.2 Hz, 1H), 8.11 (dd, J = 6.8 Hz, 2.4 Hz, 1H), 8.05 (s, 2H), 7.85- 7.94 (m, 2H), 7.55 (t, J = 9.2 Hz, 1H), 7.47 (s, 1H), 4.26 (t, J = 6.4 Hz, 2H), 4.01 (s, 3H), 3.55 (t, J = 6.0 Hz, 2H), 3.29 (s, 3H), 2.06-2.13 (m, 2H). DMSO 469.0, 471.0 (M + 1) 234.9, 235.6 (M/2 + 1) Method A (TFA) 95 Method N, G1 537

397.26  1H-NMR (400 MHz, DMSO- d6): δ 10.08 (s, 1H), 9.54 (s, 1H), 8.76 (s, 2H), 8.49 (d, J = 7.0 Hz, 1H), 8.36 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.66- 7.23 (m, 2H), 7.33 (s, 2H), 3.98 (s, 3H). DMSO 397.1, 399.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 538

397.26  1H-NMR (400 MHz, DMSO- d6): δ 10.00 (s, 1H), 8.54 (d, J = 1.3 Hz, 1H), 8.71-8.56 (m, 2H), 8.47 (d, J = 9.2 Hz, 1H), 8.17 (s, 1H), 8.16 (s, 1H), 7.59-7.56 (m, 1H), 7.35-7.30 (m, 3H), 3.98 (s, 3H). DMSO 397.0, 399.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 539

364.35  1H-NMR (400 MHz, DMSO- d6): δ 9.94 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.70-8.65 (m, 2H), 8.47 (d, J = 8.4 Hz, 1H), 8.12 (ddd, J = 13.2, 7.6, 2.8 Hz, 1H), 7.72-7.70 (m, 1H), 7.58-7.49 (m, 2H), 7.32- 7.27 (m, 2H), 3.97 (s, 3H). DMSO 365.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 540

353.38  1H-NMR (400 MHz, DMSO- d6): δ 10.06 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.71-8.66 (m, 2H), 8.50-8.43 (m, 2H), 8.26- 8.24 (m, 1H), 7.70-7.54 (m, 3H), 7.34-7.30 (m, 2H), 3.98 (s, 3H). . DMSO 354.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 541

394.37  1H-NMR (400 MHz, DMSO- d6): δ 9.93 (s, 1H), 9.54 (s, 1H), 8.68 (d, J = 5.2 Hz, 2H), 8.51 (d, J = 9.2 Hz, 1H), 7.96 (s, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.55-7.10 (m, 5H), 6.96 (dd, J = 8.0, 2.0 Hz, 1H), 3.96 (s, 3H). DMSO 395.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 542

371.39  1H-NMR (400 MHz, DMSO- d6): δ 12.97 (s, 1H), 9.60 (s, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.75-8.71 (m, 2H), 8.48 (s, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.95-7.90 (m, 2H), 7.74- 7.70 (m, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.35-7.33 (m, 2H), 7.19 (t, J = 7.2 Hz, 1H), 3.97 (s, 3H). DMSO 372.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 543

431.7   1H-NMR (400 MHz, DMSO- d6): δ 10.03 (s, 1H), 9.49-9.48 (m, 1H), 8.69- 8.67 (m, 1H), 8.63-8.59 9m, 1H), 8.31 (d, J = 2.4 Hz, 1H), 8.04 (s, 1H), 8.00 (s, 1H), 7.93-7.90 (m, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.56-7.53 (m, 1H), 4.07 (s, 3H). DMSO 430.9, 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 544

431.7   1H-NMR (400 MHz, DMSO- d6): δ 9.94 (s, 1H), 9.46 (d, J = 3.2 Hz, 1H), 8.68 (dd, J = 4.8, 2.0 Hz, 1H), 8.60-8.57 (m, 1H), 8.09 (s, 1H), 8.08 (s, 1H), 7.97 (s, 2H), 7.54 (dd, J = 8.8, 4.8 Hz, 1H), 7.38 (t, J = 2.0 Hz, 1H), 4.05 (s, 3H). DMSO 430.9, 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 545

415.25  1H-NMR (400 MHz, DMSO- d6): δ 10.02 (s, 1H), 9.47 (s, 1H), 8.70-8.62 (m, 2H), 8.19- 8.17 (m, 1H), 8.04 (s, 1H), 8.00 (s, 1H), 7.84-7.88 (m, 1H), 7.59-7.53 (m, 2H), 4.07 (s, 3H). DMSO 415.1, 417.0, 419.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 546

398.79  1H-NMR (400 MHz, DMSO- d6): δ 10.01 (s, 1H), 9.47 (d, J = 1.6 Hz, 1H), 8.69-8.67 (m, 1H), 8.62-8.59 (m, 1H), 8.08- 8.04 (m, 2H), 8.00 (s, 1H), 7.65-7.53 (m, 3H), 4.07 (s, 3H). DMSO 399.1, 401.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 547

428.82  1H-NMR (400 MHz, DMSO- d6): δ 10.32 (s, 1H), 9.45 (d, J = 1.2 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.83 (d, J = 4.0 Hz, 1H), 8.21 (s, 1H), 8.00 (s, 1H), 7.85-7.78 (m, 3H), 7.55- 7.51 (m, 1H), 7.31 (t, J = 72.8 Hz, 1H), 7.05- 7.03 (m, 1H), 4.07 (s, 3H). DMSO 429.1, 431.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 548

387.82  1H-NMR (400 MHz, DMSO- d6): δ 10.62 (s, 1H), 9.38 (s, 1H), 8.97-8.90 (m, 2H), 8.32- 8.26 (m, 3H), 7.97-7.94 (m, 2H), 7.69-7.65 (m, 2H), 4.08 (s, 3H). DMSO 387.9, 390.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 549

405.84  1H-NMR (400 MHz, DMSO- d6): δ 12.98 (s, 1H), 9.36 (s, 1H), 8.94-8.77 (m, 3H), 8.48 (s, 1H), 7.98-7.83 (m, 4H), 7.59- 7.14 (m, 2H), 7.17 (s, 1H), 3.96 (s, 3H). DMSO 405.9, 408.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 550

436.12  1H-NMR (400 MHz, DMSO- d6): δ 10.24 (s, 1H), 9.39 (s, 1H), 8.87 (s, 1H), 8.81 (d, J = 4.4 Hz, 1H), 8.73 (d, J = 8.0 Hz, 1H), 8.24 (s, 1H), 8.01 (s, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.76-7.73 (m, 1H), 7.66 (d, J = 8.8 Hz, 1H). DMSO 434.9, 436.9, 438.8 (M + 1) Method B (NH4HCO3) 95 Method N, G1 551

410.26  1H-NMR (400 MHz, DMSO- d6): δ 13.15 (s, 1H), 9.46 (s, 1H), 8.87 (d, J = 8.4 Hz, 1H), 8.74 (d, J = 3.6 Hz, 1H), 8.68 (d, J = 7.2 Hz, 1H), 8.49 (s, 1H), 8.23 (s, 1H), 8.02 (s, 2H), 7.94 (d, J = 8.0 Hz, 1H), 7.69- 7.61 (m, 2H), 7.23-7.20 (m, 1H). DMSO 410.0, 412.0, 413.9 (M + 1) 432.0 (M + 22) Method A (TFA) 95 Method N, G1 552

433.24  1H-NMR (400 MHz, DMSO- d6): δ 10.30 (s, 1H), 9.53 (s, 1H), 9.02 (s, 1H), 8.83-8.80 (m, 2H), 8.20 (s, 1H), 7.91 (s, 1H), 7.81- 7.79 (m, 1H), 7.74-7.71 (m, 1H), 7.56-7.52 (m, 1H), 7.30 (t, J = 73.6 Hz, 1H), 7.05 (d, J = 8.8 Hz, 1H). DMSO 432.9, 434.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 553

419.67  1H-NMR (400 MHz, DMSO- d6): δ 10.43 (s, 1H), 9.40 (s, 1H), 8.97 (s, 1H), 8.89-8.85 (m, 2H), 8.15- 8.14 (m, 1H), 8.05 (s, 1H), 7.89-7.87 (m, 2H), 7.51-7.47 (m, 1H). DMSO 419.0, 421.0, 423.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 554

403.21  1H-NMR (400 MHz, DMSO- d6): δ 10.39 (s, 1H), 9.40 (s, 1H), 8.96 (s, 1H), 8.84-8.89 (m, 2H), 8.04- 8.00 (m, 2H), 7.88 (s, 1H), 7.69-7.67 (m, 1H), 7.54-7.47 (m, 1H). DMSO 402.9, 404.9 (M + 1) Method B (NH4HCO3) 95 Method N, G1 555

436.12  1H-NMR (400 MHz, DMSO- d6): δ 10.26 (s, 1H), 8.28 (s, 1H), 8.88 (d, J = 4.8 Hz, 1H), 8.85 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 7.97 (s, 1H), 7.96 (s, 1H), 7.90-7.86 (m, 2H), 7.29 (s, 1H). DMSO 434.9, 436.9, 438.9 (M + 1) Method A (TFA) 95 Method N, G1 556

441.31  1H-NMR (400 MHz, DMSO- d6): δ 9.74 (s, 1H), 9.50 (s, 1H), 8.66-8.64 (m, 2H), 8.31 (s, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.84 (s, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.52 (dd, J = 7.4, 5.0 Hz, 1H), 7.29 (s, 1H), 4.22 (q, J = 6.8 Hz, 2H), 3.97 (s, 3H), 1.45 (t, J = 6.8 Hz, 3H). DMSO 441.0, 443.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 557

424.86  1H-NMR (400 MHz, DMSO- d6): δ 9.93 (s, 1H), 9.48 (s, 1H), 8.74-8.73 (m, 2H), 8.18- 8.16 (m, 1H), 7.90-7.85 (m, 2H), 7.67-7.65 (m, 1H), 7.53 (t, J = 9 Hz, 1H), 7.33 (s, 1H), 4.24 (q, J = 7.2 Hz, 2H), 3.98 (s, 3H), 7.2 Hz, 2H), 3.98 (s, 3H), 1.46 (t, J = 7.2 Hz, 3H). DMSO 425.0, 427.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 558

408.4   1H-NMR (400 MHz, DMSO- d6): δ 9.68 (s, 1H), 9.49 (s, 1H), 8.66-8.61 (m, 2H), 8.10- 8.04 (m, 1H), 7.84 (s, 1H), 7.66-7.64 (m, 1H), 7.56-7.49 (m, 2H), 7.30 (s, 1H), 4.23 (q, J = 6.8 Hz, 2H), 3.98 (s, 3H), 1.46 (t, J = 6.8 Hz, 3H). DMSO 409.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 559

397.43  1H-NMR (400 MHz, DMSO- d6): δ 10.67 (s, 1H), 9.43 (s, 1H), 8.82-8.78 (m, 2H), 8.32 (s, 1H), 8.23 (d, J = 7.6 Hz, 1H), 7.98 (s, 1H), 7.77-7.73 (m, 1H), 7.68-7.60 (m, 2H), 7.35 (s, 1H), 4.23 (q, J = 6.8 Hz, 2H), 3.96 (s, 3H), 1.44 (t, J = 6.8 Hz, 3H). DMSO 398.1 (M + 1) Method B (NH4HCO3) 95 Method N, G1 560

410.83  1H-NMR (400 MHz, DMSO- d6): δ 9.89 (s, 1H), 9.48 (s, 1H), 8.74 (d, J = 6.0 Hz, 2H), 8.16 (dd, J = 6.8, 2.4 Hz, 1H), 7.85- 7.88 (m, 2H), 7.67 (t, J = 6.4 Hz, 1H), 7.53 (t, J = 8.7 Hz, 1H), 7.32 (s, 1H), 3.98 (s, 6H). DMSO 411.1, 413.1 (M + 1) Method A (TFA) 95 Method N, G1 561

394.37  1H-NMR (400 MHz, DMSO- d6): δ 9.92 (s, 1H), 9.49 (s, 1H), 8.77 (d, J = 6.4 Hz, 2H), 8.02- 8.08 (m, 1H), 7.90 (s, 1H), 7.70-7.74 (m, 1H), 7.64-7.66 (m, 1H), 7.52- 7.59 (m, 1H), 7.33 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H). DMSO 395.0 (M + 1), 198.1 (M/2 + 1) Method A (TFA) 95 Method N, G1 562

383.4   1H-NMR (400 MHz, DMSO- d6): δ 9.87 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.63-8.68 (m, 2H), 8.38 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.52- 7.56 (m, 1H), 7.33 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H). DMSO 384.2 (M + 1) Method B (NH4HCO3) 95 Method N, G1 563

427.28  1H-NMR (400 MHz, DMSO- d6): δ 9.70 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.66 (d, J = 4.8 Hz, 1H), 8.62 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 1.2 Hz, 2H), 7.79 (s, 1H), 7.53 (dd, J = 7.6, 4.8 Hz, 1H), 7.31 (s, 1H), 7.28 (s, 1H), 3.97 (s, 6H). DMSO 427.1, 429.1, 431.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 564

2HCl 389.3824 1H-NMR (400 MHz, DMSO- d6): δ 13.08 (s, 1H), 9.40 (s, 1H), 8.86 (d, J = 8.1 Hz, 1H), 8.78 (s, 1H), 8.53 (d, J = 10.0 Hz, 1H), 8.46 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 8.00- 7.88 (m, 2H), 7.73 (t, J = 7.8 Hz, 1H), 7.66 (d, J = 10.3 Hz, 2H), 7.28 (t, J = 7.6 Hz, 1H), 3.99 (s, 3H). DMSO 390.0 (M + 1) Method B (NH4HCO3) 95 Method N, G1 565

2HCl 401.4180 1H-NMR (400 MHz, CD3OD): δ 9.20 (s, 1H), 8.85 (s, 1H), 8.78 (s, 1H), 8.72 (d, J = 8.2 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 7.77- 7.67 (m, 3H), 7.39 (t, J = 7.6 Hz, 1H), 4.18 (s, 3H), 4.08 (s, 3H). MeOD 402.1 (M + 1) Method B (NH4CO3) 95 Method N, G1

Method O1: CuI/Pd(PPh₃)₂Cl₂/Et₃N/DMF/rt

-   -   O2: Propargyl bromide/CuI/Pd(PPh₃)₂Cl₂/Nucleophile/DMF/rt     -   O3: Pd(OAc)₂/PPh₃/TBAB/piperdine/THF—H₂O/rt

Method O1: 6-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xv-a)

A suspension of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (1.00 g, 2.10 mmol), tert-butyldimethyl(2-propynyloxy)silane (0.85 ml, 4.20 mmol), copper(I) iodide (4.0 mg, 0.021 mmol), dichlorobis(triphenylphosphine) palladium (II) (Pd(PPh₃)₂Cl₂) (29 mg, 0.042 mmol), and triethylamine (1.17 ml, 8.39 mmol) in DMF (15 mL) was stirred overnight at room temperature under argon atmosphere. Water (30 mL) and ethyl acetate (30 mL) were added to the mixture. The resultant precipitate was removed by filtration. The filtrate was extracted with EtOAc (2×50 mL). The combined organic layer was washed with water (1×100 mL) and brine (1×100 mL) and was dried over Na₂SO₄. After filtration and evaporation, the crude product was obtained, which was purified by column chromatography on silica gel (eluted with hexane/ethyl acetate 6:1 to 1:3) to give 0.73 g of 6-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine as light brown solid (67%). LCMS m/z=519 (M+1) (Method D) (retention time=3.22 min). ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.35 (s, 1H), 8.62-8.44 (m, 3H), 8.11 (dd, J=6.8, 2.6 Hz, 1H), 7.76-7.66 (m, 3H), 7.45-7.30 (m, 2H), 4.48 (s, 2H), 0.75 (s, 9H), 0.16 (s, 6H).

Method P: 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xvi-a)

A suspension of 6-(3-(tert-butyldimethylsilyloxy)prop-1-ynyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (0.20 g, 0.39 mmol) and 5% Pd—S—C(40 mg) in EtOAc (5 mL) and MeOH (5 mL) was stirred overnight at room temperature under hydrogen atmosphere. The reaction mixture was filtered through Celite. The filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluted with hexane/ethyl acetate 6:1 to 2:3) to give 0.15 g of 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine as yellow solid (74%). LCMS m/z=523 (M+1) (Method D) (retention time=3.35 min). ¹H NMR (300 MHz, CDCl₃) δ 9.69 (dd, J=2.2, 0.8 Hz, 1H), 8.79-8.65 (m, 2H), 8.07 (dd, J=6.5, 2.7 Hz, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.76-7.61 (m, 3H), 7.47-7.37 (m, 2H), 7.31-7.18 (m, 1H), 3.68 (t, J=6.1 Hz, 2H), 3.01-2.83 (m, 2H), 2.03-1.86 (m, 2H), 0.94 (s, 9H), 0.08 (s, 6H).

Method Q: 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol (xvii-a)

To a suspension of 6-(3-(tert-butyldimethylsilyloxy)propyl)-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (0.35 g, 0.67 mmol) in MeOH (10 mL) was added 1-chloroethyl chloroformate (7.2 μl, 0.067 mmol). The mixture was stirred overnight at room temperature. Methanol was removed in vacuo. Sat. NaHCO₃ aqueous (10 mL) and CH₂Cl₂ (10 mL) were added to the residue and stirred for a while. The resultant solid was collected by filtration and dried to give 0.25 g of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol as light yellow solid (91%). MS m/z=409 (M+1) (Method D) (retention time=1.71 min). ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.51 (s, 1H), 8.66 (m, 2H), 8.37 (s, 1H), 8.29-8.20 (m, 1H), 7.94-7.67 (m, 3H), 7.63-7.43 (m, 2H), 4.60 (t, J=5.0 Hz, 1H), 3.56-3.35 (m, 2H), 2.94-2.69 (m, 2H), 2.15-1.56 (m, 2H).

Method R: 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate (xviii-a)

To a suspension of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propan-1-ol (0.25 g, 0.61 mmol) and triethylamine (0.17 ml, 1.22 mmol) in CH₂Cl₂ (10 mL) was added methanesulfonyl chloride (0.057 ml, 0.73 mmol). The mixture was stirred at room temperature for 1 h. Water (10 mL) was added to the mixture and stirred for a while. The resultant precipitate was collected by filtration and washed with CH₂Cl₂ and dried to give 0.27 g of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate as pale yellow solid (91%), which was used without further purification.

Method G4: N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (xviv-a)

This method is representative of method G4 and G5. These two methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) A solution of 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate (40 mg, 82 mmol) and 40% Me₂NH aqueous (1 mL) in methanol (2 mL) was placed in a microwave reaction vial. The mixture was heated under microwave irradiation conditions at 150° C. for 30 minutes after which the solvent was removed in vacuo. The crude product was obtained, which was purified by column chromatography on basic silica gel (eluted with ethyl acetate/methanol 1:0→5:1). The HCl salt generated by 4 M HCl in dioxane was crystallized from 2-propanol to give 10 mg of N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as pale brown powder (24%). LCMS m/z=436 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 10.18 (s, 1H), 9.51 (s, 1H), 8.98-8.76 (m, 2H), 8.65 (s, 1H), 8.26 (dd, J=6.8, 2.6 Hz, 1H), 8.05-7.74 (m, 4H), 7.54 (t, J=9.1 Hz, 1H), 3.19-3.03 (m, 2H), 2.97-2.83 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 2.16 (s, 2H).

N-(3-chloro-4-fluorophenyl)-6-(3-morpholinoprop-1-ynyl)-2-(pyridin-3-yl) quinazolin-4-amine (xx-a)

To a solution of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (2.19 g, 4.6 mmol, 1 eq.), Pd(PPh₃)₂Cl₂ (161 mg, 0.23 mmol, 0.05 eq.), CuI (87 mg, 0.46 mmol, 0.1 eq.) in morpholine (15 mL) was added 3-bromoprop-1-yne (814 mg, 6.9 mmol, 1.5 eq.) at 0° C. under Ar atmosphere, following a procedure from Tetrahedron, 2007, 63, 10671-10683. The mixture was stirred at 40° C. overnight. After cooling, the mixture was filtered and methanol (60 mL) was added to the filtrate to form a precipitate. The precipitate was collected and re-crystallized from ethyl acetate twice to afford 1.60 g of xx-a as yellow solid (yield 74%). LCMS m/z=474.1 (M+1), 476.1 (M+3) (Method C) (retention time=1.97 min)

The compounds in the following table were prepared in a manner analogous to that described in Scheme 8 substituting with appropriate nucleophile.

TABLE 3 Re- ten- Pu- Method Mole- ¹H- tion rity for Num- Salt cular NMR Time LCMS per- Coup- ber Product type Mass ¹H-NMR Solvent LCMS (Min) Protocol cent ling 566

519.085 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.35 (s, 1H), 8.62-8.44 (m, 3H), 8.11 (dd, J = 6.8, 2.6 Hz, 1H), 7.76-7.66 (m, 3H), 7.45- 7.30 (m, 2H), 4.48 (s, 2H), 0.75 (s, 9H), 0.00 (s, 6H). DMSO 519 (M + 1) 3.22 Method D  96 Method O1 567

523.117 1H NMR (300 MHz, CDCl3) δ 9.69 (dd, J = 2.2, 0.8 Hz, 1H), 8.79-8.65 (m, 2H), 8.07 (dd, J = 6.5, 2.7 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 7.76-7.61 (m, 3H), 7.47-7.37 (m, 2H), 7.31- 7.18 (m, 1H), 3.68 (t, J = 6.1 Hz, 2H), 3.01- 2.83 (m, 2H), 2.03-1. CDCl3 523 (M + 1) 3.35 Method D 100 Methods O1, P 568

408.856 1H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.51 (s, 1H), 8.66 (m, 2H), 8.37 (s, 1H), 8.29-8.20 (m, 1H), 7.94-7.67 (m, 3H), 7.63- 7.43 (m, 2H), 4.60 (t, J = 5.0 Hz, 1H), 3.56- 3.35 (m, 2H), 2.94-2.69 (m, 2H), 2.15-1.56 (m, 2H). DMSO 409 (M + 1) 1.71 Method D 100 Methods O1, P, Q 569

2 HCl 508.846 1H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 10.18 (s, 1H), 9.51 (s, 1H), 8.98-8.76 (m, 2H), 8.65 (s, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.05-7.74 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.19-3.03 (m, 2H), 2.97- 2.83 (m, 2H), 2.78 (s, 3H), 2.77 (s, 3H), 2. DMSO 436 (M + 1) 1.68 Method C 100 Method G4 570

409.841 1H NMR (300 MHz, CDCl3) δ 9.49 (d, J = 1.4 Hz, 1H), 8.73-8.51 (m, 2H), 8.14 (s, 1H), 8.01 (d, J = 8.6 Hz, 1H), 7.81 (dd, J = 8.6, 1.9 Hz, 1H), 7.51-7.13 (m, 4H), 3.77 (dd, J = 11.5, 6.2 Hz, 2H), 3.11-2.86 (m, 2H), 2.16- 1.93 (m, 2H), 1.44 (t, J = 5 CDCl3 410 (M + 1) 1.95 Method D 100 Methods O1, P, Q 571

2 HCl 550.882 1H NMR (300 MHz, DMSO) δ 10.83-10.37 (m, 2H), 9.51 (s, 1H), 8.97- 8.74 (m, 2H), 8.62 (s, 1H), 8.27 (d, J = 4.2 Hz, 1H), 8.05-7.72 (m, 4H), 7.54 (t, J = 9.0 Hz, 1H), 3.96 (d, J = 12.7 Hz, 2H), 3.76 (t, J = 12.1 Hz, 2H), 3.47 (d, J = 12.0 Hz, 2H), 3.24 DMSO 478 (M + 1) 2.01 Method C 100 Method G4 572

422.882 1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.51 (s, 1H), 8.75-8.60 (m, 2H), 8.37 (s, 1H), 8.26 (dd, J = 6.9, 2.6 Hz, 1H), 7.99-7.88 (m, 1H), 7.88- 7.73 (m, 2H), 7.60-7.46 (m, 2H), 3.39 (dd, J = 8.4, 4.1 Hz, 2H), 3.27 (s, 3H), 2.92-2.78 (m, 2H), 2.05 DMSO 423 (M + 1) 2.09 Method D 100 Method G4 573

HCl 548.909 1H NMR (300 MHz, DMSO) δ 10.69 (s, 1H), 10.12 (s, 1H), 9.51 (s, 1H), 9.02-8.80 (m, 2H), 8.69 (s, 1H), 8.27 (dd, J = 6.9, 2.7 Hz, 1H), 8.08-7.78 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.46 (d, J = 10.2 Hz, 2H), 3.17-3.00 (m, 2H), 2.99- 2.75 (m, 4H), 2.3 DMSO 476 (M + 1) 1.79 Method C 100 Method G4 574

HCl 500.395 1H NMR (300 MHz, DMSO) δ 10.68 (s, 1H), 9.49 (s, 1H), 9.12-8.99 (m, 1H), 8.94 (d, J = 3.9 Hz, 1H), 8.58 (d, J = 11.5 Hz, 1H), 8.17 (dd, J = 6.7, 2.6 Hz, 1H), 8.07-7.82 (m, 5H), 7.55 (t, J = 9.1 Hz, 1H), 3.43-3.29 (m, 2H), 3.08- 2.65 (m, 5H), 2.09- DMSO 464 (M + 1) 1.78 Method D  95 Method G4 follow- ed by acyla- tion with acetyl chlo- ride/ TEA/ DCM, rt 575

HCl 600.39  1H NMR (300 MHz, DMSO) δ 11.79 (s, 1H), 10.81 (s, 1H), 9.50 (s, 1H), 8.98 (d, J = 8.2 Hz, 1H), 8.89 (d, J = 5.0 Hz, 1H), 8.75 (s, 1H), 8.27 (d, J = 4.8 Hz, 1H), 8.10-7.79 (m, 4H), 7.53 (t, J = 9.1 Hz, 1H), 5.18-3.09 (m, 10H), 3.01- 2.69 (m, 5H), 2.37 DMSO 491 (M + 1) 1.76 Method C 100 Method G4 576

473.93  1H NMR (300 MHz, DMSO) δ 10.17 (s, 1H), 9.52 (s, 1H), 8.70 (s, 1H), 8.66 (d, J = 8.1 Hz, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.93 (s, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.61-7.51 (m, 2H), 3.67-3.61 (m, 6H), 2.61- 2.55 (m, 4H). DMSO   473.9 (M + 1) 2.2  Method C 100 Method O1 577

435.92  1H NMR (300 MHz, DMSO) δ 10.06 (s, 1H), 9.54 (s, 1H), 8.77-8.63 (m, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 6.8 Hz, 1H), 7.93 (s, 1H), 7.79 (s, 1H), 7.64-7.51 (m, 3H), 3.00 (t, J = 8.2 Hz, 2H), 2.87 (t, J = 7.6 Hz, 2H), 2.72 (s, 6H), 2.14-1.99 ( DMSO   436.0 (M + 1) 1.68 Method C 100 Methods O1, P 578

519.09  1H NMR (300 MHz, DMSO) δ 10.17 (s, 1H), 9.67-9.43 (m, 1H), 8.68 (s, 2H), 8.55 (d, J = 8.4 Hz, 1H), 8.28 (s, 1H), 7.89 (s, 2H), 7.68 (s, 1H), 7.56 (d, J = 9.1 Hz, 2H), 4.64 (s, 2H), 0.92 (s, 9H), 0.18 (s, 6H). DMSO   518.8 (M + 1) 3.18 Method C 100 Method O1 579

404.82  1H NMR (300 MHz, DMSO) δ 10.19 (s, 1H), 9.51 (s, 1H), 8.65 (d, J = 8.1 Hz, 2H), 8.54 (d, J = 8.4 Hz, 1H), 8.26 (s, 1H), 7.85 (s, 2H), 7.67-7.60 (m, 1H), 7.52 (d, J = 7.0 Hz, 2H), 5.48 (s, 1H), 4.39 (d, J = 5.8 Hz, 2H). DMSO   404.9 (M + 1) 2.05 Method C 100 Methods O1, Q 580

477.96  1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.51 (s, 1H), 8.73-8.61 (m, 2H), 8.45 (d, J = 8.6 Hz, 1H), 8.28 (dd, J = 6.8, 2.5 Hz, 1H), 7.97-7.86 (m, 1H), 7.71 (s, 1H), 7.60- 7.47 (m, 3H), 3.63-3.51 (m, 4H), 2.82 (t, J = 7.5 Hz, 2H), 2.42-2.25 (m, 6H), DMSO   477.9 (M + 1) 1.99 Method C 100 Methods O1, P 581

523.12  1H NMR (300 MHz, CDCl3) δ 9.67 (d, J = 1.3 Hz, 1H), 8.76-8.66 (m, 2H), 8.03 (dd, J = 6.5, 2.7 Hz, 1H), 7.82- 7.74 (m, 2H), 7.64 (ddd, J = 8.9, 4.0, 2.7 Hz, 1H), 7.46 (s, 1H), 7.44- 7.37 (m, 2H), 7.20 (t, J = 8.7 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 2.95 CDCl3   523.1 (M + 1) 3.35 Method C 100 Methods O1, P 582

408.86  1H NMR (300 MHz, CD3OD) δ 9.50 (d, J = 1.3 Hz, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.62 (dd, J = 4.9, 1.6 Hz, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.18 (dd, J = 6.7, 2.6 Hz, 1H), 7.83-7.71 (m, 2H), 7.61- 7.47 (m, 2H), 7.30 (t, J = 9.0 Hz, 1H), 3.65 (t, J = 6.4 Hz CD3OD   409.0 (M + 1) 1.99 Method C 100 Methods O1, P, Q 583

494.03  1H NMR (300 MHz, CD3OD) δ 9.50-9.46 (m, 1H), 8.77-8.70 (m, 1H), 8.61 (dd, J = 4.9, 1.6 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.17 (dd, J = 6.8, 2.6 Hz, 1H), 7.75 (ddd, J = 9.0, 4.2, 2.7 Hz, 1H), 7.70 (s, 1H), 7.54 (ddd, J = 8.0, 4.9, 0.8 Hz, 1H), 7.46 (d CD3OD   494.0 (M + 1) 2.29 Method C  91 Method G4 584

522    1H NMR (300 MHz, DMSO) δ 10.15 (s, 1H), 8.74-8.61 (m, 2H), 8.25 (d, J = 3.5 Hz, 1H), 7.96-7.80 (m, 4H), 7.59-7.46 (m, 2H), 3.79 (s, 2H), 3.18 (s, 4H), 3.06 (s, 4H). DMSO   522.0 (M + 1) 2.18 Method C 100 Method O2 585

526.06  1H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.52 (d, J = 2.0 Hz, 1H), 8.72- 8.62 (m, 2H), 8.37 (s, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.96-7.88 (m, 1H), 7.83 (d, J = 2.6 Hz, 2H), 7.61-7.50 (m, 2H), 3.10 (s, J = 17.4 Hz, 6H), 2.95-2.80 (m, 8H), 2.58- DMSO   526.1 (M + 1) 2.11 Method C  91 Methods O2, P 586

HCl 494.82  1H NMR (300 MHz, DMSO) δ 10.49 (s, 1H), 9.50 (s, 1H), 8.96-8.53 (m, 5H), 8.25 (dd, J = 6.9, 2.5 Hz, 1H), 8.05-7.73 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 3.02-2.78 (m, 4H), 2.64- 2.37 (m, 3H), 2.15-1.99 (m, 2H). DMSO 422 (M + 1) 1.64 Method B (Ammon- ium formate) 100 Method O2 587

HCl 480.79  1H NMR (300 MHz, DMSO) δ 10.61 (s, 1H), 9.50 (s, 1H), 9.00-8.78 (m, 2H), 8.66 (s, 1H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 8.13-7.75 (m, 7H), 7.54 (t, J = 9.1 Hz, 1H), 3.02-2.73 (m, 4H), 2.14- 1.94 (m, 2H). DMSO 408 (M + 1) 1.60 Method B (Ammon- ium formate) 100 Method O2 588

431.89  1H NMR (300 MHz, DMSO) δ 10.18 (s, 1H), 8.65 (d, J = 6.6 Hz, 1H), 8.56 (d, J = 8.7 Hz, 1H), 8.23 (dd, J = 6.9, 2.4 Hz, 1H), 8.01 (s, 1H), 7.91 (dd, J = 7.0, 3.5 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.68-7.39 (m, 3H), 4.07 (s, 2H), 2.67 (s, 6H). DMSO   431.9 (M + 1) Method C  99 Method O1 589

435.92  1H NMR (300 MHz, DMSO) δ 10.06 (s, 1H), 9.53 (s, 1H), 8.76-8.62 (m, 2H), 8.51 (d, J = 8.4 Hz, 1H), 8.28 (dd, J = 6.9, 2.5 Hz, 1H), 7.92 (dd, J = 4.5, 1.8 Hz, 1H), 7.79 (s, 1H), 7.65-7.49 (m, 3H), 3.08- 2.95 (m, 2H), 2.86 (t, J = 7.6 Hz, 2H), 2.71 (s, J = 7.2 Hz, 6H), 2.05 (dt, J = 13.8, 7.1 Hz, 2H). DMSO   436.0 (M + 1) Method C  99 Method O1, P 590

409.44  1H NMR (300 MHz, DMSO): δ 13.19 (s, 1H), 9.11 (s, 1H), 8.88 (s, 1H), 8.53 (s, 1H), 8.29 (s, 1H), 8.06 (s, 1H), 7.94 (d, J = 10.6 Hz, 4H), 7.78 (s, 1H), 7.25 (s, 1H), 4.44 (s, 2H), 3.37 (s, 3H). DMSO   410.5 (M + 1) Method C  95 Method O1 591

413.47  DMSO   415.5 (M + 1) Method C  95 Method O1, P

Method N1: Pd(APhos)₂Cl₂/K₃PO₄ or Cs₂CO₃/Boronic acid or ester/Dioxane—H₂O, heat Method N2: Pd(PPh₃)₂Cl₂/K₂CO₃/Boronic acid or ester/DME-EtOH—H₂O/microwave, 120° C.

Method N3: Pd(OAc)₂/Xphos/Cs₂CO₃/THF—H₂O, 80° C.

Method N4: Pd(OAc)₂/Sphos/K₂CO₃/MeCN—H₂O, microwave, 120° C. Method N5: Pd(PPh₃)₄/K₃PO₄/Dioxane—H₂O, heat Method N6: Pd(dppf)Cl₂—CH₂Cl₂/K₃PO₄/Dioxane—H₂O, heat

N-(3-chloro-4-fluorophenyl)-6-(6-methoxypyridin-3-yl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-a)

A 2.0 dram reaction vial was charged with 6-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol, 1.0 equiv), 6-methoxypyridin-3-ylboronic acid (44.5 mg, 0.291 mmol, 1.25 equiv), Pd(APhos)₂Cl₂ (6.6 mg, 0.0093 mmol, 4 mol %) and potassium phosphate monohydrate (69 mg, 0.70 mmol, 3.0 equiv). The mixture was suspended in dioxane/water (9:1, 4 mL), and the reaction was heated at 90° C. for 14 h. The reaction mixture was cooled to room temperature, diluted with water (15 mL) and the resultant precipitate was collected by filtration. The crude product was purified by stirring in methanol for 30 min at 60° C. to give the desired product as a pale yellow solid (58 mg, 54%) LCMS m/z=458.1 (M+1) (Method C) (retention time=2.56 min). ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (s, 1H), 8.82 (s, 1H), 8.70 (dd, J=16.9, 5.4 Hz, 3H), 8.25 (d, J=8.6 Hz, 3H), 8.01-7.87 (m, 2H), 7.57 (dd, J=11.2, 6.0 Hz, 2H), 7.03 (d, J=8.6 Hz, 1H), 3.94 (s, 3H).

N-(3-chloro-4-fluorophenyl)-7-(6-methoxypyridin-3-yl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-b)

A microwave vial was charged with 7-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 4-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol), 6-methoxypyridin-3-ylboronic acid (44.5 mg, 0.291 mmol, 1.25 equiv), Pd(PPh₃)₂Cl₂ (8.1 mg, 5 mol %) and potassium carbonate (160.1 mg, 1.16 mmol, 5.0 equiv). The mixture was suspended in DME/water/ethanol (7:3:2, 4 mL), and the reaction was heated under microwave irradiation conditions at 120° C. for 10 minutes. The crude reaction mixture was diluted with water (10 mL) and then filtered. The solid residue was dissolved in methanol/THF (1:1, 5 mL) with heating and then filtered through Celite to remove the catalyst. The resulting filtrate was concentrated to afford the desired product as a tan solid (7.0 mg, 6.5%). LCMS m/z=458.1 (M+1) (Method C) (retention time=2.51 min). ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.76 (d, J=2.5 Hz, 1H), 8.72-8.65 (m, 2H), 8.62 (d, J=8.6 Hz, 1H), 8.34-8.26 (m, 2H), 8.15 (d, J=1.6 Hz, 1H), 8.02 (d, J=8.7 Hz, 1H), 7.97-7.88 (m, 1H), 7.61-7.49 (m, 2H), 6.99 (d, J=8.7 Hz, 1H), 3.94 (s, 3H).

N-(3-chloro-4-fluorophenyl)-7-(piperidin-1-ylmethyl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-c)

A dry 15 mL sealed tube was charged with 7-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 4-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol), potassium 1-trifluoroboratomethylpiperidine (52.5 mg, 0.256 mmol), cesium carbonate (227.5 mg, 0.698 mmol), Pd(OAc)₂ (1.6 mg, 3 mol %) and XPhos (6.7 mmol, 6 mol %) in THF/water (10:1, 3.3 mL). The reaction mixture was stirred at 80° C. for 16 hours. The reaction mixture was filtered through a pad of Celite and solvent was removed in vacuo. The crude product was purified by ISCO (silica, 12 g column, 97% dichloromethane—3% methanol—0.1% NH₄OH) to yield the desired compound as a yellow solid (23.3 mg, 22%). LCMS m/z=448.0 (M+1) (Method C) (retention time=1.95 min). ¹H NMR (300 MHz, CD₃OD) δ 9.40 (d, J=1.4 Hz, 1H), 8.70-8.62 (m, 1H), 8.56 (dd, J=4.9, 1.6 Hz, 1H), 8.18-8.09 (m, 2H), 7.69 (ddd, J=6.8, 4.1, 2.1 Hz, 2H), 7.54-7.45 (m, 2H), 7.23 (t, J=9.0 Hz, 1H), 3.61 (s, 2H), 2.47 (s, 4H), 1.64 (dd, J=13.9, 8.9 Hz, 5H), 1.49 (d, J=4.1 Hz, 2H).

N-(3-chloro-4-fluorophenyl)-6-(3-chlorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (xxi-d)

A mixture of N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (1.0 g, 2.10 mmol), 3-chlorophenylboronic acid (0.49 g, 3.13 mmol), Pd(PPh₃)₄ (0.24 g, 0.210 mmol), K₃PO₄ (1.34 g, 6.31 mmol) in dioxane (20 mL) and water (2.0 mL) was stirred under reflux for 2 h. Ethyl acetate (20 mL) was added to the cooled mixture and filtered. The filtered solid was recrystallized from DMF and water to give the title compound (0.50 g, 51.6%). ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.87 (s, 1H), 8.74-8.65 (m, 2H), 8.31-8.23 (m, 2H), 8.04-7.85 (m, 4H), 7.64-7.49 (m, 4H).

2-(7-(3-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide dihydrochloride (xxi-e)

A mixture of 2-(7-bromo-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (0.40 g, 0.952 mmol), 3-fluorophenylboronic acid (0.20 g 1.43 mmol), Pd(dppf)₂Cl₂(77 mg, 0.094 mmol), K₃PO₄ (606 mg, 2.85 mmol) in dioxane (8 mL) and water (2 mL) was refluxed under argon atmosphere for 4 h and cooled. Ethyl acetate (10 mL) was added to the mixture and a precipitate formed and was filtered. The filtered solid was recrystallized from DMF and water to give the title compound as free form. The solid as free form was suspended in ethyl acetate (10 mL) and 4N HCl in ethyl acetate (0.71 mL) was added to the suspension. A precipitate formed and was subjected to sonication for 20 min, filtered and dried to give the title compound (0.24 g, 49.6%). ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.64 (s, 1H), 9.21-9.08 (m, 1H), 9.07-8.89 (m, 2H), 8.51 (s, 1H), 8.38-8.26 (m, 2H), 8.16 (d, J=8.5 Hz, 1H), 8.07-7.87 (m, 3H), 7.83-7.70 (m, 3H), 7.62 (dd, J=14.2, 7.7 Hz, 1H), 7.40-7.22 (m, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 11 substituting with appropriate boronic acid/ester or boronate salt, catalyst and solvent

TABLE 4 Salt Molecular ¹H-NMR Retention LCMS Purity Method for Number PRODUCT type Mass ¹H-NMR Solvent LCMS Time (min) Protocol percent Coupling 592

2 HCl 536.401 ¹H NMR (300 MHz, DMSO) δ 11.34 (s, 1H), 10.53 (s. 1H), 9.56 (s, 1H), 9.17- 8.95 (m, 2H), 8.89 (d, J = 4.5 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H). 8.08-7.81 (m, 4H), 7.62-6.98 (m, 3H), 4.53 (s, 2H), 4.05-3.74 (m, 4H), 3.48-3.07 (m, 4H). DMSO 464 (M + 1) 2.01 Method C 100 Method N3 593

HCl 515.406 ¹H NMR (300 MHz, DMSO) δ 10.40 (s, 1H), 9.51 (s, 1H), 9.00-8.78 (m, 2H), 8.55 (s, 1 H), 8.20 (d, J = 4.4 Hz, 1H), 8.03- 7.75 (m, 4H), 7.54 (t, J = 9.1 Hz, 1H), 4.68 (s, 2H), 3.83 (d, J = 11.2 Hz, 2H), 3.44-3.18 (m, 4H), 1.98-1.78 (m, 1H), 1.62 (d, J DMSO 479 (M + 1) 2.08 Method D 97 Method N3 594

448.920 ¹H NMR (300 MHz, DMSO) δ 10.10 (s, 1H, 9.51 (s, 1 H), 8.75-8.60 (m, 2H), 8.47 (s, 1H), 8.32-8.19 (m, 1H), 7.97- 7.77 (m, 3H), 7.63-7.44 (m, 2H), 4.62 (s, 2H), 4.16-3.97 (m, 1H), 1.88-1.42 (m, 8H). DMSO 449 (M + 1) 2.62 Method D 92 Method N3 595

457.89 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (s, 1H), 8.82 (s, 1H), 8.70 (dd, J = 16.9, 5.4 Hz, 3H), 8.25 (d, J = 8.6 Hz, 3H), 8.01-7.87 (m, 2H), 7.57 (dd, J = 11.2, 6.0 Hz, 2H), 7.03 (d, J = 8.6 Hz, 1H), 3.94 (s, 3H). DMSO 458.2 (M + 1) 2.56 Method C 100 Method N1 596

449.91 ¹H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.52 (s, 1H), 8.67 (d, J = 9.8 Hz, 2H), 8.47 (s, 1H), 8.34-8.20 (m, 1H), 8.02- 7.84 (m, 3H), 7.54 (t, J = 9.2 Hz, 2H), 3.64 (d, J = 17.6 Hz, 6H), 2.43 (s, 4H). DMSO 449.9 (M + 1) 2.13 Method C 100 Method N3 597

456.9 DMSO 456.0 (M + 1) 2.64 Method C 100 Method N1 598

445.88 ¹H NMR (300 MHz, DMSO) δ 10.04 (s, 1H), 9.52 (s, 1H), 8.68 (t, J = 6.5 Hz, 2H), 8.51 (s, 1 H), 8.22 (dd, J = 6.7, 2.4 Hz, 1H), 8.03-7.83 (m, 3H), 7.54 (dd, J = 11.9, 6.6 Hz, 2H), 2.50 (s, 3H), 2.33 (s, 3H). DMSO 446 (M + 1) 2.35 Method C 100 Method N1 599

427.86 ¹H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 9.51 (s, 1H), 9.13 (s, 1H), 8.86 (s, 1H), 8.66 (s, 3H), 8.24 (s, 3H), 7.94 (d, J = 8.7 Hz, 2H), 7.55 (dd, J = 16.7, 9.9 Hz, 3H). DMSO 427.95 (M + 1) 2.25 Method C 100 Method N1 600

430.86 ¹H NMR (300 MHz, DMSO) δ 9.98 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.66 (dd, J = 11.7, 2.2 Hz, 3H), 8.38-8.20 (m, 2H), 8.20-8.02 (m, 2H), 8.02-7.80 (m, 2H), 7.71-7.42 (m, 2H), 3.93 (s, 3H). DMSO 430.9 (M + 1) 2.17 Method C 100 Method N1 601

449.91 ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.77- 8.55 (m, 2H), 8.41 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.03-7.77 (m, 3H), 7.65-7.44 (m, 2H), 3.34 (s, 8H), 3.15-2.90 (m, 5H), 2.90-2.64 (m, 5H). DMSO 449.9 (M + 1) 2.04 Method C 100 Method N1 602

445.85 ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.50 (s, 1 H). 8.88-8.74 (m, 2H), 8.66 (dd, J = 14.1, 5.5 Hz, 2H), 8.56- 8.42 (m, 1H), 8.23 (dd, J = 10.0, 5.7 Hz, 2H), 7.98-7.85 (m, 2H), 7.62-7.46 (m, 2H), 7.45-7.36 (m, 1H). DMSO 445.9 (M + 1) 2.43 Method C 99 Method N1 603

512.97 ¹H NMR (300 MHz, DMSO) δ 10.05 (s, 1H), 9.51 (s, 1H), 8.70 (dd, J = 24.1, 7.0 Hz, 4H), 8.22 (dd, J = 14.3, 7.3 Hz, 2H), 8.10 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.4 Hz, 2H), 7.00 (d, J = 8.8 Hz, 1H), 3.74 (s, 4H), 3.55 (d, J = 4.7 DMSO 512.9 (M + 1) 2.5 Method C 100 Method N1 604

456.9 ¹H NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 9.53 (s, 1H), 8.81 (s, 1H), 8.73-8.60 (m, 2H), 8.30-8.20 (m, 2H), 7.99-7.89 (m, 2H), 7.55 (dd, J = 8.2, 4.7 Hz, 2H), 7.46 (t, J = 7.6 Hz, 3H), 7.10-6.96 (m, 1H), 3.88 (s, 3H). DMSO 458.9 (M + 2) 2.65 Method C 100 Method N1 605

486.92 ¹H NMR (300 MHz, DMSO) δ 10.16 (s, 1H), 9.54 (s, 1H), 8.79 (d, J = 9.7 Hz, 1 H), 8.71 (s, 2H), 8.26 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 8.7, 3.7 Hz, 2H), 7.56 (dd, J = 11.7, 6.4 Hz, 1H), 7.43 (d, J = 15.2 Hz, 2H), 7.22-7.06 (m, 2H), 3.92 (s, 3H), 3.84 (s, DMSO 486.9 (M + 1) 2.48 Method C 100 Method N1 606

486.92 DMSO 487.1 (M + 1) 2.58 Method C 100 Method N1 607

390.84 DMSO 390.9 (M + 1) 2.48 Method C 100 Method N1 608

539.99 ¹H NMR (300 MHz, DMSO) δ 10.15 (s, 1H), 9.51 (s. 1H), 8.84 (s, 1H), 8.66 (dd, J = 9.7, 6.5 Hz, 2H), 8.29-8.19 (m, 2H), 7.92 (ddd, J = 8.9, 7.5, 4.6 Hz, 4H), 7.65 - 7.48 (m, 4H), 3.64 (s, 6H), 3.35 (s, 2H). DMSO 539.9 (M + 1) 2.23 Method C 100 Method N1 609

526 526.16 (M + 1) 2.55 Method C 94 Method N1 610

471.91 ¹H NMR (300 MHz, DMSO) δ 10.03 (s, 1H), 9.56 (d, J = 2.1 Hz, 1H), 8.77-8.66 (m, 3H), 8.64 (s, 1H), 8.24 (ddd, J = 8.7, 6.6, 2.6 Hz, 2H), 8.13 (s, 1 H), 7.96-7.90 (m, 1H), 7.62-7.52 (m, 2H), 7.01 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H), 2.78 (s, 3H). CDCl₃ 471.9 (M + 1) 2.93 Method C 100 Method N1 611

474.34 ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.53 (s, 1H), 8.77 (s, 1H), 8.67 (dd, J = 12.3, 4.1 Hz, 3H), 8.35 (d, J = 2.3 Hz, 1H), 8.27-8.13 (m, 2H), 8.02-7.88 (m, 2H), 7.72 (d, J = 8.8 Hz, 1H), 7.55 (dd, J = 7.7, 4.6 Hz, 1H), 7.00 (d, J = 8.6 Hz, 1H), 3. DMSO 474.02 (M + 1) 2.72 Method C 100 Method N1 612

442.88 DMSO 443.1 (M + 1) 2.37 Method C 100 Method N1 613

465.91 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.54 (s, 1H), 8.75-8.63 (m, 3H), 8.20 (dd, J = 8.2, 5.6 Hz, 2H), 8.09 (d, J = 8.5 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H), 7.88 (s, 1H), 7.55 (d, J = 9.1 Hz, 2H), 2.76 (s, 3H). DMSO 466.1 (M + 1) 2.78 Method C 100 Method N1 614

457.89 ¹H NMR (300 MHz, DMSO) D 10.18 (s, 1H), 9.51 (s, 1H), 8.92 (s, 1H), 8.67 (dd, J = 12.7, 5.8 Hz, 2H), 8.39-8.16 (m, 3H), 7.91 (dd, J = 14.8, 5.7 Hz, 2H), 7.65-7.45 (m, 3H), 7.35 (s, 1H), 3.94 (s, 3H). DMSO 458.1 (M + 1) 2.62 Method C 100 Method N1 615

514.93 ¹H NMR (300 MHz, DMSO) d 10.19 (s, 1H), 9.52(s, 1H), 8.86 (s, 1H), 8.67 (dd, J = 7.7, 2.1 Hz, 2H), 8.06-7.75 (m, 2H), 7.54 (dd, J = 9.0, 4.1 Hz, 4H), 3.99 (s, 3H), 3.82 (s, 3H) DMSO 515.1 (M + 1) 2.54 Method C 100 Method N1 616

451.88 1H NMR (300 MHz, DMSO) d 10.16 (s, 1H), 9.50 (s, 1H), 8.86 (s, 1H), 8.66 (dd, J = 15.2, 6.9 Hz, 2H), 8.35-8.16 (m, 2H), 8.15-7.82 (m, 6H), 7.55 (dd, 11.1, 6.0 Hz, 2H). DMSO 452.0 (M + 1) 2.61 Method C 96 Method N1 617

436.47 437.2 (M + 1) 2.08 Method C 95 Method N1 618

421.45 422.2 (M + 1) 1.8 Method C 100 Method N1 619

449.91 ¹H NMR (300 MHz, DMSO) δ 10.06 (s, 1H). 9.52 (d, J = 1.3 Hz, 1H), 8.73-8.64 (m, 2H), 8.51 (d, J = 8.5 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 7.96-7.86 (m, 1H), 7.82 (s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.57 (t, J = 3.9 Hz, 1H), 7.52 (t, J = 9.1 Hz, 1H), 3.69 (s, 2H), 3.62 (s, 4H), 2.44 (s, 4H). DMSO 449.9 (M + 1) 2.13 Method C 100 Method N3 620

457.89 ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.76 (d, J = 2.5 Hz, 1H), 8.72-8.65 (m, 2H), 8.62 (d, J = 8.6 Hz, 1H), 8.34-8.26 (m, 2H), 8.15 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.97- 7.88 (m, 1H), 7.61-7.49 (m, 2H), 6.99 (d, J = 8.7 Hz, 1H), 3.94 (s, 3H). DMSO 458.1 (M + 1) 2.51 Method C 100 Method N2 621

462.95 ¹H NMR (300 MHz, CD₃OD) δ 9.40 (s, 1H), 8.66 (d, J = 8.0 Hz, 1 H), 8.56 (s, 1H), 8.19-8.09 (m, 2H), 7.74 (s, 1H), 7.72- 7.65 (m, 1H), 7.54-7.45 (m, 2H), 7.24 (t, J = 9.0 Hz, 1H), 3.68 (d, J = 8.0 Hz, 2H), 2.75-2.41 (m, 8H), 2.30 (s, 3H). CD₃OD 463.0 (M + 1) 1.71 Method C 100 Method N3 622

433.91 434.0 (M + 1) 1.73 Method C 100 Method N3 623

435.92 436.0 (M + 1) 1.84 Method C 100 Method N3 624

430.865 ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.72-8.60 (m, 2H), 8.49 (d, J = 8.6 Hz, 1H), 8.44 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (s, 1H), 8.03 (d, J = 1.5 Hz, 1H), 7.95- 7.83 (m, 2H), 7.60-7.45 (m, 2H), 3.91 (s, 3H). DMSO 431.0 (M + 1) 2.12 Method C 100 Method N2 625

465.97 ¹H NMR (300 MHz, CD₃OD) δ 9.56-9.50 (m, 1H), 8.79 (dt, J = 8.1, 1.6 Hz, 1H), 8.63 (dd, J = 4.9, 1.7 Hz, 1H), 8.30 (s, 1H), 8.19 (dd, J = 6.7, 2.6 Hz, 1H), 7.91 (d, J = 1.1 Hz, 2H), 7.80 (ddd, J = 9.0, 4.2, 2.7 Hz, 1H), 7.58 (dd, J = 8.0, 4.9 Hz, 1H), 7.33 (t, J = 9.0 Hz, 1H), 3.75 (s, 2H), 2.84- 2.66 (m, 8H). CD₃OD 466.0 (M + 1) 2.46 Method C 94 Method N3 626

491.94 ¹H NMR (300 MHz, DMSO) δ 10.00 (s, 1H), 9.52 (s, 1H), 8.73-8.63 (m, 2H), 8.42 (s, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 7.92 (ddd, J = 6.8, 4.2, 2.0 Hz, 1H), 7.85 (s, 2H), 7.60-7.50 (m, 2H), 3.56- 3.43 (m, 9H), 3.07 (t, J = 7.6 Hz, 2H), 2.79 (t, J = 7.7 Hz, 2H). DMSO 491.9 (M + 1) 2 Method C 93 Method N1 627

463.93 ¹H NMR (300 MHz, DMSO) δ 9.99 (s, 1H), 9.54 (s, 1 H), 8.67 (d, J = 5.3 Hz, 2H), 8.30- 8.22 (m, 2H), 7.96-7.87 (m, 1H), 7.73 (s, 1H), 7.60-7.46 (m, 2H), 3.60 (s, 6H), 2.71 (s, 3H), 2.41 (s, 4H). DMSO 464.0 (M + 1) 2.52 Method C 100 Method N3 628

419.43 ¹H NMR (300 MHz, DMSO) δ 9.41 (d, J = 1.4 Hz, 1H), 9.15 (d, J = 1.7 Hz, 1H), 8.74- 8.64 (m, 3H), 8.55 (dt, J = 7.9, 1.8 Hz, 1H), 8.42 (dd, J = 8.7, 2.0 Hz, 1H), 8.36- 8.29 (m, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.90 (dd, J = 7.8, 1.7 Hz, 1 H), 7.61 (dd, J = 8.0, 4.8 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.93 (d, J = 7.7 Hz, 1 H). DMSO 420.1 (M + 1) 2.12 Method C 99 Method N4

¹H Purity Method Num- Starting Starting Salt NMR Per- of ber Material 1 Material 2 Product type ¹H NMR Solvent cent Coupling 629

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.87 (s, 1H), 8.74- 8.65 (m, 2H), 8.31- 8.23 (m, 2H), 8.04-7.85 (m, 4H), 7.64-7.49 (m, 4H). DMSO >98 N5 630

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (d, J = 1.4 Hz, 1H), 8.86 (s, 1H), 8.76-8.64 (m, 2H), 8.26 (dd, J = 6.8, 2.3 Hz, 2H), 8.03-7.89 (m, 4H), 7.70-7.52 (m, 4H). DMSO >98 N5 631

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (d, J = 1.4 Hz, 1H), 8.86 (s, 1H), 8.76-8.64 (m, 2H), 8.26 (dd, J = 6.8, 2.3 Hz, 2H), 8.03-7.89 (m, 4H), 7.70-7.52 (m, 4H). DMSO >98 N5 632

¹H NMR (400 MHz, DMSO) δ 10.22- 10.11 (m, 1H), 9.54 (s, 1H), 8.86- 8.77 (m, 1H), 8.74- 8.65 (m, 2H), 8.30-8.17 (m, 2H), 8.01-7.90 (m, 2H), 7.74-7.66 (m, 2H), 7.60-7.51 (m, 2H), 7.51-7.42 (m, 1H), 7.28 (d, J = 7.5 Hz, 1H), 2.45 (s, 3H). DMSO >98 N5 633

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.61-9.53 (m, 1H), 8.92 (s, 1H), 8.78-8.67 (m, 2H), 8.43-8.24 (m, 3H), 8.14-7.89 (m, 3H), 7.84-7.76 (m, 1H), 7.66-7.53 (m, 2H) DMSO >98 N5 634

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.89 (s, 1H), 8.75-8.67 (m, 2H), 8.35-8.22 (m, 2H), 8.00 (d, J = 8.7 Hz, 1H), 7.96- 7.90 (m, 1H), 7.84- 7.75 (m, 2H), 7.66-7.52 (m, 3H), 7.34-7.27 (m, 1H). DMSO >98 N5 635

¹H NMR (400 MHz, DMSO) δ 10.27 (s, 1H), 9.54 (d, J = 1.2 Hz, 1H), 8.94 (s, 1H), 8.77-8.66 (m, 3H), 8.40-8.21 (m, 4H), 7.99 (d, J = 8.9 Hz, 1H), 7.88 (t, J = 8.0 Hz, 2H), 7.61-7.50 (m, 2H). DMSO >98 N5 636

¹H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 9.56 (s, 1H), 8.77- 8.68 (m, 2H), 8.65 (s, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.04-7.97 (m, 2H), 7.96-7.88 (m, 1H), 7.70-7.43 (m, 6H). DMSO >98 N5 637

¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.56 (s, 1H), 8.76-8.68 (m, 2H), 8.63 (s, 1H), 8.28 (dd, J = 6.7, 2.7 Hz, 1H), 8.05 (dd, J = 8.7, 1.8 Hz, 1H), 8.00-7.90 (m, 2H), 7.70-7.43 (m, 4H), 7.21 (d, J = 8.1 Hz, 1H), 7.14 (t, J = 7.4 Hz, 1H), 3.82 (s, 3H). DMSO >98 N5 638

¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.54 (s, 1H), 8.81 (s, 1H), 8.74- 8.64 (m, 2H), 8.30- 8.17 (m, 2H), 8.01-7.87 (m, 4H), 7.61-7.51 (m, 2H), 7.42 (t, J = 8.8 Hz, 2H). DMSO >98 N5 639

1H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.57 (s, 1H), 8.80 (d, J = 1.8 Hz, 1H), 8.76-8.69 (m, 2H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.14 (dd, J = 8.6, 1.8 Hz, 1H), 8.10-8.02 (m, 2H), 7.97- 7.88 (m, 2H), 7.83 (d, J = 6.8 Hz, 1H), 7.70 (td, J = 7.6, 1.2 Hz, 1H), 7.63- DMSO >98 N5 7.52 (m, 2H). 640

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (s, 1H), 8.77-8.66 (m, 2H), 8.62 (s, 1H), 8.25 (dd, J = 6.8, 2.3 Hz, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.99- 7.80 (m, 4H), 7.80- 7.71 (m, 2H), 7.61-7.49 (m, 2H). DMSO >98 N5 641

¹H NMR (400 MHz, DMSO) δ 9.57 (s, 1H), 8.85-8.55 (m, 3H), 8.20-7.95 (m, 3H), 7.85-7.20 (m, 7H) DMSO >98 N5 642

¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.83 (s, 1H), 8.74-8.66 (m, 2H), 8.32-8.23 (m, 2H), 8.02-7.89 (m, 2H), 7.61- 7.53 (m, 2H), 7.05 (d, J = 2.2 Hz, 2H), 6.62 (t, J = 2.1 Hz, 1H), 3.88 (s, 6H). DMSO >98 N5 643

¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.55 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 1.7 Hz, 1H), 8.74-8.65 (m, 2H), 8.31-8.20 (m, 2H), 8.04-7.88 (m, 2H), 7.65-7.53 (m, 2H), 7.42-7.34 (m, 1H), 7.23-7.09 (m, 2H), 6.83 (dd, J = 8.3, 1.9 Hz, 1H), 3.02 (s, 6H). DMSO >98 N5 644

1H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.55 (s, 1H), 8.77-8.68 (m, 2H), 8.65 (d, J = 1.5 Hz, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.05 (dd, J = 8.6, 1.7 Hz, 1H), 8.01-7.90 (m, 2H), 7.60- 7.51 (m, 2H), 7.29- 7.21 (m, 1H), 7.18 (dd, J = 8.3, 1.6 Hz, 1H), 7.12 DMSO >98 N5 (dd, J = 7.6, 1.6 Hz, 1H), 3.89 (s, 3H), 3.58 (s, 3H). 645

1H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (s, 1H), 8.74-8.67 (m, 2H), 8.64 (s, 1H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.06 (dd, J = 8.6, 1.7 Hz, 1H), 7.98-7.89 (m, 2H), 7.62-7.51 (m, 2H), 7.14 (d, J = 9.0 Hz, 1H), 7.09 (d, J = 3.1 Hz, 1H), 7.02 (dd, J = 8.9, 3.1 DMSO >98 N5 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H). 646

¹H NMR (400 MHz, DMSO) δ 9.99 (s, 1H), 9.56 (d, J = 0.9 Hz, 1H), 8.71 (dd, J = 7.1, 1.6 Hz, 2H), 8.46 (d, J = 1.5 Hz, 1H), 8.29 (dd, J = 6.9, 2.6 Hz, 1H), 8.00-7.87 (m, 2H), 7.73 (dd, J = 8.5, 1.7 Hz, 1H), 7.63- 7.47 (m, 2H), 7.41 (t, J = 8.4 Hz, 1H), 6.84 (d, J = 8.5 Hz, DMSO >98 N5 2H), 3.77-3.66 (m, 6H). 647

¹H NMR (400 MHz, DMSO) δ 10.06- 9.96 (m, 1H), 9.52 (s, 1H), 8.75-8.62 (m, 3H), 8.40-8.33 (m, 1H), 8.28- 8.22 (m, 1H), 8.22- 8.14 (m, 1H), 7.97-7.85 (m, 3H), 7.64-7.49 (m, 2H), 7.16 (s, 1H). DMSO >98 N5 648

¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.54 (s, 1H), 8.85 (s, 1H), 8.77- 8.65 (m, 2H), 8.32 (d, J = 8.7 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.12 (s, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.86- 7.76 (m, 2H), 7.64- 7.54 (m, 2H). DMSO >98 N5 649

1H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.53 (s, 1H), 8.78 (s, 1H), 8.71- 8.64 (m, 2H), 8.26- 8.19 (m, 2H), 7.95-7.90 (m, 2H), 7.77-7.69 (m, 2H), 7.60-7.53 (m, 2H), 7.26 (t, J = 3.7 Hz, 1H). DMSO >98 N5 650

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (d, J = 2.2 Hz, 1H), 8.75- 8.67 (m, 3H), 8.33- 8.23 (m, 2H), 8.13 (dd, J = 8.7, 1.8 Hz, 1H), 8.00- 7.90 (m, 3H), 7.63- 7.51 (m, 2H), 7.22 (dd, J = 7.3, 5.0 Hz, 1H), 3.95 (s, 3H). DMSO >98 N5 651

¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.53 (s, 1H), 8.97 (s, 1H), 8.75 (d, J = 5.5 Hz, 2H), 8.73-8.64 (m, 2H), 8.38-8.30 (m, 1H), 8.24 (d, J = 6.8 Hz, 1H), 8.05- 7.97 (m, 1H), 7.97- 7.88 (m, 3H), 7.63- 7.51 (m, 2H). DMSO >98 N5 652

1H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.50 (s, 1H), 9.33 (s, 2H), 9.26 (s, 1H), 8.90 (s, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.22 (dd, J = 6.7, 2.0 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.93- 7.86 (m, 1H), 7.61-7.48 (m, 2H). DMSO >98 N5 653

¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.77- 8.67 (m, 2H), 8.61 (s, 1H), 8.26 (dd, J = 6.9, 2.6 Hz, 1H), 8.12 (dd, J = 8.7, 1.8 Hz, 1H), 8.01- 7.89 (m, 3H), 7.62- 7.51 (m, 2H), 4.02 (s, 3H), 4.00 (s, 3H). DMSO >98 N5 654

¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (s, 1H), 8.77-8.68 (m, 2H), 8.65 (d, J = 1.6 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 8.17 (dd, J = 8.7, 1.7 Hz, 1H), 7.99-7.88 (m, 2H), 7.61- 7.50 (m, 2H), 7.42- 7.33 (m, 2H), 7.21-7.08 (m, 2H), 2.53 (s, 6H). DMSO >98 N5 655

¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.55 (s, 1H), 8.74-8.66 (m, 2H), 8.63 (s, 1H), 8.26 (dd, J = 6.8, 2.5 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.97- 7.88 (m, 3H), 7.62- 7.51 (m, 2H), 6.61 (d, J = 8.1 Hz, 1H), 3.97 (s, 3H), 3.96 (s, 3H). DMSO >98 N5 656

¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.91 (s, 1H), 8.76-8.65 (m, 2H), 8.31 (d, J = 8.8 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.15-7.89 (m, 7H), 7.61-7.52 (m, 2H), 7.46 (s, 1H). DMSO >98 N5 657

¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.54 (d, J = 2.0 Hz, 1H), 8.91 (s, 1H), 8.76-8.65 (m, 2H), 8.31 (d, J = 8.8 Hz, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.15-7.89 (m, 7H), 7.61-7.52 (m, 2H), 7.46 (s, 1H). DMSO >98 N5 658

¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.54 (s, 1H), 8.88 (s, 1H), 8.79- 8.61 (m, 2H), 8.34- 8.22 (m, 2H), 8.05-7.84 (m, 4H), 7.72 (t, J = 8.0 Hz, 1H), 7.65-7.53 (m, 2H), 7.47 (d, J = 8.4 Hz, 1H). DMSO >98 N5 659

1H NMR (400 MHz, DMSO) δ 10.06 (s, 1H), 9.53 (s, 1H), 8.75 (s, 1H), 8.75- 8.66 (m, 3H), 8.28- 8.21 (m, 1H), 8.20 (dd, J = 7.7, 1.8 Hz, 1H), 8.06 (dd, J = 8.9, 2.5 Hz, 1H), 7.96-7.90 (m, 2H), 7.58-7.54 (m, 2H), 6.81 (d, J = 8.9 Hz, 1H), 3.11 (s, 6H). DMSO >98 N5 660

¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.54 (s, 1H), 8.91 (s, 1H), 8.76 (s, 1H), 8.74-8.66 (m, 2H), 8.39 (d, J = 2.7 Hz, 1H), 8.37- 8.30 (m, 1H), 8.26 (dd, J = 6.8, 2.6 Hz, 1H), 8.03-7.97 (m, 1H), 7.97-7.90 (m, 1H), 7.85 (d, J = 1.9 Hz, 1H), 7.62-7.52 (m, 2H), 3.98 (s, 3H). DMSO >98 N5 661

¹H NMR (400 MHz, DMSO) δ 10.06 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.76 (d, J = 19.6 Hz, 1H), 8.73-8.61 (m, 3H), 8.29-8.16 (m, 3H), 7.99-7.87 (m, 2H), 7.61-7.51 (m, 2H), 6.98 (d, J = 8.6 Hz, 1H), 4.39 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H). DMSO >98 N5 662

¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.53 (dd, J = 2.1, 0.7 Hz, 1H), 8.75 (d, J = 1.9 Hz, 1H), 8.73-8.64 (m, 2H), 8.25 (dd, J = 6.9, 2.6 Hz, 1H), 8.19 (dd, J = 8.7, 1.9 Hz, 1H), 7.97-7.89 (m, 2H), 7.61-7.50 (m, 3H), 7.41 (dd, J = 8.1, 1.9 Hz, 1H), DMSO >98 N5 7.11 (d, J = 8.1 Hz, 1H), 6.13 (s, 2H). 663

¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.54 (s, 1H), 8.85 (s, 1H), 8.76- 8.66 (m, 2H), 8.33- 8.22 (m, 2H), 8.00-7.89 (m, 2H), 7.62-7.52 (m, 3H), 7.43 (s, 1H), 7.14 (s, 1H), 3.91 (s, 3H). DMSO >98 N5 664

¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.52 (d, J = 1.3 Hz, 1H), 8.89- 8.81 (m, 1H), 8.73- 8.64 (m, 2H), 8.37-8.28 (m, 1H), 8.28-8.21 (m, 1H), 8.01-7.86 (m, 2H), 7.81-7.69 (m, 2H), 7.60- 7.51 (m, 2H), 7.33 (s, 1H), 3.97 (s, 3H). DMSO >98 N5 665

1H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.53 (d, J = 1.9 Hz, 1H), 8.89 (s, 1H), 8.73-8.61 (m, 2H), 8.57 (d, J = 4.5 Hz, 1H), 8.34- 8.18 (m, 2H), 8.09- 7.86 (m, 5H), 7.62- 7.49 (m, 2H), 2.88-2.80 (m, 4H). DMSO >98 N5 666

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.21 (s, 2H), 9.08-9.02 (m, 1H), 9.02-8.96 (m, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.39-8.30 (m, 1H), 8.25-8.18 (m, 1H), 8.07-7.87 (m, 3H), 7.56 (t, J = 9.1 Hz, 1H). DMSO >98 N5 667

HCl ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.53 (s, 1H), 9.16-9.02 (m, 2H), 8.99-8.88 (m, 1H), 8.66-8.55 (m, 1H), 8.38 (d, J = 8.2 Hz, 1H), 8.20 (d, J = 5.0 Hz, 1H), 8.04 (dt, J = 27.3, 13.6 Hz, 7H), 7.57 (t, J = 8.8 Hz, 1H), 2.84 (d, J = 3.8 Hz, 3H). DMSO >98 N5 668

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.53 (d, J = 1.5 Hz, 1H), 8.99- 8.83 (m, 3H), 8.34- 8.25 (m, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.98-7.91 (m, 1H), 7.86 (dd, J = 7.8, 5.2 Hz, 1H), 7.78- 7.70 (m, 2H), 7.57 (t, J = 9.1 Hz, 1H), DMSO >98 N5 7.47 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 7.5 Hz, 1H), 2.45 (s, 6H). 669

HCl ¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.81- 8.70 (m, 3H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 8.13-8.05 (m, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.97-7.89 (m, 1H), 7.64 (dd, J = 7.9, 4.9 Hz, 1H), 7.61- 7.49 (m, 2H), 7.37- 7.26 (m, 2H), DMSO >98 N5 2.41 (s, 3H). 670

HCl ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.09- 8.95 (m, 2H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.41-8.29 (m, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 8.01-7.88 (m, 2H), 7.56 (t, J = 9.1 Hz, 1H), 7.50-7.38 (m, 2H), DMSO >98 N5 7.32 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 2.23 (s, 3H). 671

HCl ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 9.09- 8.95 (m, 2H), 8.90 (dd, J = 5.2, 1.5 Hz, 1H), 8.41-8.29 (m, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 8.01-7.88 (m, 2H), 7.56 (t, J = 9.1 Hz, 1H), 7.50-7.38 (m, 2H), DMSO >98 N5 7.32 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 2.23 (s, 3H). 672

HCl ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.47 (d, J = 1.6 Hz, 1H), 9.04- 8.94 (m, 2H), 8.89 (dd, J = 5.3, 1.5 Hz, 1H), 8.26 (dd, J = 8.8, 1.9 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.09- 8.00 (m, 1H), 8.00- 7.87 (m, 3H), 7.86-7.77 (m, 1H), 7.68-7..57 (m, DMSO >98 N5 1H), 7.53 (t, J = 9.1 Hz, 1H). 673

HCl ¹H NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 9.53 (s, 1H), 9.17-9.04 (m, 1H), 9.04-8.93 (m, 2H), 8.34 (dd, J = 8.7, 1.7 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 8.05- 7.89 (m, 2H), 7.57 (t, J = 9.0 Hz, 1H), 7.53-7.44 (m, 3H), 7.09-6.98 (m, 1H), 4.82 (dt, J = DMSO >98 N5 11.7, 5.9 Hz, 1H), 1.33 (d, J = 6.0 Hz, 6H). 674

HCl ¹H NMR (400 MHz, DMSO) δ 10.60 (s, 1H), 9.50 (d, J = 1.7 Hz, 1H), 9.11- 9.02 (m, 1H), 8.99- 8.91 (m, 1H), 8.76 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 1.4 Hz, 1H), 8.19 (dd, J = 6.8, 2.6 Hz, 1H), 8.10-7.92 (m, 4H), 7.82-7.72 (m, 1H), 7.65-7.56 (m, 1H), 7.52 (t, DMSO >98 N5 J = 9.1 Hz, 1H). 675

HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.51 (d, J = 1.7 Hz, 1H), 9.07- 9.00 (m, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.75 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 1.7 Hz, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.10 (dd, J = 8.7, 1.9 Hz, 1H), 8.02-7.93 (m, 2H), 7.74-7.65 (m, 2H), 7.52 (t, J = 9.1 Hz, 1H), 7.40- DMSO >98 N5 7.31 (m, 1H). 676

HCl ¹H NMR (400 MHz, DMSO) δ 10.63 (s, 1H), 9.54 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.26- 8.14 (m, 2H), 8.08- 7.91 (m, 3H), 7.75-7.64 (m, 1H), 7.51 (ddd, J = 14.7, 14.2, 6.9 Hz, 2H), 7.44-7.34 DMSO >98 N5 677

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.60-9.49 (m, 1H), 9.37-9.31 (m, 1H), 8.99 (d, J = 8.3 Hz, 1H), 8.95- 8.81 (m, 3H), 8.75 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 1.7 Hz, 1H), 8.30- 8.18 (m, 2H), 8.04- 7.87 (m, 3H), 7.56 (t, J = 9.1 Hz, 1H). DMSO >98 N5 678

HCl ¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 9.38 (s, 2H), 9.30 (s, 1H), 9.00-8.92 (m, 1H), 8.92-8.86 (m, 1H), 8.76 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 1.7 Hz, 1H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 8.15 (dd, J = 8.6, 1.8 Hz, 1H), 7.99-7.85 (m, 2H), DMSO >98 N5 7.52 (t, J = 9.1 Hz, 1H). 679

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.58-9.49 (m, 1H), 9.21 (s, 2H), 9.09-8.98 (m, 1H), 8.92 (d, J = 3.8 Hz, 1H), 8.77 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.27-8.20 (m, 1H), 8.15 (dd, J = 8.7, 1.8 Hz, 1H), 8.03-7.89 (m, 2H), 7.55 (t, J = 9.1 DMSO >98 N5 Hz, 1H), 4.02 (s, 3H). 680

¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.56 (d, J = 1.3 Hz, 1H), 8.75- 8.67 (m, 2H), 8.60 (d, J = 8.7 Hz, 1H), 8.32 (dd, J = 6.9, 2.6 Hz, 1H), 8.10 (d, J = 1.6 Hz, 1H), 8.03-7.87 (m, 4H), 7.60-7.50 (m, 2H), 7.12 (d, J = 8.8 Hz, 2H), 3.85 (s, DMSO >98 N5 681

¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.55-9.46 (m, 1H), 8.69-8.60 (m, 2H), 8.56 (d, J = 8.7 Hz, 1H), 8.25 (dd, J = 6.9, 2.6 Hz, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.96 (dd, J = 8.7, 1.9 Hz, 1H), 7.91-7.85 (m, 1H), 7.55-7.35 (m, 5H), 7.03-6.95 (m, 1H), 3.83 (s, DMSO >98 N5 3H). 682

¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.55 (d, J = 1.9 Hz, 1H), 8.74- 8.67 (m, 2H), 8.57 (d, J = 8.7 Hz, 1H), 8.32 (dd, J = 6.9, 2.6 Hz, 1H), 8.00- 7.91 (m, 2H), 7.80 (dd, J = 8.6, 1.7 Hz, 1H), 7.60-7.41 (m, 4H), 7.21 (d, J = 7.8 Hz, 1H), 7.12 (td, J = 7.4, 0.9 Hz, 1H), 3.84 (s, 3H). DMSO >98 N5 683

¹H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 9.55 (s, 1H), 8.74-8.65 (m, 2H), 8.56 (d, J = 8.6 Hz, 1H), 8.35-8.26 (m, 1H), 7.99-7.89 (m, 2H), 7.81 (s, 1H), 7.70 (dd, J = 8.6, 1.6 Hz, 1H), 7.63-7.47 (m, 6H), 7.40 (s, 1H). DMSO >98 N5 684

¹H NMR (400 MHz, DMSO) δ 10.16 (s, 1H), 9.61-9.53 (m, 1H), 8.76-8.62 (m, 3H), 8.35-8.28 (m, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.16-7.99 (m, 6H), 7.99-7.92 (m, 1H), 7.63-7.51 (m, 2H), 7.45 (s, 1H). DMSO >98 N5 685

¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 8.78- 8.62 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.15-8.00 (m, 2H), 8.00- 7.80 (m, 5H), 7.74- 7.65 (m, 1H), 7.64-7.51 (m, 2H). DMSO >98 N5 686

¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.60-9.55 (m, 1H), 8.77-8.65 (m, 2H), 8.46 (s, 1H), 8.37-8.28 (m, 2H), 8.17-8.10 (m, 1H), 7.99-7.93 (m, 2H), 7.81-7.72 (m, 2H), 7.62- 7.50 (m, 3H). DMSO >98 N5 687

¹H NMR (400 MHz, DMSO) δ 10.18 (s, 1H), 9.56 (d, J = 2.2 Hz, 1H), 8.75- 8.61 (m, 3H), 8.32 (dd, J = 6.8, 2.6 Hz, 1H), 8.07 (s, 1H), 7.99-7.91 (m, 1H), 7.91-7.85 (m, 1H), 7.82-7.75 (m, 1H), 7.61-7.50 (m, 3H), 7.47- 7.36 (m, 2H). DMSO >98 N5 688

¹H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.60-9.53 (m, 1H), 8.74-8.61 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.20 (d, J = 1.8 Hz, 1H), 8.06 (dd, J = 8.7, 1.9 Hz, 1H), 7.99-7.90 (m, 1H), 7.86-7.77 (m, 2H), 7.65-7.48 (m, 3H), 7.37- 7.26 (m, 1H). DMSO >98 N5 689

¹H NMR (400 MHz, DMSO) δ 10.13 (s, 1H), 9.56 (d, J = 1.5 Hz, 1H), 8.75- 8.60 (m, 3H), 8.31 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.07- 7.88 (m, 4H), 7.65- 7.49 (m, 2H), 7.39 (t, J = 8.8 Hz, 2H). DMSO >98 N5 690

¹H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.76- 8.60 (m, 3H), 8.34- 8.25 (m, 1H), 8.21 (d, J = 1.7 Hz, 1H), 8.13 (d, J = 8.4 Hz, 2H), 8.10- 7.97 (m, 3H), 7.97- 7.87 (m, 1H), 7.62- 7.45 (m, 2H). DMSO >98 N5 691

HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.99- 8.91 (m, 1H), 8.91- 8.83 (m, 1H), 8.75 (d, J = 8.8 Hz, 1H), 8.42 (s, 1H), 8.31 (t, J = 3.2 Hz, 1H), 8.29-8.22 (m, 2H), 8.13 (dd, J = 8.7, 1.8 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H), 8.03- DMSO >98 N5 7.92 (m, 2H), 7.86 (dd, J = 8.0, 5.2 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.59- 7.46 (m, 2H). 692

HCl ¹H NMR (400 MHz, DMSO) δ 10.38 (s, 1H), 9.56 (d, J = 1.5 Hz, 1H), 8.93 (d, J = 8.2 Hz, 1H), 8.85 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.27 (dd, J = 6.8, 2.6 Hz, 1H), 8.21 (d, J = 1.7 Hz, 1H), 8.10 (dd, J = 8.7, 1.8 Hz, 1H), 8.01-7.90 (m, 3H), 7.83 (dd, J = DMSO >98 N5 7.8, 5.0 Hz, 1H), 7.64-7.46 (m, 4H). 693

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.91 (s, 1H), 9.52 (d, J = 1.5 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 9.00 (dd, J = 5.4, 1.2 Hz, 1H), 8.91 (d, J = 8.8 Hz, 1H), 8.34 (d, J = 5.1 Hz, 1H), 8.20 (dd, J = 6.8, 2.6 Hz, 1H), 8.14- 8.04 (m, 2H), 8.04- 7.89 (m, 2H), 7.75- 7.48 (m, 4H), DMSO >98 N5 3.18 (s, 6H). 694

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.99 (s, 1H), 9.52 (d, J = 1.7 Hz, 1H), 9.08 (d, J = 8.0 Hz, 1H), 8.97 (dd, J = 5.3, 1.4 Hz, 1H), 8.80 (d, J = 8.8 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 8.18 (dd, J = 6.8, 2.6 Hz, 1H), 8.10 (dd, J = 8.8, 1.8 Hz, 1H), 8.04-7.91 (m, 2H), 7.85 (d, J = 8.7 Hz, 2H), 7.56 (t, J = 9.1 Hz, 1H), DMSO >98 N5 7.09 (s, 2H), 3.05 (s, 6H). 695

HCl ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.07 (d, J = 8.2 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.78 (d, J = 8.7 Hz, 1H), 8.26 (s, 1H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 8.09 (dd, J = 8.7, 1.8 Hz, 1H), 8.04- 7.92 (m, 2H), 7.79- 7.67 (m, 2H), DMSO >98 N5 7.55 (t, J = 9.1 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 2.45 (s, 3H). 696

HCl ¹H NMR (400 MHz, DMSO) δ 10.48 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 8.97 (d, J = 8.1 Hz, 1H), 8.93-8.84 (m, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.30-8.16 (m, 2H), 8.08 (dd, J = 8.7, 1.8 Hz, 1H), 8.01-7.78 (m, 4H), 7.55 (t, J = 9.1 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), DMSO >98 N5 2.40 (s, 3H). 697

HCl ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 9.52 (s, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.95 (d, J = 4.7 Hz, 1H), 8.82 (d, J = 8.7 Hz, 1H), 8.25-8.12 (m, 2H), 8.06-7.88 (m, 3H), 7.63-7.48 (m, 3H), 7.47-7.35 (m, 1H). DMSO >98 N5 698

HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.01- 8.92 (m, 1H), 8.87 (dd, J = 5.1, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.24 (dd, J = 6.8, 2.6 Hz, 1H), 8.09 (s, 1H), 7.99-7.78 (m, 4H), 7.59-7.42 (m, 2H), 7.37-7.25 (m, 1H). DMSO >98 N5 699

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.12 (s, 1H), 9.59 (s, 1H), 9.10 (d, J = 8.1 Hz, 1H), 9.00-8.86 (m, 2H), 8.50 (s, 1H), 8.22-8.07 (m, 2H), 8.03-7.86 (m, 4H), 7.72 (t, J = 7.9 Hz, 1H), 7.28 (t, J = 7.1 Hz, 1H). DMSO >98 Scheme 4 synthesis using method N6 coupling 700

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.64 (s, 1H), 9.21-9.08 (m, 1H), 0.07-8.89 (m, 2H), 8.51 (s, 1H), 8.38- 8.26 (m, 2H), 8.16 (d, J = 8.5 Hz, 1H), 8.07-7.87 (m, 3H), 7.83-7.70 (m, 3H), 7.62 (dd, J = 14.2, 7.7 Hz, 1H), 7.40-7.22 (m, 2H). DMSO >98 N6 701

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 9.65 (s, 1H), 9.13-8.99 (m, 2H), 8.89 (d, J = 5.1 Hz, 1H), 8.50 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 1.8 Hz, 1H), 8.11 (dd, J = 8.6, 1.9 Hz, 1H), 8.05-7.84 (m, 5H), 7.81-7.67 (m, 1H), 7.46-7.34 (m, 2H), 7.27 (dd, J = 11.8, 4.5 Hz, 1H). DMSO >98 N6 702

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.66 (d, J = 1.8 Hz, 1H), 9.20 (d, J = 7.5 Hz, 1H), 9.04-8.89 (m, 2H), 8.50 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.17 (s, 1H), 8.11- 7.86 (m, 4H), 7.86- 7.68 (m, 2H), 7.65- 7.52 (m, 1H), 7.52-7.39 (m, 2H), 7.39-7.23 (m, 1H). DMSO >98 N6 703

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.03-8.91 (m, 2H), 8.51 (s, 1H), 8.34- 8.20 (m, 2H), 8.16- 7.86 (m, 5H), 7.84- 7.68 (m, 2H), 7.68-7.54 (m, 1H), 7.35-7.19 (m, 1H). DMSO >98 N6 704

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 9.61 (d, J = 1.8 Hz, 1H), 9.32- 9.22 (m, 1H), 9.02 (dd, J = 5.5, 1.2 Hz, 1H), 8.88 (d, J = 7.8 Hz, 1H), 8.75 (s, 1H), 8.53 (s, 1H), 8.28 (d, J = 8.7 Hz, 1H), 8.16- 8.07 (m, 2H), 8.01- 7.88 (m, 3H), 7.85-7.76 (m, 1H), 7.76-7.65 (m, 1H), 7.54-7.42 (m, DMSO >98 N6 1H), 7.37-7.19 (m, 2H). 705

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.20 (s, 1H), 9.63 (s, 1H), 9.26 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.0 Hz, 1H), 8.91 (d, J = 8.3 Hz, 1H), 8.52 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.21- 8.06 (m, 2H), 8.06-7.87 (m, 3H), 7.72 (t, J = 7.7 Hz, 1H), 7.66-7.52 (m, 2H), 7.49- 7.35 (m, 1H), 7.29 (t, J = 7.5 Hz, 1H). DMSO >98 N6 706

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.64 (d, J = 1.7 Hz, 1H), 9.25 (d, J = 8.2 Hz, 1H), 9.05-8.89 (m, 2H), 8.67-8.45 (m, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.19 (s, 1H), 8.09 (dd, J = 8.0, 5.5 Hz, 1H), 8.04-7.88 (m, 3H), 7.79-7.62 (m, 2H), 7.56-7.35 (m, 2H), 7.35-7.23 (m, 1H). DMSO >98 N6 707

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.18 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.16 (d, J = 8.1 Hz, 1H), 9.08-8.88 (m, 2H), 8.51 (s, 1H), 8.37- 8.23 (m, 2H), 8.19- 8.09 (m, 1H), 8.09- 7.88 (m, 3H), 7.83-7.63 (m, 3H), 7.43-7.32 (m, 1H), 7.32-7.21 (m, 1H). DMSO >98 N6 708

HCl ¹H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.8 Hz, 1H), 8.92 (d, J = 4.8 Hz, 1H), 8.78 (d, J = 8.8 Hz, 1H), 8.24 (d, J = 1.7 Hz, 1H), 8.13-8.08 (m, 2H), 8.08-7.98 (m, 3H), 7.98-7.88 (m, DMSO >98 N6/F5 followed by G1 1H), 7.63 (t, J = 8.2 Hz, 1H), 7.42 (t, J = 8.8 Hz, 2H), 7.28-7.15 (m, 1H). 709

HCl ¹H NMR (400 MHz, DMSO) δ 10.60 (s, 1H), 9.56 (s, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.93 (d, J = 4.3 Hz, 1H), 8.77 (d, J = 8.7 Hz, 1H), 8.41 (s, 1H), 8.37- 8.27 (m, 1H), 8.24 (d, J = 1.7 Hz, 1H), 8.11 (dd, J = 8.7, 1.8 Hz, 1H), 8.08- 7.94 (m, 3H), 7.79- 7.65 (m, 2H), DMSO >98 N6/F5 followed by G1 7.41 (t, J = 8.8 Hz, 2H). 710

1H NMR (DMSO-d6) ppm 3.81(s, 3H), 3.88 (s, 3H), 7.11- 7.71 (m, 9H), 7.91 (d, 1H, J = 8.7 Hz), 8.23 (d, 1H, J = 8.7 Hz), 8.53-8.64 (m, 2H), 8.87 (d, 1H, J = 1.5 Hz), 9.37 (d, 1H, J = 1.5 Hz), 9.83 (s, 1H) DMSO >98 N6/F5 followed by G1 711

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.04 (d, 1H, J = 4.1 Hz), 7.48-7.57 (m, 5H), 7.98 (dd, 1H, J = 7.1, 1.7 Hz), 8.26-8.29 (m, 3H), 8.27 (dd, 1H, J = 7.1, 8.7 Hz), 8.78- 9.53 (m, 3H), 9.54 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 712

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05 (d, 1H, J = 4.1 Hz), 7.48-7.57 (m, 4H), 7.88 (dd, 1H, J = 7.1, 1.7 Hz), 8.25-8.29 (m, 3H), 8.37 (dd, 1H, J = 7.1, 8.7 Hz), 8.78- 9.53 (m, 3H), 9.54 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 713

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.05-7.51 (m, 9H), 7.95 (d, 1H, J = 8.7 Hz), 8.26 (d, 1H, J = 8.7 Hz), 8.54- 8.88 (m, 3H), 9.38 (s, 1H), 10.19 (s, 1H) DMSO >98 N6/F5 followed by G1 714

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.04-7.06 (m, 2H), 7.46-7.76 (m, 8H), 7.95 (d, 2H, J = 8.6 Hz), 8.24 (d, 1H, J = 1.7 Hz), 8.69- 8.87 (m, 3H), 9.56 (s, 1H), 10.18 (s, 1H) DMSO >98 N6/F5 followed by G1 715

1H NMR (DMSO-d6) ppm 3.84 (s, 3H), 3.89 (s, 3H), 6.81- 7.56 (m, 2H), 7.40- 7.70 (m, 7H), 7.95 (d, 1H, J = 8.5 Hz), 8.23 (d, 1H, J = 1.5 Hz), 8.69-8.89 (m, 3H), 9.58 (s, 1H), 10.06 (s, 1H) DMSO >98 N6/F5 followed by G1 716

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.06 (m, 1H), 7.50-8.39 (m, 10H), 8.86-8.98 (m, 3H), 9.58 (s, 1H), 10.06 (s, 1H) DMSO >98 N6/F5 followed by G1 717

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.02-7.07 (m, 2H), 7.31 (s, 1H), 7.47- 7.56 (m, 5H), 7.81- 8.26 (m, 4H), 8.26- 8.90 (m, 3H), 9.57 (s, 1H), 10.27 (s, 1H) DMSO >98 N6/F5 followed by G1 718

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 7.03-7.50 (m, 8H), 7.98 (d, 1H, J = 8.7 Hz), 8.30 (d, 1H, J = 8.7 Hz), 8.48- 8.91 (m, 3H), 9.30 (s, 1H), 10.19 (s, 1H) DMSO >98 N6/F5 followed by G1 719

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.54 (m, 8H), 7.97 (d, 1H, J = 8.7 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.56- 8.86 (m, 3H), 9.40 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 720

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.52 (m, 8H), 7.95 (d, 1H, J = 8.7 Hz), 8.26 (d, 1H, J = 8.7 Hz), 8.52- 8.85 (m, 3H), 9.38 (s, 1H), 10.17 (s, 1H) DMSO >98 N6/F5 followed by G1 721

1H NMR (DMSO-d6) ppm 3.87 (s, 3H), 7.05-7.54 (m, 8H), 8.00 (d, 1H, J = 8.7 Hz), 8.27 (d, 1H, J = 8.7 Hz), 8.55- 8.87 (m, 3H), 9.38 (s, 1H), 10.34 (s, 1H) DMSO >98 N6/F5 followed by G1 722

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05-7.53 (m, 7H), 7.93 (s, 1H), 7.96 (d, 1H, J = 8.7 Hz), 8.16 (s, 1H), 8.26 (d, 1H, J = 8.7 Hz), 8.74-8.89 (m, 3H), 9.55 (s, 1H), 10.27 (s, 1H) DMSO >98 N6/F5 followed by G1 723

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.54 (m, 7H), 7.92 (s, 1H), 7.97 (d, 1H, J = 8.7 Hz), 8.28 (d, 1H, J = 8.7 Hz), 8.56-8.85 (m, 3H), 9.40 (s, 1H), 10.25 (s, 1H) DMSO >98 N6/F5 followed by G1 724

1H NMR (DMSO-d6) ppm 3.88 (s, 3H), 7.03-7.74 (m, 8H), 7.98 (d, 1H, J = 8.7 Hz), 8.27 (d, 1H, J = 8.7 Hz), 8.52- 8.87 (m, 3H), 9.32 (s, 1H), 10.22 (s, 1H) DMSO >98 N6/F5 followed by G1 725

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.05-7.71 (m, 8H), 7.99 (d, 1H, J = 8.6 Hz), 8.30 (d, 1H, J = 8.7 Hz), 8.67- 8.92 (m, 3H), 9.37 (s, 1H), 10.52 (s, 1H) DMSO >98 N6/F5 followed by G1 726

1H NMR (DMSO-d6) ppm 3.89 (s, 3H), 7.03-7.71 (m, 9H), 7.99 (d, 1H, J = 8.7 Hz), 8.29 (d, 1H, J = 8.7 Hz), 8.67- 8.92 (m, 3H), 9.37 (s, 1H), 10.52 (s, 1H) DMSO >98 N6/F5 followed by G1 727

1H NMR (DMSO-d6 at 70° C.) ppm 3.89 (s, 3H), 7.02-7.52 (m, 8H), 7.90 (d, 1H, J = 8.5 Hz), 7.93 (s, 1H), 7.99 (d, 1H, J = 8.6 Hz), 8.22 (s, 1H), 8.74- 8.91 (m, 3H), 9.52 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 728

1H NMR (DMSO-d₆) ppm 2.50 (s, 3H), 3.89 (s, 3H), 7.06 (s, 1H), 7.49-7.85 (m, 9H), 8.01-8.96 (m, 4H), 9.58 (s, 1H), 10.50 (s, 1H) DMSO >98 N6/F5 followed by G1 729

¹H NMR (DMSO-d₆) ppm 3.89 (s, 3H), 7.04 (br s, 1H), 7.22 (s, 1H), 7.49-8.30 (m, 9H), 8.77-8.91 (m, 3H), 9.55 (s, 1H), 10.37 (s, 1H) DMSO >98 N6/F5 followed by G1 730

¹H NMR (DMSO-d₆) ppm 3.89 (s, 3H), 7.04 (s, 1H), 7.49- 8.32 (m, 9H), 8.91- 9.04 (m, 3H), 9.54 (s, 1H), 10.63 (s, 1H) DMSO >98 N6/F5 followed by G1 731

¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), 7.03 (s, 1H), 7.44- 8.25 (m, 9H), 8.71- 8.84 (m, 3H), 9.52 (s, 1H), 10.23 (s, 1H) DMSO >98 N6/F5 followed by G1 732

¹H NMR (400 MHz, DMSO) δ 12.02 (s, 1H), 10.53 (s, 1H), 9.49 (s, 1H), 9.02- 8.72 (m, 3H), 8.30 (dd, J = 8.7, 1.6 Hz, 1H), 8.05 (dd, J = 32.2, 5.3 Hz, 2H), 7.81-7.72 (m, 2H), 7.49 (dd, J = 8.0, 5.4 Hz, 3H), 7.25 (t, J = 9.2 Hz, 1H), 7.11-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 733

¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 9.43 (s, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 21.1, 5.9 Hz, 2H), 8.31 (dd, J = 8.7, 1.9 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.59-7.45 (m, 4H), 7.42-7.30 (m, 3H), 7.09-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 734

¹H NMR (400 MHz, DMSO) δ 13.18 (s, 1H), 10.57 (s, 1H), 9.48 (s, 1H), 8.98 (d, J = 1.3 Hz, 1H), 8.78 (t, J = 7.1 Hz, 2H), 8.30 (dd, J = 8.7, 1.7 Hz, 1H), 8.18 (d, J = 8.4 Hz, 2H), 8.01 (d, J = 8.7 Hz, 1H), 7.83 (dd, J = 8.9, 1.8 Hz, 1H), 7.74-7.62 (m, 2H), 7.56-7.43 (m, DMSO >98 N6/F5 followed by G1 2H), 7.09-7.01 (m, 1H), 3.90 (s, 3H). 735

¹H NMR (400 MHz, DMSO) δ 11.16 (s, 1H), 10.11 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.91 (d, J = 1.7 Hz, 1H), 8.71- 8.58 (m, 2H), 8.23 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (dd, J = 23.9, 5.2 Hz, 2H), 7.60-7.34 (m, 5H), 7.06-6.98 (m, 1H), 6.06 (s, 2H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 736

¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 10.65 (s, 1H), 10.08 (s, 1H), 9.55 (d, J = 2.0 Hz, 1H), 8.88 (d, J = 1.8 Hz, 1H), 8.76-8.66 (m, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.94 (d, J8.7 Hz, 1H), 7.65 (d, J = 1.9 Hz, 1H), 7.58 (dd, J = 7.7, 5.1 Hz, 1H), 7.49 (dt, J = 4.7, DMSO >98 N6/F5 followed by G1 3.1 Hz, 3H), 7.41 (dd, J = 8.4, 2.0 Hz, 1H), 7.08-6.99 (m, 3H), 3.88 (s, 3H). 737

HCl ¹H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 9.40 (s, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.64 (dd, J = 28.9, 5.8 Hz, 2H), 8.27 (dd, J = 8.7, 1.9 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 2.6 Hz, 1H), 7.61-7.45 (m, 5H), 7.38 (dd, J = 8.8, 2.6 Hz, 1H), 7.24 (d, J = 8.9 Hz, DMSO >98 N6/F5 followed by G1 1H), 7.09-6.98 (m, 1H), 3.89 (d, J = 2.9 Hz, 1H), 3.83 (s, 3H). 738

¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.56 (s, 1H), 8.88 (d, J = 1.7 Hz, 1H), 8.75 (t, J = 7.2 Hz, 2H), 8.27 (dd, J = 8.6, 1.4 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.84 (dd, J = 8.2, 2.0 Hz, 1H), 7.63 (dd, J = 7.7, 4.9 Hz, 1H), 7.48 (dd, J = 11.4, 4.0 Hz, 4H), 7.10- DMSO >98 N6/F5 followed by G1 6.98 (m, 1H), 3.89 (s, 3H), 3.83 (s, 3H). 739

¹H NMR (400 MHz, DMSO) δ 10.07 (s, 1H), 9.55 (s, 1H), 8.85 (s, 1H), 8.70 (d, J = 5.5 Hz, 2H), 8.24 (dd, J = 8.7, 1.5 Hz, 1H), 8.10 (d, J = 2.4 Hz, 1H), 7.99-7.83 (m, 2H), 7.60-7.40 (m, 4H), 7.30 (d, J = 9.0 Hz, 1H), 7.04 (dd, J = 7.1, 4.4 Hz, 1H), 3.90 (s, 3H), DMSO >98 N6/F5 followed by G1 2.29 (s, 3H). 740

¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.60 (s, 1H), 8.89 (d, J = 1.8 Hz, 1H), 8.71 (dd, J = 12.8, 6.3 Hz, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.61-7.45 (m, 5H), 7.44-7.37 (m, 1H), 7.24 (d, J = 8.0 Hz, 1H), 3.89 (s, 3H), 3.65 (s, 3H). DMSO >98 N6/F5 followed by G1 741

¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.60 (s, 1H), 8.89 (d, J = 1.7 Hz, 1H), 8.71 (dd, J = 12.7, 6.3 Hz, 2H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.68 (d, J = 1.7 Hz, 1H), 7.59-7.45 (m, 4H), 7.44-7.37 (m, 1H), 7.25 (t, J = 6.7 Hz, 1H), 7.07- 6.98 (m, 1H), 3.89 (s, 6H), 2.19 (s, 3H). DMSO >98 N6/F5 followed by G1 742

¹H NMR (400 MHz, DMSO) δ 9.73 (s, 1H), 9.37 (s, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.63 (d, J = 3.4 Hz, 1H), 8.54 (d, J = 8.0 Hz, 1H), 8.23 (dd, J = 8.7, 1.8 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H), 7.55- 7.42 (m, 5H), 7.05- 6.98 (m, 1H), 6.77 (d, J = 2.6 Hz, 1H), 6.68 (dd, J = 8.6, 2.6 Hz, 1H), 3.89 (s, 3H), 3.85 (s, DMSO >98 N6/F5 followed by G1 3H), 3.79 (s, 3H). 743

¹H NMR (400 MHz, DMSO) δ 10.25 (s, 1H), 9.56 (s, 1H), 8.84 (d, J = 1.7 Hz, 1H), 8.71 (d, J = 9.1 Hz, 1H), 8.27 (dd, J = 8.7, 1.8 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.86- 7.77 (m, 2H), 7.65- 7.56 (m, 1H), 7.52- 7.44 (m, 4H), 7.09-6.99 (m, 2H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 744

¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.55 (s, 1H), 8.87 (d, J = 26.7 Hz, 3H), 8.31 (dd, J = 8.7, 1.7 Hz, 2H), 8.17 (d, J = 1.7 Hz, 2H), 8.02 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.54-7.39 (m, 3H), 7.11-6.98 (m, 1H), 3.89 (s, 3H). DMSO >98 N6/F5 followed by G1 745

¹H NMR (400 MHz, DMSO) δ 14.27 (s, 1H), 9.79 (s, 1H), 9.32 (d, J = 8.4 Hz, 1H), 8.98 (d, J = 5.2 Hz, 1H), 8.34 (dd, J = 8.7, 1.8 Hz, 1H), 8.29-8.19 (m, 2H), 8.07 (dd, J = 14.6, 8.3 Hz, 2H), 7.93 (s, 1H), 7.64 (d, J = 5.9 Hz, 1H), 7.52 (t, J = 7.9 Hz, 1H), 7.39 (dd, J = 8.9, 4.9 Hz, 2H), 7.23 (d, J = 5.8 Hz, DMSO >98 N6/F5 followed by G1 1H), 7.08 (dd, J = 8.2, 1.8 Hz, 1H), 3.86 (s, 3H). 746

2 HCl ¹H NMR (400 MHz, DMSO) δ 11.10 (s, 1H), 9.36 (s, 1H), 9.11 (s, 1H), 9.00 (dd, J = 23.2, 6.7 Hz, 2H), 8.41 (d, J = 9.1 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 8.05 (dd, J = 7.9, 5.5 Hz, 1H), 7.80- 7.65 (m, 2H), 7.59-7.44 (m, 3H), 7.41-7.32 (m, 1H), 7.06 (d, J = 8.0 Hz, 1H), 3.90 (s, 3H). DMSO N6/F5 followed by G1 747

¹H NMR (400 MHz, DMSO) δ 12.92 (d, J = 17.9 Hz, 1H), 9.64 (s, 1H), 9.09 (d, J = 7.9 Hz, 1H), 8.92 (d, J = 4.9 Hz, 1H), 8.52 (d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 8.30 (dd, J = 8.7, 1.7 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.98-7.84 (m, 3H), 7.50 (t, J = 7.9 Hz, 1H), 7.39 (dd, J = 8.1, 5.0 Hz, 2H), 7.06 (dd, J = DMSO >98 N6/F5 followed by G1 8.2, 1.8 Hz, 2H), 3.89 (s, 3H).

Pu- Method ¹H rity of Num- Starting Starting Salt NMR per- Cou- LCMS ber Material 1 Material 2 Product type ¹H NMR Solvent cent pling LCMS Method 748

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.56 (s, 1H), 9.45 (s, 2H), 9.29 (s, 1H), 9.22 (s, 1H), 9.13 (d, J = 7.8 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.16- 8.08 (m, 2H), 8.07- 7.99 (m, 1H), 7.75 (s, 1H), 7.59 (dd, J = 19.3, 9.0 DMSO >98 Method N6 Hz, 1H). 749

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.74-8.66 (m, 3H), 8.28 (d, J = 4.9 Hz, 1H), 8.17-8.08 (m, 2H), 7.98- 7.91 (m, 2H), 7.73 (d, J = 9.1 Hz, 1H), 7.61-7.51 (m, 2H), 7.22 (dd, J = 7.3, 5.0 Hz, 1H), 3.95 (s, 3H). DMSO >98 Method N6 750

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.92 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 9.33 (s, 1 H), 9.10- 8.99 (m, 2H), 8.93 (d, J = 5.2 Hz, 1H), 8.54 (d, J = 2.5 Hz, 1H), 8.46 (dd, J = 8.8, 1.8 Hz, 1H), 8.33 (s, 1H), 8.18 (ddd, J = 13.0, 7.4, 2.4 Hz, 1H), 8.08 (d, J = DMSO >98 Method N6 8.7 Hz, 1H), 8.01- 7.93 (m, 1H), 7.84 (d, J = 9.0 Hz, 1H), 7.57 (dd, J = 19.7, 9.1 Hz, 1H), 4.03 (s, 3H). 751

HCl ¹H NMR (400 MHz, DMSO) δ 10.57 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.00 (dd, J = 14.9, 4.8 Hz, 2H), 8.90 (dd, J = 5.1, 1.4 Hz, 1H), 8.78 (d, J = 2.1 Hz, 1H), 8.31 (dt, J = 8.7, 2.2 Hz, 2H), 8.11 (ddd, J = 12.9, 7.5, 2.5 Hz, 1H), 8.03 (d, J = 8.7 Hz, DMSO >98 Method N6 1H), 7.93 (dd, J = 8.0, 5.1 Hz, 1H), 7.75 (dd, J = 6.0, 2.9 Hz, 1H), 7.63- 7.51 (m, 1H), 7.03 (d, J = 8.6 Hz, 1H), 3.94 (d, J = 8.4 Hz, 3H). 752

¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.52 (s, 1H), 9.14 (d, J = 5.6 Hz, 2H), 8.84 (s, 1H), 8.68 (dd, J = 14.0, 6.4 Hz, 2H), 8.28 (dd, J = 8.7, 1.7 Hz, 1H), 8.17-8.06 (m, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.62-7.50 (m, DMSO >98 Method N6 2H), 4.02 (s, 3H). 753

¹H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.16 (d, J = 1.9 Hz, 1H), 8.93 (d, J = 1.7 Hz, 1H), 8.74- 8.60 (m, 3H), 8.35-8.26 (m, 2H), 8.19-8.07 (m, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.77- 7.69 (m, 1H), 7.64- 7.51 (m, 3H). DMSO >98 Method N6 754

¹H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 9.53 (d, J = 1.4 Hz, 1H), 8.79-8.62 (m, 3H), 8.24-8.06 (m, 2H), 7.94 (t, J = 7.7 Hz, 1H), 7.73 (dd, J = 6.2, 2.9 Hz, 1H), 7.56 (ddd, J = 15.3, 10.1, 4.8 Hz, 3H), 7.41 (dd, J = 8.1, 1.8 Hz, 1H), 7.11 (d, J = DMSO >98 Method N6 8.1 Hz, 1H), 6.13 (s, 2H). 755

2 HCl ¹H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 9.73 (d, J = 1.7 Hz, 1H), 9.52 (d, J = 1.8 Hz, 1H), 9.13-9.02 (m, 3H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.79 (d, J = 6.9 Hz, 2H), 8.56 (dd, J = 8.9, 1.9 Hz, 1 H), 8.19 (ddd, J = 13.0, 7.5, 2.5 Hz, 1H), 8.09 (d, DMSO >98 Method N6 J = 8.8 Hz, 1 H), 8.02 (dd, J= 8.0, 5.4 Hz, 1H), 7.90 (dt, J = 9.0, 2.8 Hz, 1H), 7.62-7.50 (m, 1H). 756

¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.69 (dd, J = 8.8, 2.9 Hz, 2H), 8.25 (dd, J = 8.7, 1.8 Hz, 1H), 8.18-8.07 (m, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 7.2 Hz, 2H), 7.78- 7.68 (m, 1H), DMSO >98 Method N6 7.62-7.53 (m, 4H), 7.47 (t, J = 7.4 Hz, 1H). 757

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.84 (s, 1H), 9.55 (s, 1H), 9.19-9.05 (m, 2H), 8.95 (d, J = 4.1 Hz, 1H), 8.53 (s, 1H), 8.41 (dd, J = 8.7, 1.7 Hz, 1H), 8.28 (s, 1H), 8.16-8.07 (m, 3H), 8.05-7.92 (m, 2H), 7.79 (d, J = 9.1 Hz, 1H), 7.70-7.46 (m, 3H). DMSO >98 Method N6 758

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.55 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.6 Hz, 2H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.40 (dd, J = 8.8, 1.8 Hz, 1H), 8.16- 7.96 (m, 8H), 7.79-7.71 (m, 1H), 7.64-7.53 (m, 1H), 7.47 (s, 1H). DMSO >98 Method N6 759

HCl ¹H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.56 (s, 1H), 8.98-8.77 (m, 3H), 8.23-8.02 (m, 4H), 7.99- 7.65 (m, 5H), 7.56 (dd, J = 19.1, 9.4 Hz, 1H). DMSO >98 Method N6 760

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 8.1 Hz, 1 H), 8.95-8.84 (m, 2H), 8.21-8.02 (m, 3H), 7.93 (dt, J = 10.6, 5.3 Hz, 1H), 7.77- 7.68 (m, 1H). 7.63- 7.51 (m, 3H), 7.49-7.38 (m, 1H). DMSO >98 Method N6 761

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.51 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 9.03 (d, J = 8.2 Hz, 1H), 8.91 (dd, J = 5.3, 1.5 Hz, 1H), 8.82 (s, 1H), 8.16-8.00 (m, 3H), 7.94 (dd, J = 8.0, 5.2 Hz, 1H), 7.87-7.78 (m, 1H), 7.75-7.66 (m, 1H), 7.61- DMSO >98 Method N6 7.44 (m, 2H), 7.39- 7.28 (m, 1H). 762

HCl ¹H NMR (400 MHz, DMSO) δ 10.75 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.07 (dd, J = 23.2, 4.9 Hz, 2H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.36 (dd, J = 8.8, 1.9 Hz, 1H), 8.15-7.96 (m, 3H), 7.76 (dd, J = 9.0, 4.1 Hz, 1H), 7.64-7.50 (m, 1H), 7.41 (dt, J = DMSO >98 Method N6 12.9, 1.6 Hz, 2H), 6.99-6.90 (m, 1H), 3.90 (s, 3H). 763

HCl ¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H), 9.55 (s, 1H), 9.05 (d, J = 8.2 Hz, 1H), 8.92 (d, J = 4.6 Hz, 1H), 8.84 (s, 1H), 8.17-8.02 (m, 3H), 7.96 (dd, J = 7.9, 5.4 Hz, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.56 (dd, J = 19.6, 9.1 Hz, 1H), 7.39-7.21 (m, DMSO >98 Method N6 3H), 3.89 (s, 3H). 764

HCl ¹H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 9.51 (d, J = 1.3 Hz, 1H), 9.04 (d, J = 8.1 Hz, 1H), 8.97-8.87 (m, 2H), 8.51 (s, 1H), 8.32-8.22 (m, 2H), 8.16-8.05 (m, 2H), 8.00- 7.90 (m, 2H), 7.80- 7.73 (m, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.60-7.47 DMSO >98 Method N6 (m, 2H). 765

HCl ¹H NMR (400 MHz, DMSO) δ 10.43 (s, 1H), 9.46 (d, J = 1.3 Hz, 1H), 9.01 (d, J = 8.1 Hz, 1H), 8.91 (d, 1H), 8.63 (s, 1H), 8.13-7.91 (m, 3H), 7.73-7.66 (m, 1H), 7.59- 7.49 (m, 2H), 7.44 (dd, J = 8.2, 1.8 Hz, 1H), 7.07 (d, DMSO >98 Method N6 J = 8.1 Hz, 1H), 6.12 (s, 2H). 766

¹H NMR (400 MHz, DMSO) δ 10.33 (s, 1H), 9.52 (s, 1H), 8.83 (s, 1H), 8.70 (d, J = 6.3 Hz, 2H), 8.32 (d, J = 8.6 Hz, 2H), 8.13- 8.03 (m, 1H), 7.70 (d, J = 7.3 Hz, 1H), 7.58 (dd, J = 7.3, 5.7 Hz, 3H), 7.42 (s. 1 H), 3.95 (s, 3H). DMSO >98 Method N6 767

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.71 (s, 1H), 9.52-9.41 (m, 3H), 9.26 (s, 1H), 9.11-9.02 (m, 2H), 8.96 (d, J = 5.4 Hz, 1H), 8.37 (d, J = 11.6 Hz, 1H), 8.14-7.99 (m, 2H), 7.80- 7.71 (m, 1H), 7.55 (d, J = 9.1 Hz, 1H). DMSO >98 Method N6 768

HCl ¹H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 9.07-9.00 (m, 1H), 8.91 (dd, J = 5.3, 1.5 Hz, 1H), 8.79 (s, 1H), 8.20 (dd, J = 11.9, 1.6 Hz, 1H), 8.13- 8.03 (m, 1H), 8.00- 7.91 (m, 3H), 7.76-7.68 (m, 1H), 7.62-7.44 (m, 4H). DMSO >98 Method N6 769

3 HCl ¹H NMR (400 MHz, DMSO) δ 11.13 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.47 (d, J = 1.5 Hz, 1H), 9.38 (s, 1H), 9.09 (t, J = 7.3 Hz, 2H), 9.01- 8.94 (m, 1H), 8.91- 8.83 (m, 1H), 8.39 (dd, J = 11.6, 1.3 Hz, 1H), 8.22- 8.13 (m, 1H), 8.11- 7.98 (m, 2H), DMSO >98 Method N6 7.93-7.84 (m, 1H), 7.53 (dd, J = 19.7, 9.2 Hz, 1H). 770

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.69 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.4, 1.4 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 1.3 Hz, 1H), 8.15-7.99 (m, 3H), 7.96-7.88 (m, 2H), 7.81-7.72 (m, 1H), 7.63- DMSO >98 Method N6 7.47 (m, 4H). 771

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.89 (s, 1H), 9.54-9.45 (m, 2H), 9.17 (t, J = 8.6 Hz, 1H), 9.10-8.93 (m, 4H), 8.48 (d, J = 1.5 Hz, 1H), 8.25- 8.06 (m, 4H), 7.89- 7.79 (m, 1H), 7.53 (dd, J = 19.6, 9.2 Hz, 1H). DMSO >98 Method N6 772

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 9.54 (d, J = 1.7 Hz, 1H), 9.40 (s, 2H), 9.31 (s, 1H), 9.20 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 4.3 Hz, 1H), 8.89 (d, J = 8.7 Hz, 1H), 8.43 (s, 1H), 8.22 (dd, J = 8.7, 1.9 Hz, 1H), 8.17-8.06 (m, 2H), 7.82- DMSO >98 Method N6 7.74 (m, 1H), 7.56 (dd, J = 19.7, 9.2 Hz, 1H). 773

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.81 (s, 1H), 9.56 (s, 1H), 9.11 (d, J = 8.2 Hz, 1H), 8.94 (dd, J = 17.5, 6.7 Hz, 2H), 8.42 (d, J = 11.9 Hz, 2H), 8.28 (s, 1H), 8.22- 7.94 (m, 5H), 7.81 (d, J = 8.8 Hz, 1H), 7.71-7.46 (m, 3H). DMSO >98 Method N6 774

HCl ¹H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 9.54 (s, 1H), 8.95-8.78 (m, 2H), 8.65 (d, J = 8.8 Hz, 1H), 8.19-8.09 (m, 2H), 8.02 (d, J = 8.7, 1H), 7.85-7.69 (m, 2H), 7.62- 7.37 (m, 3H), 7.09 (d, J = 7.0 Hz, 1H), 6.13 (s, 2H). DMSO >98 Method N6 775

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.59 (s, 1H), 9.56 (d, J = 1.7 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 9.01-8.88 (m, 1H), 8.79 (d, J = 8.7 Hz, 1H), 8.18-8.06 (m, 2H), 8.05-7.91 (m, 2H), 7.82-7.72 (m, 2H), 7.61- 7.52 (m, 2H), 7.48- 7.37 (m, 2H). DMSO >98 Method N6 776

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.46 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 9.04 (dt, J = 8.1, 1.6 Hz, 1H), 8.91 (dd, J = 5.2, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.24 (d, J = 1.8 Hz, 1H), 8.15-8.04 (m, 2H), 7.96 (dd, J = 8.0, 5.3 Hz, 1H), 7.84-7.70 (m, DMSO >98 Method N6 2H), 7.65-7.48 (m, 2H), 7.39- 7.25 (m, 1H). 777

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.78 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 1.7 Hz, 1H), 8.16-7.91 (m, 6H), 7.81-7.69 (m, 1H), 7.56 (dd, J = 19.7, 9.1 Hz, 1H), DMSO >98 Method N6 7.41 (t, J = 8.8 Hz, 1H). 778

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.65 (s, 1H), 9.55 (d, J = 1.7 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.4, 1.3 Hz, 1H), 8.81 (d, J = 8.7 Hz, 1H), 8.20-8.00 (m, 3H), 7.96- 7.71 (m, 3H), 7.63- 7.42 (m, 2H), 7.38-7.25 (m, 1H). DMSO >98 Method N6 779

HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.2, 1.4 Hz, 1H), 8.71 (d, J = 8.7 Hz, 1H), 8.23 (d, J = 1.8 Hz, 1H), 8.17-8.01 (m, 3H), 7.93 (dd, J = 8.0, 5.2 Hz, 1H), 7.84-7.71 (m, DMSO >98 Method N6 2H), 7.69-7.49 (m, 2H). 780

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.78 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.19 (d, J = 8.1 Hz, 1H), 9.06-8.96 (m, 1H), 8.87 (d, J = 8.7 Hz, 1H), 8.22-8.04 (m, 3H), 7.93 (t, J = 10.1 Hz, 1H), 7.78 (dd, J = 6.1, 2.9 Hz, 1H), 7.64-7.49 (m, 3H), 7.47- DMSO >98 Method N6 7.35 (m, 1H). 781

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.53 (d, J = 1.7 Hz, 1H), 9.08 (d, J = 8.1 Hz, 1H), 8.94 (dd, J = 5.3, 1.3 Hz, 1H), 8.74 (d, J = 8.8 Hz, 1H), 8.29 (d, J = 1.8 Hz, 1H), 8.17-7.95 (m, 3H), 7.80-7.65 (m, 3H), 7.61-7.48 (m, 1H), 7.42- 7.30 (m, 1H). DMSO >98 Method N6 782

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.20 (s, 1H), 9.63 (s, 1H), 9.20 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.3, 1.3 Hz, 1H), 8.89 (d, J = 8.3 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.46 (s, 1H), 8.31 (dd, J = 8.7, 1.8 Hz, 1H), 8.13-7.92 (m, 4H), 7.90-7.83 (m, 2H), 7.77-7.70 (m, 1H), 7.59 (dd, DMSO >98 Method N6 J = 10.4, 4.8 Hz, 2H), 7.53-7.46 (m, 2H), 7.34-7.25 (m, 1H). 783

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.22 (s, 1H), 9.65 (s, 1H), 9.19 (d, J = 8.1 Hz, 1H), 9.00- 8.91 (m, 2H), 8.44 (d, J = 12.8 Hz, 2H), 8.18- 7.89 (m, 5H), 7.84- 7.70 (m, 2H), 7.56-7.45 (m, 1H), 7.38-7.23 (m, 2H). DMSO >98 Method N6 784

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.15 (s, 1H), 9.65 (s, 1H), 9.38-9.27 (m, 3H), 9.17 (d, J = 9.2 Hz, 1H), 8.92 (dd, J = 25.3, 6.7 Hz, 2H), 8.68 (s, 1H), 8.45 (d, J = 8.9 Hz, 2H), 8.12 (d, J = 9.8 Hz, 1H), 8.04-7.92 (m, 3H), 7.74 (t, J = 7.6 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H). DMSO >98 Method N6 785

2 HCl ¹H NMR (400 MHz, DMSO) δ 13.10 (s, 1H), 9.63 (s, 1H), 9.18 (d, J = 8.0 Hz, 1H), 8.96 (dd, J = 5.3, 1.3 Hz, 1H), 8.87 (d, J = 8.1 Hz, 1H), 8.46 (d, J = 21.1 Hz, 2H), 8.27 (dd, J = 8.7, 1.8 Hz, 1H), 8.09-7.89 (m, 4H), 7.74 (t, J = 7.1 Hz, 1H), 7.46 (d, J = 1.8 Hz, 1H), 7.38 (dd, J = DMSO >98 Method N6 8.1, 1.9 Hz, 1H), 7.30 (t, J = 7.2 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 6.12 (s, 2H). 786

2 HCl 1H NMR (DMSO- d6) ppm 9.79 (d, J = 1.56 Hz, 1H), 9.26 (brd, J = 7.2 Hz, 1H), 9.00-8.90 (brm, 2H), 8.18 (d, J = 8.64 Hz, 1H), 8.11 (d, J = 8.64 Hz, 1 H), 8.01 (brt, J = 6.28 Hz, 1H), 7.86-7.80 (brm, 1H), 7.72 (d, J = 3.96 Hz, 1H), DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄ 7.53-7.46 (m, 2H), 7.37-7.32 (brm, 1H). The 1H of 2HCl and NH- were not observed. 787

1H NMR (DMSO- d6) ppm 12.63 (brs, 1H), 9.80 (d, J = 1.64 Hz, 1H), 9.05- 8.91 (brm, 2H), 8.76 (brd, J = 4.6 Hz, 1H), 8.10 (brd, J = 8.64 Hz, 1H), 8.02 (d, J = 8.64 Hz, 1H), 7.86- 7.80 (brm, 1H), 7.66-7.62 (brm, 1H), 7.51-7.45 (brm, 1H), 7.34-7.30 (brm, 1H), 6.94 DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄ (brs, 1H), 2.35 (brs, 3H). 788

1H NMR (300 MHz, CD3OD) δ 9.40 (s, 1H), 8.65 (d, J = 8.0 Hz, 1H), 8.56 (d, J = 3.2 Hz, 1H), 8.18-8.08 (m, 2H), 7.76-7.65 (m, 2H), 7.54- 7.44 (m, 2H), 7.23 (t, J = 9.0 Hz, 1H), 3.66 (s, J = 8.0 Hz, 2H), 2.55 (s, J = 20.6 Hz, 8H), 2.30 (s, 3H). CD3OD 99 Method N3 463.0 (M + 1) Method C 789

— 99 Method N3 434.0 (M + 1) Method C 790

— 99 Method N3 436.0 (M + 1) Method C 791

¹H-NMR (400 MHz, DMSO-d₆): δ 12.20 (s, 1H), 9.64 (s, 1H), 9.58 (s, 1H), 8.73 (d, J = 5.5 Hz, 2H), 8.60 (s, 1H), 8.53 (dd, J = 7.2, 1.5 Hz, 1H), 8.28-8.25 (m, 1H), 7.99 (d, DMSO 95 Method N1 422.2 (M + 1) Method B (NH4HCO3) J = 8.7 Hz, 1H), 7.61-7.58 (m, 1H), 7.50 (t, J = 4.5 Hz, 3H), 7.30 (d, J = 5.8 Hz, 1H), 7.06 (dd, J = 7.4, 4.1 Hz, 1H), 6.49 (t, J = 6.9 Hz, 1H), 3.91 (s, 3H). 792

HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 13.42 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.64 (td, J = 7.6, 2.0 Hz, 1H), 8.51 (s, 1H), 8.44 (d, J = 4.4 Hz, 1H), 8.01-7.95 (m, 3H), 7.68- 7.58 (m, 4H), 7.24 (t, J = 7.8 Hz, 1H), 4.26 (q, J = 2.8 Hz, 2H), 1.47 (t, J = 2.8 Hz, 3H). DMSO 95 Method N1 404.0 (M + 1) Method B (NH4HCO3) 793

HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.31 (s, 1H), 9.13 (d, J = 2.0 Hz, 1H), 8.83 (td, J = 8.4, 2.4 Hz, 1H), 8.09 (d, J = 1.2 Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H), 7.66- 7.60 (m, 2H), 7.36 (dd, J = 8.8, DMSO 95 Method N1 445.0 (M + 1) Method B (NH4HCO3) 2.4 Hz, 1H), 7.22 (d, J = 8.0 Hz, 1 H), 4.28 (q, J = 6.8 Hz, 2H), 1.47 (t, J = 6.8 Hz, 3H). 794

2HCl DMSO 95 Method N1 382.5 (M + 1) Method C 795

3HCl 1H-NMR (300 MHz, DMSO): δ 13.10 (s, 1H), 9.61 (s, 1H), 9.12 (d, J = 9.8 Hz, 1H), 8.93 (s, 1H), 8.83 (d, J = 15.2 Hz, 2H), 8.66 (s, 1H), 8.58-8.36 (m, 3H), 8.08 (d, J = 11.6 Hz, 2H), 7.96 (d, J = 9.2 Hz, 3H), 7.73 (s, 1H), 7.29 (t, J = 8.7 Hz, 1H), 4.02 (s, 3H). DMSO 95 Method N1 449.4 (M + 1) Method C 796

3HCl 1H-NMR (300 MHz, DMSO): δ 12.79 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.08 (d, J = 6.7 Hz, 2H), 9.05-8.96 (m, 2H), 8.63-8.46 (m, 4H), 8.39 (s, 1H), 8.08 (dd, J = 11.6, 8.5 Hz, 2H), 7.92 (d, J = 6.7 Hz, 1H), 7.77 (s, 1 H), 7.68 (t, J = 7.1 Hz, 1H), 7.32 (t, DMSO 95 Method N1 419.1 (M + 1) Method C J = 7.2 Hz, 1H). 797

3HCl 1H-NMR (300 MHz, DMSO): δ 12.81 (s, 1H), 9.54 (s, 1H), 9.45 (s, 1H), 9.23 (d, J = 8.2 Hz, 1H), 9.08- 8.93 (m, 3H), 8.83 (s, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.47-8.34 (m, 2H), 8.14 (ddd, J = 12.9, 8.1, 4.9 Hz, 3H), 7.92 (d, J = 6.6 Hz, 1H), 7.79 (s, 1H), 7.68 (t, J = 7.2 Hz, DMSO 95 Method N1 419.1 (M + 1) Method C 1H), 7.32 (t, J = 7.2 Hz, 1H). 798

2HCl 1H-NMR (300 MHz, DMSO): δ 13.20 (s, 1H), 9.62 (s, 1H), 9.13 (d, J = 8.1 Hz, 1H), 8.94 (d, J = 3.5 Hz, 2H), 8.55 (s, 1H), 8.48 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.96 (s, 3H), 7.74 (s, 1H), 7.55-7.40 (m, 3H), 7.29 (s, 1H), 7.06 (d, J = 7.4 Hz, 1H), 3.90 (s, DMSO 95 Method N1 448.1 (M + 1) Method C 3H). 799

1H-NMR (300 MHz, DMSO): δ 13.13 (s, 1H), 9.60 (d, J = 1.4 Hz, 1H), 9.12 (d, J = 7.8 Hz, 1H), 8.73 (dd, J = 9.7, 6.4 Hz, 2H), 8.52 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.08-7.88 (m, 4H), 7.76 (d, J = 7.2 Hz, 1H), 7.59 (dd, J = 7.4, 4.8 Hz, 1H), 7.23 (t, J = DMSO 95 Method N1 422.2 (M + 1) Method C 7.1 Hz, 1H), 3.94 (s, 3H). 800

¹H NMR (400 MHz, DMSO) δ 10.08 (s, 1H), 9.59-9.49 (m, 1H), 8.79- 8.63 (m, 3H), 8.55 (d, J = 2.1 Hz, 1H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.18 (dd, J = 8.7, 1.9 Hz, 1H), 8.02- 7.90 (m, 3H), 7.63- 7.51 (m, 2H), 6.62 (d, J = 8.6 Hz, 1H), 6.24 (s, DMSO >98 N5 2H). 801

MsOH 1H NMR (DMSO- d6) ppm 9.78 (brs, 1H), 9.20- 8.80 (br, 3H), 8.14 (brd, J = 8.64 Hz, 1H), 8.04 (d, J = 8.64 Hz, 1H), 7.83 ′brm, 2H), 7.52- 7.47 (m,1H), 7.35- 7.31 (m, 1H), 7.00 (brs, 1H), 2.36 (brs, 3H), 2.30 (brs, 3H). The 1H of MsOH and NH were not observed. DMSO >98 N6 using Na₂CO₃ instead of K₃PO₄

Number PRODUCT Salt type Molecular Mass ¹H-NMR ¹H-NMR Solvent LCMS LCMS Protocol Purity percent Method for Coupling 802

494.87 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.18 (s. 1H), 9.21 (d, J = 1.8 Hz, 1H), 8.65-8.60 (m, 2H), 8.34-8.24 (m, 2H), 7.96-7.90 (m, 2H), 7.85-7.68 (m, 4H), 7.56 (t, J = 9.0 Hz, 1H), 7.51-7.44 (m, 2H). DMSO 495.0, 497.0  (M + 1) Method B (NH4HCO3) 95 Method N1 803

458.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.14 (s, 1H), 9.44 (s, 1H), 8.73-8.63 (m, 1H), 8.55 (t, J = 6.6 Hz, 2H), 8.27 (d, J = 4.6 Hz, 1H), 7.96 (d, J = 6.8 Hz, 2H), 7.76-7.64 (m, 3H), 7.58-7.52 (m, 2H), 7.31 (t, J = 9.2 Hz, 1H), 2.37 (s, 3H). DMSO 459.0, 461.0  (M + 1) Method B (NH4HCO4) 95 Method N1 804

427.86 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.42 (d, J = 1.5 Hz, 1H), 8.74 (d, J = 5.6 Hz, 2H), 8.69-8.63 (m, 2H), 8.52 (d, J = 8.0 Hz, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 8.05 (d, J = 7.2 Hz, 1H), 7.96-7.91 (m, 1H), 7.80 (dd, J = 14.6, 6.8 Hz, 3H), 7.59-7.52 (m, 2H). DMSO 428.0, 430.0  (M + 1) 214.6 (M/2 + 1) Method A (TFA) 95 Method N1 805

426.87 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.43 (d, J = 1.6 Hz, 1H), 8.66 (dd, J = 4.7, 1.6 Hz, 1H), 8.59-8.56 (m, 1H), 8.52 (td, J = 7.9, 1.8 Hz, 1H), 8.30 (dd, J = 6.84, 2.60 Hz, 1H), 7.99-7.92 (m, 2H), 7.82-7.73 (m, 3H), 7.58-7.51 (m, 4H), 7.46 (t, J = 7.4 Hz, 1H). DMSO 427.1, 429.1  (M + 1) Method A (TFA) 95 Method N1 806

456.9 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.13 (s, 1H), 9.45 (s, 1H), 8.67 (dd, J = 4.7, 1.7 Hz, 1H), 8.62-8.49 (m, 2H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.03-7.88 (m, 2H), 7.81-7.68 (m, 1H), 7.62-7.49 (m, 2H), 7.48-7.30 (m, 3H), 7.04 (dd, J = 7.8, 2.1 Hz, 1H), 3.87-3.81 (m, 3H). DMSO 457.1, 459.1  (M + 1) Method A (TFA) 95 Method N1 807

456.9 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10 (s, 1H), 9.31 (d, J = 1.6 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 8.61-8.52 (m, 1H), 8.41 (td, J = 8.0, 1.9 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 7.97-7.92 (m, 1H), 7.83 (dd, J = 7.2, 1.2 Hz, 1H), 7.78- 7.66 (m, 1H), 7.62-7.40 (m, 3H), 7.36 (dd, J = 7.4, 1.7 Hz, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 3.66 (s, 3H). DMSO 457.1, 459.1  (M + 2) Method B (NH4HCO3) 95 Method N1

Method S: N⁴-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-N⁶-(3-(pyrrolidin-1-yl)propyl)quinazoline-4,6-diamine (xxii-a)

A 2.0 dram reaction vial was charged with 6-bromo-N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (synthesized as described in Scheme 1 and 4, substituting 5-bromo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid and 3-chloro-4-fluoroaniline for 2-aminobenzamide) (100 mg, 0.233 mmol, 1.0 equiv), 3-(pyrrolidin-1-yl)propan-1-amine (40 mg, 0.345 mmol, 1.5 equiv), copper(I) iodide (4.4 mg, 0.023 mmol, 0.1 equiv), L-proline (5.3 mg, 0.046 mmol, 0.2 equiv), and potassium carbonate (96 mg, 0.69 mmol, 3.0 equiv) in DMF (3 mL). The reaction mixture was heated at 100° C. overnight. After cooling, water was added to the reaction mixture, and the resultant precipitate was collected by filtration. The crude product was purified via prep-TLC (silica, 2000 micron plate, 95% dichloromethane −5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid (17.2 mg, 15%). LCMS m/z=477.4 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 9.68 (s, 1H), 9.46 (s, 1H), 8.59 (d, J=9.4 Hz, 2H), 8.25 (dd, J=6.8, 2.6 Hz, 1H), 7.93 (dd, J=8.3, 3.5 Hz, 1H), 7.69-7.59 (m, 1H), 7.52 (dd, J=11.0, 7.1 Hz, 2H), 7.36-7.19 (m, 2H), 6.41 (s, 1H), 3.34 (m, 2H), 2.69 (m, 6H), 2.02-1.82 (m, 2H), 1.75 (bs, 4H).

Method T: N-(3-chloro-4-fluorophenyl)-6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-amine (xxii-b)

A 2.5 dram reaction vial was charged with N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine (0.250 g, 0.524 mmol), 2-morpholinoethanol (1 ml, 8.17 mmol) as solvent, copper(I) iodide (0.020 g, 0.105 mmol), racemic-2,2′-diamino-1,1′-binaphthyl (0.030 g, 0.105 mmol), and cesium carbonate (0.513 g, 1.573 mmol). The reaction mixture was heated at 110° C. overnight. After cooling, water was added to the reaction mixture, and the resultant precipitate was collected by filtration. The solid residue was purified via ISCO (silica, 12 g column, 95% dichloromethane—5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid. The solid was further washed with a mixture of water and saturated NaHCO₃ solution and dried. The product off the column was further purified by prep TLC (silica gel, 1000 micron, 95% dichloromethane—5% methanol—0.1% NH₄OH) to afford the desired product as a light brown solid (21.2 mg, 8%). LCMS m/z=480.0 (M+1) (Method C) (retention time=2.09 min). ¹H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.47 (d, J=1.8 Hz, 1H), 8.66-8.57 (m, 2H), 8.21 (dd, J=6.8, 2.6 Hz, 1H), 7.92 (d, J=2.5 Hz, 1H), 7.87 (ddd, J=8.9, 4.3, 2.7 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.57-7.47 (m, 3H), 4.25 (t, J=5.8 Hz, 2H), 3.64-3.55 (m, 4H), 2.78 (t, J=5.7 Hz, 2H), 2.55-2.49 (m, 4H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 20 substituting with appropriate amine or alcohol

TABLE 5 Salt Molecular ¹H-NMR Retention LCMS Purity Method for Number Product type Mass ¹H-NMR Solvent LCMS Time (min.) Protocol Percent Coupling 808

476.98 1H NMR (300 MHz, DMSO) δ 9.68 (s, 1H), 9.46 (s, 1H), 8.59 (d, J = 9.4 Hz, 2H), 8.25 (dd, J = 6.8, 2.6 Hz, 1H), 7.93 (dd, J = 8.3, 3.5 Hz, 1H), 7.69-7.59 (m, 1H), 7.52 (dd, J = 11.0, 7.1 Hz, 2H), 7.36-7.19 (m, 2H), 6.41 (s, 1H), 3.34 (m, 2H), 2.69 (m, DMSO 477.4 (M + 1) 1.68 Method C 95 Method S 809

492.98 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.46 (s, 1H), 8.60 (td, J = 4.2, 2.4 Hz, 2H), 8.23 (dd, J = 6.8, 2.6 Hz, 1H), 7.90 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.57-7.45 (m, 2H), 7.32 (dd, J = 9.1, 2.2 Hz, 1H), 7.20 (s, 1H), 6.38 (s DMSO 493 (M + 1) 1.97 Method C 100 Method S 810

423.87 1H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 9.46 (s, 1H), 8.60 (dd, J = 9.1, 3.1 Hz, 2H), 8.22 (dd, J = 6.9, 2.5 Hz, 1H), 7.89 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.58-7.46 (m, 2H), 7.37 (dd, J = 9.1, 2.2 Hz, 1H), 7.25 (s, 1H), 6.40 (t DMSO 423.9 (M + 1) 2.16 Method C 100 Method S 811

463.93 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 9.49 (d, J = 1.7 Hz, 1H), 8.70- 8.59 (m, 2H), 8.27 (dd, J = 6.9, 2.5 Hz, 1H), 8.19 (dd, J = 9.0, 5.0 Hz, 1H), 7.91- 7.82 (m, 1H), 7.57-7.43 (m, 2H), 7.01 (dd, J = 9.0, 2.1 Hz, 1H), 6.77 (t, J = 5.3 Hz, 1H), 6.72 DMSO 464.0 (M + 1) 2.19 Method C 100 Method S 812

449.91 1H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.49 (d, J = 2.1 Hz, 1H), 8.69- 8.59 (m, 2H), 8.27 (dd, J = 6.9, 2.6 Hz, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.87 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.56- 7.43 (m, 2H), 7.00 (dd, J = 9.1, 2.2 Hz, 1H), 6.79 (d, J = 2.1 Hz, DMSO 449.9 (M + 1) 2.12 Method C 100 Method S 813

409.84 1H NMR (300 MHz, DMSO) δ 9.71 (s, 1H), 9.46 (s, 1H), 8.66-8.55 (m, 2H), 8.24 (d, J = 4.3 Hz, 1H), 7.96-7.87 (m, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.58- 7.46 (m, 3H), 7.36 (d, J = 9.0 Hz, 1H), 7.28 (s, 1H), 6.38 (s, 1H), 4.96 (s, 1H), 3.69 (s, 2H), 3.42 DMSO 409.9 (M + 1) 1.86 Method C 100 Method S 814

463.93 1H NMR (300 MHz, DMSO) δ 9.59 (s, 1H), 9.45 (d, J = 1.2 Hz, 1H), 8.60 (dd, J = 7.4, 5.7 Hz, 2H), 8.23 (dd, J = 6.8, 2.5 Hz, 1H), 7.90 (dd, J = 9.0, 2.7 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.57- 7.46 (m, 2H), 7.36 (d, J = 9.1 Hz, 1H), 7.19 (s, 1H), 6.38 (s DMSO 464.0 (M + 1) 2.19 Method C 95 Method S 815

479.93 1H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.47 (d, J = 1.8 Hz, 1H), 8.66- 8.57 (m, 2H), 8.21 (dd, J = 6.8, 2.6 Hz, 1H), 7.92 (d, J = 2.5 Hz, 1H), 7.87 (ddd, J = 8.9, 4.3, 2.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.57-7.47 (m, 3H), 4.25 (t, J = 5.8 Hz, 2H). DMSO 480.0 (M + 1) 2.09 Method C 91 Method T 816

423.87 1H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 9.47 (s, 1H), 8.67-8.55 (m, 2H), 8.23 (dd, J = 6.9, 2.5 Hz, 1H), 7.90 (ddd, J = 9.0, 4.3, 2.7 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.58-7.47 (m, 2H), 7.37 (dd, J = 9.1, 2.2 Hz, 1H), 7.25 (d, J = 1.3 Hz, 1H), 6.41 (t, J = 5.6 Hz, 1H), 3.63 (t, J = 5.7 Hz, 2H), 3.48- 3.35 (m, 5H). DMSO 423.9 (M + 1) Method C 99 Method S 817

437.9 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.47 (s, 1H), 8.66-8.55 (m, 2H), 8.23 (dd, J = 6.9, 2.5 Hz, 1H), 7.90 (ddd, J = 8.8, 4.3, 2.5 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.58-7.45 (m, 2H), 7.32 (dd, J = 9.0, 1.8 Hz, 1H), 7.21 (s, 1H), 6.34 (t, J = 5.0 Hz, 1H), 3.50 (t, J = 6.1 Hz, 2H), 3.31-3.20 (m, 5H), 1.92 (p, J = 6.5 Hz, 2H). DMSO 438.1 (M + 1) Method C 99 Method S 818

449.91 1H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 9.46 (d, J = 2.1 Hz, 1H), 8.65- 8.56 (m, 2H), 8.23 (dd, J = 6.9, 2.6 Hz, 1H), 7.90 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.58- 7.47 (m, 2H), 7.40 (dd, J = 8.9, 2.2 Hz, 1H), 7.26 (d, J = 1.7 Hz, 1H), 6.39 (t, J = 5.7 Hz, 1H), 4.12 (t, J = 6.2 Hz, 1H), 3.85 (dd, J = 14.2, 7.7 Hz, 1H), 3.34-3.25 (m, 5H), 2.15-1.99 (m ,1H), 1.97- 1.80 (m, 3H), 1.74-1.58 (m, 2H). DMSO 449.9 (M + 1) Method C 94 Method S 819

1H-NMR (300 MHz, DMSO): δ 10.04 (s, 1H), 9.48 (s, 1H), 8.67 (s, 2H), 8.43- 8.31 (m, 1H), 8.14-8.01 (m, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.65 (s, 1H), 7.54 (dd, J = 9.7 Hz, 2H), 7.35 (d, J = 9.0 Hz, 1H), 6.77 (s, 1H), 3.67 (broad doublet, 4H), 3.41 (bs, 2H), 3.08 (d, J = 4.7 Hz, 2H), 2.03 (bs, 2H), 1.91 (bs, 2H). DMSO 463.9 (M + 1) Method C 95 Method S

Method U: 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxiii-a)

To a suspension of 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 1 and 4, substituting 5-methoxy-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (371 mg, 1.0 mmol) in CH₂Cl₂ (4.5 mL) was slowly added boron tribromide, 1M solution in dichloromethane (4.5 ml, 4.5 mmol) at 0° C. The reaction mixture was stirred overnight at room temperature after which it was carefully poured into a vigorously stirring mixture of ice and saturated solution of aqueous NaHCO₃. The resultant solid was collected by filtration, dried and then stirred in a saturated solution of aqueous NH₄Cl for 1 h after which the suspension was filtered to give the desired product as a yellowish tan solid (262 mg, 73%). LCMS m/z=357.9 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 12.80 (s, 1H), 10.50 (s, 1H), 9.57 (s, 1H), 9.15 (d, J=8.5 Hz, 1H), 8.70 (t, J=7.3 Hz, 2H), 8.50 (s, 1H), 8.08-7.79 (m, 3H), 7.73 (t, J=7.5 Hz, 1H), 7.57 (dd, J=7.6, 4.8 Hz, 1H), 7.46 (d, J=8.5 Hz, 2H), 7.19 (t, J=7.6 Hz, 1H).

Method V: 2-(6-(2-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxiv-a)

The suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (50 mg, 0.14 mmol), 1-bromo-2-chloroethane (0.015 ml, 0.15 mmol), and potassium carbonate (23 mg, 0.17 mmol) in DMF (5 mL) was stirred for 3 days at room temperature. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×10 mL). The combined organic layer was washed with water (1×20 mL) and brine (1×20 mL) and was dried over MgSO₄. After filtration and evaporation, the crude product was obtained, which was washed with hexane and dried to give 48 mg of 2-(6-(2-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as light brown solid (79%).

Method G4: 2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxv-a)

2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide was prepared from 2-(6-(3-chloroethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide and morpholine in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride in Scheme 9 using Method G4 to give 50 mg of 2-(6-(2-morpholinoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as light yellow solid. LCMS m/z=485 (M+1) (Method C) (retention time=1.71 min) ¹H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 9.12 (d, J=8.5 Hz, 1H), 8.78-8.63 (m, 2H), 8.48 (s, 1H), 8.02-7.93 (m, 2H), 7.88 (d, J=9.0 Hz, 1H), 7.73 (t, J=8.0 Hz, 1H), 7.63-7.49 (m, 3H), 7.20 (t, J=7.6 Hz, 1H), 4.29-4.16 (m, 2H), 3.65-3.51 (m, 4H), 3.44-3.21 (m, 2H), 2.45-2.31 (m, 4H), 2.06-1.91 (m, 2H).

Method W: 2-(6-(2-(methylamino)-2-oxoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide

The suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 24) (0.20 g, 0.56 mmol), 2-chloro-N-methylacetamide (90 mg, 0.80 mmol), cesium carbonate (0.37 g, 1.12 mmol) and potassium iodide (0.19 g. 1.12 mmol) in DMF (10 mL) was stirred for 4 days at room temperature. Water (20 mL) was added to the mixture. The resultant solid was collected by filtration. The obtained solid was washed with CH₂Cl₂-THF (1:1) solution and dried to give 0.11 g of 2-(6-(2-(methylamino)-2-oxoethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide as pale brown solid (46%). LCMS m/z=429 (M+1) (Method C) (retention time=1.65 min). ¹H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.12 (d, J=8.4 Hz, 1H), 8.82-8.64 (m, 2H), 8.48 (s, 1H), 8.32-8.17 (m, 1H), 8.10-7.87 (m, 3H), 7.81-7.49 (m, 4H), 7.21 (t, J=7.5 Hz, 1H), 4.66 (s, 2H), 2.71 (d, J=4.5 Hz, 3H).

Method X: 2-(6-(2-(dimethylamino)ethoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide

A suspension of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (synthesized as described in Scheme 24) (25 mg, 0.07 mmol), 2-chloro-N,N-dimethylethylamine hydrochloride (20 mg, 0.14 mmol) and cesium carbonate (68.4 mg, 0.21 mmol) in DMF (1 mL) was stirred at 60° C. overnight. The reaction mixture was cooled to room temperature, diluted with water (5 mL) and extracted with dichloromethane (3×5 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by prep-TLC (silica, 2000 micron plate, 95% dichloromethane—5% methanol—0.1% NH₄OH) to yield the desired compound as a brown solid (12.6 mg, 40%). LCMS m/z=428.9 (M+1) (Method C) (retention time=1.41 min). ¹H NMR (300 MHz, DMSO) δ 12.99 (s, 1H), 9.59 (d, J=1.3 Hz, 1H), 9.12 (d, J=8.4 Hz, 1H), 8.81-8.66 (m, 2H), 8.52 (s, 1H), 8.06-7.88 (m, 3H), 7.80-7.53 (m, 4H), 7.22 (t, J=7.6 Hz, 1H), 4.46 (s, 2H), 3.35 (s, 2H), 2.69 (s, 6H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 23 substituting with appropriate nucleophile.

TABLE 6 ¹H- Reten- Puri- Meth- Molecu- NMR tion LCMS ty od for Num- Salt lar Sol- Time Proto- Per- Coupl- ber Product type Mass ¹H-NMR vent LCMS (min.) col cent ing 820

484.550 1H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 9.12 (d, J = 8.5 Hz, 1H), 8.78-8.63 (m, 2H), 8.48 (s, 1H), 8.02-7.93 (m, 2H), 7.88 (d, J = 9.0 Hz, 1H), 7.73 (t, J = 8.0 Hz, 1H), 7.63-7.49 (m, 3H), 7.20 (t, J = 7.6 Hz, 1H), 4.29- 4.16 (m, 2H), 3.65-3.51 (m DMSO 485 (M + 1) 1.71 Method C 100 Methods V, G4 821

470.523 1H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.24-9.08 (m, 1H), 8.82-8.61 (m, 2H), 8.49 (s, 1H), 8.09-7.84 (m, 3H), 7.73 (t, J = 7.8 Hz, 1H), 7.67-7.47 (m, 3H), 7.19 (t, J = 7.5 Hz, 1H), 4.29- 4.09 (m, 2H), 3.63-3.42 (m, 2H), 3.07-2.77 (m, 3H), 2.2 DMSO 471 (M + 1) 1.75 Method C 100 Methods V, G4 followed by acylation with acetyl chloride/ TEA in DCM at rt. 822

442.470 1H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.16 (d, J = 8.4 Hz, 1H), 8.82-8.60 (m, 2H), 8.49 (s, 1H), 8.05-7.80 (m, 3H), 7.79- 7.68 (m, 1H), 7.67-7.51 (m, 2H), 7.43 (s, 1H), 7.29-7.12 (m, 1H), 5.03 (s, 2H), 3.10 (s, 3H), 2.89 (s, 3H). DMSO 443 (M + 1) 1.63 Method C 100 Method W 823

HCl 561.94 1H NMR (300 MHz, DMSO) δ 10.51 (s, 1H), 9.49 (s, 1H), 8.95 (d, J = 6.6 Hz, 1H), 8.85 (d, J = 5.0 Hz, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 8.03-7.80 (m, 3H), 7.73- 7.51 (m, 2H), 7.19 (d, J = 7.4 Hz, 1H), 5.12 (s, 2H), 3.75-3.36 (m, 8H). DMSO 526 (M + 1) 2.02 Method C 100 Method W 824

HCl 598.44 1H NMR (300 MHz, DMSO) δ 10.98 (s, 1H), 10.59 (s, 1H), 9.50 (s, 1H), 8.96 (d, J = 8.1 Hz, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.31 (s, 1H), 8.10 (s, 1H), 8.07-7.93 (m, 2H), 7.92-7.80 (m, 1H), 7.71- 7.54 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 4.47-4.23 (m, 2 DMSO 526 (M + 1) 2.25 Method C 100 Methods V, G4 825

469.42 1H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.51 (s, 1H), 8.76- 8.56 (m, 2H), 8.26-8.08 (m, 2H), 8.01 (s, 1H), 7.95-7.81 (m, 2H), 7.70-7.56 (m, 2H), 7.52 (dd, J = 7.9, 4.9 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 4.69 (s, 2H), 2.71 (d, J = 4.5 Hz, 3H). DMSO 470 (M + 1) 2.04 Method C 100 Method W 826

483.44 1H NMR (300 MHz, DMSO) δ 9.92 (s, 1H), 9.51 (s, 1H), 8.74- 8.57 (m, 2H), 8.17 (s, 1H), 8.01 (d, J = 2.5 Hz, 1H), 7.96-7.83 (m, 2H), 7.70-7.46 (m, 3H), 7.16 (d, J = 7.0 Hz, 1H), 5.03 (s, 2H), 3.06 (s, 3H), 2.88 (s, 3H). DMSO 484 (M + 1) 1.71 Method D 1.00 Method W 827

HCl 564.91 1H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 9.99 (s, 1H), 9.49 (s, 1H), 8.97 (d, J = 7.7 Hz, 1H), 8.87 (d, J = 5.3 Hz, 1H), 8.33- 8.18 (m, 2H), 8.04-7.83 (m, 3H), 7.68-7.47 (m, 2H), 4.41- 4.27 (m, 2H), 3.55-3.43 (m, 2H), 3.34-3.20 (m, 2H), 3.03- 2. DMSO 492 (M + 1) 1.81 Method C 1.00 Methods V, G4 828

437.85 1H NMR (300 MHz, DMSO) δ 9.87 (s, 1H), 9.49 (s, 1H), 8.76- 8.53 (m, 2H), 8.32-8.08 (m, 2H), 8.01-7.77 (m, 3H), 7.69- 7.43 (m, 3H), 4.67 (s, 2H), 2.71 (d, J = 4.6 Hz, 3H). DMSO 438 (M + 1) 1.65 Method D 1.00 Method W 829

493.92 1H NMR (300 MHz, DMSO) δ 9.86 (s, 1H), 9.50 (s, 1H), 8.76- 8.57 (m, 2H), 8.27 (d, J = 7.0 Hz, 1H), 8.05-7.80 (m, 3H), 7.69- 7.45 (m, 3H), 5.04 (s, 2H), 3.78- 3.41 (m, 8H). DMSO 494 (M + 1) 1.98 Method C 98 Method W 830

479.93 1H NMR (300 MHz, DMSO) δ 9.85 (s, 1H), 9.50 (s, 1H), 8.76- 8.53 (m, 2H), 8.26 (dd, J = 6.9, 2.5 Hz, 1H), 8.08-7.76 (m, 3H), 7.71-7.41 (m, 3H), 4.98 (s, 2H), 3.52-3.09 (m, 4H), 1.37-0.88 (m, 6H). DMSO 480 (M + 1) 2.20 Method C 100 Method W 831

HCl 580.91 1H NMR (300 MHz, DMSO) δ 10.71 (s, 2H), 9.48 (s, 1H), 9.10- 8.95 (m, 1H), 8.94-8.79 (m, 1H), 8.36-8.27 (m, 1H), 8.26- 8.16 (m, 1H), 8.07-7.83 (m, 3H), 7.68-7.46 (m, 2H), 4.39- 4.18 (m, 2H), 4.05-3.89 (m, 2H), 3.79 (t, J = 11.9 Hz, 2H), 3.53- DMSO 508 (M + 1) 2.14 Method C 100 Methods V, G4 832

451.88 1H NMR (300 MHz, DMSO) δ 9.85 (s, 1H), 9.50 (s, 1H), 8.71- 8.58 (m, 2H), 8.25 (dd, J = 6.8, 2.5 Hz, 1H), 8.01-7.80 (m, 3H), 7.66-7.45 (m, 3H), 5.02 (s, 2H), 3.06 (s, 3H), 2.88 (s, 3H). DMSO 452 (M + 1) 1.99 Method C 100 Method W 833

HCl 566.88 1H NMR (300 MHz, DMSO) δ 11.18 (s, 1H), 10.93 (s, 1H), 9.48 (s, 1H), 9.08 (d, J = 8.4 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.23 (dd, J = 6.8, 2.5 Hz, 1H), 8.12-7.89 (m, 3H), 7.63 (d, J = 9.1 Hz, 1H), 7.54 (t, J = 9.1 Hz, 1H), 4.45-4.26 (m, DMSO 494 (M + 1) 2.10 Method C 100 Methods V, G4 834

366.78 1H NMR (300 MHz, DMSO) δ 9.98-9.59 (m, 1H), 9.53-9.41 (m, 1H), 8.71-8.48 (m, 2H), 8.31 (dd, J = 6.9, 2.5 Hz, 1H), 8.01-7.85 (m, 1H), 7.83-7.66 (m, 2H), 7.59-7.35 (m, 3H). DMSO 367 (M + 1) 1.69 Method D 100 Method U 835

428.44 1H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.82-8.64 (m, 2H), 8.48 (s, 1H), 8.32-8.17 (m, 1H), 8.10- 7.87 (m, 3H), 7.81-7.49 (m, 4H), 7.21 (t, J = 7.5 Hz, 1H), 4.66 (s, 2H), 2.71 (d, J = 4.5 Hz, 3H). DMSO 429 (M + 1) 1.65 Method C 100 Method W 836

484.51 1H NMR (300 MHz, DMSO) δ 9.58 (s, 1H), 9.13 (d, J = 8.3 Hz, 1H), 8.78-8.64 (m, 2H), 8.50 (s, 1H), 8.02-7.80 (m ,3H), 7.73 (t, J = 7.9 Hz, 1H), 7.68-7.53 (m, 2H), 7.49 (s, 1H), 7.20 (t, J = 7.5 Hz, 1H), 5.07 (s, 1H), 3.79-3.40 (m, 8H). DMSO 485 (M + 1) 1.72 Method C  91 Method W 837

442.47 1H NMR (300 MHz, DMSO) δ 9.59 (s, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.78-8.63 (m, 1H), 8.49 (s, 1H), 8.29 (s, 1H), 8.11-7.88 (m, 2H), 7.79-7.47 (m, 4H), 7.26- 7.14 (m, 1H), 4.58 (s, 2H), 3.27- 3.08 (m ,2H), 1.18-0.93 (m, 3H). DMSO 443 (M + 1) 1.69 Method C 100 Method W 838

357.37 1H NMR (300 MHz, DMSO) δ 12.80 (s, 1H), 10.50 (s, 1H), 9.57 (s, 1H), 9.15 (d, J = 8.5 Hz, 1H), 8.70 (t, J = 7.3 Hz, 2H), 8.50 (s, 1H), 8.08-7.79 (m, 3H), 7.73 (t, J = 7.5 Hz, 1H), 7.57 (dd, J = 7.6, 4.8 Hz, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H). DMSO 357.9 (M + 1) 1.68 Method C 100 Method U 839

2HCl 443.86 1H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 9.49 (s, 1H), 8.97 (d, J = 8.2 Hz, 1H), 8.89 (s, 1H), 8.81 (s, 1H), 8.16 (ddd, J = 12.2, 10.9, 5.2 Hz, 3H), 8.05 (d, J = 2.3 Hz, 1H), 8.00-7.86 (m, 3H), 7.55 (t, J = 9.1 Hz, 1H), 6.55 (d, J = 9.5 Hz, 1H). DMSO 443.9 (M + 1) 1.87 Method C 100 Method U 840

2HCl 457.89 1H NMR (300 MHz, DMSO) δ 10.27 (s, 1H), 9.47 (s, 1H), 9.09 (d, J = 8.1 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 8.56 (s, 1H), 8.18- 8.08 (m, 2H), 8.01 (d, J = 6.3 Hz, 3H), 7.96-7.89 (m, 1H), 7.49 (t, J = 9.1 Hz, 1H), 6.52 (d, J = 9.6 Hz, 1H), 2.71 (s, 3H). DMSO 458.0 (M + 1) 2.12 Method D 100 Method U 841

448.48 1H NMR (300 MHz, DMSO) δ 13.08 (s, 1H), 9.59 (s, 1H), 9.16 (d, J = 8.4 Hz, 1H), 8.88-8.44 (m, 5H), 8.12-7.85 (m, 4H), 7.73 (q, J = 8.7 Hz, 3H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 7.49 (dd, J = 7.8, 4.8 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 5.36 (s, 2H). DMSO 449.2 (M + 1) 1.93 Method C  96 Method X 842

448.48 1H NMR (300 MHz, DMSO) δ 13.00 (s, 1H), 9.57 (s, 1H), 9.12 (d, J = 8.4 Hz, 1H), 8.76-8.60 (m, 4H), 8.50 (s, 1H), 8.03-7.89 (m, 3H), 7.68 (dd, J = 15.6, 5.2 Hz, 3H), 7.57 (t, J = 4.6 Hz, 3H), 7.19 (t, J = 7.6 Hz, 1H), 5.37 (s, 2H). DMSO 449.1 (M + 1) 1.89 Method C 100 Method X 843

425.48 1H NMR (300 MHz, DMSO) δ 12.95 (s, 1H), 9.56 (s, 1H), 9.10 (d, J = 8.4 Hz, 1H), 8.75-8.64 (m, 2H), 8.46 (s, 1H), 7.98-7.91 (m, 2H), 7.85 (dd, J = 9.0, 0.8 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.61-7.48 (m, 3H), 7.18 (t, J = 7.6 Hz, 1H), 4.12 (d, J = 6.6 Hz, 2H), 2.84 (dd, J = 14.3, 7.4 Hz, 1H), 2.18-2.05 (m, 2H), 1.97- 1.84 (m, 5H). DMSO 426.2 2.46 Method C 100 Method X 844

457.89 1H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.82 (d, J = 1.7 Hz, 1H), 8.78- 8.59 (m, 3H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.16 (d, J = 2.5 Hz, 1H), 8.06-7.86 (m, 3H), 7.69 (dd, J = 9.1, 2.5 Hz, 1H), 7.64- 7.47 (m, 3H), 5.37 (s, 2H). DMSO 458.1, 460.1 (M + 1) 229.6, 230.3 (m/2 + 1) Method A  95 Method X 845

487.91 1H-NMR (400 MHz, DMSO-d6): δ 9.74 (s, 1H), 9.34 (s, 1H), 8.57- 8.41 (m, 2H), 8.22 (d, J = 2.2 Hz, 1H), 8.10 (dd, J = 6.8, 2.6 Hz, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.80-7.63 (m, 3H), 7.53-7.30 (m, 3H), 6.82-6.68 (m, 1H), 5.07 (s, 2H), 3.71 (s, 3H). DMSO 488.1, 490.1 (M + 1) 244.6, 245.4 (M/2 + 1) Method A  95 Method X Starting Starting Number Material R¹ Material R³ Product 846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

1757

Salt ¹H NMR Purity Method Number Type ¹H NMR Solvent percent of Coupling 846 HCl 1H NMR (400 MHz, DMSO) δ 9.31 (d, J = 1.7 Hz, DMSO >98 Method X using K₂CO₃ instead of 1H), 8.83-8.76 (m, 1H), 8.76-8.67 (m, 1H), Cs₂CO₃ 8.07 (d, J = 9.2 Hz, 1H), 7.86 (dd, J = 6.3, 2.8 Hz, 1H), 7.83-7.73 (m, 2H), 7.70 (d, J = 2.8 Hz, 1H), 7.68-7.61 (m, 1H), 7.60-7.52 (m, 1H), 5.12 (s, 2H), 3.05 (s, 3H), 2.88 (s, 3H). 847 1H NMR (400 MHz, DMSO) δ 9.28 (dd, J = 2.2, 0.8 DMSO >98 Method X using K₂CO₃ instead of Cs₂CO₃ Hz, 1H), 8.66 (dd, J = 4.8, 1.7 Hz, 1H), 8.50- 8.44 (m, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.92 (d, J = 2.7 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.75 (dd, J = 9.2, 2.9 Hz, 1H), 7.67 (d, J = 2.8 Hz, 1H), 7.56 (dd, J = 8.8, 2.7 Hz, 1H), 7.52 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 5.10 (s, 2H), 3.05 (s, 3H), 2.88 (s, 3H). 848 ¹H NMR (400 MHz, CDCl₃) δ 9.45 (dd, J = 2.1, 0.8 CDCl3 >98 Method X using K₂CO₃ instead of Cs₂CO₃ Hz, 1H), 8.61 (dd, J = 4.8, 1.7 Hz, 1H), 8.59- 8.53 (m, 1H), 8.01 (dd, J = 8.7, 0.8 Hz, 1H), 7.72- 7.62 (m, 2H), 7.56-7.47 (m, 2H), 7.39-7.29 (m, 4H), 4.90 (s, 2H), 3.15 (s, 3H), 3.04 (s, 3H). 849 2 HCl 1H NMR (300 MHz, DMSO) δ 13.01-11.72 (m, DMSO >98 W 1H), 9.70 (s, 1H), 9.40-9.30 (m ,1H), 8.99 (d, J = 4.5 Hz, 1H), 8.23 (d, J = 2.6 Hz, 1H), 8.12 (dd, J = 8.1, 5.5 Hz, 1H), 8.06-7.98 (m, 2H), 7.92 (d, J = 9.1 Hz, 1H), 7.84 (d, J = 4.9 Hz, 1H), 7.63 (dd, J = 9.1, 2.6 Hz, 1H), 7.56-7.49 (m, 2H), 5.05 (s, 3H), 3.11 (s, 3H), 2.92 (s, 3H). 850 2 HCl 1H NMR (300 MHz, DMSO) δ 9.74 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.47-9.36 (m, 1H), 9.01 (dd, J = 5.5, 1.2 Hz, 1H), 8.28 (d, J = 2.6 Hz, 1H), 8.16 (dd, J = 8.2, 5.5 Hz, 1H), 8.06-7.93 (m, 3H), 7.81 (s, 1H), 7.66 (dd, J = 9.1, 2.6 Hz, 1H), 7.54-7.44 (m, 2H), 7.42-7.33 (m, 1H), 5.07 (s, 2H), 3.11 (s, 3H), 2.91 (s, 3H). 851 2 HCl 1H NMR (300 MHz, DMSO) δ 12.67 (s, 1H), 9.31- DMSO >98 W 9.25 (m, 1H), 8.73 (dd, J = 4.8, 1.6 Hz, 1H), 8.52- 8.42 (m, 1H), 7.74 (d, J = 8.9 Hz, 1H), 7.66 (d, J = 2.9 Hz, 1H), 7.61-7.47 (m, 4H), 7.45-7.31 (m, 3H), 5.27 (s, 2H), 3.30 (s, 3H). 852 3 HCl 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.25 (d, J = 8.2 Hz, 1H), 9.08-8.98 (m, 1H), 8.81 (d, J = 4.5 Hz, 1H), 8.31 (td, J = 7.8, 1.6 Hz, 1H), 8.20-8.08 (m, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.88-7.63 (m, 4H), 7.47 (d, J = 2.1 Hz, 1H), 7.30 (dd, J = 8.6, 2.2 Hz, 1H), 5.60 (s, 2H), 4.63 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 7.7 Hz, 2H). 853 3 HCl 1H NMR (300 MHz, DMSO) δ 9.56 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.22 (d, J = 8.3 Hz, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.80 (d, J = 4.4 Hz, 1H), 8.29 (td, J = 7.8, 1.6 Hz, 1H), 8.21-8.05 (m, 2H), 8.00-7.66 (m, 5H), 7.29 (dd, J = 8.4, 2.6 Hz, 1H), 7.12 (td, J = 9.0, 2.8 Hz, 1H), 5.59 (s, 2H), 4.66 (t, J = 7.8 Hz, 2H), 3.25 (t, J = 7.6 Hz, 2H). 854 2 HCl 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.8 Hz, DMSO >98 W 1H), 9.30-99.18 (m, 1H), 9.00 (dd, J = 5.5, 1.3 Hz, 1H), 8.18-8.02 (m, 2H), 7.87 (dd, J = 8.8, 4.8 Hz, 1H), 7.71 (dd, J = 9.2, 2.7 Hz, 1H), 7.49 (d, J = 2.7 Hz, 1H), 7.29 (dd, J = 8.4, 2.6 Hz, 1H), 7.13 (td, J = 9.1, 2.8 Hz, 1H), 5.05 (s, 2H), 4.63 (d, J = 7.7 Hz, 2H), 3.25 (t, J = 7.5 Hz, 2H), 3.02 (s, 3H), 2.86 (s, 3H). 855 2 HCl 1H NMR (300 MHz, DMSO) δ 9.55 (d, J = 1.7 Hz, DMSO >98 W 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.99-8.90 (m, 1H), 8.10-7.98 (m, 2H), 7.77 (dd, J = 8.9, 4.7 Hz, 1H), 7.67 (dd, J = 9.1, 2.7 Hz, 1H), 7.51 (d, J = 2.6 Hz, 1H), 7.28 (dd, J = 8.4, 2.7 Hz, 1H), 7.12 (dd, J = 10.3, 7.7 Hz, 1H), 4.70 (t, J = 7.8 Hz, 2H), 4.23-4.14 (m, 2H), 3.26 (t, J = 7.9 Hz, 2H), 1.41 (t, J = 6.9 Hz, 3H). 856 2 HCl 1H NMR (300 MHz, DMSO) δ 9.54 (d, J = 1.7 Hz, DMSO >98 W 1H), 9.19 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.15-8.02 (m, 2H), 7.90-7.72 (m, 2H), 7.60 (d, J = 2.6 Hz, 1H), 7.53-7.41 (m, 1H), 7.40- 7.05 (m, 5H), 5.34 (s, 2H), 4.59 (t, J = 7.8 Hz, 2H), 3.22 (t, J = 7.5 Hz, 2H). 857 HCl ¹H NMR (400 MHz, DMSO) δ 10.56 (s, 1H), 9.49 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.0 Hz, 1H), 8.95 (dd, J = 5.4, 1.3 Hz, 1H), 8.26 (dd, J = 24.6, 3.5 Hz, 2H), 8.12-7.95 (m, 3H), 7.71 (dt, J = 9.1, 4.5 Hz, 2H), 7.56 (dd, J = 19.7, 9.1 Hz, 1H), 4.75 (s, 2H), 2.72 (d, J = 5.0 Hz, 3H). 858 ¹H NMR (400 MHz, DMSO) δ 9.77 (br s, J = 81.7 DMSO >98 Method W Hz, 1H), 9.50 (d, J = 1.5 Hz, 1H), 8.71-8.57 (m, 2H), 8.22-8.07 (m, 1H), 7.97 (t, J = 5.1 Hz, 1H), 7.87 (d, J = 9.1 Hz, 1H), 7.81-7.39 (m, 4H), 5.01 (s, 2H), 3.07 (s, 3H), 2.90 (s, 3H). 859 HCl ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.7 Hz, 1H), 9.01 (d, J = 8.1 Hz, 1H), 8.90 (dd, J = 5.3, 1.5 Hz, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.20-8.09 (m, 1H), 7.95 (dd, J = 8.5, 4.7 Hz, 2H), 7.83-7.74 (m, 1H), 7.67 (dd, J = 9.1, 2.6 Hz, 1H), 7.55 (dd, J = 19.7, 9.1 Hz, 1H), 5.15 (s, 2H), 4.29-3.00 (m, 8H). 860 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.51 DMSO >98 Method W (d, J = 1.6 Hz, 1H), 8.81 (dd, J = 19.3, 6.0 Hz, 2H), 8.29 (s, 1H), 8.16 (dd, J = 10.6, 7.5 Hz, 1H), 7.94 (d, J = 9.0 Hz, 1H), 7.77 (s, 2H), 7.69-7.51 (m, 2H), 4.67 (s, 2H), 3.99 (s, 2H), 3.81 (br s, 4H), 3.70 (br s, 4H). 861 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.82 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.3 Hz, 1H), 9.02 (d, J = 8.0 Hz, 1H), 8.90 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.21-8.10 (m, 1H), 8.03-7.90 (m, 2H), 7.84 (d, J = 8.7 Hz, 2H), 7.68 (dd, J = 9.1, 2.3 Hz, 1H), 7.55 (dd, J = 19.5, 9.3 Hz, 1H), 4.67 (s, 2H), 3.23-3.05 (m, 6H), 2.10-1.78 (m, 4H). 862 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.77 (s, 1H), 9.49 DMSO >98 Method W (d, J = 1.6 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.99- 8.91 (m, 1H), 8.23 (d, J = 2.1 Hz, 1H), 8.12- 7.99 (m, 3H), 7.78-7.71 (m, 1H), 7.66-7.54 (m, 2H), 4.02 (d, J = 6.5 Hz, 2H), 2.24-2.00 (m, 1H), 1.07 (d, J = 6.7 Hz, 6H). 863 2 HCl ¹H NMR (400 MHz, CDCl₃) δ10.71 (s, 1H), 9.80 (s, DMSO >98 Method W 1H), 9.40 (d, J = 8.2 Hz, 1H), 8.95 (d, J = 5.2 Hz, 1H), 8.54 (d, J = 2.4 Hz, 1H), 8.24 (d, J = 9.2 Hz, 1H), 8.08 (dd, J = 8.0, 5.6 Hz, 1H), 7.86-7.76 (m, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.56 (d, J = 8.8, 2.2 Hz, 1H), 7.31 (s, 1H), 5.08 (s, 2H), 3.69 (t, J = 6.8 Hz, 2H), 3.55 (t, J = 6.9 Hz, 2H), 2.13-2.01 (m, 2H), 1.98-1.85 (m, 2H). 864 2 HCl 1H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.9 Hz, 1H), 9.12 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.5, 1.4 Hz, 1H), 8.27 (d, J = 2.6 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 8.15-7.97 (m, 3H), 7.75 (ddd, J = 11.9, 7.4, 3.3 Hz, 2H), 7.56 (dt, J = 10.6, 9.1 Hz, 1H), 4.74 (s, 2H), 4.07-3.93 (m, 1H), 1.13 (d, J = 6.6 Hz, 6H). 865 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.83 (s, 1H), 9.51 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.97 (dd, J = 5.4, 1.3 Hz, 1H), 8.82-8.74 (m, 1H), 8.55 (d, J = 2.6 Hz, 1H), 8.28-8.19 (m, 1H), 8.16- 8.01 (m, 3H), 7.94 (d, J = 7.9 Hz, 1H), 7.85- 7.75 (m, 2H), 7.70 (dd, J = 7.0, 5.8 Hz, 1H), 7.61- 7.49 (m, 1H), 5.63 (s, 2H). 866 4 HCl ¹H NMR (400 MHz, DMSO) δ 10.62 (s, 1H), 9.50 DMSO >98 Method W (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.1 Hz, 1H), 8.95 (d, J = 5.4 Hz, 1H), 8.76 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.18 (t, J = 7.8 Hz, 1H), 8.08-7.96 (m, 4H), 7.89 (d, J = 7.8 Hz, 1H), 7.80 (dd, J = 9.1, 2.6 Hz, 1H), 7.64 (t, J = 8.2 Hz, 2H), 7.24 (d, J = 8.3 Hz, 1H), 5.57 (s, 2H). 867 HCl 1H NMR (300 MHz, DMSO) d 9.58 (s, 1H), 9.05 (d, DMSO 94 Method X (K2CO3, J = 8.2 Hz, 1H), 8.98 (d, J = 8.1 Hz, 1H), 8.88 (d, DMF-THF (1:1), rt) J = 5.1 Hz, 1H), 8.47 (s, 1H), 8.05-7.85 (m, 4H), 7.71 (m, 1H), 7.61 (d, J = 8.1 Hz, 2H), 7.24 (dd, J = 7.6 Hz, 1H). 868 2 HCl 1H NMR (300 MHz, DMSO) δ 13.07 (s, 1H), 9.59 DMSO 99 Method W (d, J = 1.4 Hz, 1H), 9.13 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 7.8 Hz, 1H), 8.92 (d, J = 4.1 Hz, 1H), 8.49 (s, 1H), 8.08-7.92 (m, 4H), 7.80-7.64 (m, 3H), 7.26 (td, J = 7.8, 1.1 Hz, 1H), 7.14 (d, J = 1.5 Hz, 1H), 7.09 (dd, J = 7.9, 1.6 Hz, 1H), 6.95 (d, J = 7.9 Hz, 1H), 6.03 (s, 2H), 5.19 (s, 2H). 869 3HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.40 DMSO 98 Method X (d, J = 7.6 Hz, 1H), 9.01 (d, J = 8.4 Hz, 2H), 8.93 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 7.6 Hz, 1H), 8.22 (t, J = 7.2 Hz, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.97- 7.92 (m, 2H), 7.79-7.71 (m, 3H), 7.33 (t, J = 8.0 Hz, 1H), 5.54 (s, 2H). 870 2HCl ¹H-NMR (400 MHz, CD3OD): δ 9.62 (d, J = 6.9 Hz, MeOD 95 Method W 1H), 9.40 (d, J = 8.2 Hz, 1H), 8.99 (d, J = 5.3 Hz, 1H), 8.82 (t, J = 8.2 Hz, 1H), 8.22 (dd, J = 8.1, 5.7 Hz, 1H), 8.02-7.88 (m, 2H), 7.76-7.60 (m, 3H), 7.31 (t, J = 7.6 Hz, 1H), 4.81 (q, J = 8.1 Hz, 2H). 871 4HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 12.96 (s, 1H), DMSO- 95 Method X 9.59 (s, 1H), 9.24 (d, J = 8.1 Hz, 1H), 9.00 (s, d₆ 1H), 8.80 (d, J = 5.7 Hz, 2H), 8.50 (s, 1H), 8.22 (t, J = 7.2 Hz, 1H), 8.09 (d, J = 9.2 Hz, 2H), 7.99- 7.79 (m, 5H), 7.74-7.54 (m, 6H), 7.30 (t, J = 7.5 Hz, 1H), 5.55 (s, 2H). 872 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 12.82 (s, 1H), DMSO 95 Method X 9.58 (s, 1H), 9.13 (d, J = 6.9 Hz, 1H), 8.93 (s, 1H), 8.82 (d, J = 8.0 Hz, 1H), 8.43 (s, 1H), 8.04- 7.88 (m, 4H), 7.74-7.69 (m, 3H), 7.28 (t, J = 7.6 Hz, 1H), 7.01-6.91 (m, 2H), 6.87-6.85 (m, 2H), 4.74-4.70 (m, 1H), 4.55-4.53 (m, 1H), 4.50- 4.47 (m, 1H), 4.29-4.24 (m, 1H). 873 3HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 13.07 (s, 1H), DMSO 95 Method X 9.61 (s, 1H), 9.05-9.00 (m, 2H), 8.88 (d, J = 4 Hz, 1H), 8.51 (s, 1H), 8.25 (s, 1H), 8.11-8.08 (m, 2H), 7.99-7.97 (m, 3H), 7.91-7.88 (m, 2H), 7.76-7.72 (m, 2H), 7.47 (dd, J = 2.0, 8.8 Hz, 1H), 7.27 (t, J = 8.8 Hz, 1H), 5.61 (s, 2H). 874 2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 12.89 (s, 1h), DMSO 95 Method X 10.72 (s, 1H), 9.83 (s, 1H), 9.38 (d, J = 8.2 Hz, 1H), 9.22 (d, J = 5.6 Hz, 1H), 9.03 (d, J= 8.3 Hz, 1H), 8.51 (s, 1H), 8.37-8.27 (m, 1H), 8.02-7.86 (m, 3H), 7.71 (t, J = 7.6 Hz, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.51 (s, 1H), 7.25 (t, J = 7.5 Hz, 1H), 4.71 (d, J = 7.3 Hz, 2H), 1.56 (s, 1H), 0.81-0.64 (m, 4H). 875 3HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 12.88 (s, 1H), DMSO 95 Method X 9.57 (s, 1H), 9.24 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.3 Hz, 1H), 8.73 (d, J = 8.2 Hz, 1H), 8.49 (s, 1H), 8.37 (t, J = 7.8 Hz, 1H), 8.10 (dd, J = 11.3, 7.0 Hz, 2H), 7.97 (d, J = 7.8 Hz, 2H), 7.86 (s, 2H), 7.80 (d, J = 7.1 Hz, 2H), 7.71 (t, J = 7.8 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 5.65 (s, 2H), 2.78 (s, 3H). 876 CF3COOH ¹H-NMR (400 MHz, DMSO-d₆): δ 12.93 (s, 1H), DMSO 95 Method W 10.74 (s, 1H), 9.75 (s, 1H), 9.40 (s, 1H), 9.05 (d, J = 8.0 Hz, 2H), 8.99 (d, J = 6.0 Hz, 1H), 7.99 (s, 1H), 7.98-7.96 (m, 1H), 7.89-7.86 (m, 2H), 7.72-7.51 (m, 2H), 7.24 (t, J = 6.0 Hz, 1H), 5.84 (s, 2H), 3.60-3.56 (m, 2H), 3.43-3.39 (m, 2H), 2.06-2.01 (m, 2H), 1.99-1.84 (m, 2H). 1757  ¹H NMR (400 MHz, DMSO) δ 9.32-9.27 (m, 1H), DMSO >98 Method W using K₂CO₃ 8.66 (dd, J = 4.8, 1.7 Hz, 1H), 8.64-8.60 (m, instead of Cs₂CO₃ 1H), 8.50-8.43 (m, 1H), 8.30-8.03 (m, 1H), 7.93-7.80 (m, 4H), 7.68-7.60 (m, 2H), 7.59- 7.49 (m, 2H), 7.39 (ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 5.43 (s, 2H).

Method Y: 2-Amino-N-cyclohexyl-benzamide (ii-b)

To a dry reaction vial was added cyclohexylamine (40 μmol, 1.0 eq) and PS-carbodiimide resin (72 μmol, 1.8 eq). The solution of 2-amino-benzoic acid (44 μmol, 1.1 eq), diisopropyl ethyl amine (10 μLl) and HOBt (44 μmol, 1.1 eq) in THF (500 μL) was added to the above vial. The reaction mixture was heated at 40° C. for 6 h on a shaker. The resin was removed by filtration and washed with 10% MeOH/CH₂Cl₂. The solvent was removed in vacuo and the residue was applied to solid phase extraction cartridge (basic silica, 200 mg) and eluted with 50% EtOAc/CH₂Cl₂. After removal of the solvents, the crude 2-amino-N-cyclohexyl-benzamide was obtained and used for the following reaction.

Method Z: N-Cyclohexyl-2-(6-methoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide (xiv-f)

To the crude amide was added the solution of 4-chloro-6-methoxy-2-pyridin-3-yl-quinazoline (20 μmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF(1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 27, replacing cyclohexylamine with the appropriate amine.

TABLE 7 Method Exact LCMS of Number Product Mass (M + 1) Coupling 877

489 490 Methods Y, Z 878

453 454 Methods Y, Z 879

495 496 Methods Y, Z 880

495 496 Methods Y, Z 881

491 492 Methods Y, Z 882

491 492 Methods Y, Z 883

493 494 Methods Y, Z 884

467 468 Methods Y, Z 885

441 442 Methods Y, Z 886

529 530 Methods Y, Z 887

543 544 Methods Y, Z 888

543 544 Methods Y, Z 889

543 544 Methods Y, Z 890

487 488 Methods Y, Z 891

493 494 Methods Y, Z 892

467 468 Methods Y, Z 893

441 442 Methods Y, Z 894

529 530 Methods Y, Z 895

543 544 Methods Y, Z 896

543 544 Methods Y, Z 897

543 544 Methods Y, Z 898

487 488 Methods Y, Z 899

467 468 Methods Y, Z 900

501 502 Methods Y, Z 901

465 466 Methods Y, Z 902

435 436 Methods Y, Z 903

519 520 Methods Y, Z 904

487 488 Methods Y, Z 905

487 488 Methods Y, Z 906

467 468 Methods Y, Z 907

501 502 Methods Y, Z 908

465 466 Methods Y, Z 909

435 436 Methods Y, Z 910

519 520 Methods Y, Z

Method Z: Synthesis of N-(4-chlorophenyl)-6-methoxy-2-(pyridin-3-yl)quinazolin-4-amine (vi-k)

To 4-chloroaniline (24 μmol) was added the solution of 4-chloro-6-methoxy-2-pyridin-3-yl-quinazoline (20 μmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF(1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound as the TFA salt whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 29, replacing 4-chloroaniline with the appropriate aniline

TABLE 8 Exact LCMS Method of Number Product Mass (M + 1) Coupling 911

362 363 Method Z 912

358 359 Method Z 913

396 397 Method Z 914

392 393 Method Z 915

388 389 Method Z 916

372 373 Method Z 917

388 389 Method Z 918

342 343 Method Z 919

353 354 Method Z 920

416 417 Method Z 921

396 397 Method Z 922

396 397 Method Z 923

356 357 Method Z 924

364 365 Method Z 925

372 373 Method Z 926

392 393 Method Z 927

376 377 Method Z 928

426 427 Method Z 929

407 408 Method Z 930

430 431 Method Z 931

440 441 Method Z 932

392 393 Method Z 933

380 381 Method Z 934

380 381 Method Z 935

380 381 Method Z 936

434 435 Method Z 937

421 422 Method Z 938

378 379 Method Z 939

376 377 Method Z 940

387 388 Method Z 941

414 415 Method Z 942

392 393 Method Z 943

380 381 Method Z 944

390 391 Method Z 945

428 429 Method Z 946

428 429 Method Z 947

391 392 Method Z 948

356 357 Method Z 949

377 378 Method Z 950

392 393 Method Z 951

368 369 Method Z 952

397 398 Method Z 953

441 442 Method Z 954

379 380 Method Z 955

401 402 Method Z 956

383 384 Method Z 957

382 383 Method Z 958

379 380 Method Z 959

393 394 Method Z 960

411 412 Method Z 961

379 380 Method Z 962

370 371 Method Z 963

385 386 Method Z 964

427 428 Method Z 965

395 396 Method Z 966

379 380 Method Z 967

402 403 Method Z 968

384 385 Method Z

Method Z: Synthesis of 6-chloro-N-(4-chlorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (vi-c)

To 4-chloroaniline (24 μmol) was added the solution of 4,6-dichloro-2-(pyridin-3-yl)quinazoline (20 μmol) in 2-propanol (200 μL). The mixture was refluxed for 8 h. After evaporation, the residue was dissolved in 5% TFA/MeOH-DMF(1:1) and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound as the TFA salt whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 31, replacing 4-chloroaniline with the appropriate aniline

TABLE 9 Exact LCMS Method Number Product Mass (M + 1) Coupling 969

366 367 Method Z 970

362 363 Method Z 971

366 367 Method Z 972

346 347 Method Z 973

392 393 Method Z 974

392 393 Method Z 975

419 420 Method Z 976

392 393 Method Z 977

346 347 Method Z 978

350 351 Method Z 979

350 351 Method Z 980

350 351 Method Z 981

376 377 Method Z 982

420 421 Method Z 983

360 361 Method Z 984

360 361 Method Z 985

360 361 Method Z 986

360 361 Method Z 987

368 369 Method Z 988

368 369 Method Z 989

380 381 Method Z 990

376 377 Method Z 991

396 397 Method Z 992

380 381 Method Z 993

430 431 Method Z 994

392 393 Method Z 995

396 397 Method Z 996

380 381 Method Z 997

382 383 Method Z 998

384 385 Method Z 999

465 466 Method Z 1000 

357 358 Method Z 1001 

396 397 Method Z 1002 

425 426 Method Z 1003 

380 381 Method Z 1004 

434 435 Method Z 1005 

396 397 Method Z 1006 

384 385 Method Z 1007 

446 447 Method Z 1008 

415 416 Method Z 1009 

381 382 Method Z 1010 

381 382 Method Z 1011 

396 397 Method Z

N-(3-Carbamoylthiophen-2-yl)nicotinamide (iii-b)

To a solution of 2-aminothiophene-3-carboxamide (800 mg, 5.63 mmol, 1.0 eq.) in THF (15 mL) and Et₃N (626 mg, 6.19 mmol, 1.1 eq.) was added nicotinoyl chloride (795 mg, 5.63 mmol, 1.0 eq.) in anhydrous THF (15 mL) dropwise. The resulted mixture was stirred at room temperature overnight. After the reaction was completed, the volatiles were evaporated. The residue was washed with CH₂Cl₂ (20 mL). The resulting solid was collected and dried in vacuo to give 1.50 g of N-(3-carbamoylthiophen-2-yl)nicotinamide as a brown solid (quantitative yield). LCMS m/z=248.1(M+1) (Method B) (retention time=1.34 min).

2-(Pyridin-3-yl) thieno[2,3-d]pyrimidin-4(3H)-one (iv-b)

A mixture of N-(3-carbamoylthiophen-2-yl)nicotinamide (1.50 g salt, 6.07 mmol, 1.0 eq.) in EtOH (300 mL) was added NaOH (1.50 g, 37.5 mmol, 6.18 eq.). The resulting mixture was stirred at 80° C. for 7 days. After the reaction was completed, the volatiles were removed in vacuo. Water (20 mL) was added to the residue and the pH was adjusted to around 2 by adding dilute HCl (2N in water). The solution was concentrated in vacuo to give 11.0 g of the HCl salt as a beige solid. LCMS m/z=230.0 (M+1) (Method B) (retention time=1.21 min). The crude product containing salts were used for the next step without further purification.

4-Chloro-2-(pyridin-3-yl) thieno[2,3-d]pyrimidine (v-c)

The suspension of 2-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4(3H)-one (6.0 g, containing salts) in POCl₃ (30 mL) was stirred at 120° C. for 10 h. After the reaction was completed, the mixture was added to ice-water slowly. The pH was adjusted to ˜7 by slowly adding NH₃.H₂O at 0° C., then a precipitate formed. The solid was collected and 540 mg of 4-chloro-2-(pyridin-3-yl) thieno[2,3-d]pyrimidine was obtained as a brown solid. LCMS m/z=247.9, 250.0 (M+1) (Method B) (retention time=1.85 min)

N-(3-Chloro-4-fluorophenyl)-2-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4-amine (vi-l)

A mixture of 4-chloro-2-(pyridin-3-yl)thieno[2,3-d]pyrimidine (80 mg, 0.32 mmol, 1.0 eq.) and 3-chloro-4-fluorobenzenamine (93 mg, 0.64 mmol, 2.0 eq.) in i-AmOH (8 mL) was stirred at 130° C. overnight. A yellow precipitate formed and was collected and washed with MeOH (10 mL). The solid was suspended in H₂O (10 mL) and NH₃—H₂O (1 mL) was added. After filtration and drying in vacuo, 23.0 mg of the product was obtained as a yellow solid (20.0%). LCMS m/z=357.0, 359.0 (M+1) (Method B) (retention time=1.96 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.99 (s, 1H), 9.48 (d, J=1.6 Hz, 1H), 8.70-8.67 (m, 1H), 8.63 (d, J=8.0 Hz, 1H), 8.27 (dd, J=6.8, 2.6 Hz, 1H), 7.76-7.93 (m, 3H), 7.54-7.57 (m, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 33, replacing 4-fluoro-3-chloroaniline with the appropriate aniline

TABLE 10 Salt Molecular Number PRODUCT type Mass ¹H-NMR 1012

347.39 1H-NMR (400 MHz, DMSO-d6): δ 12.69 (s, 1H), 9.55 (d, J = 1.3 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.44 (s, 1H), 8.60-8.78 (m, 2H), 7.82- 8.00 (m, 3H), 7.42-7.79 (m, 3H), 7.20 (t, J = 7.2 Hz, 1H). 1013

370.38 1H-NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 9.51 (d, J = 1.2 Hz, 1H), 8.60-8.77 (m, 2H), 7.98- 7.94 (m, 2H), 7.71-7.86 (m, 2H), 7.56-7.50 (m, 1H), 7.30 (t, J = 74.0 Hz, 1H), 6.96 (dd, J = 8.8, 2.0 Hz, 1H). 1014

388.37 1H-NMR (400 MHz, DMSO-d6): δ 10.04 (s, 1H), 9.50 (d, J = 1.6 Hz, 1H), 8.58-8.75 (m, 2H), 8.18 (s, 1H), 7.77-8.00 (m, 3H), 7.50- 7.65 (m, 2H), 7.08-7.18 (m, 1H) 1015

356.8  1H-NMR (400 MHz, DMSO-d6): δ 9.99 (s, 1H), 9.48 (d, J = 1.6 Hz, 1H), 8.70-8.67 (m, 1H), 8.63 (d, J = 8.0 Hz, 1H), 827 (dd, J = 6.8, 2.6 Hz, 1H), 7.76-7.93 (m, 3H), 7.54-7.57 (m, 2H). Number ¹H-NMR Solvent LCMS LCMS Protocol Purity percent Method for Coupling 1012 DMSO 348.1 Method B 95 Method C, G3 (M + 1) (NH4HCO3) 1013 DMSO 371.0 Method B 95 Method C, G3 (M + 1) (NH4HCO3) 1014 DMSO 389.0 Method B 95 Method C, G3 (M + 1) (NH4HCO3) 1015 DMSO 357.0, 359.0 Method B 95 Method C, G3 (M + 1) (NH4HCO3)

Method AA: 2-Amino-N-(cyclopropylmethyl)benzamide (ii-c)

A 100 mL round bottom flask was charged with anthranilic acid (500 mg, 3.65 mmol), added DMF (15 mL) under nitrogen atmosphere and stirring. Then, added N-methylmorpholine (1 mL, 9.12 mmol), aminomethylcyclopropane (311 mg, 4.38 mmol), N-ethyl-N′-dimethylaminopropylcarbodiimide (EDCI) (840 mg, 4.38 mmol) and HOBt (670 mg, 4.38 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with diethyl ether (50 mL x 2). The organic extracts were combined, washed with brine, dried over MgSO₄, filtered and concentrated to afford amorphous colorless 2-amino-N-(cyclopropylmethyl)benzamide (500 mg, 72% yield), which was checked by NMR and used for next step without further purification. ¹H-NMR (Bruker 300 MHz, DMSO-d6) δ 0.20-1.01 (m, 4H), 1.01-1.04 (m, 1H), 3.06-3.11 (m, 2H), 6.37-8.21 (m, 7H).

Method Z: 2-(6-chloro-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-(cyclopropylmethyl) benzamide (xiv-g)

A 100 mL round bottom flask was charged with 4,6-dichloro-2-(pyridin-3-yl)quinazoline (synthesized as described in Scheme 1 and 4, substituting 5-chloro-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (150 mg, 0.54 mmol) and 2-amino-N-(cyclopropylmethyl)benzamide) (310 mg, 1.63 mmol) and anhydrous i-PrOH (20 mL) was added and refluxed for 3 h. The reaction mixture was cooled to room temperature and Et₃N (3eq) was added. The solvent was removed in vacuo. To the crude product was added a water-methanol mixture (5:1, 50 mL), and then sonicated for 5 min. The solidified compound was collected by filtration, and the solid was recrystallized from hot methanol and washed with water. The product was dried at 50° C. to give 2-(6-chloro-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-(cyclopropylmethyl)benzamide as a colorless cotton (220 mg, 94%). The structure was confirmed by NMR and elemental analysis. ¹H NMR (Bruker 300 MHz, DMSO-d₆) ppm 0.20-0.98 (m, 5H), 3.07-3.21 (m, 2H), 7.24-8.26 (m, 7H), 8.68-9.55 (m, 5H), 12.22 (s, 1H). CHN Calcd. C, 67.05; H, 4.69; N, 16.29 Found C, 67.15; H, 4.89; N, 16.25.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 34, replacing aminomethylcyclopropane with the appropriate amine.

TABLE 11 ¹H NMR Purity Method of Number Product ¹H NMR Solvent percent Coupling 1016

¹H NMR (DMSO-d₆) ppm 1.46 (d, 3H, J = 6.7 Hz), 3.90 (s, 3H), 5.17-5.22 (m, 1H), 7.19-7.98 (m, 12H), 8.67-8.71 (m, 2H), 8.90 (d, 1H, J = 8.2 Hz), 9.22 (d, 1H, J = 8.3 Hz), 9.55 (s, 1H), 12.18 (s, 1H). DMSO >98 Method Z 1017

¹H NMR (DMSO-d₆) ppm 1.49- 1.62 (m, 8H), 3.99 (s, 3H), 4.24- 4.26 (m, 1H), 7.24-7.71 (m, 7H), 8.65-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1018

¹H NMR (DMSO-d₆) ppm 0.88- 1.99 (m, 7H), 3.14-3.16 (m, 2H), 3.02 (s, 3H), 7.57-7.91 (m, 7H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1019

¹H NMR (DMSO-d₆) ppm 1.07- 1.12 (m, 3H), 3.44-3.52 (m, 2H), 4.01 (s, 3H), 7.24-786 (m, 8H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1020

1H NMR (DMSO-d₆) ppm 0.87- 0.92 (m, 3H), 1.53-1.62 (m, 2H,), 3.30-3.32 (m, 2H), 3.98 (s, 3H), 7.21-7.89 (m, 7H), 8.67-9.55 (m, 5H), 12.38 (s, 1H). DMSO >98 Method Z 1021

1H NMR (DMSO-d₆) ppm 0.83- 1.51 (m, 7H), 3.30-3.32 (m, 2H), 3.99 (s, 3H), 7.24-7.90 (m, 7H), 8.67-9.55 (m, 5H), 12.38 (s, 1H). DMSO >98 Method Z 1022

1H NMR (DMSO-d₆) ppm 0.79- 1.52 (m, 9H), 3.25-3.30 (m, 2H), 3.98 (s, 3H), 7.21-7.88 (m, 7H), 8.68-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1023

1H NMR (DMSO-d₆) ppm 0.80- 1.49 (m, 11H), 3.26-3.30 (m, 2H), 3.99 (s, 3H), 7.24-7.90 (m, 7H), 8.67-9.56 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1024

1H NMR (DMSO-d₆₎ ppm 3.99- 4.10 (m, 5H), 5.07-5.33 (m, 2H), 5.89-5.91 (m, 1H), 7.24-7.90 (m, 7H), 8.68-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1025

1H NMR (DMSO-d₆) ppm 3.13 (s, 1H), 3.99-4.12 (m, 5H), 7.21-7.89 (m, 7H), 8.67-9.54 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1026

1H NMR (DMSO-d₆) ppm 1.68- 2.22 (m, 6H), 3.99 (s, 3H), 4.24- 4.26 (m, 1H), 7.22-7.92 (m, 7H), 8.66-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1027

1H NMR (DMSO-d₆) ppm 1.41- 1.86 (m, 12H), 3.90 (br s, 4H), 7.23-7.89 (m, 7H), 8.63-9.55 (m, 5H), 12.30 (s, 1H). DMSO >98 Method Z 1028

1H NMR (DMSO-d₆) ppm 0.85- 1.60 (m, 9H), 3.27-3.33 (m, 2H), 3.99 (s, 3H), 7.21-7.91 (m, 7H), 8.68-9.55 (m, 5H), 12.19 (s, 1H). DMSO >98 Method Z 1029

1H NMR (DMSO-d₆) ppm 1.03- 1.34 (m, 6H), 3.17-3.31 (m, 4H), 7.40-7.88 (m, 7H), 8.55-10.03 (m, 5H), 12.32 (s, 1H). DMSO >98 Method Z 1030

1H NMR (DMSO-d₆) ppm 0.83- 1.52 (m, 5H), 3.20-3.29 (m, 2H), 7.27-8.21 (m, 7H), 8.67-9.53 (m, 5H), 12.33 (s, 1H). DMSO >98 Method Z 1031

1H NMR (DMSO-d₆) ppm 1.02- 1.07 (m, 3H), 3.24-3.32 (m, 2H), 7.27-8.22 (m, 7H), 8.67-9.53 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1032

1H NMR (DMSO-d₆) ppm 0.75- 1.37 (m, 7H), 3.18-3.20 (m, 2H), 7.21-8.19 (m, 7H), 8.64-9.48 (m, 5H), 12.15 (s, 1H). DMSO >98 Method Z 1033

1H NMR (DMSO-d₆) ppm 3.90- 3.92 (m, 2H), 5.02-5.17 (m, 2H), 5.81-5.86 (m, 1H), 7.27-8.23 (m, 7H), 8.68-9.55 (m, 5H), 12.25 (s, 1H). DMSO >98 Method Z 1034

1H NMR (DMSO-d₆) ppm 0.78- 1.42 (m, 11H), 3.20-3.29 (m, 2H), 7.25-7.91 (m, 7H), 8.23-9.53 (m, 5H), 12.17 (s, 1H). DMSO >98 Method Z 1035

¹H NMR (DMSO-d₆) ppm 3.06 (s, 1H), 4.05-4.08 (m, 2H), 7.28-8.22 (m, 7H), 8.65-9.51 (m, 5H), 12.12 (s, 1H). DMSO >98 Method Z 1036

1H NMR (DMSO-d₆) ppm 0.88- 1.92 (m, 7H), 3.05-3.16 (m, 2H), 7.23-7.94 (m, 7H), 8.22-9.54 (m, 5H), 12.21 (s, 1H). DMSO >98 Method Z 1037

1H NMR (DMSO-d₆) ppm 1.37- 1.79 (m, 12H), 3.90-3.96 (m, 1H), 7.25-8.24 (m, 7H), 8.55-9.52 (m, 5H), 12.07 (s, 1H). DMSO >98 Method Z 1038

1H NMR (DMSO-d₆) ppm 1.49- 1.85 (m, 8H), 4.24-4.26 (m, 1H), 7.23-7.69 (m, 6H), 7.85-9.53 (m, 6H), 12.06 (s, 1H). DMSO >98 Method Z 1039

1H NMR (DMSO-d₆) ppm 1.12- 1.14 (m, 6H), 4.11-4.18 (m, 1H), 7.23-7.94 (m, 8H), 8.33-9.53 (m, 4H), 12.30 (s, 1H). DMSO >98 Method Z 1040

1H NMR (DMSO-d₆) ppm 0.84- 1.16 (m, 9H), 3.28-3.34 (m, 2H), 7.23-7.91 (m, 6H), 8.25-9.53 (m, 6H), 12.16 (s, 1H). DMSO >98 Method Z 1041

1H NMR (DMSO-d₆) ppm 0.79- 1.52 (m, 9H), 3.25-3.32 (m, 2H), 7.24-7.91 (m, 6H), 8.23-9.53 (m, 6H), 12.18 (s, 1H). DMSO >98 Method Z 1042

1H NMR (DMSO-d₆) ppm 1.04- 1.81 (m, 10H), 3.77-3.82 (m, 1H), 7.21-8.05 (m, 8H), 8.65-9.52 (m, 4H), 11.96 (s, 1H). DMSO >98 Method Z 1043

1H NMR (DMSO-d₆₎ ppm 0.47- 0.67 (m, 4H), 2.85-2.88 (m, 1H), 7.26-8.26 (m, 7H), 8.66-9.52 (m, 5H), 12.26 (s, 1H). DMSO >98 Method Z 1044

1H NMR (DMSO-d₆) ppm 1.14 (s, 9H), 7.30-7.93 (m, 7H), 8.21- 9.50 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1045

1H NMR (DMSO-d₆) ppm 3.98 (s, 3H), 4.36 (s, 2H), 6.47 (s, 1H), 7.21-7.91 (m, 9H), 8.68-9.56 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1046

1H NMR (DMSO-d₆) ppm 4.30 (s, 2H), 6.42 (s, 1H), 7.28-8.24 (m, 9H), 8.70-9.53 (m, 5H), 12.22 (s, 1H). DMSO >98 Method Z 1047

1H NMR (DMSO-d₆) ppm 1.69- 2.55 (m, 6H), 4.41-4.44 (m, 1H), 7.23-8.24 (m, 7H), 8.65-9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1048

1H NMR (DMSO-d₆) ppm 4.55 (s, 2H), 7.17-8.21 (m, 12H), 8.65- 9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1049

1H NMR (DMSO-d₆) ppm 7.02- 8.67 (m, 15H), 9.47 (s, 1H), 10.04 (s, 1H), 12.06 (s, 1H). DMSO >98 Method Z 1050

1H NMR (DMSO-d₆) ppm 2.75- 2.80 (m, 2H), 3.48-3.54 (m, 2H), 7.08-8.20 (m, 12H), 8.69-9.56 (m, 5H), 12.16 (s, 1H). DMSO >98 Method Z 1051

1H NMR (DMSO-d₆) ppm 4.01- 4.10 (m, 2H), 7.28-8.27 (m, 7H), 8.59-9.51 (m, 5H), 11.45 (s, 1H). DMSO >98 Method Z 1052

1H NMR (DMSO-d₆) ppm 4.38- 4.57 (m, 4H), 7.27-8.24 (m, 7H), 8.69-9.56 (m, 5H), 12.10 (s, 1H). DMSO >98 Method Z 1053

1H NMR (DMSO-d₆) ppm 2.85- 2.92 (br s, 3H), 7.20-8.22 (m, 7H), 8.67-9.56 (m, 5H), 12.61 (s, 1H). DMSO >98 Method Z 1054

1H NMR (DMSO-d₆) ppm 1.04- 1.81 (m, 10H), 3.77-3.82 (m, 1H), 7.24-8.05 (m, 8H), 8.65-9.52 (m, 4H), 12.27 (s, 1H). DMSO >98 Method Z 1055

1H NMR (DMSO-d₆) ppm 2.49- 2.51 (m, 2H), 3.57-3.59 (m, 2H), 7.21-8.16 (m, 12H), 8.69-9.56 (m, 5H), 12.16 (s, 1H). DMSO >98 Method Z 1056

1H NMR (DMSO-d₆) ppm 0.79- 1.44 (m, 11H), 3.26-3.30 (m, 2H), 7.24-7.92 (m, 7H), 8.67-9.52 (m, 5H), 12.45 (s, 1H). DMSO >98 Method Z 1057

1H NMR (DMSO-d₆) ppm 1.04- 1.16 (m, 3H), 3.33-3.38 (m, 2H), 7.20-8.22 (m, 7H), 8.60-9.53 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1058

1H NMR (DMSO-d₆) ppm 7.09- 8.68 (m, 15H), 9.51 (s, 1H), 10.34 (s, 1H), 12.06 (s, 1H). DMSO >98 Method Z 1059

1H NMR (DMSO-d₆) ppm 3.78 (s, 3H), 4.43 (s, 2H), 6.77-8.23 (m, 11H), 8.68-9.54 (m, 5H), 12.06 (s, 1H). DMSO >98 Method Z 1060

1H NMR (DMSO-d₆) ppm 3.69 (s, 3H), 4.48 (s, 2H), 6.89-8.15 (m, 11H), 8.68-9.54 (m, 5H), 12.44 (s, 1H). DMSO >98 Method Z 1061

1H NMR (DMSO-d₆) ppm 2.24 (s, 3H), 4.46 (s, 2H), 7.03-8.13 (m, 11H), 8.67-9.54 (m, 5H), 12.21 (s, 1H). DMSO >98 Method Z 1062

1H NMR (DMSO-d₆) ppm 4.51 (s, 2H), 7.11-8.14 (m, 11H), 8.67- 9.54 (m, 5H), 12.34 (s, 1H). DMSO >98 Method Z 1063

1H NMR (DMSO-d₆) ppm 4.47 (s, 2H), 7.05-8.14 (m, 11H), 8.67- 9.54 (m, 5H), 12.37 (s, 1H). DMSO >98 Method Z 1064

1H NMR (DMSO-d₆) ppm 3.95 (s, 3H), 4.47 (s, 2H), 7.05-8.14 (m, 11H), 8.67-9.54 (m, 5H), 12.32 (s, 1H). DMSO >98 Method Z Starting Starting Number Material R¹ Material R³ Product 1065

1066

1067

1068

1069

1070

1071

1072

¹H NMR Number Salt Type ¹H NMR Solvent Purity percent Method of Coupling 1065 ¹H NMR (DMSO-d₆) ppm 4.52 (d, 2H, J = 5.8 Hz), DMSO >98 Method Y, Z 7.21-7.30 (m, 5H), 7.50 (t, J = 7.9 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.89-7.92 (m, 3H), 8.21 (d, J = 1.8 Hz, 1H), 8.65-8.70 (m, 3H), 8.99 (s, 1H), 9.52 (s, 1H), 11.88 (s, 1H) 1066 ¹H NMR (DMSO-d₆) ppm 4.49 (d, 2H, J = 5.6 Hz), DMSO >98 Method Y, Z 7.24-7.35 (m, 5H), 7.50 (t, J = 7.2 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.91-7.95 (m, 3H), 8.22 (d, J = 1.5 Hz, 1H), 8.67-8.73 (m, 3H), 9.19 (s, 1H), 9.53 (s, 1H), 11.98 (s, 1H) 1067 ¹H NMR (DMSO-d₆) ppm 4.58 (d, 2H, J = 5.7 Hz), DMSO >98 Method Y, Z 7.16-7.36 (m, 5H), 7.50 (t, J = 7.5 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.88-7.96 (m, 3H), 8.22 (d, J = 1.5 Hz, 1H), 8.65-8.69 (m, 3H), 8.98 (s, 1H), 9.52 (s, 1H), 11.87 (s, 1H) 1068 ¹H NMR (DMSO-d₆) ppm 4.47 (d, 2H, J = 5.6 Hz), DMSO >98 Method Y, Z 7.30 (br s, 5H), 7.54 (t, J = 7.7 Hz, 1 H), 7.70 (t, J = 7.8 Hz, 1H), 7.88-7.96 (m, 3H), 8.15 (d, J = 1.5 Hz, 1H), 8.68-8.81 (m, 3H), 8.98 (s, 1H), 9.52 (s, 1H), 12.29 (s, 1H) 1069 ¹H NMR (DMSO-d₆) ppm 4.57 (d, 2H, J = 5.6 Hz), DMSO >98 Method Y, Z 7.23-7.29 (m, 5H), 7.39 (t, J = 7.9 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.94-7.99 (m, 3H), 8.15 (d, J = 1.4 Hz, 1H), 8.68-8.84 (m, 3H), 9.24 (s, 1H), 9.55 (s, 1H), 12.23 (s, 1H) 1070 ¹H NMR (DMSO-d₆) ppm 4.50 (d, 2H, J = 5.5 Hz), DMSO >98 Method Y, Z 7.25-7.53 (m, 5H), 7.69 (t, J = 7.1 Hz, 1H), 7.73 (t, J = 7.0 Hz, 1H), 7.94-8.15 (m, 3H), 8.18 (d, J = 1.4 Hz, 1H), 8.68-8.82 (m, 3H), 9.24 (s, 1H), 9.54 (s, 1H), 12.21 (s, 1H) 1071 ¹H NMR (DMSO-d₆) ppm 3.90 (s, 3H), 4.56 (d, DMSO >98 Method Y, Z 2H, J = 5.6 Hz), 7.22-7.44 (m, 7H), 7.44 (t, J = 7.9 Hz, 1H), 7.74 (t, J = 7.9 Hz, 1H), 7.94-7.99 (m, 2H), 8.68-8.81 (m, 3H), 9.24 (s, 1H), 9.55 (s, 1H), 12.19 (s, 1H) 1072 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 12.17 (s, 1H), DMSO  95 Method Y, Z 9.52 (s, 1H), 9.08 (s, 1H), 8.95 (d, J = 7.6 Hz, 1H), 8.85 (s, 1H), 8.66 (d, J = 7.8 Hz, 1H), 7.91 (t, J = 9.4 Hz, 2H), 7.84 (s, 1H), 7.75-7.67 (m, 1H), 7.65 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.30 (t, J = 7.3 Hz, 1H), 4.47 (d, J = 47.3 Hz, 2H), 4.26 (d, J = 6.8 Hz, 2H), 3.58-3.50 (m, 2H), 1.47 (t, J = 6.7 Hz, 3H).

Method AB: Methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate (xxvi-a)

To a solution of 6-iodo-2-(pyridin-3-yl) quinazolin-4-ol (synthesized as described in Scheme 1 and 4, substituting 5-iodo-2-nitrobenzoic acid for 2-nitro-5-propoxy-benzoic acid) (3.00 g, 8.6 mmol, 1.0 eq.), Pd(OAc)₂ (48 mg, 0.21 mmol, 0.025 eq.) and PPh₃ (113 mg, 0.43 mmol, 0.05 eq.) in DMF (8 mL) was added methyl acrylate (3.22 g, 25.8 mmol, 3.0 eq.) and DIPEA (1.22 g, 9.46 mmol, 1.1 eq.) under Ar atmosphere. The mixture was stirred at 110° C. overnight. After cooling, the mixture was filtered and the solid was washed with ethyl acetate three times to afford 1.30 g of xxxvi-a as green solid (yield 49%). LCMS m/z=308.0 (M+1) (Method B) (retention time=1.41 min).

Methyl 3-(4-hydroxy-2-(pyridin-3-yl) quinazolin-6-yl)propanoate (xxvii-a)

Methyl 3-(4-hydroxy-2-(pyridin-3-yl) quinazolin-6-yl) propanoate was prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate to afford 1.40 g of xxvii-a in quantitative yield as a yellow solid. LCMS m/z=310.0 (M+1) (Method B) (retention time=1.42 min).

3-(4-Chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester (xxviii-a)

3-(4-Chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline using Method F, replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)propanoate) was obtained in quantitative yield to give 1.50 g of xxvii-a as a red solid. LCMS m/z=328.1, 330.0 (M+1) (Method B) (retention time=1.86 min).

3-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (xxviv-a)

3-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (prepared in a manner analogous to that described for 2-(6-propoxy-2-pyridin-3-yl-quinazolin-4-ylamino)-benzamide in Method G1, replacing 4,7-dichloro-2-(4-chlorophenyl)quinazoline and 2-aminobenzamide with 3-(4-chloro-2-pyridin-3-yl-quinazolin-6-yl)-propionic acid methyl ester and 3-chloro-4-fluoro-phenylamine) was obtained in a 43% yield to give 1.04 g of xxviv-a as a yellow solid. LCMS m/z=437.1, 439.1 (M+1) (Method B) (retention time=1.62 min).

Method AC: 3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl) quinazolin-6-yl)propanoic acid (xxx-a)

To a solution of 3-[4-(3-chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-propionic acid methyl ester (1.04 g, 2.39 mmol, 1.0 eq.) in DMF (20 mL) was added a solution of NaOH (0.57 g, 14.3 mmol, 6.0 eq.) in H₂O (8 mL). The mixture was stirred at room temperature for 2 h. 50 mL of water was added to the mixture. After filtration, the resulting filter cake was washed with water and dried in vacuo to give 933 mg of xxx-a as a yellow solid (yield 93%). LCMS m/z=423.1, 425.1 (M+1) (Method A) (retention time=1.51 min).

3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)-N,N-dimethyl propanamide (xxxi-a)

3-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)-N,N-dimethyl propanamide (prepared in a manner analogous to that described for 2-benzamido-5-methoxy-3-methylbenzamide in Method D, replacing nicotinic acid and 2-amino-5-methoxy-3-methylbenzamide with 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propanoic acid and dimethylamine hydrochloride) was obtained in 90% yield to give 891 mg of xxxi-a as a yellow solid. LCMS m/z=450.0, 452.0 (M+1) (Method B) (retention time=1.834 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.95 (s, 1H), 9.51 (d, J=1.6 Hz, 1H), 8.69-8.63 (m, 2H), 8.38 (s, 1H), 8.28 (dd, J=6.8, 2.4 Hz, 1H), 7.94-7.90 (m, 1H), 7.81 (s, 2H), 7.55-7.51 (m, 2H), 3.04 (t, J=7.6 Hz, 2H), 2.99 (s, 3H), 2.85 (s, 3H), 2.77 (t, J=8.0 Hz, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 36, replacing dimethylamine with the appropriate amine and 4-fluoro, 3-chloro aniline with the appropriate aniline.

TABLE 12 Salt Molecular ¹H-NMR LCMS Purity Method for Number PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1073

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.52 (s, 1H), 8.65-8.69 (m, 2H), 8.39 (s, 1H), 8.28 (d, J = 5.2 Hz, 1H), 7.92-7.93 (m, 1H), 7.82 (q, J = 8.0 Hz, 2H), 7.52-7.57 (m, 2H), 7.35 (s, 1H), 6.84 (s, 1H), 3.05 (t, J = 7.2 Hz, 2H), 2.51-2.54 (m, 2H). DMSO 422.1 (M + 1) Method B (NH4HCO3) 95 Method C 1074

435.43 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.55 (d, J = 2.4 Hz, 1H), 8.68-8.70 (m, 2H), 8.47 (s, 1H), 7.97-7.99 (m, 1H), 7.79-7.86 (m, 3H), 7.50- 7.55 (m, 2H), 7.36 (s, 1H), 7.30 (t, J = 73.6 Hz, 1H), 6.99 (dd, J = 8.4, 2.4 Hz, 1H), 6.82 (s, 1H), 3.05 (t, J = 8.0 Hz, 2H), 2.52 (t, J = 8.4 Hz, 2H). DMSO 436.2 (M + 1) Method B (NH4HCO3) 95 Method C 1075

435.88 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.00 (s, 1H), 9.52 (s, 1H), 8.65-8.69 (m, 2H), 8.39 (s, 1H), 8.27- 8.29 (m, 1H), 7.79 (dd, J = 9.2, 2.4 Hz, 1H), 7.76- 7.85 (m, 3H), 7.52-7.57 (m, 2H), 3.05 (t, J = 7.6 Hz, 2H), 2.57 (d, J = 4.4 Hz, 3H), 2.52-2.54 (m, 2H). DMSO 436.1 (M + 1) Method B (NH4HCO3) 95 Method D 1076

449.91 ¹H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.51 (d, J = 1.6 Hz, 1H), 8.63-8.69 (m, 2H), 8.38 (s, 1H), 8.28 (dd, J = 6.8, 2.4 Hz, 1H), 7.90-7.94 (m, 1H), 7.81 (s, 2H), 7.51-7.55 (m, 2H), 3.04 (t, J = 7.6 Hz, 2H), 2.99 (s, 3H), 2.85 (s, 3H), 2.77 (t, J = 8.0 Hz, 2H). DMSO 450.0 (M + 1) Method B (NH4HCO3) 95 Method D 1077

540.01 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.01 (s, 1H), 9.52 (d, J = 1.6 Hz, 1H), 8.61-8.74 (m, 2H), 8.41 (s, 1H), 8.28 (dd, J = 6.8, 2.6 Hz, 1H), 7.80-7.99 (m, 3H), 7.46-7.63 (m, 2H), 3.89 (s, 4H), 3.20 (s, 2H), 3.08 (t, J = 7.4 Hz, 4H), 2.90 (t, J = 7.6 Hz, 2H). DMSO 540.2, 542.2 (M + 1) Method B (NH4HCO3) 95 Method D

(E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile (xxxii-a)

(E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile (prepared in a manner analogous to that described for (E)-methyl 3-(4-hydroxy-2-(pyridin-3-yl)quinazolin-6-yl)acrylate using Method AB, replacing 6-iodo-2-(pyridin-3-yl)quinazolin-4-ol and methyl acrylate with N-(3-chloro-4-fluorophenyl)-6-iodo-2-(pyridin-3-yl)quinazolin-4-amine and but-3-enenitrile) was obtained in a 48% yield to give 400 mg of xxxii-a as grey solid. LCMS m/z=416.0 (M+1) (Method B) (retention time=1.99 min).

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (xxxiii-a)

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with (E)-4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)but-3-enenitrile) was obtained in a 95% yield to give 190 mg of xxxiii-a as a brown solid. LCMS m/z=418.1(M+1) (Method B) (retention time=1.95 min).

Method AD: 4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)butanoic acid (xxxiv-a)

4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-butyronitrile (190 mg, 046 mmol, 1.0 eq.) was treated with concentrated HCl (8 mL). The mixture was stirred at 100° C. for 2 days. The volatiles were removed in vacuo, and the residue was washed with water to afford 70 mg of xxxiv-a in a 35% yield as a yellow solid. LCMS m/z=437.1, 439.1 (M+1) (Method B) (retention time=1.46 min).

4-(4-(3-Chloro-4-fluorophenylamino)-2-(pyridin-3-yl) quinazolin-6-yl)-1-morpholino butan-1-one (xxxv-a)

4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl) quinazolin-6-yl)-1-morpholinobutan-1-one was prepared in a manner analogous to that described for 2-benzamido-5-methoxy-3-methylbenzamide in Method D, replacing nicotinic acid and 2-amino-5-methoxy-3-methylbenzamide with 4-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl) butanoic acid and morpholine to give 32 mg of xxxv-a in a 40% yield as a beige solid. LCMS m/z=506.2, 508.1 (M+1) (Method B) (retention time=1.85 min). ¹H NMR (400 MHz, DMSO-d₆): δ 10.04 (s, 1H), 9.52 (d, J=1.6 Hz, 1H), 8.69-8.65 (m, 2H), 8.39-8.38 (m, 1H), 8.27 (dd, J=6.8, 2.8 Hz, 1H), 7.94-7.90 (m, 1H), 7.86-7.84 (m, 1H), 7.80-7.77 (m, 1H), 7.57-7.52 (m, 2H), 3.56-3.53 (m, 4H), 3.46-3.41 (m, 4H), 2.85 (t, J=8.0 Hz, 2H), 2.40 (t, J=7.6 Hz, 2H), 1.97 (t, J=7.6 Hz, 2H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 38 in the synthesis of 4-(4-(3-Chloro-4-fluorophenyl amino)-2-(pyridin-3-yl) quinazolin-6-yl)-1-morpholino butan-1-one, replacing (E)-4-[4-(3-Chloro-4-fluoro-phenylamino)-2-pyridin-3-yl-quinazolin-6-yl]-but-3-enenitrile with 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carbonitrile.

TABLE 13 Salt Molecular ¹H-NMR LCMS Purity Method for Number PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1078

411.46 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 1.6 Hz, 1H), 8.78 (td, J = 7.9, 1.8 Hz, 1H), 8.71 (dd, J = 4.7, 1.6 Hz, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.59 (brs, 1H), 7.58 (dd, J = 7.6, 4.8 Hz, 1H), 7.52 (dd, J = 9.2, 2.8 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 7.08 (d, J = 6.4 Hz, 1H), 6.84 (dd, J = 8.0, 1.1 Hz, 1H), 6.69 (s, 1H), 4.36 (t, J = 6.5 Hz, 2H), 4.09 (t, J = 6.4 Hz, 2H), 3.46 (s, 3H), 2.30 (s, 3H). DMSO 412.2 (M + 1) Method B (NH4HCO3) 95 Method C, G 1079

506.96 ¹H NMR (400 MHz, DMSO-d₆): δ 10.42 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.08 (d, J = 1.2 Hz, 1H), 8.73- 8.65 (m, 3H), 8.28 (dd, J = 6.8, 2.4 Hz, 1H), 7.97- 7.93 (m, 2H), 7.60-7.53 (m, 2H), 3.60-3.58 (m, 4H), 3.51-3.46 (m, 2H), 2.55-2.53 (m, 2H), 2.41- 2.48 (m, 4H). DMSO 508.1 (M + 1) 254.1 254.9 (M/2 + 1) Method B (NH4HCO3) 95 Method C, G, C 1080

461.92 ¹H NMR (400 MHz, DMSO-d₆): δ 10.21 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.72-8.67 (m, 2H), 8.64 (d, J = 1.2 Hz, 1H), 8.28 (dd, J = 7.0, 2.6 Hz, 1H), 7.95- 7.86 (m, 3H), 7.60-7.53 (m, 2H), 3.68 (d, J = 2.4 Hz, 2H), 3.37-3.34 (m, 2H), 1.65-1.51 (m, 6H). DMSO 462.0 464.0 (M + 1) 232.3 (M/2 + 1) Method A (TFA) 95 Method C, G, C 1081

479.96 ¹H NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.72-8.67 (m, 2H), 8.64 (d, J = 1.2 Hz, 1H), 8.28 (dd, J = 6.8, 2.8 Hz, 1H), 7.97- 7.90 (m, 3H), 7.60-7.54 (m, 2H), 3.97-3.94 (m, 2H), 3.66-3.60 (m, 2H), 2.77-2.67 (m, 4H). DMSO 480.0 482.0 (M + 1) 240.6 (M/2 + 1) Method A (TFA) 95 Method C, G, C 1082

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.79-8.64 (m, 3H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.01-7.87 (m, 3H), 7.53-7.60 (m, 2H), 3.15-3.05 (m, 3H), 3.02 (s, 3H). DMSO 422.1, 424.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1083

463.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.55 (d, J = 1.4 Hz, 1H), 8.77-8.65 (m, 3H), 8.02-7.87 (m, 3H), 7.60-7.54 (m, 2H), 3.56-3.39 (m, 2H), 3.82-3.55 (m, 6H). DMSO 464.1, 466.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1084

407.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.41 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 9.08 (d, J = 1.3 Hz, 1H), 8.76- 8.63 (m, 3H), 8.32-8.20 (m, 2H), 7.96-7.93 (m, 2H), 7.63-7.50 (m, 2H), 2.88 (d, J = 4.5 Hz, 3H). DMSO 408.0, 410.0 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1085

447.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.55 (d, J = 1.5 Hz, 1H), 8.68-8.77 (m, 3H), 8.28 (dd, J = 6.9, 2.6 Hz, 1H), 8.02 (dd, J = 8.6, 1.6 Hz, 1H), 7.99-7.90 (m, 2H), 7.53-7.58 (m, 2H), 3.57 (t, J = 6.8 Hz, 2H), 3.51 (t, J = 6.4 Hz, 2H), 1.85-1.95 (m, 4H). DMSO 448.1, 420.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1086

476.93 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.54 (d, J = 1.5 Hz, 1H), 8.75-8.63 (m, 3H), 8.29 (dd, J = 6.8, 2.6 Hz, 1H), 8.01-7.84 (m, 3H), 7.60-7.53 (m, 2H), 3.72 (d, J = 2.2 Hz, 2H), 3.51-3.39 (m, 2H), 2.48-2.40 (m, 2H), 2.33 (d, J = 1.3 Hz, 2H), 2.24 (s, 3H). DMSO 477.1, 479.1 (M + 1) 239.1, 239.9 (M/2 + 1) Method B (NH₄HCO₃) 95 Method C, G, D 1087

511.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.59-8.82 (m, 3H), 8.26 (dd; J = 6.8, 2.6 Hz, 1H), 7.81-8.14 (m, 3H), 7.57 (m, 2H), 3.83-4.10 (m, 4H), 3.33-3.35 (m, 4H). DMSO 512.1, 514.1 (M + 1) Method B (NH4HCO3) 95 Method C, G, C 1088

481.91 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.47 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 9.23 (d, J = 1.2 Hz, 1H), 8.72- 8.74 (m, 3H), 8.22-8.42 (m, 2H), 7.85-8.12 (m, 2H), 7.55-7.59 (m, 2H), 4.61 (t, J = 5.4 Hz, 1H), 3.47 (t, J = 5.2 Hz, 2H), 3.37 (s, 6H). DMSO 482.1, 484.2 (M + 1) Method B (NH4HCO3) 95 Method C, G, D 1089

421.85 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.72-8.77 (m, 2H), 8.68 (d, J = 8.4 Hz, 1H), 8.34 (dd, J = 7.2, 2.0 Hz, 1H), 7.96- 8.00 (m, 1H), 7.92 (m, 1H), 7.72-7.74 (m, 1H), 7.58-7.65 (m, 2H), 3.13 (s, 3H), 3.03 (s, 3H). DMSO 422.0 (M + 1) Method A (TFA) 95 Method C, G, D 1090

394.79 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.54 (s, 1H), 8.68-8.70 (m, 2H), 8.60 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.32 (dd, J = 7.2, 2.8 Hz, 1H), 8.11 (d, J = 7.2 Hz, 1H), 7.93-7.97 (m, 1H), 7.51- 7.58 (m, 2H). DMSO 395.0 (M + 1) Method A (TFA) 95 Method C, G, D 1091

476.93 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (s, 1H), 8.62-8.72 (m, 3H), 8.29 (dd, J = 6.8, 2.4 Hz, 1H), 7.91-7.94 (m, 1H), 7.83 (s, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.53-7.59 (m, 2H), 3.69-3.71 (s, 2H), 3.36-3.38 (s, 2H), 2.42-2.44 (s, 2H), 2.30- 2.32 (s, 2H), 2.23 (s, 3H). DMSO 477.2 (M + 1) 239.1 (1/2M + 1) Method B (NH4HCO3) 95 Method C, G, D 1092

463.89 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.18 (s, 1H), 9.52 (S, 1H), 8.62-8.71 (m, 3H), 8.28 (d, J = 4.8 Hz, 1H), 7.87-7.96 (m, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.52-7.58 (m, 2H), 3.61-3.71 (m, 6H), 3.40 (m, 2H). DMSO 464.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1093

393.8 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.54 (d, J = 1.6 Hz, 1H), 8.62-8.72 (m, 3H), 8.42 (d, J = 1.2 Hz, 1H), 8.37 (s, 1H), 8.30 (dd, J = 7.2, 2.8 Hz, 1H), 8.08 (dd, J = 8.4, 1.2 Hz, 1H), 7.91-7.95 (m, 1H), 7.71 (s, 1H), 7.53-7.60 (m, 2H). DMSO 394.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1094

407.83 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.19 (s, 1H), 9.53 (s, 1H), 8.84 (d, J = 4.0 Hz, 1H), 8.60-8.72 (m, 3H), 8.35 (s, 1H), 8.29 (dd, J = 6.8, 2.8 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.90-7.93 (m, 1H), 7.52- 7.59 (m, 2H), 2.87 (d, J = 4.8 Hz, 3H). DMSO 408.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1095

506.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.53 (d, J = 1.6 Hz, 1H), 8.85 (t, J = 5.6 Hz, 1H), 8.61- 8.72 (m, 3H), 8.36 (d, J = 1.2 Hz, 1H), 7.98 (dd, J = 6.4, 2.4 Hz, 1H), 8.03 (dd, J = 8.8, 1.6 Hz, 1H), 7.91- 7.95 (m, 1H), 7.52-7.59 (m, 2H), 3.60 (t, J = 4.4 Hz, 4H), 3.46-3.48 (q, J = 6.4 Hz, 2H), 2.51-2.54 (m, 2H), 2.42-2.48 (m, 4H). DMSO 507.1 (M + 1) 254.1 (M/2 + 1) Method B (NH4HCO3) 95 Method G, C 1096

511.96 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (s, 1H), 9.56 (d, J = 1.8 Hz, 1H), 8.61-8.79 (m, 3H), 8.31 (dd, J = 6.8, 2.6 Hz, 1H), 7.88-8.11 (m, 2H), 7.78 (dd, J = 8.4, 1.4 Hz, 1H), 7.51-7.66 (m, 2H), 4.12 (brs, 2H), 3.76 (brs, 2H), 3.30-3.33 (m, 4H). DMSO 512.1, 514.1 (M + 1) Method B (NH4HCO3) 95 Method G, D 1097

474 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.64 (brs, 1H), 9.53 (s, 1H), 9.44 (t, J = 6.4 Hz, 1H), 9.35 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.85 (d, J = 4.8 Hz, 1H), 8.35 (dd, J = 8.4, 1.2 Hz, 1H), 8.27 (dd, J = 6.8, 2.4 Hz, 1H), 8.00-7.97 (m, 2H), 7.82 (dt, J = 13.2, 5.2 Hz, 1H), 7.55 (t, J = 8.8 Hz, 1H), 4.22-4.18 (m, 2H). DMSO 475.7, 476.6 (M + 1) Method B (NH4HCO3) 95 Method C, G, D

Method AE: 2-(7-(Methylamino)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xxxvi-a)

A mixture of 2-(7-amino-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (160 mg, 0.449 mmol, 1.0 eq.) and HCHO (40%, 37 mg, 0.494 mmol, 1.1 eq.), acetic acid (2 drops) were stirred at room temperature for 0.5 h. NaBH₃CN (34 mg, 0.449 mmol, 1.0 eq.) was added and the mixture was stirred at room temperature overnight. After filtration, the filtrate was concentrated to give the crude product, which was purified by reverse phase chromatography (MeOH/H₂O=3:7) to afford 28 mg of xxxvi-a as a white solid (17%). LCMS m/z=371.1 (M+1), 372.1 (M+2) (Method B) (retention time=1.60 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 12.71 (s, 1H), 9.58 (d, J=1.6 Hz, 1H), 9.14-9.12 (m, 1H), 8.74-8.69 (m, 2H), 8.45 (s, 1H), 7.93-7.91 (m, 1H), 7.85 (d, J=9.2 Hz, 2H), 7.67-7.71 (m, 1H), 7.59-7.55 (m, 1H), 7.12-7.16 (m, 1H), 7.06-7.03 (m, 1H), 6.82-6.81 (m, 1H), 6.70 (d, J=2.4 Hz, 1H), 2.84 (d, J=4.8 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 41, replacing formaldehyde with the appropriate aldehyde and 2-aminobenzamide with the appropriate aniline.

TABLE 14 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1098

370.41 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.87 (s, 1H), 9.57 (d, J = 1.2 Hz, 1H), 9.25 (d, J = 8.8 Hz, 1H), 8.65- 8.71 (m, 2H), 8.47 (s, 1 H), 7.95- 7.99 (m, 2H), 7.69-7.74 (m, 2H), 7.56 (dd, J = 7.7, 5.0 Hz, 1H), 7.33 (dd, J = 9.1, 1.9 Hz, 1H), 7.16 (t, J = 7.2 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 6.62 (d, J = 4.8 Hz, 1H), 2.88 (d, J = 4.8 Hz, 3H). DMSO 371.1 (M + 1) Method B (NH₄HCO₃) 95 Method AE 1099

370.41 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.71 (s, 1H), 9.58 (d, J = 1.4 Hz, 1H), 9.13 (d, J = 7.7 Hz, 1H), 8.80- 8.64 (m, 2H), 8.45 (s, 1H), 7.92 (dd, J = 7.9, 1.4 Hz, 1H), 7.85 (d, J = 9.2 Hz, 2H), 7.76-7.62 (m, 1H), 7.57 (dd, J = 7.9, 4.8 Hz, 1H), 7.15 (dd, J = 11.2, 4.0 Hz, 1H), 7.04 (dd, J = 9.0, 2.3 Hz, 1H), 6.81 (q, J = 4.8 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 2.85 (d, J = 4.9 Hz, 3H). DMSO 371.1 (M + 1) Method B (NH₄HCO₃) 95 Method AE

Method AG: 1-(Benzyloxy)-3-chloro-7-methoxyisoquinoline (xxxvii-a)

1,3-dichloro-7-methoxyisoquinoline (2.00 g, 8.8 mmol, 1.0 eq.) was dissolved in 30 mL anhydrous toluene and sodium benzyloxide (2.30 g, 17.6 mmol, 2.0 eq.) was added. The mixture was heated to 80° C. for 18 h. TLC indicated the reaction was complete. The mixture was concentrated to give the crude product, which was purified by chromatography on silica gel (eluted with petroleum ether) to give 2.20 g of xxxvii-a as a white solid (84.6%). LCMS m/z=300.1, 302.0 (M+1) (Method B) (retention time=2.23 min).

1-(Benzyloxy)-7-methoxy-3-(pyridin-3-yl)isoquinoline (xxxviii-a)

1-(Benzyloxy)-7-methoxy-3-(pyridin-3-yl)isoquinoline was prepared using Method N2. 1-(Benzyloxy)-3-chloro-7-methoxyisoquinoline (93 mg, 0.5 mmol, 1.0 eq.), potassium carbonate (357 mg, 2.5 mmol, 5.0 eq.), and Pd(PPh₃)₂Cl₂ (18 mg, 0.026 mmol, 0.05 eq.) was dissolved in the mixed solvent of 1,4-dioxane (3 mL) and water (1 mL). The resulting mixture was stirred at 120° C. for 30 min under the microwave condition. The solid was filtrated off and the filtrate was concentrated. The residue was partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration and evaporation, the residue was purified by silica gel chromatography (petroleum ether/ethyl acetate=1:10) to afford 100 mg of xxxviii-a as a yellow solid (84.7%).

7-Methoxy-3-(pyridin-3-yl)isoquinolin-1-ol (xxxviv-a)

7-Methoxy-3-(pyridin-3-yl)isoquinolin-1-ol (prepared in a manner analogous to that described for 2-amino-5-methoxybenzoic acid in Method K, replacing 5-methoxy-2-nitrobenzoic acid with 1-(benzyloxy)-7-methoxy-3-(pyridin-3-yl) isoquinoline) was obtained in a 63.6% yield to give 280 mg of xxxviv-a as a yellow solid. This was carried on without further purification.

1-Chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (xl-a)

1-Chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline in Method F1, replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with 3-(pyridin-3-yl)isoquinolin-1-ol) was obtained in a 73.0% yield to give 60 mg of xl-a as a brown solid. MS m/z=241.1 (M+1) (Method A) (retention time=1.34 min)

N-(3-Chloro-4-fluorophenyl)-7-methoxy-3-(pyridin-3-yl)isoquinolin-1-amine (xli-a)

N—(N-(3-chloro-4-fluorophenyl)-7-methoxy-3-(pyridin-3-yl)isoquinolin-1-amine was prepared using Method J. A mixture of 1-chloro-7-methoxy-3-(pyridin-3-yl)isoquinoline (40 mg, 0.17 mmol, 1.0 eq.), 3-chloro-4-fluoro aniline (30 mg, 0.21 mmol, 1.2 eq.), Pd₂(dba)₃ (10 mg, 0.011 mmol, 0.06 eq.), Xantphos (15 mg, 0.026 mmol, 0.15 eq.), cesium carbonate (167 mg, 0.52 mmol, 3.0 eq.) was suspended in the mixed solvent of 1,4-dioxane (4 mL) and water (1 mL). The resulting mixture was stirred at 120° C. for 30 min under the microwave conditions. After cooling, the resulting mixture was partitioned between water and ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate. After filtration and evaporation, the residue was purified by prep-HPLC to afford 3 mg of xli-a as a yellow solid (yield 5.2%). LCMS m/z=380.1 (M+1) (Method B). ¹H NMR (400 MHz, DMSO-d₆): δ 9.35 (s, 1H), 9.30 (d, J=2.0 Hz, 1H), 8.57 (dd, J=4.7, 1.5 Hz, 1H), 8.41 (td, J=8.0, 1.8 Hz, 1H), 8.30 (dd, J=6.9, 2.6 Hz, 1H), 7.94-7.87 (m, 4H), 7.43-7.49 (m, 3H), 3.99 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 43, replacing with the appropriate isoquinoline and aniline.

TABLE 15 Pu- Method Molec- ¹H- rity for Num- Salt ular NMR LCMS per- Cou- ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol cent pling 1100

379.81 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.35 (s, 1H), 9.30 (d, J = 2.0 Hz, 1H), 8.57 (dd, J = 4.7, 1.5 Hz, 1H), 8.41 (td, J = 8.0, 1.8 Hz, 1H), 8.30 (dd, J = 6.9, 2.6 Hz, 1H), 7.94-7.87 (m, 4H), 7.43- 7.49 (m, 3H), 3.99 (s, 3H). DMSO 380.1, 382.0 (M + 1) Method B (NH4HCO3) 95 Method J 1101

411.38 ¹H-NMR (400 MHz, DMSO-d₆): δ 9.46 (s, 1H), 9.31 (d, J = 1.75 Hz, 1H), 8.57 (dd, J = 4.6, 1.3 Hz, 1H), 8.45-8.41 (m, 1 H), 8.19 (s, 1H), 7.99-7.94 (m, 2H), 7.91-7.86 (m, 2H), 7.54-7.44 (m, 3H), 7.01 (d, J = 8.1 Hz, 1H), 4.00 (s, 3H). DMSO 412.1 (M + 1) Method B (NH4HCO3) 95 Method J 1102

388.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.35 (s, 1H), 9.34 (d, J = 1.9 Hz, 1H), 8.80 (d, J = 8.4 Hz, 1H), 8.59 (dd, J = 4.7, 1.48 Hz, 1H), 8.49-8.45 (m, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 8.02 (s, 1H), 7.97- 7.92 (m, 1H), 7.61 (td, J = 14.9, 7.5 Hz, 1H), 7.56-7.48 (m, 3H), 6.95 (dd, J = 10.3, 8.3 Hz, 1H), 3.98 (s, 3H). DMSO 389.1 (M + 1) Method B (NH4HCO3) 95 Method J 1103

370.4 ¹H-NMR (400 MHz, CDCl3): δ 11.89 (s, 1H), 9.39 (s, 1H), 9.29 (s, 1H), 8.63-8.59 (m, 1H), 8.42- 8.37 (m, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.60-7.62 (m, 4H), 7.44-7.33 (m, 3H), 7.05-7.00 (m, 1H), 4.06 (s, 3H). CDCl3 371.1 (M + 1) Method B (NH4HCO3) 95 Method J 1104

407.37 ¹H-NMR (400 MHz, CDCl3): δ 9.28 (s, 1H), 8.60 (d, J = 4.6 Hz, 1H), 8.34 (d, J = 7.8 Hz, 1H), 7.85 (s, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.63 (s, 1H), 7.43-7.35 (m, 2H), 7.22 (d, J = 8.6 Hz, 1H), 7.17 (s, 1H), 7.09-7.03 (m, 2H), 4.00 (s, 3H). CDCl3 408.1 (M + 1) Method B (NH4HCO3) 95 Method J 1105

454.4 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.00 (s, 1H), 9.43 (d, J = 1.2 Hz, 1H), 9.35 (s, 1H), 8.63 (d, J = 3.7 Hz, 1H), 8.53 (s, 1H), 8.48-8.44 (m, 1H), 8.03-8.09 (m, 3H), 7.97 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.56-7.50 (m, 2H), 7.05 (dd, J = 8.6, 1.93 Hz, 1H), 4.01 (s, 3H). DMSO 455.1 (M + 1) Method B (NH4HCO3) 95 Method J 1106

455.91 1H-NMR (400 MHz, DMSO-d₆): δ 9.65 (s, 1H), 9.37 (d, J = 1.7 Hz, 1H), 8.83 (s, 1H), 8.63 (dd, J = 4.7, 1.3 Hz, 1H), 8.54-8.43 (m, 1H), 8.35 (dd, J = 6.9, 2.6 Hz, 1H), 8.15 (dd, J = 8.5, 1.4 Hz, 1 H), 8.03 (t, J = 4.3 Hz, 2H), 7.91-7.95 (m, 1H), 7.46- 7.55 (m, 5H), 7.11-7.01 (m, 1H), 3.91 (s, 3H). DMSO 456.1, 458.1 (M + 1) Method B (NH₄HCO₃) 95 Method J 1107

¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 9.36 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 1.9 Hz, 1H), 8.91 (s, 1H), 8.67 (dd, J = 4.8, 1.5 Hz, 1H), 8.62 (dd, J = 4.7, 1.5 Hz, 1H), 8.53-8.44 (m, 1H), 8.35-8.32 (m, 2H), 8.19 (dd, J = 8.5, 1.5 Hz, 1H), 8.13-8.01 (m, 2H), 7.92 (ddd, J = 9.1, 4.3, 2.7 Hz, 1H), 7.61 (dd, J = 7.9, 4.8 Hz, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 7.50 (t, J = 9.1 Hz, 1H). DMSO 426.7 428.7 (M + 1) Method B (NH4HCO3) 95 Method J

Method AI: Ethyl 2-cyano-4,4-diethoxybutanoate (xlii-a)

2-Bromo-1,1-diethoxyethane (4 g, 20 mmol, 1.0 eq.) was added to a mixture of ethyl 2-cyanoacetate (11.4 g, 101 mmol, 5.0 eq.), K₂CO₃ (2.8 g, 20 mmol, 1.0 eq.) and NaI (200 mg, 1.3 mmol, 0.06 eq.), as described in J. Chem. Soc., 1960, 131-138. The reaction mixture was refluxed for 4 h at 145° C. After cooling, the reaction mixture was purified by chromatography on silica gel (eluted with petroleum ether/ethyl acetate (80:1→40:1→40:1) to give 3.57 g of xlii-a as a colorless oil (78%). ¹H NMR (400 MHz, CDCl₃): δ 4.70 (t, J=5.6 Hz, 1H), 4.26 (q, J=7.2 Hz, 2H), 3.78-3.64 (m, 3H), 3.62-3.45 (m, 2H), 2.35-2.14 (m, 2H), 1.34 (q, J=7.2 Hz, 3H), 1.25-1.16 (m, 6H).

Method AJ: 2-(Pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (xliii)

To a solution of nicotinimidamide (5.03 g, 41.6 mmol, 1.2 eq.) in EtOH (100 mL), was added NaOMe (4.8 g, 88.8 mmol, 2.5 eq.). The mixture was stirred at room temperature for 4 h. The reaction mixture was added to ethyl 2-cyano-4,4-diethoxybutanoate (8.00 g, 34.9 mmol, 1 eq.). This mixture was stirred at 105° C. overnight. After cooling, the reaction mixture was acidified with conc. HCl and stirred at room temperature for 2 h. A precipitate formed and was collected and washed with H₂O (20 mL×2). After lyophilization, 3.10 g of product was obtained as a gray yellow solid (yield 41.8%). LCMS m/z=213.1 (M+1) (Method B) (retention time=1.07 min). ¹H NMR (400 MHz, DMSO-d₆): δ 12.26 (s, 1H), 12.04 (s, 1H), 9.23 (d, J=1.6 Hz, 1H), 8.70 (dd, J=4.8, 1.2 Hz, 1H), 8.43-8.40 (m, 1H), 7.55 (dd, J=8.0, 4.8 Hz, 1H), 7.12 (d, J=1.6 Hz, 1H), 6.51 (d, J=2.8 Hz, 1H).

4-Chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (xlv-a)

4-Chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (prepared in a manner analogous to that described for 4-chloro-6-propoxy-2-pyridin-3-yl-quinazoline in Method F1, replacing 6-propoxy-2-pyridin-3-yl-1H-quinazolin-4-one with 2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol) to give 450 mg of xliv-a in a 69.0% yield as a brown solid. LCMS m/z=231.0, 233.0 (M+1) (Method B) (retention time=1.60 min)

N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (xlv-a)

N-(3-chloro-4-fluorophenyl)-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (prepared in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine using Method G6, replacing 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate with 4-chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine) to give a 11.3% yield, 10 mg of xlv-a as brown solid. LCMS m/z=340.1, 342.0 (M+1) (Method B) (retention time=1.814 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.48 (d, J=1.6 Hz, 1H), 8.62 (dd, J=4.8, 1.6 Hz, 1H), 8.60-8.56 (m, 1H), 8.27 (dd, J=6.4, 2.4 Hz, 1H), 8.06 (ddd, J=8.8, 4.0, 2.8 Hz, 1H), 7.71 (d, J=3.6 Hz, 1H), 7.66 (t, J=9.2 Hz, 1H), 7.50 (dd, J=8.0, 4.8 Hz, 1H), 7.41 (br s, 2H), 6.85 (d, J=3.6 Hz, 1H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 45, replacing with the appropriate aniline.

TABLE 16 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1108

330.34 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.29 (s, 1H), 12.09 (s, 1H), 9.54 (d, J = 1.2 Hz, 1H), 9.11 (d, J = 8.4 Hz, 1H), 8.65-8.68 (m, 1H), 8.35 (s, 1H), 7.89 (dd, J = 8.0, 1.2 Hz, 1H), 7.79 (s, 1H), 7.67 (td, J = 8.8, 1.2 Hz, 1H), 7.55 (dd, J = 7.2, 4.8 Hz, 1H), 7.43-7.41 (m, 1H), 7.10 (td, J = 8.0, 1.2 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H). DMSO 331.1 (M + 1) Method B (NH4HCO3) 95 Method AJ, F, G6 1109

371.32 ¹H-NMR (400 MHz, DMSO-d₆): δ 12.02 (d, J = 1.3 Hz, 1H), 9.75 (s, 1H), 9.50 (d, J = 1.5 Hz, 1H), 8.68-8.53 (m, 2H), 8.29 (s, 1H), 7.94-7.75 (m, 1H), 7.61-7.44 (m, 2H), 7.41-7.29 (m, 1H), 7.04 (s, 1H), 6.88 (dd, J = 3.4, 1.9 Hz, 1H). DMSO 372.0 (M + 1) Method A (TFA) 95 Method AJ, F, G6 1110

366.32 1H-NMR (400 MHz, DMSO-d6): δ 11.98 (s, 1H), 9.69 (s, 1H), 9.48 (d, J = 1.8 Hz, 1H), 8.64-8.59 (m, 2H), 8.19 (d, J = 2.0 Hz, 1H), 7.63 (dd, J = 8.8, 2.0 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 3.0 Hz, 1H), 6. DMSO 368.1 (M + 1) Method A (TFA) 95 Method AJ, F, G6 1111

339.75 ¹H-NMR (400 MHz, DMSO-d₆): δ 11.51 (s, 1H), 8.78 (d, J = 8.0 Hz, 2H), 8.17 (d, J = 9.2 Hz, 1H), 7.80 (dd, J = 9.2, 2.8 Hz, 1H), 7.70-7.64 (m, 1H), 7.46 (d, J = 2.8 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 4.0 Hz, 2H), 7.16-7.08 (m, 1H). DMSO 340.1, 342.0 (M + 1) Method B (NH4HCO3) 95 Method AJ, F, G6

Method AK: 4-Chloro-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (xliv-a)

To a solution of 4-chloro-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine (80 mg, 0.34 mmol, 1.0 eq.) in dry DMF (20 mL) was added Cs₂CO₃ (221 mg, 0.68 mmol, 2.0 eq.) and iodomethane (54.3 mg, 0.38 mmol, 1.1 eq.) at 0° C. The reaction mixture was warmed to room temperature and stirred for 2.5 h. The reaction mixture was poured into ice water and extracted with EtOAc (20 mL x 3). The combined organic layers were dried over anhydrous Na₂SO₄. After filtration and concentration, the residue was purified by chromatography on silica gel (petroleum ether/ethyl acetate 8:1) to give 65 mg of xlvi-a as brown solid (56.7%).

N-(3-chloro-4-fluorophenyl)-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (xlvii-a)

N-(3-chloro-4-fluorophenyl)-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (prepared in a manner analogous to that described for N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)propyl)-2-(pyridin-3-yl)quinazolin-4-amine using Method G6, replacing 3-(4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazolin-6-yl)propyl methanesulfonate with 4-chloro-7-methyl-2-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine) to give a 70.0% yield, 30 mg of xlvii-a as a brown solid. LCMS m/z=354.1, 356.1 (M+1) (Method B) (retention time=1.94 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.97 (s, 1H), 9.53 (s, 1H), 9.15 (d, J=8.0 Hz, 1H), 8.91 (d, J=5.2 Hz, 1H), 8.25 (dd, J=6.8, 2.4 Hz, 1H), 8.04 (dd, J=7.6, 5.6 Hz, 1H), 7.94-7.90 (m, 1H), 7.48-7.43 (m, 2H), 6.95 (d, J=3.2 Hz, 1H), 3.88 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 46, replacing with the appropriate aniline.

TABLE 17 Molec- ¹H- Method Num- Salt ular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1112

HCl 353.78 ¹H NMR (400 MHz, DMSO-d₆): δ 9.97 (s, 1H), 9.53 (s, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.91 (d, J = 5.2 Hz, 1H), 8.25 (dd, J = 6.8, 2.4 Hz, 1H), 8.04 (dd, J = 7.6, 5.6 Hz, 1H), 7.94-7.90 (m, 1H), 7.48-7.43 (m, 2H), 6.95 (d, J = 3.2 Hz, 1H), 3.88 (s, 3H). DMSO 354.1, 356.1 (M + 1) Method B (NH4HCO3) 95 Method AK, G6 1113

385.34 ¹H NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 8.69-8.64 (m, 2H), 8.29 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.55-7.51 (m, 2H), 7.41 (d, J = 3.6 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.90 (d, J = 3.6 Hz, 1H), 3.87 (s, 3H). DMSO 386.1 (M + 1) Method B (NH4HCO3) 95 Method AK, G6 1114

1H-NMR (400 MHz, DMSO-d6): δ 12.32 (s, 1H), 9.61 (s, 1H), 9.11 (d, J = 7.6 Hz, 1H), 9.11 (d, J = 7.6 Hz, 1H), 8.74 (dt, J = 8.0, 1.9 Hz, 1H), 8.67 (d, J = 3.6 Hz, 1H), 8.38 (s, 1H), 8.38 (s, 1H), 7.90 (dd, J = 7.9, 1.4 Hz, 1H), 7.82 (s, 1H), 7.68 (dd DMSO 344.9 (M + 1) Method B (NH4HCO3) 95 Method AK, G6

Method AL: 4-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)-2-(pyridin-3-yl)quinazoline-6-carboxamide (xlviii-a)

To a suspension of 4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinazoline-6-carboxamide (prepared as described in scheme 4) (100 mg, 0.376 mmol, 1.0 eq.) in dry DMF (20 mL) was added benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (216 mg, 0.488 mmol, 1.3 eq.) and diaza(1,3)bicyclo[5.4.0]undecene (114.5 mg, 0.752 mmol, 2.0 eq.) following a procedure outlined in J. Org. Chem., 2007, 72, 10194-10210. To the clear solution was then added 5,6-dimethyl-1H-benzo[d]imidazole (165.2 mg, 1.13 mmol, 3.0 eq.) and the mixture was stirred overnight at room temperature. The resultant precipitate was then collected by filtration and washed with dichloromethane, water, and ether. The product was dried in vacuo to give 26.3 mg of the desired product (xlviii-a) as an off-white solid (6.7%). LCMS m/z=395.1 (M+1) (Method C) (retention time=1.68 min). ¹H NMR (300 MHz, DMSO) δ 9.69 (s, 1H), 8.90 (s, 1H), 8.82 (d, J=15.2 Hz, 2H), 8.66 (s, 1H), 8.54 (d, J=8.6 Hz, 1H), 8.42 (s, 1H), 8.30 (d, J=8.5 Hz, 1H), 7.79 (s, 1H), 7.68 (s, 3H), 2.39 (s, 3H), 2.36 (s, 3H).

Method AM: Synthesis of 2-(6-(2-(piperidin-1-yl)ethoxy)-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (xlviv-a)

To 1-(2-chloroethyl)piperidine (45 μmol) was added the solution of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (30 μmol) in NMP (200 μL). PS-BEMP (90 μmol) was added to the vials by resin dispenser. After the reaction mixture was heated at 90° C. for 12 h, the residue was diluted with methanol and purified by mass triggered PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 51, replacing 1-(2-chloroethyl)piperidine with the appropriate alkyl halide.

TABLE 18 Mass Num- Starting Starting Salt Exact Found Purity ber Material 1 Material 2 Product Type Mass (M + 1) (%) 1116

468 469 98 1117

454 455 98 1118

456 457 98 1119

468 469 98 1120

482 483 98 1121

TFA 496 497 98 1122

465 466 98 1123

505 506 98

To a suspension of ethyl 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-4-phenylthiazole-5-carboxylate (1.3956 g, 2.89 mmol) in dioxane (40 mL) was added 1N NaOH (20 ml, 20.00 mmol) at room temperature to give a clear solution. The reaction mixture was stirred at room temperature for 1 h and then warmed to 50° C. overnight, however starting material remained. An additional 20 mL of 1N NaOH was added and heating was continued at 50° C. for 1 h and at 70° C. for 5 h 30 min. The reaction mixture was cooled to room temperature and diluted with water and ethyl acetate. The water phase was removed and adjusted to an acidic pH with 1N HCl (40 mL). A precipitate formed and was collected and washed with water. The product was dried in vacuo to give 1.20 g of a brown solid in a 91% yield. ¹H NMR (DMSO-d₆) ppm 12.88 (br, 2H), 9.77 (dd, J=2.12, 0.6 Hz, 1H), 8.92-8.89 (m, 1H), 8.78 (dd, J=4.8, 1.68 Hz, 1H), 8.32 (br, 1H), 7.96 (d, J=9.12 Hz, 1H), 7.82-7.80 (m, 2H), 7.70-7.67 (m, 1H), 7.63 (dd, J=9.12, 2.68 Hz, 1H), 7.50-7.44 (m, 3H), 3.98 (s, 3H).

Method AN: 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-N-methyl-4-phenylthiazole-5-carboxamide

To a suspension of 2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-4-phenylthiazole-5-carboxylic acid (291.8 mg, 0.641 mmol) in DMF(20 mL) under nitrogen atmosphere was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (189 mg, 0.986 mmol) and 1-hydroxybenzotriazole hydrate (147 mg, 0.961 mmol) at room temperature. The reaction mixture was stirred at room temperature for 10 min to give a clear solution and methylamine in a methanol solution (4 mL) was added at room temperature. The reaction mixture was stirred at room temperature for 2 h 15 min. Additional methyl amine in a methanol solution (4 mL) was added at room temperature and then heated to 50° C. for 1 h followed by room temperature for 2 days. The reaction mixture was partitioned between water and ethyl acetate. The water phase was collected and a solid precipitated from the water phase. The solid was filtered and dried in an oven at 60° C. to give 107.9 mg (0.23 mmol) as the parent compound. The parent compound was suspended in methanol and 4N HCl in ethyl acetate (ca. 2 mL) was added to give a clear solution which precipitated over time. The solid was collected by filtration and dried in oven at 60° C. for 2 days to give 82.4 mg of the HCl salt as a yellow solid in 24% yield. ¹H NMR (DMSO-d₆) δ 12.77 (brs, 1H), 9.76 (d, J=1.72 Hz, 1H), 9.18 (d, J=7.88 Hz, 1H), 8.92 (d J=5.04 Hz, 1H), 8.35 (brs, 1H), 8.27 (brd, J=4.56 Hz, 1H), 7.99-7.965 (m, 2H), 7.79 (brd, J=7.16 Hz, 2H), 7.65 (dd, J=9.12, 2.56 Hz, 1H), 7.50-7.41 (m, 3H), 4.00 (s, 3H), 2.76 (d, J=4.56 Hz, 3H). The 1H of 2HCl was not observed.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 53, replacing N-methyl amine with the appropriate alkyl amine.

TABLE 19 Number Starting Material 1 Starting Material 2 Product 1124

1125 NH₃

1126

Method Salt ¹H NMR Purity of Number Type ¹H NMR Solvent percent Coupling 1124 2 HCl 1H NMR (DMSO-d6) ppm 12.77 (brs, DMSO >98 Method AN 1H), 9.76 (d, J = 1.72 Hz, 1H), 9.18 (d, J = 7.88 Hz, 1H), 8.92 (d, J = 5.04 Hz, 1H), 8.35 (brs, 1H), 8.27 (brd, J = 4.56 Hz, 1H), 7.99-7.965 (m, 2H), 7.79 (brd, J = 7.16 Hz, 2H), 7.65 (dd, J = 9.12, 2.56 Hz, 1H), 7.50-7.41 (m, 3H), 4.00 (s, 3H), 2.76 (d, J = 4.56 Hz, 3H). The 1H of 2HCl was not observed. 1125 2 HCl 1H NMR (DMSO-d6) ppm 12.75 (brs, DMSO >98 Method AN 1H), 9.77 (d, J = 1.52 Hz, 1H), 9.13 (brs, 1H), 8.88 (brd, J = 5.08 Hz, 1H), 8.34 (d, J = 2.04 Hz, 1H), 7.98 (d, J = 9.12 HZ, 1H), 7.90 (brm, 1H), 7.83-7.80 (m, 2H), 7.66-7.53 (brm, 3H), 7.52-7.42 (m, 3H), 4.00 (s, 3H). The 1H of 2HCl was not observed. 1126 1H NMR (DMSO-d6) ppm 12.66 (s, DMSO >98 Method AN 1H), 9.76 (s, 1H), 8.88 (d, J = 7.76 HZ, 1H), 8.75 (d, J = 3.68 Hz, 1H), 8.40-8.20 (br, 2H), 7.94 (br, 1H), 7.80 (d, J = 7.16 Hz, 2H), 7.63 (m, 2H), 7.49-7.41 (m, 3H), 3.99 (s, 3H), 3.24 (q, J = 7.24 Hz, 2H), 1.07 (t, J = 7.24 Hz, 3H)

Method AO: N-tert-butyl-2-(4-(3,4-difluorophenyl-amino)-2-(pyridin-3-yl)quinazolin-6-yloxy)acetamide

To a solution of carboxylic acid derivative (500 mg, 1.2 mmol) in DMF was added 2-aminoisobutane (134 mg, 1.8 mmol), NMM (0.4 mL, 3.6 mmol), WSCDI (282 mg, 1.4 mmol) and HOBT (225 mg, 1.4 mmol). The reaction mixture was stirred at room temperature overnight. The resulting solution was poured into ice-water and the precipitate formed and was filtered off. The solid was washed with water and dried to give 350 mg (62% yield) of desired product. ¹H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.49 (d, J=1.5 Hz, 1H), 8.71-8.57 (m, 2H), 8.11 (ddd, J=13.3, 7.5, 2.5 Hz, 1H), 8.00-7.93 (m, 1H), 7.87 (d, J=9.1 Hz, 1H), 7.67 (ddd, J=11.7, 7.1, 2.1 Hz, 2H), 7.59-7.47 (m, 3H), 4.61 (s, 2H), 1.35 (s, 9H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 54, replacing 2-aminoisobutane with the appropriate alkyl amine

TABLE 20 Num- Starting Starting ber Material R¹ Material R³ Product 1127

1128

1129

Method Salt ¹H NMR Purity of Number Type ¹H NMR Solvent percent Coupling 1127 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.60 DMSO >98 Method AO (s, 1H), 9.48 (d, J = 1.9 Hz, 1H), 9.14 (dt, J = 8.2, 1.6 Hz, 1H), 8.96 (dd, J = 5.5, 1.3 Hz, 1H), 8.37 (t, J = 6.0 Hz, 1H), 8.24 (d, J = 2.6 Hz, 1H), 8.11-7.97 (m, 3H), 7.74 (ddd, J = 11.8, 7.4, 3.3 Hz, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.79 (s, 2H), 3.01 (t, J = 6.5 Hz, 2H), 1.86-1.59 (m, 1H), 0.85 (d, J = 6.7 Hz, 6H). 1128 3 HCl ¹H NMR (400 MHz, DMSO) δ 10.81 DMSO >98 Method AO (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.40 (d, J = 2.5 Hz, 1H), 8.29 (t, J = 6.4 Hz, 1H), 8.18-7.95 (m, 3H), 7.83-7.67 (m, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.88 (s, 2H), 2.98 (d, J = 6.4 Hz, 1H), 0.84 (s, 9H). 1129 2 HCl ¹H NMR (400 MHz, DMSO) δ 10.87 DMSO >98 Method AO (s, 1H), 9.50 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.2 Hz, 1H), 8.98 (dd, J = 5.5, 1.3 Hz, 1H), 8.41 (d, J = 2.5 Hz, 1H), 8.23-7.96 (m, 4H), 7.85- 7.66 (m, 2H), 7.55 (dt, J = 10.5, 9.1 Hz, 1H), 4.85 (s, 2H), 3.80-3.43 (m, 1H), 1.65-1.21 (m, 4H), 0.81 (t, J = 7.4 Hz, 6H).

2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-N,N-dimethyl-1H-benzo[d]imidazole-1-carboxamide (334.1 mg, 0.760 mmol) was dissolved in concentrated HCl (0.063 ml, 0.760 mmol). The solution was stirred at room temperature overnight and then at 50° C. for 3 h 30 min followed by 100° C. for 3 h. The solid was collected and dried in vacuo to give 116.2 mg of a yellow solid in a yield 35%. ¹H NMR (DMSO-d₆) δ 13.22 (br, 1H), 9.55 (s, 1H), 8.92 (dd, J=4.96, 1.36 Hz, 1H), 8.88 (br, 1H), 8.01 (d, J=9.12 Hz, 1H), 7.92 (br, 1H), 7.83 (br, 1H), 7.67 (dd, J=9.12, 2.80 Hz, 1H), 7.61 (m, 2H), 7.38 (m, 2H), 3.97 (s, 3H). The 1H of 2HCl and NH—were not observed.

4-(4-chlorophenyl)-2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)-N,N-dimethyl-1H-imidazole-1-carboxamide and concentrated HCl_((aq)) (10 mL) were added to a round bottom flask, a precipitate appeared upon refluxing the mixture for 3 h. The solid was collected (373.4 mg) and trituated with CH₂Cl₂/methanol overnight. The product was filtered and dried to give 261.7 mg of a solid. A suspension of the product in methanol was added to a 1N solution of NaOH_((aq.)) (5 mL) followed by CH₂Cl₂ and H₂O. The solid was collected and washed with methanol to give 255.7 mg (0.596 mmol) of the parent product. The free parent was suspended in CH₂Cl₂/methanol and converted to the HCl salt by addition of a 0.3 ml solution of 4N HCl in ethyl acetate. The HCl salt was collected and dried in vacuo to give 248.4 mg as brown solid in a 26% yield. ¹H NMR (DMSO-d₆) δ 13.61 (br, 1H), 12.81 (br, 1H), 9.46 (s, 1H), 8.87 (d, J=5.24 Hz, 1H), 8.70 (br, 1H), 7.91-7.87 (m, 5H), 7.75 (m, 1H), 7.62-7.56 (m, 3H), 3.95 (s, 3H). The 1H of 2HCl was not observed.

To a mixture of N-(6-(benzyloxy)-2-(pyridin-3-yl)quinazolin-4-yl)-4-(4-chlorophenyl)thiazol-2-amine and catechol, dimethyl ether (0.16 g, 1.15 mmol) was added methanesulfonic acid (4.0 mL). The mixture was stirred for 1 hr and was then poured into water. The slurry was added to a stirring sat. NaHCO_(3(aq).) solution slowly and allowed to stir for 30 min. The precipitate was filtered to give a brown solid which was washed with methanol to give 4-(4-(4-chlorophenyl)thiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol (0.23 g, 91.0%).

Scheme 59: Synthesis of 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol (Compound 1133)

Synthesis of 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol was performed in a similar manner to that described for 4-(4-(4-chlorophenyl)thiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol substituting for 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol for the N-(6-(benzyloxy)-2-(pyridin-3-yl)quinazolin-4-yl)-4-(4-chlorophenyl)thiazol-2-amine giving 4-(4-phenylthiazol-2-ylamino)-2-(pyridin-3-yl)quinazolin-6-ol. ¹H NMR (300 MHz, DMSO) δ 10.06-9.22 (m, 2H), 8.95 (dt, J=7.9, 1.6 Hz, 1H), 8.62 (dd, J=4.7, 1.4 Hz, 1H), 7.99 (d, J=7.5 Hz, 2H), 7.87 (d, J=2.8 Hz, 1H), 7.59-7.47 (m, 2H), 7.45-7.32 (m, 3H), 7.30-7.09 (m, 2H).

To a mixture of 4-chloro-6-methoxy-2-(pyridin-3-yl)quinazoline (0.50 g, 1.84 mmol) and 5-fluorospiro[[1,3]dioxolane-2,3′-indolin]-2′-one (0.42 g, 2.02 mmol) in dry DMSO (4 mL) was added KOH powder (0.11 g, 2.02 mmol). The reaction mixture was stirred for 15 h at room temperature and then the reaction mixture was poured into water. The aqueous layer was washed with ethyl acetate (2×20 mL) and the resulting aqueous layer was acidified with 5N HCl to give a precipitate. The solid was filtered to give 2-(5-fluoro-2-(6-methoxy-2-(pyridin-3-yl)quinazolin-4-ylamino)phenyl)-1,3-dioxolane-2-carboxylic acid as a light yellow powder (0.27 g, 0.58 mmol, 32%). LCMS m/z=432 (M+1) (Method C)¹H NMR (300 MHz, DMSO) δ 9.50-9.38 (m, 2H), 8.69-8.59 (m, 2H), 8.42 (dd, J=9.7, 5.3 Hz, 1H), 7.86 (d, J=9.1 Hz, 1H), 7.64 (d, J=2.6 Hz, 1H), 7.61-7.41 (m, 4H), 4.25-4.11 (m, 4H), 3.98 (s, 3H).

In a 50 mL round-bottomed flask was added 2,4-dichloro-6-iodoquinazoline (0.52 g, 1.6 mmol), 3-chloro-4-fluoroaniline (0.30 g, 2.1 mmol), and sodium acetate (0.20 g, 2.4 mmol) in THF (6 mL) and water (2 mL) to give a brown suspension. After being stirred at room temperature for 6 days, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), dried over Na₂SO₄, filtered and concentrated. The resulting product was washed with CH₂Cl₂ and dried to give 0.51 g of 2-chloro-N-(3-chloro-4-fluorophenyl)-6-iodoquinazolin-4-amine as a light brown solid in a 73% yield. ¹H NMR (300 MHz, DMSO) δ 10.29 (s, 1H), 8.95 (s, 1H), 8.14 (dd, J=1.5, 9.0 Hz, 1H), 8.06 (dd, J=2.7, 6.6 Hz, 1H), 7.81-7.76 (m, 1H), 7.52-7.46 (m, 2H).

In a 50 mL round-bottomed flask was added 2-chloro-N-(3-chloro-4-fluorophenyl)-6-iodoquinazolin-4-amine (200 mg, 0.46 mmol), N,N-dimethylpropargylamine (99 mL, 0.92 mmol), NEt₃ (0.26 mL, 1.84 mmol), CuI (0.88 mg, 4.6 mmol) and PdCl₂(PPh₃)₂ (6.5 mg, 9.2 mmol) in DMF (3 mL) to give a light yellow suspension. The mixture was stirred at room temperature overnight under an argon atmosphere. The reaction mixture was diluted with water (10 mL) and ethyl acetate (10 mL) and then a precipitate formed. The resulting precipitate was removed by filtration through Celite. The filtrate was extracted with ethyl acetate (2×10 mL). The combined organic layer was washed with water (1×15 mL) and brine (1×15 mL) and was dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with CH₂Cl₂/MeOH 1:0 to 9:1). The desired product was washed with CH₂Cl₂ to give 61 mg of 2-chloro-N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)quinazolin-4-amine as pale yellow solid in a 34% yield. LCMS m/z=389 (M+1) (Method C) (retention time=2.24 min). ¹H NMR (300 MHz, DMSO) δ 10.30 (s, 1H), 8.68 (s, 1H), 8.07 (dd, J=2.7, 6.9 Hz, 1H), 7.86 (dd, J=1.8, 8.7 Hz, 1H), 7.81-7.70 (m, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.49 (t, J=9.2 Hz, 1H), 3.52 (s, 2H), 2.28 (s, 6H).

In a 50 mL round-bottomed flask was added 2-chloro-N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)quinazolin-4-amine (61 mg, 0.16 mmol), 3-pyridineboronic acid (25 mg, 0.20 mmol), K₂CO₃ (0.11 mg, 0.78 mmol) and PdCl₂(PPh₃)₂ (5.5 mg, 7.8 mM) in dioxane (2 mL) to give a yellow suspension. The mixture was heated at reflux for 3 h under argon. After cooling to room temperature, water (10 mL) and ethyl acetate (10 mL) were added to the mixture to form a precipitate. The resulting precipitate was filtered through Celite. The filtrate was extracted with ethyl acetate (2×10 mL) and the combined organic layers were washed with water (1×15 mL) and brine (1×15 mL) and then dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with AcOEt/MeOH 1:0 to 9:1). The desired product was washed with CH₂Cl₂ to give 25 mg of N-(3-chloro-4-fluorophenyl)-6-(3-(dimethylamino)prop-1-ynyl)-2-(pyridin-3-yl)quinazolin-4-amine as a light brown solid in 37% yield. LCMS m/z=432 (M+1) (Method C) (retention time=1.86 min). ¹H NMR (300 MHz, DMSO) δ 10.13 (s, 1H), 9.51 (s, 1H), 8.77-8.56 (m, 3H), 8.26 (dd, J=6.9, 2.5 Hz, 1H), 8.02-7.78 (m, 3H), 7.64-7.47 (m, 2H), 3.54 (s, 2H), 2.30 (s, 6H).

A mixture of 2-(6-hydroxy-2-(pyridin-3-yl)quinazolin-4-ylamino)benzamide (200 mg, 0.283 mmol), (isocyanatomethyl)benzene (5 mL) and Et₃N (57 mg, 0.283 mmol) in tetrahydrofuran (THF) (10 mL) was stirred at room temperature overnight. Water (10 mL) was added to the above mixture and the mixture was concentrated in vacuo. The precipitate was collected by filtration and washed with water (6 mL×2) to afford 72 mg of the desired product as a white solid in a yield 26.0%. LCMS: rt=1.829 min, [MH]⁺=491.1 ¹H-NMR (400 MHz, DMSO-d₆): δ 13.05 (s, 1H), 9.63 (s, 1H), 9.07 (d, J=8.5 Hz, 1H), 8.87 (d, J=8.0 Hz, 1H), 8.79 (d, J=3.7 Hz, 1H), 8.59 (t, J=6.1 Hz, 1H), 8.49 (s, 1H), 8.02-7.89 (m, 4H), 7.82-7.68 (m, 3H), 7.46-7.22 (m, 6H), 4.35 (d, J=6.1 Hz, 2H).

4-(2-carbamoylphenylamino)-2-(pyridin-3-yl)quinazolin-6-yl ethylcarbamate was synthesized in a similar manner to that described for 4-(2-carbamoylphenylamino)-2-(pyridin-3-yl)quinazolin-6-yl benzylcarbamate substituting isocyanatoethane for (isocyanatomethyl)benzene. The resulting product was analyzed by LCMS: rt=1.11 min, [M+1]⁺=429.0. ¹H-NMR (400 MHz, DMSO-d₆): δ 13.06 (s, 1H), 9.66 (s, 1H), 9.10 (d, J=8.3 Hz, 1H), 8.87-8.80 (m, 2H), 8.51 (s, 1H), 8.06-7.94 (m, 4H), 7.88 (s, 1H), 7.79-7.63 (m, 3H), 7.24 (t, J=7.6 Hz, 1H), 3.22-3.11 (m, 2H), 1.14 (t, J=7.2 Hz, 3H).

A mixture of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carbonitrile (1.5 g, 4.0 mmol) in HCl (conc, 25 mL) was heated to 100° C. and stirred overnight. After cooling and filtration, the solid was washed with water (10 mL) twice to give 1.4 g of the desired product 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carboxylic acid as a yellow solid in a 89.0% yield. LCMS: r.t=1.271 min, NM⁺=394.9

A mixture of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)quinazoline-6-carboxylic acid (900 mg, 2.4 mmol), DIPEA (620 mg, 4.8 mmol) and HATU (1.4 g, 3.6 mmol) in DMF (10 mL) was pre-stirred for 20 min, and 2,2,2-trifluoro-N-methylethanamine (360 mg, 2.4 mmol) was added in one portion. The resulting mixture was stirred at room temperature overnight. Water (80 mL) was added and a precipitate formed which was collected and purified by prep-HPLC to afford 490 mg of the desired product 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide as a white solid in 42.0% yield. LCMS: r.t=1.970 min, [MH]⁺=490.0 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.79 (brs, 1H), 9.59 (s, 1H), 9.19 (d, J=7.6 Hz, 1H), 9.04 (d, J=4.8 Hz, 1H), 8.90 (s, 1H), 8.22-8.00 (m, 5H), 7.62 (t, J=9.2 Hz, 1H), 4.55-4.52 (m, 2H), 3.22 (s, 3H).

To a mixture of 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide (60 mg, 0.12 mmol) in THF (1 mL) was added BH₃-THF (2 mol/L, lmL). The mixture was stirred at room temperature overnight. Methanol (0.2 mL) was added to quench the reaction mixture. The mixture was purified by prep-HPLC to give the desired product N-(3-chloro-4-fluorophenyl)-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-2-(pyridin-3-yl)quinazolin-4-amine (GL001H-3309) as a white solid 15 mg in a yield of 26.0%. LCMS: r.t=2.154 min, [MH]⁺=476.1. ¹H-NMR (400 MHz, DMSO-d₆): δ 10.09 (s, 1H), 9.53 (s, 1H), 8.70-8.66 (m, 2H), 8.44 (s, 1H), 8.27-8.25 (m, 1H), 7.93-7.91 (m, 3H), 7.57-7.55 (m, 2H), 3.93 (s, 2H), 3.39-3.32 (m, 2H), 2.40 (s, 3H).

Synthesis of 4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide (compound 1139)

4-(3-chloro-4-fluorophenylamino)-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide was synthesized in a similar manner to that described for 4-(3-chloro-4-fluorophenylamino)-N-methyl-2-(pyridin-3-yl)-N-(2,2,2-trifluoroethyl)quinazoline-6-carboxamide substituting 2,2,2-trifluoroethylamine for 2,2,2-trifluoro-N-methylethylamine. The resulting product was analyzed. LCMS: r.t=1.934 min, [M+1]⁺=476.0. ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.54 (s, 1H), 9.32 (t, J=6.1 Hz, 1H), 9.14 (s, 1H), 8.72 (d, J=4.6 Hz, 1H), 8.68 (d, J=8.0 Hz, 1H), 8.32 (d, J=8.7 Hz, 1H), 8.27 (dd, J=6.7, 2.2 Hz, 1H), 7.98 (d, J=8.7 Hz, 1H), 7.96-7.90 (m, 1H), 7.62-7.51 (m, 2H), 4.27-4.14 (m, 2H).

Method E for Cyclization

E1: Sodium methoxide/Toluene

E2: NaOH/EtOH Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/reflux

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux

Method D: N-(2-carbamoylphenyl)pyridazine-4-carboxamide (iii-c)

A mixture of pyridazine-4-carboxylic acid (500 mg, 4.0 mmol, 1.0 eq.), 2-aminobenzamide (603 mg, 4.4 mmol, 1.1 eq.) and HBTU (3.0 g, 8.0 mmol, 2.0 eq.) was suspended in 15 mL of DMF. DIPEA (2.0 mL, 1.56 g, 12.0 mmol, 3.0 eq.) was added dropwise at room temperature and was stirred over night. After quenching with water, the resulting precipitate was collected and washed with a small amount of DCM. A white solid (388 mg) was obtained, LCMS m/z=243.1 (M+1) (Method B) (retention time=0.99 min), was used in the next step without further purification.

Method E1: 2-(pyridazin-4-yl) quinazolin-4(3H)-one (iv-f)

A 100 mL round-bottom flask equipped with a Dean-Stark trap was charged with a mixture of N-(2-carbamoylphenyl)pyridazine-4-carboxamide (300 mg, 1.0 eq.), sodium methoxide (401 mg, 7.4 mmol, 6.0 eq.) and 10 mL of anhydrous toluene. The reaction mixture was heated to 110° C. and refluxed overnight. After cooling, the volatiles were removed in vacuo and the residue was quenched with a saturated aqueous solution of NH₄Cl (10 mL). The pH of the mixture was adjusted to 3 with 10% HCl in water. The solution was extracted with DCM (50 ml×3). The combined organic layers were washed with brine, dried over Na₂SO₄. After filtration and evaporation, 88 mg of a yellow solid was obtained, LCMS m/z=225.1 (M+1) (Method A) (retention time=1.10 min) which was used in the next step without further purification.

Method F5: 4-chloro-2-(pyridazin-4-yl)quinazoline (v-f)

A 100-mL round-bottom flask was charged with 2-(pyridazin-4-yl) quinazolin-4(3H)-one (30 mg) which was suspended in 3 mL of POCl₃. The reaction mixture was heated to reflux for 1 h. The reaction mixture turned to a clear brown solution. After cooling, 50 mL of ice/water was carefully added. An aqueous ammonia solution (25% by weight in water) was added dropwise to the mixture with stirring until the pH of the mixture was adjusted to 7-8. An internal temperature of 0° C. was maintained by the addition of ice. The mixture was warmed to room temperature and extracted with DCM (50 ml x 3). The combined organic layers were washed with brine, dried over Na₂SO₄. After filtration and evaporation, 32 mg was obtained as a light brown solid. LCMS m/z=242.9 (M+1) (Method B) (retention time=1.65 min) The solid was used directly in the next step without further purification.

Method G1: N-(3,4-difluorophenyl)-2-(pyridazin-4-yl)quinazolin-4-amine (vi-r)

(This method is representative of method G1, G2, and G3. These three methods can be implemented in a similar way except for substitution of the appropriate solvent and temperature) The mixture of 4-chloro-2-(pyridazin-4-yl)quinazoline (10 mg, 0.041 mmol, 1 eq.) and 3,4-difluorobenzenamine (11 mg, 0.082 mmol, 2eq.) was suspended in i-PrOH. The mixture was heated at 85° C. overnight. After cooling, the resulting precipitate was filtered and purified on HPLC (Condition C). 7.3 mg of N-(3,4-difluorophenyl)-2-(pyridazin-4-yl)quinazolin-4-amine was obtained (yield 53%). LCMS m/z=336.0 (M+1) (Method B) (retention time=1.731 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 10.23 (s, 1H), 10.00 (dd, J=2.2, 1.3 Hz, 1H), 9.44 (dd, J=5.4, 1.2 Hz, 1H), 8.59 (d, J=8.1 Hz, 1H), 8.39 (dd, J=5.4, 2.4 Hz, 1H), 8.05-8.13 (m, 1H), 7.99 (s, 1H), 7.97 (d, J=3.6 Hz, 1H), 7.72-7.79 (m, 2H), 7.51-7.61 (m, 1H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 1 and 64 (prepared according to method procedure A-G as designated).

TABLE 21 Pu- Molec- rity Method Num- Salt ular ¹H-NMR LCMS per- for ber Product type Mass ¹H-NMR Solvent LCMS Protocol cent Coupling 1140

402.66 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 9.84-9.86 (m, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.15 (s, 1H), 8.02 (s, 1H), 7.84 (dd. J = 9.2, 2.4 Hz, 1H), 7.66-7.67 (m, 2H). CD3OD 402.0, 404.0, 405.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1141

386.21 1H-NMR (400 MHz, DMSO-d6): δ 10.78 (s, 1H), 9.49 (s, 1H), 8.89 (d, J = 10.8 Hz, 2H), 8.75 (d, J = 8.8 Hz, 1H), 8.44 (dd, J = 6.8, 2.4 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 7.94- 7.99 (m, 1H), 7.87 (dd, DMSO 386.0, 388.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 J = 8.8, 2.0 Hz, 1H), 7.56 (t, J = 9.2 Hz, 1H). 1142

369.76 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 8.76 (d, J = 10.8 Hz, 2H), 8.40 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 2.0 Hz, 1H), 7.80-7.86 (m, 1H), 7.68 (dd, J = 8.8, 1.6 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), CD3OD 370.0, 372.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 7.33 (q, J = 9.2 Hz, 1H). 1143

376.8 1H-NMR (400 MHz, CD3OD): δ 9.55 (s, 1H), 8.80 (d, J = 7.2 Hz, 3H), 8.26 (d, J = 8.8 Hz, 1H), 8.04 (s, 1H), 7.85 (d, J = 6.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.66 (t, J = 7.2 Hz, 1H), 7.28 (t, J = CD3OD 377.1, 379.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 7.6 Hz, 1H). 1144

358.78 1H-NMR (400 MHz, CD3OD): δ 9.39 (d, J = 1.6 Hz, 1H), 8.79 (d, J = 6.8 Hz, 2H), 8.47 (d, J = 9.2 Hz, 1H), 8.20 (s, 1H), 8.05-8.10 (m, 2H), 7.77 (dd, J = 8.8, 2.0 Hz, 1H), 7.63-7.65 (m 2H). CD3OD 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1145

399.78 1H-NMR (400 MHz, DMSO-d6): δ 10.63 (s, 1H), 9.52 (d, J = 1.2 Hz, 1H), 8.86 (t, J = 6.0 Hz, 2H), 8.77 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 15.6 Hz, 2H), 7.85 (d, J = 8.8 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.04 (dd, DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 J = 8.0, 1.6 Hz, 1H). 1146

402.66 1H-NMR (400 MHz, CD3OD): δ 9.40 (s, 1H), 8.85-8.88 (m, 2H), 8.53 (d, J = 9.2 Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 7.80- 7.88 (m, 3H), 7.46 (s, 1H). CD3OD 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1147

377.78 1H-NMR (400 MHz, DMSO-d6): δ 12.28 (s, 1H), 9.58 (s, 1H), 9.14 (d, J = 8.4 Hz, 1H), 8.87 (s, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.28 (d, J = 9.2 Hz, 1H), 8.07- 8.12 (m, 2H), 7.86 (dd, J = 8.8, 2.0 Hz, DMSO 378.1, 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1H), 7.77 (t, J = 8.8 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H). 1148

381.79 1H-NMR (400 MHz, DMSO-d6): δ 11.69- 11.49 (m, 1H), 9.40 (d, J = 1.2 Hz, 1H), 9.00-8.86 (m, 3H), 8.24 (dd, J = 6.6, 2.1 Hz, 1H), 7.91 (ddd, J = 8.9, 4.2, 2.6 Hz, 1H), 7.71 (d, J = 1.4 Hz, 1H), DMSO 382.1, 384.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 7.61 (t, J = 9.0 Hz, 1H), 7.49 (dd, J = 9.2, 2.3 Hz, 1H) 4.00 (s, 3H). 1149

395.36 1H-NMR (400 MHz, DMSO-d6): δ 9.96 (s, 1H), 9.57 (d, J = 1.4 Hz, 1H), 8.83- 8.74 (m, 2H), 8.57 (d, J = 9.1 Hz, 1H), 8.28 (t, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.2, 1.2 Hz, 1H), 7.50- 7.32 (m, 3H), 7.31 (t, J = 74.0 Hz, 1H), 6.94 (dd, J = DMSO 396.1, (M + 1), 397.2 (M + 2) Method B (NH4HCO3) 95 Method C, G1 8.0, 2.2 Hz, 1H), 3.98 (s, 3H). 1150

383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 9.57 (s, 1H), 8.80 (dd, J = 19.8, 1.7 Hz, 2H), 8.72-8.66 (m, 1H), 8.50 (s, 1H), 8.07- 7.94 (m, 3H), 7.75 (t, J = 7.2 Hz, DMSO 384.1, (M + 1) Method B (NH4HCO3) 95 Method C, G1 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.14 (d, J = 8.8 Hz, 1H). 1151

385.42 1H-NMR (400 MHz, DMSO-d6): δ 13.01 (s, 1H), 10.04 (s, 1H), 9.40 (d, J = 5.4 Hz, 1H), 9.20 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 8.42 (dd, J = 5.3, 1.9 Hz, 1H), 8.04-7.94 (m, 2H), 7.84 (d, J = 9.2 DMSO 386.0 (M + 1) Method A (TFA) 95 Method D, G1 Hz, 1H), 7.75 (t, J = 7.9 Hz, 1H), 7.58 (d, J = 9.2 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.13 (s, 1H), 3.15 (s, 6H). 1152

HCl 394.83 1H-NMR (400 MHz, DMSO-d6): δ 10.96 (s, 1H), 9.97 (d, J = 1.1 Hz, 1H), 9.55 (d, J = 5.5 Hz, 1H), 8.61 (dd, J = 5.5, 2.2 Hz, 1H), 8.15 (dd, J = 6.8, 2.6 Hz, 1H), 8.08 (d, J = DMSO 395.1, 397.1 (M + 1) Method A (TFA) 95 Method D, G1 9.3 Hz, 1H), 7.94 (ddd, J = 8.9, 4.3, 2.6 Hz, 1H), 7.74 (s, 1H), 7.62 (dd, J = 9.4, 2.5 Hz, 1H), 7.56 (t, J = 9.1 Hz, 1H), 3.16 (s, 6H). 1153

HCl 408.4 1H-NMR (400 MHz, DMSO-d6): δ 10.71 (brs, 1H), 10.01- 9.99 (m, 1H), 9.52 (dd, J = 5.5, 1.0 Hz, 1H), 8.60 (dd, J = 5.5, 2.3 Hz, 1H), 8.07 ((d, J = DMSO 409.1 (M + 1) Method A (TFA) 95 Method D, G1 9.2 Hz 1H), 7.85-7.78 (m, 2H), 7.71 (s, 1H), 7.65 (dd, J = 9.3, 2.5 Hz, 1H), 7.56 (t, J = 8.2 Hz, 1H), 7.33 (t, J = 74.0 Hz, 1H), 7.09 (dd, J = 8.1, 2.1 Hz, 1H), 3.17 (s, 6H). 1154

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.13 (s, 1H), 9.63 (d, J = 1.2 Hz, 1H), 9.34 (d, J = 7.6 Hz, 1H), 8.91- 8.84 (m, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.49 (s, 1H), 8.12 (d, J = 9.6 Hz, 1H), 8.03-7.85 DMSO 373.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 (m, 2H), 7.75- 7.61 (m, 1H), 7.48- 7.30 (m, 2H), 7.28-7.06 (m, 1H), 3.99 (s, 3H). 1155

381.79 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 9.99- 9.95 (m, 1H), 9.42 (dd, J = 5.2, 1.2 Hz, 1H), 8.58- 8.51 (m, 1H), 8.35 (dd, J = 5.2, 2.4 Hz, 1H), 8.21 (dd, J = 6.8, 2.4 Hz, 1H), 7.93 (ddd, J = DMSO 382.0, 384.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 8.8, 4.2, 2.7 Hz, 1H), 7.53 (dd, J = 11.7, 6.4 Hz, 1H), 7.32 (dd, J = 6.6, 2.6 Hz, 2H), 3.97 (s, 3H). 1156

395.36 1H-NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 10.01 (d, J = 1.3 Hz, 1H), 9.43 (dd, J = 5.2, 1.2 Hz, 1H), 8.55 (d, J = 10.0 Hz, 1H), 8.40 (dd, J = 5.2, 2.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.86-7.77 (m, 1H), 7.55- 7.35 (m, 3H), 7.32 (t, DMSO 396.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 J = 74.0 Hz, 1H), 7.01 (dd, J = 8.0, 2.0 Hz, 1H), 3.99 (s, 3H). 1157

376.80 1H-NMR (400 MHz, DMSO-d6): δ 13.34 (s, 1H), 9.61 (s, 1H), 9.28 (d, J = 8.4 Hz, 1H), 8.87 (s, 1H), 8.80 (s, 1H), 8.53 (s, 1H), 8.25 (s, 1H), 7.94- 8.06 (m, 4H), 7.70 (t, J = 8.0 Hz, 1H), 7.23 (t, J = DMSO 377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 7.6 Hz, 1H). 1158

358.78 1H-NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H), 9.54 (s, 1H), 8.77- 8.84 (m, 4H), 8.32 (d, J = 8.0 Hz, 1H), 8.00-8.03 (m, 2H), 7.62- 7.70 (m, 2H). DMSO 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1159

386.21 1H-NMR (400 MHz, DMSO-d6): δ 10.55 (s, 1H), 9.50 (s, 1H), 8.83 8.87 (m, 3H), 8.47-8.49 (m, 1H), 7.96- 8.06 (m, 3H), 7.54 (t, J = 9.2 Hz, 1H). DMSO 386.0, 388.0, 390.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1160

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.54 (s, 1H), 9.53 (s, 1H), 8.84- 8.88 (m, 3H), 8.62 (d, J = 2.0 Hz, 1H), 8.01-8.07 (m, 3H), 7.73 (d, J = 8.8 Hz, 1H). DMSO 401.9, 403.9, 406.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1161

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.55 (d, J = 1.6 Hz, 1H), 8.87- 8.88 (m, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 2.0 Hz, 2H), 8.00-8.07 (m, 2H), 7.40 (t, J = 1.6 Hz, 1H). DMSO 401.9, 403.8, 405.8 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1162

468.2 1H-NMR (400 MHz, DMSO-d6): δ 13.36 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 9.15- 9.12 (m, 1H) 8.90-8.85 (m, 2H), 8.68 (d, J = 1.2 Hz, 1H), 8.52 (s, 1H), 8.28- 8.25 (m, 1H), 8.07 (s, 1H), 7.99- DMSO 469.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 7.96 (m, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.74-7.70 (m, 1H), 7.28 (t, J = 7.6 Hz, 1H). 1163

491.23 1H-NMR (400 MHz, DMSO-d6): δ 10.83 (s, 1H), 9.32 (s, 1H), 9.07 (s, 1H), 8.74 (s, 2H), 8.16 (dd, J = 8.0, 1.6 Hz, 1H), 7.87 (s, 1H), 7.74-7.64 DMSO 492.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 (m, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.16 (t, J = 74.0 Hz, 1H), 6.95- 6.92 (m, 1H). 1164

477.66 1H-NMR (400 MHz, DMSO-d6): δ 11.48 (s, 1H), 9.42 (s, 1H), 9.34 (s, 1H), 8.95- 8.93 (m, 2H), 8.35-8.30 (m, 2H), 7.97- 7.90 (m, 2H), 7.60 (t, J = 9.0 Hz, 1H). DMSO 478.0, 480.0 (M + 1) Method B (NH4HCO3) 90 Method C, G1 1165

413.81 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.99 (s, 1H), 9.40 (d, J = 5.6 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.36 (dd, J = 5.2, 2.0 Hz, 1H), 7.87 DMSO 414.1, 416.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 (m, 1H), 7.81 (m, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.30 (t, J = 74.0 Hz, 1H), 8.36 (dd, J = 8.4, 2.0 Hz, 1H), 2.70 (s, 3H). 1166

400.24 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 10.01 (s, 1H), 9.46 (d, J = 5.2 Hz, 1H), 8.56 (d, J = 1.6 Hz, 1H), 8.39 (dd, J = 5.4, 2.2 Hz, 1H), 8.20 (dd, J = 7.2, 2.6 Hz, DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1H), 7.95- 7.91 (m, 1H), 7.89 (s, 1H), 7.57 (t, J = 9.0 Hz, 1H), 2.75 (s, 3H). 1167

409.39 1H-NMR (400 MHz, DMSO-d6): δ 10.05- 10.3 (m, 2H), 9.45 (dd, J = 5.2, 1.2 Hz, 1H), 8.42 (dd, J = 5.2, 1.2 Hz, 1H), DMSO 410.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 8.06 (d, J = 2.8 Hz, 1H), 7.97-7.94 (m, 2H), 7.86 (dd, J = 8.0, 1.2 Hz, 1H), 7.66-7.60 (m, 2H), 7.38 (t, J = 74.0 Hz, 1H), 7.10- 7.08 (m, 1H), 4.32 (q, J = 6.8 Hz, 2H), 1.51 (t, J = 7.0 Hz, 3H). 1168

379.36 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H), 10.07 (d, J = 2.0 Hz, 1H), 9.44 (dd, J = 5.2, 2.4 Hz, 1H), 8.48-8.44 (m, 2H), 7.93 (t, J = 2.0 Hz, 1H), 7.86- 7.84 (m, 2H), 7.66-7.62 (m, 1H), 7.54 (t, J = 8.4 Hz, 1H), 7.32 (t, J = 74.0 DMSO 380.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 Hz, 1H), 7.02 (dd, J = 8.0, 2.4 Hz, 1H), 2.77 (s, 3H). 1169

444.23 1H-NMR (400 MHz, DMSO-d6): δ 10.17 (s, 1H), 9.55 (s, 1H), 8.98 (s, 1H), 8.79 (d, J = 12.8 Hz, 2H), 8.26 (s, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.92- DMSO 444.0, 446.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 7.88 (m, 2H), 7.52-7.50 (m, 1H), 7.32 (t, J = 71.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H). 1170

430.66 1H-NMR (400 MHz, DMSO-d6): δ 10.11 (s, 1H), 9.52 (s, 1H), 8.89 (d, J = 1.2 Hz, 1H), 8.83 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.56 (dd, J = 6.8, 2.4 Hz, 1H), 8.05 (dd, J = DMSO 430.0, 432.0, 434.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 9.2, 2.0 Hz, 1H), 8.02- 7.96 (m, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.49 (t, J = 9.2 Hz, 1H). 1171

386.41 1H-NMR (400 MHz, DMSO-d6): δ 13.07 (s, 1H), 9.63 (s, 2H), 9.33 (s, 1H), 8.95 (d, J = 8.0 Hz, 1H), 8.50 (s, 1H), 7.99- 7.94 (m, 3H), 7.76-7.71 (m, 1H), 7.62-7.59 (m, DMSO 387.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 2H), 7.24 (t, J = 7.4 Hz, 1H), 4.23 (q, J = 7.0 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). 1172

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.11 (s, 1H), 9.61 (s, 2H), 9.34 (s, 1H), 8.91 (d, J = 8.0 Hz, 1H), 8.49 (s, 1H), 7.98- 7.95 (m, 3H), 7.72 (t, J = 8.0 Hz, 1H), 7.62-7.60 (m, 2H), 7.24 (t, J = 7.6 DMSO 373.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 Hz, 1H), 3.97 (s, 3H). 1173

HCl 379.32 1H-NMR (400 MHz, DMSO-d6): δ 10.55 (brs, 1H), 9.59 (s, 2H), 9.35 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.09- 8.07 (m, 1H), 8.00-7.96 (m, 2H), 7.76- 7.72 (m, 1H), 7.67 (dd, DMSO 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 J = 8.8, 2.0 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H). 1174

HCl 464.47 1H-NMR (400 MHz, DMSO-d6): δ 10.14 (s, 1H), 9.59 (s, 1H), 8.80 (m, 2H), 8.62 (d, J = 7.6 Hz, 1H), 8.30 (s, 1H), 7.90 (s, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.53- 7.45 (m, 1H), 7.39-6.86 DMSO 465.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 (m, 1H), 7.30 (t, J = 74.1 Hz, 1H), 3.73 (s, 2H), 3.63- 3.58 (m, 4H), 2.48-2.43 (m, 4H). 1175

357.37 1H-NMR (400 MHz, DMSO-d6): δ 9.70 (s, 1H), 9.43 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.78 (d, J = 2.0 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 7.60-7.65 DMSO 358.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 (m, 2H), 7.09- 7.13 (m, 3H), 2.76 (s, 3H). 1176

365.79 1H-NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.62 (s, 1H), 8.85 (s, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.45 (d, J = 8.0 Hz, 1H), 8.03- 8.07 (m, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.61 (t, J = 7.6 Hz, DMSO 366.0, 368.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1H), 7.49 (t, J = 9.2 Hz, 1H), 2.75 (s, 3H). 1177

379.36 1H-NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H), 9.64 (s, 1H), 8.83 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H), 8.38 (s, 1H), 7.92 (d, DMSO 380.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 J =8.4 Hz, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.61 (t, J =7.8 Hz, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.32 (t, J = 74.0 Hz, 1H), 6.95 (d, J = 7.2 Hz, 1H), 2.75 (s, 3H). 1178

382.25 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.62 (s, 1H), 8.86 (t, J = 2.4 Hz, 1H), 8.78 (t, J = 3.2 Hz, 2H), 8.52 (d, J = 8.4 Hz, 1H), 8.10-8.13 (m, 1H), 7.83 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 9.2 DMSO 381.9, 383.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 Hz, 1H), 7.63 (t, J = 7.6 Hz, 1H), 2.75 (s. 3H). 1179

349.34 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.60 (s, 1H), 8.87 (s, 1H), 8.78 (d, J = 2.4 Hz 1H), 8.50- 8.60 (m, 2H), 7.80-7.85 (m, 2H), 7.61 (t, J = 7.8 Hz, 1H), 7.46- 7.54 (m, 1H), 2.74 (s, DMSO 350.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 3H). 1180

382.25 1H-NMR (400 MHz, DMSO-d6): δ 10.20 (s, 1H), 9.62 (s, 1H), 8.85 (s, 1H), 8.77 (d, J = 2.8 Hz, 1H), 8.47- 8.52 (m, 3H), 7.81 (d, J = 3.2 Hz 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.31 (t, J = 1.6 Hz, 1H), DMSO 381.9, 383.9 (M + 1) Method B (NH4HCO3) 95 Method C, G1 2.51 (s, 3H). 1181

338.37 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H) 9.64 (s, 1H), 8.86 (d, J = 9.2 Hz, 2H), 8.78 (d, J = 8.0 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.84 (d, DMSO 339.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 J = 7.2 Hz, 1H), 7.61- 7.65 (m, 3H), 2.76 (s, 3H). 1182

383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.24 (s, 1H), 9.99 (s, 1H), 9.41 (d, J = 5.2 Hz, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.36-8.38 (m, 1H), 8.10 (s, 1H), 7.95-7.98 (m, 3H), 7.73- DMSO 384.2 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.74 (m, 1H), 7.62 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H). 1183

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.19 (s, 1H), 10.01 (s, 1H), 9.41- 9.43 (m, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.39-8.41 (m, 1H), 7.93- 7.97 (m, 3H), 7.84 (d, DMSO 366.2 (M + 1) Method B (NH4HCO3) 95 Method D, G1 J = 8.4 Hz, 1H), 7.74 (m, 1H), 7.54- 7.56 (m, 1H), 7.32 (t, J = 74.0 Hz, 1H), 7.02-7.04 (m, 1H). 1184

398.25 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 9.96 (s, 1H), 9.44 (d, J = 4.8 Hz, 1H), 8.40- 8.41 (m, 1H), 8.29 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 2.4 Hz, 1H), 7.99-8.02 (m, 1H), 7.89 (d, J = 8.8 DMSO 398.0, 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.56- 7.58 (m, 1H), 3.99 (s, 3H). 1185

381.79 1H-NMR (400 MHz, DMSO-d6): δ 9.92 (s, 1H), 9.36- 9.38 (m, 1H), 8.27-8.29 (m, 1H), 8.14- 8.16 (m, 1H), 7.51 (s, 1H), 7.83- 7.91 (m, 3H), 7.51-7.56 (m, 2H), 3.97 (s, 3H). DMSO 382.1, 384.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1186

365.34 1H-NMR (400 MHz, DMSO-d6): δ 9.95- 10.00 (m, 2H), 9.40 (d, J = 5.6 Hz, 1H), 8.32-8.33 (m, 1H), 8.06 (m, 1H), 7.96 (s, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.69 (m, 1H), 7.54-7.59 (m, 2H), 3.98 DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 (s, 3H). 1187

354.36 1H-NMR (400 MHz, DMSO-d6): δ 10.00 (s, 1H), 9.90 (m, 1H), 9.35- 9.36 (m, 1H), 8.23-8.30 (m, 3H), 7.84-7.90 (m, 2H), 7.62-7.71 (m, 2H), 7.54-7.57 (m, 1H), 3.96 (s, 3H). DMSO 355.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1188

413.35 1H-NMR (400 MHz, DMSO-d6): δ 9.96-10.0 (m, 2H), 8.39-8.40 (m, 1H), 8.31- 8.33 (m, 1H), 8.07 (s, 1H), 7.88-7.96 (m, 3H), 7.57-7.67 (m, 2H), 7.22 (d, J = 8.0 Hz, 1H), 4.01 (s, 3H). DMSO 414.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1189

373.36 1H-NMR (400 MHz, DMSO-d6): δ 12.15 (s, 1H), 10.02 (s, 1H), 9.41 (d, J = 5.2 Hz, 1H), 8.94 (d, J = 7.6 Hz, 1H), 8.41 (m, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.80 (t, J = 8.4 DMSO 374.1, 376.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 Hz, 1H), 7.60-7.62 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 4.01 (s, 3H). 1190

398.25 1H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.54 (s, 1H), 8.81- 8.82 (m, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.06 (dd, J = 8.8, 2.4 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.92 (d, DMSO 397.9, 400.0, 401.9 (M + 1) Method B (NH4HCO3) 95 Method D, G6 J = 8.8 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.60 (dd, J = 8.8, 2.4 Hz, 1H), 3.40 (s, 3H). 1191

381.79 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s,1H), 9.52 (s, 1H), 8.81 (m, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.53 (dd, J = 6.8, 2.4 Hz, 1H), 7.98- 8.03 (m, 2H), 7.91 (d, J = 9.2 Hz, 1H), 7.59 (dd, J = 5.2, 2.4 Hz, DMSO 382.0, 384.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 7.51 (t, J = 8.8 Hz, 1H), 3.40 (s, 3H). 1192

365.34 1H-NMR (400 MHz, DMSO-d6): δ 9.89 (s, 1H), 9.52- 9.53 (m, 1H), 8.81-8.82 (m, 1H), 8.73 (d, J = 2.4 Hz, 1H), 8.45- 8.51 (m, 1H), 7.98 (m, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.75- 7.78 (m, 1H), DMSO 366.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 7.47-7.59 (m, 2H), 3.40 (s, 3H). 1193

354.36 1H-NMR (400 MHz. DMSO-d6): δ 10.06 (s, 1H), 9.54 (s, 1H), 8.74- 8.81 (m, 3H), 8.35 (d, J = 8.4 Hz, 1H), 8.04 (m, 1H), 7.92-7.95 (m, 1H), 7.59- 7.69 (m, 3H), 3.40 (s, 3H). DMSO 355.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1194

398.25 1H-NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 9.55 (d, J = 1.2 Hz, 1H), 8.81 (t, J = 2.0 Hz, 1H), 8.74 (d, J = 2.4 Hz, 1H), 8.39 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.92 (d, J = 8.8 Hz, DMSO 398.0, 399.9, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 7.59 (dd, J = 8.8, 2.4 Hz, 1H), 7.32 (t, J = 1.6 Hz. 1H), 3.40 (s, 3H). 1195

395.36 1H-NMR (400 MHz, DMSO-d6): δ 9.91 (s, 1H), 9.55 (m, 1H), 874- 8.79 (m, 2H), 8.25 (s, 1H), 8.03 (d, J = 2.4 Hz. 1H), 7.92 (d, J = 9.2 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 9.2, 2.4 Hz, 1H), 7.48-7.52 (m, 1H), 7.34 (t, DMSO 396.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 J = 74.0 Hz, 1H), 6.96- 6.98 (m, 1H), 3.40 (s, 3H). 1196

377.78 1H-NMR (400 MHz, DMSO-d6): δ 12.26 (s, 1H), 9.94 (s, 1H), 9.41- 9.42 (m, 1H), 8.75 (d, J = 8.0 Hz, 1H,), 8.33-8.34 (m, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 7.93 (m, 1H), DMSO 378.0, 380.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 7.75-7.77 (m, 2H), 7.05- 7.30 (m, 2H). 1197

343.34 1H-NMR (400 MHz, DMSO-d6): δ 13.86 (s, 1H), 12.39 (s, 1H), 9.62 (d, J = 0.8 Hz, 1H), 9.29 (d, J = 8.0 Hz, 1H), 8.87 (s, 1H), 8.80 (d, J = 2.4 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.12 (dd, J = 8.0, DMSO 344.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1.6 Hz, 1H), 7.97-8.05 (m, 3H), 7.75-7.79 (m, 2H), 7.24 (t, J = 7.6 Hz, 1H). 1198

372.38 1H-NMR (400 MHz, DMSO-d6): δ 13.05 (s, 1H), 9.99 (s, 1H), 9.39 (d, J = 5.2 Hz, 1H), 9.05 (d, J = 8.4 Hz, 1H), 8.47 (s, 1H), 8.36- 8.38 (m, 1H), 7.85-7.98 (m, 3H), 7.71 (t, J = 7.6 Hz, 1H), 7.46- DMSO 373.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.60 (m, 2H), 7.20 (t, J = 7.6 Hz, 1H), 3.95 (s, 3H). 1199

376.8 1H-NMR (400 MHz, DMSO-d6): δ 13.15 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 4.2 Hz, 1H), 8.95 (d, J = 8.4 Hz, 1H), 8.49 (s, 1H), 8.40- 8.42 (m, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.91- 7.97 (m, 3H), DMSO 377.0, 379.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.80 (t, J = 7.6 Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H). 1200

399.78 1H-NMR (400 MHz, DMSO-d6): δ 12.29 (s, 1H), 9.98 (s, 1H), 9.42 (d, J = 5.2 Hz, 1H), 8.66 (d, J = 9.2 Hz, 1H), 8.36-8.38 (m, 1H), 8.00 (d, J = 1.5 Hz, 1H), 7.89 (s, 1H), 7.79-7.81 (m, 2H), 7.49- 7.57 (m, 1H), 7.31 (t, J = 74.0 Hz, 1H), DMSO 400.0, 401.9 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.04 (dd, J = 8.0, 1.2 Hz, 1H). 1201

386.21 1H-NMR (400 MHz, DMSO-d6): δ 9.94 (s, 1H), 9.43 (d, J = 5.2 Hz, 1H), 8.72 (d, J = 8.8 Hz, 1H), 8.33 (dd, J = 5.6, 2.4 Hz, 1H), 8.21 (dd, J = 6.4, 1.6 Hz, 1H), 7.93-7.98 DMSO 386.0, 387.8 (M + 1) Method A (TFA) 95 Method D, G1 (m, 2H), 7.78 (dd, J = 8.8, 2.0 Hz, 1H), 7.54 (t, J = 9.2 Hz, 2H). 1202

369.76 1H-NMR (400 MHz, DMSO-d6): δ 10.28 (s, 1H), 9.95 (m, 1H), 9.44- 9.45 (m, 1H), 8.60 (d, J = 8.8 Hz, 1H), 8.32-8.34 (m, 1H), 8.02- 8.08 (m, 1H), 7.98 (d, J = 6.4 Hz, DMSO 369.9, 371.0 (M + 1) Method A (TFA) 95 Method D, G1 1H), 7.79 (dd, J = 9.2, 2.4 Hz, 1H), 7.70- 7.72 (m, 1H), 7.56 (q, J = 9.2 Hz, 1H). 1203

358.78 1H-NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H), 9.92 (s, 1H), 9.42 (d, J = 4.8 Hz, 1H), 8.59 (d, J = 8.4 Hz, 1H), 8.23-8.33 (m, 3H), 7.96 (d, J = 1.6 Hz, 1H), 7.65- 7.79 (m, DMSO 359.0, 361.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 3H). 1204

402.66 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.96 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.28-8.35 (m, 2H), 7.94- 7.99 (m, 2H), 7.79 (d, J = 8.8 Hz, DMSO 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1H), 7.73 (d, J = 8.8 Hz, 1H). 1205

402.66 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.42 (d, J = 4.8 Hz, 1H), 8.58 (d, J = 8.8 Hz, 1H), 8.27 (s, 1H), 8.07 (s, 2H), 7.92 (s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H). DMSO 401.9, 403.9, 405.9 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1206

351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.59 (s, 1H), 9.43 (m, 1H), 9.07 (d, J = 5.2 Hz, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.50 (dd, J = 6.4, 2.0 Hz, 1H), 8.31 (dd, J = 5.2, 0.8 Hz, 1H), 8.00- 8.09 (m, 3H), DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.80 (t, J = 7.2 Hz, 1H), 7.53 (t, J = 9.2 Hz, 1H). 1207

342.35 1H-NMR (400 MHz, DMSO-d6): δ 13.31 (s, 1H), 9.38- 9.43 (m, 2H), 9.05 (d, J = 5.2 Hz, 1H), 8.52 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.95-8.04 (m, 4H), 7.82 (t, J = 7.2 DMSO 343.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H). 1208

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.13 (s, 1H), 9.37 (d, J = 1.2 Hz, 1H), 9.01 (d, J = 5.2 Hz, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.40 (dd, J = 5.2, 1.2 Hz, 1H), 8.28 (t, J = 1.2 Hz, 1H), 7.92-8.00 (m, 3H), 7.77- 7.79 (m, 1H), 7.47-7.52 (m, DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1H), 7.34 (t, J = 74.0 Hz, 1H), 6.97 (dd, J = 8.4, 2.4 Hz, 1H). 1209

HCl (batch 02) 351.6 1H-NMR (400 MHz, DMSO-d6): δ 10.82 (s, 1H), 9.59 (s, 2H), 9.36 (s, 1H), 8.74 (d, J = 8.4 Hz, 1H), 8.22 (dd, J = 6.8, 2.4 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 8.00 (t, J = 7.6 Hz, 1H), 7.90- 7.94 (m, DMSO 352.0, 354.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1H), 7.75 (t, J = 7.2 Hz, 1H), 7.56 (t, J = 9.2 Hz, 1H). 1210

342.35 1H-NMR (400 MHz, DMSO-d6): δ 13.17 (s, 1H), 9.65 (s, 2H), 9.36 (s, 1H), 8.93 (d, J = 8.0 Hz, 1H), 8.51 (s, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.92- 8.02 (m, 4H), 7.72-7.79 (m, 2H), 7.26 (t, J = 7.6 DMSO 343.1 (M + 1) Method B (NH4HCO3) 95 Method D, G4 Hz, 1H). 1211

365.34 1H-NMR (400 MHz, DMSO-d6): δ 10.15 (s, 1H), 9.62 (s, 2H), 9.32 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 7.94- 7.97 (m, 3H), 7.81 (dd, J = 8.4, 1.2 Hz, 1H), 7.69- 7.74 (m, 1H), 7.50-7.55 (m, 1H), 7.31 (t, J = 74.0 Hz, 1H), 7.01 (dd, J = 8.4, DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 2.4 Hz, 1H). 1212

399.78 1H-NMR (400 MHz, DMSO-d6): δ 10.27 (s, 1H), 10.01- 10.02 (m, 1H), 9.44- 9.46 (m, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.40 (dd, J = 5.2, 2.0 Hz, 1H), 8.04 (t, J = 1.6 Hz, DMSO 400.0, 402.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 8.00 (d, J = 3.2 Hz, 2H), 7.94 (m, 1H), 7.76- 7.80 (m, 1H), 7.38 (t, J = 73.6 Hz, 1H), 7.16 (t, J = 2.0 Hz, 1H),. 1213

398.79 1H-NMR (400 MHz, DMSO-d6): δ 10.16 (s, 1H), 9.56 (m, 1H), 8.69- 8.72 (m, 2H), 8.59 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.94-7.97 (m, 2H), 7.69- 7.73 (m, DMSO 399.0, 401.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 7.55- 7.58 (m, 1H), 7.36 (t, J = 73.6 Hz, 1H), 7.13 (t, J = 2.0 Hz, 1H). 1214

365.34 1H-NMR (400 MHz, DMSO-d6): δ 11.17 (s, 1H), 9.49 (s, 1H), 8.88- 8.92 (m, 3H), 8.16 (d, J = 8.0 Hz, 1H), 8.07 (t, J = 7.6 Hz, 2H), 7.84 (t, J = 8.0 Hz, 2H), 7.57 (t, J = 8.0 Hz, 1H), 7.36 (t, J = 74.0 Hz, 1H), 7.10-7.12 (m, 1H). DMSO 366.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1215

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.23 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.38 (dd, J = 2.4, 5.2 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), DMSO 367.8, 369.8, 371.8 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.96-8.00 (m, 3H), 7.73- 7.77 (m, 2H). 1216

351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.99 (s, 1H), 9.43 (d, J = 5.2 Hz, 1H), 8.58 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 5.2, 2.0 Hz, 1H), 8.22 (dd, J = 7.0, 2.6 Hz, 1H), DMSO 351.9, 353.8 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.89-7.93 (m, 3H), 7.68- 7.72 (m, 1H), 7.55 (t, J = 8.6 Hz, 1H). 1217

324.34 1H-NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H), 9.99 (dd, J = 2.0, 1.2 Hz, 1H), 9.44 (dd, J = 5.2, 0.8 Hz, 1H), 8.61 (d, J = 8.4 Hz, 1H), 8.38-8.40 (m, 2H), 8.28-8.31 (m, DMSO 325.0 (M + 1) Method B (NH4HCO3) 95 Method D, G1 1H), 7.99 (s, 1H), 7.97 (d, J = 3.6 Hz, 1H), 7.66- 7.80 (m, 3H). 1218

368.22 1H-NMR (400 MHz, DMSO-d6): δ 11.94 (s, 1H), 9.44 (d, J = 0.8 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 2.4 Hz, 1H), 8.97 (t, J = 1.8 Hz, 1H), 8.38 (d, J = 2.4 Hz, DMSO 367.9, 369.9, 371.8 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 8.38 (d, J = 2.4 Hz, 1H), 8.12 (t, J = 7.4 Hz, 1H), 8.00 (dd, J = 8.6, 2.2 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H). 1219

351.76 1H-NMR (400 MHz, DMSO-d6): δ 11.62 (s, 1H), 9.40 (d, J = 0.8 Hz, 1H), 8.60- 8.83 (m, 3H), 8.32 (dd, J = 6.6, 2.2 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.09 (t, J = 7.4 Hz, DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 1H), 7.95- 8.00 (m, 1H), 7.85 (t, J = 7.8 Hz, 1H), 7.61 (t, J = 9.2 Hz, 1H). 1220

335.31 1H-NMR (400 MHz, DMSO-d6): δ 11.05 (s, 1H), 9.48 (d, J = 0.8 Hz, 1H), 8.91- 8.93 (m, 2H), 8.81 (d, J = 8.4 Hz, 1H), 8.28-8.33 (m, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.06 DMSO 336.1 (M + 1) Method B (NH4HCO3) 95 Method D, G6 (t, J = 7.6 Hz, 1H), 7.77- 7.85 (m, 2H), 7.56-7.63 (m, 1H) 1221

324.34 1H-NMR (400 MHz, DMSO-d6): δ 12.09 (s, 1H), 9.40 (d, J = 1.6 Hz, 1H), 9.10 (d, J = 8.4 Hz, 1H), 9.00 (d, J = 2.0 Hz, 1H), 8.97 (t, J = 2.0 Hz, 1H), 8.49 (s, 1H), 8.26- DMSO 324.9 (M + 1) Method B (NH4HCO3) 95 Method D, G6 8.30 (m, 2H), 8.12-8.06 (m, 1H), 7.87- 7.91 (m, 1H), 7.76- 7.84 (m, 2H) 1222

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.21 (s, 1H), 9.59 (d, J = 1.2 Hz, 1H), 8.85 (t, J = 1.8 Hz, 1H), 3.78 (d, J = 2.0 Hz, 1H), 8.64 (d, J = 8.4 Hz, 1H), 3.42 (d, J = 1.6 Hz, 2H), 7.96- 8.02 (m, 2H), DMSO 368.0, 370.0, 372.0 (M + 1) Method B (NH4HCO3) 95 Method D, G6 7.74-7.78 (m, 1H), 7.35 (d, J = 1.6 Hz, 1H). 1223

368.22 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 10.00 (s, 1H), 9.45 (d, J = 5.2 Hz, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.38 (dd, J = 5.0, 1.8 Hz, 1H), 8.09 (s, 2H), 7.94 (s, 1H), 7.92 (d, J = 9.2 Hz, 1H), DMSO 368.1, 370.1 (M + 1) Method B (NH4HCO3) 95 Method D, G1 7.70-7.74 (m, 1H), 7.35 (s,1H). 1224

413.81 1H-NMR (400 MHz, DMSO-d6): δ 10.05 (s, 1H), 9.63 (s, 1H), 8.82 (s, 1H), 8.78 (s, 1H), 8.66 (s, 1H), 8.31 (s, 1H), 7.89- 7.91 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 73.6 Hz, 1H), 6.96 (d, J = 7.6 Hz, 1H), 2.74 (s, 3H). DMSO 414.0 416.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1225

400.24 1H-NMR (400 MHz, DMSO-d6): δ 9.90 (s, 1H), 9.54 (s, 1H), 8.77- 8.80 (m, 2H), 8.60 (s, 1H), 8.50 (s, 1H), 7.99 (s, 1H), 7.76 (s, 1H), 7.44 (s, 1H), 2.67 (s, 3H). DMSO 400.0 401.9 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1226

390.83 1H-NMR (400 MHz, DMSO-d6): δ 13.33 (s, 1H), 9.67 (s, 1H), 9.38 (d, J = 8.0 Hz, 1H), 8.88 (s, 1H), 8.79 (s, 1H), 8.52 (s, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.88 (s, 1H), 7.69 (d, DMSO 391.0 392.0 (M + 1) Method A (TFA) 95 Method C, G3 J = 7.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 2.75 (s, 3H). 1227

391.81 1H-NMR (400 MHz, DMSO-d6): δ 16.00 (s, 1H), 9.69 (s, 1H), 9.39 (d, J = 8.4 Hz, 1H), 8.90 (s, 1H), 8.79 (s, 1H), 8.29 (s, 1H), 8.13 (d, J = 7.6 Hz, 1H), 7.82 (s, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.06 (t, DMSO 392.0 393.1 (M + 1) Method A (TFA) 95 Method C, G3 J = 7.2 Hz, 1H), 2.73 (s, 3H). 1228

372.81 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.57 (s, 1H), 8.82 (s, 2H), 8.76 (s, 1H), 8.57 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 7.81 (s, 1H), 7.57- 7.63 (m, 2H), 2.70 (s, 3H). DMSO 373.0 374.0 (M + 1) Method B (NH4HCO3) 95 Method C, G3 1229

416.69 1H-NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1H), 9.63 (d, J = 1.2 Hz, 1H), 8.85 (dd, J = 2.4, 1.6 Hz, 1H), 8.78 (d, J = 2.4 Hz, 2H), 8.63 (d, J = 1.6 Hz, 1H), 8.45 (s, 2H), 7.34 (t, J = 2.0 Hz, 1H), DMSO 416.9 417.9 (M + 1) Method B (NH4HCO3) 95 Method C, G3 2.74 (s, 3H). 1230

HCl 351.76 1H-NMR (400 MHz, DMSO-d6): δ 10.42 (s, 1H), 9.60 (s, 2H), 9.34 (s, 1H), 8.64 (d, J = 8.4 Hz, 1H), 8.24 (dd, J = 8.4, 2.4 Hz, 1H), 7.98- 7.92 (m, 3H), 7.76- 7.71 (m, 1H), 7.56 (t, J = 8.8 Hz, 1H). DMSO 352.0, 354.0 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1231

HCl 383.33 1H-NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 9.61 (s, 2H), 9.34 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.13 (s, 1H), 8.04- 7.93 (m, 3H), 7.78-7.73 (m, 1H), 7.62 (t, J = 8.4 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H). DMSO 384.1 (M + 1) Method B (NH4HCO3) 95 Method C, G1 1232

421.25 1H-NMR (400 MHz, DMSO-d6): 10.34 (s, 1H), 9.58 (s, 1H), 9.27-9.25 (m, 1H), 8.84- 8.77 (m, 2H), 9.52 (s, 1H), 8.35 (s, 1H), 8.07- 7.67 (m, 5H), 7.20 (t, J = 7.5 Hz, 1H). DMSO 421.0, 423.0 (M + 1) Method B (NH4HCO3) 95 Method C, G6 1233

1H-NMR (400 MHz, DMSO-d6): δ 13.15 (s, 1H), 10.00 (s, 1H), 9.44 (d, J = 5.2 Hz, 1H), 8.95 (d, J = 8.4 Hz, 1H), 8.48 (s, 1H), 8.42- 8.40 (m, 1H), 8.16 (d, J = 9.2 Hz, 1H), 7.97- 7.91 (m, 3H), 7.81-7.73 DMSO 377.0 (M + 1) Method B (NH4HCO3) 95 Method G (m, 2H), 7.25 (t, J = 2.4 Hz, 1H). 1234

1H-NMR (400 MHz, DMSO-d6): δ 9.95 (s, 1H), 9.54 (s, 1H), 8.82 (s, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.07 (dd, J = 8.8, 2.4 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.70 DMSO 397.9, 400.0 (M + 1) Method B (NH4HCO3) 95 Method G (d, J = 8.8 Hz, 1H), 7.60 (dd, J = 8.8, 2.4 Hz, 1H), 4.00 (s, 3H).

Method C: 5-Nitro-2-(pyrazine-2-carboxamido)benzoic acid (li-a)

To a solution of pyrazine-2-carboxylic acid (1.36 g, 10.9 mmol, 1 eq.) in SOCl₂ (20 mL) was added DMF (2 drops). The mixture was stirred at 60° C. for 20 min. The volatiles were removed in vacuo to give crude pyrazine-2-carbonyl chloride, which was used in the next step directly. To a suspension of 2-amino-5-nitrobenzoic acid (2.00 g, 10.9 mmol, 1.0 eq.) in THF (50 mL) was added Et₃N (1.09 g) and pyrazine-2-carbonyl chloride in anhydrous THF (50 mL) dropwise. The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed. The residue was suspended in H₂O (10 mL) and the pH was adjusted to 5 by slow addition of 2N HCl in water. The resulting solid was collected and dried in vacuo to give 3.12 g of 5-nitro-2-(pyrazine-2-carboxamido)benzoic acid as a brown solid (99%). LCMS m/z=289.0 (M+1) (Method B) (retention time=1.24 min)

Method A: N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide (iii-d)

A mixture of 5-nitro-2-(pyrazine-2-carboxamido)benzoic acid (3.12 g, 10.8 mmol) in SOCl₂ (20 mL) was stirred at 80° C. for 2 h. After cooling, the volatiles were removed and the residue was suspended in DCM (150 mL), and a solution of NH₃.H₂O (25% by weight in water, 40 mL) was added and stirred for 4 h. The resulting precipitate was collected and dried in vacuo to give 2.42 g of N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide as a dark red solid (74.6%). LCMS m/z=288.0 (M+1) (Method B) (retention time=1.11 min)

Method E2: 6-nitro-2-(pyrazin-2-yl)quinazolin-4(1H)-one (iv-g)

To a mixture of N-(2-carbamoyl-4-nitrophenyl)pyrazine-2-carboxamide (2.42 g, 8.43 mmol, 1.0 eq.) in EtOH (60 mL) was added NaOH (1.98 g, 49.5 mmol, 5.0 eq.). The resulting mixture was stirred at room temperature for 18 h. After the reaction was completed, the volatiles were removed in vacuo. The residue was partitioned between H₂O (50 mL) and ethyl acetate (50 mL). The aqueous layer was neutralized to pH 5 by slow addition of aqueous citric acid. The resulting precipitate was collected and dried to give 2.00 g of 6-nitro-2-(pyrazin-2-yl)quinazolin-4(3H)-one as a yellow solid (88%). LCMS m/z=270.1 (M+1) (Method A) (retention time=1.36 min)

Method F2: 4-Chloro-6-nitro-2-(pyrazin-2-yl)quinazoline (v-g)

To a mixture of 6-nitro-2-(pyrazin-2-yl)quinazolin-4(3H)-one (1.00 g, 3.7 mmol) in POCl₃ (10 mL) was added N,N-dimethylbenzenamine (0.1 mL). The resulting mixture was stirred at 120° C. for 2 h. After the reaction was completed, POCl₃ was removed in vacuo, and the residue was co-evaporated with toluene twice to give a dark crude product, which was used for the next step without further purification.

Method G6: N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl)quinazolin-4-amine (vi-s)

A mixture of 4-chloro-6-nitro-2-(pyrazin-2-yl)quinazoline (1.00 g, crude, 3.7 mmol, 1.0 eq.), 3-(difluoromethoxy)benzenamine (600 mg, 3.7 mmol, 1.0 eq.) and Et₃N (1.00 g, 10 mmol, 3.0 eq) in THF (80 mL) was stirred at 75° C. for 18 h. After cooling, the volatiles were removed in vacuo and the residue was washed with H₂O (100 mL×2). The solid was dried in vacuo to afford 1.40 g of N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl)quinazolin-4-amine as a black solid (90.2% of two steps). LCMS m/z=411.0 (M+1) (Method A) (retention time=1.61 min)

Method B: N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine (lii-a)

To a mixture of N-(3-(difluoromethoxy)phenyl)-6-nitro-2-(pyrazin-2-yl) quinazolin-4-amine (1.40 g, 3.4 mmol, 1.0 eq.) in MeOH—H₂O (v/v, 3:1, 110 mL) was added NH₄Cl (1.80 g, 34 mmol, 10.0 eq.) and Fe (1.91 g, 34 mmol, 10.0 eq.). The resulting mixture was stirred at 60° C. for 3 h. After the reaction was completed, the mixture was cooled to room temperature, and the iron was filtered off. The filtrate was concentrated to 15 mL and a precipitate formed and was collected and dried in vacuo to give 1.13 g of N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine as a pale yellow solid (87.5%). LCMS m/z=381.1 (M+1) (Method B) (retention time=1.60 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.69 (s, 1H), 9.52 (d, J=1.2 Hz, 1H), 8.75 (d, J=2.4 Hz, 1H), 8.69 (d, J=2.4 Hz, 1H), 8.30 (s, 1H), 7.87 (dd, J=8.4, 0.8 Hz, 1H), 7.72 (d, J=8.8 Hz, 1H), 7.49-7.42 (m, 2H), 7.33-7.32 (m, 1H), 7.31 (t, J=74 Hz, 1H), 5.85 (s, 2H).

Method C: N-(4-(3-(difluoromethoxy)phenylamino)-2-(pyrazin-2-yl)quinazolin-6-yl)-6-methoxynicotinamide (liii-a)

To a solution of 6-methoxynicotinic acid (100 mg, 0.65 mmol) in SOCl₂ (2 mL) was added DMF (1 drop). The mixture was stirred at 60° C. for 20 min. The volatiles were removed in vacuo to give 6-methoxynicotinoyl chloride, which was used for the next step directly. To a suspension of N⁴-(3-(difluoromethoxy)phenyl)-2-(pyrazin-2-yl)quinazoline-4,6-diamine (130 mg, 0.34 mmol, 0.5 eq.) in THF (5 mL) and Et₃N (101 mg, 1 mmol, 3.0 eq) was added 6-methoxynicotinoyl chloride in anhydrous THF (5 mL) dropwise. The resulting mixture was stirred at room temperature for 18 h. The volatiles were removed in vacuo. The residue was washed with MeOH and re-crystallized from THF/MeOH twice, and purified by reverse phase chromatography PREP-HPLC (A=NH₄HCO₃—H₂O, 10 mmol/L, B=MeOH) to afford 33 mg of N-(4-(3-(difluoromethoxy)phenylamino)-2-(pyrazin-2-yl)quinazolin-6-yl)-6-methoxynicotinamide as a pale yellow solid (18.8%). LCMS m/z=516.1 (M+1), 258.6 (M/2+1) (Method A) (retention time=1.57 min). ¹H-NMR (400 MHz, DMSO-d₆): δ 10.71 (s, 1H), 10.18 (s, 1H), 9.57 (d, J=1.6 Hz, 1H), 9.01 (d, J=1.6 Hz, 1H), 8.91 (d, J=2.4 Hz, 1H), 8.81 (t, J=2.0 Hz, 1H), 8.76 (d, J=2.4 Hz, 1H), 8.34 (dd, J=8.8, 2.8 Hz, 1H), 8.23 (s, 1H), 8.08 (dd, J=8.8, 2.0 Hz, 1H), 8.00 (d, J=9.2 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 7.46-7.50 (m, 1H), 7.32 (t, J=74.4 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 6.95 (dd, J=8.0, 2.0 Hz, 1H), 3.97 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 67 (prepared according to method procedure A-G as designated).

TABLE 22 Pu- Method Molec- ¹H- rity for Num- Salt ular NMR LCMS per- Cou- ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol cent pling 1242

422.39 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.10- 10.45 (m, 2H), 9.68 (s, 1H), 8.45-9.10 (m, 2H), 7.68-8.37 (m, 4H), 7.36-7.52 (m, 2H), 7.02-7.08 (m, 1H), 2.21 (s, 3H). DMSO 423.0 (M + 1) Method A (TFA) 95 Method C, G4, C 1243

515.47 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.71 (s, 1H), 10.18 (s, 1H), 9.57 (d, J = 1.6 Hz, 1H), 9.01 (d, J = 1.6 Hz, 1H), 8.91 (d, J = 2.4 Hz, 1H), 8.81 (t, J = 2.0 Hz, 1H), 8.76 (d, J = 2.4 Hz, 1H), 8.34 (dd, J = 8.8, 2.8 Hz, 1H), 8.23 (s, 1H), 8.08 (dd, J = 8.8, 2.0 Hz, 1H), 8.00 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 9.2 Hz, DMSO 516.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 1 H), 7.46-7.50 (m, 1H), 7.32 (t, J = 74.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 6.95 (dd, J = 8.0, 2.0 Hz, 1H), 3.97 (s, 3H). 1244

514.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.56 (s, 1H), 10.16 (s, 1H), 9.57 (s, 1H), 9.00 (d, J = 1.6 Hz, 1H), 8.81 (d, J = 2.4 Hz, 1H), 8.76 (d, J = 2.8 Hz, 1H), 8.23 (s, 1H), 8.07-8.12 (m, 3H), 7.99 (d, J = 9.2 Hz, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.46-7.50 (m, 1H), 7.32 (t, J = 72.8 Hz, 1H), 7.11- 7.13 (m, 2H), 6.95 DMSO 515.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C (dd, J = 8.4, 2.4 Hz, 1H), 3.87 (s, 3H). 1245

520.53 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.30 (s, 1H), 10.16 (s, 1H), 9.54 (s, 1H), 8.89 (s, 1H), 8.79 (t, J = 2.4 Hz, 1H), 8.74 (d, J = 2.8 Hz, 1H), 8.20 (s, 1H), 7.93 (s, 2H), 7.87 (d, J = 8.4 Hz, 1H), 7.48 (dd, J = 10.0, 2.0 Hz, 1H), 7.31 (t, J = 74.0 Hz, 1H), 6.94 (dd, J = 8.4, 2.0 Hz, 1H), 3.26 (s, 3H), 3.18-3.22 (m, DMSO 521.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 1H), 1.91-1.96 (m, 2H), 1.66-1.78 (m, 2H), 1.53-1.63 (m, 2H), 1.38-1.49 (m, 2H). 1246

492.48 ¹H-NMR (400 MHz, DMSO-d₆): δ 10.35 (s, 1H), 10.15 (s, 1H), 9.54 (s, 1H), 8.90 (d, J = 2.0 Hz, 1H), 8.80 (dd, J = 2.4, 1.2 Hz, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.19 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.86-7.91 (m, 2H), 7.48 (dd, J = 10.8, 2.8 Hz, 1H), 7.31 (t, J = 74.4 Hz, 1H), 6.94 (dd, J = 7.6, 2.0 Hz, 1H), DMSO 493.2 (M + 1) Method B (NH4HCO3) 95 Method C, G4, C 3.94-3.97 (m, 2H), 3.40-3.43 (m, 2H), 2.70-2.73 (m, 1H), 1.65-1.78 (m, 4H).

Method BF: 6-(3-methoxyphenyl)-N-methyl-2-(pyrimidin-5-yl)quinazolin-4-amine (compound 1247)

In a 10 mL microwave vial was added 2-chloro-6-(3-methoxyphenyl)-N-methylquinazolin-4-amine (0.080 g, 0.267 mmol), pyrimidine-5-boronic acid (0.099 g, 0.801 mmol), dichlorobis(triphenylphosphine)palladium (II) (Pd(PPh₃)₂Cl₂) (9.37 mg, 0.013 mmol), and potassium carbonate (0.111 g, 0.801 mmol) in DME (3 mL), EtOH (1.286 mL), and water (0.857 mL) to give a yellow suspension. The vial was irradiated at 120° C. for 15 min under argon. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL) and then dried over MgSO₄, filtered and concentrated. The residue was washed with MeOH—CH₂Cl₂ and dried to give 35 mg of 6-(3-methoxyphenyl)-N-methyl-2-(pyrimidin-5-yl)quinazolin-4-amine as a white solid (38%). LCMS m/z=344 (M+1) (Method D) (retention time=1.78 min). ¹H NMR (300 MHz, DMSO) δ 9.79-9.59 (m, 2H), 9.30 (s, 1H), 8.72 (d, J=4.6 Hz, 1H), 8.59 (s, 1H), 8.16 (d, J=8.6 Hz, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.53-7.28 (m, 3H), 7.00 (d, J=6.8 Hz, 1H), 3.86 (s, 3H), 3.18 (d, J=3.9 Hz, 3H).

In a 100 mL round-bottomed flask was added 6-iodo-2-(pyrazin-2-yl)quinazolin-4(3H)-one (0.500 g, 1.428 mmol), BOP (0.821 g, 1.857 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.426 ml, 2.86 mmol) in DMF (10 mL) to give a colorless solution. Methylamine, 2M in THF (2.142 ml, 4.28 mmol) was added and stirred at room temperature overnight. The reaction mixture was diluted with water (50 mL) and then a precipitate formed. The resulting solid was collected by filtration and dried to give 0.515 g of 6-iodo-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine as a pale brown solid in a 99% yield. LCMS m/z=364 (M+1) (Method D) (retention time=1.25 min). ¹H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 8.89-8.65 (m, 3H), 8.65-8.48 (m, 1H), 8.06 (d, J=8.7 Hz, 1H), 7.59 (d, J=8.7 Hz, 1H), 3.11 (d, J=4.2 Hz, 3H).

In a 50 mL round-bottomed flask was added 6-iodo-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine (0.100 g, 0.275 mmol), 3-methoxyphenylboronic acid (0.063 g, 0.413 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloropalladium(II) (0.016 g, 0.022 mmol), and potassium phosphate tribasic monohydrate (0.190 g, 0.826 mmol) in dioxane (5 mL) and water (0.5 mL) to give a brown suspension. The reaction mixture was heated at 80° C. overnight under argon. After cooling to room temperature, the reaction mixture was diluted with water (10 mL) and then a precipitate formed. The resulting solid was collected by filtration and washed with ethyl acetate and dried to give 25 mg of 6-(3-methoxyphenyl)-N-methyl-2-(pyrazin-2-yl)quinazolin-4-amine as a pale yellow solid in a 26% yield. LCMS m/z=344 (M+1) (Method D) (retention time=1.43 min). ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.85-8.78 (m, 1H), 8.77-8.71 (m, 1H), 8.70-8.63 (m, 1H), 8.63-8.55 (m, 1H), 8.18 (d, J=8.8 Hz, 1H), 7.89 (d, J=8.9 Hz, 1H), 7.53-7.31 (m, 3H), 7.09-6.92 (m, 1H), 3.86 (s, 3H), 3.17 (d, J=3.6 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 69 (prepared according to method described for 6-(3-methoxyphenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine).

TABLE 23 Molecular ¹H-NMR Number PRODUCT Salt type Mass ¹H-NMR Solvent LCMS LCMS Protocol Purity percent Method for Coupling 1235

343.38 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.85-8.78 (m, 1 H), 8.77-8.71 (m, 1H), 8.70-8.63 (m, 1 H), 8.63- 8.55 (m, 1H), 8.18 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.9 Hz, 1H), 7.53-7.31 (m, 3H), 7.09-6.92 (m, 1H), 3.86 (s, 3H), 3.17 (d, J = 3.6 Hz, 3H). DMSO 344 (M + 1) Method D 100 Method AP/AQ 1236

338.37 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.87-8.61 (m, 4H), 8.24 (d, J = 8.8 Hz, 1H), 8.15-7.98 (m, 4H), 7.92 (d, J = 8.7 Hz, 1H), 3.17 (d, J = 4.0 Hz, 3H). DMSO 339 (M + 1) Method D 100 Method C, G1 1237

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 9.54 (6, J = 5.2 Hz, 1H), 9.36 (s, 1H), 8.63 (s, 2H), 8.13- 8.06 (m, 2H), 7.58-7.51 (m, 2H), 7.43-7.38 (m, 1H), 3.23 (d, J = 4.0 Hz, 3H). DMSO 350.1, 351.1, (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1238

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.14 (s, 1H), 9.50 (d, J = 5.2 Hz, 1H), 9.24 (s, 1H), 8.60 (dd, J = 5.4, 1.8 Hz, 1H), 8.55 (s, 1H), 8.04 (q, J = 8.8 Hz, 2H), 7.76 (dd, J = 15.4, 9.0 Hz, 1 H), 7.51-7.45 (m, 1H), 7.32 (dt, J = 8.4, 2.0 Hz, 1H), 3.23 (d, J = 4.4 Hz, 3H). DMSO 350.0, 351.0, (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1239

¹H-NMR (400 MHz, DMSO-d₆): δ 9.73(s, 1H), 9.32 (s, 1H), 8.74 (d, J = 4.4Hz, 1H), 8.51 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.54-7.49 (m, 2H), 7.42-7.37 (m, 1H), 4.12 (q, J = 5.2 Hz, 1H), 3.17 (t, J = 4.5 Hz, 3H). DMSO 350.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1240

2HCl ¹H-NMR (400 MHz, CD3OD): δ 9.77 (s, 1H), 8.85 (d, J = 11.4 Hz, 2H), 8.42 (s, 1H), 8.19-8.03 (m, 2H), 7.60 (dd, J = 15.6, 7.8 Hz, 1H), 7.10 (t, J = 8.4 Hz, 2H), 3.38 (s, 3H). CD3OD 350.1 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1 1241

2HCl ¹H-NMR (400 MHz, DMSO): δ 10.84 (d, J = 1.8 Hz, 1 H), 9.87 (s, 1H), 9.06 (d, J = 13.6 Hz, 2H), 8.90 (s, 1H), 8.32 (t, J = 9.8 Hz, 2H), 7.67-7.35 (m, 3H), 3.39 (s, 3H). DMSO 349.9 (M + 1) Method B (NH₄HCO₃) 95 Method C, G1

Method B2: 2-Amino-3-methylbenzoic acid (lv-a)

Pd/C catalyst (150 mg) was suspended in a solution of 3-methyl-2-nitrobenzoic acid (1.50 g, 8.28 mmol 1.0 eq) in THF (60 mL), the mixture was stirred under H₂ atmosphere at room temperature overnight. The Pd/C was removed by filtration over Celite and the THF was removed in vacuo to give 1.23 g of lv-a as a white solid (yield 98%). LCMS m/z=152.1 (M+1) (Method B) (retention time=0.73 min). The product was used further without purification.

Method AZ: 2-Amino-5-bromo-3-methylbenzoic acid (lvi-a)

To a solution of 2-amino-3-methylbenzoic acid (1.23 g, 8.14 mmol, 1.0 eq) in 15 mL of DMSO was added 40% HBr (6.00 mL, 44.7 mmol, 5 eq). The resulting mixture was stirred at room temperature overnight. A white precipitate formed during the course of the reaction. The reaction mixture was quenched with saturated aqueous NaHCO₃ resulting in a white solid that was filtered and dried in vacuo to yield 950 mg in 51% yield of lvi-a as white solid. LCMS m/z=229.9 (M+1) (Method B) (retention time=1.20 min).

Method C: 2-Amino-5-bromo-3-methylbenzamide (ii-c)

A mixture of 2-amino-5-bromo-3-methylbenzoic acid (950 mg, 4.15 mmol) and SOCl₂ (20 mL) was stirred at 80° C. for 2 h. After the reaction was completed, the mixture was cooled to room temperature. The SOCl₂ was removed in vacuo and the residue was dissolved in anhydrous THF (10 mL). The THF solution was then added dropwise to a 28% by weight solution of NH₃—H₂O (10 mL). After 1 h, the resulting precipitate was collected and dried in vacuo to give 820 mg of ii-c as a yellow solid (87%). LCMS m/z=288.9, 230.9 (M+1) (Method B) (retention time=1.49 min).

Method G for Coupling Conditions

G1: i-PrOH/85-100° C.

G2: THF/heat

G3: i-AmOH/100-130° C.

G4: MeOH/microwave/150° C.

G5: i-AmOH/microwave/150° C.

G6: THF/Et₃N/reflux G7: THF—H₂O/NaOAc/rt-60° C. G8: NaH/THF

G9: n-BuLi/THF

G10: LHMDS/THF G11: LDA/THF G12: K₂CO₃/DMF/60° C. G13: Cs₂CO₃/DMA/80° C. G14: NaOtBu/DMF/Microwave/100° C. Method AQ for Coupling Conditions AQ1: Pd(PPh₃)₂Cl₂/K₂CO₃/Dioxane-H₂O AQ2: Pd₂(APhos)₂Cl₂/K₃PO₄/Dioxane-H₂O AQ3: Pd(PPh₃)₄/K₃PO₄/Dioxane-H₂O AQ4: Pd(dppf)Cl₂—CH₂Cl₂/K₃PO₄/Dioxane-H₂O AQ5: Pd(OAc)₂Cl₂/S-Phos/K₃PO₄/Dioxane-H₂O AQ6: Pd(dppf)Cl₂—CH₂Cl₂/Na₂CO₃/Dioxane-H₂O

Method C: N-(4-bromo-2-carbamoyl-6-methylphenyl)nicotinamide (iii-e)

To a solution of 2-amino-5-bromo-3-methylbenzamide (820 mg, 3.55 mmol, 1.0 eq.) in THF (15 mL) and Et₃N (0.7 mL) was added nicotinoyl chloride (551 mg, 3.91 mmol, 1.1 eq.) in anhydrous THF (15 mL) dropwise. The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the resultant precipitate was filtered and dried in vacuo to give 1.74 g of crude iii-e as a yellow solid. LCMS m/z=333.8, 335.8 (M+1) (Method B) (retention time=1.42 min)

Method E: 6-Bromo-8-methyl-2-(pyridin-3-yl)quinazolin-4-ol (iv-h)

A mixture of N-(4-bromo-2-carbamoyl-6-methylphenyl)nicotinamide (1.74 g salt, 5.22 mmol, 1.0 eq) in EtOH (50 mL) was treated with NaOH (1.04 g, 26.1 mmol, 5.0 eq). The resulting mixture was stirred at room temperature overnight. After the reaction was completed, the volatiles were removed in vacuo. Water (30 mL) was added to the residue and the mixture was adjusted to pH ˜1 or 2 by slow addition of aqueous HCl. The resultant precipitate was collected and dried to give 870 mg of iv-h as a yellow solid (77% yield after two steps). LCMS m/z=315.7, 317.7 (M+1) (Method B) (retention time=1.74 min).

Method F5: 6-Bromo-4-chloro-8-methyl-2-(pyridin-3-yl)quinazoline (v-h)

6-Bromo-8-methyl-2-(pyridin-3-yl)quinazolin-4-ol (870 mg, 2.76 mmol) was added to POCl₃ (10 mL). The resulting mixture was stirred at 120° C. overnight. After the reaction was completed, the mixture was carefully poured into ice-water. The pH was adjusted to 7 by slow addition of NH₄OH at 0° C. The resultant solid was collected to give 1.00 g of v-h as a beige solid (quantitative yield). LCMS m/z=333.9, 335.9 (M+1) (Method B) (retention time=2.23 min)

Method G6: 6-Bromo-N, 8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (vi-t)

A mixture of 6-bromo-4-chloro-8-methyl-2-(pyridin-3-yl)quinazoline (200 mg, 0.60 mmol, 1.0 eq.), methylamine (81 mg, 1.20 mmol, 2.0 eq.) and Et₃N (0.2 mL) in i-PrOH (10 mL) was stirred at 85° C. overnight. The resultant yellow precipitate was collected to afford 125 mg of vi-t as a beige solid (63.4%). LCMS m/z=328.8, 330.8 (M+1) (Method B) (retention time=1.95 min)

Method G2: 7-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (vi-u)

To a suspension of 7-bromo-4-chloro-2-(pyridin-3-yl)quinazoline (5.0 g, 0.0156 mol) in THF (100 mL) was added dropwise a methylamine solution (40 wt. % in H₂O) (24 ml, 0.272 mmol) with cooling. The suspension was stirred at 60° C. for 3 h, cooled, filtered, and dried to give the title compound. (3.62 g, 73.5%)

Method AQ1: 6-(3-Methoxyphenyl)-N, 8-dimethyl-2-(pyridin-3-yl) quinazolin-4-amine (lviii-a)

(This method is representative of method AQ2 and can be implemented in a similar way except for substitution of the appropriate catalyst and base) To a mixture of 6-bromo-N, 8-dimethyl-2-(pyridin-3-yl) quinazolin-4-amine (130 mg, 0.396 mmol, 1.0 eq), 3-methoxyphenylboronic acid (60 mg, 0.396 mmol, 1.0 eq), K₂CO₃ (295 mg, 2.14 mmol, 5.4 eq.) in dioxane (8 mL) and H₂O (4 mL) was added Pd(PPh₃)₂Cl₂ (15 mg, 0.021 mmol, 0.054 eq) under N₂ atmosphere. The resulting mixture was stirred at 120° C. under N₂ atmosphere overnight. After the reaction was completed, the mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by reverse phase HPLC column to afford 11 mg of lviii-a as a white solid (yield 7.8%). LCMS m/z=357.2, (M+1) (Method B (retention time=2.11 min) 1H NMR (400 MHz, DMSO-d₆): δ 9.68 (d, J=1.2 Hz, 1H), 8.75 (d, J=8.0 Hz, 1H), 8.62 (d, J=4.6 Hz, 1H), 8.49 (d, J=4.4 Hz, 1H), 8.35 (s, 1H), 7.97 (s, 1H), 7.49 (dd, J=7.8, 4.8 Hz, 1H), 7.44-7.29 (m, 3H), 6.93 (dd, J=6.8, 2.4 Hz, 1H), 3.81 (s, 3H), 3.12 (d, J=4.4 Hz, 3H), 2.68 (s, 3H).

Method AQ3: 6-(4-Fluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lviii-b)

6-Bromo-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (340 mg, 1.03 mmol), 3-fluorobenzeneboronic acid (217 mg, 1.55 mmol), K₃PO₄ (658 mg, 3.10 mmol) and Pd(PPh₃)₄ (59.7 mg, 0.052 mmol) were dissolved in the mixed solvent of 1,4-dioxane (10 mL) and water (1 mL). The resulting mixture was stirred at 90° C. for 6 hours under a nitrogen atmosphere. After the reaction was completed, water was added to the mixture and stirred for 30 minutes. The resulting precipitate was collected by filtration and purified by column chromatography on NH-silica gel (eluted with THF) to give a yellow powder. The solid was suspended in ethanol and 5N HCl (1 mL) was added to the mixture. The mixture was sonicated for 10 min and the resulting precipitate was collected by filtration and dried to give 304 mg of 6-(3-fluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as a yellow powder in 71% yield.

Method AQ4: 6-(2,4-Difluorophenyl)-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine(lviii-c)

6-Bromo-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (350 mg, 1.06 mmo 1), 2,4-difluorophenylboronic acid (252 mg, 1.595 mmol), K₃PO₄ (677 mg, 3.19 mmol) and Pd(dppf)Cl₂-CH₂Cl₂ (87 mg, 0.106 mmol) were dissolved in the mixed solvent of 1,4-dioxane (10 mL) and water (1 mL). The resulting mixture was stirred at 90° C. for 2.5 hours under N₂. After the reaction was completed, water was added to the mixture and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over Na₂SO₄. After filtration and evaporation, the crude product was purified by column chromatography on NH-silica gel (eluted with isocratic 33% ethyl acetate/67% hexane) to give a white powder. The solid was suspended in ethanol and 5N HCl (1.0 mL) was added to the mixture. The mixture was sonicated for 10 min and the resultant precipitate was collected by filtration and dried to give 139 mg of 6-(2,4-difluorophenyl)-N,5-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as a pale yellow powder in a 30% yield.

Method AQ5: 7-(3-fluorophenyl)-N,6-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lviii-d)

A mixture of 7-chloro-N,6-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (400 mg, 1.40 mmol), 3-fluorophenylboronic acid (294 g, 2.10 mmol), Pd(OAc)₂ (15.8 mg, 0.070 mmol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (86.7 mg, 0.211 mmol), K₃PO₄ (900 mg, 4.23 mmol) in dioxane (10 mL) and water (2 mL) was stirred under reflux for 2.5 h. Ethyl acetate (20 mL) was added to the cooled mixture and a precipiate formed and was filtered. The solid was recrystallized from DMF and water to give the title compound as free form. The solid was suspended in ethyl acetate (10 mL) and 4N HCl in ethyl acetate (1.0 mL) was added. The resulting solid was subjected to sonication for 20 min, filtered and dried to give the title compound as the bis-HCl salt (0.10 g, 18.7%).

Method AQ6:7-(3,4-difluorophenyl)-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lviii-e)

To a suspension of 3,4-difluorophenylboronic acid (389 mg, 2.46 mmol) and 7-bromo-N,8-dimethyl-2-(pyridin-3-yl)quinazolin-4-amine (395.4 mg, 1.201 mmol) in dioxane/H₂O (2/1) (30 mL) under a nitrogen atmosphere was added Na₂CO₃ (633.2 mg, 5.97 mmol) and (1,1′-bis(diphenylphosphino)ferrocene)-dichloropalladium(II) (98 mg, 0.120 mmol) at room temperature. The mixture was stirred at 100° C. for 1.5 h. Water was added to the reaction mixture and then a precipitate formed. The solid was filtered and washed with water and dried. The dried solid was then heated in a methanol/dioxane mixture to give a clear solution and filtered through Celite. The filtrate was concentrated to give the crude product. The crude product was sonicated in methanol/CH₂Cl₂ for ca.15 min and filtered to give 305.2 mg of a pale brown solid as the parent compound. To a suspension of parent compound in methanol was added 4N HCl in ethyl acetate (ca. 4 mL) to give a clear solution. The solution was concentrated and recystallized from ethanol to give the HCl salt. The salt was collected and dried in an oven at 60° C. to give 231.3 mg in a 44% yield as pale yellow solid. ¹H NMR (DMSO-d₆) δ 9.73 (s, 1H), 9.37 (brd, J=8.08 Hz, 1H), 8.97 (brd, J=5.24 Hz, 1H), 8.77 (brs, 1H), 8.20 (d, J=8.48 Hz, 1H), 8.10-8.07 (brm, 1H), 7.63-7.55 (brm, 2H), 7.47 (d, J=8.48 Hz, 1H), 7.32 (brm, 1H), 3.20 (d, J=4.20 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed.

Method AP: 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (vi-u)

To a solution of 6-bromo-2-(pyridin-3-yl)quinazolin-4(3H)-one (5.00 g, 16.6 mmol), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (9.52 g, 21.5 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (4.94 ml, 33.1 mmol) in DMF (50 mL) was added methylamine, 2M in THF (16.6 mL, 33.1 mmol). The mixture was stirred overnight at room temperature. Water (100 mL) was added to the mixture and stirred. The resultant precipitate was collected by filtration and dried to give 5.15 g of 6-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as pale yellow solid (99%). LCMS m/z=315 (M+1) (Method D) (retention time=1.34 min). ¹H NMR (300 MHz, DMSO) δ 9.60 (dd, J=2.1, 0.8 Hz, 1H), 8.79-8.70 (m, 1H), 8.67 (dd, J=4.8, 1.7 Hz, 1H), 8.57 (s, 1H), 8.51 (d, J=2.0 Hz, 1H), 7.90 (dd, J=8.9, 2.1 Hz, 1H), 7.71 (d, J=8.9 Hz, 1H), 7.52 (ddd, J=7.9, 4.8, 0.9 Hz, 1H), 3.13 (d, J=4.5 Hz, 3H).

Method AQ2: 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (lviii-f)

To a 1 dram reaction vial was added 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine (35 mg, 0.111 mmol), 6-methoxypyridin-3-ylboronic acid (20.4 mg, 0.133 mmol), Pd(APhos)₂Cl₂ (3.2 mg, 0.004 mmol) and potassium phosphate monohydrate (77 mg, 0.33 mmol) in a mixture of dioxane-water (9:1, 2 mL). The reaction mixture was heated to 90° C. for 14 h after which it was cooled to room temperature and diluted with water (5 mL). The resultant precipitate was collected by filtration and recrystallized from methanol to give 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine as a pale yellow solid (19.1 mg, 51%). LCMS m/z=344 (M+1) (Method C) (retention time=2.01 min). ¹H NMR (300 MHz, DMSO) δ 9.64 (d, J=1.3 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J=6.2, 1.7 Hz, 2H), 8.57 (d, J=1.6 Hz, 2H), 8.16 (ddd, J=14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J=4.3 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 72 or 74, replacing methylamine with the appropriate amine and 6-methoxypyridin-3-ylboronic acid with the appropriate boronic acid.

TABLE 24 Reten- Method Num- Molecular ¹H-NMR tion LCMS Purity for ber Product Salt Mass ¹H-NMR Solvent LCMS Time Protocol percent Coupling 1248

HCl 342.4 ¹H-NMR (400 MHz, DMSO-d6): δ 9.66 (s, 1H), 8.50-8.89 (m, 3H), 8.16 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.30-7.61 (m, 4H), 7.01 (d, J = 6.4 Hz, 1 H), 3.88 (s, 3H), 3.32 (brs, 1H), 3.19 (s, 3H). DMSO 343.1 (M + H) Method B (NH4HCO3) 95 Method AQ1 1249

372.4 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.67 (d, J = 3.7 Hz, 1H), 8.50 (s, 1H), 8.11 (s, 1H), 7.56-7.53 (m, 2H), 7.48-7.40 (m, 3H), 7.01 (d, J = 3.9 Hz, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 3.17 (d, J = 4.0 Hz, 3H). DMSO 372.9 (M + H) Method B (NH4HCO3) 95 Method AQ1 1250

356.4 1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.79-8.74 (m, 1H), 8.69 (d, J = 4.0 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.57-7.51 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.37-7.30 (m, 1H), 7.02-6.92 (m, 3H), 3.82 (s, 3H), 3.18 (d, J = 4.0 Hz, 3H), 2.69 (s, 3H). DMSO 357.1 (M + H) Method B (NH4HCO3) 95 Method AQ1 1251

356.4 1H-NMR (400 MHz, DMSO-d6): δ 9.68 (d, J = 1.2 Hz, 1H), 8.75 (d, J = 8.0 Hz, 1 H), 8.62 (d, J = 4.6 Hz, 1H), 8.49 (d, J = 4.4 Hz, 1H), 8.35 (s, 1H), 7.97 (s, 1H), 7.49 (dd, J = 7.8, 4.8 Hz, 1H), 7.44-7.29 (m, 3H), 6.93 (dd, J = 6.8, 2.4 Hz, 1H), 3.81 (s, 3H), 3.12 (d, J = 4.4 Hz, 3H), 2.68 (s, 3H). DMSO 357.2 (M + H) Method B (NH4HCO3) 95 Method AQ1 1252

329.3 1H NMR (300 MHz, DMSO) δ 9.31 (s, 1H), 8.76 (d, J = 4.7 Hz, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.18 (dd, J = 8.5, 2.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.59 (dd, J = 7.9, 4.8 Hz, 1H), 7.49-7.23 (m, 3H), 6.99 (d, J = 6.7 Hz, 1H), 3.85 (s, 3H). DMSO 330 (M + H) 1.76 Method D 100 1253

HCl 342.4 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.63 (s, 1H), 9.07-8.86 (m, 2H), 8.58 (s, 1H), 8.16 (s, 2H), 7.92-7.77 (m, 1H), 7.54- 7.36 (m, 2H), 7.20 (d, J = 8.6 Hz, 1H), 7.16- 7.07 (m, 1H), 3.81 (s, 3H), 3.29 (d, J = 3.9 Hz, 3H). DMSO 343 (M + H) 1.47 Method D 100 Method AQ2 1254

330.3 1H NMR (300 MHz, DMSO) δ 9.59 (s, 1H), 8.73 (d, J = 8.3 Hz, 1H), 8.65 (d, J = 4.7 Hz, 1H), 8.37-8.22 (m, 1H), 8.18-8.05 (m, 1H), 7.76 (d, J = 9.0 Hz, 1H), 7.71 (s, 1H), 7.56- 7.43 (m, 2H), 4.58 (s, 2H), 3.14 (d, J = 4.4 Hz, 3H), 2.69 (d, J = 4.6 Hz, 3H). DMSO 331 (M + H) 1.52 Method D 100 Method AQ2 1255

312.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.88-8.47 (m, 4H), 8.25-8.05 (m, 1H), 7.97-7.72 (m, 3H), 7.67-7.35 (m, 4H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 313 (M + H) 1.48 Method D 100 Method AQ2 1256

HCl 337.4 1H NMR (300 MHz, DMSO) δ 9.93 (s, 1H), 9.63 (s, 1H), 9.00 (d, J = 8.3 Hz, 1H), 8.95- 8.82 (m, 2H), 8.46-8.32 (m, 2H), 8.25 (d, J = 7.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 7.2 Hz, 1H), 7.88-7.70 (m, 2H), 3.29 (d, J = 4.2 Hz, 3H). DMSO 338 (M + H) 1.50 Method D 100 Method AQ2 1257

337.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.73-8.59 (m, 3H), 8.21 (d, J = 8.8 Hz, 1H), 8.11-7.94 (m, 4H), 7.87 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 3.18 (d, J = 4.0 Hz, 3H). DMSO 338 (M + H) 1.50 Method D 100 Method AQ2 1258

346.8 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 7.9 Hz, 1H), 8.72-8.52 (m, 3H), 8.14 (d, J = 8.7 Hz, 1H), 7.97-7.74 (m, 3H), 7.68-7.45 (m, 3H), 3.18 (d, J = 4.0 Hz, 3H). DMSO 347 (M + H) 1.60 Method D 100 Method AQ2 1259

346.8 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.72-8.54 (m, 3H), 8.17 (d, J = 8.7 Hz, 1H), 7.94 (s, 1H), 7.90- 7.78 (m, 2H), 7.61-7.42 (m, 3H), 3.19 (d, J = 4.4 Hz, 3H). DMSO 347 (M + H) 1.66 Method D 100 Method AQ2 1260

372.4 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.77 (dd, J = 7.9, 1.8 Hz, 1H), 8.67 (d, J = 4.7 Hz, 1H), 8.46 (d, J = 4.4 Hz, 1H), 8.26 (s, 1H), 7.95-7.84 (m, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 6.77-6.60 (m, 2H), 3.80 (ss, 6H), 3.14 (d, J = 4.3 Hz, 3H). DMSO 373 (M + H) 1.49 Method D 100 Method AQ2 1261

348.3 1H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.77 (dd, J = 8.0, 1.9 Hz, 1H), 8.68 (d, J = 4.6 Hz, 1H), 8.59 (s, 2H), 8.21-8.09 (m, 1H), 8.02-7.88 (m, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.71 (s, 1H), 7.67-7.58 (m, 1H), 7.53 (dd, J = 7.6, 5.1 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 349 (M + H) 1.61 Method D 100 Method AQ2 1262

313.4 1H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.09 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.73- 8.55 (m, 4H), 8.30-8.14 (m, 2H), 7.89 (d, J = 8.6 Hz, 1H), 7.63-7.47 (m, 2H), 3.19 (d, J = 4.3 Hz, 3H). DMSO 314 (M + H) 1.70 Method C 96 Method AQ2 1263

343.4 1H NMR (300 MHz, DMSO) δ 9.64 (d, J = 1.3 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J = 6.2, 1.7 Hz, 2H), 8.57 (d, J = 1.6 Hz, 2H), 8.16 (ddd, J = 14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.00 (d, J = 8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J = 4.3 Hz, 3H). DMSO 344.1 (M + H) 1.94 Method C 95 Method AQ2 1264

356.4 1H NMR (300 MHz, DMSO) δ 10.76 (s, 1H), 9.75 (d, J = 1.6 Hz, 1H), 9.23 (d, J = 8.2 Hz, 1H), 9.05-8.86 (m, 2H), 8.41-8.24 (m, 2H), 8.24-8.05 (m, 2H), 7.96 (dd, J = 8.1, 5.2 Hz, 1H), 6.56 (d, J = 9.5 Hz, 1H), 4.81 (s, 2H), 3.34 (s, 3H), 3.29 (d, J = 4.3 Hz, 3H). DMSO 357.1 (M + H) 2.13 Method C 100 Method AQ2 1265

342.4 1H NMR (300 MHz, DMSO) d 9.64 (s, 1H), 8.78 (dd, J = 8.0, 1.9 Hz, 1H), 8.67 (dd, J = 6.3, 4.7 Hz, 2H), 8.58 (s, 1H), 8.17-8.06 (m, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.79 (s, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.60-7.44 (m, 2H), 7.37 (d, J = 7.5 Hz, 1H), 5.31 (t, J = 5.4 Hz, 1H), 4.62 (d, J = 4.9 Hz, 2H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 343.1 (M + H) 1.78 Method C 99 Method AQ2 1266

344.4 1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.92-8.59 (m, 3H), 8.59-8.47 (m, 1H), 8.40-8.11 (m, 2H), 8.04 (d, J = 8.5 Hz, 1H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.29 (s, 3H), 3.93 (s, 3H). DMSO 345.1 (M + H) 2.32 Method C 100 Method AQ2 1267

329.4 1H NMR (300 MHz, DMSO) δ 12.77 (s, 1H), 9.33 (d, J = 1.7 Hz, 1H), 8.77 (dd, J = 4.7, 1.5 Hz, 1H), 8.60-8.46 (m, 1H), 8.23 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 1.5 Hz, 1H), 7.87 (dd, J = 8.3, 1.8 Hz, 1H), 7.67-7.53 (m, 1H), 7.52- 7.29 (m, 3H), 7.04 (ddd, J = 7.7, 2.4, 1.5 Hz, 1H), 3.57 (s, 3H). DMSO 330 (M + H) 1.78 Method C 100 Method AQ2 1268

342.4 1H NMR (300 MHz, DMSO) δ 9.65 (dd, J = 2.1, 0.8 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.52 (d, J = 4.4 Hz, 1H), 8.30 (d, J = 8.6 Hz, 1H), 8.03 (d, J = 1.7 Hz, 1 H), 7.85 (dd, J = 8.5, 1.8 Hz, 1H), 7.54 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.47-7.34 (m, 3H), 7.08-6.96 (m, 1H), 3.34 (s, 3H), 3.17 (d, J = 4.4 Hz, 3H). DMSO 343.3 (M + H) 2.09 Method C Method AQ2 1269

342.4 1H NMR (300 MHz, DMSO) δ 9.53 (d, J = 2.0 Hz, 1 H), 8.65 (dd, J = 5.9, 3.5 Hz, 2H), 8.51 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 8.3 Hz, 1H), 7.84 (d, J = 7.3 Hz, 1H), 7.65-7.25 (m, 5H), 7.00 (dd, J = 8.1, 2.6 Hz, 1H), 3.33 (s, 3H), 3.17 (d, J = 4.2 Hz, 3H). DMSO 343.3 (M + H) 2.16 Method C 100 Method AQ2 1270

2HCl 374.5 1H NMR (300 MHz, DMSO) δ 10.67 (s, 1H), 9.69 (s, 1H). 9.12 (d, J = 11.6 Hz. 2H), 8.97 (d, J = 5.0 Hz, 1H), 8.43 (d, J = 7.4 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 8.20 (s, 1H), 8.07 (s, 1H), 7.98-7.86 (m, 1H), 7.77 (s, 2H), 3.31 (d, J = 3.9 Hz, 3H), 2.90 (s, 3H). DMSO 375.1 (M + H) 1.67 Method C 95 Method AQ2 1271

374.5 1H NMR (300 MHz, DMSO) δ 9.70-9.57 (m, 1H), 8.84-8.72 (m, 1H), 8.73-8.62 (m, 3H), 8.19 (dd, J = 8.7, 1.9 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.86 (dd, J = 10.6, 8.5 Hz, 3H), 7.60- 7.49 (m, 1H), 3.19 (d, J = 4.4 Hz, 2H), 2.81 (s, 3H). DMSO 375.1 (M + H) 1.64 Method C 95 Method AQ2 1272

2HCl 425.5 1H NMR (300 MHz, DMSO) δ 10.54 (s, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.98 (dd, J = 5.5, 4.0 Hz, 2H), 8.37 (dd, J = 26.8, 7.9 Hz, 2H), 8.09-7.84 (m, 3H), 7.63 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 3.67 (bs, 8H), 3.31 (d, J = 4.3 Hz, 3H). DMSO 426.2 (M + H) 1.72 Method C 95 Method AQ2 1273

HCl 342.4 1H NMR (300 MHz, DMSO) δ 9.64 (s, 1 H), 8.77 (d, J = 7.9 Hz, 1H), 8.71-8.65 (m, 1H), 8.60 (s, 1H), 8.53 (s, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.87-7.77 (m, 3H), 7.59-7.49 (m, 1H), 7.10 (d, J = 8.7 Hz, 2H), 3.83 (d, J = 0.9 Hz, 3H), 3.19 (s, 3H). DMSO 343.1 (M + H) 2.06 Method C 100 Method AQ2 1274

329.4 1H NMR (300 MHz, DMSO) δ 9.34 (d, J = 1.5 Hz, 1 H), 8.74 (dd, J = 4.8, 1.6 Hz, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 2.1 Hz, 1H), 8.10 (dd, J = 8.5, 2.3 Hz, 1H), 7.79 (d, J = 8.6 Hz, 1H), 7.76 (s, 1H), 7.73 (s, 1H), 7.58 (dd, J = 8.0, 4.8 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 3.82 (s, 3H). DMSO 330.0 (M + H) 1.75 Method C 100 Method AQ2 1275

343.4 1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.5 Hz, 1H), 8.84-8.65 (m, 4H), 8.31 (d, J = 5.4 Hz, 1H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.59-7.46 (m, 2H), 7.33 (d, J = 0.9 Hz, 1H), 3.93 (s, 3H), 3.20 (d, J = 4.4 Hz, 3H). DMSO 344.1 (M + H) 1.95 Method C 95 Method AQ2 1276

331.3 1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.81-8.74 (m, 1H), 8.73 (d, J = 2.3 Hz, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.66- 8.56 (m, 2H), 8.44 (td, J = 8.2, 2.6 Hz, 1H), 8.18 (dd, J = 8.7, 2.0 Hz, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.38 (dd, J = 8.5, 2.9 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). DMSO 332.1 (M + H) 1.89 Method C 100 Method AQ2 1277

425.5 1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.70-8.59 (m, 3H), 8.15 (dd, J = 8.7, 1.6 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.62-7.48 (m, 3H), 3.62 (s, J = 54.7 Hz, 8H), 3.17 (d, J = 4.2 Hz, 3H). DMSO 426.2 (M + H) 1.69 Method C 100 Method AQ2 1278

343.4 1H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.5 Hz, 1H), 8.86-8.77 (m, 1H), 8.74 (dd, J = 4.7, 1.6 Hz, 1H), 8.37-8.25 (m, 2H), 8.06 (d, J = 8.7 Hz, 1H), 7.60 (dd, J = 7.9, 4.1 Hz, 1H), 7.50-7.30 (m, 3H), 7.02 (dd, J = 7.9, 1.4 Hz, 1H), 4.31 (s, 3H), 3.87 (s, 3H). DMSO 344.2 (M + H) 2.47 Method C 100 Method AQ2

¹H Pu- Method NMR rity of Num- Starting Starting Salt Sol- Per- Cou- LCMS ber Material 1 Material 2 Product type ¹H NMR vent cent pling LCMS Method 1279

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.69 (d, J = 1.8 Hz, 1H), 9.40- 9.33 (m, 1H), 9.03-8.93 (m, 2H), 8.64-8.59 (m, 1H), 8.18-8.14 (m, 1H), 8.13- 8.05 (m, 3H), 8.04-7.97 (m, DMSO >98 AQ3       2H), 3.21 (d, J = 4.4 Hz, 3H), 2.77 (s, 3H). 1280

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.71-9.65 (m, 1H), 9.44-9.36 (m, 1H), 9.06-8.94 (m, 2H), 8.59- 8.54 (m, 1H), 8.19-8.10 (m, 2H), 7.79-7.71 (m, 2H), 7.61- 7.54 (m, 1H), 7.29- 7.22 (m, 1H), 3.21 (d, J = 3.9 Hz, 3H), DMSO >98 AQ3 2.76 (s, 3H). 1281

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.72-9.65 (m, 1H), 9.43-9.36 (m, 1H), 9.04-8.91 (m, 2H), 8.63- 8.55 (m, 1H), 8.36-8.31 (m, 1H), 8.26-8.20 (m, 1H), 8.20- 8.11 (m, 2H), DMSO >98 AQ3 7.91-7.85 (m, 1H), 7.78-7.70 (m, 1H), 3.22 (d, J = 4.2 Hz, 3H), 2.76 (s, 3H). 1282

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.70-9.65 (m, 1H), 9.37 (d, J = 8.2 Hz, 1H), 9.03- 8.90 (m, 2H), 8.49-8.42 (m, 1H), 8.12 (dd, J = 8.1, 5.6 Hz, 1H), 8.08-8.03 (m, 1H), 7.88-7.78 DMSO >98 AQ3 (m, 2H), 7.15- 7.04 (m, 2H), 3.84 (s, 3H), 3.21 (d, J = 3.9 Hz, 3H), 2.76 (s, 3H). 1283

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.73-9.67 (m, 1H), 9.36 (d, J = 7.4 Hz, 1H), 9.02-8.96 (m, 1H), 8.82 (s, 1H), 8.26-8.19 (m, 1H), 8.15-8.07 (m, 1H), 7.89-7.83 (m, 1H), 7.47- 7.38 (m, 2H), DMSO >98 AQ3 7.21-7.15 (m, 1H), 7.14-7.06 (m, 1H), 3.81 (s, 3H), 3.19 (d, J = 4.5 Hz, 3H), 2.77 ( s, 3H). 1284

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.72 (d, J = 1.8 Hz, 1H), 9.34- 9.28 (m, 1H), 8.95 (dd, J = 5.4, 1.4 Hz, 1H), 8.88-8.78 (m, 1H), 8.38 (d, J = 1.5 Hz, 1H), 8.07- 8.00 (m, 2H), DMSO >98 AQ3 7.95-7.90 (m, 1H), 7.90-7.83 (m, 1H), 7.76 (dd, J = 7.8, 0.7 Hz, 1H), 7.68- 7.63 (m, 1H), 3.19 (d, J = 4.5 Hz, 3H), 2.77 (s, 3H). 1285

¹H NMR (400 MHz, DMSO) δ 9.63 (dd, J = 2.1, 0.8 Hz, 1H), 8.80-8.75 (m, 1H), 8.69 (dd, J = 3.7, 1.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.58-7.49 (m, DMSO >98 AQ4 2H), 7.46-7.40 (m, 1H), 7.39- 7.32 (m, 1H), 7.28-7.18 (m, 1H), 3.18 (d, J = 4.4 Hz, 3H), 2.64 (s, 3H). 1286

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.67-9.60 (m, 1H), 9.06-8.88 (m, 3H), 8.12 (d, J = 8.8 Hz, 1H), 7.91- 7.79 (m, 2H) 7.53-7.40 (m, 2H), 7.34- 7.24 (m, 1H), 3.34 (d, J = 4.6 DMSO >98 AQ4 Hz, 3H), 2.66 (s, 3H). 1287

HCl ¹H NMR (400 MHz, DMSO) δ 9.62-9.57 (m, 1H), 8.94-8.86 (m, 2H), 8.62 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.86- 7.75 (m, 2H), 7.52-7.36 (m, 2H), 7.35-7.28 (m, 1H), 3.31 (d, J = 4.5 Hz, 3H), 2.67 (s, 3H). DMSO >98 AQ4 1288

HCl ¹H NMR (400 MHz, DMSO) δ 9.63-9.58 (m, 1H), 8.95-8.86 (m, 2H), 8.73 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.87-7.75 (m, 2H), 7.61-7.50 (m, 1H), 7.45-7.33 (m, 3H), 3.32 (d, DMSO >98 AQ4 J = 4.5 Hz, 3H), 2.66 (s, 3H). 1289

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.64-9.60 (m, 1H), 9.00-8.86 (m, 3H), 8.06 (d, J = 8.5 Hz, 1H), 7.91-7.79 (m, 2H), 7.65-7.55 (m, 1H), 7.37- 7.29 (m, 1H), 7.29-7.22 (m, 2H), 3.35 (d, J = 4.6 Hz, 3H), DMSO >98 AQ4 2.72 (s, 3H). 1290

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.69-9.64 (m, 1H), 9.14-8.99 (m, 2H), 8.96 (dd, J = 5.0, 1.5 Hz, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.90-7.81 (m, 2H), 7.50-7.34 (m, 4H), 3.35 (d, DMSO >98 AQ4 J = 4.6 Hz, 3H), 2.72 (s, 3H). 1291

HCl ¹H NMR (300 MHz, CDCl₃) δ 9.63 (s, 2H), 8.96 (d, J = 8.2 Hz, 1H), 8.90 (d, J = 5.0 Hz, 1H), 8.50 (s, 1H), 8.16- 7.99 (m, 2H), 7.82 (dd, J = 8.0, 4.9 Hz, 1H), 7.71-7.62 (m, 1H), 7.61-7.47 DMSO >98 G2/AQ3 (m, 3H), 3.26 (d, J = 4.5 Hz, 3H). 1292

2 HCl ¹H NMR (300 MHz, CDCl₃) δ 10.27 (s, 1H), 9.69 (s, 1H), 9.09 (d, J = 8.1 Hz, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.56 (s, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.89 (dd, J = DMSO >98 G2/AQ3 8.0, 5.1 Hz, 1H), 7.45-7.26 (m, 4H), 3.29 (d, J = 4.2 Hz, 3H), 2.32 (s, 3H). 1293

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.40 (s, 1H), 9.73 (s, 1H), 9.15 (d, J = 7.9 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.67 (s, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 7.9, 5.2 Hz, DMSO >98 G2/AQ3 1H), 7.45 (m, 2H), 7.20 (d, J = 8.2 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 3.82 (s, 3H), 3.29 (d, J = 4.1 Hz, 3H). 1294

¹H NMR (300 MHz, CDCl₃) δ 9.66 (s, 1H), 8.80 (d, J = 7.9 Hz, 1H), 8.74-8.67 (m, 1H), 8.60 (m, 1H), 8.49 (s, 1H), 8.00 (dd, J = 18.5, 10.4 Hz, 2H), 7.96-7.81 (m, 2H), 7.76 (d, DMSO >98 G2/AQ3 J = 7.6 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.56 (dd, J = 7.6, 5.0 Hz, 1H), 3.18 (d, J = 4.2 Hz, 3H). 1295

2 HCl ¹H NMR (300 MHz, CDCl₃) δ 9.88 (s, 1H), 9.66 (s, 1H), 9.01 (d, J = 8.3 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 8.70 (s, 1H), 8.27- 8.08 (m, 2H), 7.81 (dd, J = 8.0, 5.1 Hz,1H), 7.72 DMSO >98 G2/AQ3 (t, J = 7.6 Hz, 1H), 7.60-7.48 (m, 1H), 7.48- 7.27 (m, 2H), 3.27 (d, J = 4.3 Hz, 3H). 1296

2 HCl ¹H NMR (300 MHz, CDCl₃) δ 9.63 (m, 2H), 8.93 (d, J = 7.7 Hz, 1H), 8.88 (d, J = 4.1 Hz, 1H), 8.76 (s, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.94 (dd, J = 8.6, 5.5 DMSO >98 G2/AQ3 Hz, 2H), 7.82- 7.73 (m, 1H), 7.41 (t, J = 8.7 Hz, 2H), 3.28 (d, J = 4.3 Hz, 3H). 1297

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.95- 8.86 (m, 2H), 8.69 (t, J = 1.9 Hz, 1H), 8.51-8.34 (m, 2H), 8.30 (dd, J = 7.9, 1.8 DMSO >98 G2/AQ3 Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H), 7.93-7.76 (m, 2H), 3.30 (d, J = 4.5 Hz, 3H). 1298

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.30 (s, 1H), 9.70 (d, J = 2.1 Hz, 1H), 9.11 (d, J = 8.2 Hz, 1H), 9.04-8.83 (m, 1H), 8.56 (s, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.01- 7.80 (m, 3H), DMSO >98 G2/AQ3 7.78-7.64 (m, 1H), 7.60 (t, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H), 3.29 (d, J = 4.4 Hz, 3H), 2.44 (s, 3H). 1299

¹H NMR (300 MHz, DMSO) δ 10.50 (s, 1H), 9.66 (s, 1H), 9.09 (d, J = 8.2 Hz, 1H), 9.01 (s, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 8.13- DMSO >98 G2/AQ3 8.00 (m, 4H), 7.88 (dd, J = 8.0, 5.2 Hz, 1H), 3.30 (d, J = 4.1 Hz, 3H), 2.62 (s, 3H). 1300

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.49 (s, 1H), 9.66 (s, 1H), 9.09 (d, J = 7.9 Hz, 1H), 9.01 (s, 1H), 8.95 (d, J = 5.0 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.15- 7.94 (m, 4H), 7.88 (dd, J = DMSO >98 G2/AQ3 7.9, 5.2 Hz, 1H), 3.31 (d, J = 4.1 Hz, 3H), 2.63 (s, 3H). 1301

3 HCl ¹H NMR (300 MHz, DMSO) δ 10.97 (s, 1H), 9.71 (d, J = 2.0 Hz, 1H), 9.29 (s, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.98 (dd, J = 5.0, 1.3 Hz, 1H), 8.49-8.38 (m, 1H), 8.34 (d, DMSO >98 G2/AQ3 J = 8.8 Hz, 1H), 8.21 (s, 1H), 7.92 (dd, J = 8.1, 5.1 Hz, 1H), 7.84 (s, 1H), 7.69-7.52 (m, 2H), 3.31 (d, J = 4.3 Hz, 3H), 3.23 (s, 6H). 1302

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (s, 1H), 9.73 (d, J = 1.7 Hz, 1H), 9.20 (d, J = 8.0 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.68 (s, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 7.9 DMSO >98 G2/AQ3 Hz, 1H), 8.01- 7.93 (m, 2H), 7.90 (t, J = 7.2 Hz, 1H), 7.74 (dd, J = 15.4, 7.7 Hz, 2H), 3.24 (t, J = 18.2 Hz, 3H). 1303

HCl ¹H NMR (300 MHz, DMSO) δ 10.46 (s, 1H), 9.76 (d, J = 2.1 Hz, 1H), 9.21 (d, J = 8.2 Hz, 1H), 9.00 (dd, J = 5.1, 1.2 Hz, 1H), 8.58 (d, J = 1.3 Hz, 1H), 8.41 (d, J = 8.6 Hz, 1H), DMSO >98 G2/AQ3 8.08-7.86 (m, 2H), 7.36-7.09 (m, 3H), 3.29 (d, J = 4.3 Hz, 3H), 2.33 (s, 3H), 2.17 (s, 3H). 1304

¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.79 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.6 Hz, 1H), 8.46 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 1.7 Hz, 1H), 7.83 (d, J = 8.5 DMSO >98 G2/AQ3 Hz, 1H), 7.75 (dd, J = 8.5, 1.6 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.28- 7.02 (m, 3H), 3.33 (s, 6H), 3.15 (d, J = 4.4 Hz, 3H), 2.51 (dt, J = 3.6, 1.7 Hz, 1H), 2.35 (s, 3H), 2.27 (s, 3H). 1305

HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (s, 1H), 9.70 (s, 1H), 9.11 (d, J = 7.8 Hz, 1H), 8.97 (d, J = 4.7 Hz, 1H), 8.90 (s, 1H), 8.36 (d, J = 8.6 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 7.98- DMSO >98 G2/AQ3 7.80 (m, 1H), 7.74 (s, 1H), 7.65 (d, J = 7.5 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 3.32 (d, J = 4.0 Hz, 3H), 2.33 (d, J = 10.0 Hz, 3H), 2.29 (s, 3H). 1306

HCl ¹H NMR (300 MHz, DMSO) δ 10.45-10.35 (m, 1H), 9.69 (s, 1H), 9.09 (s, 1H), 8.99 (s, 1H), 8.88 (s, 1H), 8.37 (d, J = 8.6 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H), 7.94 (s, 1H), 7.54 (s, 1H), 7.11 (s, 1H), 3.34 (d, J = DMSO >98 G2/AQ3 4.3 Hz, 3H), 2.40 (s, 3H). 1307

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.28 (s, 1H), 9.84-9.66 (m, 1H), 9.17 (d, J = 8.1 Hz, 1H), 8.99 (d, J = 5.0 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 8.6 Hz, 1H), 7.98-7.80 (m, DMSO >98 G2/AQ3 2H), 7.41 (t, J = 8.4 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 3.71 (s, 6H), 3.29 (d, J = 4.2 Hz, 3H). 1308

HCl ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.96- 8.91 (m, 1H), 8.89-8.83 (m, 2H), 8.41 (d, J = 9.1 Hz, 2H), 8.38- 8.32 (m, 1H), 8.16 (d, J = 9.0 Hz, 2H), 8.02 (d, J = 9.1 Hz, 1H), 7.81-7.73 (m, 1H), 3.27 (d, J = DMSO >98 G2/AQ3 4.3 Hz, 3H). 1309

¹H NMR (300 MHz, DMSO) δ 9.64 (d, J = 2.0 Hz, 1H), 8.78 (ddd, J = 14.6, 8.2, 6.5 Hz, 1H), 8.70 (dd, J = 4.7, 1.4 Hz, 1H), 8.56 (d, J = 4.3 Hz, 1H), 8.33 (d, J = 1.5 Hz, 1H), 8.06 DMSO >98 G2/AQ3 (dd, J = 8.6, 1.4 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 7.9, 4.8 Hz, 1H), 7.34 (t, J = 7.5 Hz, 2H), 7.20- 7.00 (m, 2H), 3.16 (d, J = 4.4 Hz, 3H). 1310

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.63 (s, 1H), 9.69 (s, 1H), 9.16 (s, 1H), 9.10 (d, J = 7.9 Hz, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.52 (s, 1H), 8.45 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.7 Hz, 2H), 8.07 (d, J = 7.8 Hz, 1H), 8.01-7.84 (m, DMSO >98 G2/AQ3 2H), 7.63 (t, J = 7.8 Hz, 1H), 7.54 (s, 1H), 3.31 (d, J = 4.3 Hz, 3H). 1311

HCl ¹H NMR (300 MHz, DMSO) δ 10.20 (s, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.95 (s, 2H), 8.43 (d, J = 8.7 Hz, 1H), 8.26- 8.14 (m, 1H), 8.04 (dd, J = 18.8, 8.1 Hz, 4H), 7.88 (s, 1H), 7.47 (s, 1H), 3.32 (s, DMSO >98 G2/AQ3 3H), 3.17 (d, J = 1.8 Hz, 9H). 1312

HCl ¹H NMR (300 MHz, DMSO) δ 9.79 (s, 1H), 9.66 (d, J = 1.7 Hz, 1H), 9.02 (d, J = 8.1 Hz, 1H), 8.96-8.86 (m, 1H), 8.57 (s, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.05 (dd, J = 8.7, 1.4 Hz, DMSO >98 G2/AQ3 1H), 7.82 (dd, J = 8.1, 5.0 Hz, 1H), 7.79-7.72 (m, 1H), 7.64-7.45 (m, 2H), 3.25 (d, J = 4.4 Hz, 3H). 1313

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.65 (s, 1H), 9.06 (d, J = 7.8 Hz, 1H), 8.95 (d, J = 4.8 Hz, 1H), 8.59 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 9.1 Hz, 1H), 7.95- DMSO >98 G2/AQ3 7.77 (m, 2H), 7.66-7.52 (m, 2H), 3.27 (d, J = 4.3 Hz, 3H), 3.17 (d, J = 0.7 Hz, 1H). 1314

HCl ¹H NMR (300 MHz, DMSO) δ 10.10 (s, 1H), 9.69 (s, 1H), 9.13 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.62 (s, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 8.3 Hz, 1H), 8.02- 7.83 (m, 1H), 7.77-7.65 (m, DMSO >98 G2/AQ3 2H), 7.60 (d, J = 8.5 Hz, 1H), 3.29 (d, J = 3.9 Hz, 3H). 1315

HCl ¹H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 9.02- 8.93 (m, 1H), 8.89 (d, J = 4.5 Hz, 1H), 8.80 (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.18 (s, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.96-7.75 (m, DMSO >98 G2/AQ3 2H), 3.29 (d, J = 4.2 Hz, 3H). 1316

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.67 (s, 1H), 9.13 (d, J = 8.2 Hz, 1H), 9.01-8.82 (m, 2H), 8.40 (d, J = 9.1 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 7.97 (s, 2H), 7.90 (dd, J = 8.0, 5.2 Hz, 1H), 7.65 (s, 1H), DMSO >98 G2/AQ3 3.31 (d, J = 4.3 Hz, 3H). 1317

¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.9 Hz, 1H), 8.89- 8.75 (m, 1H), 8.74-8.67 (m, 1H), 8.67-8.56 (m, 1H), 8.48 (s, 1H), 8.06-7.94 (m, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.68- 7.51 (m, 2H), 7.46 (td, J = 9.6, DMSO >98 G2/AQ3 4.7 Hz, 1H), 7.39-7.21 (m, 1H), 3.18 (d, J = 4.4 Hz, 3H). 1318

HCl ¹H NMR (300 MHz, DMSO) δ 10.57 (s, 1H), 9.69 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 9.02 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.40 (d, J = 8.8 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 7.91 (dd, J = 8.0, 5.2 DMSO >98 G2/AQ3 Hz, 1H), 7.77- 7.63 (m, 2H), 7.37-7.18 (m, 1H), 3.29 (d, J = 4.3 Hz, 3H). 1319

¹H NMR (300 MHz, CDCl₃) δ 9.58 (d, J = 2.0 Hz, 1H), 8.78-8.60 (m, 2H), 8.35 (d, J = 1.7 Hz, 1H), 8.11-7.84 (m, 3H), 7.78 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.48- DMSO >98 G2/AQ3 7.34 (m, 2H), 7.17 (d, J = 8.1 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 3.81 (s, 3H).

1320

¹H NMR (300 MHz, CDCl₃) δ 9.62 (d, J = 2.1 Hz, 1H), 8.82- 8.72 (m, 1H), 8.72-8.66 (m, 1H), 8.30 (s, 1H), 7.93 (dd, J = 8.7, 1.2 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = DMSO >98 G2/AQ3       7.9, 4.8 Hz, 1H), 7.50-7.33 (m, 2H), 7.18 (d, J = 8.3 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 3.82 (s, 3H), 3.46 (s, 6H). 1321

¹H NMR (300 MHz, CDCl₃) δ 9.59 (d, J = 2.1 Hz, 1H), 8.76- 8.66 (m, 2H), 8.50 (s, 2H), 8.06 (brs, 1H), 7.99 (dt, J = 8.6, 1.7 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.75-7.63 (m, DMSO >98 G2/AQ3 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.52-7.44 (m, 1H), 7.44-7.32 (m, 2H). 1322

¹H NMR (300 MHz, CDCl₃) δ 9.59 (d, J = 2.1 Hz, 1H), 8.79- 8.62 (m, 3H), 8.21 (dd, J = 8.8, 1.9 Hz, 1H), 8.10 (brs, 2H), 7.86 (d, J = 8.7 Hz, 1H), 7.80-7.69 (m, 2H), 7.68-7.49 (m, DMSO >98 G2/AQ3 2H), 7.32- 7.20 (m, 1H). 1323

¹H NMR (300 MHz, CDCl₃) δ 9.58 (d, J = 2.0 Hz, 1H), 8.80-8.64 (m, 2H), 8.62 (d, J = 1.8 Hz, 1H), 8.14 (dd, J = 8.7, 1.9 Hz, 1H), 8.07 (brs, 2H), 7.98-7.87 (m, 2H), 7.85 (d, J = DMSO >98 G2/AQ3 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.38 (t, J = 8.8 Hz, 2H). 1324

¹H NMR (300 MHz, CDCl₃) δ 9.65-9.57 (m, 1H), 8.82-8.70 (m, 1H), 8.70-8.63 (m, 1H), 8.36 (d, J = 1.8 Hz, 1H), 8.11 (dd, J = 8.7, 1.7 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.72- DMSO >98 G2/AQ3 7.60 (m, 2H), 7.60-7.47 (m, 2H), 7.32-7.18 (m, 1H), 3.49 (s, 6H). 1325

¹H NMR (400 MHz, DMSO) δ 9.64 (d, J = 1.4 Hz, 1H), 8.78 (dt, J = 8.3, 1.8 Hz, 1H), 8.69 (dd, J = 4.7, 1.8 Hz, 1H) 8.61-8.46 (m, 2H), 8.40 (d, J = 1.6 Hz, 1H), 7.99 (dd, J = DMSO >98 G2/AQ3 9.0, 1.8 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 7.54 (dd, J = 8.4, 4.5 Hz, 1H), 3.99 (d, J = 8.9 Hz, 6H), 3.17 (d, J = 4.6 Hz, 3H). 1326

¹H NMR (300 MHz, DMSO) δ 9.64-9.55 (m, 1H), 8.81-8.62 (m, 3H), 8.40 (s, 1H), 8.23 (dd, J = 8.8, 1.4 Hz, 1H), 8.13 (d, J = 7.7 Hz, 1H), 8.00 (d, J = 7.7 Hz, 2H), DMSO >98 G2/AQ3 7.89 (d, J = 8.7 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 2.71 (s, 3H). 1327

¹H NMR (300 MHz, DMSO) δ 9.58 (d, J = 2.1 Hz, 1H), 8.76- 8.65 (m, 3H), 8.24 (dd, J = 8.7, 1.8 Hz, 1H), 8.19- 7.93 (m, 6H), 7.88 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 2.65 (s, 3H). DMSO >98 G2/AQ3 1328

¹H NMR (300 MHz, DMSO) δ 9.60 (d, J = 1.8 Hz, 1H), 8.73 (dt, J = 8.0, 1.8 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (s, 1H), 7.99 (brs, 2H), 7.92-7.81 (m, 2H), 7.67-7.60 DMSO >98 G2/AQ3 (m, 1H), 7.60- 7.52 (m, 2H), 7.52-7.43 (m, 2H). 1329

¹H NMR (300 MHz, DMSO) δ 9.60 (d, J = 2.0 Hz, 1H), 8.77-8.65 (m, 3H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.09 (brs, 2H), 7.99- 7.94 (m, 1H), 7.90-7.79 (m, 2H), 7.63-7.51 DMSO >98 G2/AQ3 (m, 2H), 7.48 (d, J = 8.1 Hz, 1H). 1330

¹H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 8.87- 8.75 (m, 1H), 8.70 (s, 1H), 8.55 (s, 1H), 8.41 (s, 1H), 8.25 (s, 1H), 8.09-7.76 (m, 3H), 7.62-7.44 (m, 1H), 7.18 (s, 1H), 3.93 (s, 3H), DMSO >98 G2/AQ3 3.17 (s, 3H). 1331

¹H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 8.75 (d, J = 7.6 Hz, 1H), 8.68 (s, 1H), 8.45 (s, 1H), 8.18 (d, J = 9.2 Hz, 1H), 8.07 (d, J = 8.2 Hz, 2H), 8.01-7.87 (m, 3H), 7.55 (s, 1H), 3.51 (s, 6H), 2.63 (s, 3H). DMSO >98 G2/AQ3 1332

¹H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 8.83- 8.72 (m, 1H), 8.70 (d, J = 3.8 Hz, 1H), 8.21 (s, 1H), 7.89 (q, J = 8.6 Hz, 2H), 7.74- 7.41 (m, 5H), 3.47 (s, 6H). DMSO >98 G2/AQ3 1333

¹H NMR (300 MHz, DMSO) δ 9.62 (d, J = 2.0 Hz, 1H), 8.76 (dt, J = 7.9, 1.8 Hz, 1H), 8.70 (dd, J = 4.8, 1.6 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.13 (dd, J = 8.7, 1.9 Hz, 1H), 7.98-7.84 DMSO >98 G2/AQ3 (m, 2H), 7.78 (d, J = 7.6 Hz, 1H), 7.66-7.41 (m, 3H), 3.51 (s, 6H). 1334

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.81-9.63 (m, 1H), 9.18 (d, J = 8.4 Hz, 1H), 9.07- 8.89 (m, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 1.7 Hz, 1H), 8.22-8.07 (m, 1H), 8.02 (dd, DMSO >98 G2/AQ3 J = 8.7, 1.7 Hz, 1H), 7.98-7.91 (m, 1H), 7.91- 7.83 (m, 1H), 7.80-7.68 (m, 2H), 3.65 (s, 6H). 1335

¹H NMR (300 MHz, DMSO) δ 9.65- 9.62 (m, 1H), 8.82-8.75 (m, 1H), 8.73-8.68 (m, 1H), 8.61- 8.56 (m, 1H), 8.50 (d, J = 2.0 Hz, 1H), 8.34-8.20 (m, 3H), 7.97 (d, J = 8.7 Hz, 1H), DMSO >98 G2/AQ3 7.82 (t, J = 8.0 Hz, 1H), 7.57 (dd, J = 8.3, 5.2 Hz, 1H), 3.54 (s, 6H). 1336

¹H NMR (300 MHz, DMSO) δ 9.61 (d, J = 1.8 Hz, 1H), 8.80-8.72 (m, 1H), 8.72- 8.67 (m, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.39- 8.29 (m, 2H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.14-8.07 (m, 2H), 7.94 (d, J = 8.7 DMSO >98 G2/AQ3 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 3.52 (s, 6H). 1337

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.67- 9.61 (m, 1H), 8.82-8.73 (m, 1H), 8.73-8.65 (m, 1H), 8.39 (s, 1H), 8.03-7.96 (m, 3H), 7.90- 7.72 (m, 2H), 7.72-7.60 (m, 1H), 7.56 (dd, DMSO >98 G2/AQ3 J = 7.6, 5.1 Hz, 1H), 3.53 (s, 6H). 1338

¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.78 (dt, J = 8.1, 1.8 Hz, 1H), 8.71-8.59 (m, 3H), 8.19 (dd, J = 8.6, 1.7 Hz, 1H), 8.07-7.95 (m, 2H), 7.93- 7.81 (m, 2H), 7.54 (dd, J = 7.9, DMSO >98 G2/AQ3 4.7 Hz, 1H), 7.47-7.34 (m, 2H), 3.23-3.20 (m, 3H). 1339

¹H NMR (300 MHz, DMSO) δ 9.68-9.64 (m, 1H), 8.83-8.75 (m, 1H), 8.69 (d, J = 4.7 Hz, 1H), 8.56-8.45 (m, 2H), 8.17-8.05 (m, 1H), 8.05- 7.87 (m, 4H), 7.58-7.40 (m, 3H), 3.18 (d, J = 4.1 Hz, 3H). DMSO >98 G2/AQ3 1340

¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.5 Hz, 1H), 8.80 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.57-8.41 (m, 2H), 8.08 (dd, J = 6.1, 2.6 Hz, 1H), 7.99 (dd, J = 8.6, 1.8 Hz, DMSO >98 G2/AQ3 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.84 (d, J = 5.6 Hz, 1H), 7.62- 7.44 (m, 4H), 3.17 (d, J = 4.5 Hz, 3H). 1341

¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 8.79 (dt, J = 7.9, 1.9 Hz, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 8.65 (d, J = 1.9 Hz, 1H), 8.61- 8.53 (m, 1H), 8.35 (d, J = 1.6 DMSO >98 G2/AQ3 Hz, 1H), 8.21 (dd, J = 8.7, 2.0 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.92-7.80 (m, 3H), 7.59-7.48 (m, 2H), 3.21 (d, J = 4.5 Hz, 3H). 1342

¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.6 Hz, 1H), 8.79 (dt, 7 = 8.0, 1.9 Hz, 1H), 8.73-8.61 (m, 3H), 8.50 (s, 1H), 8.24 (dd, J = 8.7, 1.9 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.96- 7.82 (m, 3H), 7.60-7.50 (m, DMSO >98 G2/AQ3 2H), 3.21 (d, J = 4.4 Hz, 3H). 1343

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.41 (brs, 1H), 9.75 (d, J = 1.7 Hz, 1H), 9.24- 9.19 (m, 1H), 9.01 (dd, J = 5.2, 1.5 Hz, 1H), 8.90 (d, J = 1.5 Hz, 1H), 8.46 (d, J = 8.7 Hz, 1H), 8.39 (dd, J = 8.7, 1.7 Hz, 1H), DMSO >98 G2/AQ3 8.06-7.91 (m, 2H), 7.86 (d, J = 5.5 Hz, 1H), 7.66-7.52 (m, 3H), 3.29 (d, J = 4.5 Hz, 3H). 1344

HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (brs, 1H), 9.78 (d, J = 2.0 Hz, 1H), 9.23 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 5.0 Hz, 1H), 8.73 (s, 1H), 8.48 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 8.0 Hz, 2H), 7.95 (dd, J = DMSO >98 G2/AQ3 8.1, 5.2 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.72- 7.50 (m, 4H), 3.27 (d, J = 4.3 Hz, 3H). 1345

¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.4 Hz, 1H), 8.85- 8.77 (m, 1H), 8.77-8.62 (m, 3H), 8.40 (s, 1H), 8.30 (dd, J = 8.7, 1.6 Hz, 1H), 8.14- 7.95 (m, 4H), 7.91 (d, J = 8.7 Hz, 1H), 7.63- 7.50 (m, 3H), 3.22 (d, J = 4.3 Hz, 3H). DMSO >98 G2/AQ3 1346

¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 2.0 Hz, 1H), 8.80 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.7 Hz, 1H), 8.67-8.55 (m, 2H), 8.25 (dd, J = 8.7, 1.8 Hz 1H), 8.13-8.09 (m, 1H), 7.92- 7.77 (m, 4H), 7.71 DMSO >98 G2/AQ3 (d, J = 7.8 Hz, 1H), 7.67-7.47 (m, 4H), 7.47- 7.37 (m, 1H), 3.20 (d, J = 4.4 Hz, 3H). 1347

¹H NMR (300 MHz, DMSO) δ 9.68-9.65 (m, 1H), 8.79 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.68- 8.60 (m, 2H), 8.20 (dd, J = 8.7, 1.9 Hz, 1H), 7.99-7.95 (m, 2H), 7.92-7.81 DMSO >98 G2/AQ3 (m, 3H), 7.80- 7.73 (m, 2H), 7.61-7.46 (m, 3H), 7.46-7.36 (m, 1H), 3.20 (d, J = 4.4 Hz, 3H). 1348

¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.5 Hz, 1H), 8.80 (dt, J = 7.9, 1.9 Hz, 1H), 8.70 (dd, J = 4.7, 1.7 Hz, 1H), 8.55 (d, J = 4.6 Hz, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 1.8 DMSO >98 G2/AQ3 Hz, 1H), 7.92- 7.84 (m, 3H), 7.60-7.50 (m, 3H), 7.50-7.42 (m, 1H), 3.18 (d, J = 4.5 Hz, 3H). 1349

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.23 (brs, 1H), 9.67 (d, J = 2.1 Hz, 1H), 9.04 (d, J = 7.7 Hz, 1H), 8.98-8.91 (m, 1H), 8.57 (d, J = 8.7 Hz, 1H), 8.48 (s, 1H), 8.08 (d, J = 8.3 Hz, 1H), DMSO >98 G2/AQ3 7.91-7.76 (m, 3H), 7.22-7.10 (m, 2H), 3.85 (s, 3H), 3.31 (d, J = 4.4 Hz, 3H). 1350

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (brs, 1H), 9.74 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 8.3 Hz, 1H), 9.07-8.97 (m, 1H), 8.71 (d, J = 8.8 Hz, 1H), 8.64 (s, 1H), 8.36 (s, 1H), 8.19 (d, J = DMSO >98 G2/AQ3 7.6 Hz, 1H), 8.16-8.06 (m, 2H), 7.95 (dd, J = 8.1, 5.0 Hz, 1H), 7.75 (t, J = 7.7 Hz, 1H), 3.31 (d, J = 4.4 Hz, 3H), 2.71 (s, 3H). 1351

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.47 (brs, 1H), 9.73 (d, J = 1.3 Hz, 1H), 9.19 (d, J = 8.3 Hz, 1H), 9.03-8.94 (m, 1H), 8.69-8.62 (m, 2H), 8.15- 8.07 (m, 3H), 8.02-7.77 (m, 3H), 3.29 (d, J = 4.3 Hz, 3H), 2.65 DMSO >98 G2/AQ3 (s, 3H). 1352

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.44 (brs, 1H), 9.74 (s, 1H), 9.19 (d, J = 7.3 Hz, 1H), 8.99 (d, J = 5.2 Hz, 1H), 8.68 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.03-7.90 (m, 1H), 7.83 (d, J = DMSO >98 G2/AQ3 8.2 Hz, 1H), 7.72-7.62 (m, 1H), 7.53 (d, J = 9.6 Hz, 3H), 3.32 (d, J = 4.0 Hz, 3H). 1353

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.48 (brs, 1H), 9.77 (s, 1H), 9.29- 9.23 (m, 1H), 9.05-8.97 (m, 1H), 8.74-8.59 (m, 2H), 8.20- 8.08 (m, 1H), 8.02-7.95 (m, 1H), 7.90 (s, DMSO >98 G2/AQ3 1H), 7.84-7.79 (m, 1H), 7.68-7.57 (m, 2H), 3.35- 3.29 (m, 3H). 1354

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.35 (brs, 1H), 9.72 (d, J = 2.0 Hz, 1H), 9.21- 9.11 (m, 1H), 8.98 (dd, J = 5.1, 1.4 Hz, 1H), 8.65 (d, J = 8.7 Hz, 1H), 8.59 (s, 1H), 8.09 (dd, DMSO >98 G2/AQ3 J = 8.8, 1.7 Hz, 1H), 7.95-7.82 (m, 3H), 7.70- 7.60 (m, 2H), 3.30 (d, J = 4.4 Hz, 3H). 1355

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.51 (brs, 1H), 9.77 (d, J = 1.9 Hz, 1H), 9.22 (d, J = 8.2 Hz, 1H), 9.01 (dd, J = 5.1, 1.4 Hz, 1H), 8.69 (s, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.17 (dd, DMSO >98 G2/AQ3 J = 8.7, 1.6 Hz, 1H), 7.96 (dd, J = 8.1, 5.2 Hz, 1H), 7.30-7.15 (m, 2H), 7.10 (dd, J = 7.3, 1.9 Hz, 1H), 3.89 (s, 3H), 3.59 (s, 3H), 3.30 (d, J = 4.5 Hz, 3H). 1356

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.42 (s, 1H), 9.71 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (s, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.19 (dd, J = 8.7, 1.6 Hz, 1H), 7.90 (dd, J = 7.9, 5.1 Hz, DMSO >98 G2/AQ3 1H), 7.18-7.06 (m, 2H), 7.01 (dd, J = 8.9, 3.1 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). 1357

HCl ¹H NMR (300 MHz, DMSO) δ 10.21 (brs, 1H), 9.63 (s, 1H), 8.99 (d, J = 8.0 Hz, 1H), 8.93 (d, J = 3.7 Hz, 1H), 8.87 (s, 1H), 8.37 (d, J = 8.9 Hz, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.91- 7.78 (m, 1H), 7.05 (d, J = 2.1 DMSO >98 G2/AQ3 Hz, 2H), 6.66- 6.58 (m, 1H), 3.87 (s, 6H), 3.31 (d, J = 4.2 Hz, 3H). 1358

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.43 (brs, 1H), 9.73 (d, J = 1.8 Hz, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.0, 1.3 Hz, 1H), 8.69 (d, J = 8.6 Hz, 1H), 8.49 (s, 1H), 8.05-7.88 DMSO >98 G2/AQ3 (m, 2H), 7.71 (t, J = 7.9 Hz, 1H), 7.64-7.50 (m, 1H), 7.50-7.33 (m, 2H), 3.32 (d, J = 4.3 Hz, 3H). 1359

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.29 (s, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.14 (d, J = 8.3 Hz, 1H), 8.97 (dd, J = 5.1, 1.3 Hz, 1H), 8.63 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.15-8.04 DMSO >98 G2/AQ3 (m, 1H), 7.90 (dd, J = 8.0, 5.1 Hz, 1H), 7.75- 7.57 (m, 3H), 7.43-7.30 (m, 1H), 3.30 (d, J = 4.3 Hz, 3H). 1360

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.41 (brs, 1H), 9.73 (d, J = 1.9 Hz, 1H), 9.16 (d, J = 8.3 Hz, 1H), 8.98 (dd, J = 5.1, 1.4 Hz, 1H), 8.65 (d, J = 8.8 Hz, 1H), 8.60 (s, 1H), 8.12-8.02 DMSO >98 G2/AQ3 (m, 1H), 8.00- 7.84 (m, 3H), 7.49-7.33 (m, 2H), 3.30 (d, J = 4.4 Hz, 3H).

1361

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.39 (s, 1H), 9.71 (d, J = 1.8 Hz, 1H), 9.17-9.08 (m, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.64 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.07 (dd, J = 8.6, DMSO >98 G2/AQ3       1.7 Hz, 1H), 7.88 (dd, J = 8.1, 5.2 Hz, 1H), 7.70-7.58 (m, 2H), 7.46 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 3.30 (d, J = 4.4 Hz, 3H), 2.43 (s, 3H). 1362

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.37 (brs, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 8.1 Hz, 1H), 8.96 (dd, J = 5.0, 1.4 Hz, 1H), 8.62 (d, J = 8.7 Hz, 1H), 8.58 (s, 1H), 8.08 (dd, DMSO >98 G2/AQ3 J = 8.6, 1.6 Hz, 1H), 7.87 (dd, J = 7.9, 5.0 Hz, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.40 (s, 3H). 1363

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.82 (brs, 1H), 9.65 (s, 1H), 9.14- 9.02 (m, 1H), 9.02-8.90 (m, 1H), 8.64-8.51 (m, 1H), 8.20 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.00-7.85 (m, DMSO >98 G2/AQ3 3H), 7.85-7.66 (m, 2H), 3.30 (s, 3H). 1364

HCl ¹H NMR (300 MHz, DMSO) δ 9.83 (brs, 1H), 9.68-9.63 (m, 1H), 9.12-9.02 (m, 1H), 9.01-8.91 (m, 1H), 8.56 (d, J = 9.2 Hz, 1H), 8.42 (s, 1H), 8.35 (s, 1H), 8.19 (d, J = 8.7 Hz, DMSO >98 G2/AQ3 1H), 8.13 (d, J = 9.3 Hz, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.93-7.84 (m, 1H), 7.79 (t, J = 8.2 Hz, 1H), 3.28 (d, J = 4.5 Hz, 3H). 1365

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.27 (brs, 1H), 9.72 (s, 1H), 9.23- 9.10 (m, 1H), 8.98 (s, 1H), 8.77- 8.55 (m, 2H), 8.18-7.86 (m, 6H), 3.34-3.27 (m, 3H). DMSO >98 G2/AQ3 1366

¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 2.0 Hz, 1H), 8.79 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.7, 1.6 Hz, 1H), 8.65-8.53 (m, 2H), 8.22-8.12 (m, 3H), 7.92 (dd, J = 8.8, 1.5 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), DMSO >98 G2/AQ3 7.80 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 4.11 (s, 3H), 3.20 (d, J = 4.4 Hz, 3H). 1367

¹H NMR (300 MHz, DMSO) δ 11.10 (s, 1H), 9.63 (d, J = 2.0 Hz, 1H), 8.85 (d, J = 1.7 Hz, 1H), 8.81-8.70 (m, 2H), 8.39 (dd, J = 8.9, 1.9 Hz, 1H), 8.15-8.02 (m, 5H), 7.60 (dd, J = 8.0, 4.8 Hz, 1H), 2.65 (s, 3H), DMSO >98 G2/AQ3 2.61 (s, 3H). 1368

HCl ¹H NMR (300 MHz, DMSO) δ 9.72 (d, J = 1.8 Hz, 1H), 9.27-9.21 (m, 1H), 8.97 (dd, J = 5.3, 1.4 Hz, 1H), 8.50 (dd, J = 8.8, 2.1 Hz, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.15- 8.09 (m, 2H), DMSO >98 G2/AQ3 8.09-7.98 (m, 3H), 3.55 (s, 3H), 2.65 (s, 3H), 2.22 (s, 3H). 1369

HCl ¹H NMR (300 MHz, DMSO) δ 11.16 (s, 1H), 9.67 (s, 1H), 9.20 (d, J = 8.2 Hz, 1H), 8.97 (d, J = 4.3 Hz, 1H), 8.75 (s, 1H), 8.23 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.02 (dd, J = 8.0, 5.5 Hz, 1H), 7.66-7.47 DMSO >98 G2/AQ3 (m, 2H), 7.47- 7.34 (m, 1H), 2.56 (s, 3H). 1370

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.17 (brs, 1H), 9.68 (d, J = 2.0 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 8.95 (dd, J = 5.0, 1.4 Hz, 1H), 8.77 (s, 1H), 8.31 (s, 2H), 8.16 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 7.8, 5.2 Hz, 1H), DMSO >98 G2/AQ3 7.72 (d, J = 7.8 Hz, 1H), 7.61- 7.47 (m, 2H), 7.19 (d, J = 1.4 Hz, 1H), 3.31 (d, J = 4.4 Hz, 3H). 1371

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.28 (brs, 1H), 9.71 (s, 1H), 9.16 (d, J = 7.9 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.67 (d, J = 8.9 Hz, 1H), 8.45 (s, 1H), 8.01-7.83 (m, 2H), 7.68-7.50 DMSO >98 G2/AQ3 (m, 2H), 7.50- 7.35 (m, 1H), 3.31 (d, J = 4.1 Hz, 3H). 1372

HCl ¹H NMR (300 MHz, DMSO) δ 9.72-9.45 (m, 2H), 8.95 (d, J = 7.6 Hz, 1H), 8.88 (d, J = 3.8 Hz, 1H), 8.49 (d, J = 8.5 Hz, 1H), 8.13 (s, 1H), 7.91-7.75 (m, 3H), 7.53- 7.43 (m, 1H), DMSO >98 G2/AQ3 7.36-7.25 (m, 1H), 3.27 (d, J = 4.3 Hz, 3H). 1373

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.04 (brs, 1H), 9.70 (s, 1H), 9.22-9.07 (m, 1H), 8.93 (s, 1H), 8.62 (d, J = 7.6 Hz, 1H), 8.55 (s, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.99-7.79 (m, DMSO >98 G2/AQ3 2H), 7.79-7.55 (m, 2H), 3.33-3.27 (m, 3H). 1374

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 9.34 (brs, 1H), 9.06- 8.92 (m, 1H), 8.86 (s, 1H), 8.50- 8.37 (m, 1H), 8.25 (s, 1H), 8.11- 7.95 (m, 1H), 7.85-7.74 (m, 1H), 7.74-7.57 (m, 2H), 7.43- 7.29 (m, 1H), 3.28- DMSO >98 G2/AQ3 3.21 (m, 3H). 1375

HCl ¹H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.6 Hz, 1H), 9.38 (brs, 1H), 9.01-8.91 (m, 1H), 8.84 (dd, J = 5.0, 1.6 Hz, 1H), 8.60 (s, 1H), 8.08 (s, 2H), 7.76 (dd, J = 7.9, 5.1 Hz, 1H), 7.64-7.38 (m, 2H), 3.26 (d, J = DMSO >98 G2/AQ3 3.7 Hz, 3H). 1376

HCl ¹H NMR (300 MHz, DMSO) δ 9.88 (brs, 1H), 9.65 (s, 1H), 9.18- 8.99 (m, 1H), 8.90 (s, 1H), 8.70 (s, 1H), 8.31-8.03 (m, 2H), 7.94- 7.77 (m, 2H), 7.77-7.57 (m, 1H), 3.28 (s, 3H). DMSO >98 G2/AQ3 1377

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (s, 1H), 9.67 (s, 1H), 9.10 (d, J = 7.8 Hz, 1H), 9.02 (s, 1H), 8.92 (d, J = 5.0 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 8.8 Hz, 1H), 8.03- 7.76 (m, 3H), 3.31 (s, 3H). DMSO >98 G2/AQ3 1378

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J = 1.7 Hz, 1H), 9.56-9.34 (m, 1H), 9.26- 9.10 (m, 1H), 9.05 (d, J = 4.7 Hz, 1H), 8.44 (s, 1H), 8.19 (dd, J = 8.1, 5.7 Hz, 1H), 7.95 (d, J = DMSO >98 G2/AQ3 11.5 Hz, 1H), 7.63-7.45 (m, 2H), 7.45-7.26 (m, 1H), 3.19 (d, J = 4.4 Hz, 3H). 1379

HCl ¹H NMR (300 MHz, DMSO) δ 9.67-9.59 (m, 1H), 9.38 (d, J = 8.3 Hz, 1H), 9.22- 9.10 (m, 1H), 9.03 (d, J = 4.9 Hz, 1H), 8.37 (s, 1H), 8.16 (dd, J = 8.1, 5.6 Hz, 1H), 7.89 (d, J = DMSO >98 G2/AQ3 11.6 Hz, 1H), 7.78 (td, J = 8.9, 6.6 Hz, 1H), 7.54-7.36 (m, 1H), 7.30 (td, J = 8.3, 2.0 Hz, 1H), 3.18 (d, J = 4.4 Hz, 3H). 1380

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.72 (d, J = 1.6 Hz, 1H), 9.25- 9.14 (m, 1H), 8.99 (dd, J = 5.2, Hz, 1H), 8.51 (s, 1H), 8.44 (d, J = 8.7 Hz, 1H), 8.26-8.11 (m, 1H), 7.94 (dd, DMSO >98 G2/AQ3 J = 8.0, 5.2 Hz, 1H), 7.65-7.49 (m, 2H), 7.49- 7.29 (m, 1H), 3.69 (s, 6H). 1381

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.71 (s, 1H), 9.18 (d, J = 8.0 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.49-8.36 (m, 2H), 8.16 (d, J = 8.8 Hz, 1H), 7.99- 7.86 (m, 1H), 7.86-7.72 (m, DMSO >98 G2/AQ3 1H), 7.46 (t, J = 10.2 Hz, 1H), 7.29 (t, J = 8.5 Hz, 1H), 3.69 (s, 6H). 1382

HCl ¹H NMR (300 MHz, DMSO) δ 10.25 (brs, 1H), 9.66 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 8.2 Hz, 1H), 8.94 (dd, J = 5.0, 1.6 Hz, 1H), 8.70 (s, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.16 (dd, J = 8.7, 1.5 Hz, 1H), 7.84 (dd, DMSO >98 G2/AQ3 J = 8.0, 5.1 Hz, 1H), 7.71 (dd, J = 8.0, 1.4 Hz, 1H), 7.65-7.55 (m, 2H), 3.90 (s, 3H), 3.29 (d, J = 4.5 Hz, 3H), 2.64 (s, 3H). 1383

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.18 (brs, 1H), 9.68 (d, J = 1.8 Hz, 1H), 9.17 (d, J = 8.0 Hz, 1H), 8.99 (dd, J = 5.2, 1.4 Hz, 1H), 8.86 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.22 (d, J = DMSO >98 G2/AQ3 8.8 Hz, 1H), 7.97 (dd, J = 8.0, 5.3 Hz, 1H), 7.64-7.49 (m, 2H), 7.49-7.34 (m, 1H), 4.06- 3.92 (m, 2H), 3.73 (t, J = 5.5 Hz, 2H), 3.33 (s, 3H). 1384

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.18 (brs, 1H), 9.67 (d, J = 1.6 Hz, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.80 (s, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.18 (d, J = DMSO >98 G2/AQ3 8.7 Hz, 1H), 7.95 (dd, J = 8.2, 5.2 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 1H), 7.50 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 2.3 Hz, 1H), 4.08-3.94 (m, 3H), 3.73 (t, J = 5.5 Hz, 3H), 3.32 (s, 3H). 1385

2 HCl ¹H NMR (300 MHz, DMSO) δ 10.33 (brs, 1H), 9.70 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.81 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.18 (d, J = DMSO >98 G2/AQ3 8.7 Hz, 1H), 7.95 (dd, J = 8.1, 5.2 Hz, 1H), 7.81 (td, J = 8.9, 6.6 Hz, 1H), 7.49 (ddd, J = 11.5, 9.3, 2.5 Hz, 1H), 7.32 (td, J = 8.5, 2.2 Hz, 1H), 3.96-3.78 (m, 2H), 3.48 (t, J = 6.1 Hz, 2H), 3.27 (s, 3H), 2.14-1.93 (m, 2H). 1386

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.73 (s, 1H), 9.17 (d, J = 8.4 Hz, 1H), 8.99 (s, 1H), 8.52 (s, 1H), 8.43 (d, J = 8.8 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.02-7.90 (m, 1H), 7.87-7.78 (m, 1H), 7.57-7.38 (m, 1H), 7.38-7.24 DMSO >98 G2/AQ3 (m, 1H), 4.31-4.18 (m, 4H), 2.08 (s, 4H). 1387

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.17 (d, J = 8.3 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.24-8.12 (m, 2H), 7.97 (dd, J = 8.0, 5.2 Hz, 1H), 7.81 (td, J = 8.9, 6.6 Hz, 1H), 7.49 (ddd, J = DMSO >98 G2/AQ3 11.6, 9.3, 2.5 Hz, 1H), 7.30 (td, J = 8.4, 2.1 Hz, 1H), 4.16 (brs, 4H), 1.80 (brs, 6H). 1388

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.7 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.01 (dd, J = 5.3, 1.4 Hz, 1H), 8.37- 8.19 (m, 2H), 8.15 (d, J = 8.7 Hz, 1H), 8.02 (dd, J = 8.1, 5.3 Hz, 1H), 7.81 (td, J = 8.9, 6.5 Hz, 1H), 7.48 DMSO >98 G2/AQ3 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.30 (td, J = 8.4, 2.3 Hz, 1H), 4.23-4.12 (m, 4H), 3.90-3.80 (m, 4H). 1389

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.17 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.27-8.13 (m, 2H), 7.97 (dd, J = 8.1, 5.4 Hz, 1H), 7.67-7.48 (m, 2H), 7.41 (ddd, J = 14.7, 9.9, 4.9 DMSO >98 G2/AQ3 Hz, 1H), 4.16 (brs, 4H), 1.80 (brs, 6H). 1390

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.8 Hz, 1H), 9.26 (d, J = 8.3 Hz, 1H), 9.01 (dd, J = 5.3, 1.4 Hz, 1H), 8.36- 8.23 (m, 2H), 8.18 (d, J = 8.7 Hz, 1H), 8.03 (dd, J = 8.0, 5.4 Hz, 1H), 7.64- 7.46 (m, 2H), 7.46-7.29 (m, DMSO >98 G2/AQ3 1H), 4.23-4.16 (m, 4H), 3.85 (d, J = 4.7 Hz, 4H). 1391

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.18 (d, J = 8.2 Hz, 1H), 9.00 (dd, J = 5.2, 1.2 Hz, 1H), 8.62 (s, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.98 (dd, DMSO >98 G2/AQ3 J = 8.0, 5.2 Hz, 1H), 7.64-7.47 (m, 2H), 7.46- 7.27 (m, 1H), 4.26 (t, J = 5.2 Hz, 2H), 3.85 (t, J = 5.3 Hz, 2H), 3.72 (s, 3H), 3.33 (s, 3H). 1392

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.67 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.1 Hz, 1H), 8.99 (d, J = 4.1 Hz, 1H), 8.56 (s, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.96 (dd, J = 8.1, DMSO >98 G2/AQ3 5.2 Hz, 1H), 7.86- 7.70 (m, 1H), 7.55- 7.40 (m, 1H), 7.30 (td, J = 8.5, 2.2 Hz, 1H), 4.36-4.18 (m, 2H), 3.88- 3.77 (m, 2H), 3.72 (s, 3H), 3.33 (s, 3H). 1393

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.7 Hz, 1H), 9.24-9.06 (m, 1H), 8.99 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.40 (d, J = 8.7 Hz, 1H), 8.30-8.14 (m, 1H), 7.93 (dd, J = 8.0, DMSO >98 G2/AQ3 5.2 Hz, 1H), 7.63-7.46 (m, 2H), 7.46-7.25 (m, 1H), 4.22- 4.11 (m, 2H), 3.73 (s, 3H), 3.59 (t, J = 5.9 Hz, 2H), 2.10-1.92 (m, 2H). 1394

2 HCl ¹H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.7 Hz, 1H), 9.11 (d, J = 8.3 Hz, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.46 (s, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.90 DMSO >98 G2/AQ3 (dd, J = 8.1, 5.2 Hz, 1H), 7.80 (td, J = 8.9, 6.6 Hz, 1H), 7.47 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.29 (td, J = 8.4, 2.1 Hz, 1H), 4.22-4.08 (m, 2H), 3.72 (s, 3H), 3.59 (t, J = 5.9 Hz, 2H), 2.10- 1.94 (m, 2H). 1395

HCl ¹H NMR (300 MHz, DMSO) δ 9.97- 9.66 (m, 2H), 9.66-9.58 (m, 1H), 9.17-9.05 (m, 1H), 8.99 (dd, J = 5.2, 1.5 Hz, 1H), 8.66 (d, J = 8.6 Hz, 1H), 8.50 (s, 1H), DMSO >98 G2/AQ3 8.01-7.88 (m, 2H), 7.62 (ddd, J = 9.1, 6.1, 3.1 Hz, 1H), 7.58- 7.36 (m, 2H). 1396

HCl ¹H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.8 Hz, 1H), 9.16 (d, J = 8.3 Hz, 1H), 8.98 (d, J = 3.9 Hz, 1H), 8.58-8.42 (m, 2H), 8.00- 7.82 (m, 2H), 7.69-7.38 (m, 3H), 3.69 (s, 6H). DMSO >98 G2/AQ3

1397

HCl ¹H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 9.68 (d, J = 1.8 Hz, 1H), 9.11 (d, J = 8.0 Hz, 1H), 9.04 (s, 1H), 8.96 (dd, J = 5.1, 1.4 Hz, 1H), 8.41 (dd, J = 8.8, 1.6 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), DMSO >98 AQ4         8.14 (d, J = 8.2 Hz, 2H), 7.90 (d, J = 8.4 Hz, 3H), 3.34 (t, J = 17.1 Hz, 3H). 1398

HCl ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.06 (d, J = 7.9 Hz, 1H), 8.99-8.90 (m, 2H), 8.44 (d, J = 7.2 Hz, 1H), 8.28- 8.17 (m, 3H), 7.94-7.76 (m, 3H), 3.32 (d, J = 4.5 Hz, 3H). DMSO >98 AQ4 1399

HCl ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.65 (d, J = 2.1 Hz, 1H), 9.10-9.00 (m, 1H), 8.96 (dd, J = 5.1, 1.5 Hz, 1H), 8.65 (s, 1H), 8.26-8.17 (m, 1H), 8.16- 8.07 (m, 1H), 7.90 (dd, J = 7.8, 5.3 Hz, 1H), DMSO >98 AQ4 7.77-7.69 (m, 1H), 7.68-7.55 (m, 3H), 3.29 (d, J = 4.6 Hz, 3H). 1400

HCl ¹H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 9.63 (d, J = 1.7 Hz, 1H), 9.04-8.85 (m, 2H), 8.63 (s, 1H), 8.12 (q, J = 8.7 Hz, 2H), 7.83 (dd, J = 7.8, 4.9 Hz, 1H), 7.38- 7.25 (m, 2H), DMSO >98 AQ4 7.25-7.17 (m, 1H), 3.92 (s, 3H). 1401

HCl ¹H NMR (400 MHz, DMSO) δ 10.05 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.04 (d, J = 7.6 Hz, 1H), 8.99-8.92 (m, 1H), 8.89 (s, 1H), 8.41 (d, J = 8.8 Hz, 1H), 8.33- 8.20 (m, 2H), 8.16 DMSO >98 AQ4 (d, J = 8.6 Hz, 1H), 7.94-7.84 (m, 1H), 7.81- 7.68 (m, 1H), 3.32 (d, J = 4.5 Hz, 3H). 1402

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.30 (s, 1H), 9.68 (d, J = 1.8 Hz, 1H), 9.15-9.05 (m, 1H), 8.97 (dd, J = 5.1, 1.4 Hz, 1H), 8.52 (s, 1H), 8.10 (s, 1H), 7.96-7.82 (m, 1H), 7.67-7.55 DMSO >98 AQ5 (m, 1H), 7.42- 7.26 (m, 3H), 3.31 (d, J = 4.5 Hz, 3H), 2.40 (s, 3H). 1403

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.87 (s, 1H), 9.59 (d, J = 1.5 Hz, 1H), 9.00-8.89 (m, 2H), 8.42 (s, 1H), 7.93-7.80 (m, 2H), 7.62- 7.54 (m, 1H), 7.49-7.36 (m, 3H), 3.30 (d, J = 4.6 DMSO >98 AQ5 Hz, 3H), 2.32 (s, 3H). 1404

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.19 (s, 1H), 9.68-9.61 (m, 1H), 9.05-8.98 (m, 1H), 8.94 (dd, J = 5.0, 1.6 Hz, 1H), 8.48 (d, J = 5.7 Hz, 1H), 8.02 (s, 1H), 7.91-7.82 (m, DMSO >98 AQ5 1H), 7.59-7.50 (m, 2H), 7.43- 7.36 (m, 2H), 3.31 (d, J = 4.6 Hz, 3H), 2.40 (s, 3H). 1405

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.69-9.61 (m, 1H), 9.11-9.02 (m, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.05 (s, 1H), 7.89 (dd, J = 8.1, 5.1 Hz, 1H), DMSO >98 AQ5 7.68-7.56 (m, 1H), 7.48-7.38 (m, 1H), 7.33- 7.25 (m, 1H), 3.31 (d, J = 4.6 Hz, 3H), 2.33 (s, 3H). 1406

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 9.63 (dd, J = 2.2, 0.7 Hz, 1H), 9.09-9.00 (m, 1H), 8.95 (dd, J = 5.1, 1.6 Hz, 1H), 8.48 (s, 1H), 8.00 (s, 1H), 7.89 (dd, J = 7.9, 5.2 Hz, 1H), 7.54- 7.35 (m, 3H), DMSO >98 AQ5 3.30 (d, J = 4.6 Hz, 3H), 2.33 (s, 3H). 1407

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.08-8.98 (m, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.46 (s, 1H), 7.98 (s, 1H), 7.87 (dd, J = 8.1, 5.1 Hz, 1H), DMSO >98 AQ5 7.64 (ddt, J = 16.8, 14.3, 5.3 Hz, 2H), 7.40- 7.30 (m, 1H), 3.30 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). 1408

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.92 (s, 1H), 9.61 (d, J = 1.6 Hz, 1H), 9.03-8.97 (m, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.42 (s, 1H), 7.93 (s, 1H), 7.87 (dd, J = 8.1, 5.0 Hz, 1H), 7.44- 7.36 (m, 1H), 7.33-7.23 (m, DMSO >98 AQ5 2H), 3.29 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). 1409

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.11 (s, 1H), 9.64 (d, J = 2.2 Hz, 1H), 9.10-9.03 (m, 1H), 8.96 (dd, J = 5.1, 1.5 Hz, 1H), 8.49 (s, 1H), 8.05-7.94 (m, 3H), 7.94- 7.88 (m, 1H), DMSO >98 AQ5 7.88-7.82 (m, 1H), 7.77 (t, J = 7.7 Hz, 1H), 3.31 (d, J = 4.5 Hz, 3H), 2.40 (s, 3H). 1410

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.22 (s, 1H), 9.67 (d, J = 1.6 Hz, 1H), 9.14-9.07 (m, 1H), 8.97 (dd, J = 5.1, 1.5 Hz, 1H), 8.52 (s, 1H), 8.10-8.00 (m, 3H), 7.91 (dd, J = 7.9, 5.3 DMSO >98 AQ5 Hz, 1H), 7.75- 7.67 (m, 2H), 3.31 (d, J = 4.5 Hz, 3H), 2.39 (s, 3H). 1411

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.20-9.85 (m, 1H), 9.58 (s, 1H), 8.94-8.85 (m, 2H), 8.38 (s, 1H), 7.88-7.76 (m, 2H), 7.54- 7.44 (m, 1H), 7.24-7.16 (m, 2H), 7.12 (td, DMSO >98 AQ5 J = 7.4, 0.9 Hz, 1H), 3.76 (s, 3H), 3.31 (d, J = 4.5 Hz, 3H), 2.24 (s, 3H). 1412

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.69-9.61 (m, 1H), 9.01 (d, J = 7.8 Hz, 1H), 8.93 (dd, J = 5.0, 1.6 Hz, 1H), 8.49 (s, 1H), 8.06 (s, 1H), 7.83 DMSO >98 AQ5 (dd, J = 8.0, 5.1 Hz, 1H), 7.51- 7.41 (m, 1H), 7.13-7.05 (m, 1H), 7.05-6.95 (m, 2H), 3.81 (d, J = 10.8 Hz, 3H), 3.31 (d, J = 4.6 Hz, 3H), 2.41 (s, 3H). 1413

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.09 (s, 1H), 9.60 (s, 1H), 9.00- 8.88 (m, 2H), 8.42 (s, 1H), 7.94 (s, 1H), 7.86-7.78 (m, 1H), 7.48- 7.39 (m, 2H), 7.16-7.06 (m, 2H), 3.85 (s, 3H), DMSO >98 AQ5 3.31 (d, J = 4.6 Hz, 3H), 2.43 (s, 3H). 1414

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.63 (s, 1H), 9.05- 8.91 (m, 2H), 8.36 (s, 1H), 8.10- 7.99 (m, 1H), 7.91-7.80 (m, 1H), 7.59-7.50 (m, 2H), 7.44- 7.32 (m, 2H), 3.27 DMSO >98 AQ5 (d, J = 4.5 Hz, 3H), 2.45 (s, 3H). 1415

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.01 (s, 1H), 9.65 (s, 1H), 9.10- 8.99 (m, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H), 8.09 (s, 1H), 7.97-7.83 (m, 1H), 7.61-7.41 (m, 2H), 7.31 (td, DMSO >98 AQ5 J = 8.4, 2.2 Hz, 1H), 3.26 (d, J = 4.5 Hz, 3H), 2.35 (s, 3H). 1416

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.01-9.69 (m, 1H), 9.61 (s, 1H), 8.94 (m, J = 5.0 Hz, 2H), 8.36 (s, 1H), 7.99 (s, 1H), 7.92- 7.81 (m, 1H), 7.71-7.57 (m, 2H), 7.41-7.31 (m, 1H), 3.26 (d, J = 4.5 Hz, 3H), DMSO >98 AQ5 2.47 (s, 3H). 1417

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.63 (d, J = 1.8 Hz, 1H), 9.08-8.89 (m, 2H), 8.40 (s, 1H), 8.02 (s, 1H), 7.92-7.81 (m, 1H), 7.44-7.25 (m, 3H), 3.27 (d, J = 4.5 Hz, 3H), 2.49 (s, 3H). DMSO >98 AQ5 1418

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.99 (s, 1H), 9.62 (s, 1H), 8.95 (d, J = 5.0 Hz, 2H), 8.27 (s, 1H), 8.11- 7.99 (m, 1H), 7.89-7.80 (m, 1H), 7.53-7.45 (m, 1H), 7.24 (dd, J = 7.4, 1.7 DMSO >98 AQ5 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.12 (td, J = 7.4, 0.9 Hz, 1H), 3.74 (d, J = 8.9 Hz, 3H), 3.26 (d, J = 4.6 Hz, 3H), 2.28 (s, 3H). 1419

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.30 (s, 1H), 9.72 (d, J = 1.6 Hz, 1H), 9.20-9.10 (m, 1H), 8.98 (dd, J = 5.1, 1.5 Hz, 1H), 8.45 (s, 1H), 8.21 (s, 1H), 7.91 (dd, J = 8.0, 5.1 Hz, 1H), 7.48-7.40 (m, 1H), 7.08-7.01 (m, 3H), 3.84 (s, DMSO >98 AQ5 3H), 3.26 (d, J = 4.5 Hz, 3H), 2.45 (s, 3H). 1420

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.08-9.71 (m, 1H), 9.58 (d, J = 2.0 Hz, 1H), 8.96-8.83 (m, 2H), 8.31 (s, 1H), 7.94 (s, 1H), 7.87- 7.79 (m, 1H), 7.47-7.39 (m, 2H), 7.10 (d, J = DMSO >98 AQ5 8.8 Hz, 2H), 3.84 (s, 3H), 3.27 (d, J = 4.5 Hz, 3H), 2.47 (s, 3H). 1421

2 HCl 1H NMR (400 MHz, DMSO) δ 9.69-9.63 (m, 1H), 9.10-8.93 (m, 3H), 8.12 (d, J = 8.4 Hz, 1H), 7.90-7.82 (m, 2H), 7.68-7.58 (m, 1H), 7.56- 7.48 (m, 1H), 7.30-7.22 (m, 1H), 3.35 (d, J = 4.6 Hz, 3H), 2.73 DMSO >98 AQ4 (s, 3H). 1422

2 HCl 1H NMR (400 MHz, DMSO) δ 9.62 (s, 1H), 8.95 (d, J = 5.0 Hz, 3H), 8.03 (s, 1H), 7.85 (t, J = 9.9 Hz, 2H), 7.44- 7.34 (m, 1H), 7.17 (dd, J = 8.2, 2.2 Hz, 2H), 3.34 (d, J = 4.5 Hz, 3H), 2.73 (s, 3H). DMSO >98 AQ4 1423

2 HCl 1H NMR (400 MHz, DMSO) δ 9.62 (d, J = 2.1 Hz, 1H), 9.00- 8.75 (m, 3H), 8.08-7.99 (m, 1H), 7.99-7.93 (m, 1H), 7.93-7.79 (m, 3H), 7.79- 7.73 (m, 2H), 3.34 (d, J = 4.5 Hz, 3H), 2.70 (s, 3H). DMSO >98 AQ4 1424

2 HCl 1H NMR (400 MHz, DMSO) δ 9.61 (s, 1H), 8.99- 8.63 (m, 3H), 8.07-7.98 (m, 3H), 7.89-7.78 (m, 2H), 7.65-7.59 (m, 2H), 3.33 (d, J = 4.5 Hz, 3H), 2.70 (s, 3H). DMSO >98 AQ4 1425

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.49 (s, 1H), 9.56 (s, 1H), 9.19 (s, 1H), 8.95 (d, J = 5.3 Hz, 1H), 8.83 (d, J = 5.5 Hz, 1H), 8.73 (d, J = 6.4 Hz, 1H), 8.41 (d, J = 5.6 Hz, 1H), 8.26 DMSO >98 Method AQ3 (s, 1H), 8.09 (s, 1H), 8.02-7.91 (m, 2H), 7.85 (s, 1H), 7.78-7.68 (m, 1H), 7.61- 7.51 (m, 1H), 7.48-7.36 (m, 2H), 5.36 (s, 2H). 1426

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.53 (s, 1H), 9.67 (d, J = 1.8 Hz, 1H), 9.32 (dd, J = 5.8, 4.1 Hz, 1H), 8.97 (dd, J = 5.4, 1.4 Hz, 1H), 8.75 (d, J = 8.7 Hz, 1H), 8.35 (t, J = 7.9 DMSO >98 Method AQ3 Hz, 1H), 8.24 (d, J = 13.5 Hz, 1H), 8.03 (dd, J = 8.1, 5.4 Hz, 1H), 7.92 (dd, J = 13.5, 4.8 Hz, 2H), 7.85-7.73 (m, 2H), 7.53-7.43 (m, 1H), 7.36-7.25 (m, 1H), 5.40 (d, J = 5.6 Hz, 2H), 2.85 (s, 3H). 1427

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 9.64 (d, J = 1.7 Hz, 1H), 9.26 (d, J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.71 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 18.0 Hz, 2H), DMSO >98 Method AQ3 8.04-7.84 (m, 3H), 7.74 (dd, J = 7.8, 6.0 Hz, 2H), 7.62-7.33 (m, 3H), 5.38 (d, J = 5.5 Hz, 2H), 2.84 (s, 3H). 1428

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 8.1 Hz, 1H), 8.95 (dd, J = 5.3, 1.4 Hz, 1H), 8.69 (d, J = 8.7 Hz, 1H), 8.41- 8.22 (m, 2H), DMSO >98 Method AQ3 8.09 (dd, J = 8.7, 1.8 Hz, 1H), 8.01- 7.84 (m, 4H), 7.74 (d, J = 7.8 Hz, 1H), 7.46- 7.33 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.83 (s, 3H). 1429

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 9.62 (s, 1H), 9.19 (d, J = 7.8 Hz, 1H), 8.93 (d, J = 4.6 Hz, 1H), 8.68 (d, J = 8.6 Hz, 1H), 8.26 (dd, J = 28.0, 20.1 Hz, 2H), 8.04-7.80 DMSO >98 Method AQ3 (m, 3H), 7.72 (d, J = 7.8 Hz, 1H), 7.64-7.50 (m, 2H), 7.46-7.33 (m, 1H), 5.33 (d, J = 5.3 Hz, 2H), 2.81 (s, 3H). 1430

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.40 (s, 1H), 9.66 (d, J = 1.8 Hz, 1H), 9.31 (d, J = 8.2 Hz, 1H), 8.96 (dd, J = 5.4, 1.4 Hz, 1H), 8.73 (d, J = 8.7 Hz, 1H), 8.33 (t, J = 7.9 Hz, 1H), DMSO >98 Method AQ3 8.23 (s, 1H), 8.03 (dd, J = 8.1, 5.4 Hz, 1H), 7.93 (dd, J = 11.7, 8.3 Hz, 2H), 7.76 (d, J = 7.9 Hz, 1H), 7.70-7.60 (m, 1H), 7.54- 7.35 (m, 2H), 5.38 (d, J = 5.5 Hz, 2H), 2.85 (s, 3H). 1431

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H), 9.61 (s, 1H), 9.22 (t, J = 7.3 Hz, 1H), 8.98-8.90 (m, 1H), 8.65 (dd, J = 8.6, 3.0 Hz, 1H), 8.36- 8.26 (m, 2H), 8.13 (dd, J = 8.7, 1.9 Hz, 1H), 8.05-7.95 (m, DMSO >98 Method AQ3 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.76-7.64 (m, 3H), 7.43-7.33 (m, 1H), 5.33 (s, 2H), 2.82 (s, 3H). 1432

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.26 (s, 1H), 9.62 (d, J = 1.8 Hz, 1H), 9.23 (d, J = 8.2 Hz, 1H), 8.94 (dd, J = 5.4, 1.5 Hz, 1H), 8.78 (s, 1H), 8.30 (t, J = 7.9 Hz, 1H), 8.20-8.15 DMSO >98 Method AQ3 (m, 1H), 8.10 (d, J = 8.7 Hz, 1H), 8.00 (dd, J = 7.9, 5.3 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.80- 7.71 (m, 2H), 7.59-7.50 (m, 1H), 7.47-7.35 (m, 2H), 5.35 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). 1433

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.39 (s, 1H), 9.61 (d, J = 1.7 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 9.01 (d, J = 1.8 Hz, 1H), 8.93 (dd, J = 5.3, 1.5 Hz, 1H), 8.38 (dd, J = 8.8, 1.9 Hz, 1H), 8.29 (t, J = 7.9 Hz, 1H), DMSO >98 Method AQ3 8.09 (d, J = 8.7 Hz, 1H), 7.97 (dd, J = 8.1, 5.3 Hz, 1H), 7.92-7.80 (m, 3H), 7.72 (d, J = 7.8 Hz, 1H), 7.66-7.57 (m, 1H), 7.35-7.26 (m, 1H), 5.36 (d, J = 5.5 Hz, 2H), 2.81 (s, 3H).

1434

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.60 (d, J = 1.9 Hz, 1H), 9.19 (d, J = 8.2 Hz, 1H), 9.01-8.89 (m, 2H), 8.36-8.25 (m, 2H), 8.10 (d, J = 8.7 Hz, 1H), 8.05-7.94 (m, DMSO >98 Method AQ3 3H), 7.88 (dd, J = 12.8, 5.4 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.46- 7.35 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). 1435

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.28 (s, 1H), 9.63 (d, J = 1.8 Hz, 1H), 9.24 (d, J = 8.2 Hz, 1H), 8.95 (d, 1H), 8.83 (s, 1H), 8.30 (t, J = 7.9 Hz, 1H), 8.19 (dd, J = 8.7, 1.8 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 8.00 (dd, DMSO >98 Method AQ3 J = 8.1, 5.4 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.64- 7.51 (m, 2H), 7.46-7.37 (m, 1H), 5.36 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). 1436

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 9.56 (d, J = 1.6 Hz, 1H), 9.06 (d, J = 8.0 Hz, 1H), 8.88 (dd, J = 5.2, 1.5 Hz, 1H), 8.75 (s, 1H), 8.25- 8.13 (m, 2H), 8.04 (d, J = 8.7 DMSO >98 Method AQ3 Hz, 1H), 7.89 (dd, J = 7.8, 5.3 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70-7.60 (m, 2H), 7.53-7.44 (m, 1H), 7.38 (ddd, J = 12.2, 8.4, 3.5 Hz, 1H), 5.27 (d, J = 5.3 Hz, 2H), 2.77 (s, 3H). 1437

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.60 (d, J = 1.7 Hz, 1H), 9.19 (d, J = 8.1 Hz, 1H), 8.93 (dd, J = 5.4, 1.5 Hz, 1H), 8.75 (s, 1H), 8.29 (t, J = 7.9 Hz, 1H), 8.17-8.05 DMSO >98 Method AQ3 (m, 2H), 7.98 (dd, J = 8.0, 5.4 Hz, 1H), 7.83 (ddd, J = 15.5, 8.4, 6.0 Hz, 2H), 7.72 (d, J = 7.8 Hz, 1H), 7.54- 7.44 (m, 1H), 7.38-7.28 (m, 1H), 5.33 (d, J = 5.5 Hz, 2H), 2.81 (s, 3H). 1438

4 HCl ¹H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 9.62 (d, J = 1.7 Hz, 1H), 9.21 (d, J = 8.1 Hz, 1H), 9.03 (d, J = 1.7 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.39- 8.26 (m, 2H), DMSO >98 Method AQ3 8.15-8.04 (m, 2H), 8.00-7.81 (m, 3H), 7.76- 7.59 (m, 2H), 5.36 (d, J = 5.5 Hz, 2H), 2.82 (s, 3H). 1439

3 HCl ¹H NMR (400 MHz, DMSO) δ 10.29 (s, 1H), 9.53 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 8.0 Hz, 1H), 8.93 (dd, J = 5.3, 1.4 Hz, 1H), 8.78 (d, J = 2.5 Hz, 2H), 8.31 (t, J = 7.8 Hz, 1H), DMSO >98 Method AQ3 8.13 (q, J = 8.7 Hz, 2H), 8.04- 7.89 (m, 2H), 7.87-7.68 (m, 2H), 7.50 (ddd, J = 11.6, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 1.9 Hz, 1H), 5.30 (d, J = 5.4 Hz, 2H). 1440

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.41 (s, 1H), 9.63 (d, J = 1.7 Hz, 1H), 9.15 (d, J = 8.1 Hz, 1H), 8.97 (dd, J = 5.2, 1.4 Hz, 1H), 8.83 (s, 1H), 8.20 (s, 2H), 7.97 (dd, J = 8.0, 5.3 Hz, 1H), 7.73- 7.56 (m, 2H), DMSO >98 Method AQ3 7.54-7.28 (m, 4H), 5.03 (d, J = 5.7 Hz, 2H). 1441

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.59 (d, J = 1.6 Hz, 1H), 9.07-8.94 (m, 2H), 8.84 (s, 1H), 8.76 (s, 1H), 8.22-8.13 (m, 2H), 7.96 (dd, J = 8.0, 5.3 Hz, 1H), 7.66 (ddd, J = 9.2, 6.1, 3.2 Hz, 1H), 7.53-7.32 (m, DMSO >98 Method AQ3 2H), 1.69 (s, 9H). 1442

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.93 (s, 1H), 9.62 (d, J = 1.6 Hz, 1H), 9.06-8.87 (m, 2H), 8.39 (s, 1H), 8.06-7.98 (m, 3H), 7.87 (dd, J = 8.0, 5.1 Hz, 1H), 7.77-7.67 (m, 2H), 3.26 (d, J = DMSO >98 Method AQ3 4.6 Hz, 3H), 2.45 (s, 3H). 1443

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.98 (s, 1H), 9.64 (s, 1H), 8.99 (dd, J = 27.3, 6.4 Hz, 2H), 8.41 (s, 1H), 8.10-7.93 (m, 3H), 7.88 (dd, J = 7.7, 6.0 Hz, 2H), 7.76 (t, J = 7.8 Hz, 1H), 3.27 (d, J = 4.5 Hz, 3H), 2.46 (s, 3H). DMSO >98 Method AQ3 1444

2 HCl ¹H NMR (400 MHz, DMSO) δ 9.76-9.69 (m, 1H), 9.37 (t, J = 5.4 Hz, 1H), 8.99 (dd, J = 11.7, 7.5 Hz, 1H), 8.81 (dt, J = 7.9, 4.0 Hz, 1H), 8.70 (t, J = 7.3 Hz, 1H), 8.52 (d, J = 9.2 Hz, 1H), 8.35-8.27 (m, 1H), 8.10 (dd, J = 12.8, 7.3 DMSO >98 Method AQ3, F, G2 (reflux) Hz, 1H), 8.01- 7.90 (m, 2H), 7.77-7.71 (m, 1H), 7.50-7.37 (m, 3H), 7.06- 7.01 (m, 1H), 5.19 (t, J = 17.9 Hz, 2H), 3.88 (s, 3H). 1445

2 HCl 1H NMR (DMSO- d6) ppm 9.73 (s, 1H), 9.37 (brd, J = 8.08 Hz, 1H), 8.97 (brd, J = 5.24 Hz, 1H), 8.77 (brs, 1H), 8.20 (d, J = 8.48 Hz, 1H), 8.10-8.07 (brm, 1H), 7.63- 7.55 (brm, 2H), DMSO >98 AQ6 7.47 (d, J = 8.48 Hz, 1H), 7.32 (brm, 1H), 3.20 (d, J = 4.20 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. 1446

3 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.76 Hz, 1H), 9.39 (brd, J = 8.16 Hz, 1H), 8.98 (dd, J = 5.44, 1.20 Hz, 1H), 8.80 ′brs, 1H), 8.22 (d, J = 8.48 Hz, 1H), 8.12-8.08 (brm, 1H), 7.57- DMSO >98 AQ6 7.51 (m, 1H), 7.46-7.35 (m, 4H), 3.21 (d, J = 4.32 Hz, 3H), 2.55 (s, 3H). The 1H of 3HCl was not observed. 1447

3 HCl 1H NMR (DMSO- d6) ppm 9.72 (d, J = 1.68 Hz, 1H), 9.26 (brd, J = 8.48 Hz, 1H), 8.91 (dd, J = 5.28, 1.40 Hz, 1H), 8.69 (brs, 1H), 8.18 (d, J = 8.56 Hz, 1H), 8.00-7.96 (brm, 1H), 7.53- DMSO >98 AQ6 7.49 (m, 2H), 7.44 (d, J = 8.56 Hz, 1H), 7.38- 7.33 (m, 2H), 3.20 (d, J = 4.40 Hz, 3H), 2.63 (s, 3H). The 1H of 3HCl was not observed. 1448

2 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.44 Hz, 1H), 9.36 (brd, J = 7.88 Hz, 1H), 8.96 (d, J = 5.04 Hz, 1H), 8.77 (brs, 1H), 8.21 (d, J = 8.56 Hz, 1H), 8.07 (brm, 1H), 7.48 (d, J = 8.56 Hz, 1H), 7.38- 7.32 (m, 1H), DMSO >98 AQ6 7.27-7.22 (m, 2H), 3.20 (d, J = 4.4 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. 1449

3 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.32 (brd, J = 7.56 Hz, 1H), 8.94 (brd, J = 5.48 Hz, 1H), 8.74 (brs, 1H), 8.20 (d, J = 8.56 Hz, 1H), 8.08-8.02 (m, 1H), 7.60- DMSO >98 AQ6 7.54 (m, 1H), 7.47 (d, J = 7.35-7.27 (m, 3H), 3.20 (d, J = 4.4 Hz, 3H), 2.65 (s, 3H). The 1H of 3HCl was not observed. 1450

2 HCl 1H NMR (DMSO- d6) ppm 9.74 (d, J = 1.76 Hz, 1H), 9.37 (brd, J = 8.16 Hz, 1H), 8.97 (brdd, J = 5.44, 1.24 Hz, 1H), 8.79 (brs, 1H), 8.22 (d, J = 8.52 Hz, 1H), 8.10-8.06 (brm, 1H), 7.48-7.35 (m, 4H), 3.21 DMSO >98 AQ6 (d, J = 4.36 Hz, 3H), 2.56 (brs, 3H). The 1H of 2HCl was not observed. 1451

3 HCl 1H NMR (DMSO- d6) ppm 9.74 (d, J = 1.52 Hz, 1H), 9.37 (d, J = 8.08 Hz, 1H), 8.97 (dd, J = 5.54, 1.16 Hz, 1H), 8.80 (brs, 1H), 8.23 (d, J = 8.52 Hz, 1H), 8.10- 8.07 (m, 1H), DMSO >98 AQ6 7.60-7.53 (m, 1H), 7.48 (d, J = 8.52 Hz, 1H), 7.41- 7.36 (m, 1H), 7.30-7.26 (m, 1H), 3.21 (d, J = 4.36 Hz, 3H), 2.56 (s, 3H). The 1H of 3HCl was not observed. 1452

3 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.68 Hz, 1H), 9.26 (brd, J = 7.8 Hz, 1H), 8.91 (brdd, J = 5.28, 1.36 Hz, 1H), 8.71 (brs, 1H), 8.21 (d, J = 8.52 Hz, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.99- 7.95 (m, 1H), DMSO >98 AQ6 7.69 (d, 8.4 Hz, 2H),7.46 (d, J = 8.52 Hz, 1H), 3.20 (d, J = 4.4 Hz, 3H), 2.63 (s, 3H). The 1H of 3HCl was not observed. 1453

2 HCl 1H NMR (DMSO- d6) ppm 9.73 (d, J = 1.72 Hz, 1H), 9.33 (brd, J = 7.64 Hz, 1H), 8.95 (brd, J = 5.28 Hz, 1H), 8.76 (brs, 1H), 8.22 (d, J = 8.48 Hz, 1H), 8.05 (brm, J = 7.64, 5.28 Hz, 1H), 7.98-7.93 (m, 2 H), 7.84-7.81 (m, 1H), 7.74 (dd, J = 7.84, DMSO >98 AQ6 7.76 Hz, 1H), 7.49 (d, J = 8.84 Hz, 1H), 3.21 (d, J = 4.4 Hz, 3H), 2.63 (s, 3H). The 1H of 2HCl was not observed. 1454

2 HCl ¹H NMR (DMSO- d₆) ppm 9.72 (d, J = 1.76 Hz, 1H), 9.42 (brd, J = 8.00 Hz, 1H), 9.00 (d, J = 5.52 Hz, 1H), 8.83 (bsr, 1H), 8.22 (d, J = 8.56 Hz, 1H), 8.13 (brm, 1H), 7.55-7.51 (m, 2H), DMSO >98 AQ6 7.48-7.43 (m, 4H), 3.21 (brd, J = 4.16 Hz, 3H), 2.64 (s, 3H). The 1H of 2HCl was not observed. 1455

2 HCl ¹H NMR (DMSO- d₆) ppm 9.72 (s, 1H), 9.33 (d, J = 8.24 Hz, 1H), 8.96 (d, J = 5.40 Hz, 1H), 8.75 (brs, 1H), 8.17 (d, J = 8.60 Hz, 1H), 8.06 (brm, 1H), 7.45 (d, J = 8.80 Hz, 1H), 7.40 (d, J = 8.64 Hz, 2H), 7.08 (d, DMSO >98 AQ6 J = 8.64 Hz, 2H), 3.84 (s, 3H), 3.20 (d, J = 4.20 Hz, 3H), 2.66 (s, 3H). The 1H of 2HCl was not observed. 1456

2 HCl ¹H NMR (DMSO- d₆) ppm 9.72 (d, J = 1.64 Hz, 1H), 9.38 (d, J = 8.04 Hz, 1H), 8.98 (dd, J = 5.48, 1.24 Hz, 1H), 8.79 (brs, 1H), 8.20 (d, J = 8.52 Hz, 1H), 8.12-8.09 (m, 1H), 7.48-7.42 (m, 2H), 7.04-6.97 (m, 3H), 3.82 (s, 3H), 3.21 (d, J = DMSO >98 AQ6 4.28 Hz, 3H), 2.65 (s, 3H). The 1H of 2HCl was not observed. 1457

2 HCl ¹H NMR (DMSO- d₆) ppm 9.71 (d, J = 1.32 Hz, 1H), 9.40 (d, J = 7.64 Hz, 1H), 8.99 (dd, J = 5.52, 1.16 Hz, 1H), 8.82 (brs, 1H), 8.17 (d, J = 8.48 Hz, 1H), 8.13 (m, 1H), 7.47-7.43 (m, DMSO >98 AQ6 1H), 7.37 (d, J = 8.48 Hz, 1H), 7.22-7.16 (m, 2H), 7.11-7.07 (m, 1H), 3.73 (s, 3H), 3.21 (d, J = 4.12 Hz, 3H), 2.47 (s, 3H). The 1H of 2HCl was not observed. 1458

2 HCl ¹H NMR (DMSO- d₆) ppm 9.57 (d, J = 1.88 Hz, 1H), 8.93 (dd, J = 4.88, 1.56 Hz, 1H), 8.87 (brd, J = 6.52 Hz, 1H), 7.95 (d, J = 8.36 Hz, 1H), 7.84 (d, J = 8.36 Hz, 1H), 7.81 (m, DMSO >98 AQ6 1H), 7.34 (d, J = 8.72 Hz, 2H), 7.11 (d, J = 8.72 Hz, 2H), 3.84 (s, 3H), 3.34 (d, J = 4.56 Hz, 3H), 2.72 (s, 3H). The 1H of 2HCl and NH- were not observed. 1459

2 HCl ¹H NMR (DMSO- d₆) ppm 9.59 (s, 1H), 8.94 (dd, J = 4.92, 1.48 Hz, 1H), 8.89 (br, 1H), 7.98 (d, J = 8.48 Hz, 1H), 7.86 (d, J = 8.48 Hz, 1H), 7.82 (m, 1H), 7.46 (t, J = 7.96 Hz, 1H), DMSO >98 AQ6 7.06-7.03 (m, 1H), 6.98-6.94 (m, 2H), 3.83 (s, 3H), 3.34 (d, J = 4.56 Hz, 3H), 2.72 (s, 3H). The 1H of 2HCl and NH- were not observed. 1460

¹H NMR (300 MHz, DMSO) δ 9.60 (s, 1H), 8.84- 8.57 (m, 3H), 8.30 (d, J = 7.0 Hz, 1H), 8.18 (d, J = 8.8 Hz, 1H), 8.12-7.93 (m, 4H), 7.85 (dd, J = 8.7, 1.5 Hz, 1H), 7.60-7.46 (m, 1H), 4.85-4.58 DMSO 100 AQ1 366 (M + 1) Method A (Formic acid) (m, 1H), 1.37 (d, J = 6.5 Hz, 6H). 1461

HCl ¹H NMR (300 MHz, DMSO) δ 9.81 (s, 1H), 9.60 (s, 1H), 8.95 (s, 3H), 8.39 (d, J = 8.9 Hz, 1H), 8.19 (s, 1H), 7.96-7.73 (m, 3H), 7.68- 7.55 (m, 1H), 7.39-7.25 (m, 1H), 4.99-4.81 (m, 1H), 1.42 (d, J = 6.5 Hz, 6H). DMSO 100 AQ1 359 (M + 1) Method A (Formic acid) 1462

¹H NMR (300 MHz, DMSO) δ 9.43 (s, 1H), 8.75- 8.47 (m, 3H), 8.29 (d, J = 7.2 Hz, 1H), 7.79 (d, J = 7.1 Hz, 1H), 7.72- 7.54 (m, 2H), 7.48 (dd, J = 7.8, 4.9 Hz, 1H), 7.44-7.32 (m, 1H), 7.30-7.12 (m, 1H), 3.32 (s, 3H), 3.16 (d, J = 4.3 Hz, 3H). DMSO 100 AQ1 349 (M + 1) Method A (Formic acid) 1463

1H NMR (300 MHz, DMSO) δ 9.68 (dd, J = 2.1, 0.8 Hz, 1H), 8.86- 8.78 (m, 1H), 8.74 (dd, J = 4.8, 1.7 Hz, 1H), 8.34-8.25 (m, 2H), 8.09-8.02 (m, 1H), 7.80 (d, J = 8.9 Hz, 2H), 7.60 DMSO 99 Method AQ2 344.0 (M + 1) Method C (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 7.09 (d, J = 8.9 Hz, 2H), 4.31 (s, 3H), 3.83 (s, 3H). 1464

1H NMR (300 MHz, DMSO) δ 9.67 (d, J = 2.1 Hz, 1H), 8.82 (d, J = 7.9 Hz, 1H), 8.74 (dd, J = 4.8, 1.7 Hz, 1H), 8.46 (d, J = 1.7 Hz, 1H), 8.36 (dd, J = 8.8, 2.2 Hz, 1H), 8.15-7.94 (m, 5H), 7.60 (ddd, J = DMSO 99 Method AQ2 338.9 (M + 1) Method C 8.0, 4.8, 0.8 Hz, 1H), 4.31 (s, 3H). 1465

2 HCl 1H NMR (300 MHz, DMSO) δ 9.71 (d, J = 1.8 Hz, 1H), 9.15 (d, J = 8.0 Hz, 1H), 8.90 (dd, J = 5.2, 1.4 Hz, 1H), 8.58 (s, J = 1.8 Hz, 1H), 8.48 (d, J = 1.6 Hz, 1H), 8.43 DMSO 99 Method AQ2 359.0 (M + 1) Method C (dd, J = 8.7, 2.2 Hz, 1H), 8.32 (dd, J = 7.8, 0.9 Hz, 1H), 8.28 (dd, J = 8.2, 2.2 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.92 (dd, J = 8.0, 5.2 Hz, 1H), 7.81 (t, J = 8.0 Hz, 1H), 4.34 (s, 3H). 1466

2 HCl 1H NMR (300 MHz, DMSO) δ 9.71 (d, J = 2.0 Hz, 1H), 9.12 (dd, J = 8.0, 1.4 Hz, 1H), 8.89 (dd, J = 5.2, 1.5 Hz, 1H), 8.49 (d, J = 1.6 Hz, 1H), 8.42 (dd, J = 8.8, 2.2 Hz, 1H), 8.34 (d, J = 9.0 Hz, 2H), DMSO 99 Method AQ2 359.0 (M + 1) Method C 8.14 (dd, J = 9.2, 2.4 Hz, 3H), 7.88 (dd, J = 7.8, 5.5 Hz, 1H), 4.34 (s, 3H). 1467

2 HCl 1H NMR (300 MHz, DMSO) δ 9.36 (s, 1H), 9.00 (d, J = 6.5 Hz, 2H), 8.78 (d, J = 4.5 Hz, 2H), 8.58 (s, 1H), 8.06 (s, 2H), 7.75 (dd, J = 15.6, 8.9 Hz, 1H), 7.47 (ddd, J = 11.7, 9.4, 2.6 Hz, DMSO 99 Method AQ2 349.6 (M + 1) Method C 1H), 7.31 (td, J = 8.4, 2.7 Hz, 1H), 3.22 (d, J = 4.2 Hz, 3H).

1468

3 HCl 1H NMR (300 MHz, DMSO) δ 9.97 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.0 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.76 (d, J = 0.7 Hz, 1H), 8.41-8.05 (m, DMSO 99 Method AQ2 332.4 (M + 1) Method C 4H), 7.89 (dd, J = 7.1, 4.8 Hz, 1H), 7.59 (ddd, J = 7.1, 4.9, 1.8 Hz, 1H), 3.27 (d, J = 4.3 Hz, 3H). 1469

2 HCl 1H NMR (300 MHz, DMSO) δ 10.04 (s, 1H), 9.65 (d, J = 1.5 Hz, 1H), 9.06 (d, J = 7.3 Hz, 1H), 8.95 (dd, J = 5.1, 1.5 Hz, 1H), 8.71 (s, 1H), 8.19 (s, 2H), 7.89 (dd, J = 7.6, 5.1 DMSO 95 Method AQ2 365.3 (M + 1) Method C Hz, 1H), 7.76- 7.61 (m, 2H), 7.42 (td, J = 7.9, 0.9 Hz, 1H), 3.27 (d, J = 4.4 Hz, 3H). 1470

2 HCl 1H NMR (300 MHz, DMSO) δ 10.03 (s, 1H), 9.63 (d, J = 1.5 Hz, 1H), 9.04 (d, J = 7.9 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.68 (s, 1H), 8.16 (s, 2H), 7.88 (dd, J = 7.6, 5.1 DMSO 94 Method AQ2 365.3 (M + 1) Method C Hz, 1H), 7.74 (t, J = 8.5 Hz, 1H), 7.67 (dd, J = 10.8, 2.0 Hz, 1H), 7.51 (dd, J = 8.3, 1.6 Hz, 1H), 3.27 (d, J = 4.4 Hz, 3H). 1471

2 HCl 1H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.07 (d, J = 7.9 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.75 (s, 1H), 8.18 (s, 2H), 8.09 (d, J = 11.1 Hz, 1H), 7.92 DMSO 96 Method AQ2 356.4 (M + 1) Method C (d, J = 4.0 Hz, 3H), 3.27 (d, J = 4.4 Hz, 3H). 1472

2 HCl 1H NMR (300 MHz, DMSO) δ 10.01 (s, 1H), 9.63 (d, J = 1.5 Hz, 1H), 9.03 (d, J = 7.8 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.73 (s, 1H), 8.25- 8.12 (m, 3H), 7.93-7.76 (m, 4H), 7.63 (d, J = DMSO 95 Method AQ2 374.4 (M + 1) Method C 0.8 Hz, 1H), 3.28 (d, J = 4.4 Hz, 3H). 1473

2 HCl 1H NMR (300 MHz, DMSO) δ 9.97 (s, 1H), 9.61 (d, J = 2.1 Hz, 1H), 8.98 (d, J = 4.6 Hz, 1H), 8.93 (dd, J = 5.1, 1.5 Hz, 1H), 8.68- 8.60 (m, 1H), 8.13 (d, J = 6.1 Hz, 2H), 7.85 (dd, DMSO 95 Method AQ2 377.5 (M + 1) Method C J = 7.7, 5.2 Hz, 1H), 7.63 (t, J = 8.3 Hz, 1H), 7.37- 7.23 (m, 2H), 3.27 (d, J = 4.5 Hz, 3H), 2.56 (s, J = 5.2 Hz, 3H). 1474

2 HCl 1H NMR (300 MHz, DMSO) δ 9.98 (s, 1H), 9.64 (d, J = 1.6 Hz, 1H), 9.06 (d, J = 8.8 Hz, 1H), 8.94 (dd, J = 5.1, 1.5 Hz, 1H), 8.75 (s, 1H), 8.26-8.11 (m, 2H), 8.04- 7.85 (m, 5H), 3.35 (s, 3H), 3.27 (d, J = 4.1 Hz, DMSO 96 Method AQ2 409.5 (M + 1) Method C 3H). 1475

2 HCl 1H NMR (300 MHz, DMSO) δ 10.25 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 7.1 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.79 (s, 1H), 8.31 (dd, J = 8.8, 1.5 Hz, 1H), 8.17 DMSO 99 Method AQ2 357.5 (M + 1) Method C (d, J = 8.5 Hz, 1H), 7.84 (dd, J = 7.5, 4.8 Hz, 1H), 7.51 (d, J = 1.8 Hz, 1H), 7.40 (dd, J = 8.2, 1.9 Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 6.10 (s, 2H), 3.29 (d, J = 4.3 Hz, 3H). 1476

2 HCl 1H NMR (300 MHz, DMSO) δ 10.26 (s, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.01 (d, J = 8.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.77 (s, 1H), 8.31 (dd, J = 8.8, 1.4 Hz, 1H), 8.18 DMSO 99 Method AQ2 371.5 (M + 1) Method C (d, J = 8.6 Hz, 1H), 7.84 (dd, J = 6.9, 5.8 Hz, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.39 (dd, J = 8.4, 2.3 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 4.30 (s, 4H), 3.29 (d, J = 4.4 Hz, 3H). 1477

2 HCl 1H NMR (300 MHz, DMSO) δ 10.19 (s, 1H), 9.61 (d, J = 1.6 Hz, 1H), 8.98 (d, J = 8.8 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.82 (s, 1H), 8.35 (dd, J = 8.8, DMSO 99 Method AQ2 357.5 (M + 1) Method C 1.3 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 8.1, 5.2 Hz, 1H), 7.76-7.66 (m, 2H), 7.46 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 3.69 (t, J = 7.0 Hz, 2H), 3.31 (d, J = 4.4 Hz, 3H), 2.84 (t, J = 7.0 Hz, 2H). 1478

2 HCl 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.60 (d, J = 1.9 Hz, 1H), 8.93 (dd, J = 10.3, 5.4 Hz, 2H), 8.80 (d, J = 0.6 Hz, 1H), 8.34 (dd, J = 8.0, 0.5 Hz, 1H), DMSO 99 Method AQ2 357.5 (M + 1) Method C 8.10 (d, J = 8.3 Hz, 1H), 7.88- 7.75 (m, 3H), 7.40 (d, J = 8.3 Hz, 2H), 3.65 (t, J = 6.9 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.79 (t, J = 6.9 Hz, 2H). 1479

2 HCl 1H NMR (300 MHz, DMSO) δ 10.27 (s, 1H), 9.62 (d, J = 1.5 Hz, 1H), 8.99 (s, 1H), 8.96-8.88 (m, 2H), 8.37 (d, J = 8.9 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.96 (d, J = 8.5 Hz, 2H), DMSO 99 Method AQ2 380.5 (M + 1) Method C 7.85 (s, 1H), 7.70 (d, J = 8.5 Hz, 2H), 3.30 (d, J = 4.3 Hz, 3H), 1.74 (s, 6H). 1480

2 HCl 1H NMR (300 MHz, DMSO) δ 10.23 (s, 1H), 9.62 (d, J = 1.8 Hz, 1H), 9.02 (d, J = 6.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 1H), 8.88 (d, J = 0.5 Hz, 1H), 8.33 (d, DMSO 99 Method AQ2 393.4 (M + 1) Method C J = 8.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 1.7 Hz, 1H), 7.86 (dd, J = 7.4, 5.1 Hz, 1H), 7.75 (dd, J = 8.5, 1.8 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 3.29 (d, J = 4.3 Hz, 3H). 1481

1H NMR (300 MHz, DMSO) δ 9.63 (d, J = 1.4 Hz, 1H), 8.81-8.73 (m, 1H), 8.68 (dd, J = 4.7, 1.7 Hz, 1H), 8.61 (d, J = 4.3 Hz, 1H), 8.45 (s, 1H), 7.97 (d, J = 8.6 Hz, DMSO 99 Method AQ2, fol- lowed by hydrol- ysis with 30% H₂O₂ 374.5 (M + 1) Method C 1H), 7.86 (d, J = and 8.7 Hz, 2H), NAOH 7.77-7.61 (m, in 3H), 7.53 (dd, J = ethanol 7.9, 4.8 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 3.15 (d, J = 4.3 Hz, 3H). 1482

2 HCl 1H NMR (300 MHz, DMSO) δ 10.60 (s, 1H), 10.29 (s, 1H), 9.62 (d, J = 1.5 Hz, 1H), 9.00 (d, J = 7.1 Hz 1H), 8.92 (dd, J = 4.9, 1.4 Hz, 1H), 8.76 (s, 1H), 8.29 (d, J = DMSO 94 Method AQ1, except that dioxane water was replaced with DME/ 368.5 (M + 1) Method C 8.9 Hz, 1H), 8.20 water/ (d, J = 8.4 Hz, EtOH in 1H), 7.84 (dd, J = the 7.8, 4.8 Hz, micro- 1H), 7.79-7.68 wave (m, 2H), 6.95 (d, at 120° J = 8.0 Hz, 1H), C. for 3.57 (s, 2H), 10 min 3.29 (d, J = 4.3 Hz, 3H). 1483

2 HCl 1H NMR (300 MHz, DMSO) δ 10.67 (s, 1H), 9.60 (d, J = 2.4 Hz, 1H), 8.99-8.88 (m, 2H), 8.73 (d, J = 1.0 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), DMSO 99 Method AQ1, except that dioxane water was replaced with DME/ 368.5 (M + 1) Method C 7.83 (dd, J = 6.9, water/ 4.3 Hz, 1H), EtOH in 7.40 (q, J = 8.3 the Hz, 2H), 7.20 (s, micro- 1H), 3.56 (s, 2H), wave 3.29 (d, J = 4.1 at 120° Hz, 3H). C. for 10 min 1484

2 HCl 1H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.61 (d, J = 1.9 Hz, 1H), 9.04-8.89 (m, 2H), 8.84 (d, J = 1.2 Hz, 1H), 8.36 (dd, J = 8.7, 1.3 Hz, 1H), 8.14 (d, J = 8.1 DMSO 99 Method AQ1, except that dioxane water was replaced with DME/ 357.5 (M + 1) Method C Hz, 1H), 7.94- water/ 7.78 (m, 3H), 7.50 EtOH in (d, J = 8.3 Hz, the 2H), 4.49 (s, 2H), micro- 3.39-3.23 (m, 6H). wave at 120° C. for 10 min 1485

1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.76 (td, J = 8.0, 1.6 Hz, 1H), 8.71 (dd, J = 4.8, 1.6 Hz, 1H), 8.37 (s, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.59-7.54 (m, 1H), DMSO 95 Method G1, AQ1 377.0 379.0 (M + 1) Method C 7.43 (t, J = 8.0 Hz, 1H), 7.06- 6.98 (m, 3H), 3-82 (s, 3H), 1486

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 9.81 (s, 1H), 9.38 (d, J = 8.4 Hz, 1H), 9.15 (d, J = 5.2 Hz, 1H), 8.69 (d, J = 1.6 Hz, 1H), 8.41 (dd, J = 8.8, 2.0 DMSO 95 Method G1, AQ1 401.1 (M + 1) Method B (NH₄HCO₃) Hz, 1H), 8.29- 8.26 (m, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.50-7.41 (m, 3H), 7.11- 7.08 (m, 1H), 4.80-4.76 (m, 1H), 3.66-3.57 (m, 2H), 3.50 (s, 3H), 3.44 (s, 3H), 1.35 (d, J = 6.4 Hz, 3H). 1487

2HCl 1H-NMR (400 MHz, CD3OD): δ 9.55 (s, 1H), 8.92 (d, J = 4.9 Hz, 1H), 8.89 (dt, J = 8.2, 1.8 Hz, 1H), 8.62 (s, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.03 (d, MeOD 95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) J = 8.7 Hz, 1H), 7.83 (dd, J = 8.0, 5.0 Hz, 1H), 7.49 (t, J = 8.1 Hz, 1H), 7.43 (s, 2H), 7.10 (d, J = 7.6 Hz, 1H), 4.01 (s, 2H), 3.46 (s, 3H), 3.35 (s, 3H), 1.37 (s, 6H). 1488

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.34 (s, 1H), 9.65 (s, 1H), 9.04 (d, J = 6.9 Hz, 1H), 8.99-8.87 (m, 2H), 8.39 (d, J = 9.2 Hz, 1H), DMSO 95 Method G1, AQ1 400.9 (M + 1) Method B (NH₄HCO₃) 8.24 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.47-7.43 (m, 3H), 7.05 (d, J = 6.8 Hz, 1H), 4.26-4.22 (m, 2H), 3.77-3.73 (m, 2H), 3.56- 3.50 (m, 2H), 3.32 (d, J = 4.3 Hz, 3H), 1.15 (t, J = 7.0 Hz, 3H). 1489

1H-NMR (400 MHz, DMSO-d6): δ 9.68 (s, 1H), 8.81- 8.78 (m, 2H), 8.71 (d, J = 3.6 Hz, 1H), 8.54 (s, 1H), 8.32 (d, J = 1.2 Hz, 1H), 7.57 (dd, J = 7.6, 4.8 Hz, 1H), 7.46-7.42 (m, DMSO 95 Method G1, AQ1 377.1, 379.1 (M + 1) Method B (NH₄HCO₃) 3H), 7.04-7.01 (m, 1H), 3.88 (s, 3H), 3.19 (d, J = 4.0 Hz, 3H). 1490

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.50 (brs, 1H), 9.68 (d, J = 2.0 Hz, 1H), 9.09 (d, J = 8.0 Hz, 1H), 8.96 (dd, J = 5.2, 1.2 Hz, 1H), 8.94 (s, 1H), DMSO 95 Method G1, AQ1 427.2 (M + 1) Method B (NH₄HCO₃) 8.40 (d, J = 9.2 Hz, 1H), 8.29 (d, J = 8.8 Hz, 1H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.48-7.43 (m, 3H), 7.03 (d, J = 7.2 Hz, 1H), 4.06- 4.05 (m, 2H), 3.92 (d, J = 11.6 Hz, 1H), 3.69- 3.66 (m, 1H), 3.42-3.39 (m, 1H), 3.32 (d, J = 4.4 Hz, 3H), 1.86-1.83 (m, 1H), 1.69 (d, J = 12.4 Hz, 1H), 1.52-1.51 (m, 3H), 1.38-1.35 (m, 1H). 1492

3HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.80 (s, 1H), 9.70 (s, 1H), 9.13 (d, J = 8.0 Hz, 1H), 9.07 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.94 (s, DMSO 95 Method G1, AQ1 488.0 (M + 1) Method B (NH₄HCO₃) 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.98 (t, J = 8.0 Hz, 1H), 7.90 (t, J = 6.2 Hz, 1H), 7.68 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 5.50 (s, 2H), 3.30 (d, J = 2.4 Hz, 3H). 1493

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 9.71 (s, 1H), 9.14 (d, J = 7.6 Hz, 1H), 8.98 (d, J = 8.0 Hz, 2H), 8.40 (d, J = 8.8 Hz, 1H), 8.31 (d, J = DMSO 95 Method G1, AQ1 496.2 (M + 1) Method B (NH₄HCO₃) 8.8 Hz, 1H), 7.92 (t, J = 6.2 Hz, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.47-7.43 (m, 3H), 7.02 (d, J = 7.2 Hz, 1H), 4.10 (t, J = 6.0 Hz, 2H), 3.53 (d, J = 6.4 Hz, 1H), 3.32 (d, J = 2.4 Hz, 3H), 2.26 (t, J = 7.0 Hz, 2H), 2.00-1.93 (m, 2H), 1.73-1.63 (m, 4H), 1.55- 1.51 (m, 1H), 1.28-1.02 (m, 5H). 1494

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.60 (s, 1H), 8.92 (d, J = 4.4 Hz, 2H), 8.76 (s, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.85-7.83 (m, DMSO 95 Method G1, AQ1 428.1, 429.1, (M + 1) Method B (NH₄HCO₃) 4H), 7.11 (d, J = 8.8 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.30 (d, J = 4.0 Hz, 3H), 2.58 (d, J = 4.0 Hz, 3H), 2.26 (t, J = 7.4 Hz, 2H), 2.00-1.93 (m, 2H). 1495

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.63 (s, 1H), 9.73 (s, 1H), 9.17 (d, J = 7.6 Hz, 1H), 8.99 (s, 1H), 8.91 (s, 1H), 8.34 (s, 2H), 7.93 (t, J = 6.0 Hz, 1H), 7.88 (d, J = 7.2 DMSO 95 Method G1, AQ1 442.1, 443.1, (M + 1) Method B (NH₄HCO₃) Hz, 2H), 7.09 (d, J = 7.6 Hz, 2H), 4.08-4.06 (m, 2H), 3.32 (s, 3H), 2.98 (s, 3H), 2.84 (s, 3H), 2.47- 2.46 (m, 2H), 1.98-1.94 (m, 2H). 1496

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.26 (s, 1H), 9.64 (s, 1H), 9.01 (d, J = 7.0 Hz, 1H), 8.94 (s, 1H), 8.89 (s, 1H), 8.39 (d, J = 8.2 Hz, 1H), 8.19 (d, J = DMSO 95 Method G1, AQ1 413.1, 414.1 (M + 1) Method B (NH₄HCO₃) 8.1 Hz, 1H), 7.85 (s, 1H), 7.47 (d, J = 5.8 Hz, 3H), 7.05 (d, J = 3.4 Hz, 1H), 4.21 (dt, J = 10.8, 5.5 Hz, 1H), 4.08 (qd, J = 10.1, 5.2 Hz, 2H), 3.82 (dd, J = 14.4, 7.0 Hz, 1H), 3.71 (dd, J = 14.1, 7.4 Hz, 1H), 3.31 (d, J = 4.2 Hz, 3H), 2.08- 2.00 (m, 1H), 1.98-1.79 (m, 2H), 1.72-1.68 (m, 1H). 1497

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.53 (s, 1H), 9.68 (s, 1H), 9.09 (d, J = 7.7 Hz, 1H), 8.96 (d, J = 5.9 Hz, 2H), 8.39 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 7.94-7.79 (m, 1H), 7.48-7.45 (m, 3H), 7.04 (d, J = 7.5 Hz, 1H), DMSO- d₆ 95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) 4.30-4.18 (m, 2H), 3.80-3.70 (m, 2H), 3.44 (t, J = 6.6 Hz, 2H), 3.31 (d, J = 4.2 Hz, 3H), 1.56- 1.54 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H). 1498

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.07 (s, 1H), 9.67 (s, 1H), 9.03 (d, J = 8.0 Hz, 1H), 8.95 (d, J = 4.5 Hz, 1H), 8.51 (s, 1H), 7.85 (s, 2H), 7.41 (t, J = 7.9 Hz, 1H), 7.18 (dd, J = 7.8, 5.1 DMSO 95 Method G1, AQ1 373.1 (M + 1) Method B (NH₄HCO₃) Hz, 2H), 7.02 (dd, J = 8.2, 2.3 Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H), 1499

2HCl 1H-NMR (400 MHz, DMSO-d6): δ 10.06 (s, 1H), 9.66 (s, 1H), 9.02 (d, J = 7.5 Hz, 1H), 8.95 (s, 1H), 8.89 (s, 1H), 8.39 (d, 2 = 8.5 Hz, 1H), 8.22 (d, J = DMSO 95 Method G1, AQ1 415.1 (M + 1) Method B (NH₄HCO₃) 8.6 Hz, 1H), 7.85 (dd, J = 7.0, 5.4 Hz, 1H), 7.52-7.43 (m, 3H), 7.09-7.01 (m, 1H), 4.17- 4.15 (m, 2H), 3.32-3.30 (m, 4H), 3.25 (s, 3H), 1.98-1.82 (m, 2H), 1.17 (d, J = 6.1 Hz, 3H). 1500

2HCl 1H-NMR (400 MHz, CD3OD): δ 9.80 (s, 1H), 9.37 (d, J = 8.2 Hz, 1H), 9.13 (d, J = 5.3 Hz, 1H), 8.90 (s, 1H), 8.45 (d, J = 8.4 Hz, CD₃OD 95 Method G1, AQ1 468.1 (M + 1) Method B (NH₄HCO₃) 1H), 8.25 (dd, J = 7.9, 5.6 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J = 5.1 Hz, 2H), 7.17 (dd, J = 7.5, 3.6 Hz, 1H), 4.70-4.62 (m, 2H), 4.42 (q, J = 9.0 Hz, 2H), 3.93-3.86 (m, 2H), 3.51 (s, 3H), 3.24 (s, 3H). 1501

2HCl 1H-NMR (400 MHz, DMSO): δ 10.45 (brs, 1H), 9.72 (s, 1H), 9.12 (d, J = 7.6 Hz, 1H), 8.97 (d, J = 4.0 Hz, 1H), 8.70 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), DMSO 95 Method G1, AQ1 428.1 (M + 1) Method B (NH₄HCO₃) 8.23 (d, J = 8.4 Hz, 1H), 7.90- 7.87 (m, 2H), 7.49 (d, J = 7.2 Hz, 1H), 7.43 (t, J = 7.2 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 4.03 (t, J = 6.4 Hz, 2H), 3.30 (d, J = 4.4 Hz, 3H), 2.54 (d, J = 4.0 Hz, 3H), 2.19 (t, J = 7.4 Hz, 2H),1.93-1.86 (m, 2H).

1502      

1H-NMR (400 MHz, DMSO-d6): δ 9.65 (s, 1H), 8.88 (s, 1H), 8.81 (d, J = 8 Hz, 1H), 8.73 (s, 1H), 8.62 (s, 1H), 8.19 (d, J = 8 Hz, 1H), 788 (d, J = 9.2 Hz, 1H), 7.61- DMSO 95 Method G1, AQ1 413.1 (M + 1) Method B (NH₄HCO₃) 7.58 (m, 1H), 7.47-7.44 (m, 3H), 7.06-7.04 (m, 1H), 4.56- 4.54 (m, 1H), 3.87 (dd, J = 11.2, 2.0 Hz, 1H), 3.68- 3.64 (m, 1H), 3.56-3.53 (m, 2H), 3.21 (d, J = 4.4 Hz, 3H), 2.09- 2.05 (m, 1H), 1.83-1.72 (m, 2H), 1.61-1.55 (m, 1H). 1503

2HCl 1H-NMR (400 MHz, CD3OD): δ 9.77 (s, 1H), 9.43 (d, J = 8.1 Hz, 1H), 9.08 (d, J = 5.6 Hz, 1H), 8.46 (s, 1H), 8.34- 8.25 (m, 1H), CD₃OD 95 Method G1, AQ1 496.2 (M + 1) Method B (NH₄HCO₃) 8.20 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 3.98 (t, J = 6.1 Hz, 2H), 3.44 (t, J = 11.1 Hz, 1H), 3.35 (s, 3H), 2.17 (t, J = 7.3 Hz, 2H), 1.93-1.89 (m, 2H), 1.70- 1.53 (m, 4H), 1.48 (d, J = 12.5 Hz, 1H), 1.22- 1.12 (m, 2H), 1.08-1.02 (m, 3H). 1504

1H-NMR (400 MHz, DMSO-d6): δ 9.63 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 3.6 Hz, 1H), 8.50 (d, J = 4.0 Hz, 1H), 8.10 (s, 1H), 7.56-7.53 (m, 2H), 7.46- DMSO 95 Method G1, AQ1 372.9 (M + 1) Method B (NH₄HCO₃) 7.42 (m, 3H), 7.03-7.01 (m, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 3.17 (d, J = 4.0 Hz, 1H). 1505

1H-NMR (400 MHz, DMSO): δ 9.28 (s, 1H), 8.94 (t, J = 7.6 Hz, 1H), 8.62 (d, J = 4.2 Hz, 1H), 8.42 (s, 1H), 7.94 (d, 7 = 8.8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.73-7.71 (m, DMSO 95 Method G1, AQ1 367.0 (M + 1) Method B (NH₄HCO₃) 1H), 7.46 (t, J = 10.0 Hz, 1H), 7.33-7.27 (m, 2H), 3.16 (d, J = 4.4 Hz, 3H). 1506

1H-NMR (400 MHz, DMSO): δ 8.77 (s, 1H), 8.66 (t, J = 8.6 Hz, 1H), 8.52 (s, 1H), 8.44-8.31 (m, 1H), 8.03 (d, J = 8.6 Hz, 1H), 7.88 (d, J = 8.6 Hz, 1H), 7.62- 7.49 (m, 3H), DMSO 95 Method G1, AQ1 366.9 (M + 1) Method B (NH₄HCO₃) 7.42-7.37 (m, 1H), 3.12 (d, J = 3.0 Hz, 3H). 1507

1H-NMR (400 MHz, DMSO): δ 9.29 (d, J = 2.0 Hz, 1H), 8.95 (dt, J = 8.4, 2.4 Hz, 1H), 8.65 (d, J = 4.4 Hz, 1H), 8.49 (s, 1H), 7.94- 7.93 (m, 2H), 7.60-7.26 (m, 4H), 3.16 (d, DMSO 95 Method G1, AQ1 367.1 (M + 1) Method B (NH₄HCO₃) J = 4.4 Hz, 3H). 1508

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.46 (s, 1H), 8.77 (s, 1H), 8.65 (t, J = 8.5 Hz, 1H), 8.55 (s, 1H), 8.19 (d, J = 8.7 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.79 (dd, J = 15.8, 7.8 Hz, DMSO 95 Method G1, AQ1 367.0 (M + 1) Method B (NH₄HCO₃) 1H), 7.71-7.66 (m, 1H), 7.51 (t, J = 10.2 Hz, 1H), 7.34 (t, J = 8.5 Hz, 1H), 3.23 (d, J = 3.3 Hz, 3H). 1509

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.98 (s, 1H), 9.55 (d, J = 1.8 Hz, 1H), 9.07 (d, J = 7.2 Hz, 1H), 8.67 (s, 1H), 8.16 (dd, J = 18.0, 8.4 Hz, 2H), 7.84 (d, J = 8.3 Hz, 1H), 7.78 (td, J = DMSO 95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) 8.9, 6.6 Hz, 1H), 7.55-7.45 (m, 1H), 7.33 (td, J = 8.4, 2.0 Hz, 1H), 3.28 (d, J = 4.4 Hz, 3H), 2.74 (s, 3H). 1510

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.17 (s, 1H), 8.82 (dd, J = 7.9, 6.7 Hz, 2H), 8.65 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 7.80 (s, 1H), 7.65-7.50 (m, 2H), 7.42 (dd, DMSO 95 Method G1, AQ1 363.0 (M + 1) Method B (NH₄HCO₃) J = 12.7, 7.6 Hz, 1H), 3.20 (d, J = 4.4 Hz, 3H), 2.94 (s, 3H). 1511

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.24 (s, 1H), 8.84 (d, J = 4.0 Hz, 1H), 8.77 (s, 1H), 8.64 (s, 1H), 8.18 (d, J = 8.6 Hz, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 2H), 7.57- DMSO 95 Method G1, AQ1 362.9 (M + 1) Method B (NH₄HCO₃) 7.46 (m, 1H), 7.34 (td, J = 8.5, 2.2 Hz, 1H), 3.20 (d, J = 4.5 Hz, 3H), 2.93 (s, 3H). 1512

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (s, 1H), 8.83 (dd, J = 8.0, 1.6 Hz, 1H), 8.63 (dd, J = 4.8, 2.0 Hz, 1H), 8.38 (s, 1H), 7.95-7.86 (m, 2H), 7.67- 7.57 (m, 2H), 7.15-7.09 (m, 2H), 4.44 (brs, 1H), 2.17 (t, J = 7.6 Hz, 1H), DMSO 95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) 1.91-1.89 (m, 1H), 1.78 (d, J = 12.0 Hz, 1H), 1.56-1.48 (m, 4H), 1.32-1.28 (m, 1H). 1513

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.94-8.89 (m, 2H), 8.58 (s, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.85 (t, J = 6.8 Hz, 1H), 7.73 (dd, J = 14.4, 8.0 Hz, 1H), 7.25-7.19 (m, 2H), 4.01 (q, DMSO 95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) J = 7.2 Hz, 2H), 1.48 (t, J = 7.2 Hz, 3H). 1514

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.71 (s, 1H), 9.21 (d, J = 8.4 Hz, 1H), 9.08 (d, J = 4.4 Hz, 1H), 8.68 (s, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.15-8.12 (m, 2H), 7.50- 7.38 (m, 3H), 4.04 (q, J = 7.2 Hz, 2H), 1.49 (t, J = DMSO 95 Method G1, AQ1 363.1 (M + 1) Method B (NH₄HCO₃) 7.2 Hz, 3H). 1515

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.25 (d, J = 8.0 Hz, 1H), 9.03 (d, J = 5.2 Hz, 1H), 8.60 (s, 1H), 8.21- 8.14 (m, 2H), 8.06 (d, J = 8.4 Hz, 1H), 7.40- 7.26 (m, 3H), 4.26 (brs, 4H), 2.14 (brs, 4H). DMSO- d₆ 95 Method G1, AQ1 389.1 (M + 1) Method B (NH₄HCO₃) 1516

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 9.14 (d, J = 8.0 Hz, 1H), 9.10 (d, J = 5.2 Hz, 1H), 8.69 (s, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.09 (dd, J = 8.0, 5.2 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.39-7.27 (m, 3H), 4.60-4.50 DMSO 95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) (m, 1H), 2.08 (d, J = 11.6 Hz, 2H), 1.84 (d, J = 12.0 Hz, 2H), 1.69 (d, J = 8.4 Hz, 1H), 1.57- 1.45 (m, 4H), 1.18-1.10 (m, 1H). 1517

¹H-NMR (400 MHz, DMSO-d₆): δ 12.04 (brs, 1H), 9.58 (s, 1H), 9.38 (brs, 1H), 8.84 (d, J = 5.6 Hz, 2H), 8.72 (s, 1H), 8.28 (d, J = 9.2 Hz, 1H), 7.75 (t, J = 6.8 Hz, 1H), 7.51-7.41 (m, DMSO 95 Method G1, AQ1 428.9 (M + 1) Method B (NH₄HCO₃) 3H), 7.07-7.03 (m, 1H), 3.88 (s, 3H), 3.80 (q, J = 5.6 Hz, 2H), 2.32 (t, J = 7.2 Hz, 2H), 1.86-1.74 (m, 2H), 1.73- 1.64 (m, 2H). 1518

¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (td, J = 8.0, 1.6 Hz, 1H), 8.71- 8.66 (m, 1H), 8.31 (d, J = 1.6 Hz, 1H), 8.08 (dd, J = 8.8, 2.0 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), DMSO 95 Method G1, AQ1 345.1 (M + 1) Method B (NH₄HCO₃) 7.87-7.81 (m, 2H), 7.58-7.49 (m, 1H), 7.39- 7.30 (m, 2H), 3.49 (s, 6H). 1519

¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (d, J = 7.2 Hz, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.32 (s, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 7.6 DMSO 95 Method G1, AQ1 361.1 363.1 (M + 1) Method B (NH₄HCO₃) Hz, 2H), 7.62- 7.48 (m, 3H), 3.48 (s, 6H). 1520

¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.74 (td, J = 8.0, 1.6 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H), 8.16 (dd, J = 8.8, 2.0 Hz, 1H), 8.04-7.89 (m, 5H), 7.54 (q, J = DMSO 95 Method G1, AQ1 352.1 (M + 1) Method B (NH₄HCO₃) 5.2 Hz, 1H), 3.51 (s, 6H). 1521

¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.68-8.60 (m, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.56 (q, J = 4.8 Hz, 1H), 7.49-7.40 (m, DMSO 95 Method G1, AQ1 428.1 (M + 1) Method B (NH₄HCO₃) 3H), 7.30 (s, 1H), 7.06-6.97 (m, 1H), 6.73 (s, 1H), 3.87 (s, 5H), 2.14 (t, J = 7.2 Hz, 2H), 1.80- 1.71 (m, 2H), 1.71-1.62 (m, 2H). 1522

2 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (s, 1H), 9.39 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.3 Hz, 1H), 8.31 (d, J = 9.3 Hz, 2H), 8.24- 8.10 (m, 3H), 7.88 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 3.54 (s, 6H), 2.78 (s, 3H). DMSO 95 Method G1, AQ1 366.1 (M + 1) Method B (NH₄HCO₃) 1523

¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (d, J = 1.7 Hz, 1H), 8.88- 8.32 (m, 4H), 8.16 (dd, J = 8.7, 1.8 Hz, 1H), 7.86 (t, J = 9.2 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H), 7.50-7.34 (m, 3H), 7.01 (dt, J = 7.3, 2.1 Hz, 1H), 3.96- 3.84 (m, 5H), 2.78 (t, J = 6.9 Hz, DMSO 95 Method G1, AQ1 400.9 (M + 1) Method B (NH₄HCO₃) 2H). 1524

¹H-NMR (400 MHz, DMSO-d₆): 9.63 (s, 1H), 8.77 (d, J = 8 Hz, 1H), 8.66-8.63 (m, 3H), 8.15 (d, J = 8.8 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.45- 7.41 (m, 3H), DMSO 95 Method G1, AQ1 414.1 (M + 1) Method B (NH₄HCO₃) 7.33 (s, 1H), 7.01 (d, J = 7.0 Hz, 1H), 6.79 (s, 1H), 3.88 (s, 3H), 3.72 (d, J = 6.0 Hz, 2H), 2.24 (t, J = 7.2 Hz, 2H), 2.04-1.94 (m, 2H). 1525

¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (d, J = 1.2 Hz, 1H), 8.73- 8.68 (m, 3H), 8.37 (s, 1H), 8.27- 8.22 (m, 4H), 7.89-7.87 (m, 2H), 7.75 (t, J = 8.0 Hz, 1H), 7.55 (dd, J = 8.0, 5.2 DMSO 95 Method G1, AQ1 324.1 (M + 1) Method B (NH₄HCO₃) Hz, 1H). 1526

¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (d, J = 1.6 Hz, 1H), 8.72- 8.66 (m, 2H), 8.57 (d, J = 1.6 Hz, 1H), 8.19-7.91 (m, 3H), 7.83 (d, J = 8.0 Hz, 3H), 7.54 (dd, J = 7.6, 4.8 Hz, 1H), DMSO 95 Method G1, AQ1 329.1 (M + 1) Method B (NH₄HCO₃) 7.10 (d, J = 8.4 Hz, 2H), 3.83 (s, 3H). 1527

¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 8.72- 8.66 (m, 3H), 8.16 (d, J = 8.4 Hz, 3H), 7.91 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.54 (dd, J = 7.6, DMSO 95 Method G1, AQ1 333.1, 335.0 (M + 1) Method B (NH₄HCO₃) 4.8 Hz, 1H). 1528

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (s, 1H), 9.28 (d, J = 8.0 Hz, 1H), 9.01 (d, J = 5.6 Hz, 1H), 8.65 (s, 2H), 8.37 (s, 2H), 8.25 (d, J = 8.0 Hz, 1H), 8.22 (s, 1H), 8.13 (t, J = 6.8 DMSO 95 Method G1, AQ1 338.1 (M + 1) Method B (NH₄HCO₃) Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 2.77 (s, 3H). 1529

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.78 (s, 1H), 9.72 (d, J = 1.8 Hz, 1H), 9.18 (d, J = 8.1 Hz, 1H), 8.98 (dd, J = 5.1, 1.2 Hz, 1H), 8.78 (s, 1H), 8.29 (d, J = 8.6 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 7.95 (dd, J = 7.9, 5.3 Hz, 1H), 7.80 (td, J = 8.9, 6.6 Hz, 1H), DMSO 95 Method G1, AQ1 434.1 (M + 1) Method B (NH₄HCO₃) 7.55-7.45 (m, 1H), 7.34 (td, J = 8.4, 2.3 Hz, 1H), 7.26 (s, 1H), 6.96 (s, 1H), 3.98 (d, J = 6.1 Hz, 2H), 1.24 (s, 6H). 1530

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.58 (s, 1H), 9.04- 8.89 (m, 2H), 8.71-8.66 (m, 1H) 8.15- 8.11 (m, 2H), 7.82-7.76 (m, 2H), 7.51 (t, J = 9.2 Hz, 1H), 7.34 (t, J = 8.8 Hz, 1H), 4.64 (s, 2H), 3.19 (s, 3H), 2.91 (s, DMSO 95 Method G1, AQ1 420.1 (M + 1) Method B (NH₄HCO₃) 3H). 1531

¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 8.78 (d, J = 7.9 Hz, 1H), 8.72 (d, J = 3.2 Hz, 1H), 8.19 (s, 2H), 8.08-7.97 (m, 2H), 7.80 (dd, J = 15.5, 8.9 Hz, 1H), 7.58 (dd, J = 7.6, 4.9 Hz, 1H), 7.52-7.41 (m, 1H), 7.29 (td, J = 8.3, 1.9 Hz, 1H), DMSO 95 Method G1, AQ1 418.1 (M + 1) Method B (NH₄HCO₃) 4.48 (s, 2H), 4.15 (s, 2H), 3.48 (s, 2H). 1532

¹H-NMR (400 MHz, DMSO-d₆): δ 9.65 (s, 1H), 8.87 (s, 1H), 8.79 (d, J = 7.7 Hz, 1H), 8.70 (s, 1H), 8.59 (s, 1H), 8.23 (s, 1H), 8.05- 7.89 (m, 3H), 7.75 (dd, J = 15.1, 7.6 Hz, 1H), 7.56 (s, 1H), 7.48 (t, J = 9.9 Hz, 1H), 7.32 (t, J = 8.1 Hz, 1H), 4.46 (t, DMSO 95 Method G1, AQ1 442.0 (M + 1) Method B (NH₄HCO₃) J = 13.4 Hz, 2H). 1533

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.63 (s, 1H), 8.95- 9.03 (m, 2H), 8.78 (s, 1H), 8.14- 8.24 (m, 2H), 7.88 (t, J = 6.0 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.54-7.48 (m, 1H), 7.35-7.32 (m, 1H), 4.89 (m, 1H), 1.39 (d, DMSO 95 Method G1, AQ1 377.1 (M + 1) Method B (NH₄HCO₃) J = 1.2 Hz, 6H). 1534

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.69- 8.74 (m, 2H), 8.59 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.71-7.77 (m, 1H), 7.66 (s, 1H), 7.56-7.60 (m, 1H), 7.42-7.48 (m, 1H), 7.27- 7.32 (m, 1H), DMSO 95 Method G1, AQ1 391.1 (M + 1) Method B (NH₄HCO₃) 1.66 (s, 9H). 1535

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 9.66 (s, 1H), 9.22 (d, J = 7.6 Hz, 1H), 8.99 (d, J = 4.8 Hz, 1H), 8.83 (s, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.95 (t, J = 6.2 Hz, 1H), 7.58 (q, J = 8.6 Hz, 1H), 7.51 (t, J = 7.0 Hz, 1H), 7.46-7.41 (m, 1H), 7.25 (s, DMSO 95 Method G1, AQ1 446.0 (M + 1) Method B (NH₄HCO₃) 1H), 6.72 (s, 1H), 5.13-5.06 (m, 1H), 3.21 (q, J = 7.3 Hz, 1H), 2.22-1.92 (m, 5H), 1.68-1.57 (m, 1H). 1536

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.81 (s, 2H), 9.32 (d, J = 8.0 Hz, 1H), 9.02 (d, J = 5.2 Hz, 1H), 8.81 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.00 (dd, J = 7.8, 5.8 Hz, 1H), 7.76 (dd, J = 15.4, 8.6 Hz, 1H), 7.51 (t, J = 10.0 Hz, 1H), 7.35 (t, J = 8.2 Hz, 1H), DMSO 95 Method G1, AQ1 446.1 (M + 1) Method B (NH₄HCO₃) 7.29 (s, 1H), 6.73 (s, 1H), 5.15- 5.07 (m, 1H), 3.21 (q, J = 7.3 Hz, 1H), 2.23- 1.87 (m, 5H), 1.68-1.57 (m, 1H). 1537

¹H-NMR (400 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.79 (d, J = 7.6 Hz, 1H), 8.69 (dd, J = 4.4, 1.2 Hz, 1H), 8.61 (d, J = 1.6 Hz, 1H), 8.40 (d, J = 7.2 Hz, 1H), 8.13 (dd, J = 8.6, 1.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 7.6, 4.8 Hz, 1H), 7.49-7.40 (m, 3H), 7.11 (s, 1H), DMSO 95 Method G1, AQ1 Method B (NH₄HCO₃) 7.02 (d, J = 7.2 Hz, 1H), 6.69 (s, 1H), 5.03-4.96 (m, 1H), 3.87 (s, 3H), 3.20 (dd, J = 15.0, 7.4 Hz, 1H), 2.22-1.88 (m, 5H), 1.70-1.56 (m, 1H). 1538

¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 8.86 (d, J = 7.7 Hz, 1H), 8.74 (d, J = 8.0 Hz, 1H), 8.69 (d, J = 3.3 Hz, 1H), 8.65 (s, 1H), 8.19 (d, J = 7.4 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.54 (dd, J = 7.8, 4.8 Hz, 1H), 7.50- 7.40 (m, 3H), DMSO 95 Method G1, AQ1 426.1, 427.1 (M + 1) Method B (NH₄HCO₃) 7.01 (dd, J = 7.3, 3.9 Hz, 1H), 4.85 (dd, J = 16.9, 8.7 Hz, 1H), 3.88 (s, 3H), 2.16 (s, 2H), 1.96 (s, 2H).

1539      

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.34 (s, 1H), 9.67 (s, 1H), 9.07 (s, 1H), 8.97 (d, J = 5.0 Hz, 1H), 8.92 (s, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 7.4 Hz, 1H), 7.99 (s, 1H), 7.90 (s, 1H), 7.48 DMSO 95 Method G1, AQ1 414.0, 415.0 (M + 1) Method B (NH₄HCO₃) (d, J = 5.8 Hz, 3H), 7.09-6.99 (m, 1H), 4.03 (d, J = 6.1 Hz, 2H), 3.89 (s, 3H), 2.65 (t, J = 6.8 Hz, 2H), 2.56 (d, J = 4.4 Hz, 3H). 1540

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48 (s, 1H), 9.64 (s, 1H), 9.05 (d, J = 7.9 Hz, 1H), 9.01-8.92 (m, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.93- 7.83 (m, 1H), 7.55-7.43 (m, DMSO 95 Method G1, AQ1 428.1, 429.1 (M + 1) Method B (NH₄HCO₃) 3H), 7.08-6.98 (m, 1H), 4.04 (dd, J = 12.4, 6.6 Hz, 2H), 3.89 (s, 3H), 2.98 (s, 3H), 2.89 (t, J = 7.0 Hz, 2H), 2.84 (s, 3H). 1541

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.02 (brs, 1H), 9.75 (d, J = 1.6 Hz, 1H), 9.07 (dd, J = 8.0, 1.6 Hz, 1H), 8.83 (s, 1H), 8.35 (d, J = 9.2 Hz, 1H), 8.19 (d, J = 8.0 Hz, 1H), 8.14 (d, J = DMSO 95 Method G1, AQ1 411.1 (M + 1) Method B (NH₄HCO₃) 8.8 Hz, 1H), 7.48-7.46(m, 3H), 7.06-7.03 (m, 1H), 3.89 (s, 3H), 3.30 (d, J = 4.0 Hz, 3H). 1542

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.22 (brs, 1H), 9.64 (s, 1H), 9.01 (d, J = 6.4 Hz, 1H), 8.95 (d, J = 4.0 Hz, 1H), 8.89 (s, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.85 (t, J = 5.2 Hz, 1H), 7.52-7.42 (m, 4H), 7.08-7.05 (m, 1H), 6.89 (s, 1H), 3.89 (s, 4H), 3.83-3.76 (m, 2H), 2.83- 2.79 (m, 1H), 1.65-1.56 (m, DMSO 95 Method G1, AQ1 510.2 (M + 1) Method B (NH₄HCO₃) 7H), 1.24-1.07 (m, 6H), 0.89- 0.81 (m, 2H). 1543

¹H-NMR (400 MHz, DMSO-d₆): δ 9.67 (d, J = 1.6 Hz, 1H), 8.80 (dt, J = 8.0, 2.0 Hz, 1H), 8.70 (dd, J = 4.4, 2.0 Hz, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.71- 7.67 (m, 1H), 7.58-7.55 (m, DMSO 95 Method G1, AQ1 359.1 (M + 1) Method B (NH₄HCO₃) 1H), 7.47 (d, J = 2.4 Hz, 1H), 7.34 (m, 2H), 3.45 (s, 6H), 2.76 (s, 3H). 1544

¹H-NMR (400 MHz, DMSO-d₆): δ 9.66 (s, 1H), 8.82-8.79 (m, 1H), 8.70 (d, J = 4.0 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.02 (s, 1H), 7.86-7.84 (m, 2H), 7.58-7.55 (m, 3H), 3.48 (s, DMSO 95 Method G1, AQ1 375.1 (M + 1) Method B (NH₄HCO₃) 6H), 2.77 (s, 3H). 1545

¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (s, 1H), 9.01 (d, J = 8.0 Hz, 1H), 8.82 (d, J = 4.4 Hz, 1H), 8.18 (d, J = 1.6 Hz, 1H), 8.03 (s, 1H), 7.88-7.84 (m, 2H), 7.80- 7.77 (m, 1H), DMSO 95 Method G1, AQ1 359.1 (M + 1) Method B (NH₄HCO₃) 7.37-7.33 (m, 2H), 3.50 (s, 6H), 2.78 (s, 3H). 1546

¹H-NMR (400 MHz, CD₃OD): δ 9.51 (s, 1H), 8.81 (d, J = 7.8 Hz, 1H), 8.54 (s, 1H), 8.35 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.29 (dt, J = 11.2, 4.8 CD3OD 95 Method G1, AQ1 416.1 (M + 1) Method B (NH₄HCO₃) Hz, 3H), 6.88 (d, J = 7.5 Hz, 1H), 4.43 (dd, J = 7.1, 4.0 Hz, 1H), 4.16 (dd, J = 13.8, 4.0 Hz, 1H), 3.86 (dd, J = 13.7, 7.4 Hz, 1H), 3.80 (s, 3H). 1547

2HCl ¹H-NMR (400 MHz, CD₃OD): δ 9.74 (s, 1H), 9.44 (d, J = 8.2 Hz, 1H), 9.02 (d, J = 5.5 Hz, 1H), 8.50 (s, 1H), 8.24 (dd, J = 8.0, 5.9 Hz, 1H), 8.16 (q, J = 8.7 Hz, 2H), 7.70-7.58 (m, 1H), 7.12- 7.00 (m, 2H), 6.13 (s, 1H), 4.44- CD₃OD 95 Method G1, AQ1 457.0 (M + 1) Method B (NH₄HCO₃) 4.41 (m, 1H), 4.29-4.27 (m, 1H), 2.37-2.16 (m, 3H), 2.09- 2.07 (m, 1H). 1548

2HCl ¹H-NMR (400 MHz, CD₃OD): δ 9.85 (s, 1H), 9.57 (d, J = 8.0 Hz, 1H), 9.10 (d, J = 4.8 Hz, 1H), 8.64 (s, 1H), 8.34-8.22 (m, 3H), 7.51 (t, J = 6.9 Hz, 1H), 7.47- 7.33 (m, 2H), 6.23 (s, 1H), 4.53- 4.51 (m, 1H), 4.38-4.36 (m, CD₃OD 95 Method G1, AQ1 457.1 (M + 1) Method B (NH₄HCO₃) 1H), 2.51-2.30 (m, 3H), 2.19- 2.18 (m, 1H). 1549

2HCl ¹H-NMR (400 MHz, DMSO): δ 10.38 (brs, 1H), 9.63 (d, J = 1.6 Hz, 1H), 9.00 (d, J = 8.0 Hz, 1H), 8.95-8.94 (m, 2H), 8.39 (d, J = 9.2 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.88-7.85 (m, 1 H), 7.49- 7.48 (m, 3H), 7.07-7.04 (m, 1H), 3.94-3.89 (m, 5H), 3.60- DMSO 95 Method G1, AQ1 387.1 (M + 1) Method B (NH₄HCO₃) 3.57 (m, 2H), 1.96-1.93 (m, 2H). 1550

¹H-NMR (400 MHz, DMSO): δ 9.62 (s, 1H), 8.72- 8.70 (m, 2H), 8.40 (s, 1H), 8.11- 7.94 (m, 2H), 7.91-7.74 (m, 3H), 7.54 (dd, J = 7.6, 4.8 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H), 3.83 (s, DMSO 95 Method G1, AQ1 343.1 (M + 1) Method B (NH₄HCO₃) 3H), 2.74 (s, 3H). 1551

¹H-NMR (400 MHz, DMSO): δ 9.64 (s, 1H), 8.76 (d, J = 8.0 Hz, 1H), 8.70 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.12-7.83 (m, 5H), 7.57 (dd, J = 7.8, 4.8 Hz, 1H), 7.39 (t, J = 8.7 Hz, 2H), DMSO 95 Method G1, AQ1 331.1 (M + 1) Method B (NH₄HCO₃) 2.84 (s, 3H). 1552

1H-NMR (400 MHz, DMSO): δ 9.62 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.71 (d, J = 4.4 Hz, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 8.07- 8.00 (m, 2H), 7.60-7.50 (m, 3H), 7.40-7.37 (m, 1H), 4.48 (s, 2H), 4.12-4.10 (m, 2H), 3.48- 3.46 (m, 2H). DMSO 95 Method G1, AQ1 418.1 (M + 1) Method B (NH₄HCO₃) 1553

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 9.45 (s, 1H), 9.27 (d, J = 8.8 Hz, 1H), 8.97 (s, 1H), 8.69 (s, 1H), 8.12- 8.00 (m, 3H), 7.83-7.76 (m, 1H), 7.51-7.32 (m, 2H), 480- 4.64 (m, 2H). DMSO 95 Method G1, AQ1 417.1 (M + 1) Method B (NH₄HCO₃) 1554

2HCl ¹H-NMR (400 MHz, CD3OD): δ 9.86 (s, 1H), 9.48 (d, J = 8.8 Hz, 1H), 9.18 (d, J = 5.2 Hz, 1H), 8.72 (s1H), 8.92 (s, 1H), 8.37-8.31 (m, 2H), 8.22 (d, J = 8.8 Hz, 1H), 7.80-7.55 (m, 1H), 7.26- 7.20 (m, 2H), 4.92 (d, J = 4.8 Hz, CD3OD 95 Method G1, AQ1 380.9 (M + 1) Method B (NH₄HCO₃) 1H), 4.81 (t, J = 4.8 Hz, 1H), 4.39-4.30 (m, 2H). 1555

¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 8.7-8.68 (m, 2H), 8.32 (s, 1H), 7.97- 7.93 (m, 2H), 7.91-7.36 (m, 5H), 347 (s, 6H). DMSO 95 Method G1, AQ1 345.1 (M + 1) Method B (NH₄HCO₃) 1556

¹H-NMR (400 MHz, DMSO-d₆): δ 9.61 (s, 1H), 8.75 (d, J = 8.0 Hz, 1H), 8.67 (d, J = 3.6 Hz, 1H), 8.48 (s, 1H), 8.13 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.59-7.49 (m, 3H), 7.45-7.30 (m, 5H), 7.02- 6.92 (m, 1H), 4.50 (q, J = 3.2 Hz, 1H), 4.39- 4.20 (m, 2H), 4.14-4.09 (m, DMSO 95 Method G1, AQ1 493.0 495.0 (M + 1) Method B (NH₄HCO₃) 1H), 3.98-3.83 (m, 1H), 3.38 (s, 3H), 2.49-2.40 (m, 1H), 2.35- 2.18 (m, 1H). 1557

¹H-NMR (400 MHz, DMSO-d₆): δ 9.60 (s, 1H), 8.73 (dd, J = 7.6, 1.2 Hz, 1H), 8.67 (dd, J = 8.4, 1.2 Hz, 1H), 8.47 (s, 1H), 8.11 (dd, J = 8.4, 1.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.54- 7.50 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.38- 7.32 (m, 2H), 7.32-7.23 (m, 2H), 7.05 (d, J = DMSO 95 Method G1, AQ1 489.1 (M + 1) Method B (NH₄HCO₃) 8.4 Hz, 1H), 7.00-6.92 (m, 2H), 4.45 (t, J = 8.4 Hz, 1H), 4.24 (s, 2H), 4.08- 3.95 (m, 1H), 3.88-3.80 (m, 7H), 2.44-2.33 (m, 1H), 2.29- 2.15 (m, 1H). 1558

¹H-NMR (400 MHz, DMSO-d₆): δ 9.56 (s, 1H), 9.02 (s, 1H), 8.19 (d, J = 7.5 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.58 (dd, J = 7.7, 4.9 Hz, 1H), 7.52- 7.37 (m, 3H), 7.37-7.24 (m, 3H), 7.12 (t, J = 8.8 Hz, 2H), 7.02 (d, J = 7.5 Hz, 1H), 6.84 (s, DMSO 95 Method G1, AQ1 506.1 (M + 1) Method B (NH₄HCO₃) 1H), 3.89-3.78 (m, 4H), 3.72-3.66 (m, 1H), 3.13 (s, 1H), 2.97-2.90 (m, 1H), 2.86- 2.78 (m, 1H). 1559

2 HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.48-10.00 (m, 1H), 9.70 (s, 1H), 9.12-8.77 (m, 3H), 8.42- 8.32 (m, 1H), 8.30-8.17 (m, 1H), 7.95-7.79 (m, 1H), 7.55- 7.44 (m, 6H), 7.26 (d, J = 7.2 Hz, 1H), 7.05 (s, 1H), 6.94 (s, 1H), 3.89 (s, 5H), 3.22 (s, 1H), 2.97- 2.81 (m, 2H). DMSO 95 Method G1, AQ1 558.1 560.0 562.0 (M + 1) Method B (NH₄HCO₃) 1560

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.25 (s, 1H), 9.61 (d, J = 1.5 Hz, 1H), 8.96 (d, J = 4.0 Hz, 1H), 8.87 (s, 1H), 8.39 (d, J = 8.5 Hz, 1H), 8.25 (d, J = 7.7 Hz, 1H), 7.87 (s, 1H), 7.52- 7.44 (m, 4H), 7.36 (t, J = 7.6 Hz, 1H), 7.28 (dd, J = 13.5, 6.0 Hz, 1H), 7.22-7.10 (m, 2H), 7.06 (d, J = 7.5 Hz, 1H), 6.89 (s, 1H), 3.95- DMSO 95 Method G1, AQ1 508.2 (M + 1) Method B (NH₄HCO₃) 3.81 (m, 5H), 3.21 (d, J = 9.0 Hz, 1H), 2.94 (d, J = 7.3 Hz, 2H). 1561

¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (s, 1H), 8.74 (m, 2H), 8.69 (d, J = 3.5 Hz, 1H), 8.64 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.58-7.49 (m, 1H), 7.43 (m, 4H), 7.28-7.18 (m, 4H), 7.15 (m, 1H), 7.01 (d, DMSO 95 Method G1, AQ1 503.9 (M + 1) Method B (NH₄HCO₃) J = 7.2 Hz, 1H), 6.94 (s, 1H), 3.82- 3.73 (m, 5H), 2.90-2.87 (m. 1H), 2.68-2.65 (m, 2H), 1.89- 1.86 (m, 2H). 1562

¹H-NMR (400 MHz, DMSO-d₆): 9.85 (s, 1H), 8.76 (s, 1H), 8.65 (d, J = 3.6 Hz, 1H), 8.64 (s, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.51 (dd, J = 8.0, 4.7 Hz, 1H), 7.45 (d, J = 6.7 Hz, 2H), 7.40 (s, 1H), DMSO 95 Method G1, AQ1 489.9 (M + 1) Method B (NH₄HCO₃) 7.31-7.27 (m, 5H), 7.24 (d, J = 6.6 Hz, 1H), 7.00 (d, J = 6.9 Hz, 1H), 6.80 (s, 1H), 3.77-3.70 (m, 5H), 3.17-3.15 (m, 1H), 2.98- 2.81 (m, 2H). 1563

¹H-NMR (400 MHz, DMSO-d₆): δ 9.57 (s, 1H), 8.74-8.68 (m, 2H), 8.21 (s, 1H), 8.15 (dd, J = 8.7, 1.6 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.56-7.52 (m, 2H), 7.46- 7.31 (m, 4H), 7.12 (d, J = 6.5 Hz, 2H), 6.95-6.93 (m, 1H), 5.16 (s, 2H), 3.78 (s, 3H), 3.53 (s, 3H). DMSO 95 Method G1, AQ1 467.1, 469.1 (M + 1) Method B (NH₄HCO₃) 1564

¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 1.4 Hz, 1H), 8.75 (d, J = 7.9 Hz, 1H), 8.70 (d, J = 4.6 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = DMSO 95 Method G1, AQ1 507.2 (M + 1) Method B (NH₄HCO₃) 7.9, 4.8 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.36- 7.29 (m, 2H), 7.01-6.98 (m, 1H), 6.88 (s, 1H), 6.83 (s, 2H), 4.12-4.03 (m, 2H), 3.85 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H), 3.56 (d, J = 8.0 Hz, 3H), 3.16-3.02 (m, 2H). 1565

¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (d, J = 2.0 Hz, 1H), 8.77- 8.69 (m, 2H), 8.68 (d, J = 1.6 Hz, 1H), 8.64 (d, J = 1.6 Hz, 1H), 8.16 (dd, J = 8.8, 1.6 Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 7.55- 7.52 (m, 1H ), 7.46-7.41 (m, 4H), 7.29 (t, J = 7.2 Hz, 1H), 7.23-7.19 (m, 1H), 7.14-7.06 (m, 2H), 7.01 (dt, J = DMSO 95 Method G1, AQ1 522.3 (M + 1) Method B (NH₄HCO₃) 9.2, 2.0 Hz, 1H), 6.96 (s, 1H), 3.87-3.76 (m, 5H), 2.94- 2.93 (m, 1H), 2.68 (t, J = 7.8 Hz, 2H), 1.89- 1.83 (m, 2H). 1566

¹H-NMR (400 MHz, DMSO-d₆): δ 9.59 (s, 1H), 8.76 (t, J = 5.2 Hz, 1H), 8.69 (dd, J = 4.4, 1.2 Hz, 1H), 8.63 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.15 (dd, J = 8.8, 1.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.53-7.50 (m, 1H), 7.48-7.40 (m, 3H), 7.36- 7.32 (m, 3H), 7.30-7.24 (m, 2H), 7.02-7.00 (m, 1H), 6.85 (s, DMSO 95 Method G1, AQ1 524.2, 526.2 (M + 1) Method B (NH₄HCO₃) 1H), 3.92-3.83 (m, 4H), 3.72- 3.69 (m, 1H), 3.18-3.14 (m, 1H), 2.96-2.84 (m, 2H). 1567

¹H-NMR (400 MHz, DMSO-d₆): δ 9.64 (s, 1H), 9.08 (s, 1H), 8.79- 8.69 (m, 2H), 8.51 (s, 1H), 8.31 (s, 1H), 8.00- 7.89 (m, 2H), 7.85- 7.69 (m, 1H), 7.67-7.42 (m, 2H), 7.30-7.21 (m, 2H), 5.00 (d, J = 5.1 Hz, 2H). DMSO 95 Method G1, AQ1 416.0 (M + 1) Method B (NH₄HCO₃) 1568

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.58 (s, 1H), 10.09 (d, J = 4.4 Hz, 1H), 9.65 (s, 1H), 9.05-9.02 (m, 2H), 8.95 (d, J = 4.4 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.30- 8.27 (m, 1H), DMSO 95 Method G1, AQ1 504.1 (M + 1) Method B (NH₄HCO₃) 7.85 (t, J = 6.2 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.49-7.43 (m, 3H), 7.24 (t, J = 7.8 Hz, 2H), 7.03-6.97 (m, 2H), 3.89 (s, 3H), 3.86- 3.84 (m, 2H), 2.44 (t, J = 7.0 Hz, 2H), 1.87- 1.77 (m, 4H). 1569

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.62 (s, 1H), 9.67 (s, 1H), 9.08 (d, J = 7.2 Hz, 1H), 9.03 (s, 1H), 8.97 (d, J = 5.2 Hz, 1H), 8.44 (t, J = 5.6 Hz, 1H), DMSO 95 Method G1, AQ1 518.1 (M + 1) Method B (NH₄HCO₃) 8.40 (dd, J = 8.8, 0.8 Hz, 1H), 8.32 (dd, J = 9.2, 2.8 Hz, 1H), 7.89 (t, J = 6.4 Hz, 1H), 7.50-7.44 (m, 3H), 7.25-7.14 (m, 5H), 7.03 (d, J = 7.2 Hz, 1H), 4.24 (d, J = 6.0 Hz, 2H), 3.89 (s, 3H), 3.87-3.82 (m, 2H), 2.26 (t, J = 7.0 Hz, 2H), 1.84-1.69 (m, 4H). 1570

¹H-NMR (400 MHz, DMSO-d₆): δ 9.55 (s, 1H), 8.69 (dd, J = 11.3, 6.2 Hz, 2H), 8.23 (s, 1H), 8.15 (d, J = 8.7 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.59- 7.50 (m, 2H), 7.44-7.26 (m, 3H), 7.23 (t, J = 7.5 Hz, 1H), 7.15 (s, 1H), 7.12 (d, J = 7.7 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 5.18 DMSO 95 Method G1, AQ1 451.2, 452.2, 453.2 (M + 1) Method B (NH₄HCO₃) (s, 2H), 3.79 (s, 3H), 3.54 (s, 3H). 1571

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.62 (s, 1H), 9.60 (s, 1H), 8.88 (d, J = 4.3 Hz, 1H), 8.82 (s, 1H), 8.78 (d, J = 8.1 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.75 (dd, J = 7.8, 5.1 Hz, 1H), 7.53-7.39 (m, 4H), 7.33 (dd, J = 14.3, 7.9 Hz, 1H), 7.12 (t, J = 7.8 Hz, 2H), 7.03 (dd, J = 11.0, 6.3 Hz, DMSO 95 Method G1, AQ1 508.1, 509.1, 510.1 (M + 1) Method B (NH₄HCO₃) 2H), 6.90 (s, 1H), 3.97-3.90 (m, 4H), 3.82 (dd, J = 18.0, 9.5 Hz, 1H), 3.19 (dd, J = 13.4, 7.5 Hz, 1H), 2.98 (dd, J = 13.6, 7.9 Hz, 1H), 2.87 (dd, J = 13.6, 6.7 Hz, 1H). 1572

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.20 (s, 1H), 9.61 (s, 1H), 8.94 (d, J = 4.8 Hz, 1H), 8.86 (s, 2H), 8.37 (d, J = 8.4 Hz, 1H), 8.22 (s, 1H), 7.83 (s, 1H), 7.56-7.32 (m, 6H), 7.31-7.19 (m, 2H), 7.06 (d, J = 7.2 Hz, 1H), 6.89 (s, 1H), 4.03-3.93 (m, 1H), 3.88 (s, 3H), 3.82 (dd, J = 14.4, 5.5 Hz, 1H), 3.22 (s, 1H), 3.02 DMSO 95 Method G1, AQ1 524.1, 525.1, 526.0 (M + 1) Method B (NH₄HCO₃) (d, J = 7.2 Hz, 2H). 1573

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.31 (s, 1H), 9.63 (s, 1H), 8.96 (d, J = 4.4 Hz, 1H), 8.90 (s, 1H), 8.84 (d, J = 7.7 Hz, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.91- 7.80 (m, 1H), 7.48 (dd, J = 15.6, 7.7 Hz, 3H), 7.36 (s, 1H), 7.24-7.03 (m, 5H), 6.85 (s, 1H), 4.03-3.93 (m, 1H), 3.88 (s, 3H), DMSO 95 Method G1, AQ1 504.1, 505.2, 506.1 (M + 1) Method B (NH₄HCO₃) 3.83 (dd, J = 14.7, 7.6 Hz, 1H), 3.15 (s, 1H), 2.94 (dd, J = 13.8, 8.0 Hz, 1H), 2.84 (dd, J = 13.8, 6.6 Hz, 1H), 2.29 (s, 3H). 1574

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 9.71 (s, 1H), 9.05 (d, J = 4.7 Hz, 1H), 9.01 (d, J = 7.6 Hz, 1H), 8.96 (s, 1H), 8.45 (d, J = 8.6 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 7.99- 7.89 (m, 1H), 7.61-7.41 (m, 4H), 7.23 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 7.6 Hz, 3H), 6.93 (s, 1H), 4.01-3.84 (m, 5H), 3.31-3.21 (m, 1H), 3.02- 2.97 (m, 7.5 Hz, DMSO 95 Method G1, AQ1 504.1 (M + 1) Method B (NH₄HCO₃) 1H), 2.87-2.81 (m, 1H), 2.29 (s, 3H).

1575

¹H-NMR (400 MHz, CD₃OD): δ 9.39 (s, 1H), 8.69 (d, J = 8.0 Hz, 1H); 8.65 (s, 1H), 8.38 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.60-7.53 (m, 1H), 7.35-7.25 (m, 5H), 7.18 (dd, J = 13.6, 7.2 Hz, 2H), 7.12 (s, 1H), 6.88 (dd, J = 7.9, 2.1 Hz, 1H), 4.49 (dd, J = 11.3, 7.9 Hz, 1H), 4.36-4.17 (m, 2H), 4.04 (t, J = CD3OD 95 Method G1, AQ1 459.0 (M + 1) Method B (NH₄HCO₃) 10.4 Hz, 1H), 3.74 (s, 3H), 3.60- 3.49 (m, 1H), 2.50- 2.39 (m, 1H), 2.27- 2.14 (m, 1H). 1576

¹H-NMR (400 MHz, DMSO- d₆): δ 9.67 (d, J = 1.7 Hz, 1H), 9.05 (s, 1H), 8.94 (d, J = 3.7 Hz, 1H), 8.59 (s, 1H), 8.40-8.22 (m, 2H), 7.85 (s, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.52- DMSO 95 Method G1, AQ1 527.0, 529.0 (M + 1) Method B (NH₄HCO₃) 7.36 (m, 4H), 7.04 (d, J = 7.6 Hz, 1H), 4.74-4.72 (m, 2H), 4.48-4.43 (m, 3H), 3.85 (s, 3H), 3.74-3.60 (m, 1H), 2.25-2.23 (m, 1H). 1577

2HCl ¹H-NMR (400 MHz, DMSO): δ 9.69 (d, J = 1.6 Hz, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.79 (d, J = 1.6 Hz, 1H), 8.73 (s, 1H), 8.21 (d, J = 9.2 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.67 (dd, J = 7.6, 4.8 Hz, 1H), 7.56- 7.38 (m, 7H), 7.05- 7.02 (m, 1H), 5.59 (s, 4H), 3.89 (s, 3H). DMSO 95 Method G1, AQ1 431.1 (M + 1) Method B (NH₄HCO₃) 1578

¹H-NMR (400 MHz, DMSO): δ 9.59 (d, J = 1.6 Hz, 1H), 8.81-8.64 (m, 2H), 8.28- 8.10 (m, 2H), 7.96 (d, J = 8.6 Hz, 1H), 7.55 (td, J = 8.5, 5.0 Hz, 3H), 7.40-7.06 (m, 5H), 6.94 (dd, J = 8.2, 2.0 Hz, 1H), 5.15 (s, 2H), 3.78 (s, 3H), 3.51 (s, 3H). DMSO 95 Method G1, AQ1 451.2 (M + 1) Method B (NH₄HCO₃) 1579

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 10.61 (s, 1H), 9.66 (s, 1H), 9.00 (d, J = 13.5 Hz, 3H), 8.43-8.31 (m, 2H), 7.89 (s, 1H), 7.48 (dd, J = 14.6, 7.2 Hz, 3H), 7.33-7.22 (m, 4H), 7.21- 7.14 (m, 1H), DMSO 95 Method G1, AQ1 491.2 (M + 1) Method B (NH₄HCO₃) 7.05 (d, J = 7.2 Hz, 1H), 4.10- 3.85 (m, 2H), 3.90 (s, 3H), 3.37- 3.27 (m, 1H), 3.07-2.91 (m, 2H). 1580

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.91 (s, 1H), 9.60 (s, 1H), 9.11 (s, 1H), 8.95 (s, 1H), 8.66 (s, 1H), 8.20-8.02 (m, 3H), 7.97 (s, 1H), 7.78 (dd, J = 13.3, 6.5 Hz, 1H), 7.50 (t, J = 11.3 Hz, 1H), 7.33 (t, J = 8.1 Hz, 1H), 7.21 (s, 1H), 5.08 (d, J = 3.8 Hz, 2H). DMSO 95 Method G1, AQ1 416.0 (M + 1) Method B (NH₄HCO₃) 1581

2HCl ¹H-NMR (400 MHz, DMSO- d₆): δ 9.84 (s, 1H), 9.71 (s, 1H), 9.12 (d, J = 6.2 Hz, 1H), 8.96 (d, J = 4.8 Hz, 1H), 8.91 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.30 (s, 1H), 7.88 (s, 1H), 7.57-7.38 (m, 3H), 7.24 (s, 1H), 7.08 (d, J = 7.9 Hz, 1H), 6.73 (s, 1H), 5.18- 5.05 (m, 1H), DMSO 95 Method G1, AQ1 440.2 (M + 1) Method B (NH₄HCO₃) 3.88 (s, 3H), 3.23 (dd, J = 14.8, 7.4 Hz, 1H), 2.31- 2.17 (m, 1H), 2.15-1.89 (m, 4H), 1.71-1.57 (m, 1H). 1583

2HCl 1H-NMR (300 MHz, DMSO): δ 10.39 (s, 1H), 9.71 (s, 1H), 9.14 (d, J = 8.1 Hz, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.71 (s, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.25-8.19 (m, 1H), 7.96-7.89 DMSO 95 Method AQ2, AP 361.7 (M + 1) Method C (m, 1H), 7.38 (dd, J = 9.2, 3.0 Hz, 1H), 7.34- 7.14 (m, 2H), 3.81 (s, 4H), 3.30 (d, J = 4.4 Hz, 4H). 1584

2HCl 1H-NMR (300 MHz, DMSO): δ 10.84 (s, 1H), 9.01 (s, 1H), 8.95 (d, J = 3.9 Hz, 1H), 8.72 (d, J = 7.8 Hz, 1H), 8.50- 8.40 (m, 1H), 8.33 (d, J = 8.8 Hz, 1H), 8.24 (td, J = 7.8, 1.7 Hz, DMSO 95 Method AQ2, AP 343.5 (M + 1) Method C 1H), 7.85 (dd, J = 6.5, 4.8 Hz, 1H), 7.57-7.43 (m, 3H), 7.09- 7.02 (m, 1H), 3.90 (s, 3H), 3.38 (s, 3H) 1585

2HCl 1H-NMR (300 MHz, DMSO): δ 10.44-10.13 (m, 1H), 9.66 (s, 1H), 9.08 (d, J = 10.1 Hz, 2H), 8.96 (d, J = 3.7 Hz, 1H), 8.44 (d, J = 8.9 Hz, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.13 (dd, J = 13.3, 5.3 DMSO 95 Method AQ2, AP 356.4 (M + 1) Method C Hz, 2H), 8.00 (d, J = 8.2 Hz, 1H), 7.91 (s, 1H), 3.30 (d, J = 4.4 Hz, 3H). 1586

1H-NMR (300 MHz, DMSO): δ 9.64 (s, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.73-8.69 (m, 1H), 8.63 (s, 2H), 8.47-8.37 (m, 1H), 8.32- 8.25 (m, 1H), 8.23-8.12 (m, 1H), 7.87 (d, J = DMSO 95 Method AQ2, AP 356.4 (M + 1) Method C 8.6 Hz, 1H), 7.73 (t, J = 9.0 Hz, 1H), 7.55 (dd, J = 7.9, 4.7 Hz, 1H), 3.20 (d, J = 4.3 Hz, 3H). 1587

1H-NMR (300 MHz, DMSO): δ 9.65 (s, 1H), 8.79 (d, J = 8.0 Hz, 1H), 8.72-8.57 (m, 2H), 8.24 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, DMSO 95 Method AQ2, AP 401.5 (M + 1) Method C 1H), 7.53 (t, J = 10.9 Hz, 2H), 7.45-7.36 (m, 1H), 3.99 (s, 3H), 3.94 (s, 3H), 3.21 (d, J = 4.1 Hz, 3H). 1588

2HCl 1H-NMR (300 MHz, DMSO): δ 10.77 (s, 1H), 9.66 (s, 1H), 9.06 (s, 2H), 8.95 (d, J = 3.8 Hz, 1H), 8.38 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 7.87 (s, 1H), 7.71 (d, J = 8.1 DMSO 95 Method AQ2, AP 361.5 (M + 1) Method C Hz, 1H), 7.38 (dd, J = 22.8, 11.6 Hz, 2H), 4.03 (s, 3H), 3.31 (d, J = 4.1 Hz, 3H). 1589

2HCl 1H-NMR (300 MHz, DMSO): δ 10.23-10.05 (m, 1H), 9.64 (s, 1H), 9.00 (s, 1H), 8.94 (s, 1H), 8.89 (s, 1H), 8.38 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 7.85 (s, 1H), 7.36 (d, J = 8.7 Hz, 2H), 6.95 (d, J = DMSO 95 Method AQ2, AP 361.5 (M + 1) Method C 10.9 Hz, 1H), 3.90 (s, 1H), 3.30 (d, J = 4.3 Hz, 3H). 1590

2HCl 1H-NMR (300 MHz, DMSO): δ 10.34 (s, 1H), 9.70 (s, 1H), 9.14 (d, J = 7.4 Hz, 1H) 8.98 (d, J = 3.9 Hz, 1H), 8.75 (s, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.93 (d, DMSO 95 Method AQ2, AP 361.3 (M + 1) Method C J = 4.8 Hz, 1H), 7.27 (dd, J = 19.5, 6.3 Hz, 3H), 3.88 (s, 3H), 3.28 (d, J = 4.1 Hz, 3H). 1591

2HCl 1H-NMR (300 MHz, DMSO): δ 10.21 (s, 1H), 9.66 (d, J = 1.6 Hz, 1H), 9.04 (d, J = 7.3 Hz, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.67 (s, 1H), 8.28-8.12 (m, 2H), 7.88 (s, 1H), 7.66 (t, J = DMSO 95 Method AQ2, AP 361.3 (M + 1) Method C 8.8 Hz, 1H), 7.11- 6.97 (m, 2H), 3.86 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). 1592

3HCl 1H-NMR (300 MHz, DMSO): δ 10.77 (s, 1H), 9.69 (s, 1H), 9.39 (s, 1H), 9.16 (d, J = 7.8 Hz, 1H), 9.04 (s, 1H), 8.97 (d, J = 3.6 Hz, 1H), 8.63 (d, J = 2.5 Hz, 1H), 8.53 (s, 2H), 8.31 DMSO 95 Method AQ2, AP 343.1 (M + 1) Method C (d, J = 8.5 Hz, 1H), 7.91 (d, J = 5.4 Hz, 1H), 4.11 (s, 3H), 3.30 (d, J = 4.4 Hz, 3H). 1593

2HCl DMSO 95 Method AQ2, AP 359.1 (M + 1) Method C 1594

1H-NMR (300 MHz, DMSO): δ 9.64 (d, J = 1.3 Hz, 1H), 8.82- 8.75 (m, 1H), 8.68 (dd, J = 4.8, 1.7 Hz, 1H), 8.60 (s, 1H), 8.53 (d, J = 1.7 Hz, 1H), DMSO 95 Method AQ2, AP 371.1 (M + 1) Method C 8.10 (dd, J = 8.7, 1.9 Hz, 1H), 7.86-7.77 (m, 4H), 7.58-7.48 (m, 2H), 7.09 (d, J = 8.8 Hz, 2H), 6.97 (d, J = 8.8 Hz, 1H), 3.99 (d, J = 6.0 Hz, 2H), 3.18 (d, J = 4.4 Hz, 3H), 1.82- 1.69 (m, 2H), 1.07 (d, J = 6.7 Hz, 3H). 1595

2HCl 1H-NMR (300 MHz, DMSO): δ 10.24-10.10 (bs, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.96 (d, J = 3.8 Hz, 1H), 8.90 (s, 1H), 8.39 (s, DMSO 95 Method AQ2, AP 443.5 (M + 1) Method C 1H), 8.20 (s, 1H), 8.07 (s, 1H), 7.98 (s, 1H), 7.89 (s, 1H), 7.54 (t, J = 9.1 Hz, 1H), 3.70 (bs, 4H), 3.59 (bs, 4H), 3.32 (d, J = 4.4 Hz, 3H). 1596

2HCl 1H-NMR (300 MHz, DMSO): δ 10.37 (s, 1H), 9.69 (d, J = 1.7 Hz, 1H), 9.10 (d, J = 7.0 Hz, 1H), 9.03-8.93 (m, 2H), 8.42 (d, J = 8.6 Hz, 1H), DMSO 95 Method AQ2, AP 428.5 (M + 1) Method C 8.28 (d, J = 9.3 Hz, 1H), 8.05 (d, J = 3.5 Hz, 1H), 7.99 (dd, J = 6.2, 2.4 Hz, 2H), 7.52 (t, J = 9.1 Hz, 1H), 3.54-3.43 (m, 4H), 3.30 (t, J = 10.4 Hz, 3H), 1.98-1.81 (m, 4H). 1597

2HCl 1H-NMR (300 MHz, DMSO): δ 10.71 (s, 1H), 8.96 (d, J = 3.9 Hz, 1H), 8.81 (s, 1H), 8.74 (d, J = 7.9 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.29-8.19 (m, 2H), 7.87 (dd, J = 6.5, 4.7 Hz, 1H), DMSO 95 Method AQ2, AP 349.4 (M + 1) Method C 7.80 (dd, J = 15.5, 8.9 Hz, 1H), 7.61-7.50 (m, 1H), 7.36 (d, J = 8.1 Hz, 1H), 3.37 (d, J = 4.5 Hz, 3H). 1598

1H-NMR (300 MHz, DMSO): δ 9.27 (d, J = 1.5 Hz, 1H), 8.61 (dd, J = 12.6, 3.0 Hz, 2H), 8.41 (d, J = 2.9 Hz, 1H), 8.34-8.27 (m, 1H), 8.16 (dd, J = 8.7, 1.9 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.45 (dd, J = 16.0, 9.2 Hz, 3H), DMSO 95 Method AQ2, AP 373.4 (M + 1) Method C 7.05-6.97 (m, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 3.19 (d, J = 4.3 Hz, 3H). 1599

2HCl 1H-NMR (300 MHz, DMSO): δ 10.44-10.13 (m, 1H), 9.65 (s, 1H), 9.02 (s, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.87 (s, 1H), 8.37 (d, J = 9.1 Hz, 1H), 8.24 (s, 1H), 7.86 (s, 2H), 7.78 (d, J = DMSO 95 Method AQ2, AP 343.5 (M + 1) Method C 7.9 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 4.64 (s, 2H), 3.33 (d, J = 4.2 Hz, 3H), 3.17 (s, 1H). 1600

MSA 1H-NMR (300 MHz, DMSO): δ 9.90 (s, 1H), 9.57 (d, J = 1.6 Hz, 1H), 8.93 (dd, J = 5.0, 1.5 Hz, 2H), 8.73 (s, 1H), 8.32 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.85 (dd, J = 10.1, DMSO 95 Method AQ2, AP 343.5 (M + 1) Method C 7.0 Hz, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 4.63 (s, 2H), 3.30 (d, J = 4.3 Hz, 3H), 2.32 (s, 3H). 1601

MsOH ¹H NMR (300 MHz, DMSO) δ 9.72 (brs, 1H), 9.58 (d, J = 1.6 Hz, 1H), 9.03-8.89 (m, 2H), 8.45 (d, J = 8.7 Hz, 1H), 8.11 (s, 1H), 7.99-7.84 (m, 2H), DMSO >98 G2/ AQ3 7.64 (ddd, J = 9.2, 6.1, 3.1 Hz, 1H), 7.58- 7.31 (m, 2H), 3.28 (d, J = 4.5 Hz, 3H), 2.39 (s, 3H). 1602

¹H NMR (300 MHz, DMSO) δ 9.59 (d, J = 2.0 Hz, 1H), 9.33 (s, 2H), 9.24 (s, 1H), 8.79 (d, J = 1.5 Hz, 1H), 8.76- 8.64 (m, 2H), 8.30 (dd, J = 8.7, 1.5 DMSO >98 G2/ AQ3 Hz, 1H), 8.12 (brs, 2H), 7.91 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H). 1603

¹H NMR (300 MHz, DMSO) δ 9.64-9.53 (m, 1H), 8.77-8.58 (m, 2H), 8.53 (s, 1H), 8.43 (d, J = 1.5 Hz, 1H), 8.11- 7.90 (m, 3H), 7.82 (d, J = 8.7 DMSO >98 G2/ AQ3 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 4.00 (s, 3H), 3.98 (s, 3H). 1604

¹H NMR (300 MHz, DMSO) δ 9.59 (d, J = 2.0 Hz, 1H), 8.83- 8.66 (m, 2H), 8.55 (s, 1H), 8.27- 7.99 (m, 4H), 7.99- 7.82 (m, 2H), 7.77 (d, J = 7.7 DMSO >98 G2/ AQ3 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.56 (dd, J = 7.9, 4.8 Hz, 1H). 1605

¹H NMR (300 MHz, DMSO) δ 9.58 (d, J = 2.1 Hz, 1H), 8.80-8.64 (m, 2H), 8.25 (dd, J = 8.7, 1.6 Hz, 1H), 8.10 (d, J = 8.3 Hz, 2H), 8.02 (d, J = 8.3 DMSO >98 G2/ AQ3 Hz, 2H), 7.88 (d, J = 8.7 Hz, 1H), 7.55 (dd, J = 7.9, 4.8 Hz, 1H). 1606

2HCl ¹H NMR (300 MHz, DMSO) δ 9.95-9.43 (m, 3H), 9.05 (d, J = 8.2 Hz, 1H), 8.99 (dd, J = 5.1, 1.5 Hz, 1H), 8.74 (s, 1H), 8.33 (d, J = 8.7 DMSO >98 G2/ AQ3 Hz, 1H), 8.21 (d, J = 8.7 Hz, 1H), 7.93 (dd, J = 8.0, 5.1 Hz, 1H), 7.79 (td, J = 8.9, 6.6 Hz, 1H), 7.51 (ddd, J = 11.5, 9.3, 2.6 Hz, 1H), 7.33 (td, J = 8.3, 1.9 Hz, 1H). 1607

3HCl ¹H NMR (300 MHz, DMSO) δ 11.88 (s, 1H), 9.77 (d, J = 1.7 Hz, 1H), 9.56-9.28 (m, 1H), 9.19- 9.01 (m, 1H), 8.31-8.11 (m, 4H), 7.75-7.47 (m, 2H), 7.47- 7.23 (m, 1H), 4.83-4.67 (m, 2H), 3.96 (t, J = DMSO >98 G2/ AQ3 12.2 Hz, 2H), 3.57 (d, J = 11.9 Hz, 2H), 3.46- 3.19 (m, 2H), 2.83 (d, J = 3.1 Hz, 3H). 1608

HCl ¹H NMR (300 MHz, DMSO) δ 14.45 (s, 1H), 10.36 (s, 1H), 9.31 (d, J = 2.2 Hz, 1H), 8.82 (s, 1H), 8.73 (ddd, J = 8.8, 2.5, 0.9 Hz, DMSO 100 Method AQ2/BF 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.56- 7.36 (m, 3H), 7.11 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 7.1 Hz, 1H), 3.99 (s, 3H), 3.87 (s, 3H), 3.30 (d, J = 3.9 Hz, 3H). 1609

HCl ¹H NMR (300 MHz, DMSO) δ 10.97 (s, 1H), 9.56-9.35 (m, 2H), 9.04-8.81 (m, 2H), 8.66 (t, J = 7.7 Hz, 1H), 8.61-8.45 (m, 2H), 8.15 (d, J = 8.6 Hz, 1H), 8.10-7.96 (m, DMSO 100 Method AQ2/BF 1H), 7.77-7.58 (m, 1H), 3.25 (d, J = 4.1 Hz, 3H). 1610

2 MsOH ¹H NMR (300 MHz, CDCl₃) δ 9.93 (brs, 1H), 9.61 (d, J = 1.8 Hz, 1H), 9.10-8.96 (m, 2H), 8.64 (s, 1H), 8.21 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.99 DMSO >98 G2/ AQ3 Method 3 (dd, J = 8.0, 5.3 Hz, 1H), 7.69- 7.47 (m, 2H), 7.47-7.34 (m, 1H), 3.30 (d, J = 4.5 Hz, 3H), 2.42 (s, 6H). 1611

2HCl ¹H NMR (300 MHz, CDCl₃) δ 10.42 (brs, 1H), 9.71 (d, J = 1.9 Hz, 1H), 9.17 (d, J = 8.1 Hz, 1H), 8.99 (dd, J = 5.1, 1.3 Hz, 1H), 8.78 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.17 (d, J = DMSO >98 G2/ AQ3 8.7 Hz, 1H), 7.94 (dd, J = 8.1, 5.2 Hz, 1H), 7.79 (td, J = 8.9, 6.7 Hz, 1H), 7.55-7.37 (m, 1H), 7.31 (td, J = 8.4, 2.2 Hz, 1H), 3.29 (d, J = 4.4 Hz, 3H). 1612

HCl ¹H NMR (300 MHz, DMSO) δ 9.95 (brs, 1H), 9.65 (s, 1H), 9.18- 9.02 (m, 1H), 8.95 (d, J = 4.7 Hz, 1H), 8.58 (d, J = 8.7 Hz, 1H), 8.28 (s, 1H), 8.09- 7.70 (m, 4H), 3.29 (d, J = 4.4 Hz, DMSO >98 G2/ AQ3 3H). 1613

¹H NMR (300 MHz, DMSO) δ 9.64 (d, J = 1.5 Hz, 1H), 8.77 (dt, J = 7.9, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.61-8.48 (m, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 1.8 Hz, 1H), 8.00- 7.83 (m, 3H), 7.55 DMSO >98 G2/ AQ3 (dd, J = 7.9, 4.8 Hz, 1H), 3.17 (d, J = 4.4 Hz, 3H). 1614

¹H NMR (300 MHz, DMSO) δ 9.65 (dd, J = 2.1, 0.8 Hz, 1H), 8.78 (dt, J = 8.0, 1.9 Hz, 1H), 8.69 (dd, J = 4.8, 1.7 Hz, 1H), 8.65- 8.50 (m, 1H), 8.33 (d, J = 8.6 Hz, 1H), 8.04-7.85 DMSO >98 G2/ AQ3 Method 3 (m, 1H), 7.69 (dt, J = 8.5, 1.8 Hz, 1H), 7.65- 7.37 (m, 3H), 3.18 (d, J = 4.5 Hz, 3H). 1615

¹H NMR (300 MHz, DMSO) δ 9.65 (d, J = 1.7 Hz, 1H), 8.84-8.74 (m, 1H), 8.69 (dd, J = 4.7, 1.5 Hz, 1H), 8.65- 8.52 (m, 1H), 8.34 (d, J = 8.6 Hz, 1H), 7.98 (s, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.69-7.43 (m, 3H), DMSO >98 G2/ AQ3 Method 3 3.18 (d, J = 4.3 Hz, 3H). 1760

2 HCl ¹H NMR (400 MHz, DMSO) δ 10.04 (s, 1H), 9.65 (s, 1H), 9.11- 8.99 (m, 1H), 8.96 (dd, J = 5.0, 1.4 Hz, 1H), 8.41 (s, 1H), 8.13- 8.05 (m, 1H), 7.92- 7.82 (m, 1H), 7.64-7.55 (m, 1H), 7.44- 7.26 (m, 3H), 3.27 DMSO >98 AQ5 ND 4 (d, J = 4.6 Hz, 3H), 2.47 (s, 3H).

6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-ol (lix-a)

6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-ol was prepared from 6-bromo-2-(pyridin-3-yl)quinazolin-4-ol (synthesized following Scheme 70 substituting 2-amino-5-bromobenzamide for 2-amino-5-bromo-3-methylbenzamide) and 3-methoxylphenylboronic acid as described in Scheme 72 using method AQ2. The resultant product, 6-(6-methoxypyridin-3-yl)-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine, was a pale yellow solid (19.1 mg, 51%). LCMS m/z=344 (M+1) (Method C) (retention time=2.01 min). ¹H NMR (300 MHz, DMSO) δ 9.64 (d, J=1.3 Hz, 1H), 8.84-8.74 (m, 1H), 8.68 (dd, J=6.2, 1.7 Hz, 2H), 8.57 (d, J=1.6 Hz, 2H), 8.16 (ddd, J=14.4, 8.7, 2.2 Hz, 2H), 7.85 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.00 (d, J=8.7 Hz, 1H), 3.93 (s, 3H), 3.18 (d, J=4.3 Hz, 3H).

Method AP: 6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline (lviii-g)

6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline was prepared from 6-(3-methoxyphenyl)-2-(pyridine-3-yl)quinazoline-4-ol and pyrrolidine in a manner analogous to that described for 6-bromo-N-methyl-2-(pyridine-3-yl)quinazoline-4-amine using Method AP in Scheme 72. 6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline was a pale yellow solid (43 mg, 31%). LCMS m/z=383 (M+1) (Method C) (retention time=2.49 min). ¹H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.94 (d, J=5.0 Hz, 2H), 8.56 (s, 1H), 8.32 (dd, J=19.9, 8.5 Hz, 2H), 7.83 (s, 1H), 7.56-7.30 (m, 3H), 7.04 (d, J=6.8 Hz, 1H), 4.27 (s, 4H), 3.86 (s, 3H), 2.08 (s, 4H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 76, replacing pyrrolidine with the appropriate amine and 3-methoxyphenylboronic acid with the appropriate boronic acid.

TABLE 25 Pur- Method ¹H- Re- ity for Num- NMR tention LCMS Per- Coup- ber Product Salt ¹H-NMR Solvent LCMS Time Protocol cent ling 1616

HCl 1H NMR (300 MHz, DMSO) δ 9.82 (s, 1H), 9.59 (s, 1H), 9.08-8.81 (m, 3H), 8.36 (d, J = 8.8 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 7.95-7.77 (m, 1H), 7.58- 7.37 (m, 3H), 7.05 (d, J = 6.5 Hz, 1H), 5.01- 4.79 (m, 1H), 3.87 (s, 3H), 1.42 (d, J = 6.5 Hz, 6H). DMSO 371 (M + 1) 2.36 Method C 100 Method AP 1617

HCl 1H NMR (300 MHz, DMSO) δ 10.38 (s, 1H), 9.64 (s, 1H), 9.43 (s, 1H), 9.28 (s, 1H), 9.07 (d, J = 7.9 Hz, 1H), 9.00- 8.76 (m, 3H), 8.48 (d, J = 7.5 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.08-7.95 (m, 1H), 7.94- 7.81 (m, 1H), 3.97-3.74 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H). DMSO 328 (M + 1) 1.82 Method C 100 Method AP 1618

HCl 1H NMR (300 MHz, DMSO) δ 10.11 (s, 1H), 9.58 (s, 1H), 9.03-8.79 (m, 3H), 8.35 (d, J = 8.7 Hz, 1H), 8.23-8.09 (m, 1H), 7.90- 7.75 (m, 1H), 7.58-7.36 (m, 3H), 7.04 (d, J = 3.3 Hz, 1H), 3.88 (s, 3H), 3.65 (t, J = 6.0 Hz, 2H), 2.29-2.09 (m, 1H), 1.02 (d, J = 6.7 Hz, 6H). DMSO 385 (M + 1) 1.76 Method D 100 Method AP 1619

HCl 1H NMR (300 MHz, DMSO) δ 9.83-9.52 (m, 2H), 9.27 (d, J = 7.1 Hz, 1H), 8.95 (d, J = 5.1 Hz, 1H), 8.87 (s, 1H), 8.32 (d, J = 8.9 Hz, 1H), 8.15- 7.92 (m, 2H), 7.59-7.33 (m, 3H), 7.04 (d, J = 3.4 Hz, 1H), 4.86-4.57 (m, 2H), 3.88 (s, 3H). DMSO 411 (M + 1) 1.99 Method D 100 Method AP 1620

HCl 1H NMR (300 MHz, DMSO) δ 10.50 (s, 1H), 9.64 (d, J = 1.4 Hz, 1H), 9.12- 8.85 (m, 3H), 8.46-8.33 (m, 1H), 8.27 (d, J = 8.9 Hz, 1H), 7.88 (dd, J = 7.9, 5.1 Hz, 1H), 7.57-7.37 (m, 3H), 7.11- 6.94 (m, 1H), 4.00-3.76 (m, 5H), 1.37 (t, J = 7.2 Hz, 3H). DMSO MS not work 1.56 Method D 100 Method AP 1621

1H NMR (300 MHz, DMSO) δ 9.57 (s, 1H), 8.78-8.50 (m, 3H), 8.33-7.89 (m, 3H), 7.83 (d, J = 8.7 Hz, 1H), 7.53 (dd, J = 7.9, 4.8 Hz, 1H), 7.47-7.32 (m, 3H), 7.04- 6.91 (m, 1H), 3.86 (s, 3H). DMSO 329 (M + 1) 1.47 Method D 100 Method AP 1622

HCl 1H NMR (300 MHz, DMSO) δ 9.56 (s, 1H), 9.14-8.87 (m, 2H), 8.50 (s, 1H), 8.33 (s, 2H), 7.94-7.77 (m, 1H), 7.52- 7.25 (m, 3H), 7.02 (d, J = 7.9 Hz, 1H), 3.84 (s, 3H), 3.71 (s, 6H). DMSO 357 (M + 1) 1.55 Method D 100 Method AP 1623

1H NMR (300 MHz, DMSO) δ 9.60 (d, J = 1.4 Hz, 1H), 8.81-8.55 (m, 3H), 8.42 (d, J = 1.8 Hz, 1H), 8.11 (ddd, J = 18.8, 8.7, 2.2 Hz, 2H), 7.86 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 7.9, 4.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.27 (s, 4H), 3.92 (s, 3H), 2.08 (s, 4H). DMSO 384.1 (M + 1) 2.33 Method C 100 Method AP 1624

2HCl 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.94 (d, J = 5.0 Hz, 2H), 8.56 (s, 1H), 8.32 (dd, J = 19.9, 8.5 Hz, 2H), 7.83 (s, 1H), 7.56-7.30 (m, 3H), 7.04 (d, J = 6.8 Hz, 1H), 4.27 (s, 4H), 3.86 (s, 3H), 2.08 (s, 4H). DMSO 383.2 (M + 1) 2.47 Method C  95 Method AP 1625

1H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.4 Hz, 1H), 8.85 (d, J = 7.9 Hz, 1H), 8.80- 8.72 (m, 2H), 8.45 (d, J = 8.7 Hz, 1H), 8.27 (dd, J = 14.9, 5.9 Hz, 3H), 7.63 (dd, J = 7.3, 4.8 Hz, 1H), 7.52-7.33 (m, 4H), 7.04 (d, J = 7.1 Hz, 1H), 3.88 (s, 3H). DMSO 380.1 (M + 1) 2.01 Method C 100 Method AP 1626

HCl 1H NMR (300 MHz, DMSO) δ 9.61 (s, 1H), 8.75 (d, J = 7.7 Hz, 1H), 8.68 (d, J = 4.6 Hz, 1H), 8.30 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.54 (dd, J = 7.6, 5.0 Hz, 1H), 7.07 (d, J = 8.7 Hz, 2H), 3.82 (s, 4H), 3.49 (s, 7H). DMSO 358.0 (M + 1) 2.25 Method C 100 Method AP 1627

HCl 1H NMR (300 MHz, DMSO) δ 9.62 (s, 1H), 8.76 (d, J = 7.9 Hz, 1H), 8.73- 8.66 (m, 1H), 8.19-8.09 (m, 2H), 7.97 (d, J = 8.6 Hz, 1H), 7.82-7.73 (m, 2H), 7.61-7.52 (m, 1H), 7.14- 7.05 (m, 2H), 3.94 (s, 5H), 3.89-3.80 (m, 9H). DMSO 399.2 (M + 1) 2.19 Method C 100 Method AP 1628

1H NMR (300 MHz, DMSO) δ 9.55 (dd, J = 2.1, 0.8 Hz, 1H), 8.76-8.62 (m, 3H), 8.60 (d, J = 1.7 Hz, 1H), 8.24-8.10 (m, 2H), 8.02 (s, 2H), 7.83 (d, J = 8.7 Hz, 1H), 7.56-7.46 (m, 1H), 6.98 (d, J = 9.2 Hz, 1H), 3.91 (s, 3H). DMSO 330.1 (M + 1) 1.72 Method C 100 Method AP 1629

1H NMR (300 MHz, DMSO) δ 9.65 (d, J = 2.1 Hz, 1H), 8.79 (d, J = 8.0 Hz, 1H), 8.73 (dd, J = 4.7, 1.6 Hz, 1H), 8.36-8.25 (m, 2H), 8.06 (d, J = 8.7 Hz, 1H), 7.59 (dd, J = 7.6, 4.4 Hz, 1H), 7.48-7.40 (m, 1H), 7.41- 7.29 (m, 2H), 7.01 (dd, J = 8.0, 2.4 Hz, 1H), 4.80 (q, J = 7.1 Hz, 2H), 3.85 (s, 3H), 1.53 (t, J = 7.0 Hz, 3H). DMSO 358 (M + 1) Method C  99 Method AP 1630

2 HCl 1H NMR (300 MHz, DMSO) δ 9.68 (d, J = 1.8 Hz, 1H), 9.07 (d, J = 5.5 Hz, 1H), 8.96 (d, J = 3.5 Hz, 1H), 8.90 (s, 1H), 8.37 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.94-7.83 (m, 1H), 7.57-7.39 (m, 3H), 7.22 (d, J = 1.0 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.72 (s, 1H), 5.18-5.04 (m, 1H), 3.88 (s, J = 2.7 Hz, 3H), 3.23 (dd, J = 13.7, 6.1 Hz, 1H), 2.31- 2.17 (m, 1H), 2.17-1.88 (m, 4H), 1.74-1.55 (m, 1H). DMSO 440.6 (M + 1) Method C  99 Method AP 1631

2 HCl 1H NMR (300 MHz, DMSO) δ 9.70 (d, J = 1.6 Hz, 1H), 9.24 (d, J = 7.4 Hz, 1H), 8.99 (dd, J = 5.3, 1.4 Hz, 1H), 8.34 (dd, J = 15.7, 6.1 Hz, 3H), 8.21 (d, J = 8.4 Hz, 1H), 8.01 (dd, J = 7.7, 5.1 Hz, 1H), 7.51-7.33 (m, 3H), 7.04 (dd, J = 7.8, 2.4 Hz, 1H), 4.67 (s, 2H), 4.33 (s, 2H), 3.87 (s, J = 3.6 Hz, 3H), 3.50 (s, 2H). DMSO 412.4 (M + 1) Method C  99 Method AP 1632

2 HCl 1H NMR (300 MHz, DMSO) δ 9.00 (d, J = 6.5 Hz, 2H), 8.78 (d, J = 6.5 Hz, 2H), 8.46-8.32 (m, 2H), 8.15 (d, J = 8.4 Hz, 1H), 7.53-7.30 (m, 3H), 7.02 (d, J = 7.8 Hz, 1H), 4.34 (s, J = 2.4 Hz, 3H), 3.86 (s, J = 2.5 Hz, 3H). DMSO 344.4 (M + 1) Method C  99 Method AP 1633

1H NMR (300 MHz, DMSO) δ 9.55 (dd, J = 2.1, 0.8 Hz, 1H), 8.76-8.62 (m, 3H), 8.60 (d, J = 1.7 Hz, 1H), 8.24-8.10 (m, 2H), 8.02 (s, 2H), 7.83 (d, J = 8.7 Hz, 1H), 7.56-7.46 (m, 1H), 6.98 (d, J = 9.2 Hz, 1H), 3.91 (s, 3H). DMSO 330.1 (M + 1) Method C  99 Method AP Num- ber Starting Material R¹ Starting Material R³ Product 1634

1635

1636

1637

1638

1639

1640

1641

1642

1643

1644

1645

1646

1647

1648

1649

1650

1651

1652

1653

1654

1655

1656

1657

1658

1659

1660

1661

1662

1663

1664

1665

1666

1667

1668

1669

1670

1671

1672

1673

1674

1675

1676

1677

1678 NH3

Salt ¹HNMR Purity Method Number Type ¹H NMR Solvent percent of Coupling 1634 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.78 (d, 2H, J = 5.4 Hz), 6.58 (d, 1H, J = F5, G2 1.1 Hz), 7.00-7.75 (m, 8H), 7.85 (d, (reflux) 1H, J = 8.6 Hz), 8.64-8.97 (m, 4H), 9.64 (s, 1H) 1635 ¹H NMR (DMSO-d₆) ppm 3.84-3.95 (m, DMSO >98 Method AQ3, 11H), 7.01 (d, 1H, J = 8.1 Hz), 7.32- F5, G2 7.46 (m, 3H), 7.56 (dd, 1H, J = 6.1, 8.1 (reflux) Hz), 7.97 (d, 1H, J = 8.2 H), 8.16- 8.76 (m, 4H), 9.61 (s, 1H) 1636 ¹H NMR (DMSO-d₆) ppm 2.23 (m, 2H), DMSO >98 Method AQ3, 3.85 (s, 3H), 4.71 (br s, 4H), 6.98 (dd, F5, G2 1H, J = 2.1, 8.0 Hz), 7.31-7.55 (m, 4H), (reflux) 7.87 (d, 1H, J = 8.2 Hz), 8.12-8.74 (m, 4H), 9.59 (s, 1H) 1637 1H NMR (DMSO-d6) ppm 1.77 (br s, DMSO >98 Method AQ3, 6H), 3.86-3.89 (br m, 7H), 6.99 (dd, F5, G2 1H, J = 1.4, 8.6 Hz), 7.31-7.57 (m, 4H), (reflux) 7.93 (d, 1H, J = 1.4, 8.6 Hz), 8.11-8.16 (m, 2H), 8.69-8.76 (m, 2H), 9.61 (s, 1H) 1638 1H NMR (DMSO-d6) ppm 2.18-2.22 DMSO >98 Method AQ3, (m, 1H), 3.00-3.09 (m, 1H), 3.11-3.22 F5, G2 (m, 2H), 3.31-3.34 (m, 1H), 3.86 (s, (relux) 3H), 6.29-6.31 (m, 1H), 7.17-8.82 (m, 14H), 9.63 (s, 1H) 1639 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.10-4.13 (m, 2H), 4.35-4.38 (m, 2H), F5, G2 6.92-7.46 (m, 10H), 7.85 (d, 1H, J = (reflux) 8.6 Hz), 8.16 (d, 1H, J = 8.6 Hz), 8.66- 8.75 (m, 4H), 9.61 (s, 1H) 1640 1H NMR (DMSO-d6) ppm 3.07 (t, 2H, DMSO >98 Method AQ3, J = 6.9 Hz), 3.87 (s, 3H), 3.92-3.96 (m, F5, G2 2H), 7.00-7.58 (m, 10H), 7.84 (d, 1H, J = (reflux) 8.6 Hz), 8.14 (d, 1H, J = 8.6 Hz), 8.59-8.78 (m, 4H), 9.64 (s, 1H) 1641 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.95 (d, 2H, J = 5.6 Hz), 7.01-7.51 (m, F5, G2 10H), 7.85 (d, 1H, J = 8.6 Hz), 8.16 (d, (reflux) 1H, J = 8.6 Hz), 8.65-8.73 (m, 4H), 9.56 (s, 1H) 1642 1H NMR (DMSO-d6) ppm 1.66-1.781 DMSO >98 Method AQ3, (m, 6H), 2.16-2.19 (m, 2H), 3.87 (s, F5, G2 3H), 4.78 (br s, 1H), 7.00-7.55 (m, 5H), (reflux) 7.83 (d, 1H, J = 8.6 Hz), 8.12 (d, 1H, J = 8.6 Hz), 8.29 (s, 1H), 8.67-8.77 (m, 3H), 9.62 (s, 1H) 1643 HCl 1H NMR (DMSO-d6) ppm 0.81 (t, 3H, DMSO >98 Method AQ3, J = 7.4 Hz), 1.47-1.54 (m, 2H), 2.00- F5, G2 2.05 (m, 2H), 3.32-3.37 (m, 4H), 3.86- (reflux) 3.91 (m, 5H), 7.03-7.80 (m, 5H), 8.16 (d, 1H, J = 8.7 Hz), 8.34 (d, 1H, J = 8.7 Hz), 8.86-8.96 (m, 3H), 9.61 (s, 1H), 10.03 (s, 1H) 1644 1H NMR (DMSO-d6) ppm 0.38-0.54 DMSO >98 Method AQ3, (m, 4H), 1.30-1.32 (m, 1H), 3.58-3.62 F5, G2 (m, 2H), 3.87 (s, 3H), 7.00-7.54 (m, (reflux) 5H), 7.86 (d, 1H, J = 8.6 Hz), 8.14 (d, 1H, J = 8.6 Hz), 8.64-8.76 (m, 4H), 9.62 (s, 1H) 1645 1H NMR (DMSO-d6) ppm 1.83-1.88 DMSO >98 Method AQ3, (m, 2H), 2.21-2.27 (m, 2H), 2.49 (br s, F5, G2 2H), 3.87 (s, 3H), 4.88-4.91 (m, 1H), (reflux) 7.03-7.57 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.13 (d, 1H, J = 8.6 Hz), 8.62-8.77 (m, 4H), 9.63 (s, 1H) 1646 1H NMR (DMSO-d6) ppm 3.21 (s, 1H), DMSO >98 Method AQ3, 3.88 (s, 3H), 4.52 (dd, 2H, J = 2.2, 5.2 F5, G2 Hz), 7.01-7.58 (m, 5H), 7.88 (d, 1H, J = (reflux) 8.7 Hz), 8.19 (d, 1H, J = 8.6 Hz), 8.64- 9.01 (m, 4H), 9.66 (s, 1H) 1647 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.37 (br s, 2H), 5.19 (dd, 1H, J = 1.5, F5, G2 10.2 Hz), 5.31 (dd, 1H, J = 1.5, 17.2 (reflux) Hz), 6.01-6.22 (m, 1H), 7.00-7.56 (m, 5H), 7.85 (d, 1H, J = 8.6 Hz), 8.16 (d, 1H, J = 8.6 Hz), 8.67-8.82 (m, 4H), 9.61 (s, 1H) 1648 1H NMR (DMSO-d6) ppm 0.94-0.99 (t, DMSO >98 Method AQ3, 6H, J = 7.4 Hz), 1.68-1.80 (m, 4H), F5, G2 3.87 (s, 3H), 4.49-4.52 (m, 1H), 7.01- (reflux) 7.47 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.11-8.15 (m, 2H), 8.67-8.75 (m, 3H), 9.63 (s, 1H) 1649 1H NMR (DMSO-d6) ppm 1.68 (s, 9H), DMSO >98 Method AQ3, 3.87 (s, 3H), 7.01-7.70 (m, 6H), 7.82 F5, G2 (d, 1H, J = 8.6 Hz), 8.11 (d, 1H, J = 8.6 (reflux) Hz), 8.67-8.74 (m, 3H), 9.60 (s, 1H) 1650 1H NMR (DMSO-d6) ppm 0.97 (t, 3H, DMSO >98 Method AQ3, J = 7.2 Hz), 1.44-1.48 (m, 2H), 1.74- F5, G2 1.78 (m, 2H), 3.71-3.75 (m, 2H), 3.89 (reflux) (s, 3H), 7.00-7.56 (m, 5H), 7.83 (d, 1H, J = 8.6 Hz), 8.15 (d, 1H, J = 8.6 Hz), 8.59-8.76 (m, 4H), 9.62 (s, 1H) 1651 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.98 (d, 2H, J = 5.6 Hz), 7.02-7.46 (m, F5, G2 7H), 7.87 (d, 1H, J = 8.7 Hz), 8.51 (dd, (reflux) 1H, J = 1.5, 4.5 Hz), 8.50-8.71 (m, 5H), 9.26 (s, 1H), 9.48 (s, 1H) 1652 1H NMR (DMSO-d6) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.98 (d, 2H, J = 5.5 Hz), 7.00-7.46 (m, F5, G2 6H), 7.86-7.90 (m, 2H), 8.16 (d, 1H, J = (reflux) 1.7 Hz), 8.46 (d, 1H, J = 1.7 Hz), 8.66-8.76 (m, 4H), 9.22 (s, 1H), 9.56 (s, 1H) 1653 1H NMR (DMSO-d6) ppm 3.22-3.27 DMSO >98 Method AQ3, (m, 2H), 3.87 (s, 3H), 4.04-4.11 (m, F5, G2 2H), 7.02-7.46 (m, 8H), 7.83 (d, 1H, J = (reflux) 8.6 Hz), 8.13 (d, 1H, J = 1.6 Hz), 8.67-8.78 (m, 5H), 9.64 (s, 1H) 1654 1H NMR (DMSO-d6) ppm 1.76-1.88 DMSO >98 Method AQ3, (m, 4H), 2.66 (br s, 1H), 3.37-3.48 (m, F5, G2 2H), 3.86 (s, 3H), 4.39-4.47 (m, 2H), (reflux) 6.95-7.57 (m, 7H), 7.95 (d, 1H, J = 8.7 Hz), 8.15-8.19 (m, 2H), 8.69-8.76 (m, 2H), 9.61 (s, 1H) 1655 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.97 (d, 2H, J = 5.6 Hz), 7.00-7.50 (m, F5, G2 8H), 7.85 (d, 1H, J = 8.7 Hz), 8.16 (s, (reflux) 1H), 8.66-8.77 (m, 3H), 9.11 (s, 1H), 9.61 (s, 1H) 1656 ¹H NMR (DMSO-d₆) ppm 2.28 (s, 3H), DMSO >98 Method AQ3, 3.87 (s, 3H), 4.91 (d, 2H, J = 5.5 Hz), F5, G2 7.00-7.52 (m, 9H), 7.86 (d, 1H, J = 8.6 (reflux) Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.16 (m, 3H), 9.18-9.16 (m, 1H), 9.57 (s, 1H) 1657 ¹H NMR (DMSO-d₆) ppm 3.71 (s, 3H), DMSO >98 Method AQ3, 3.87 (s, 3H), 4.91 (d, 2H, J = 5.7 Hz), F5, G2 6.82-7.52 (m, 9H), 7.86 (d, 1H, J = 8.7 (reflux) Hz), 8.17 (dd, 1H, J = 8.7, 1.8 Hz), 8.66-9.15 (m, 3H), 9.17-9.19 (m, 1H), 9.57 (s, 1H) 1658 ¹H NMR (DMSO-d₆) ppm 2.25 (s, 3H), DMSO >98 Method AQ3, 3.87 (s, 3H), 4.91 (d, 2H, J = 5.7 Hz), F5, G2 7.00-7.53 (m, 9H), 7.86 (d, 1H, J = 8.6 (reflux) Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.15 (m, 3H), 9.17-9.19 (m, 1H), 9.57 (s, 1H) 1659 ¹H NMR (DMSO-d₆) ppm 2.44 (s, 3H), DMSO >98 Method AQ3, 3.86 (s, 3H), 4.95 (d, 2H, J = 5.7 Hz), F5, G2 7.01-7.53 (m, 9H), 7.86 (d, 1H, J = 8.6 (reflux) Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.65-9.02 (m, 3H), 9.50-9.52 (m, 1H), 9.54 (s, 1H) 1660 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 7.03 (s, 1H), 7.44-7.94 (m, 10H), 8.07- F5, G2 8.70 (m, 4H), 9.41 (s, 1H) (reflux) 1661 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.91 (d, 2H, J = 5.5 Hz), 7.00-7.04 (m, F5, G2 1H), 7.04-7.55 (m, 7H), 7.87 (d, 1H, J = (reflux) 8.6 Hz), 8.18 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.18 (m, 3H), 9.18-9.21 (m, 1H), 9.55 (s, 1H) 1662 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.99 (d, 2H, J = 5.5 Hz), 7.01-7.05 (m, F5, G2 2H), 7.15-7.56 (m, 6H), 7.88 (d, 1H, J = (reflux) 8.6 Hz), 8.20 (dd, 1H, J = 8.6, 1.8 Hz), 8.64-9.18 (m, 3H), 9.19-9.21 (m, 1H), 9.50 (s, 1H) 1663 ¹H NMR (DMSO-d₆) ppm 3.49 (s, 3H), DMSO >98 Method AQ3, 3.74 (s, 3H), 5.15 (s, 2H), 6.90 (d, J = F5, G2 8.2 Hz, 1H), 7.04-7.29 (m, 2H), 7.33- (reflux) 7.54 (m, 7H), 7.93 (d, 1H, J = 8.6 Hz), 8.15 (dd, 1H, J = 8.6, 1.8 Hz), 8.21 (s, 1H), 8.68-8.75 (m, 2H), 9.59 (s, 1H) 1664 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.94 (d, 2H, J = 5.5 Hz), 7.01-7.03 (m, F5, G2 1H), 7.35-7.57 (m, 7H), 7.88 (d, 1H, J = (reflux) 8.6 Hz), 8.20 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.22 (m, 3H), 9.19-9.21 (m, 1H), 9.50 (s, 1H) 1665 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.96 (d, 2H, J = 5.5 Hz), 7.00-7.03 (m, F5, G2 2H), 7.33-7.52 (m, 7H), 7.88 (d, 1H, J = (reflux) 8.6 Hz), 8.19 (dd, 1H, J = 8.6, 1.8 Hz), 8.65-9.20 (m, 3H), 9.19-9.21 (m, 1H), 9.54 (s, 1H) 1666 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.93 (d, 2H, J = 5.5 Hz), 7.00-7.19 (m, F5, G2 3H), 7.41-7.55 (m, 6H), 7.88 (d, 1H, J = (reflux) 8.6 Hz), 8.17 (dd, 1H, J = 8.6, 1.8 Hz), 8.65-9.18 (m, 3H), 9.19-9.21 (m, 1H), 9.57 (s, 1H) 1667 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.92 (d, 2H, J = 5.5 Hz), 7.01-7.03 (d, F5, G2 1H, J = 7.0 Hz), 7.37-7.53 (m, 6H), (reflux) 7.72 (d, 1H, J = 8.6 Hz), 8.18 (dd, 1H, J = 8.6, 1.8 Hz), 8.66-9.19 (m, 3H), 9.20-9.23 (m, 1H), 9.56 (s, 1H) 1668 ¹H NMR (DMSO-d₆) ppm 1.68 (d, 3H, J = DMSO >98 Method AQ3, 7.0 Hz), 3.87 (s, 3H), 4.92 (d, 2H, J = F5, G2 5.5 Hz), 5.75-5.78 (m, 1H), 7.02 (d, (reflux) 1H, J = 7.0 Hz), 7.32-7.56 (m, 9H), 7.84 (d, 1H, J = 8.6 Hz), 8.15 (dd, 1H, J = 8.6, 1.8 Hz), 8.64-8.84 (m, 4H), 9.51 (s, 1H) 1669 ¹H NMR (DMSO-d₆) ppm 3.70 (s, 3H), DMSO >98 Method AQ3, 3.86 (s, 3H), 4.92 (d, J = 5.1 Hz, 2H), F5, G2 6.89-7.01 (m, 3H), 7.41-7.54 (m, 6H), (reflux) 7.85 (d, J = 8.6 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 8.67-8.75 (m, 3H), 9.19 (s, 1H), 9.56 (s, 1H) 1670 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 3.91 (s, 3H), 4.92 (d, J = 5.0 Hz, 2H), F5, G2 6.87-7.52 (m, 9H), 7.85 (d, J = 8.5 Hz, (reflux) 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.64-8.73 (m, 3H), 9.05 (s, 1H), 9.52 (s, 1H) 1671 ¹H NMR (DMSO-d₆) ppm 3.87 (s, 3H), DMSO >98 Method AQ3, 4.93 (d, J = 5.6 Hz, 2H), 7.02 (s, 1H), F5, G2 7.41-7.61 (m, 7H), 7.83 (d, J = 8.9 Hz, (reflux) 1H), 8.18 (d, J = 8.9 Hz, 1H), 8.66-8.71 (m, 3H), 9.21 (s, 1H), 9.54 (s, 1H) 1672 ¹H NMR (DMSO-d₆) ppm 3.69 (s, 6H), DMSO >98 Method AQ3, 3.87 (s, 3H), 4.93 (d, J = 5.6 Hz, 2H), F5, G2 6.90 (s, 1H), 7.00-7.54 (m, 7H), 7.85 (reflux) (d, J = 8.6 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H), 8.66-8.78 (m, 3H), 9.14 (s, 1H), 9.63 (s, 1H) 1673 — DMSO  95 Method AQ3, AP 1674 2HCl 1H-NMR (300 MHz, DMSO): δ 9.71 (d, DMSO  95 Method AQ3, J = 1.6 Hz, 1H), 9.16 (d, J = 8.2 Hz, AP 1H), 8.98 (dd, J = 5.1, 1.5 Hz, 1H), 8.58 (s, 1H), 8.48-8.34 (m, 3H), 8.20 (d, J = 8.0 Hz, 1H), 7.98-7.87 (m, 2H), 7.75 (t, J = 7.8 Hz, 1H), 3.73 (s, 6H). 1675 1H-NMR (300 MHz, DMSO): δ 9.59 (s, DMSO  95 Method AQ3, 1H), 8.78-8.62 (m, 2H), 8.38 (s, 1H), AP 8.05 (dd, J = 8.6, 1.8 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.73 (d, J = 8.7 Hz, 2H), 7.52 (dd, J = 7.8, 4.7 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 4.04 (s, 4H), 3.82 (s, 3H), 2.02 (s, 4H). 1676 3HCl 1H-NMR (300 MHz, DMSO): δ 10.40 DMSO  95 Method AQ3, (s, 1H), 9.48 (d, J = 2.0 Hz, 1H), 8.95 AP (s, 2H), 8.88 (d, J = 5.2 Hz, 1H), 8.72 (d, J = 4.3 Hz, 1H), 8.35 (d, J = 8.9 Hz, 1H), 8.18 (s, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.94-7.81 (m, 2H), 7.64 (s, 1H), 7.54-7.45 (m, 3H), 7.06-7.00 (m, 1H), 5.25 (d, J = 5.1 Hz, 2H), 3.88 (s, 3H). 1677 1H-NMR (300 MHz, DMSO): δ 12.83 DMSO  95 Method AQ3, (s, 1H), 9.32 (d, J = 2.2 Hz, 1H), 8.77 AP (dd, J = 4.8, 1.5 Hz, 1H), 8.63 (d, J = 2.5 Hz, 1H), 8.56-8.49 (m, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.23-8.14 (m, 2H), 7.85 (d, J = 8.5 Hz, 1H), 7.60 (dd, J = 8.0, 4.8 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 3.92 (s, 3H). 1678 2HCl ¹H NMR (300 MHz, DMSO) δ 9.79 DMSO >98 Method AQ3, (brs, 1H), 9.60 (s, 2H), 9.07 (d, J = 7.4 F5, G2 Hz, 1H), 9.00 (d, J = 4.5 Hz, 1H), 8.80 (reflux) (s, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.02-7.88 (m, 1H), 7.67-7.48 (m, 2H), 7.49-7.37 (m, 1H).

Method AT for Alkylation: Method AT1: NaOMe/MeOH/microwave/150° C. Method AT2: MeOH/microwave/150° C. Method AT3: DIPEA/KI/DMF/microwave/150° C.

Method AR: 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (lxi-a)

To a suspension of 6-(3-methoxyphenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (prepared in a similar method described for 6-(3-methoxyphenyl)-2-(pyridine-3-yl)-4-(pyrrolidin-1-yl)quinazoline using Scheme 74, substituting N-methylamine for pyrrolidine) (1.00 g, 2.9 mmol) in CH₂Cl₂ (15 mL) and boron tribromide 1M solution in dichloromethane (8.76 ml, 8.76 mmol) was added at 0° C. The reaction mixture was stirred overnight at room temperature after which it was carefully poured into a vigorously stirring mixture of ice and saturated aqueous solution of NaHCO₃. The resultant solid was collected by filtration, dried and then dissolved in a mixture of K₂CO₃ (2 g) and methanol (50 mL). The solution was then acidified using aqueous NH₄Cl solution. (50 mL) and the precipitate which formed was collected by filtration and dried to give 0.95 g of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol as pale yellow solid (99%). LCMS m/z=329 (M+1) (Method D) (retention time=1.30 min). ¹H NMR (300 MHz, DMSO) δ 9.63 (s, 1H), 9.60 (s, 1H), 8.77 (d, J=8.0 Hz, 1H), 8.74-8.59 (m, 2H), 8.54 (s, 1H), 8.05 (d, J=8.7 Hz, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.54 (dd, J=7.9, 4.8 Hz, 1H), 7.38-7.12 (m, 3H), 6.82 (d, J=7.8 Hz, 1H), 3.17 (d, J=4.3 Hz, 3H).

Method AS: 6-(3-(2-chloroethoxyl)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (lxii-a)

A suspension of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (0.30 g, 0.914 mmol), 1-bromo-2-chloroethane (0.38 ml, 4.57 mmol), and potassium carbonate (0.38 g, 2.74 mmol) in DMF (10 mL) was stirred for 2 days at room temperature. Water (10 mL) and ethyl acetate (10 mL) were added to the mixture and extracted. The organic layer was separated and concentrated in vacuo to leave a solid, which was collected by filtration and washed with hexane and dried to give 0.30 g of 6-(3-(2-chloroethoxyl)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as brown solid (83%). The product was used without further purification.

Method AT1: 6-(3-(2-methoxyethoxyl)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (lxiii-a)

A solution of 6-(3-(2-chloroethoxyl)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (70 mg, 0.18 mmol) and sodium methoxide (97 mg, 1.8 mmol) in methanol (3 mL) was placed in a microwave reaction vial. The mixture was heated under microwave irradiation conditions at 150° C. for 30 minutes after which the solvent was removed in vacuo. The crude product was obtained, which was purified by column chromatography on basic silica gel (eluted with hexane/ethyl acetate 3:1→1:4) to give 20 mg of 6-(3-(2-methoxyethoxyl)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine as an off-white powder (29%). LCMS m/z=387 (M+1) (Method D) (retention time=1.49 min). ¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J=8.2 Hz, 1H), 8.73-8.51 (m, 3H), 8.16 (d, J=8.7 Hz, 1H), 7.84 (d, J=8.3 Hz, 1H), 7.60-7.32 (m, 4H), 7.01 (s, 1H), 4.21 (s, 2H), 3.70 (s, 2H), 3.33 (s, 3H), 3.19 (s, 3H).

Method AT2: N-Methyl-6-(4-(2-morpholinoethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine (lxiii-b)

In a 10 mL microwave vial 6-(4-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (70.0 mg, 0.179 mmol) and morpholine (0.155 ml, 1.791 mmol) were added in methanol (3 mL) to give a yellow suspension. The vial was irradiated at 150° C. in the microwave for 30 min. The volatiles were evaporated in vacuo. Water (10 mL) was added to the reaction mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), then dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on basic silica gel (eluted with hexane/ethyl acetate 3:2 to 0:1). The product was obtained as the parent and converted to the HCl salt by addition of 4 M HCl-dioxane, then crystallized from EtOH—H2O to give 55 mg of N-methyl-6-(4-(2-morpholinoethoxyl)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine as a yellow powder (60% yield). LCMS m/z=442 (M+1) (Method D) (retention time=1.12 min). ¹H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 10.41 (s, 1H), 9.63 (s, 1H), 9.10-8.79 (m, 3H), 8.34 (d, J=8.2 Hz, 1H), 8.28-8.12 (m, 1H), 7.92 (d, J=8.0 Hz, 2H), 7.87-7.74 (m, 1H), 7.18 (d, J=8.0 Hz, 2H), 4.60-4.46 (m, 2H), 4.06-3.91 (m, 2H), 3.91-3.74 (m, 2H), 3.67-3.41 (m, 4H), 3.38-3.09 (m, J=10.1 Hz, 5H).

Method AT3: N-methyl-2-(pyridin-3-yl)-6-(3-(2-(2,2,2 trifluoroethylamino)ethoxy)phenyl)quinazolin-4-amine (lxiii-c)

In a 10 mL microwave vial was added 6-(3-(2-chloroethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (50.0 mg, 0.128 mmol), 2,2,2-trifluoroethylamine (0.100 ml, 1.279 mmol), potassium iodide (42.5 mg, 0.256 mmol), and N,N′-diisopropylethylamine (0.045 ml, 0.256 mmol) in DMF (3 mL) to give a yellow suspension. The vial was irradiated at 150° C. in the microwave for 20 min Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×20 mL). The organic layers were combined and washed with water (1×20 mL) and brine (1×20 mL), dried over MgSO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with CH₂Cl₂/CH₂Cl₂-MeOH—NH₄OH=100:20:1 1:0 to 0:1). The product was converted to the HCl salt by addition of 4 M HCl-dioxane, then crystallization from IPA-H2O to give 30 mg of N-methyl-2-(pyridin-3-yl)-6-(3-(2-(2,2,2-trifluoroethylamino)ethoxy)phenyl)quinazolin-4-amine as a yellow powder (42%). LCMS m/z=454 (M+1) (Method C) (retention time=2.26 min). ¹H NMR (300 MHz, DMSO) δ 10.73-10.36 (m, 1H), 9.65 (s, 1H), 9.13-8.98 (m, 2H), 8.93 (d, J=5.0 Hz, 1H), 8.38 (d, J=8.4 Hz, 1H), 8.24 (d, J=7.7 Hz, 1H), 7.94-7.75 (m, 1H), 7.69-7.41 (m, 3H), 7.09 (d, J=8.1 Hz, 1H), 4.61-4.43 (m, 2H), 4.28-4.07 (m, 2H), 3.59-3.39 (m, 2H), 3.30 (d, J=2.8 Hz, 3H).

Scheme 80: Method AU: N-(2-(4-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenoxy)ethyl)acetamide (lxiv-a)

In a 50 mL round-bottomed flask was added 6-(4-(2-aminoethoxy)phenyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (15.0 mg, 0.040 mmol) and triethylamine (0.017 ml, 0.121 mmol) in CH₂Cl₂ (5 mL) to give a yellow solution. Acetic anhydride (4.58 μl, 0.048 mmol) was added and the mixture was stirred for 2 h at room temperature. Water (10 mL) was added to the mixture and extracted with ethyl acetate (2×10 mL). The organic layers were combined and washed with brine (1×20 mL), dried over Mg₂SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted with CH₂Cl₂/MeOH 1:0 to 9:1). The product was converted to the HCl salt by addition of 4 M HCl-dioxane, then dissolved in a small amount of methanol, followed by ethyl acetate. The resulting solid was filtered and dried to give 10 mg of N-(2-(4-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenoxy)ethyl)acetamide as a HCl salt as a yellow solid in a 51% yield. LCMS m/z=414 (M+1) (Method C) (retention time=1.28 min). ¹H NMR (300 MHz, DMSO) δ 10.26 (s, 1H), 9.62 (s, 1H), 9.06-8.90 (m, 2H), 8.81 (s, 1H), 8.34 (d, J=9.0 Hz, 1H), 8.17 (d, J=6.6 Hz, 2H), 7.86 (d, J=8.0 Hz, 3H), 7.13 (d, J=7.9 Hz, 2H), 4.06 (t, J=5.4 Hz, 2H), 3.52-3.38 (m, 2H), 3.30 (d, J=4.1 Hz, 3H), 1.84 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 78, replacing 1-bromo-2-chloroethane with the corresponding alkyl halide.

TABLE 26 ¹H- Re- Pur- Method NMR ten- ity for Num- Sol- tion LCMS per- Coup- ber PRODUCT Salt ¹H-NMR vent LCMS Time Protocol cent ling 1679

HCl 1H NMR (300 MHz, DMSO) δ 10.36 (s, 1H), 9.65 (s, 1H), 9.13-8.99 (m, 1H), 8.99- 8.83 (m, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.30-8.16 (m, 1H), 7.94- 7.80 (m, 1H), 7.55-7.35 (m, 3H), 7.09- 6.97 (m, 1H), 4.16 (q, J = 7.0 Hz, 2H), 3.31 (d, J = 4.3 Hz, 3H), 1.37 (t, J = 6.9 Hz, 3H). DMSO 357 (M + 1) 1.62 Method D 100 Method AR/AS/ AT1 1680

1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 8.2 Hz, 1H), 8.73-8.51 (m, 3H), 8.16 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.60-7.32 (m, 4H), 7.01 (s, 1H), 4.21 (s, 2H), 3.70 (s, 2H), 3.33 (s, 3H), 3.19 (s, 3H). DMSO 387 (M + 1) 1.49 Method D 100 Method AR/AS/ AT1 1681

1H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.78 (d, J = 7.9 Hz, 1H), 8.72-8.49 (m, 3H), 8.22-8.01 (m, 2H), 7.85 (d, J = 8.6 Hz, 1H), 7.62-7.36 (m, 4H), 7.01 (s, 1H), 4.59 (s, 2H), 3.19 (d, J = 4.0 Hz, 3H), 2.68 (d, J = 4.5 Hz, 3H). DMSO 400 (M + 1) 1.31 Method D 100 Method AR/W with KI 1682

2HCl 1H NMR (300 MHz, DMSO) d 10.47 (s, 1H), 9.65 (d, J = 1.7 Hz, 1H), 9.05 (d, J = 7.9 Hz, 1H), 9.01- 8.88 (m, 2H), 8.39 (m, 1H), 8.23 (d, J = 8.8 Hz, 1H), 7.87 (dd, J = 8.0, 5.3 Hz, 1H), 7.65- 7.39 (m, 3H), 7.09 (m, 1H), 6.44 (m, 1H), 4.47 (td, J = 14.7, 3.4 Hz, 2H), 3.29 (d, J = 4.5 Hz, 3H). DMSO 393.4 (M + 1) Method C NH4HCO3) 100 Method AR/AS (K2CO3, DMF- THF (1:1), 60° C.) then Method AT 1683

HCl ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.60 (s, 1H), 9.03- 8.87 (m, 2H), 8.77 (s, 1H), 8.32 (d, J = 8.5 Hz, 1H), 8.21-8.02 (m, 1H), 7.92-7.69 (m, 3H), 7.20-7.02 (m, 2H), 4.93 (s, 2H), 3.70- 3.40 (m, 8H), 3.29 (d, J = 3.5 Hz, 3H). DMSO 456 (M + 1) 1.73 (M + 1) Method B (Ammon- ium formate) 100 Method AR/W with KI 1684

HCl ¹H NMR (300 MHz, DMSO) δ 10.38 (s, 1H), 9.64 (s, 1H), 9.02 (d, J = 6.7 Hz, 1H), 8.93 (d, J = 4.9 Hz, 1H), 8.84 (s, 1H), 8.34 (d, J = 9.0 Hz, 1H), 8.22 (d, J = 8.7 Hz, 1H), 7.98- 7.70 (m, 3H), 7.11 (d, J = 7.3 Hz, 2H), 4.26-4.05 (m, 2H), 3.78- 3.57 (m, 2H), 3.45-3.19 (m, 6H). DMSO 387 (M + 1) 1.47 Method A (Formic acid) 100 Method AR/AS/ AT1 1685

HCl ¹H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 10.41 (s, 1H), 9.63 (s, 1H), 9.10-8.79 (m, 3H), 8.34 (d, J = 8.2 Hz, 1H), 8.28-8.12 (m, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.87-7.74 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 4.60-4.46 (m, 2H), 4.06- 3.91 (m, 2H), 3.91-3.74 (m, 2H), 3.67-3.41 (m, 4H), 3.38- 3.09 (m, J = 10.1 Hz, 5H). DMSO 442 (M + 1) 1.22 Method A (Formic acid) 100 Method AR/AS/ AT2 1686

HCl ¹H NMR (300 MHz, DMSO) δ 10.32-9.70 (m, 1H), 9.61 (s, 1H), 9.13- 8.70 (m, 5H), 8.29 (d, J = 8.5 Hz, 1H), 8.20-8.01 (m, 1H), 7.89 (d, J = 8.6 Hz, 2H), 7.83- 7.67 (m, 1H), 7.16 (d, J = 8.8 Hz, 2H), 4.38-4.27 (m, 2H), 3.43-3.32 (m, 2H), 3.27 (d, J = 3.7 Hz, 3H), 2.63 (t, J = 4.8 Hz, 3H). DMSO 386 (M + 1) 1.46 Method B (Ammon- ium formate) 100 Method AR/AS/ AT2 1687

HCl ¹H NMR (300 MHz, DMSO) δ 9.95 (s, 1H), 9.62 (s, 1H), 9.13-8.86 (m, J = 5.2 Hz, 3H), 8.39 (d, J = 8.7 Hz, 1H), 8.26 (s, 1H), 7.97-7.80 (m, 1H), 7.61- 7.37 (m, 3H), 7.14- 6.98 (m, 1H), 5.01-4.81 (m, 1H), 4.31- 4.13 (m, 2H), 3.79-3.63 (m, 2H), 1.42 (d, J = 6.5 Hz, 6H). DMSO 415 (M + 1) 1.65 Method A (Formic acid) 100 Method AR/AS/ AT1 1688

HCl ¹H NMR (300 MHz, DMSO) δ 10.12 (s, 1H), 9.63 (s, 1H), 9.10-8.88 (m, 2H), 8.72 (s, 1H), 8.44 (d, J = 8.3 Hz, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.85 (dd, J = 7.6, 4.8 Hz, 1H), 7.52 (d, J = 6.3 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.22- 7.04 (m, 2H), 4.97 (s, 2H), 3.30 (d, J = 4.1 Hz, 3H), 2.97 (s, 3H), 2.85 (s, 3H). DMSO 414 (M + 1) 1.28 Method A (Formic acid) 100 Method AR/W with KI 1689

HCl ¹H NMR (300 MHz, DMSO) δ 10.22 (s, 1H), 9.63 (s, 1H), 9.10-8.87 (m, 2H), 8.75 (s, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.15 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 4.2 Hz, 1H), 7.93- 7.77 (m, 1H), 7.51 (d, J = 7.3 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 8.5 Hz, 1H), 4.54 (s, 2H), 3.29 (d, J = 3.9 Hz, 3H), 2.64 (d, J = 4.4 Hz, 3H). DMSO 400 (M + 1) 1.33 Method A (Formic acid) 100 Method AR/W with KI 1690

HCl ¹H NMR (300 MHz, DMSO) δ 10.09 (s, 1H), 9.62 (s, 1H), 9.05-8.87 (m, 2H), 8.60 (s, 1H), 8.26 (d, J = 8.6 Hz, 1H), 8.13 (d, J = 8.8 Hz, 1H), 7.90- 7.77 (m, 1H), 7.54-7.36 (m, 2H), 7.26-7.06 (m, 2H), 4.23- 4.11 (m, 2H), 3.70-3.58 (m, 2H), 3.29 (d, J = 4.4 Hz, 3H), 3.24 (s, 3H). DMSO 387 (M + 1) 1.51 Method A (Formic acid) 100 Method AR/AS/ AT1 1691

HCl ¹H NMR (300 MHz, DMSO) δ 9.65 (s, 1H), 9.04 (d, J = 7.8 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.50 (s, 1H), 8.39-8.22 (m, 2H), 7.97- 7.80 (m, 1H), 7.53-7.31 (m, 3H), 7.03 (d, J = 6.8 Hz, 1H), 4.26- 4.13 (m, 2H), 3.82-3.59 (m, 8H), 3.32 (s, 3H). DMSO 401 (M + 1) 1.47 Method A (Formic acid) 100 Method AR/AS/ AT1 1692

HCl ¹H NMR (300 MHz, DMSO) δ 9.83-9.26 (m, 3H), 9.00- 8.76 (m, 3H), 8.40 (d, J = 8.8 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.89-7.72 (m, 1H), 7.58- 7.36 (m, 3H), 7.04 (d, J = 3.4 Hz, 1H), 4.30-4.18 (m, 2H), 3.79- 3.66 (m, 2H), 3.33 (s, 3H). DMSO 373 (M + 1) 1.42 Method A (Formic acid) 100 Method AR/AS/ AT1 1693

HCl ¹H NMR (300 MHz, DMSO) δ 10.73-10.36 (m, 1H), 9.65 (s, 1H), 9.13- 8.98 (m, 2H), 8.93 (d, J = 5.0 Hz, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.24 (d, J = 7.7 Hz, 1H), 7.94-7.75 (m, 1H), 7.69- 7.41 (m, 3H), 7.09 (d, J = 8.1 Hz, 1H), 4.61-4.43 (m, 2H), 4.28- 4.07 (m, 2H), 3.59-3.39 (m, 2H), 3.30 (d, J = 2.8 Hz, 3H). DMSO 454 (M + 1) 2.26 Method B (Ammon- ium formate) 100 Method AR/AS/ AT3 1694

HCl ¹H NMR (300 MHz, DMSO) δ 10.35 (s, 1H), 9.67 (s, 1H), 9.04 (d, J = 7.3 Hz, 1H), 8.94 (d, J = 5.0 Hz, 1H), 8.78 (s, 1H), 8.24 (s, 2H), 7.96-7.77 (m, 1H), 7.60- 7.40 (m, 2H), 7.33-7.10 (m, 2H), 4.50-4.36 (m, 2H), 4.05- 3.85 (m, 2H), 3.53- 3.37 (m, 2H), 3.28 (d, J = 3.6 Hz, 3H). DMSO 454 (M + 1) 2.11 Method B (Ammon- ium formate) 100 Method AR/AS/ AT3 1695

¹H NMR (300 MHz, DMSO) δ 9.64 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 8.73-8.50 (m, 3H), 8.14 (d, J = 8.7 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.54 (dd, J = 7.9, 4.8 Hz, 1H), 7.48- 7.34 (m, 3H), 6.96 (d, J = 3.2 Hz, 1H), 4.91 (s, 2H), 3.18 (d, J = 4.3 Hz, 3H), 3.03 (s, 3H), 2.86 (s, 3H). DMSO 414 (M + 1) 1.30 Method A (Formic acid) 100 Method AR/W with KI

Method AV: 1-(Benzyloxy)-7-bromo-3-chloroisoquinoline (lxv-a)

To 20 mL of benzylalcohol was slowly added Na (2.00 g, 86.9 mmol) at 0° C., the mixture was then stirred at room temperature for 4 h. 7-bromo-1,3-dichloroisoquinoline (2.00 g, 7.2 mmol) in toluene (50 mL) was added to the mixture with stirring. The reaction mixture was heated at 80° C. overnight. The solvent was removed under reduced pressure, the residue was purified with chromatography on silica gel (petroleum ether) to give 2.00 g xiv-a as a white solid (yield 80%). LCMS m/z=257.9, 259.9 (M+1) (Method B) (retention time=1.62 min)

Method AQ1: 1-(Benzyloxy)-3-chloro-7-(3-methoxyphenyl) isoquinoline (lxvi-a)

To a mixture of 1-(benzyloxy)-7-bromo-3-chloroisoquinoline (1.00 g, 2.86 mmol, 1.0 eq), 3-methoxyphenylboronic acid (435 mg, 2.86 mmol, 1.0 eq), K₂CO₃ (2.13 g, 15.4 mmol, 5.4 eq) in dioxane (10 mL) and H₂O (5 mL) was added Pd(PPh₃)₂Cl₂ (100 mg, 0.15 mmol, 0.05 eq) under N₂ atmosphere. The resulting mixture was stirred at 110° C. under N₂ atmosphere overnight. The solvent was removed in vacuo and the residue was purified with chromatography on silica gel (hexane/ethyl acetate 250:1) to give 550 mg of lxvi-a as white solid (yield 37%). LCMS m/z=376.0 (M+1) (Method B) (retention time=2.43 min)

Method AQ3: 1-(Benzyloxy)-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (lxvii-a)

To a mixture of 1-(benzyloxy)-3-chloro-7-(3-methoxyphenyl)isoquinoline (150 mg, 0.40 mmol, 1.0 eq), pyridin-3-ylboronic acid (74 mg, 0.60 mmol, 1.5 eq), K₂CO₃ (166 mg, 1.20 mmol, 3.0 eq) in dioxane (2 mL) and H₂O (1 mL) was added Pd(PPh₃)₂Cl₂ (14 mg, 0.02 mmol, 0.05 eq) under N₂ atmosphere. The sealed tube was irradiated in the CEM microwave at 130° C. for 1 h. After the reaction was completed, the volatiles were removed in vacuo and the residue was purified with chromatography on silica gel (hexane/ethyl acetate 50:1) to give 200 mg of crude lxvii-a as a brown oil, which was used directly in the next step without purification. LCMS m/z=419.0 (M+1) (Method B) (retention time=2.25 min)

Method AW: 7-(3-Methoxyphenyl)-3-(pyridin-3-yl)isoquinolin-1-ol (lxviii-a)

A mixture of 1-(benzyloxy)-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (200 mg, 0.48 mmol), and concentrated HCl (10 mL) in ethanol (20 mL) was stirred at room temperature overnight. After the reaction was completed, the mixture was filtered and concentrated to afford 130 mg of lxviii-a as a yellow solid (yield 90% for two steps). LCMS m/z=329.0 (M+1) (Method B) (retention time=1.66 min)

Method AX: 1-Chloro-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (lxix-a)

To a mixture of 7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinolin-1-ol (130 mg, 0.395 mmol) in phenylphosphonic dichloride (5 mL) was stirred at 120° C. overnight. After the reaction was completed, the mixture was added to ice-water slowly. The pH was adjusted to 7 by slow addition of NH₃H₂O at 0° C. Then the mixture was extracted with dichloromethane (100 mL x 3). The combined organic layer were dried over MgSO₄, filtered and concentrated in vacuo to give 130 mg of crude lxix-a as a white solid, which was used directly in the next step without purification. LCMS m/z=346.9 (M+1) (Method B) (retention time=1.80 min)

Method AY: 7-(3-Methoxyphenyl)-N-methyl-3-(pyridin-3-yl)isoquinolin-1-amine (lxx-a)

A mixture of 1-chloro-7-(3-methoxyphenyl)-3-(pyridin-3-yl)isoquinoline (90 mg, 0.26 mmol), methylamine hydrochloride (200 mg, 2.96 mmol, 10.0 eq) and Et₃N (0.5 mL) was added to a sealed tube with i-AmOH (2 mL). The sealed tube was irradiated in the CEM microwave at 160° C. for 1 h. After the reaction was completed, the i-AmOH was removed in vacuo and the residue was dissolved in 10 mL of water and dichloromethane, the mixture was extracted with dichloromethane (3×50 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo and the residue was washed with MeOH to give 5 mg of lxx-a as a brown solid (yield 6%). LCMS m/z=342.1 (M+1) (Method B) (retention time=2.02 min). ¹H NMR (400 MHz, DMSO-d₆): δ 9.40 (d, J=0.9 Hz, 1H), 8.67-8.47 (m, 3H), 8.08-7.95 (m, 1H), 7.89-7.84 (m, 2H), 7.66 (s, 1H), 7.57-7.49 (m, 1H), 7.46-7.42 (m, 3H), 7.08-6.95 (m, 1H), 3.88 (s, 3H), 3.14 (d, J=4.3 Hz, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 81, replacing with the appropriate isoquinoline and aniline.

TABLE 27 Mole- ¹H- Method Num- Salt cular NMR LCMS Purity for ber PRODUCT type Mass ¹H-NMR Solvent LCMS Protocol percent Coupling 1697

341.41 1H-NMR (400 MHz, DMSO-d6): δ 9.40 (d, J = 0.9 Hz, 1H), 8.67- 8.47 (m, 3H), 8.08- 7.95 (m, 1H), 7.89- 7.84 (m, 2H), 7.66 (s, 1H), 7.57-7.49 (m, 1H), 7.46-7.42 (m, 3H), 7.08-6.95 (m, 1H), 3.88 (s, 3H), 3.14 (d, J = 4.3 Hz, 3H). DMSO 342.1 (M + 1) Method B (NH4HCO3) 95 Method AX, H1 1698

312.37 1H-NMR (400 MHz, DMSO-d6): δ 9.40 (d, J = 1.8 Hz, 1H), 9.12 (d, J = 2.1 Hz, 1H), 8.66 (s, 1H), 8.60 (m, 2H), 8.54 (dt, J = 8.0, 1.9 Hz, 1H), 8.29-8.23 (m, 1H), 8.08 (dd, J = 8.5, 1.6 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 4.5 Hz, 1H), 7.68 (s, 1H), 7.56 (dd, J = 7.8, 4.8 Hz, 1H), 7.51 (dd, J = 7.8, 4.8 Hz, 1H), 3.14 (d, J = 4.4 Hz, 3H). DMSO 312.9 (M + 1) Method B (NH4HCO3) 95 Method AX, H1

Method BA: Synthesis of 5-[3-(4-Methylamino-2-pyridin-3-yl-quinazolin-6-yl)-phenoxymethyl]-oxazolidin-2-one (lxxi-a)

To 5-(chloromethyl)oxazolidin-2-one (45 μmol) was added the solution of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (30 μmol) in NMP (200 μL). PS-BEMP (90 μmol) was added to the vials by resin dispenser. After the reaction mixture was heated at 90° C. for 12 h, the residue was diluted with methanol and purified by PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 80, replacing 5-(chloromethyl)oxazolidin-2-one with the appropriate alkyl halide.

TABLE 28 Starting Starting Number Material 1 Material 2 1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715

Mass Salt Exact Found Purity Number Product Type Mass (M + 1) (%) 1699

427 428 98 1700

421 422 98 1701

TFA 467 468 98 1702

515 516 98 1703

2TFA 468 469 98 1704

TFA 436 437 98 1705

455 456 98 1706

438 439 98 1707

421 422 98 1708

453 454 98 1709

TFA 467 468 98 1710

487 488 98 1711

TFA 515 516 98 1712

TFA 436 437 98 1713

TFA 422 423 98 1714

TFA 476 477 98 1715

2TFA 438 439 98

Method BB: Synthesis of 3-methyl-6-((3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenoxy)methyl)benzo[d]oxazol-2(3H)-one (lxxi-b)

To 6-(hydroxymethyl)-3-methylbenzo[d]oxazol-2(3H)-one (45 μmol) was added the solution of 3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenol (30 μmol) in THF (400 μL). After PS-triphenylphosphine (60 μmol) was added, the solution of DBAD (di-tert-butyl azodicarboxylate, 66 μmol) in THF was dispensed to the vials. The mixture was heated at 50° C. for 8 h. After the solvent was removed, the residue was diluted with methanol and purified by Mass triggered PREP-HPLC Condition D. The target fraction was lyophilized to afford the titled compound whose structure was finally confirmed by LCMS using LCMS Method E.

The compounds in the following table were prepared in a manner analogous to that described in Scheme 85, replacing 6-(hydroxymethyl)-3-methylbenzo[d]oxazol-2(3H)-one with the appropriate alkyl alcohol.

TABLE 29 Number Starting Material 1 Starting Material 2 1716

1717

1718

1719

1720

1721

1722

1723

1724

1725

1726

1727

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

Salt Mass Found Number Product Type Exact Mass (M + 1) Purity (%) 1716

TFA 489 490 100 1717

448 449 100 1718

TFA 422 423 100 1719

TFA 422 423 100 1720

TFA 472 473 100 1721

TFA 489 490 100 1722

TFA 489 490 100 1723

TFA 466 467 100 1724

TFA 425 426  94 1725

TFA 453 454 100 1726

TFA 489 490 100 1727

TFA 489 490 100 1728

TFA 448 449 100 1729

TFA 422 423 100 1730

TFA 504 505 100 1731

TFA 424 425 100 1732

TFA 433 434 100 1733

TFA 484 485 100 1734

TFA 466 467 100 1735

TFA 425 426 100 1736

TFA 464 465  95 1737

TFA 466 467 100 1738

TFA 489 490 100

Synthesis of N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)acetamide (lxxii-a)

A 100 mL round bottom flask was fitted with a reflux condenser and charged with 6-bromo-2-(pyridin-3-yl)quinazolin-4-amine (2.45 g, 8.14 mmol), acetic anhydride (5.81 g, 57.0 mmol) and acetic acid (30 mL). The reaction mixture was stirred at 90° C. for 20 min and then cooled to room temperature. A precipitate formed during the reaction and was collected by filtration and washed with water (100 mL). The solid was dried at 60° C. to give N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)acetamide as a white powder (1.83 g, 66%). ¹H NMR (300 MHz, CDCl₃) δ 9.72 (s, 1H), 8.84-8.69 (m, 3H), 8.22 (s, 1H), 8.02-7.90 (m, 2H), 7.53-7.41 (m, 1H), 2.83 (s, 3H).

Synthesis of N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)-N-methylacetamide (lxxiii-a)

To a solution of 6-bromo-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine (1.20 g, 3.81 mmol) in acetic acid (10 mL) was added acetic anhydride (1.94 g, 19.0 mmol) and stirred at 195° C. using microwave for 6 h. The reaction mixture was checked by LC-MS, no starting material was observed, ice was added into the reaction. The precipitate was collected by filtration and washed with water. The product was dried at 60° C. to give N-(6-bromo-2-(pyridin-3-yl)quinazolin-4-yl)-N-methylacetamide (711 mg, 52%) as a light brown powder. ¹H NMR (300 MHz, CDCl₃) δ 9.76 (dd, J=2.2, 0.8 Hz, 1H), 8.85-8.79 (m, 1H), 8.76 (dd, J=4.8, 1.7 Hz, 1H), 8.09 (dd, J=1.8, 0.8 Hz, 1H), 8.05-8.01 (m, 2H), 7.46 (ddd, J=8.0, 4.8, 0.8 Hz, 1H), 3.52 (s, 3H), 2.11 (s, 3H).

Method BC: Synthesis of 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lxxv-a) (Compound 1742)

To a solution of the hydroxyl derivative (520 mg, 1.27 mmol) in DMF (20 mL) was added methyl iodide (262 mg, 1.84 mmol) and NaH (55% in oil; 69 mg, 1.9 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 h and the ice water was added into the reaction mixture. The resulting solution was extracted with ethyl acetate (3 times), dried over Na₂SO₄, concentrated and purified by column chromatography (NH-silica gel, 50% hexane/50% ethyl acetate). The resulting product was dissolved in isopropyl alcohol and 1N—HCl (5 mL) was added and a precipitate formed which was collected by filtration and dried at 60° C. to give 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride as an orange powder (130 mg, 21%). ¹H NMR (300 MHz, DMSO) δ 9.66 (d, J=1.6 Hz, 1H), 9.09 (d, J=8.1 Hz, 1H), 8.96 (dd, J=5.1, 1.5 Hz, 1H), 8.51 (s, 1H), 8.33 (d, J=8.7 Hz, 1H), 8.20 (d, J=8.8 Hz, 1H), 7.90 (dd, J=8.1, 5.1 Hz, 1H), 7.66-7.47 (m, 2H), 7.47-7.32 (m, 1H), 4.22-4.07 (m, 2H), 3.70 (s, 3H), 3.48 (t, J=5.8 Hz, 2H), 3.22 (s, 3H), 2.19-2.01 (m, 2H).

Method BD: 2-(3-(4-(dimethylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenyl)ethanol, 2HCl (lxxvi-a)

To a reaction vial containing 2-(3-(4-(methylamino)-2-(pyridin-3-yl)quinazolin-6-yl)phenyl)ethanol (89.0 mg, 0.25 mmol) in DMF (1 mL) was added 60% sodium hydride (13 mg, 0.325 mmol) and iodomethane (0.02 mL, 0.325 mmol). The reaction mixture was allowed to stir at ambient temperature for 12 h. Water (20 mL) was added to the reaction mixture, and the crude product was extracted with ethyl acetate (4×15 mL). The crude material was purified via ISCO (silica, 4 g column, 95% CH₂Cl₂-5% MeOH-0.1% NH₄OH) to give the product as an off-white solid. The free base was then converted to the HCl salt to yield the final product as a yellow solid (24.6 mg, 0.055 mmol, 22%). LC-MS m/z=371.5 (M+1) (retention time=1.86)¹H NMR (300 MHz, DMSO) δ 9.61 (d, J=2.1 Hz, 1H), 8.99 (d, J=7.5 Hz, 1H), 8.93 (dd, J=5.0, 1.5 Hz, 1H), 8.48 (d, J=1.0 Hz, 1H), 8.28 (dd, J=17.4, 9.4 Hz, 2H), 7.84 (dd, J=7.7, 5.1 Hz, 1H), 7.69-7.60 (m, 2H), 7.44 (t, J=7.5 Hz, 1H), 7.30 (d, J=7.3 Hz, 1H), 3.78-3.61 (m, 9H), 2.82 (t, J=7.0 Hz, 2H).

Synthesis of 6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride (lxxvii-a) (Compound 1744)

6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride was synthesized in a similar manner to that described for 6-(2,3-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine dihydrochloride substituting the appropriate hydroxyl derivative. 6-(2,4-difluorophenyl)-N-(3-methoxypropyl)-N-methyl-2-(pyridin-3-yl)quinazolin-4-amine was obtained as the dihydrochloride salt ¹H NMR (300 MHz, DMSO) δ 9.69 (d, J=2.0 Hz, 1H), 9.14 (d, J=8.3 Hz, 1H), 8.97 (dd, J=5.1, 1.2 Hz, 1H), 8.45 (s, 1H), 8.39 (d, J=8.6 Hz, 1H), 8.17 (d, J=8.8 Hz, 1H), 7.92 (dd, J=8.0, 5.2 Hz, 1H), 7.86-7.73 (m, 1H), 7.57-7.38 (m, 1H), 7.36-7.23 (m, 1H), 4.19-4.04 (m, 2H), 3.71 (s, 3H), 3.48 (t, J=5.7 Hz, 2H), 3.23 (s, 3H), 2.21-1.96 (m, 2H).

Method BE: 4-(3,4-dichlorophenyl)-1-(6-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazolin-4-yl)pyrrolidin-2-one (lxxviii-a)

To a mixture of 4-chloro-6-(3-methoxyphenyl)-2-(pyridin-3-yl)quinazoline (40 mg, 0.12 mmol), 4-(3,4-dichlorophenyl)pyrrolidin-2-one (100 mg, 0.437 mmol) and Cs₂CO₃ (42 mg, 0.127 mmol) in dry toluene (6 mL) was added Pd(OAc)₂ (3 mg, 0.01 mmol) and Xantphos (10 mg, 0.02 mmol) under a nitrogen atmosphere. The resulting mixture was stirred at 100° C. for 12 h. After cooling, the mixture was filtered through a pad of celite. The residue was purified by silica gel chromatography, eluted with petroleum ether/ethyl acetate (5:4) to give the desired product as a yellow solid. 14 mg of the desired product was obtained in a 22.5%. yield, LCMS: retention time=1.802 min, [MH]⁺=541.0, 543.0. ¹H-NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.05-9.04 (m, 1H), 8.86-8.85 (m, 1H), 8.42-8.38 (m, 2H), 8.19 (d, J=8.8 Hz, 1H), 7.89 (d, J=1.6 Hz, 1H), 7.82-7.81 (m, 1H), 7.69 (d, J=8.0 Hz, 1H), 7.58 (dd, J=8.0, 1.6 Hz, 1H), 7.50 (t, J=8.0 Hz, 1H), 7.41-7.36 (m, 2H), 7.07 (dd, J=8.0, 2.0 Hz, 1H), 4.57-4.46 (m, 2H), 4.06-4.03 (m, 1H), 3.20-3.01 (m, 2H), 3.88 (s, 3H).

The compounds in the following table were prepared in a manner analogous to that described in Scheme 91, replacing 4-(3,4-dichlorophenyl)pyrrolidin-2-one with the appropriate amide

TABLE 30 ¹H Method Num- Salt NMR Purity of LCMS ber Product type ¹H NMR Solvent percent Coupling LCMS Method 1745

¹H-NMR (400 MHz, DMSO-d₆): δ 9.75 (s, 1H), 8.90 (d, J = 8.0 Hz, 1H), 8.78 (d, J = 4.0 Hz, 1H), 8.35 (s, 1H), 8.28-8.19 (m, 2H), 7.92 (d, J = 7.6 Hz, 1H), 7.82 (d, J = 5.0 Hz, 2H), 7.73-7.70 (m, 1H), 7.68-7.61 (m, 2H), 7.52-7.42 (m, 1H), 7.29 (t, J = 8.4 Hz, 1H), 5.61 (s, 2H). DMSO 95 Method BE 451.0 (M + 1) Method B (NH₄HCO₃) 1746

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.89 (d, J = 8.0 Hz, 1H), 8.77 (d, J = 3.8 Hz, 1H), 8.45 (s, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.83 (s, 2H), 7.72-7.56 (m, 2H), 7.52-7.27 (m, 3H), 7.03 (d, J = 7.9 Hz, 1H), 5.60 (s, 2H), 3.85 (s, 3H). DMSO 95 Method BE 445.1 (M + 1) Method B (NH₄HCO₃) 1747

¹H-NMR (400 MHz, DMSO-d₆): δ 9.76 (s, 1H), 8.91 (d, J = 6.4 Hz, 1H), 8.79 (s, 1H), 8.41 (s, 1H), 8.30-8.23 (m, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.83 (s, 2H), 7.65 (d, J = 3.6 Hz, 2H), 7.55-7.49 (m, 2H), 7.40 (s, 1H), 5.61 (s, 2H). DMSO 95 Method BE 451.0, 452.0, (M + 1) Method B (NH₄HCO₃) 1748

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.73 (s, 1H), 9.05-9.04 (m, 1H), 8.86-8.85 (m, 1H), 8.42-8.38 (m, 2H), 8.19 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.82-7.81 (m, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.58 (dd, J = 8.0, 1.6 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.41-7.36 (m, 2H), 7.07 (dd, J = 8.0, 2.0 Hz, 1H), 4.57-4.46 (m, 2H), 4.06-4.03 (m, 1H), 3.20-3.01 (m, 2H), 3.88 (s, 3H). DMSO 95 Method BE 541.0, 543.0 (M + 1) Method B (NH₄HCO₃) 1749

2HCl ¹H-NMR (400 MHz, DMSO-d₆): δ 9.68 (s, 1H), 8.83 (d, J = 8.0 Hz, 1H), 8.76 (s, 1H), 8.39-8.37 (m, 2H), 8.17 (d, J = 10.0 Hz, 1H), 7.63-7.31 (m, 9H), 7.06 (dd, J = 8.4, 2.0 Hz, 1H), 4.56-4.45 (m, 2H), 4.03-3.99 (m, 1H), 3.88 (s, 3H), 3.19-2.97 (m, 2H). DMSO 95 Method BE 472.9 (M + 1) Method B (NH₄HCO₃) 1750

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (d, J = 8.4 Hz, 1H), 8.89 (dt, J = 8.4, 1.6 Hz, 1H), 8.78 (dd, J = 4.4, 1.2 Hz, 1H), 8.46 (d, J = 1.6 Hz, 1H), 8.41 (dd, J = 8.8, 1.6 Hz, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.97 (s, 1H), 7.88 (s, 2H), 7.65-7.62 (m, 1H), 7.48-7.44 (m, 1H), 7.41-7.37 (m, 2H), 7.04 (dd, J = 8.0, 1.6 Hz, 1H), 5.59 (s, 2H), 3.86 (s, 3H). DMSO 95 Method BE 479.0 (M + 1) Method B (NH₄HCO₃) 1751

¹H-NMR (400 MHz, DMSO-d₆): δ 9.74 (s, 1H), 8.89 (d, J = 8.4 Hz, 1H), 8.78 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 8.41 (d, J = 9.2 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 7.91-7.87 (m, 1H), 7.77-7.62 (m, 3H), 7.48- 7.37 (m, 3H), 7.03 (d, J = 6.4 Hz, 1H), 5.58 (s, 2H), 3.86 (s, 3H). DMSO 95 Method BE 463.1 (M + 1) Method B (NH₄HCO₃)

N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (1.51 g, 3.87 mmol) was dissolved in CH₂Cl₂/MeOH (20 mL/20 mL). Methanesulfonic acid (0.251 mL, 3.87 mmol) was added to the solution. The volatiles were evaporated in vacuo. The resultant residue was crystallized from EtOH (30 mL) to give 1.35 g of N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate as a light yellow powder (72%). LCMS m/z=391 (M+1) (Method D) (Retention time=1.91 min). ¹H NMR (300 MHz, DMSO) δ 9.52 (s, 1H), 9.01-8.83 (m, 2H), 8.75 (s, 1H), 8.58 (s, 1H), 8.09 (d, J=7.2 Hz, 1H), 8.03-7.85 (m, 2H), 7.83-7.68 (m, 1H), 7.59-7.43 (m, 1H), 7.33 (t, J=7.9 Hz, 1H), 2.31 (s, 3H), 1.66 (s, 9H).

N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine (1.22 g, 3.12 mmol) was dissolved in CH₂Cl₂/MeOH (20 mL/20 mL). Fumaric acid (0.363 g, 3.12 mmol) was added to the solution. The mixture was sonicated until fumaric acid was dissolved. Then, the volatiles were evaporated in vacuo. The resultant solid was washed with MeOH and dried to give 1.28 g of N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine ½ fumarate as a light yellow powder (91%). LCMS m/z=391 (M+1) (Method D) (Retention time=1.95 min). ¹H NMR (300 MHz, DMSO) δ 13.14 (s, 1H), 9.59 (s, 1H), 8.82-8.65 (m, 2H), 8.57 (s, 1H), 7.89 (d, J=8.7 Hz, 1H), 7.82 (d, J=8.7 Hz, 1H), 7.79-7.62 (m, 2H), 7.61-7.52 (m, 1H), 7.51-7.38 (m, 1H), 7.28 (t, J=8.6 Hz, 1H), 6.61 (s, 1H), 1.64 (s, 9H).

N-methyl-6-(3-(2-propoxyethoxyl)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine fumarate was synthesized in a similar manner to that described N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine fumarate. LCMS m/z=415.5 (M+1) (Method C (NH₄HCO₃) (Retention time=2.43 min). ¹H NMR (300 MHz, CD₃OD) δ 9.57 (s, 1H), 8.84 (m, 1H), 8.63 (s, 1H), 8.35 (m, 1H), 8.07 (m, 1H), 7.88 (d, J=8.7 Hz, 1H), 7.58 (m, 1H), 7.48-7.24 (m, 4H), 7.00 (m, 1H), 6.74 (s, 1H), 4.36-4.05 (m, 2H), 4.00-3.70 (m, 2H), 3.53 (t, J=6.6 Hz, 2H), 3.29-3.13 (m, 3H), 1.75-1.51 (m, 2H), 0.95 (t, J=7.4 Hz, 3H).

N-methyl-6-(3-(2-propoxyethoxy)phenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate was synthesized in a similar manner to that described N-tert-butyl-6-(2,4-difluorophenyl)-2-(pyridin-3-yl)quinazolin-4-amine methanesulfonate. LCMS m/z=415.5 (M+1) (Method C (NH₄HCO₃) (Retention time=2.43 min). ¹H NMR (300 MHz, CD₃OD) δ 9.49 (s, 1H), 9.00-8.72 (m, 1H), 8.53 (s, 1H), 8.29 (m, 1H), 7.99 (d, J=8.7 Hz, 1H), 7.80 (dd, J=8.0, 5.1 Hz, 1H), 7.52-7.25 (m, 3H), 7.02 (m, 1H), 4.38-4.06 (m, 2H), 3.98-3.72 (m, 2H), 3.61-3.48 (m, 2H), 3.42 (d, J=0.6 Hz, 3H), 3.34-3.26 (m, 2H), 2.71 (s, 3H), 1.80-1.47 (m, 2H), 0.96 (t, J=7.4 Hz, 3H).

Biological Testing: STEP46 Biochemical Assays

Serial dilutions of compounds were performed in 100% DMSO and 1 uL of compounds were dispensed into 384-well black polystyrene plates (Corning, NY). Compounds were incubated with 24 uL of buffer containing 50 mM Hepes, 1 mM DTT, 0.02% Brij35, 1 ng/well purified STEP46 enzyme for 30 min at room temperature. The reaction was initiated by addition of 25 uL of DiFMUP (6, 8-difluoro-4-methylumbelliferyl phosphate) (InVitrogen, CA) with a final concentration of 10 μM and incubated at 27° C. for 90 min. Final DMSO concentration is 2%. Plates were read with florescence intensity at excitation/emission of 360/460 nm using a PheraStar plate reader (BMG Labtech, NC).

Data Analysis

Data were expressed as percentage (%) inhibition of enzyme activity. 0% inhibition is defined as the RFUs (relative fluorescence units) in the absence of compounds and 100% inhibition is defined as RFUs in the absence of STEP46 enzyme. IC₅₀ values of compounds with inhibitory activity against STEP46 were determined by GraphPad Prism (version 4.03) using four parameter logistic equation. Some compounds act as activators. For compounds showing STEP46 enzymatic activation, data are represented as percentage of inhibition but with negative values at three representative concentrations (25, 50 and 100 uM).

Compounds 1-1760 show either inhibition or activation >50% at 100 uM, 50 or 25 uM.

STEP IC50 Number (μM) 73 ++ 296 ++ 297 + 300 + 303 ++ 306 + 309 ++ 312 +++ 313 +++ 314 ++ 315 ++ 316 +++ 317 ++ 318 ++ 320 ++ 322 + 325 +++ 326 ++ 327 ++ 329 +++ 330 ++ 332 +++ 333 +++ 334 ++ 335 +++ 336 +++ 337 +++ 339 ++ 341 ++ 342 ++ 343 + 344 ++ 346 ++ 348 ++ 352 ++ 390 ++ 391 ++ 392 ++ 393 ++ 396 ++ 399 +++ 400 ++ 403 ++ 407 ++ 412 +++ 415 ++ 416 +++ 418 ++ 419 +++ 421 + 423 ++ 424 ++ 425 ++ 426 + 427 ++ 428 ++ 429 +++ 430 +++ 431 +++ 433 ++ 434 ++ 435 +++ 436 ++ 437 ++ 439 +++ 440 ++ 441 ++ 442 +++ 443 +++ 444 +++ 445 +++ 446 ++ 447 ++ 448 +++ 449 ++ 451 +++ 452 +++ 453 +++ 454 ++ 455 ++ 456 +++ 457 ++ 458 +++ 459 +++ 460 ++ 461 ++ 463 ++ 466 ++ 467 ++ 468 +++ 470 ++ 471 ++ 472 ++ 473 ++ 474 ++ 629 ++ 630 ++ 631 ++ 632 +++ 633 ++ 634 ++ 635 +++ 636 + 637 ++ 638 ++ 639 +++ 640 ++ 641 +++ 642 +++ 643 +++ 644 ++ 645 ++ 647 ++ 648 ++ 649 ++ 650 +++ 651 +++ 652 +++ 653 +++ 655 +++ 656 +++ 657 +++ 658 ++ 660 +++ 661 +++ 662 +++ 663 +++ 664 ++ 665 ++ 666 +++ 667 +++ 668 +++ 669 +++ 670 +++ 671 ++ 672 ++ 673 ++ 674 ++ 675 +++ 676 +++ 677 + 678 ++ 679 +++ 680 ++ 681 ++ 682 ++ 683 ++ 684 ++ 685 +++ 686 +++ 687 +++ 688 +++ 689 +++ 690 ++ 691 +++ 692 +++ 693 +++ 694 +++ 695 +++ 696 +++ 697 ++ 698 +++ 699 +++ 700 +++ 701 ++ 702 +++ 703 +++ 704 +++ 705 +++ 706 +++ 707 +++ 708 ++ 709 +++ 846 ++ 847 +++ 884 + 888 + 889 ++ 898 + 899 ++ 900 ++ 901 ++ 923 ++ 932 ++ 933 ++ 934 +++ 962 +++ 1124 +++ 1125 ++ 1126 ++ 1140 +++ 1141 +++ 1142 ++ 1143 ++ 1144 ++ 1145 ++ 1146 ++ 1148 ++ 1150 + 1151 ++ 1152 ++ 1153 ++ 1155 ++ 1157 ++ 1158 ++ 1159 ++ 1160 ++ 1161 ++ 1165 +++ 1167 ++ 1168 ++ 1171 ++ 1172 ++ 1173 + 1176 ++ 1178 ++ 1180 ++ 1181 ++ 1182 ++ 1183 ++ 1184 ++ 1185 ++ 1186 ++ 1187 +++ 1188 ++ 1191 ++ 1192 ++ 1193 ++ 1194 +++ 1198 ++ 1200 ++ 1201 ++ 1202 ++ 1203 ++ 1204 + 1205 ++ 1206 ++ 1208 + 1211 + 1212 ++ 1213 ++ 1214 ++ 1215 +++ 1216 +++ 1217 ++ 1218 ++ 1219 ++ 1220 + 1221 + 1222 ++ 1223 +++ 1225 ++ 1226 ++ 1227 ++ 1228 ++ 1229 ++ 1230 ++ 1234 ++ 1237 ++ 1238 ++ 1239 ++ 1248 ++ 1279 ++ 1280 ++ 1281 +++ 1282 ++ 1283 + 1284 ++ 1285 + 1286 ++ 1324 ++ 1327 + 1328 + 1330 + 1332 ++ 1333 + 1334 + 1335 ++ 1336 ++ 1337 ++ 1339 ++ 1340 ++ 1341 ++ 1346 ++ 1348 + 1350 ++ 1351 ++ 1352 + 1353 ++ 1354 ++ 1356 ++ 1357 ++ 1358 ++ 1359 ++ 1360 ++ 1361 + 1362 ++ 1363 ++ 1364 ++ 1365 ++ 1366 ++ 1369 ++ 1370 ++ 1371 ++ 1372 ++ 1373 ++ 1374 ++ 1375 ++ 1376 ++ 1380 ++ 1381 ++ 1382 +++ 1391 + 1395 ++ 1396 ++ 1400 ++ 1401 ++ 1402 ++ 1403 + 1404 + 1406 ++ 1407 ++ 1408 ++ 1409 ++ 1410 ++ 1411 + 1412 ++ 1413 ++ 1414 ++ 1415 + 1416 ++ 1419 ++ 1420 ++ 1422 ++ 1423 + 1424 + 1425 ++ 1430 ++ 1437 ++ 1445 ++ 1446 ++ 1447 + 1448 ++ 1449 + 1450 ++ 1451 ++ 1452 +++ 1453 ++ 1454 + 1455 ++ 1456 ++ 1458 + 1467 ++ 1497 ++ 1516 + 1601 ++ 1611 ++ 1680 ++ Key + IC₅₀ > 10 uM ++ IC₅₀ 1-10 uM +++ IC₅₀ < 1 uM

Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only. 

1-41. (canceled)
 42. A compound of formula (III):

or a salt thereof, wherein: A is N; L is NR⁶; one of X¹, X², X³, X⁴ and X⁵ is N and the others are CH; m is 1; n is 0 or 1; R¹ is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, alkoxyalkyl, hydroxyalkyl, imidazolyl, furylalkyl, pyridylalkyl, phenylalkyl, oxazolylalkyl, thienylalkyl, thiazolidinyl, isoindolyl, —C(O)R^(e), dihydroindenyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylalkyl, piperidyl, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl, each of which is optionally substituted with 1-3 R⁷; R² is phenyl, naphthyl, benzofuryl, indazolyl, benzothienyl, pyridyl, pyrimidinyl, dihydrobenzodioxinyl, benzodioxolyl, benzoimidazolyl, isoxazolyl, pyrazolyl, indolinyl or benzisoxazolyl, each of which is optionally substituted with 1-5 R⁹; each R³ or R⁴ is independently hydrogen, C₁-C₈ alkyl, halo, haloalkyl or —OR^(d); R⁶ is hydrogen or C₁-C₈ alkyl; each R⁷ and R⁹ is independently C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, oxo, —CN, —NO₂, —C(O)OR^(a), —C(O)NR^(b)R^(b′), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²; R¹² is independently C₁-C₈ alkyl, oxo, halo, haloalkyl, —CN, —C(O)NR^(b)R^(b′) or —C(O)R^(e), each of which is optionally substituted with 1-3 R¹³; R¹³ is independently C₁-C₈ alkyl, halo or pyrrolidinyl; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, pyrrolidinyl, piperidyl, morpholinyl, piperazinyl, tetrahydropyranyl, phenylalkyl, alkoxyalkyl, morpholinylalkyl, oxazolidinylalkyl, imidazolylalkyl, tetrahydropyranylalkyl, pyridylalkyl, pyrazolylalkyl, tetrazolylalkyl, thiazolylalkyl, pyrrolylalkyl, benzoxazolylalkyl, indazolylalkyl, dihydrobenzoxazinylalkyl, tetrahydrofurylalkyl, tetrahydrofuryl, alkylaminoalkyl, dialkylaminoalkyl or phenyl.
 43. The compound according to claim 42 represented by general formula (III) or a salt thereof, wherein: R³ is hydrogen, C₁-C₈ alkyl, halo, haloalkyl, or —OR^(d); R⁴ is hydrogen, C₁-C₈ alkyl, halo, or —OR^(d); R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d) each of which is optionally substituted with 1-3 R¹²; and R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f), each of which is optionally substituted with 1-3 R¹²;


44. The compound according to claim 43 represented by general formula (III) or a salt thereof, wherein: R⁷ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, oxo, —C(O)OR^(a), —C(O)NR^(b)R^(b′) or —OR^(d); R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and


45. The compound according to claim 44 represented by general formula (III) or a salt thereof, wherein: R² is phenyl, which is optionally substituted with 1-5 R⁹; and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl, tetrahydrofuryl, tetrahydrofurylalkyl, alkylaminoalkyl or phenyl.
 46. The compound according to claim 45 represented by general formula (III) or a salt thereof, wherein: n is 0; R¹ is hydrogen, C₁-C₈ alkyl or pyridylalkyl, each of which is optionally substituted with 1-3 R⁷; R⁷ is C₁-C₈ alkyl or halo; R⁹ is C₁-C₈ alkyl, phenyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, —CN, —NO₂, —C(O)NR^(b)R^(b′), —C(O)OR^(a), —NR^(b)R^(b′), —OR^(d), —C(O)R^(e) or —S(O)_(q)R^(f); and each R^(a), R^(b), R^(b′), R^(c), R^(c′), R^(d), R^(d′), R^(e) and R^(f) is independently hydrogen, C₁-C₈ alkyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, alkoxyalkyl, morpholinylalkyl, tetrahydropyranylalkyl, pyridylalkyl, thiazolylalkyl, pyrrolylalkyl or tetrahydrofurylalkyl.
 47. The compound according to claim 46 represented by general formula (III) or a salt thereof, wherein: R⁹ is halo or —OR^(d), and R^(d) is C₁-C₈ alkyl.
 48. The compound according to claim 42 or a salt thereof, wherein the compound of formula (III) is a compound selected from the group consisting of


49. A pharmaceutical composition comprising the compound according to claim 42 or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
 50. The pharmaceutical composition according to claim 49 for preventing or treating central nervous system diseases.
 51. The pharmaceutical composition according to claim 50 for treating or preventing central nervous system disorders selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; melancholy and refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; agoraphobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; generalized anxiety disorder; acute stress disorder; hysteria; somatization disorder; conversion disorder; pain disorder; hypochondriasis; factitious disorder; dissociative disorder; sexual dysfunction; sexual desire disorder; sexual arousal disorder; erectile dysfunction; anorexia nervosa; bulimia nervosa; sleep disorder; adjustment disorder; alcohol abuse; alcohol intoxication; drug addiction; stimulant intoxication; narcotism; anhedonia; iatrogenic anhedonia; anhedonia of a psychic or mental cause; anhedonia associated with depression; anhedonia associated with schizophrenia; delirium; cognitive impairment; cognitive impairment associated with Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases; cognitive impairment caused by Alzheimer's disease; Parkinson's disease and associated neurodegenerative diseases; cognitive impairment of schizophrenia; cognitive impairment caused by refractory, intractable or chronic schizophrenia; vomiting; motion sickness; obesity; migraine; pain (ache); mental retardation; autism disorder (autism); Tourette's disorder; tic disorder; attention-deficit/hyperactivity disorder; conduct disorder; and Down's syndrome.
 52. A method of treating a disorder that would benefit by the modulation of STEP (e.g., by activation of inhibition of STEP) in a subject, the method comprising administering to a compound of formula (I), (II) or (III) or a salt thereof according to claim
 42. 53. The method of claim 52, wherein the disorder is schizophrenia.
 54. The method of claim 52, wherein the disorder is cognitive deficit.
 55. The method of claim 52, wherein the compound of formula (I), (II) or (III) is administered in combination with an additional therapeutic agent.
 56. The method of claim 52, wherein the additional therapeutic agent is an atypical antipsychotic.
 57. The method of claim 52, wherein the additional therapeutic agent is selected from the group consisting of aripiprazole, clozapine, ziprasidone, risperidone, quetiapine, olanzapine, amisulpride, asenapine, iloperidone, melperone, paliperidone, perospirone, sertindole and sulpiride.
 58. The method of claim 52, wherein the additional therapeutic agent is a typical antipsychotic.
 59. The method of claim 52, wherein the additional therapeutic agent is selected from the group consisting of haloperidol, molindone, loxapine, thioridazine, molindone, thiothixene, pimozide, fluphenazine, trifluoperazine, mesoridazine, chlorprothixene, chlorpromazine, perphenazine, triflupromazine and zuclopenthixol.
 60. A kit comprising a composition comprising a compound or a salt thereof according to claim 42 and an acceptable carrier.
 61. A kit comprising a pharmaceutical composition comprising a compound or a salt thereof according to claim 42 and a pharmaceutically acceptable carrier. 